



**Ontario Health**  
Cancer Care Ontario

**Guideline 17-10 v 2**

**A Quality Initiative of the Program in Evidence-Based Care (PEBC),  
Ontario Health (Cancer Care Ontario)**

**Postmastectomy Breast Reconstruction in Patients  
with Non-Metastatic Breast Cancer**

*Toni Zhong, Glenn G Fletcher, Muriel Brackstone, Simon Frank, Renee Hanrahan,  
Vivian Miragias, Christiaan Stevens, Danny Vesprini, Alyssa Vito, Frances C Wright  
and the and the Breast Reconstruction Expert Panel*

**Report Date: March 19, 2025**

For information about this document, please contact Toni Zhong, the lead author, through the PEBC: Phone: 905-527-4322 ext. 42822; E-mail: [ccopgi@mcmaster.ca](mailto:ccopgi@mcmaster.ca)

For information about the PEBC and the most current version of all reports, please visit the OH (CCO) website at <https://www.cancercareontario.ca/en/guidelines-advice> or contact the PEBC office at:  
Phone: 905-527-4322 ext. 42822 E-mail: [ccopgi@mcmaster.ca](mailto:ccopgi@mcmaster.ca)

**PEBC Report Citation (Vancouver Style):** Zhong T, Fletcher GG, Brackstone M, Frank S, Hanrahan R, Miragias V, Stevens C, Vesprini D, Vito A, Wright FC, and the Breast Reconstruction Expert Panel. Postmastectomy breast reconstruction in patients with non-metastatic breast cancer. Toronto (ON): Ontario Health (Cancer Care Ontario); 2025 Mar 19. Program in Evidence-Based Care Guideline No.: 17-10 v2.

*Copyright*

This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

*Disclaimer*

Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinician. Ontario Health (Cancer Care Ontario) makes no representations or guarantees of any kind whatsoever regarding the report content or its use or application and disclaims any responsibility for its use or application in any way.

## Table of Contents

<b>GLOSSARY.....</b>	<b>iv</b>
<b>SECTION 1: RECOMMENDATIONS .....</b>	<b>1</b>
GUIDELINE OBJECTIVES .....	1
TARGET POPULATION .....	1
INTENDED USERS .....	1
RECOMMENDATIONS .....	1
Recommendations on Type of Reconstruction (Implants or Various Autologous Flaps).....	1
Overall Recommendation for Patient Education and Preoperative Evaluation .....	1
1. Effect of Patient and Oncologic Factors.....	2
2. Immediate versus Delayed Reconstruction.....	4
3. Nipple Sparing Mastectomy.....	5
4. Implant Plane/Location .....	8
5. Use of Acellular Dermal Matrix (ADM) or Synthetic Absorbable Matrix.....	8
6. Autologous Fat Grafting (Lipofilling).....	9
<b>SECTION 2: GUIDELINE - RECOMMENDATIONS AND KEY EVIDENCE.....</b>	<b>11</b>
GUIDELINE OBJECTIVES .....	11
TARGET POPULATION .....	11
INTENDED USERS .....	11
RECOMMENDATIONS, KEY EVIDENCE, AND JUSTIFICATION .....	11
Recommendations on Type of Reconstruction (Implants or Various Autologous Flaps)....	11
Overall Recommendation for Patient Education and Preoperative Evaluation .....	11
1. Effect of Patient and Oncologic Factors.....	12
2. Immediate versus Delayed Reconstruction.....	17
3. Nipple Sparing Mastectomy.....	19
4. Implant Plane/Location .....	27
5. Use of Acellular Dermal Matrix (ADM) or Synthetic Absorbable Matrix.....	29
6. Autologous Fat Grafting (Lipofilling).....	31
RELATED OH(CCO) GUIDELINES .....	33
<b>SECTION 3: GUIDELINE METHODS OVERVIEW .....</b>	<b>34</b>
THE PROGRAM IN EVIDENCE-BASED CARE.....	34
BACKGROUND.....	34
GUIDELINE DEVELOPERS.....	34
GUIDELINE DEVELOPMENT METHODS .....	35
Search for Guidelines and Systematic Reviews .....	35
GUIDELINE REVIEW AND APPROVAL .....	35

DISSEMINATION AND IMPLEMENTATION .....	36
ACKNOWLEDGEMENTS .....	36
<b>SECTION 4: SYSTEMATIC REVIEW .....</b>	<b>37</b>
INTRODUCTION .....	37
RESEARCH QUESTIONS.....	37
METHODS .....	38
Study Selection Criteria and Process.....	38
Outcomes of Interest .....	40
Data Extraction and Assessment of Evidence Quality/Certainty .....	40
Synthesizing the Evidence .....	41
RESULTS .....	41
Overview of Literature Search Results.....	41
Risk of Bias and Quality of the Evidence .....	42
Mastectomy Reconstruction Outcomes Consortium Study .....	43
Question 1. Patient Factors.....	44
Question 2. Immediate versus Delayed .....	48
Question 3: Nipple-Sparing Mastectomy Issues .....	54
Question 4. Implant Location .....	67
Question 5: Acellular Dermal Matrix .....	72
Question 6. Autologous Fat Grafting .....	78
Other Technical Notes .....	83
DISCUSSION AND CONCLUSIONS .....	84
Question 1. Patient and Disease Factors.....	85
Question 2. Timing of Reconstruction.....	86
Question 3. Nipple-Sparing Mastectomy .....	87
Question 4. Plane of Implants .....	87
Question 5. Acellular Dermal Matrix Use .....	88
Question 6. Autologous Fat Grafting .....	88
EVIDENCE TABLES .....	90
<b>SECTION 5: INTERNAL AND EXTERNAL REVIEW.....</b>	<b>283</b>
INTERNAL REVIEW.....	283
EXTERNAL REVIEW .....	287
CONCLUSION.....	301
<b>REFERENCES.....</b>	<b>302</b>
<b>APPENDICES .....</b>	<b>334</b>
Appendix 1: Participants, Affiliations, and Conflict of Interest Declarations.....	335
Appendix 2: Literature Search Strategy .....	339

Appendix 3: PRISMA Flow Diagram .....	344
Appendix 4. Assessment of Bias in RCTs using the Cochrane Risk of Bias 2 (RoB2) Tool ...	345
Appendix 5: Quality Assessment by AMSTAR II of Systematic Reviews in Table 4-1*.....	346
Appendix 6: Question on Types of Breast Reconstruction from 17-10 Version 1 (January 2016, not updated) .....	347
Appendix 7: Guideline Document History .....	364

## Glossary

### Tissue Flaps

#### **Autologous Flap**

A flap of tissue including skin, fat, muscle, blood vessels taken from one location and used to fill a defect in another location of the body (1).

#### **Free Flap**

A flap of tissue that is completely dissected from the original body area such as the abdomen, back, or thigh, and then reattached in the new area. Blood vessels in the flap are connected to those in the new location by microsurgery (anastomosis) (1).

#### **Pedicled Flap**

A flap rotated/moved into the reconstruction site, often with tunneling under the skin from the original to new (breast) location. Blood vessels remained intact, and the flap is not completely severed from the original body location (1).

#### **Myocutaneous Flap**

Tissue flap consisting of muscle, deep fascia, fat, skin, and vascular pedicle (2). Examples are TRAM and LD flaps.

#### **Perforator**

A vessel perforating an envelope of target tissue (superficial fascia for skin, deep fascia for muscle, perineurium for nerves) to be transferred (2).

#### **Perforator Flap**

Adipocutaneous flaps with blood circulating through a cutaneous perforator artery and its accompanying veins (vena comitans) (3) (4). The donor-site muscle is not included in the flap and therefore there is less donor-site morbidity.

#### **Latissimus Dorsi (LD) Flap**

The latissimus dorsi muscle along with skin, fat and blood vessels is translocated from the back by tunneled under the skin to form a new breast mound. This is a form of pedicled flap. It may be used alone or with implants (1).

#### **Thoracodorsal Artery Perforator (TDAP or TAP) Flap**

This flap incorporates the thoracodorsal artery perforator from the area of the latissimus dorsi muscle but is a perforator flap that spares the muscle (5, 6). It may be a pedicled or free flap. Anatomic variations can make harvesting technically challenging. There may be less shoulder dysfunction than with LD flaps (7).

#### **Transverse Rectus Abdominis Musculocutaneous (TRAM) Flap**

The rectus abdominis muscle from the lower abdomen, along with skin, fat, and blood vessels is moved to a new location to rebuild the breast. It may be either free or pedicled (pTRAM) (1).

#### **Muscle-sparing TRAM (MS-TRAM) Flap**

TRAM flap which harvests less muscle and fascia, and preserve the lateral intercostal nerve innervations (Butler and Wu). Muscle-sparing 1 preserves the lateral segment of the rectus

abdominis muscle, muscle-sparing 2 preserves the medial and lateral segments, and muscle-sparing 3 preserves the entire rectus abdominis muscle to give a DIEP flap (8-10).

**Deep Inferior Epigastric Perforator (DIEP) Flap**

Deep inferior epigastric perforator blood vessels, along with connected fat and skin (but not muscle) from the lower abdomen (1).

**Superior Gluteal Artery Perforator (S-GAP) Flap**

A flap from the superior (upper) region of the buttocks supplied by superior gluteal artery perforators (11). The perforators of the gluteal region have substantial variation in location, size, and source vessels.

**Inferior Gluteal Artery Perforator (I-GAP) Flap**

A flap (horizontal ellipse) from the inferior (lower) region of the buttock just above the gluteal crease containing inferior gluteal artery perforating vessels (11, 12). The perforators of the gluteal region have substantial variation in location, size, and source vessels.

**Superficial Inferior Epigastric Artery (SIEA) Flap**

SIEA flap is an abdominal flap similar to DIEP but requiring no incision in the abdominal fascia nor vessel dissection in the rectus abdominis muscle (13). While it offers lower donor site morbidity, anatomy of the SIEA (location and branching pattern) and associated vein are variable and may not be of sufficient calibre to support reconstructed breast tissue (13-15).

**Profunda Artery Perforator (PAP) Flap**

A flap from the posterior thigh with dominant blood supply from the profunda artery perforators (16). This is an alternative to abdominal flaps for patients that are very thin or that have had previous abdominal surgery, and (unlike flaps from the gluteal are) does not affect buttock contour.

Other terms

**Acellular Dermal Matrix (ADM)**

A biological mesh, matrix, or scaffold derived from human skin from cadavers or animal dermis, and which has been treated to remove cellular components and immunogenic elements. ADM is used to provide soft-tissue or implant support during reconstruction.

**Animation Deformity (Breast Distortion)**

Distortion of the shape of the breast in patients with submuscular or subpectoral implants during contraction of the pectoralis muscle and resulting in poor aesthetics. This may be accompanied by pain, impaired shoulder function, and reduced quality of life (17, 18).

**Anastomosis**

Connecting tubular structures after removing diseased sections (1); in breast reconstruction this usually refers to connecting blood vessels from transplanted flaps to those in the area of the breast, but also applies to nerves.

**Autologous Fat Grafting (Lipofilling)**

Fat harvested from one area such as the abdomen and injected into another. In breast reconstruction it may be used to fill defects, increase volume, and improve quality of irradiated or scar tissue (19, 20).

**Nerve Coaptation**

Surgical repair of nerves involving connection of two nerve segments, either directly or with the use of autograft (from elsewhere in the body) or allograft (from cadaver); it may be end-to-end, end-to-side, or side-to-side (21).

**Neurotization**

Growing nerve fibres reestablish a connection between the neuron and motor or sensory end organs. Surgically, either directly or through a donor nerve graft, the nerve is connected to a health distal portion of a non-functioning nerve or implanted directly into insensitive skin or denervated muscle (22). Direct neurotization involves connection of the nerve to a target organ such as the muscle, skin, nipple-areola complex (23, 24).

**Neoadjuvant Therapy**

Treatment, including radiotherapy, chemotherapy, or other systematic therapy provided prior to the main treatment, which is generally surgery for resectable tumours

**Tumescence (Tumescent Dissection, Hydrodissection)**

Injection of a crystalloid solution of local anesthetic for anesthesia and epinephrine for vasoconstriction into the subcutaneous space until tissue is firm and tense (tumescent) to cause hydrodissection and establish a bloodless plane for surgical dissection (25, 26). Composition varies, but is often 0.05-0.1% lidocaine and 1:1,000,000 epinephrine in 0.9% (normal) saline or lactated Ringers solution.



# Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

## Section 1: Recommendations

*This section is a quick reference guide and provides the guideline recommendations only. For key evidence associated with each recommendation, see [Section 2](#).*

### GUIDELINE OBJECTIVES

The objective of this work is to provide guidance on identifying which patients with breast cancer who are undergoing mastectomy are candidates for reconstruction, use of nipple-sparing mastectomy (NSM), the best timing of reconstruction (immediate or delayed), whether radiotherapy (RT) should influence timing, the choice between prepectoral versus subpectoral implants, and use of acellular dermal matrix (ADM) and autologous fat grafting as part of the reconstruction process.

For this document, “reconstruction” refers to immediate or delayed reconstruction of the breast mound, not including aesthetic flat closure.

### TARGET POPULATION

Patients diagnosed with non-metastatic breast cancer who will undergo therapeutic mastectomy and are considering or decided on reconstructive surgery. For purposes of this document, reconstruction includes both immediate and delayed reconstruction with implants and/or autologous tissue but does not include aesthetic flat closure.

### INTENDED USERS

1. Surgeons (general surgeons, surgical oncologists, plastic surgeons), radiation oncologists, and other clinicians involved in conducting mastectomies or in post-mastectomy reconstruction and adjuvant treatment.
2. Members of the Breast Cancer Advisory Committee, Ontario Health (Cancer Care Ontario), and others involved in the review and update of the Breast Cancer Pathway Map.

### RECOMMENDATIONS

#### Recommendations on Type of Reconstruction (Implants or Various Autologous Flaps)

The authors deemed that the evidence and recommendations in Version 1 of this guideline are still relevant for this question and that an update was not required. As 17-10 Version 1 will no longer be available upon posting of Version 2, the relevant portions of the 2016 Recommendations and Systematic Review are included in [Appendix 6](#). Comparison of types of reconstruction or factors influencing their selection are not within scope of the current work.

---

#### Overall Recommendation for Patient Education and Preoperative Evaluation

For women who have chosen or been recommended for therapeutic mastectomy:

- The discussion of immediate or delayed breast reconstruction should be initiated at the time that mastectomy is offered by the general surgeon, breast surgeon, or surgical oncologist.
- For women seeking immediate breast reconstruction, preoperative evaluation should include a plastic surgeon.
- For women seeking immediate breast reconstruction who will potentially require adjuvant chemotherapy or radiotherapy (RT), a medical oncologist and/or radiation oncologist should be included in preoperative evaluation, either through a formal consultation or by a multidisciplinary cancer conference.
- Decisions around the contralateral breast should be jointly made by the patient and medical team, considering the patient's family history and/or genetic profile if available and symmetry with the involved reconstructed breast, and include discussion of potential benefits and harms. Risk of new primary breast cancer may be a factor, and patients with risk factors for hereditary breast cancer should be referred for genetic assessment. The patient's preferences and values must be considered, and an informed discussion is recommended prior to mastectomy, along with a recommendation by the surgeon conducting the mastectomy (e.g., general surgeon, breast surgeon, or surgical oncologist) or reconstructive surgeon (or consensus of these) for or against contralateral prophylactic mastectomy.

### ***Qualifying Statements***

- Bilateral surgery is shown to increase complications risks.
- In absence of genetic risk factors, contralateral mastectomy may decrease rates of new cancer but does not improve survival or recurrence.
- Contralateral mastectomy with reconstruction may give better aesthetic results in some patients. When contralateral mastectomy is not indicated, balancing procedure to the contralateral breast can also produce aesthetic and symmetrical results.

---

## **1. Effect of Patient and Oncologic Factors**

**Note 1:** While an individual factor may not be sufficient to rule out reconstruction, risks of complications for different factors may be additive and must be considered together (e.g., diabetes plus smoking plus obesity). A validated risk tool may be useful in evaluating overall risks. Further, some risk factors may alter the risk-benefit analysis for some types of reconstruction more than for other types. Factors that affect flap perfusion/circulation may preclude skin- or nipple-sparing mastectomy. The degree of comorbidity (e.g., grade of obesity, controlled vs. uncontrolled diabetes, current vs. former smoking and amount smoked) need to also be considered.

**Note 2:** Published systematic reviews constitute the evidence base for Recommendations 1.2 through 1.6

The rationale for using higher level evidence was in part due to limited time and staffing resources, given the broad scope of this systematic review and is a usual trade-off. Furthermore, it is often the pragmatic choice to use higher level evidence synthesis publications for these kind of 'factor' questions, making use of work already done by others to avoid

duplication. As no systematic review was found that covered age adequately, Recommendation 1.1 on age is based on a new systematic review of this topic (see Section 4).

### ***Recommendation 1.1: Age***

- Age on its own should not be used to determine whether to offer breast reconstruction to patients who are undergoing mastectomy as treatment for breast cancer. Competing risks of mortality and patient preferences should be part of the decision-making process; life expectancy and geriatric assessment may be considered.

#### ***Qualifying Statements for Recommendation 1.1***

- Comorbidities including heart diseases and diabetes tend to increase with age and may affect suitability for operation or wound healing.
- While some older patients may place less importance on breast reconstruction, it should not be assumed for all, as individual preferences will vary.
- Some patients of any age may not want reconstruction and prefer mastectomy alone, and it should not be assumed that all younger patients will want reconstruction.

### ***Recommendation 1.2: Body Mass Index, Smoking, Diabetes, Hypertension***

- High body mass index (BMI), current and prior smoking status, diabetes, and hypertension are risk factors for complications and poorer outcomes but should not be used as absolute contraindications to reconstruction. It is recommended that uncontrolled diabetes be treated and that patients cease smoking at least several weeks prior to surgery and until incisions have healed.
- Reconstruction should be presented as an option, and patients informed that risks of specific complications such as skin or nipple necrosis and reconstructive failure are higher than in patients without risk factors.

#### ***Qualifying Statements for Recommendation 1.2***

- Obesity is often defined as BMI  $>30 \text{ kg/m}^2$ , although particularly in Asian countries a lower cut-off ( $25 \text{ kg/m}^2$ ) is often used. Risks of complications increase with BMI above these thresholds on a continuum. Incisions and reconstruction techniques may need to be altered and include contralateral reduction if matching of the breasts is considered important to the patient. The amount of tissue removed, and repositioning of the nipple may result in ischemic complications and decreased sensation.  
In patients with multiple risk factors or comorbidities, the potential effect of all combined must be considered. A validated risk assessment tool may be used.

### ***Recommendation 1.3: Breast Size***

- Pre-mastectomy breast size and desired reconstructed breast size may influence type of reconstruction, complication rates, and cosmetic/aesthetic results; however, these factors should not determine whether to perform reconstruction. Patients and surgeons should discuss risks and benefits of various procedures.

***Recommendation 1.4: Previous Surgery***

- Abdominal scars, previous abdominal surgery, and previous breast augmentation are not contraindications to breast reconstruction but may influence the surgical and reconstructive planning and type of reconstruction performed.

***Recommendation 1.5. Neoadjuvant Chemotherapy***

- Patients who received neoadjuvant chemotherapy (NACT) should be assessed and considered for reconstruction in the same manner as for patients without NACT.

***Recommendation 1.6: Radiotherapy***

- Adjuvant radiotherapy (RT) should not be considered as a contraindication to either implant-based or autologous reconstruction. Patients should be informed that adjuvant RT is associated with increased reconstructive complications, and that these are greater in expander/implant reconstruction than with autologous reconstruction .

***Qualifying Statements for Recommendation 1.6***

- The type of complications varies between implant and autologous reconstruction. Autologous reconstruction may be preferred in patients at higher risk of implant-related complications.
- Timing of RT with respect to reconstruction may influence the degree or profile of complications and is not addressed here. The timing of reconstruction and use of RT is partially addressed in Recommendation 2.

---

**2. Immediate versus Delayed Reconstruction**

***Recommendation 2***

- For patients desiring breast reconstruction, both immediate and delayed reconstruction may be considered.
- When delayed reconstruction occurs after radiotherapy (RT), reconstruction should occur at least 6 months after completion of RT, or longer if the irradiated site is still acutely tight, inflamed, and prone to complications.

***Qualifying Statements for Recommendation 2***

- Preferred timing of reconstruction will depend on factors such as patient preferences, type of mastectomy, skin perfusion, comorbidities, pre-mastectomy breast size, and desired reconstructive breast size.
- Immediate reconstruction may provide greater psychological or QoL benefits for some patients.
- Access to and resources for delayed breast reconstruction can be very lengthy in parts of Ontario and immediate reconstruction would avoid being on a lengthy waitlist.

### 3. Nipple Sparing Mastectomy

#### ***Recommendation 3.1: Nipple-Sparing versus Skin-Sparing Mastectomy***

- a) In patients who are candidates for skin-sparing mastectomy (SSM) and without clinical, radiological, and pathological indications of nipple-areolar complex (NAC) involvement, nipple-sparing mastectomy (NSM) is recommended provided it is technically feasible and acceptable aesthetic results can be achieved.
- b) Patients should be informed that in the case of tumour involvement of subareolar tissues/margins based on pathologic analysis, or of NAC necrosis not responding to treatment, the nipple or NAC may need to be excised.
- c) The patient should be involved in the decision between NSM and SSM. The patient should be informed, along with reasons, if NSM is considered inappropriate and not being offered.

#### ***Qualifying Statements for Recommendation 3.1***

- Comorbidities, larger breast size, and ptosis are risk factors for poor perfusion and subsequent skin flap and/or NAC necrosis. Reduction in breast size and repositioning of the nipple may require different incision locations. Blood supply to the skin flap/NAC may be improved with delayed reconstruction, staged mastectomy, or surgical delay when the oncologic treatment timeline allows.
- Discussion of tattooing or nipple reconstruction with realistic restorative areola tattooing needs to be a discussion for psychological and physical well-being in patients for which NSM is not suitable.

#### ***Recommendation 3.2: Patient Selection and Assessment of Nipple-Areolar Complex (NAC) Involvement***

- a) Nipple-sparing mastectomy (NSM) can be considered in all patients with non-metastatic, non-inflammatory breast cancer without clinical signs of nipple involvement (bloody or pathologic nipple discharge, nipple retraction, Paget disease) and no nipple involvement by imaging and where it is surgically feasible and suitable aesthetic results can be obtained.
- b) An oriented subareolar sample must be obtained for pathologic evaluation. A sample of ducts from the nipple or complete nipple coring (total skin-sparing mastectomy [TSSM]) may be considered.
- c) In cases where specimens taken from the area immediately under or within the nipple are found involved by tumour, but the areola is not involved, nipple excision alone (i.e., areola-sparing mastectomy [ASM]) may be conducted provided clear margins are obtainable.
- d) Involvement of areolar skin not extending to the nipple may be treated as for other skin cancers and excised with clear margins.
- e) We recommend against intraoperative/frozen section pathologic analysis. Treatment decisions should be based on definitive/final pathology results.
- f) The patient should be informed that NAC or nipple excision is the standard treatment when the subareolar area is found to be involved with tumour on final pathologic

analysis; the final decision should be made by the patient and surgical team. Planned RT may be a factor in the decision.

- g) Prior to a planned NSM, patients should be informed and consent to NAC or nipple removal if intraoperative surgical findings are indicative of cancer that cannot be resected without NAC or nipple excision.

### ***Qualifying Statements for Recommendation 3.2***

- SSM, ASM, and NSM aim to balance eliminating negative oncologic outcomes with maintaining a viable skin envelope. Differences in operative procedures and criteria may contribute to variations in oncomes between studies.
- While intraoperative frozen section analysis was used in several of the published studies, it is less accurate and may result in false positives (and unnecessary NAC excision) or false negative (with involved NAC retained). When subareolar tissue is found involved by tumour on intraoperative/frozen section analysis, re-excision to obtain clear margins may be conducted as an alternative to immediate NAC excision.
- Studies did not use a uniform definition of pathologies that would require NAC excision. Atypia and lobular carcinoma in situ (LCIS) in subareolar samples were not criteria to conduct NAC excision in several studies; frozen section analysis is not a reliable method of assessing epithelial cell atypia and is often misidentified in frozen section analysis.

## **Recommendations 3.3 to 3.7: Surgical Factors in Nipple-Sparing Mastectomy**

### ***Evidence Note***

*Authors of studies included in the systematic review indicated that incision location, nerve preservation, skin tension, thermal damage in dissection, and operative planning are important surgical factors for outcomes of nipple viability/necrosis and sensation after NSM. Several studies reported comparative data on incision location (see Recommendation 3.3) and a few on sensation (see Recommendation 3.4). For the other factors, the study authors presented these as generally accepted or based on their accumulated experience. These were not the topic of comparison/investigation. Recommendations 3.5 to 3.7 present these factors as important to be considered but do not provide specific recommendations or optimal approaches.*

### ***Recommendation 3.3: Incision Location***

- a) Periareolar incisions (including hemi-periareolar) should be avoided unless there are oncologic or other specific reasons for their use. Periareolar incisions, if used, should encompass no more than one-third of the areolar circumference.
- b) To reduce nipple necrosis, inferolateral (lateral inframammary fold) or inframammary fold (IMF; central inframammary fold) incisions are preferred.
- c) In the case of previous breast surgery with scars, it may be preferable to reoperate using the same incision. This should be determined on a case-by-case basis.

### ***Qualifying Statements for Recommendation 3.3***

- Re-excision using the same incision location as for previous surgery is sometimes used to avoid multiple sets of scars that may have negative aesthetic impact. As the previous incision already disrupted blood supply in that area, reusing the same scars may also cause less additional complications.
- Inferolateral and IMF have least necrosis associated with them. Inferior radial (vertical inferior) or lateral radial (horizontal radial) incisions have been reported as resulting in intermediate levels of nipple necrosis.
- As indicated in Question 5 on acellular dermal matrix (ADM) use, inferolateral incisions may be preferred for subpectoral implants without ADM. Some have suggested that incisions in the IMF may not allow for enough support for implants unless ADM is used. There is not enough evidence in this regard to make a recommendation, but type and location of implant may influence the incision location.

### ***Recommendation 3.4: Nerve Preservation***

- Selection of incision sites should take into account both preservation of blood supply and minimizing nerve damage.

### ***Qualifying Statements for Recommendation 3.4***

- Priority should be to minimize nerve damage and optimize conditions for nerve regeneration. Partial sensation, while much lower than prior to mastectomy, may be maintained in some patients. Reconnecting nerves is sometimes attempted in autologous flap reconstruction.

### ***Recommendation 3.5: Skin Tension***

- When nipple-sparing mastectomy (NSM) is followed by immediate expanders or implants, excess tension should be avoided as it may interfere with blood flow and lead to necrosis.

### ***Recommendation 3.6: Thermal Damage in Dissection***

- Care should be taken to minimize thermal damage to the skin, blood vessels and nerves.

### ***Recommendation 3.7: Operative planning***

- Operative planning should be conducted jointly by the surgeon conducting the mastectomy and the plastic surgeon and include assessment of blood vessel location and skin perfusion. Perfusion of flaps should be monitored after operation.
-

#### 4. Implant Plane/Location

##### **Background**

Early attempts at prepectoral breast reconstruction suffered from unacceptable rates of flap necrosis and capsular contracture (27), as well as lack of support and implant extrusion. Subpectoral implants were the standard of care for many years, but many patients experienced animation deformity, pain, restricted motion, as well as longer and more complex operations (28-30). The development and use of acellular dermal matrix (ADM), fat grafting, and tissue perfusion assessment technology to assess flap viability have reduced complications and led to more widespread use of prepectoral (and to lesser extent dual-plane) reconstruction (27, 31). In the studies included in the systematic review, ADM was usually used with prepectoral implants to provide support of the lower pole and/or to provide an additional layer between the skin envelope and the implant. In partial subpectoral (dual-plane) placement, ADM or other mesh was generally used to cover and support the lower half (lateral pole) of the expander or implant (the portion not under the pectoralis major muscle). Use of ADM is covered in Recommendation 5 and fat grafting in Recommendation 6.

##### **Recommendation 4**

- a) There is a role for both prepectoral and subpectoral implants; risks and benefits will vary, and decisions should be made during consultation between the patient and surgeons.
- b) In patients who are suitable candidates for implant reconstruction and have adequate mastectomy flap thickness and vascularity, prepectoral implants should be considered as they have some advantages over dual-plane or other subpectoral reconstructions.
- c) Patients should be informed of the possibility that subpectoral and submuscular implants may result in long-term animation deformity and related pain and sometimes implant malposition.

##### **Qualifying Statements for Recommendation 4**

- In patients with poor flap quality and vascularization, immediate prepectoral reconstruction was not generally offered; alternatives include subpectoral reconstruction, surgical delay prior to prepectoral reconstruction, or autologous flaps.
- Type and location of implants or autologous tissue should be documented in patient records and available to clinicians conducting follow-up assessments and imaging.

#### 5. Use of Acellular Dermal Matrix (ADM) or Synthetic Absorbable Matrix

##### **Background**

ADM is usually used with prepectoral implants to provide support of the lower pole and/or to provide an additional layer between the skin envelope and the implant. The expander or implant could be wrapped entirely with ADM (most common), the pocket after SSM/NSM lined entirely with ADM, or ADM used only on the anterior surface and posterior lower pole. The use of ADM has led to being able to perform prepectoral reconstruction safely. In partial subpectoral (dual-plane) placement, ADM or other mesh was generally used to cover and support the lower half (lateral pole) of the expander or implant (the portion not under the pectoralis major muscle). ADM was sutured to the lower border of the pectoralis muscle and



in the area of the IMF and often referred to as a sling providing support to the lower pole of the implant.

### ***Recommendation 5***

- a) Mastectomy flap perfusion should be assessed prior to reconstruction. ADM should not be used in case of poor mastectomy flap perfusion/ischemia that would otherwise be considered unsuitable for prepectoral reconstruction.
- b) Care should be taken in selection and handling of acellular dermal matrix (ADM) to minimize risks of infection and seroma.
- c) There is insufficient information to recommend a specific human ADM. Sterility level may be a factor in selection of a product.
- d) Undue tension on the mastectomy flaps should be avoided.
- e) Absorbable synthetic mesh may be an alternative to human ADM; however, comparative information is very limited, and no recommendation can be made.

### ***Qualifying Statements for Recommendation 5***

- Few studies with a direct comparison of reconstruction in the same plane with and without ADM were included in the systematic review. Most studies compare prepectoral reconstruction with ADM to subpectoral reconstruction (with or without ADM).
- Limited data from small studies suggest that prepectoral reconstruction without ADM may be feasible in some patients and has similar complications with and without ADM (see [Table 4-12](#)).
- Dual-plane reconstruction without ADM appears more common than prepectoral reconstruction without ADM. Alternatives to use of ADM in dual-plane reconstruction exist, including an inferolateral incision instead of IMF incision to provide more support, using fascia of serratus anterior muscle, or using the mastectomy skin alone. Repair of the IMF area may be required.
- ADM use has been associated with increased risk of infection and seroma. Risks may vary with type and preparation of ADM; seroma rates are observed to be lower when ADM is perforated or meshed.
- Fenestration generally refers to the process of creating slits (as done in meshing) but sometimes refers to perforations and this term is therefore ambiguous. In several studies, adding perforations or meshing was performed by the surgeon immediately prior to placement. These treatments are now available commercially as well but at added cost.
- Bioabsorbable mesh has been used in several studies and may be beneficial, but information is insufficient to rank any compared with the commonly used human ADM or each other.

## **6. Autologous Fat Grafting (Lipofilling)**

### ***Recommendation 6***

- a) Fat grafting is recommended as a treatment for contour irregularities.
- b) Fat grafting is recommended as treatment for rippling following implant-based reconstruction.

- c) Fat grafting may be used to improve tissue quality of the mastectomy flap after radiotherapy (RT).
- d) Patients undergoing radiologic exams should indicate that they have undergone reconstruction including autologous fat transfer.
- e) Evidence on total fat grafting is more limited, and a recommendation cannot be made at this time.

***Qualifying Statements for Recommendation 6***

- Outcomes are highly dependent on method of fat harvesting and treatment, and on amount and location of injection. Excess pressure due to overfilling can cause fat necrosis and lower rates of fat survival.
- Palpable masses as a result of fat necrosis may occur in patients who have received fat transfer. These are generally benign on imaging and can be identified without biopsy in most cases.
- Enrichment/enhancement of stem cells is an area of active research but was not within the scope of this work.
- The optimal timing of fat grafting is unclear and may vary according to indication. The first session of fat grafting is usually at the time of expander-implant exchange or as a revisionary procedure several months after the final implant or autologous reconstruction, although there are sometimes reasons to use at the time of expander insertion or autologous flap placement. In patients with poor mastectomy skin flap quality, fat grafting prior to expander insertion (for delayed-immediate reconstruction) or expander-implant exchange (in case of radiation damage) may improve tissue quality and reduce complications. In patients requiring RT, fat grafting often occurs 2 to 6 months after the end of RT.

# Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

## Section 2: Guideline - Recommendations and Key Evidence

### **GUIDELINE OBJECTIVES**

The objective of this work is to provide guidance on identifying which patients with breast cancer who are undergoing mastectomy are candidates for reconstruction, use of nipple-sparing mastectomy (NSM), the best timing of reconstruction (immediate or delayed), whether radiotherapy (RT) should influence timing, the choice between prepectoral versus subpectoral implants, and use of acellular dermal matrix (ADM) and autologous fat grafting as part of the reconstruction process.

For this document, “reconstruction” refers to immediate or delayed reconstruction of the breast mound, not including aesthetic flat closure.

### **TARGET POPULATION**

Patients diagnosed with non-metastatic breast cancer who will undergo therapeutic mastectomy and are considering or decided on reconstructive surgery. For purposes of this document, reconstruction includes both immediate and delayed reconstruction with implants and/or autologous tissue but does not include aesthetic flat closure.

### **INTENDED USERS**

1. Surgeons (general surgeons, surgical oncologists, plastic surgeons), radiation oncologists, and other clinicians involved in conducting mastectomies or in post-mastectomy reconstruction and adjuvant treatment.
2. Members of the Breast Cancer Advisory Committee, Ontario Health (Cancer Care Ontario), and others involved in the review and update of the Breast Cancer Pathway Map.

### **RECOMMENDATIONS, KEY EVIDENCE, AND JUSTIFICATION**

#### **Recommendations on Type of Reconstruction (Implants or Various Autologous Flaps)**

The authors deemed that the evidence and recommendations in Version 1 of this guideline are still relevant for this question and that an update was not required. As 17-10 Version 1 will no longer be available upon posting of Version 2, the relevant portions of the 2016 Recommendations and Systematic Review are included in [Appendix 6](#). Comparison of types of reconstruction or factors influencing their selection are not within scope of the current work.

---

#### **Overall Recommendation for Patient Education and Preoperative Evaluation**

For women who have chosen or been recommended for therapeutic mastectomy:

- The discussion of immediate or delayed breast reconstruction should be initiated at the time that mastectomy is offered by the general surgeon, breast surgeon, or surgical oncologist.

- For women seeking immediate breast reconstruction, preoperative evaluation should include a plastic surgeon.
- For women seeking immediate breast reconstruction who will potentially require adjuvant chemotherapy or radiotherapy (RT), a medical oncologist and/or radiation oncologist should be included in preoperative evaluation, either through a formal consultation or by a multidisciplinary cancer conference.
- Decisions around the contralateral breast should be jointly made by the patient and medical team, considering the patient's family history and/or genetic profile if available and symmetry with the involved reconstructed breast, and include discussion of potential benefits and harms. Risk of new primary breast cancer may be a factor, and patients with risk factors for hereditary breast cancer should be referred for genetic assessment. The patient's preferences and values must be considered, and an informed discussion is recommended prior to mastectomy, along with a recommendation by the surgeon conducting the mastectomy (e.g., general surgeon, breast surgeon, or surgical oncologist) or reconstructive surgeon (or consensus of these) for or against contralateral prophylactic mastectomy.

### ***Qualifying Statements***

- Bilateral surgery is shown to increase complications risks.
- In absence of genetic risk factors, contralateral mastectomy may decrease rates of new cancer but does not improve survival or recurrence.
- Contralateral mastectomy with reconstruction may give better aesthetic results in some patients. When contralateral mastectomy is not indicated, balancing procedure to the contralateral breast can also produce aesthetic and symmetrical results.

### ***Justification***

- The recommendations are based on the expert opinion of the authors that women should be well informed about care options and that multidisciplinary preoperative evaluation is a quality indicator of multidisciplinary breast cancer care for women seeking reconstruction. Screening with magnetic resonance imaging (MRI) has been shown to detect synchronous contralateral breast cancer (32). The American Society of Breast Surgeons consensus statement (33) states that contralateral mastectomy should be discouraged in average-risk women with unilateral breast cancer. A Canadian consensus statement recommends contralateral prophylactic mastectomy only in patients with *BRCA1/2* gene mutations or previous mantle field radiation, and consideration in case of other genetic mutations or where breast symmetry may be a major issue (34). Ontario Health documents provide guidance for referral for genetic assessment and genetic testing (35, 36).

## **1. Effect of Patient and Oncologic Factors**

Note 1: While an individual factor may not be sufficient to rule out reconstruction, risks of complications for different factors may be additive and must be considered together (e.g., diabetes plus smoking plus obesity). A validated risk tool may be useful in evaluating overall risks. Further, some risk factors may alter the risk-benefit analysis for some types of reconstruction more than for other types. Factors that affect flap perfusion/circulation may preclude skin- or nipple-sparing mastectomy. The degree of comorbidity (e.g., grade of

obesity, controlled vs. uncontrolled diabetes, current vs. former smoking and amount smoked) need to also be considered.

**Note 2:** Published systematic reviews constitute the evidence base for Recommendations 1.2 through 1.6

The rationale for using higher level evidence was in part due to limited time and staffing resources, given the broad scope of this systematic review and is a usual trade-off. Furthermore, it is often the pragmatic choice to use higher level evidence synthesis publications for these kind of ‘factor’ questions, making use of work already done by others to avoid duplication. As no systematic review was found that covered age adequately, Recommendation 1.1 on age is based on a new systematic review of this topic (see Section 4).

### ***Recommendation 1.1: Age***

- Age on its own should not be used to determine whether to offer breast reconstruction to patients who are undergoing mastectomy as treatment for breast cancer. Competing risks of mortality and patient preferences should be part of the decision-making process; life expectancy and geriatric assessment may be considered.

### ***Qualifying Statements for Recommendation 1.1***

- Comorbidities including heart diseases and diabetes tend to increase with age and may affect suitability for operation or wound healing.
- While some older patients may place less importance on breast reconstruction, it should not be assumed for all, as individual preferences will vary.
- Some patients of any age may not want reconstruction and prefer mastectomy alone, and it should not be assumed that all younger patients will want reconstruction.

### ***Key Evidence for Recommendation 1.1***

- A single institution study by Kim et al. (37) (see [Table 4-2](#) in the Systematic Review) considered age as a continuous variable. Odds ratios (OR) per year of age increase for mastectomy skin flap/nipple necrosis was OR=1.02 (95% CI=1.01 to 1.03, p<0.001), infection OR=1.01 (95% CI=1.00 to 1.03, p=0.038), seroma OR=1.02 (95% CI=1.00 to 1.03, p=0.024), and hematoma OR=1.01 (95% CI=1.00 to 1.03, p=0.14). Using the BREAST-Q, Satisfaction with Breasts was lower in older patients, while Psychosocial Well-Being was higher, and there was no difference in Physical Well-Being-Chest, nor Sexual Well-Being.
- A study of pedicled flap reconstruction using the American College of Surgeons National Surgery Quality Improvement Program (ACS-NSQIP) database (38) also used age as a continuous variable. For complications within 30 days of surgery, they reported odds ratios (OR) for overall complications of 1.010 (95% CI=1.004 to 1.006, p=0.002), severe complications OR=1.043 (95% CI=1.019 to 1.068, p<0.001), and wound complications OR=1.009 (95% CI=1.000 to 1.018, p=0.053). They concluded the effect of age does not have strong predictive power and may not be clinically relevant on its own.
- The Mastectomy Reconstruction Outcomes Consortium Study (MROC) compared outcomes according to three age groups. For patients aged >60 versus <45 years old, they reported OR=1.46 (95% CI=0.99 to 2.15, p=0.059) for any complications and OR=1.43 (95% CI=0.93 to 2.18, p=0.101) for major complications. For patients aged 45-60 versus <45 years old, they reported OR=1.23 (95% CI=0.93 to 1.62, p=0.140) for any complications and OR=1.16 (95%

CI=0.85 to 1.57,  $p=0.349$ ) for major complications. There were higher BREAST-Q scores for Sexual Well-Being for both implants and autologous reconstruction in older women than for those <45 years old, and for Psychosocial Well-Being and Physical Well-Being with autologous reconstruction.

### ***Recommendation 1.2: Body Mass Index, Smoking, Diabetes, Hypertension***

- High body mass index (BMI), current and prior smoking status, diabetes, and hypertension are risk factors for complications and poorer outcomes but should not be used as absolute contraindications to reconstruction. It is recommended that uncontrolled diabetes be treated and that patients cease smoking at least several weeks prior to surgery and until incisions have healed.
- Reconstruction should be presented as an option, and patients informed that risks of specific complications such as skin or nipple necrosis and reconstructive failure are higher than in patients without risk factors.

### ***Qualifying Statements for Recommendation 1.2***

- Obesity is often defined as BMI  $>30 \text{ kg/m}^2$ , although particularly in Asian countries a lower cut-off ( $25 \text{ kg/m}^2$ ) is often used. Risks of complications increase with BMI above these thresholds on a continuum. Incisions and reconstruction techniques may need to be altered and include contralateral reduction if matching of the breasts is considered important to the patient. The amount of tissue removed, and repositioning of the nipple may result in ischemic complications and decreased sensation.

In patients with multiple risk factors or comorbidities, the potential effect of all combined must be considered. A validated risk assessment tool may be used.

### ***Key Evidence for Recommendation 1.2***

- Diabetes. Two moderate-quality systematic reviews on diabetes found increased complications: one (39) found higher rates of overall complications, surgical complications, implant loss/failure, infection, and skin necrosis, while the other (40) found higher rate of wound dehiscence.
- Smoking. A systematic review (41) found ever smoking was a risk factor for postoperative complications, donor site complications, infection, and fat necrosis. The review was rated as low quality due to non-reporting of risk of bias of individual studies but strengthened due to study size (26 studies and  $>20,000$  patients) and consistency of results between studies.
- BMI or Obesity. A moderate-quality systematic review (42) looked at the effect of obesity (BMI  $>30 \text{ kg/m}^2$ ) in 30 studies and found higher rates of surgical complications (relative risk [RR]=2.29, 95% confidence interval [CI]=2.19 to 2.39,  $p<0.00001$ ), as well as higher rates of fat necrosis, seroma, partial or total flap failure, wound dehiscence, wound infection, hernia, medical complications, and return to operating room. In a subset of four studies that reported surgical complications by obesity class, surgical complications increased with class of obesity: class I (30 to  $34.9 \text{ kg/m}^2$ ) RR=1.32; class II (35 to  $39.9 \text{ kg/m}^2$ ) RR=1.84; and class III ( $>40 \text{ kg/m}^2$ ) RR=1.66. Another moderate-quality systematic review (43) compared autologous versus implant reconstruction in patients with obesity and found the autologous reconstruction resulted in lower infection, hematoma, seroma, and reconstructive failure; no difference in skin necrosis or wound dehiscence; and increased rates of deep vein thrombosis and pulmonary embolism compared to implant-based reconstruction.
- Hypertension. A systematic review (44) on complications after breast reconstruction found that hypertension increased the risk of any complication, major/re-operative

complications, 90-day readmissions, and infection. The studies included for other questions in our systematic review suggest the effect of hypertension to be low and therefore often not statistically significant in the small studies. Most studies did not define this variable and may have used different cut-offs. The review (44) is rated low due to non-reporting of risk of bias of individual studies, but strengthened due to large number of studies and patients (33 studies with over 100,000 patients, of which 7 studies reported any/total complications by hypertension status).

### ***Recommendation 1.3: Breast Size***

- Pre-mastectomy breast size and desired reconstructed breast size may influence type of reconstruction, complication rates, and cosmetic/aesthetic results; however, these factors should not determine whether to perform reconstruction. Patients and surgeons should discuss risks and benefits of various procedures.

#### ***Key Evidence for Recommendation 1.3***

- Several of the included studies about NSM under Question 3 in the Systematic Review (Section 4) noted that greater breast size or mastectomy weight, initial expander fill volume in two-stage implants, and final implant size in direct-to-implant reconstruction were risk factors for necrosis. These factors may affect perfusion, with the latter two putting more tension on the skin. Modifications to reconstructive procedures using lower initial fill volumes and minimizing the use of direct-to-implant reconstruction have been used by some groups.

### ***Recommendation 1.4: Previous Surgery***

- Abdominal scars, previous abdominal surgery, and previous breast augmentation are not contraindications to breast reconstruction but may influence the surgical and reconstructive planning and type of reconstruction performed.

#### ***Key Evidence for Recommendation 1.4***

- A systematic review of moderate quality on the effect of prior abdominal surgery on abdominally based flap reconstruction (45) found a small increase in donor-site delayed wound healing.
- A systematic review on the effect of pre-existing abdominal scars on reconstruction using abdominal flaps (46) suggests there may be a small increase in flap complications or flap loss; however, differences were not statistically significant. There were higher donor-site complications than in control patients without abdominal scars. The authors suggest constraints of the scar may be overcome by technical modifications and use of computed tomography angiography to assess the presence of perforator vessels if there is uncertainty. This review was rated low quality due to the absence of risk of bias assessment and study protocol.
- Another low-quality systematic review (47) based on six studies found similar rates of complications in patients with and without prior breast augmentation (early complications odds ratio [OR]=1.57, 95% CI=0.94 to 2.64; overall complications OR=1.23, 95% CI=0.76 to 2.00).

### ***Recommendation 1.5. Neoadjuvant Chemotherapy***

- Patients who received neoadjuvant chemotherapy (NACT) should be assessed and considered for reconstruction in the same manner as for patients without NACT.

#### ***Key Evidence for Recommendation 1.5***

- A high-quality systematic review (48) compared reconstruction in patients with and without NACT, and did not find a statistically significant difference in overall complications (RR=0.91, 95% CI=0.74 to 1.11, p=0.34), flap loss (RR=0.94, 95% CI=0.46 to 1.94, p=0.87), hematoma (RR=0.99, p=0.97), or wound complications (RR=1.15, p=0.22). There was an increase in implant/expander loss (17.4% vs. 11.3%, RR=1.54, 95% CI=1.04 to 2.29, p=0.03). Most studies did not report adjusted risk estimates, and patients with NACT often had more advanced disease.

### ***Recommendation 1.6: Radiotherapy***

- Adjuvant radiotherapy (RT) should not be considered as a contraindication to either implant-based or autologous reconstruction. Patients should be informed that adjuvant RT is associated with increased reconstructive complications, and that these are greater in expander/implant reconstruction than with autologous reconstruction .

#### ***Qualifying Statements for Recommendation 1.6***

- The type of complications varies between implant and autologous reconstruction. Autologous reconstruction may be preferred in patients at higher risk of implant-related complications.
- Timing of RT with respect to reconstruction may influence the degree or profile of complications and is not addressed here. The timing of reconstruction and use of RT is partially addressed in Recommendation 2.

#### ***Key Evidence for Recommendation 1.6***

- Four systematic reviews on the effect of post-mastectomy radiotherapy (PMRT) on implant-based breast reconstruction (49-52) found increased rates of complications with PMRT (see [Table 4-1](#) in Section 4 of this document). Adjuvant RT also resulted in lower patient satisfaction and aesthetic results. Two reviews were judged to be of moderate quality and two of low quality.
- A high-quality systematic review of PMRT in conjunction with autologous flap reconstruction (53) found higher rates of fat necrosis, secondary surgery, and volume loss. Observer-reported cosmetic results were lower with PMRT. It was noted that there are higher risks with PMRT, but these are not necessarily clinically significant.

#### ***Justification for Recommendations 1.1 to 1.6***

- The authors consider that the potential psychological and quality of life (QoL) benefits of reconstruction may outweigh the risks of complications related to factors in Recommendations 1.1 to 1.6 for some patients. While rates of complications are moderately increased, they are generally manageable and often modifiable. Risks of complications and reconstructive outcomes vary depending on patient and disease characteristics and type of reconstruction, and decisions should be individualized during consultation between the patient and the medical team. Considering implant-based



reconstruction in the immediate setting could be particularly beneficial for patients with limited options for autologous reconstruction due to slim body habitus. Patients valued being part of the decision-making process. Consideration of reconstruction, including a discussion of risks and benefits, may ensure equal access for patients with manageable comorbidities or conditions.

- The recommendation on age is consistent with The European Society of Breast Cancer Specialists/International Society of Geriatric Oncology guideline (54) for older patients (age  $\geq 70$  years) and the published evidence that indicates no significant differences in most outcomes by age. Breast reconstruction may improve QoL for patients of any age. Older patients have a low rate of reconstruction compared with younger patients. While this is partially related to comorbidities or patient choice, it is also due to lack of access including not being presented with the option (55). Considering reconstruction for patients of all ages would increase equity.

## 2. Immediate versus Delayed Reconstruction

### *Recommendation 2*

- For patients desiring breast reconstruction, both immediate and delayed reconstruction may be considered.
- When delayed reconstruction occurs after radiotherapy (RT), reconstruction should occur at least 6 months after completion of RT, or longer if the irradiated site is still acutely tight, inflamed, and prone to complications.

### *Qualifying Statements for Recommendation 2*

- Preferred timing of reconstruction will depend on factors such as patient preferences, type of mastectomy, skin perfusion, comorbidities, pre-mastectomy breast size, and desired reconstructive breast size.
- Immediate reconstruction may provide greater psychological or QoL benefits for some patients.
- Access to and resources for delayed breast reconstruction can be very lengthy in parts of Ontario and immediate reconstruction would avoid being on a lengthy waitlist.

### *Key Evidence for Recommendation 2*

#### *Without RT*

- The Mastectomy Reconstruction Outcomes Consortium (MROC) study (56) found that patients with delayed reconstruction scored significantly lower on most QoL scales prior to reconstruction. Two years postoperatively there were no significant differences in adjusted patient-reported outcomes (PROs) between immediate and delayed groups.
- Shamas et al. (57) used claims codes to study immediate, delayed, and staged (delayed-immediate with spacer/expander at time of mastectomy) free-flap reconstruction and associated complications within 90 days of either operation. After adjustment, relative risk of at least one complication was lower for immediate versus delayed (RR=0.78, 95% CI=0.68 to 0.88,  $p<0.001$ ), immediate versus staged (RR=0.60, 95% CI=0.53 to 0.67,  $p<0.001$ ), and delayed versus staged (RR=0.77, 95% CI=0.67 to 0.88,  $p<0.001$ ). Part of the increased

complications in delayed and staged groups appears to be due to additive complications as a result of two operations (mastectomy and later reconstruction) compared with one operation in the immediate setting.

- Huang et al. (58) found similar complications in immediate and delayed groups with deep inferior epigastric perforator (DIEP) flap reconstruction, except for higher breast skin necrosis in the immediate group. Authors suggest lower rates in the delayed group may be due to additional time to revascularize and heal after mastectomy. Prantl et al. (59) studied DIEP flap reconstruction and found similar complication rates, including flap loss, between immediate and delayed reconstruction.

#### *With RT - Implants*

- Ulrikh et al. (60) found similar rates of complications for immediate two-stage implants with PMRT to the expander and for PMRT then delayed implants.

#### *With RT - Autologous*

- A report of the MROC study compared mastectomy and immediate autologous reconstruction followed by PMRT versus mastectomy then PMRT then delayed reconstruction (61). The difference between immediate and delayed groups for any breast complication was not significant (OR=0.64,  $p=0.442$  at 1 year; OR=1.14,  $p=0.848$  at 2 years). Prior to reconstruction (before mastectomy in immediate group but after mastectomy for delayed group), the immediate group had better scores on the BREAST-Q questionnaire for Satisfaction with Breasts (59.5 vs. 36.3,  $p<0.001$ ), Psychosocial Well-Being (66.1 vs. 50.0,  $p<0.001$ ), and Sexual Well-Being (52.1 vs. 29.8,  $p<0.001$ ) and differences are likely due to presence/absence of breasts. After reconstruction, there were no significant differences in PROs at 1 year.
- Hassan et al. (62) compared staged (skin-sparing; immediate expander/spacer then reconstruction) to delayed microvascular (autologous) reconstruction. PMRT, when used, was to the expander in the staged group and prior to reconstruction in the delayed group. Complications were generally similar except for seroma (higher in delayed group without PMRT) and infection (higher in delayed group with PMRT). Expander loss, which by definition can only occur in the staged group, was 10.6%; the implications of this on treatment were not reported. The staged group had fewer flap-related complications but higher overall complications when expander loss was factored in (34.2% vs. 25.5%). The overall time from mastectomy to reconstruction was longer in the delayed group.
- A review by Koesters and Chang (63) reports on timing of flap reconstruction (immediate or delayed) in patients with PMRT. They noted heterogeneity in outcomes between studies and that RT regimes vary over time and between institutions. Using modern RT, outcomes may be more similar and complications lower than suggested by previous studies and reviews. Immediate reconstruction has benefits in avoiding psychosocial effects of an absent breast and may be preferred, although delayed reconstruction is also reasonable.

#### *Delay between PMRT and Reconstruction*

- Studies included for other questions offer guidance as to current practice. They were consistent in waiting at least 3 months to avoid the period of acute radiation injury for both delayed autologous reconstruction (58, 64, 65) and for expander-implant exchange after PMRT to the expander (66-69). While 3 months was considered an absolute minimum, and

3 to 6 months sometimes used (64, 66), a minimum of 6 months was more common (58, 68-70).

- While a systematic review was not conducted on this sub-question, three comparative studies are informative. One study (65) included for other topics reported vascular complication rates (intraoperative arterial and venous thrombosis, intraoperative technical difficulties during anastomosis, delayed vascular complications) when autologous reconstruction was conducted at various intervals after PMRT. Vascular complications were 66% with an interval <3 months after completion of PMRT, 20% with a 3 to 12 month interval, 14% with a 12 to 120 month interval, and 19% with >120 months. The probability of a difference between the <3 months and 12 to 120 months groups was  $p=0.06$ . Two other studies by the same clinical group (71, 72) reported reconstructive failure according to the interval between PMRT to the expander and expander-implant exchange. These prompted an increase in this interval from 3 months to 6 months as their general protocol, including in two of the studies (68, 69) reported for other questions in this review.
- A review by Koesters and Chang (63) indicates that many surgeons use clinical assessment of skin quality and laxity, avoiding a site that is still acutely tight, inflamed, and predisposed to complications, instead of a fixed delay between RT and reconstruction.

### ***Justification for Recommendation 2***

- The recommendation is based on better short- to medium-term QoL and psychological outcomes with immediate construction, unsuitability of immediate reconstruction for some patients, and a small increase in risk of total complications with number of operations. The benefits of reconstruction are considered to be well-established and therefore were outside the scope of the systematic review. It is the consensus of the authors, and supported by the MROC study, that worse psychological status and QoL may occur in the period between mastectomy and reconstruction, and this is reduced in immediate reconstruction. The benefits of immediate reconstruction need to be balanced against the fact there are sometimes clinical reasons such as poor perfusion, contraindications to longer operation combining mastectomy and reconstruction in immediate reconstruction, or patient uncertainty regarding reconstruction that may make delayed reconstruction preferable. In the systematic review (see Section 4), differences in complications between immediate and delayed reconstruction were small and inconsistent between studies, suggesting that patient and surgical factors may have a greater effect on complications than timing. Data on comparing complications have a high risk of bias and we only conclude that risks are similar and usually manageable. The decision of timing should be a joint decision between patients and physicians, taking into account individual situations, values, and risk profiles.
- Minimizing delay for reconstruction is important for patients. While optimal timing of reconstruction after PMRT to avoid complications has not been established, the authors support 6 months as was frequently used in the included studies. This may be modified by clinical assessment of skin quality. Fat grafting (see Recommendation 6) may be of benefit.

## **3. Nipple Sparing Mastectomy**

### ***Recommendation 3.1: Nipple-Sparing versus Skin-Sparing Mastectomy***

- a) In patients who are candidates for skin-sparing mastectomy (SSM) and without clinical, radiological, and pathological indications of nipple-areolar complex (NAC) involvement,

nipple-sparing mastectomy (NSM) is recommended provided it is technically feasible and acceptable aesthetic results can be achieved.

- b) Patients should be informed that in the case of tumour involvement of subareolar tissues/margins based on pathologic analysis, or of NAC necrosis not responding to treatment, the nipple or NAC may need to be excised.
- c) The patient should be involved in the decision between NSM and SSM. The patient should be informed, along with reasons, if NSM is considered inappropriate and not being offered.

### ***Qualifying Statements for Recommendation 3.1***

- Comorbidities, larger breast size, and ptosis are risk factors for poor perfusion and subsequent skin flap and/or NAC necrosis. Reduction in breast size and repositioning of the nipple may require different incision locations. Blood supply to the skin flap/NAC may be improved with delayed reconstruction, staged mastectomy, or surgical delay when the oncologic treatment timeline allows.
- Discussion of tattooing or nipple reconstruction with realistic restorative areola tattooing needs to be a discussion for psychological and physical well-being in patients for which NSM is not suitable.

### ***Key Evidence for Recommendation 3.1***

- Five studies (73-78) summarized in [Table 4-4](#) suggest that both NSM and SSM have similar oncologic results when pathologic analysis of retroareolar/excised tissue does not show tumour involvement. Cho et al. (76) used both propensity-score matching and Kaplan-Meier and Cox proportional hazard regression and found 5-year disease-free survival (DFS) of 89.1% versus 90.7% (hazard ratio [HR]=1.15, 95% CI=0.65 to 2.03, p=0.64), 5-year overall survival (OS) of 97.3% versus 97.4% (HR=1.05, 95% CI=0.34 to 3.20, p=0.93), and local recurrence-free survival (LRFS) of 95.8% versus 96.8% (HR=1.22, p=0.68). Kim et al. (77) adjusted for patient and tumour characteristics and found similar DFS (HR=1.004, 95% CI=0.52 to 1.93, p=0.991) and OS (HR=0.866, 95% CI=0.26 to 2.85, p=0.813).
- Racz et al. (79) found better BREAST-Q questionnaire scores on Sexual Well-Being for the NSM group (mean 64.5 vs. 58.0, p=0.002, multivariable p=0.033).
- Delayed reconstruction, staged mastectomy, or surgical delay have been used to improve blood supply to both the skin flap and the NAC (80-85).

### ***Justification for Recommendation 3.1***

- The authors judge that there is moderate certainty of evidence that survival is similar after NSM compared with SSM. It is well-established that NSM has positive psychological and QoL benefits (evidence not reviewed) and is preferred by patients. We therefore recommend NSM instead of SSM in cases without NAC involvement provided this is surgically feasible and suitable aesthetic results can be obtained.

---

### ***Recommendation 3.2: Patient Selection and Assessment of Nipple-Areolar Complex (NAC) Involvement***

- a) Nipple-sparing mastectomy (NSM) can be considered in all patients with non-metastatic, non-inflammatory breast cancer without clinical signs of nipple involvement (bloody or pathologic nipple discharge, nipple retraction, Paget disease) and no nipple involvement by imaging and where it is surgically feasible and suitable aesthetic results can be obtained.
- b) An oriented subareolar sample must be obtained for pathologic evaluation. A sample of ducts from the nipple or complete nipple coring (total skin-sparing mastectomy [TSSM]) may be considered.
- c) In cases where specimens taken from the area immediately under or within the nipple are found involved by tumour, but the areola is not involved, nipple excision alone (i.e., areola-sparing mastectomy [ASM]) may be conducted provided clear margins are obtainable.
- d) Involvement of areolar skin not extending to the nipple may be treated as for other skin cancers and excised with clear margins.
- e) We recommend against intraoperative/frozen section pathologic analysis. Treatment decisions should be based on definitive/final pathology results.
- f) The patient should be informed that NAC or nipple excision is the standard treatment when the subareolar area is found to be involved with tumour on final pathologic analysis; the final decision should be made by the patient and surgical team. Planned RT may be a factor in the decision.
- g) Prior to a planned NSM, patients should be informed and consent to NAC or nipple removal if intraoperative surgical findings are indicative of cancer that cannot be resected without NAC or nipple excision.

### ***Qualifying Statements for Recommendation 3.2***

- SSM, ASM, and NSM aim to balance eliminating negative oncologic outcomes with maintaining a viable skin envelope. Differences in operative procedures and criteria may contribute to variations in oncomes between studies.
- While intraoperative frozen section analysis was used in several of the published studies, it is less accurate and may result in false positives (and unnecessary NAC excision) or false negative (with involved NAC retained). When subareolar tissue is found involved by tumour on intraoperative/frozen section analysis, re-excision to obtain clear margins may be conducted as an alternative to immediate NAC excision.
- Studies did not use a uniform definition of pathologies that would require NAC excision. Atypia and lobular carcinoma in situ (LCIS) in subareolar samples were not criteria to conduct NAC excision in several studies; frozen section analysis is not a reliable method of assessing epithelial cell atypia and is often misidentified in frozen section analysis.

### ***Key Evidence for Recommendation 3.2***

- Studies in the systematic review (see Section 4 and [Table 4-5](#)) found that smaller tumour-to-nipple distance (TND; <5 cm, <2 cm or <1 cm) measured by MRI is a risk factor for NAC involvement but did not predict worse oncologic outcomes (86-91). TND may influence surgical strategies but should not be used to rule out NSM or ASM.
- [Table 4-6](#) and [Table 4-7](#) summarize recurrence, survival, and necrosis rates for the studies in [Table 4-5](#). Rates for most studies are similar to those expected for other types of breast

cancer treatment. Worse outcomes are often due to selection of patients with more advanced cancers or different operative techniques (see Question 3c).

- Nipple excision or ASM was used in several of the included studies (92-98). Shanno et al. (95) found no significant difference in periareolar recurrence for patients with nipple excision compared with those with NAC excision (2/64 or 3.1% vs. 0/34). Simmons et al. (99) found that of 217 mastectomy patients, 23 had nipple involvement and 2 had areola involvement (both stage III central tumours), suggesting the areola can often be preserved even with nipple involvement. They indicate that the areola does not contain breast parenchymal ducts. Pacella et al. (100) indicate that in NSM it is the ductal tissue inside and immediately below the nipple that are the oncologic concern, while the areola consists of pigmented skin with skin adnexal glands that do not connect by ducts to breast tissue, and therefore ASM may be used and produces better aesthetic outcome than SSM.
- Several studies indicate that frozen section/intraoperative pathology is less accurate and is not used by their group (89, 94, 95, 97, 98, 101-105). Spoor et al. (106) found sensitivity and specificity of frozen section analysis were 75.2% and 98.5%, respectively, compared with definitive histopathology, while Zhu et al. (96) reported sensitivity of 81.8% and specificity of 95.3%.
- The systematic review (see Section 4) found that local recurrence (LR) in the NAC in 41 studies varied from 0 to 6%, with median of 0.5% and average of 1.2% (see [Tables 4-6](#) and [4-7](#)).
  - Of 17 studies with no NAC recurrence, 8 were from USA, 6 from Italy, and 1 each from Brazil, Germany, and Canada. The nine highest values ( $\geq 1.9\%$ ) were from Korea, Japan, and China. It is not known whether these geographic differences are due to differences in surgical technique or patient populations.
  - In studies with pathologic analysis of only retroareolar samples, median and average LR recurrence in the NAC were 1.4% and 1.6%. In studies that sampled ducts or cored the nipple (sometimes referred to as TSSM), the median and average LR recurrence in the NAC were 0 and 0.5%. There were three studies with recurrence conducted in east Asia and 13 studies without NAC recurrence.
- The median rate of total nipple necrosis in 44 studies summarized in Section 4 was 1.9% (mean 2.8%). The review found that TSSM did not increase rates of total nipple necrosis.

### ***Justification for Recommendation 3.2***

- Sparing the NAC (or part of the NAC) whenever oncologically safe is important to patients. Recommendations for joint decision-making are the consensus of the authors based on the need for equity and mutual respect. The literature review indicates that absence of clinical/radiological nipple involvement is an appropriate selection criterion, provided that excision of the NAC, nipple, or (partial) areola takes place if clear margins cannot be obtained. There is lack of consensus as to the extent of excision during mastectomy and number/location of samples for pathologic assessment before resorting to NAC/nipple/areolar excision. The authors consider retroareolar sampling to be appropriate to balance oncologic safety and nipple preservation. Sampling or removal of ducts within the nipple (nipple coring or TSSM) is also reasonable as this may slightly reduce NAC recurrence, but with increased risk of sensation loss and of necrosis due to reduced perfusion of the nipple. Our review did not indicate increased risk of necrosis with TSSM, although the TSSM study authors implemented procedures to reduce necrosis such as avoiding single-stage reconstruction (101, 107); they did acknowledge potential for decreased sensation and that this may be more technically challenging surgery. Surgical

factors (see following recommendations) are also important. Some consider removing ducts in the nipple unnecessary as terminal duct lobular units are more likely at the nipple base and rare in the tip or papilla (108, 109) and therefore increase risk of adverse events without additional benefit.

### **Recommendations 3.3 to 3.7: Surgical Factors in Nipple-Sparing Mastectomy**

#### **Evidence Note**

*Authors of studies included in the systematic review indicated that incision location, nerve preservation, skin tension, thermal damage in dissection, and operative planning are important surgical factors for outcomes of nipple viability/necrosis and sensation after NSM.*

*Several studies reported comparative data on incision location (see Recommendation 3.3) and a few on sensation (see Recommendation 3.4). For the other factors, the study authors presented these as generally accepted or based on their accumulated experience. These were not the topic of comparison/investigation. Recommendations 3.5 to 3.7 present these factors as important to be considered but do not provide specific recommendations or optimal approaches.*

#### **Recommendation 3.3: Incision Location**

- a) Periareolar incisions (including hemi-periareolar) should be avoided unless there are oncologic or other specific reasons for their use. Periareolar incisions, if used, should encompass no more than one-third of the areolar circumference.
- b) To reduce nipple necrosis, inferolateral (lateral inframammary fold) or inframammary fold (IMF; central inframammary fold) incisions are preferred.
- c) In the case of previous breast surgery with scars, it may be preferable to reoperate using the same incision. This should be determined on a case-by-case basis.

#### **Qualifying Statements for Recommendation 3.3**

- Re-excision using the same incision location as for previous surgery is sometimes used to avoid multiple sets of scars that may have negative aesthetic impact. As the previous incision already disrupted blood supply in that area, reusing the same scars may also cause less additional complications.
- Inferolateral and IMF have least necrosis associated with them. Inferior radial (vertical inferior) or lateral radial (horizontal radial) incisions have been reported as resulting in intermediate levels of nipple necrosis.
- As indicated in Question 5 on acellular dermal matrix (ADM) use, inferolateral incisions may be preferred for subpectoral implants without ADM. Some have suggested that incisions in the IMF may not allow for enough support for implants unless ADM is used. There is not enough evidence in this regard to make a recommendation, but type and location of implant may influence the incision location.

#### **Key Evidence for Recommendation 3.3**

- Moo et al. (110) reported necrosis by incision type, and calculated adjusted ORs (aOR) relative to lateral radial as reference: 12.1% lateral IMF (OR=0.41; aOR=0.35, 95% CI=0.17

to 0.7,  $p=0.003$ ); 19.0% central IMF (OR=0.64; aOR=0.54, 95% CI=0.19 to 1.39,  $p=0.200$ ); 29.8% lateral radial (OR=1.0 as reference); 37.3% inferior periareolar/lateral extension (OR=1.25; aOR=1.24, 95% CI=0.52 to 2.93,  $p=0.600$ ); 41.2% superior periareolar/lateral extension (OR=1.38; aOR=1.59, 95% CI=0.65 to 3.92,  $p=0.300$ ).

- Lin et al. (111) reported relative rates of nipple necrosis by incision type compared to inferolateral inframammary fold (reference, 1.0): vertical inferior OR=2.124 (95% CI=0.453 to 9.944,  $p=0.339$ ); extension of prior incision OR=2.98 (95% CI=0.657 to 13.511,  $p=0.157$ ); horizontal radial OR=3.823 (95% CI=1.081 to 13.515,  $p=0.037$ ); and periareolar OR=14.235 (95% CI=6.248 to 32.435,  $p<0.001$ ).
- Park et al. (112) reported complete nipple necrosis of 3.4% with IMF incision, 11.3% with radial incision, and 21.3% with periareolar incision (multivariate vs. IMF; OR=3.628, 95% CI=1.596 to 8.250,  $p=0.002$ ).
- Lai et al. (113) found that periareolar incisions had higher risk of NAC ischemia or necrosis compared with upper outer radial incisions (OR=5.33, 95% CI=1.81 to 15.67,  $p<0.01$ ).
- The group at Massachusetts General Hospital (Boston) prefers use of an inferolateral IMF incision (111, 114, 115) as there are less complications including nipple and skin necrosis.
- Surgeons at University of California use primarily IMF incision or superior periareolar incision encompassing less than one-third of the areolar circumference (101, 104, 116, 117), with others being much less frequently used. For patients who are candidates for either type of incision, the inframammary location is preferred due to much lower rate of NAC complications (7.4% vs. 25%, OR=4.2, 95% CI=1.5 to 11.3,  $p=0.003$ ) (104). Wong et al. at the University of Kentucky also use inferolateral incisions for TSSM (118).
- A group of plastic surgeons from various institutions in the USA published a resource in 2024 to guide breast and plastic surgeons in mastectomy techniques that preserve nerves, including applied anatomy of breast innervation and steps to incorporate nerve-sparing mastectomy and breast neurotization (119). For most patients they prefer an inferolateral IMF incision, although a Wise pattern reduction incision may be beneficial in patients with grade 3 ptosis or macromastia. The inferolateral incision allows better visualization and exposure of the lateral intercostal nerves and good cosmetic results, while an inferior vertical incision may be useful especially for surgeons with less experience in neurotization. Further details are in the guide.

### ***Justification for Recommendation 3.3***

- Evidence is strong that the location of incisions influences the risk of nipple necrosis.

### ***Recommendation 3.4: Nerve Preservation***

- Selection of incision sites should take into account both preservation of blood supply and minimizing nerve damage.

### ***Qualifying Statements for Recommendation 3.4***

- Priority should be to minimize nerve damage and optimize conditions for nerve regeneration. Partial sensation, while much lower than prior to mastectomy, may be maintained in some patients. Reconnecting nerves is sometimes attempted in autologous flap reconstruction.



**Key Evidence for Recommendations 3.4**

- Studies cited earlier in Recommendation 3.3 regarding incision site selection mostly focused on minimizing necrosis but may be applicable to sensation as well.
- Black et al. (120) (see [Table 4-5](#)) studied 192 patients with NSM. They found better sensory recovery in 106 patients with autologous reconstruction with neurotized DIEP flaps than in 86 patients with immediate expander-implant reconstruction. Sensory recovery was experienced in both groups, although the autologous cohort had greater improvement in five of nine regions at 1 year and seven of nine regions at 4 years postoperatively.
- Other studies meeting our inclusion criteria were limited; they noted partial sensation after reconstruction. Collaboration of breast and plastic surgeons prior to surgery is beneficial (121, 122).
- A group of plastic surgeons from various institutions in the USA published a resource in 2024 to guide breast and plastic surgeons in mastectomy techniques that preserve nerves, including applied anatomy of breast innervation and steps to incorporate nerve-sparing mastectomy and breast neurotization (including when allografts are not available) (119). For most patients they prefer an inferolateral IMF incision, although a Wise pattern reduction incision may be beneficial in patients with grade 3 ptosis or macromastia. The inferolateral incision allows better visualization and exposure of the lateral intercostal nerves and good cosmetic results, while an inferior vertical incision may be useful especially for surgeons with less experience in neurotization. Further details are in the guide.

**Justification for Recommendation 3.4**

- Historically, the reconstruction goal was to only restore the appearance of the breast; however, lack of sensation has resulted in injuries such as severe burns, and psychological/QoL issues such as not being able to feel a hug, not being able to feel their own or a partner's touch, feeling like the breast is not part of them, and lower sexual well-being. While oncologic safety is always the first priority, recent studies suggest adaptations in the mastectomy technique to retain or allow regeneration of partial sensation in some patients is possible and may improve QoL. From a patient perspective this is an important consideration. Planning of incisions including identifying nerves to minimizing damage are first steps. Connecting nerves in autologous flaps to those in the mastectomy site may be possible in some patients but is not yet standard of care. While results appear promising with nerve allografts, studies are limited, expertise may not be available in Ontario, and nerve allografts are not currently funded. The authors judge evidence insufficient to make a recommendation regarding nerve allografts. Patients must be advised that even with most advanced techniques there are no guarantees of success, sensation will be different and less than before mastectomy, and it will require several months and up to 2 years before maximum recovery.

**Recommendation 3.5: Skin Tension**

- When nipple-sparing mastectomy (NSM) is followed by immediate expanders or implants, excess tension should be avoided as it may interfere with blood flow and lead to necrosis.

**Key Evidence for Recommendation 3.5**

- While there was no direct comparison, several authors commented on the effect of skin tension on necrosis. Viability of the NAC depends on preservation of the blood supply to the nipple, ducts, and surrounding skin (123). Immediate fixed-volume implants may put more tension on the skin flaps than tissue expander that are gradually inflated. Ahn et al.

(124) indicated that higher skin tension may interfere with blood flow and be the cause of higher rates of necrosis with direct-to-implant and autologous reconstruction. When using tissue expanders, they prefilled them to approximately one-third of final volume to minimize tension. Holland et al. (104) also ensured tissue expanders were filled to prevent significant wrinkling but not to an extent that would place tension on the closure or pressure on overlying skin. Park et al. (112) noted that breast volume or weight is a risk factor for necrosis and that this may be due to increased skin tension and longer distance from the blood source to the nipple, which both decrease nipple blood supply. Pek et al. (125) used a skin paddle incorporated into the closure if excessive tension was anticipated. Ng et al. (126) note that Asian women have relatively smaller breast envelopes and therefore increased potential for skin tension leading to nipple necrosis than in Western counterparts. Warren Peled et al. also advocate using only minimal expansion of thin mastectomy skin flaps, with two-stage expander-implants being preferred to minimize ischemic complications and necrosis (101).

### ***Justification for Recommendation 3.5***

- Studies comparing different degrees of skin tension in NSM were not found in the systematic review. It is the consensus of the authors, and consistent with procedures and comments in several of the included studies, that skin tension should be minimized by limiting size of implants or initial inflation of expanders to maintain NAC and skin viability and prevent necrosis.

### ***Recommendation 3.6: Thermal Damage in Dissection***

- Care should be taken to minimize thermal damage to the skin, blood vessels and nerves.

### ***Key Evidence for Recommendation 3.6***

- Many studies in our systematic review did not specify dissection methods and none made a direct comparison. The issue of avoiding thermal damage was mentioned in six of the included publications, as well as other reviews. Outcomes may depend on the surgical skills and techniques.
- Sharp dissection has been recommended to avoid thermal injury from electrocautery that may damage nerves (121, 122) and damage the skin envelope (91) and vessels in the 1 to 3 mm layer of dermal tissue and result in necrosis (127). Three studies in [Table 4-5](#) in Section 4 indicated electrocautery was used only for bleeding control, or at low setting to minimize thermal injury.
- Ng et al. (25) found that a switch from electrocautery to sharp dissection with tumescence resulted in a decrease in full-thickness necrosis from 12.8% to 1.3% and partial-thickness necrosis from 33.3% to 13.0% and reduction in operating time from 202.9 to 183.5 minutes. This was limited by the small number of patients (66 patients and 116 breasts).
- Tumescence is sometimes used together with sharp dissection to establish a bloodless plane for dissection (128). Contradictory results have been found in various studies. Tumescence is reported to interfere with indocyanine green (ICG) angiography (129) and some other assessments of perfusion.

***Justification for Recommendation 3.6***

- Studies comparing different methods of dissection in NSM were not found in the systematic review, and we are unable to recommend an optimal procedure. It is the consensus of the authors, and consistent with procedures in several of the included studies, that thermal damage should be minimized.

***Recommendation 3.7: Operative planning***

- Operative planning should be conducted jointly by the surgeon conducting the mastectomy and the plastic surgeon and include assessment of blood vessel location and skin perfusion. Perfusion of flaps should be monitored after operation.

***Key Evidence for Recommendation 3.7***

- Several techniques may be used to assess perfusion, including (but not limited to) clinical assessment, MRI, and ICG angiography (e.g., the SPY system). The latter allows visualization of blood flow in the tissue of interest and reduced rates of flap loss (130). It was used in several studies for monitoring of skin flaps and autologous flaps but was not the subject of investigation (131-139). Some studies indicated it was used early but no longer as they became more proficient at clinical assessment (140). Karin et al. (141) discuss the use of MRI blood flow information to preserve the NAC blood supply.

***Justification for Recommendation 3.7***

- The recommendation is based on consensus of the authors and informed by studies in the systematic review. While studies comparing different methods of assessment in NSM were not found, studies stressed planning and assessment are important to reduce complications including skin and nipple necrosis.

**4. Implant Plane/Location*****Background***

Early attempts at prepectoral breast reconstruction suffered from unacceptable rates of flap necrosis and capsular contracture (27), as well as lack of support and implant extrusion. Subpectoral implants were the standard of care for many years, but many patients experienced animation deformity, pain, restricted motion, as well as longer and more complex operations (28-30). The development and use of acellular dermal matrix (ADM), fat grafting, and tissue perfusion assessment technology to assess flap viability have reduced complications and led to more widespread use of prepectoral (and to lesser extent dual-plane) reconstruction (27, 31). In the studies included in the systematic review, ADM was usually used with prepectoral implants to provide support of the lower pole and/or to provide an additional layer between the skin envelope and the implant. In partial subpectoral (dual-plane) placement, ADM or other mesh was generally used to cover and support the lower half (lateral pole) of the expander or implant (the portion not under the pectoralis major muscle). Use of ADM is covered in Recommendation 5 and fat grafting in Recommendation 6.

**Recommendation 4**

- a) There is a role for both prepectoral and subpectoral implants; risks and benefits will vary, and decisions should be made during consultation between the patient and surgeons.
- b) In patients who are suitable candidates for implant reconstruction and have adequate mastectomy flap thickness and vascularity, prepectoral implants should be considered as they have some advantages over dual-plane or other subpectoral reconstructions.
- c) Patients should be informed of the possibility that subpectoral and submuscular implants may result in long-term animation deformity and related pain and sometimes implant malposition.

**Qualifying Statements for Recommendation 4**

- In patients with poor flap quality and vascularization, immediate prepectoral reconstruction was not generally offered; alternatives include subpectoral reconstruction, surgical delay prior to prepectoral reconstruction, or autologous flaps.
- Type and location of implants or autologous tissue should be documented in patient records and available to clinicians conducting follow-up assessments and imaging.

**Key Evidence for Recommendation 4**

- Studies in [Table 4-8](#), found that surgical complications are similar between prepectoral and dual-plane or subpectoral reconstruction.
- Animation deformity and associated pain is a feature of submuscular/subpectoral reconstruction and does not occur with prepectoral reconstruction. Conversion to prepectoral placement in patients with previous subpectoral or dual-plane implants suffering from animation deformity or other implant-related issues was reported in five publications (30, 142-145) summarized in [Table 4-9](#). ADM was used in four studies. After revision surgery, all presenting complaints resolved; one study also reported improved shoulder motion and overall breast aesthetics, and one noted improvement in all measures on the BREAST-Q. Minor surgical complications were noted in three studies. Two studies (not in the included studies) found animation deformity in 75% to 100% of patients with subpectoral reconstruction (146, 147). In the study by Becker et al. of 25 patients with subpectoral implants, 80% were bothered and 45% bothered to a significant degree, 48% felt it interfered with daily life, and 28% were having surgical revision. In the study by Nigro et al. of 84 patients with subpectoral dual-plane reconstruction with ADM, 26% considered animation deformity severe and 50% would have preferred a technique to eliminate it.
- Surgical complications may depend more on surgical technique than plane of implant. Avila et al. (140) noted that evolution of technique to preserve subdermal vascular supply, use of gentle retraction, and careful dissection in the supra-areolar region has improved results. As noted in Question 3, the size of expander/implant and rate of expansion may influence rates of complications. Subpectoral placement was often used if patients were judged not suitable for prepectoral implants, and therefore it is difficult to assign outcomes specifically to location of implants.

**Justification for Recommendation 4**

- It is the consensus of the authors that there is a role for both prepectoral and subpectoral implants. There is strong and consistent evidence that animation deformity and associated pain and other long-term issues may occur with submuscular implants and partial

submuscular (dual-plane) implants, and that this may be resolved by replacing implants with prepectoral implants. Short-term post-surgical pain is also lower with prepectoral implants. Surgical complications depend more on patient and surgical factors; evidence comparing these by implant plane/location is weak and insufficient to allow a recommendation as to preferred plane. As subpectoral implants were often used when patients were judged to be poor candidates for prepectoral reconstruction, no comparative data are available for this subset of patients. Modification to technique, such as indicated in Recommendation 3.3 to 3.7 and use of ADM (see Recommendation 5) may allow prepectoral reconstruction in patients who would traditionally not be considered candidates.

---

## **5. Use of Acellular Dermal Matrix (ADM) or Synthetic Absorbable Matrix**

### ***Background***

ADM is usually used with prepectoral implants to provide support of the lower pole and/or to provide an additional layer between the skin envelope and the implant. The expander or implant could be wrapped entirely with ADM (most common), the pocket after SSM/NSM lined entirely with ADM, or ADM used only on the anterior surface and posterior lower pole. The use of ADM has led to being able to perform prepectoral reconstruction safely. In partial subpectoral (dual-plane) placement, ADM or other mesh was generally used to cover and support the lower half (lateral pole) of the expander or implant (the portion not under the pectoralis major muscle). ADM was sutured to the lower border of the pectoralis muscle and in the area of the IMF and often referred to as a sling providing support to the lower pole of the implant.

### ***Recommendation 5***

- a) Mastectomy flap perfusion should be assessed prior to reconstruction. ADM should not be used in case of poor mastectomy flap perfusion/ischemia that would otherwise be considered unsuitable for prepectoral reconstruction.
- b) Care should be taken in selection and handling of acellular dermal matrix (ADM) to minimize risks of infection and seroma.
- c) There is insufficient information to recommend a specific human ADM. Sterility level may be a factor in selection of a product.
- d) Undue tension on the mastectomy flaps should be avoided.
- e) Absorbable synthetic mesh may be an alternative to human ADM; however, comparative information is very limited, and no recommendation can be made.

### ***Qualifying Statements for Recommendation 5***

- Few studies with a direct comparison of reconstruction in the same plane with and without ADM were included in the systematic review. Most studies compare prepectoral reconstruction with ADM to subpectoral reconstruction (with or without ADM).
- Limited data from small studies suggest that prepectoral reconstruction without ADM may be feasible in some patients and has similar complications with and without ADM (see [Table 4-12](#)).
- Dual-plane reconstruction without ADM appears more common than prepectoral reconstruction without ADM. Alternatives to use of ADM in dual-plane reconstruction exist, including an inferolateral incision instead of IMF incision to provide more support, using

fascia of serratus anterior muscle, or using the mastectomy skin alone. Repair of the IMF area may be required.

- ADM use has been associated with increased risk of infection and seroma. Risks may vary with type and preparation of ADM; seroma rates are observed to be lower when ADM is perforated or meshed.
- Fenestration generally refers to the process of creating slits (as done in meshing) but sometimes refers to perforations and this term is therefore ambiguous. In several studies, adding perforations or meshing was performed by the surgeon immediately prior to placement. These treatments are now available commercially as well but at added cost.
- Bioabsorbable mesh has been used in several studies and may be beneficial, but information is insufficient to rank any compared with the commonly used human ADM or each other.

### ***Key Evidence for Recommendation 5***

- Trials comparing various ADM products are summarized in [Table 4-13](#) in Section 4. Six studies compared AlloDerm™ (LifeCell Corporation, Branchburg, NJ, USA) to FlexHD® (Musculoskeletal Transplant Foundation [MTF], Edison, NJ, USA). No consistent differences were found.
- Studies comparing different forms of ADM are summarized in [Table 4-14](#). AlloDerm (aseptic/freeze-dried) had a higher risk of infections than AlloDerm RTU (ready-to-use, sterile). AlloDerm (aseptic/freeze-dried) was replaced in 2010 by AlloDerm RTU which is terminally sterilized to a Sterility Assurance Level (SAL) of  $10^{-3}$  (148).
- Palaia et al. (149) found fenestrated ADM had lower risk of seroma (11.1% vs. 20.0%,  $p=0.0098$ ). A laboratory study of biomechanical properties of meshed and perforated ADM (150) found the meshed pattern increased surface area by 97.5%, while perforations increased surface area by 0.30% and 0.59%. Egress rate of fluid was 1.974 seconds with meshing, and 6.504 and 10.369 seconds with two patterns of perforation.
- Four studies had comparisons of synthetic mesh (151-154) and are summarized in [Table 4-15](#). Data comparing ADM, poly-4-hydroxybutyrate (P4HB; GalaFLEX™ [Becton, Dickinson and Company, Lexington, MA, USA] or Phasic™ [Becton, Dickinson and Company, Franklin Lakes, NJ, USA]), and TIGR® Matrix (Novus Scientific, Uppsala, Sweden) were found but are insufficient to make any recommendations.
- Warren Peled et al. (67) conducted immediate expander-implant reconstruction after TSSM. The inferior aspect of the pectoralis major was left intact at its inferior origin superior to the IMF. ADM was sutured laterally and inferiorly to the chest wall at the inferolateral aspect of the expander. When ADM was not used the expander was placed in the same pocket but without the added coverage. The group with ADM had less infection, unplanned return to operating room, and expander-implant loss. Benefit was greater in patients with thin flaps and those receiving RT and it was suggested ADM may not be needed in patients with lower risk. The no ADM group had more risk factors (more therapeutic cases; more RT, chemotherapy, and axillary lymph node dissection) that were not adjusted for.
- Nahabedian et al. (155) compared dual-plane reconstruction with or without ADM and found no differences in infection rates. Other studies (156-158) found dual-plane reconstruction with ADM had more complications than dual-plane or submuscular without ADM.

***Justification for Recommendation 5***

- As indicated in Recommendation 4, there are some advantages to the use of prepectoral plane and dual-plane implants. Prior to the development of ADM for this purpose, prepectoral implants were rarely used. The biggest barriers to ADM use are cost and availability. Most studies with prepectoral and dual-plane reconstructions used ADM, and ADM appears to allow this without an increase in major complications. Infection and seroma are two of the complications that are sometimes reported to be higher with ADM use, and care should be taken to minimize these, including product selection, form/preparation, and handling of ADM.
  - AlloDerm (aseptic/freeze-dried) was the most commonly studied ADM but is no longer in use as it was replaced in 2010 by AlloDerm RTU. Data comparing different ADM products that are relevant to current practice are limited. Complication rates were similar, and information is insufficient to recommend a specific product.
  - Some surgical groups have conducted prepectoral or dual-plane reconstruction with good results without ADM. These reports are limited and may require adaptation of surgical techniques or be applicable to only a subset of patients. The authors recommend continued use of ADM as this increases the reconstructive options and reduces some long-term complications of submuscular implants. We acknowledge that technical improvements in mastectomy and reconstruction may reduce the use of ADM.
- 

**6. Autologous Fat Grafting (Lipofilling)*****Recommendation 6***

- a) Fat grafting is recommended as a treatment for contour irregularities.
- b) Fat grafting is recommended as treatment for rippling following implant-based reconstruction.
- c) Fat grafting may be used to improve tissue quality of the mastectomy flap after radiotherapy (RT).
- d) Patients undergoing radiologic exams should indicate that they have undergone reconstruction including autologous fat transfer.
- e) Evidence on total fat grafting is more limited, and a recommendation cannot be made at this time.

***Qualifying Statements for Recommendation 6***

- Outcomes are highly dependent on method of fat harvesting and treatment, and on amount and location of injection. Excess pressure due to overfilling can cause fat necrosis and lower rates of fat survival.
- Palpable masses as a result of fat necrosis may occur in patients who have received fat transfer. These are generally benign on imaging and can be identified without biopsy in most cases.
- Enrichment/enhancement of stem cells is an area of active research but was not within the scope of this work.
- The optimal timing of fat grafting is unclear and may vary according to indication. The first session of fat grafting is usually at the time of expander-implant exchange or as a revisionary procedure several months after the final implant or autologous reconstruction, although



there are sometimes reasons to use at the time of expander insertion or autologous flap placement. In patients with poor mastectomy skin flap quality, fat grafting prior to expander insertion (for delayed-immediate reconstruction) or expander-implant exchange (in case of radiation damage) may improve tissue quality and reduce complications. In patients requiring RT, fat grafting often occurs 2 to 6 months after the end of RT.

### **Key Evidence for Recommendation 6**

- Studies on autologous fat grafting are summarized in [Table 4-16](#). Forest plots in [Figure 4-1](#) and [Figure 4-2](#) summarize recurrence outcomes with and without fat grafting, while [Figure 4-3](#) summarizes survival outcomes. There were no statistically significant differences in local or locoregional recurrence, distant metastasis, OS, DFS, or locoregional recurrence free survival.
- The MROC study (159) included 165 patients with contour irregularities or volume deficits and fat grafting between years 1 and 2. Patients with fat grafting had lower QoL than controls before fat grafting and QoL similar to controls afterwards, suggesting that fat grafting is beneficial in patients with contour irregularities or other defects.
- Calabrese et al. (160) reported lower rates of capsular contracture (7.14% vs. 21.53%) with fat grafting, as well as lower rates of hematoma, implant displacement/rotation, pain, and revision surgery within 3 years. Using the BREAST-Q, patients with fat grafting reported significantly better for several scales of Satisfaction (softness, natural appearance and feel to touch, natural part of body) and of Physical Well-Being (pain in chest muscles; breast tightness, pulling, nagging feeling, sharp pains, aching feeling, throbbing feeling).
- A randomized controlled trial (RCT) by Gentilucci et al. (161) evaluated the effectiveness of fat grafting after RT but prior to expander-implant exchange compared with a group without fat grafting. Skin biopsies evaluated adipose thickness and found a significant increase with lipofilling (178% after the third fat injection). There was a qualitative and quantitative improvement of tissues with lipofilling. The study had 1 year follow-up and concluded fat grafting reduced PMRT damage and improved QoL and reconstructive surgery outcomes.
- Calabrese et al. (160) reported less pain in the group with fat grafting. Other comparative studies on relief of pain and postmastectomy pain syndrome meeting our criteria were not included in our systematic review but this was mentioned in smaller studies (162-165), as well as separate systematic reviews on the topic (166, 167).
- The Breast Trial (NCT02339779) (168-171) compared autologous fat transfer alone in conjunction with external expansion to implants. Primary outcomes were QoL as measured by the BREAST-Q, with other outcomes of safety (complications or adverse events), aesthetic evaluation, and sensibility. Breast-Q scores and QoL including Satisfaction with Breasts (70.3 vs. 60.4,  $p=0.002$ ), Physical Well-Being Chest (79.9 vs. 72.3,  $p=0.007$ ), and Satisfaction with Outcome (73.9 vs. 66.3,  $p=0.04$ ) were better in the fat transfer group. There were no differences in oncologic events up to 1 year; long-term follow-up is ongoing. Exploratory analysis found sensibility in a subset of patients measured at least 1 year after final surgery was significantly better in the fat transfer group.
- Cason et al. (172) reported on imaging and biopsies after fat grafting. They found more palpable masses (38.0% vs. 18.3%). These were mostly normal or benign on imaging and biopsies were only required in 11.8% vs. 7.5% of patients. Fat necrosis was the most frequent radiologic interpretation and is generally identifiable on imaging. Several other studies not included in our review also reached similar conclusions (173-175). Fracol et al. found 8.6% of breasts developed palpable nodules; these were identified by ultrasound or



mammography as presumed fat necrosis (38.2%), benign lesions (27.6%), presumed oil cysts (17.1%), indeterminate (8.9%), and concerning for malignancy (8.1%). Fiaschetti et al. (174) indicated that experienced radiologists can distinguish lipofilling changes from malignant alterations.

- The UK guideline on lipofilling of the breast (176) provides guidance on indications, training, and techniques. Applications in post-mastectomy reconstruction include its use together with implants or autologous flaps in primary reconstruction, total breast reconstruction (best suited to small-breasted women), and to improve the quality of irradiated tissue before or during implant-based reconstruction.

### ***Justification for Recommendation 6***

- There is strong evidence that fat grafting is an oncologically safe procedure and improves PROs and QoL. The use of fat grafting for improvement in contour irregularities and reduction of rippling is well established. Based on this, its continued use is recommended. Training and technique are important for optimal outcomes, including appearance and safety of the breast and site of liposuction, and minimizing fat necrosis. Some studies reported the benefit of fat grafting to relieve postmastectomy pain syndrome; however, the authors believe there is not enough evidence at this time to make a recommendation. While several studies, including the BREAST Trial with external expansion and others with internal or no pre-expansion have used fat grafting alone (without implant or autologous flaps) with good results, this is not common practice in Ontario and authors believe expertise is not currently available. From a patient perspective, total reconstruction with fat grafting should be developed and offered as an alternative to implants and autologous flaps. This would provide an additional option for those averse to implant reconstruction and who are not candidates for autologous flap reconstruction.

### **RELATED OH(CCO) GUIDELINES**

- Muradali D, Fletcher GG, Cordeiro E, Fienberg S, George R, Kulkarni S, et al. Preoperative Breast Magnetic Resonance Imaging Guideline. Toronto (ON): Ontario Health (Cancer Care Ontario); 2023 March 24. Program in Evidence-Based Care Guideline No.: 1-25 GL. Available from: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/70786>
- Brackstone M, Durocher-Allen LD, Califaretti N, Eisen A, Knowles S, Koch A, Salim A, Plexman T, et al. Management of Ductal Carcinoma in Situ of the Breast. Toronto (ON): Ontario Health (Cancer Care Ontario); 2024, Mar 31. Program in Evidence-Based Care Guideline No.: 1-10 Version 4, Available from: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/276>
- Zhong T, Spithoff K, Kellett S, Boyd K, Brackstone M, Hanrahan R, Whelan T. Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options. Toronto (ON): Cancer Care Ontario. 2016 Jan 5 [warning on BIA-ALCL added 2019 Nov 26 and note added 2021 Nov]. Program in Evidence-Based Care Series No.: 17-10 version 1. It has been withdrawn and replaced by version 2 (the current document). Version 1 may be obtained by contacting PEBC at [ccopgi@mcmaster.ca](mailto:ccopgi@mcmaster.ca).

# Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

## Section 3: Guideline Methods Overview

*This section summarizes the methods used to create the guideline. For the systematic review, see [Section 4](#).*

### THE PROGRAM IN EVIDENCE-BASED CARE

The Program in Evidence-Based Care (PEBC) is an initiative of the Ontario provincial cancer system, Ontario Health (Cancer Care Ontario) [OH (CCO)]. The PEBC mandate is to improve the lives of Ontarians affected by cancer through the development, dissemination, and evaluation of evidence-based products designed to facilitate clinical, planning, and policy decisions about cancer control.

The PEBC supports the work of Guideline Development Groups (GDGs) in the development of various PEBC products. The GDGs are composed of clinicians, other healthcare providers and decision makers, methodologists, and community representatives from across the province.

The PEBC is supported by the Ontario Ministry of Health (OMH). All work produced by the PEBC is editorially independent from the OMH.

### BACKGROUND

Review of version 1 of this guideline indicated current practice and evidence are no longer aligned. There are inequities in access across Ontario, partially because of version 1 of this guideline regarding whether to perform immediate reconstruction in patients who require RT. An update on timing of reconstruction when RT may be required, use of ADM, and autologous fat grafting were considered essential.

### GUIDELINE DEVELOPERS

This guideline was developed by the Breast Reconstruction Guideline Development Group ([Appendix 1](#)), which was convened at the request of the Surgical Oncology Program, OH (CCO).

The project was led by a small Working Group of the Breast Reconstruction GDG, which was responsible for reviewing the evidence base, drafting the guideline recommendations, and responding to comments received during the document review process. The Working Group had expertise in reconstructive (plastic) surgery, surgical oncology, general surgery, radiation oncology, and health research methodology. Other members of the Breast Reconstruction GDG served as the Expert Panel and were responsible for the review and approval of the draft document produced by the Working Group. Conflict of interest declarations for all GDG members are summarized in [Appendix 1](#), and were managed in accordance with the [PEBC Conflict of Interest Policy](#).

Two patients/survivors/caregivers also participated as active members of the Breast Reconstruction Working Group. The patient representatives had the same roles as other Working Group members; they attended and participated in Working Group meetings and teleconferences, provided feedback on draft guideline documents throughout the entire practice guideline development process, communicating the perspective of patients and members of the public.

## GUIDELINE DEVELOPMENT METHODS

The PEBC produces evidence-based and evidence-informed guidance documents using the methods of the Practice Guidelines Development Cycle (177, 178). This process includes a systematic review, interpretation of the evidence by the Working Group and draft recommendations, internal review by content and methodology experts and external review by Ontario clinicians and other stakeholders.

The PEBC uses the AGREE II framework (179) as a methodological strategy for guideline development. AGREE II is a 23-item validated tool that is designed to assess the methodological rigour and transparency of guideline development and to improve the completeness and transparency of reporting in practice guidelines.

The currency of each document is ensured through periodic review and evaluation of the scientific literature and, where appropriate, the addition of newer literature to the original evidence-base. This is described in the [PEBC Document Assessment and Review Protocol](#). PEBC guideline recommendations are based on evidence of the magnitude of the desirable and undesirable effects of an intervention or accuracy of a test, and take into account the certainty of the evidence, the values of key stakeholders (e.g., patients, clinicians, policy makers, etc.), and the potential impact on equity, acceptability, and feasibility of implementation. PEBC guideline development methods are described in more detail in the [PEBC Handbook](#) (180) and the [PEBC Methods Handbook](#) (181).

### Search for Guidelines and Systematic Reviews

As a first step in developing this guideline, a search for existing guidelines and systematic reviews from websites of organizations and guideline developers (see [Appendix 2](#)) was undertaken in September to October 2021 and updated in September to November 2022. The purpose was to determine whether any guideline could be endorsed, or systematic reviews used as the evidence base. Evidence-based guidelines with systematic reviews within the past 5 years (Nov 2017) that addressed at least one research question were included; guidelines based on consensus/expert opinion without a systematic search were excluded. Fifty-eight guidelines on topics possibly related to this work were initially identified. None of these were deemed suitable for endorsement.

In addition to the website search, systematic reviews were also identified by general scoping searches to get familiar with the topic, and from suggestions of the sponsors and working group members. Relevant systematic reviews were identified; however, they did not cover all the topics nor recent and comprehensive enough to replace a new systematic review.

## GUIDELINE REVIEW AND APPROVAL

### Internal Review

For the guideline document to be approved, 75% of the content experts who comprised the GDG Expert Panel had to cast a vote indicating whether or not they approved the document, or abstained from voting for a specified reason, and of those that voted, 75% must have approved the document. In addition, the PEBC Report Approval Panel (RAP), a three-person panel with methodology expertise, had to unanimously approve the document. The Expert Panel and RAP members could specify that approval was conditional, and that changes to the document were required.

## **External Review**

Feedback on the approved draft guideline was obtained from content experts and the target users through two processes. Through the Targeted Peer Review, several individuals with content expertise were identified by the GDG and asked to review and provide feedback on the guideline document. Through Professional Consultation, relevant care providers and other potential users of the guideline were contacted and asked to provide feedback on the guideline recommendations through a brief online survey.

## **DISSEMINATION AND IMPLEMENTATION**

All current PEBC guidelines are published on the OH (CCO) website and may be submitted for publication to a peer-reviewed journal. The Professional Consultation of the External Review was intended to facilitate the dissemination of the guideline to Ontario practitioners. Section 1 of this guideline is a summary document to support the implementation of the guideline in practice. OH (CCO)-PEBC guidelines are routinely included in several international guideline databases including the Guidelines International Network (GIN) Library.

## **ACKNOWLEDGEMENTS**

The **Breast Reconstruction** GDG would like to thank the following individuals for their assistance in developing this report:

- Lisa Durocher, Sarah Kellett, Xiaomei Yao, Caroline Zwaal, Donna Maziak, Bill Evans, Johathan Sussman, May Lynn Quan, Stephanie Wong, and Martin LeBlanc for providing feedback on draft versions.
- Gursharanjit Kaur and Wenjun Jiang for conducting a data audit.
- Marisa Deodat for assisting with quality evaluation of systematic reviews.
- Sara Miller for copy editing.

# Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

## Section 4: Systematic Review

### INTRODUCTION

- Mastectomy to treat breast cancer often has psychological sequelae including alterations in body image, feelings of attractiveness, sexual health, and a continuing visual reminder of cancer. Breast reconstruction using saline or silicone-filled implants and/or autologous tissue restores appearance and often quality of life (QoL).
- While techniques such as nipple-sparing mastectomy (NSM) and skin sparing mastectomy (SSM) and autologous fat grafting have been widely adopted, there is uncertainty regarding safety.
- Use of acellular dermal matrix (ADM) has allowed a rapid switch from primarily submuscular implants to subpectoral/dual-plane and prepectoral implants but with greatly increased cost. Circumstances where ADM is beneficial and potential adverse effects are not well-defined.
- Timing of breast reconstruction is broadly classified as immediate (commenced during the same operation as mastectomy) or delayed (commenced after mastectomy healing or even years later). The optimal timing, especially with respect to use of postmastectomy radiation therapy (PMRT) is unclear.
- The Working Group of the Breast Reconstruction Guideline Development Group developed this evidentiary base to inform clinical practice guideline recommendations. Based on the objective(s) of this guideline (Section 2), the Working Group derived the research question(s) outlined below. This guideline is an update of a previous OH (CCO) PEBC guideline on breast reconstruction.
- This systematic review has been registered on the PROSPERO website (international prospective register of systematic reviews, University of York, UK) with registration number [CRD42023409083](https://www.crd42023409083).

### RESEARCH QUESTIONS

1. What is the effect of patient factors (smoking status, body mass index, breast size, age), comorbidities (diabetes, hypertension), or oncologic factors (previous breast surgery, previous radiotherapy (RT) to the breast/chest, inflammatory breast cancer, skin involvement) on post-mastectomy breast reconstruction outcomes?  
*Due to limitations in time and resources a decision was made during the screening process to cease work on this topic in order for the other topics to be completed. Only systematic reviews on this topic have been included in the Results section, except for age.*
2. a) In patients with breast cancer undergoing therapeutic mastectomy, is there a difference in outcomes in immediate versus delayed reconstruction for patients who do not receive RT?  
b) In patients with breast cancer undergoing therapeutic mastectomy, is there a difference in outcomes in immediate versus delayed reconstruction for patients who receive RT?

3. a) In patients with breast cancer who are candidates for SSM/NSM and reconstruction, is there a difference in outcomes between NSM and SSM?  
 b) In patients with breast cancer, do oncologic outcomes for NSM vary according to the criteria used in selecting patients for NSM (e.g., tumour to nipple distance) or how nipple/areolar involvement is assessed (e.g., clinical examination, mammography, MRI, other imaging, biopsy of areola/nipple/nipple core, frozen/intraoperative or permanent section)?  
 c) In patients with breast cancer and NSM, what surgical factors have been reported that influence the rates of nipple viability or necrosis and retention of sensation after NSM?
4. Does the use of prepectoral implants for postmastectomy breast construction result in differences in outcomes than subpectoral implants?
5. After therapeutic mastectomy, do outcomes differ for breast reconstruction using human-derived ADM, synthetic absorbable matrix, or no scaffolding/matrix? Are there differences in outcomes between different human ADMs or different synthetic absorbable matrices?
6. What are the benefits and risks of autologous fat grafting (lipofilling) as an adjunct to breast reconstruction?

## METHODS

A literature search was conducted in February 2023 and updated August 21, 2024 using OVID databases of Medline, Embase, EBM Reviews-Cochrane Central Controlled Trials, and EBM Reviews-Cochrane Database of Systematic Reviews. The search strategies are reported in [Appendix 2](#). The search contained terms for breast cancer, breast reconstruction, ADM, and fat grafting.

### Study Selection Criteria and Process

#### *Systematic Reviews for Question 1*

Systematic reviews were included only if they studied patients with breast cancer and therapeutic mastectomy, focused on the one or more of the patient factors, comorbidities, or oncologic factors listed in the research question, were identified as a systematic review or meta-analysis (generally in the title), used a systematic search, reported databases search and results of the search, listed included studies and data from them, and followed some standard such as the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) (182, 183). Studies meeting these criteria but with critical risk of bias using the AMSTAR II tool were excluded.

#### *Primary Studies*

Studies were included if they addressed one of the research questions, reported one or more of the outcomes of interest (see next section), and were conducted in patients with non-metastatic breast cancer receiving therapeutic mastectomy and breast reconstruction. Studies on breast augmentation, reduction, or mastectomy for other than cancer were excluded. Studies in mixed populations but primarily focused on therapeutic mastectomy were included provided patients with therapeutic mastectomy were reported separately or patients without breast cancer (e.g., bilateral risk-reducing prophylactic mastectomy or congenital conditions) did not comprise more than 20% of the patients. For some questions most patients had therapeutic mastectomy and contralateral prophylactic mastectomy; while this was noted and considered a potential confounding factor, they were not excluded.

Except for Questions 3b and 3c, studies had to be either randomized controlled trials (RCTs) with a  $\geq 30$  patients per arm or other comparative studies with  $\geq 50$  patients per arm. Preliminary searches and other review had indicated we were unlikely to find RCTs for most topics, and thus other comparative studies were also included. For subgroup analysis, these minimum patient numbers applied to the subgroups. For Questions 3b and 3c, the initial protocol allowed RCTs with  $\geq 30$  patients per arm, other comparative studies with  $\geq 30$  patients per arm, and non-comparative studies of at least 100 patients. During the screening and data extraction process, the threshold for other (non-RCT) comparative studies was increased to  $\geq 50$  patients per arm to be consistent with other questions. Abstract-only publications were included for RCTs but excluded for all other publications. Letters, comments, commentaries, viewpoints, editorials, notes, and news articles were excluded.

Comparative studies were included only if there was an indication that groups were similar or equivalent in key characteristics. Matching (e.g., propensity score matching), stratification, or multivariable analysis were preferred. While multivariable and multivariate are distinct types of analysis, these terms are often used interchangeably in the medical or public health literature (184, 185) and articles using either term were included if their statistical analysis attempted to determine the effect of the intervention of interest while adjusting for confounding by other independent variables (186). Variables should include those with plausible or known influence on the outcome, as well as those found in initial univariate analysis to be significant at an arbitrary level such as  $p=0.2$  or  $p=0.025$  (187-189). While  $p=0.05$  is often used, this may exclude variables that when combined have an important effect and was considered suboptimal. Studies with multivariable analysis but which failed to include variables generally considered to affect the outcome reported were excluded. Variables varied among questions and outcomes and generally included stage or other indications of disease severity such as use of RT or chemotherapy, and patient characteristics (e.g., BMI), comorbidities (e.g., diabetes), or habits such as smoking. In order to have reliable results there needed to be both a sufficient number of patients and sufficient number of events. There is a rule of thumb that 10 events are required for each variable being adjusted for; while this is often debated as being too lax or too strict, it gives a starting point in the decision process as to whether the analysis is adequate (190-196). It was decided to exclude studies with  $<25$  events per outcome (or in the case of multiple outcomes of interest, to only extract data for outcomes which had  $\geq 25$  events). This often meant that for complications, only the outcome of total complications or major complications had sufficient events, while individual outcomes did not. Studies specifying multiple or multivariate linear regression, multiple or multivariate logistic regression, or Cox proportional hazards analysis were included if they met the above requirements. Studies only mentioning univariate analysis or tests generally considered univariate (t-test,  $\chi^2$ , Fisher's exact, Mann-Whitney, Wilcoxon rank sum) were generally excluded.

Equivalence could also be assumed by the presence of narrow inclusion criteria such that groups were equivalent by nature of the selection criteria, or broader criteria with the authors indicating that groups were similar/not statistically different and supported by a table comparing patient and disease characteristics for both (all) groups. A judgement was then made as to whether differences were likely to affect results. For example, for oncologic outcomes of recurrence and survival, groups had to be of similar stage, tumour size, lymph node status, and distribution of cancer types (e.g., in situ, invasive). For most other outcomes, the type of reconstruction and indication for reconstruction had to be similar.

For Question 3b (oncologic safety of NSM) and Question 3c (surgical factors in NSM), non-comparative studies with  $\geq 100$  patients were included if they reported both criteria for conducting NSM and oncologic outcomes (Question 3b) or reported both surgical

details/technique and outcomes of nipple viability/necrosis, sensation, and erection (Question 3c).

### Outcomes of Interest

A wide range of outcomes were identified as of interest, acknowledging these would vary for different questions. The full list is below and applies to Questions 1, 2, and 4 (except donor site problems). Question 5 was concerned with surgical complications, aesthetics, and patient-reported outcomes (PROs). Question 6 included outcomes specific to fat grafting (surgical outcomes of fat necrosis, infection, wound complications, reoperations, hematoma, seroma, capsular contraction, oil cysts, skin necrosis; aesthetics; PROs; oncologic outcomes of recurrence or survival; and non-comparative outcomes only in the fat grafting arm such as donor site numbness, pain, contour defects, bruising, ecchymosis, hematoma, swelling, and infection). For Question 3, outcomes were limited to oncologic outcomes (3a and 3b), surgical outcomes and aesthetics (3a), nipple viability and necrosis (3a, 3b, 3c), and nipple sensation/erection (3c).

- a) Surgical complications:
  - Short-term (<30 days): seroma, hematoma (bleeding), infection, flap necrosis, nipple necrosis, wound complications, reoperations, pulmonary embolus or deep vein thrombosis
  - Long-term: flap failure, loss of implant, fat necrosis, reoperation, capsular contracture (implants only), implant malfunction (leaking, rupture, shift), chronic breast pain, hypertrophic scarring
- b) Donor site problems: hernia, wound complications, abdominal weakness
- c) Functional: restricted mobility, decreased strength, pectoralis tightness, animation deformity, lymphedema. This may also be phrased as being able/unable to perform work and leisure related activities and assessed using a validated instrument (see Outcome e)
- d) Aesthetics (acceptable cosmetic outcome: volume, shape, symmetry, scarring, skin quality) assessed by surgeons and/or patients (see also PROs)
- e) PROs: patient satisfaction with breasts, satisfaction with overall outcome, psychosocial well-being, physical well-being, sexual well-being, health-related QoL, body image, sexual functioning
- f) Oncologic outcomes: delay in adjuvant therapy (radiation or chemotherapy), recurrence, disease-free survival (DFS), overall survival (OS)

### Data Extraction and Assessment of Evidence Quality/Certainty

All included primary studies underwent data extraction by GGF, with all extracted data and information audited subsequently by an independent auditor. Ratios, including hazard ratios or odds ratios, were expressed with a ratio of <1.0 indicating improvement in survival or reduction in recurrence or other adverse events for the experiment group (or first group) compared with the control group (or second group). A meta-analysis was conducted for the effect of fat grafting on cancer recurrence. For other topics meta-analyses were not conducted due the wide variation in populations, interventions, and outcomes. Summary statistics (range, mean, median) were calculated for Questions 3b and 3c.

As indicated under Questions, a decision was made to not complete data screening and extraction for Question 1 due to resource limitations, and data from primary studies for this



question are not included in Results. Systematic reviews on portions of this topic were identified and were assessed using the AMSTAR II tool (197).

The risk of bias for randomized studies was assessed by GGF using methods outlined in the Cochrane Handbook for Systematic Reviews of Interventions (198-200). The Cochrane risk-of-bias (RoB) tool (revised version RoB2) for RCTs and Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) for non-RCTs are described in this handbook and other publications (201-203). Risk of bias was not assessed for non-comparative studies. As described in the PEBC Handbook (180) and PEBC Methods Handbook (181), quality of studies was evaluated considering quality-related features of the studies including threats to validity. Studies with particular factors affecting bias or quality are noted in the data tables and/or narrative results. The AGREE II framework (179) was used. In evaluating overall quality of the evidence, we considered risk of bias, precision, and consistency of results, and how well the evidence answered the questions. Publication or reporting bias was not considered due to predominance of retrospective studies from medical records, small number of similar studies per comparison, and because meta-analysis was not conducted for most questions.

### Synthesizing the Evidence

When clinically homogeneous results for several studies were available, a meta-analysis was conducted using Review Manager 5.4 software (RevMan) provided by the Cochrane Collaboration (204). This was only conducted for Question 6 (fat grafting). The generic inverse variance model with random effects was used. While there is some debate as to whether odds ratio (OR) or relative risk is more meaningful and easier to interpret for clinical studies, multiple logistic regression calculates adjusted ORs (205-208). ORs and confidence intervals (CIs) were therefore the preferred statistics for meta-analysis. For retrospective studies with multivariate analysis to adjust for confounding, outcomes with adjusted ORs were reported. Forest plots include all studies, with data in subgroups according to subtype of recurrence or survival outcome.

## RESULTS

*Due to the length of tables, they are grouped together at the [end of Section 4](#). Hyperlinks above the title of each table will take you back to the section being read.*

### Overview of Literature Search Results

After removal of duplicates in OVID, there were 32,033 citations exported to Endnote. Repeated searching for duplicates in Endnote identified an additional 1400 citations that were excluded as duplicates, leaving 30,633 records to screen. The updated search identified an additional 3307 citations; after removal of duplicates from the new search as well as with publications already included, there were 2734 additional publications. A review of the titles, as well as abstracts and full text if required, was conducted by one reviewer (GGF). A PRISMA diagram showing the search results is provided in [Appendix 3](#). There were 229 primary studies that met the inclusion criteria.

RCTs were rare, and completed RCTs were only found for Question 5 (3 trials in 6 publications) and Question 6 (2 trials in 3 publications). Most other studies were of retrospective design; they often had prospective charting or entering in database but retrospective study design and data analysis. A small proportion of studies are described as prospective; however, it is suspected that some of the analyses were retrospectively designed. Further breakdown of study type is provided in the subsections for each research question.

## Risk of Bias and Quality of the Evidence

### *Randomized Controlled Trials*

Of the four RCTs for Question 5 on ADM use, all had high risk of bias (see [Appendix 4](#)) as assessed by the Cochrane RoB2 tool and evaluated as providing low certainty of evidence. For the two RCTs on fat grafting for Question 6, Gentilucci et al. (161) was rated as low risk of bias and the Breast Trial (168-171) was rated as having some concerns due to deviations from intended interventions but otherwise low risk of bias. These studies provide high-quality evidence on narrow topics. These studies are described in detail under the specific questions.

### *Other studies*

As indicated in the previous section, there were no included RCTs for most questions. Most analyses relied on non-randomized comparative studies.

Based on the ROBINS-I tool, there was potential for confounding (Domain 1) that was generally controlled for but to varying degrees in different studies. As only studies with equivalent baseline characteristics, matching, or multivariable/multivariate analysis were included in this systematic review, studies were generally of low to moderate risk of bias. Comments on this are included in the data tables for each question and discussed in the results section for the relevant questions. In general, included comparative studies were assessed as low risk of bias for Domain 2 on selection bias, Domain 3 on classification bias, and Domain 4 on departure from interventions. Missing data (Domain 5) are of potential concern for most non-randomized studies as there were a wide range of possible outcomes and hospital records likely did not capture them all; this is apparent by a lack of consistency in reported complications in different studies but is not expected to vary between arms within a particular study. For studies reporting results from the same surgeon or group of surgeons at the same institution, this is considered to be minor (low risk of bias); however, they contribute to inconsistency between studies. For large database studies representing results from many institutions these factors contribute a moderate risk of bias. Domain 6 (bias in outcome measurements) is considered low risk of bias, except for complications such as degree of necrosis that are not well defined. This is more an issue when comparing studies than within studies. Domain 7 (bias in selection of reported results) is of low risk of bias. Overall, the risk of bias for non-randomized comparative studies is low to moderate.

Studies using national or other large multi-institutional databases included thousands of patients and therefore provide some data not available elsewhere, but many important details including surgical and pathological ones were not available, therefore limiting the usefulness even when the study itself was well-designed. General conclusions such as whether reconstruction could be used in patients with specific characteristics were of high certainty, whereas they provided low-quality or no evidence on more specific issues such as how to assess patients as being suitable for a specific type of reconstruction or surgical details to minimize complications or recurrence. Some of these limitations are noted in the results section for each research question.

Large inequalities in numbers of patients per arm of study was not an exclusion criterion but was noted as a limitation in several studies. This was the case for the Mastectomy Reconstruction Outcomes Consortium Study (MROC) in which many secondary analyses were conducted covering a wide range of topics, and this study is described in detail in the next section.

Studies (often from a single institution or single surgeon) with well-conducted matching or multivariate analysis with sufficient numbers of patients and events and appropriate selection of variables were considered to have low risk of bias and provide moderate to high-quality evidence. For non-RCT comparative studies, our threshold of 50 patients per group and

requirement for either similar baseline factors or adjustment for this (matching or multivariable/multivariate analysis) eliminated many of the studies of lowest strength of evidence. Due to low number of individual complications, often only composite or total complications had sufficient numbers of events. Studies with matching (propensity score matching) were generally rated as moderate quality, as were larger studies that used multivariate/multivariable analysis.

When evaluating the evidence, consistency between outcomes was important. Study designs and patient populations were considered to be too diverse to conduct meta-analysis for most questions except the effect of fat grafting on cancer recurrence (see Question 6). Summary statistics were also reported for oncologic outcomes and necrosis after NSM (see Question 3). When small but statistically significant differences were reported for complications and these differed widely among studies, it was considered insufficient evidence to conclude the effect could be extrapolated to other studies. Complications were often reduced by subsequent modifications by the investigators and not inherent to the topic of study.

In some areas with insufficient comparative evidence or with a need for further details), we have identified other publications considered to be informative and described them, while clearly stating they are not part of the studies meeting the inclusion criteria or included in the data tables. We consider this appropriate for the field of surgery in which a baseline of prior results by the same surgeon is used, modifications are made, and the effect noted. Skills and expertise of surgeons vary greatly, and therefore such results may be useful. The formal system of evaluation of quality of evidence used for comparative studies is not appropriate. Recentness, consistency, quality of reporting, importance of outcomes, and other publications by the authors were considered. These do not address the primary question of whether to do something, but rather technical details on how to do it.

### **Mastectomy Reconstruction Outcomes Consortium Study**

The MROC study, [NCT01723423](#), addresses several different questions, and therefore a broad description is given here. MROC was a prospective multicentre observational cohort study funded by the National Cancer Institute (USA) (159, 209). It was conducted at nine institutions in the United States and two in Canada (210), although embedded studies did not always include all 11 institutions. The MROC study was designed to evaluate and compare various options for breast reconstruction. It included 4464 women undergoing immediate or delayed breast reconstruction after mastectomy using tissue expander/implant, or autologous flaps (209, 211). Flaps were latissimus dorsi (LD) (with or without implant), pedicled transverse rectus abdominis musculocutaneous (pedicled TRAM or pTRAM), free TRAM (fTRAM), deep inferior epigastric perforator (DIEP), superior gluteal artery perforator (S-GAP), inferior gluteal artery perforator (I-GAP), or superficial inferior epigastric artery (SIEA). The primary outcome was change from baseline in health-related quality of life (HRQoL), with other outcomes including complications. It accepted patients with either therapeutic or prophylactic mastectomy but excluded patients undergoing reconstruction due to complications of breast augmentation, mastopexy, or breast reduction.

Thirty publications of the MROC study reporting on different aspects of the trial were identified in the literature search. The full set of patients was not used in any of these reports. Most were secondary analyses with their own inclusion and exclusion criteria and only used subsets of patients with specific characteristics or treatments. It is suspected that many of the analyses were retrospectively designed using the prospectively collected data. PRO or HRQoL data were collected using the BREAST-Q questionnaire; however, data were not available for all patients at all timepoints, and 1360 patients did not complete the baseline survey. Sample size calculations to assure statistically significant results were not reported in most papers. The main paper on PROs (211) assumed 83% power to detect a 0.135 standard deviation

difference between implant and autologous-based reconstructions using 0.01-level two-sided test. Comparison of various type of reconstructions (i.e., implants vs. flaps or comparison of various type of flaps) was outside the scope of the current systematic review.

Some key information on study design necessary for interpretation was not included in the trial registry (209) or in the publications we included, but was found in other publications on this study. For PROs, baseline refers to before reconstruction (212), and therefore the baseline data were before mastectomy only for the immediate group; for delayed group the baseline would have been after mastectomy (and presumably after PMRT). This accounts for the much poorer baseline PRO data for the delayed reconstruction group (56). The PRO model adjusted for baseline prior to reconstruction; there was no baseline prior to mastectomy for the delayed group and therefore baseline does not measure the same state; adjustment in the model may be inappropriate in determining effect of timing of reconstruction. Based on an analysis of data from this trial, it has been proposed that a 4-point difference on a BREAST-Q scale is a clinically useful minimal important difference score (MID) (213). Most MROC publications were prior to this MID assessment and do not report on whether the differences are clinically meaningful.

Of the publications of MROC found, five were included in our systematic review for Question 2 (three comparing immediate vs. delayed, not considering the effect of RT (56, 214, 215)), one on timing of RT with respect to autologous reconstruction (61), and one on timing of RT with expanders and implants (216)), two for Question 5 (use of ADM (217, 218), and one for Question 6 (fat grafting (159)). These all appear to be secondary analyses with relatively small and unequal patient numbers in some arms. For example, the publication of immediate versus delayed reconstruction (56) had 1806 immediate and only 151 delayed reconstructions; for further subgroups by reconstruction type there were only 17 patients with delayed implants (and therefore did not meet our inclusion criteria). The large imbalance means there is an extremely small number of outcome events in the smaller group and is problematic in determining if there is a significant difference in outcomes. Other characteristics of the groups are non-equivalent; due to the large differences, the ability of multivariate analysis to make adequate adjustments is suspect. This is discussed in more detail under results for specific questions. In general, despite the large amount of information in the MROC study, it is insufficient to give definitive answers for many of the questions explored in its publications.

### **Question 1. Patient Factors**

**What is the effect of patient factors (smoking status, body mass index, breast size, age), comorbidities (diabetes, hypertension), or oncologic factors (previous breast surgery, previous RT to the breast/chest, inflammatory breast cancer, skin involvement) on post-mastectomy breast reconstruction outcomes?**

As indicated in the Methods section, Question 1 is based primarily on existing systematic reviews. Seventeen systematic reviews (39-53, 219, 220) were found that cover several of the frequently studied factors, and these tend to be those with stronger association with increased risk of complications. These reviews are summarized in [Table 4-1](#). It was determined that no published systematic review sufficiently addressed the question of age, and therefore primary studies were reviewed and are summarized in [Table 4-2](#) (37, 38, 221-224).

### ***Quality of the Evidence***

As part of the inclusion criteria, included systematic reviews had to use a systematic search, report databases used and search terms or strategy, list included studies and data from them, and follow some standard such as PRISMA (182, 183). One review used the Jadad scoring

system and included a PRISMA flow diagram, and the rest indicated they followed PRISMA requirements. Evaluation of these reviews using the AMSTAR II tool (197) is presented in [Appendix 5](#). Reviews did not report funding of individual studies, and most did not report reasons for type of studies included or list the excluded studies. Assessment of RCTs was not applicable as none were included. These factors were considered less important (non-critical) for this topic and not used in the overall quality rating. All had PICO components, description of included studies, reported conflict of interest of authors of the review, and reported on heterogeneity. Based on this, most reviews were rated as being of moderate overall quality. They were downgraded if they did not report risk of bias. Having a protocol prior to starting the review, and completeness of the search strategy and its reporting varied and were also considered in the overall evaluation.

## Age

A systematic review by Mrad et al. (44) on complications after breast reconstruction found age did not influence rates of any complication. Most included studies did not subdivide patients by age, and median age was around 50 years for all of the studies. The authors did not report how they incorporated age into the meta-analysis and therefore the effect of age on complications is unclear. While the review itself was considered of sufficient quality overall, it was considered inadequate to address the effect of age on outcomes.

A systematic review was undertaken for this specific question (see [Table 4-2](#)), with inclusion criteria (in addition to those in listed in Methods section) being that studies had to have at least 50 patients per group (by age), must have compared older and younger age groups, and used multivariate/multivariable analysis. One prospective study (MROC, (222)), three single-institutional retrospective studies (37, 221, 223), and two retrospective multi-institution database studies (38, 224) were included.

The MROC study subdivided patients into three age groups (>60, 45-60, and <45 years old). Odds ratios for total and major complications for >60 compared to <45 were OR=1.46, 95% CI=0.99 to 2.15, p=0.059 and OR=1.43, 95% CI=0.93 to 2.18, p=0.101. Older patients (>60 years) compared to younger (<45 years) had less satisfaction with breasts with implants but no difference for autologous construction. There was improved sexual well-being for both implants and autologous reconstruction in older patients.

Some of the single institution studies used a higher cut-off for the oldest age group (age 70 or 75 years), although the number of patients with age >70 years was considered sufficient in only two (37, 221). This effect of this limitation is reduced by use of age as a continuous variable in both these studies and one additional one (223). It was indicated that this is preferred over the use of age categories which can lead to loss of power and incomplete correction of confounders, especially in studies limited by sample size (221).

Honig et al. (221) included 4185 free flaps from 2598 patients to evaluate safety of their use in patients of advanced age. They used cubic spline curves to model age as a continuous variable and then reported estimates at 5-year intervals from ages 55 to 74 years; p values are assumed to be based on the trend over all ages. Comparing age 70 to 74 years versus age <55 years, there were small increases in rates of delayed healing (35.7% vs 29.2%, p=0.036), skin necrosis (15.3% vs 10.7%, p=0.039), and hematoma (9.3% vs 5.3%, p=0.005). Other surgical complications including seroma, surgical site infection, and flap loss, and medical complications such as venous thromboembolism (VTE) did not increase with age. The authors concluded that an age cutoff was not warranted.

Kim et al. (37) used age as a continuous predictor in a set of 4379 patients, and found complications (mastectomy skin flap/nipple necrosis, infection, seroma) increased by 1 to 2% per year of age. Using the BREAST-Q, Satisfaction with Breasts was lower in older patients,



while Psychosocial Well-Being was higher, and there was no difference in Physical Well-Being-Chest, nor Sexual Well-Being.

Chang et al. (223) included 818 patients and found age was not predictive of surgical complications when used as either a continuous variable or by age groups (60 to 69, 50 to 59, or <50 years old).

Two studies using the American College of Surgeons National Surgery Quality Improvement Program (ACS-NSQIP) database met our inclusion criteria (38, 224). This database has the limitation of only including short-term complications (within 30 days of operation). Cuccolo et al. looked at all pedicled flaps and also reported locations such as breast separately (38). Multivariable analysis appears to use age as a continuous variable, so that OR=1.01 would correspond to a 1% increase per year of age. They found a small increase in overall complications (OR=1.010, 95% CI=1.004 to 1.006,  $p=0.002$ ), severe complications (OR=1.043, 95% CI=1.019 to 1.068,  $p<0.001$ ), and wound complications (OR=1.009, 95% CI=1.000 to 1.018,  $p=0.053$ ), but concluded the effect of age does not have strong predictive power and may not be clinically relevant on its own. The other ACS-NSQIP study compared outcomes in patients  $\geq 65$  years versus  $<65$  years and found no significant differences. Adjusted OR (aOR) for any complication for implants was 1.16 (95% CI=0.85 to 1.57,  $p=0.346$ ) and for autologous reconstruction was 1.16 (95% CI=0.71 to 1.88,  $p=0.555$ ). As they were comparing two groups instead of using age as a continuous variable, this study had less power than that of Cuccolo et al. to detect a difference.

### **Diabetes**

Two recent systematic reviews of moderate quality on the effects of diabetes on reconstructive outcomes were found. Liu et al. (39) found higher overall complications (OR=2.04, 95% CI=1.86 to 2.25,  $p<0.0001$ ), surgical complications (OR=2.23, 95% CI=1.98 to 2.50,  $p<0.0001$ ), implant loss/flap failure (OR=1.68, 95% CI=1.27 to 2.23,  $p<0.0001$ ), infection (OR=3.88, 95% CI=2.32 to 6.51,  $p<0.01$ ), skin necrosis (OR=2.82, 95% CI=1.51 to 5.29,  $p=0.001$ ), and longer hospital stay (41.0% vs. 34.7% over 5 days long; OR=1.31, 95% CI=1.12 to 1.54,  $p<0.01$ ). Mortada et al. (40) found higher rate of wound dehiscence, but no significant difference in wound infection, total flap complications, or total flap loss. Other complications were similar but not included in the meta-analysis. While the reviews included a large number of studies (38 and 43), Mortada et al. only included a subset of five studies in the meta-analysis. A systematic review by Mrad et al. (44) on complications after breast reconstruction found that diabetes increased rates of major/re-operative complications (OR=4.54, 95% CI=1.63 to 12.64), and 90-day complications (OR=1.59, 95% CI=1.30 to 1.95,  $p<0.00001$ ). Results were also reported for any complication (OR=1.18, 95% CI=0.96 to 1.45,  $p=0.13$ ) and infection (OR=1.44, 95% CI=0.84 to 2.48,  $p=0.19$ ).

### **Smoking**

A systematic review on the role of smoking in elective plastic surgery (41) found ever smoking was a risk factor in breast reconstruction for postoperative complications (OR=1.91; 95% CI=1.69 to 2.17), donor site complications (OR=1.59, 95% CI=1.27 to 1.99,  $p<0.001$ ), infection (OR=1.66, 95% CI=1.05 to 2.63,  $p=0.03$ ), and fat necrosis (OR=1.62, 95% CI=1.06 to 2.48,  $p=0.024$ ). There were no significant differences in flap necrosis, reoperation, hematoma, or seroma. The review was rated as low quality due to non-reporting of risk of bias of individual studies but strengthened due to study size (26 studies and >20,000 patients) and consistency of results between studies. A systematic review by Mrad et al. (44) on complications after breast reconstruction found that smoking history increased the risk of any complication (OR=2.43, 95% CI=1.54 to 3.82,  $p=0.0001$ ), major/re-operative complications (OR=1.46, 95% CI=1.08 to 1.97),

90-day readmissions (OR=2.13, 95% CI=1.05 to 4.34,  $p=0.04$ ), and infection (OR=1.52, 95% CI=0.98 to 2.36,  $p=0.06$ ).

### **BMI**

A moderate-quality systematic review of DIEP flap reconstruction by Tan et al. (219) found that patients with BMI  $\leq 25$  kg/m<sup>2</sup> (mean of 22.9 kg/m<sup>2</sup>) had no difference in complete or partial flap loss, fat necrosis, all complications, abdominal wound healing, infections, or seroma compared with patients with BMI  $> 25$  to  $< 30$  kg/m<sup>2</sup> (mean BMI 27.9 kg/m<sup>2</sup>).

A moderate-quality systematic review by Panayi et al. (42) looked at the effect of obesity (BMI  $> 30$  kg/m<sup>2</sup>) and found higher rates of surgical complications (RR=2.29, 95% CI=2.19 to 2.39,  $p<0.00001$ ), fat necrosis (RR=1.65, 95% CI=1.31 to 2.07,  $p<0.0001$ ), seroma (RR=1.96, 95% CI=1.57-2.45,  $p<0.00001$ ), partial flap failure (RR=1.60, 95% CI=1.06 to 2.41,  $p=0.03$ ), total flap failure (RR=1.97, 95% CI=1.34-2.91,  $p=0.0006$ ), wound dehiscence (RR=2.51, 95% CI=1.80-3.52,  $p<0.00001$ ), wound infection (RR=2.34, 95% CI=2.03 to 2.69,  $p<0.00001$ ), hernia (RR=1.67, 95% CI=1.15 to 2.43,  $p=0.007$ ), medical complications (RR=2.89, 95% CI=2.50 to 3.35,  $p<0.00001$ ), and return to operating room (RR=1.91, 95% CI=1.75-2.07,  $p<0.00001$ ). Surgical complications (based on a subset of 4 studies) increased with class of obesity: class I (30 to 34.9 kg/m<sup>2</sup>) RR=1.32; class II (35 to 39.9 kg/m<sup>2</sup>) RR=1.84; and class III ( $> 40$  kg/m<sup>2</sup>) RR=1.66. A moderate-quality systematic review by ElAbd et al. (43) compared autologous versus implant reconstruction in patients with obesity and found the autologous reconstruction resulted in lower infection, hematoma, seroma, and reconstructive failure; there was no difference in skin necrosis or wound dehiscence but increased rates of deep vein thrombosis and pulmonary embolism. BREAST-Q QoL was slightly better in the autologous patients (but not statistically significant,  $p>0.05$ ).

### **Hypertension**

A systematic review by Mrad et al. (44) on complications after breast reconstruction found that hypertension increased the risk of any complication (OR=1.59, 95% CI=1.23 to 2.05,  $p=0.0004$ ), major/re-operative complications (OR=1.29, 95% CI=1.03 to 1.62), 90-day readmissions (OR=1.65, 95% CI=1.06 to 2.57,  $p=0.03$ ), and infection (OR=3.71, 95% CI=1.14 to 12.07,  $p=0.03$ ). The review is rated low due to non-reporting of risk of bias of individual studies but strengthened due to large number of studies and patients (33 studies with over 100,000 patients, of which 7 studies reported any/total complications by hypertension status). While we did not conduct a systematic review on this topic, the studies included for other questions suggest the effect of hypertension to be low and therefore often not statistically significant in the small studies. Most studies did not define this variable and may have used different cutoffs.

### **Previous Surgery**

A moderate-quality systematic review on the effect of prior abdominal surgery on abdominally based flap reconstruction (45) found a small increase in donor-site delayed wound healing (RR=1.27, 95% CI=1.00 to 1.61) and no statistically significant difference in other complications (flap complications of total and partial flap loss, fat necrosis, infection, reoperation; and donor site complications of seroma, hematoma, infection, and abdominal wall morbidity).

Two systematic reviews of low quality were also relevant. One on the effect of pre-existing abdominal scars on reconstruction using abdominal flaps (46) found no significant difference in flap complications or flap loss. There were higher donor-site complications than in control patients without abdominal scars (19.5% vs. 14.5%, RR=1.35, 95% CI=1.13 to 1.62,

$p=0.001$ ). The authors suggest constraints of the scar may be overcome by technical modifications and use of computed tomography angiography if there is uncertainty. A systematic review of complications in patients with prior breast augmentation compared with those without (47) found early complications of 36.7% versus 24.8% (OR=1.57, 95% CI=0.94 to 2.64,  $p=0.09$ ), hematoma of 3.39% versus 2.15% (OR=2.68, 95% CI=1.00 to 7.16,  $p=0.05$ ), and no difference in seroma, infection, skin flap necrosis, or prosthesis loss. Late complications were 10.1% versus 19.9% (OR=0.53, 95% CI=0.06 to 4.89,  $p=0.57$ ) and overall complications 36.5% versus 31.2% (OR=1.23, 95% CI=0.76 to 2.00,  $p=0.40$ ).

### ***Neoadjuvant Chemotherapy***

A high-quality systematic review (48) compared reconstruction in patients with and without neoadjuvant chemotherapy (NACT), and did not find a statistically significant difference in overall complications (RR=0.91, 95% CI=0.74-1.11,  $p=0.34$ ), flap loss (RR=0.94, 95% CI=0.46 to 1.94,  $p=0.87$ ), hematoma (RR=0.99,  $p=0.97$ ), or wound complications (RR=1.15,  $p=0.22$ ). There was an increase in implant/expander loss (17.4% vs. 11.3%, RR=1.54, 95% CI=1.04 to 2.29,  $p=0.03$ ). Most studies did not report adjusted risk estimates, and patients with NACT often had more advanced disease.

### ***Radiotherapy***

Four systematic reviews (2 moderate and 2 low quality) on the effect of PMRT on implant-based breast reconstruction (49-52) found increased rates of complications with PMRT (see [Table 4-1](#)). There was an increase in early complications including surgical site infection, mastectomy skin flap necrosis, and implant extrusion/exposure, and late complications including reconstructive failure, capsular contracture, and need for revisional surgery. Adjuvant RT also resulted in lower patient satisfaction and aesthetic results.

A high-quality systematic review of PMRT in conjunction with autologous flap reconstruction (53) found higher rates of fat necrosis (RR=1.91, 95% CI=1.45 to 2.52,  $p<0.00001$ ), secondary surgery (RR=1.62, 95% CI=1.06 to 2.48,  $p=0.03$ ), and volume loss (RR=8.16, 95% CI=4.26 to 15.63,  $p<0.00001$ ). No difference was found for infection (RR=1.14,  $p=0.60$ ), healing complications (RR=1.23,  $p=0.17$ ), hematoma (RR=1.14,  $p=0.81$ ), seroma (RR=1.19,  $p=0.67$ ), total flap loss (RR=0.80,  $p=0.81$ ), or partial flap loss/necrosis (RR=0.34,  $p=0.15$ ). Cosmetic results (observer-reported) were lower with PMRT in four of five studies. It was noted that there are higher risks with PMRT, but these are not necessarily clinically significant.

## **Question 2. Immediate versus Delayed**

**In patients with breast cancer undergoing therapeutic mastectomy, is there a difference in outcomes in immediate versus delayed reconstruction for patients who (a) do not receive RT? (b) receive RT?**

Question 2 deals with the timing of reconstruction, and the timing of RT in relation to mastectomy and reconstruction. Results of the literature search are provided in [Table 4-3](#) that includes 16 non-randomized comparative studies in 20 publications (plus two references for additional details) (56-62, 64, 65, 212-216, 225-232). Complications can arise from either the mastectomy or reconstruction processes. Immediate reconstruction occurs (or is initiated) at the same time as mastectomy, and total complications at this point and during follow-up could have components from either procedure. Expander-implant exchange or revision surgeries may



also be required, and complications need to be assessed as part of the overall evaluation. Publications did not distinguish between mastectomy-related and reconstruction-related complications. Delayed reconstruction is conducted months or years after mastectomy, and at a minimum after surgical healing has occurred, and usually after adjuvant treatment is completed. Studies on delayed reconstruction usually did not specify the timing of adverse events measured but generally appear only to capture those at the time of reconstruction or later. Most studies did not report sufficient details of when assessment was done and whether they excluded any types of complications. Immediate reconstruction entails longer initial operation, and operating time and some types of surgical complications are correlated. In contrast, delayed reconstruction requires an additional surgery, and risks associated with additional surgery and anesthesia. In the absence of studies that assess all outcomes from the time of mastectomy until years after the reconstruction process is complete, interpretation of some outcomes is difficult. PROs such as anxiety may improve after mastectomy and cancer treatment, while body image would be expected to be highest prior to mastectomy, and lowest between mastectomy and delayed reconstruction, with recovery after reconstruction is complete. Studies often did not use equivalent baselines, with some comparisons being before and after reconstruction without considering when the mastectomy occurred.

### ***Risk of Bias and Quality of the Evidence***

A general analysis according to domains in the ROBINS-I tool follows:

- For Domain 1, the inclusion criteria specify that studies were only included if they attempted to minimize bias due to confounding by use of multivariable/multivariate analysis, propensity score or other matching, or narrow selection criteria such that patients are likely to have similar characteristics, and this was confirmed in tables of baseline characteristics. Studies with large difference in baseline characteristics were excluded unless such factors were adjusted for. There is some variability in how well studies achieved matching and appropriateness of variables in multivariate analysis, and therefore bias is low to moderate. Those that would be rated as more than moderate were generally excluded; some concerns are detailed in the data tables.
- Domain 2 (bias in selection due to using variables after start of intervention) does not apply (low risk of bias).
- Domain 3 (bias in classification of interventions) is also low as there is a clear difference between immediate and delayed reconstruction and this is not subject to interpretation.
- Domain 4 (bias due to departures from intended interventions) also does not apply (low risk of bias).
- Domain 5 (missing data) is potentially serious as data were extracted from medical charts and data may not be recorded uniformly or completely. There is no evidence that recording completeness would vary according to treatment/intervention and should not influence within-study results for a single institution or single surgeon (low risk). In large databases such as SEER with data submitted from many different institutions, the risk of bias is judged to be moderate to severe.
- Domain 6 (bias in outcome measurements) is rated as low for total complications and some specific complications, while moderate for other complications such as necrosis which have no standardized definition. Risk of bias is low for outcomes such as recurrence and death. For immediate versus delayed reconstruction, timing of complication measurement is an issue for some studies and is mentioned when this appears to be the case. The risk of bias is severe when it is unclear as to timing of

complication measurement and whether all complications (mastectomy + reconstruction) or reconstruction alone are reported in each arm.

- Domain 7 (bias in selection of reported results) is considered to be of low bias.

The overall risk of bias is dependent mainly on selection of variables in multivariate analysis or matching and therefore equal to assessment of Domain 1 (low to moderate risk). The reader is referred to the data tables and the description of individual studies in the following sections. For multi-institution databases, Domain 5 (missing data) is potentially severe. Non-standardized definitions for specific complications likely contributes to a small extent and are only relevant for a few outcomes such as the distinction between complete or partial necrosis. Most studies from single institutions have low to moderate risk of bias, while those from databases have moderate to severe risk of bias, depending on the outcome. Such limitations are noted for individual studies. This is modified to a higher risk when issues in Domain 6 as noted above are present.

### ***2a, Studies without RT comparing delayed to immediate reconstruction***

Three studies, namely a national audit of mastectomy and breast reconstruction in England (225, 226), the MROC study (56, 214, 215), and a study by Knoedler et al. (227) using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database included patients with a mix of implants or autologous reconstruction. RT was used in some patients but not reported separately in relation to timing of reconstruction. These studies are confounded by the timing of assessments of complications and HRQoL.

Knoedler et al. (227) reported complications in subgroups of patients with implants and patients with autologous flaps, as well as combined data. Any complications, general complications (30-day mortality, reoperation, readmission, unplanned readmission) and surgical complications (superficial incisional infection, deep incisional infection, organ space infection, dehiscence, and bleeding) were higher in the immediate group. There was no significant difference in medical complications. Seroma and hematoma were not reported and only complications in the first 30 days were recorded so capsular contraction, aesthetics, sensation, and oncologic outcomes were not available. Delayed reconstruction requires two operations, and it is unclear whether complications of each were added together. For any/general/surgical/medical complications, all were higher in the immediate group; this may reflect a combination of mastectomy plus reconstruction complications being captured but only reconstruction complications in the delayed group.

In the audit (225, 226), the BREAST-Q was administered 18 months after surgery, but it is not mentioned whether it was after the mastectomy surgery or reconstructive surgery. There are no baseline data (prior to mastectomy), and no information on duration of delay between mastectomy and reconstruction. While it is reported to be a prospective design, due to the nature of the audit, patients who had mastectomy prior to the start of the study but delayed reconstruction during the study were included. Timing for measurement of complications is unclear but may not include complications of mastectomy in the delayed reconstruction group. This study was an audit of hospital performance and variation between institutions is often greater than between patient groups. Risk of complications was not associated with reconstructive timing. PROs differences were generally less than a clinically useful minimal important difference score. An exception is for Sexual Well-Being for which delayed group had better scores; however, the authors note that response rate was much lower for this question and varied across hospital organizations.

In MROC (56, 214, 215), the baseline BREAST-Q was administered prior to reconstruction (prior to mastectomy in the immediate group but much after mastectomy in the delayed group)

and therefore patients had lower values in the delayed group. At 2 years after reconstruction, they found no significant differences in adjusted PROs. Complications were determined by reviewing medical records 1 and 2 years after reconstruction; it is unclear whether they went back to the time of mastectomy in both groups. Patient characteristics were not equivalent for immediate and delayed groups, and about 93% of reconstructions were immediate. For implants, 98% of patients had immediate reconstruction (58.5% bilateral). Delayed reconstruction with implants was rare (only 27 and 34 patients in two publications) and therefore most delayed cases were autologous. A comparison of immediate versus delayed implants did not meet our inclusion criteria due to the low number of patients in the delayed group. For autologous reconstruction, 82% of patients were immediate (30.2% bilateral). In Yoon et al. (56) 70.6% of immediate reconstructions used implants, while 70.2% of delayed reconstructions were autologous reconstructions. The large imbalance of immediate and delayed cases by implant type raises concerns about the ability to sufficiently correct for differences in the mixed effects logistic regression model used for major complications (those requiring re-hospitalization or re-operation) and any/total complications. The immediate group had significantly more total and major complications (aOR=2.63,  $p<0.001$  and aOR=1.92,  $p=0.016$ ). The report on this study by Wilkins et al. (215) reported similar results for any complications (OR=1.82,  $p=0.017$ ) but no difference in major complications (OR=1.17, 95% CI=0.68 to 2.00,  $p=0.566$ ). This difference points out the uncertainty of these results and may be due to the inability to correct for all risk factors, the small number of delayed cases, and the strong association between timing and type of surgery.

Eight retrospective studies compared immediate versus delayed autologous reconstruction (57-59, 65, 228-232). The study in Joosen et al. (230) and Beugels et al. (229) is the only one that reported oncologic outcomes, as well as complications. The delayed group had more systemic therapy and RT, history of expanders/implants, longer follow-up, and less history of lumpectomy. These suggest the delayed group had different characteristics and more advanced disease. Six patients were excluded from the delayed group due to recurrence prior to reconstruction. This high rate of cancer recurrences also suggests a greater risk in the delayed group because of more advanced disease that is not related to reconstruction. Local and regional recurrence rates were all low (1.5% versus 1.7%; 3.7% versus 2.4%) and insufficient events to meet our criteria of multivariate analysis, although it needs to be mentioned that the apparent direction of benefit switched after multivariable regression. Distant metastasis was 2.8% versus 6.9%, HR=1.351,  $p=0.085$ ; after adjustment HR=5.244,  $p<0.001$ . The large changes in all endpoints from before to after multivariable regression suggests that groups may have been too disparate for this analysis and residual confounders may still be present. Results are therefore considered unreliable. This study reported complications on the subgroups with breast cancer and found higher rates of hematoma and seroma in the immediate group and less wound problems; major complications were similar in each group.

Kroll et al. (228) found better aesthetic scores with immediate reconstruction (mean aesthetic score 3.25 vs. 2.82, adjusted  $p=0.0001$ ), and suggested it may be due to the associated use of SSM. Bilateral reconstruction and nipple reconstruction both resulted in higher scores, while prior irradiation resulted in a lower score. Prantl et al. (59) studied DIEP flap reconstruction and found similar complication rates, including flap loss, between immediate and delayed reconstruction. This was the largest study (897 patients immediate and 3016 patients delayed); while multivariate analysis was not used, groups had similar comorbidities.

Shammas et al. (57) used claims codes to study immediate, delayed, and staged (delayed-immediate with expander at time of mastectomy) free-flap reconstruction and associated complications within 90 days of either operation. The immediate group received less chemotherapy and RT but was older and had more bilateral mastectomies. In unadjusted data, surgical, systemic, and any complications were lowest in the immediate group and highest

in the staged group. After adjustment, relative risk of at least one complication was lower for immediate versus delayed (RR=0.78, 95% CI=0.68 to 0.88,  $p<0.001$ ), immediate versus staged (RR=0.60, 95% CI=0.53 to 0.67,  $p<0.001$ ), and delayed versus staged (RR=0.77, 95% CI=0.67 to 0.88,  $p<0.001$ ). Results were similar in sensitivity analysis in patients without RT. When looking at the results tables, part of the increased complications in delayed and staged groups was due to additive complications as a result of two operations (mastectomy and later reconstruction) compared with one operation in the immediate setting.

Huang et al. (58) found similar complications in immediate and delayed groups with DIEP flap reconstruction, except for higher breast skin necrosis in the immediate group. Authors suggest lower rates in the delayed group may be due to additional time to revascularize and heal after mastectomy.

Marquez et al. (231) and Kalmar et al. (232) both used the ACS NSQIP database and therefore have the same limitations as for Knoedler et al. (227). Marquez et al. confirmed that for immediate reconstruction “it is difficult to distinguish between complications related to the mastectomy versus those related to reconstructive efforts”. They found increased odds of surgical complication in the immediate group compared with delayed or delayed-immediate, while there was no significant difference between delayed-immediate and delayed (both which require a second operation). Kalmar et al. (232) looked only at flap failure and found no difference between immediate and delayed reconstruction, but noted that flap failure rate decreased over time (2.7% in 2015 and 1.2% in 2020).

## **2b. Studies comparing delayed versus immediate reconstruction and timing of RT**

Five studies (60-62, 64, 216) examined the timing of RT in relation to timing of reconstruction. Complications differ between implants (2 studies) and autologous reconstruction (3 studies) and therefore the use of RT needs to be analyzed separately for these two methods. The MROC study has separate analyses in different publications for implants (Yoon et al. (216)) and autologous reconstruction (Billing et al. (61)).

Ulrikh et al. (60) compared implants in patients receiving PMRT (single stage then PMRT, 2-stage with PMRT to expander, or PMRT then delayed implants) and found similar rates of grade I/II infection and seroma but 9.5% versus 17.6% versus 20.4% grade III complications and 10.8% versus 19.1% versus 17.3% reconstructive failure. Immediate reconstruction with single-stage implant had less complications, except for capsular contracture, which was higher (15.2% vs. 2.9% vs. 2.0%).

In the MROC study (216), 80 patients who received PMRT after expander/implant exchange were compared with 237 patients who received PMRT to the expander (prior to exchange). There was no significant difference in overall or major complications or failure. Anxiety, depression, and fatigue at 2 years were reported to be statistically better in the group with PMRT to the implant, though differences were <MID of the Patient-Reported Outcomes Measurement Information System (PROMIS) scales. There were no differences in BREAST-Q, European Organisation for Research and Treatment of Cancer (EORTC), and other PROMIS scales.

A report of the MROC study compared mastectomy and immediate autologous reconstruction followed by PMRT versus mastectomy then PMRT then delayed reconstruction (61). This study is only partially prospective, as the delayed group was recruited subsequent to mastectomy and the delay between mastectomy and reconstruction was not reported. There were only 108 immediate and 67 delayed reconstructions. Due to the small number of patients, we considered there to be insufficient events for logistic regression of individual complications; the difference between immediate and delayed groups for any breast complication was not significant (OR=0.64,  $p=0.442$  at 1 year; OR=1.14,  $p=0.848$  at 2 years). Prior to reconstruction (before mastectomy in immediate group but after mastectomy for delayed group), the

immediate group had better Satisfaction with Breasts (59.5 vs. 36.3,  $p<0.001$ ), Psychosocial Well-being (66.1 vs. 50.0,  $p<0.001$ ), and Sexual Well-being (52.1 vs. 29.8,  $p<0.001$ ) and differences are likely due to presence/absence of breasts; Physical Well-Being (abdominal) was 87.3 vs. 82.9 ( $p=0.058$ ). The large differences in baseline PROs are likely not related to reconstruction (but rather the absence of reconstruction in the delayed group). After reconstruction, there were no significant differences in PROs at 1 year, and only difference in Physical Well-Being (chest and upper body) at 2 years. In this comparison,  $p$  values at 1 and 2 years were adjusted for baseline (but not pre-mastectomy PROs) and covariates; mean values but not preoperative values were adjusted for covariates.

A variation of immediate reconstruction, termed staged or delayed-immediate or immediate-delayed uses an expander or temporary implant after SSM or NSM to maintain the skin flap and provides a breast mound instead of flat chest while awaiting reconstruction. This allows time for recovery prior to reconstruction or while awaiting final pathology or other information that determines the need for PMRT. It has also been used on the assumption that PMRT to an expander is preferable to irradiation of the final implant or autologous flap.

A propensity-matched study (age, BMI, comorbidities) by Christopher et al. (64) used staged/delayed-immediate reconstruction (tissue expander → PMRT → autologous reconstruction) versus immediate reconstruction followed by PMRT. It found less complications (fat necrosis, skin necrosis, additional office visits and outpatient surgeries, revision surgery) due to reconstruction in the staged group but additional complications due to the expander and RT steps (24/28 complications including infection, wound dehiscence, expander exposure, and failure to expand occurred during or after RT but before reconstruction). Revision surgery (primarily for asymmetry) was higher in the immediate group (42.4% vs. 12.1%,  $p<0.001$ ).

Hassan et al. (62) compared staged (skin-sparing; immediate expander/spacer then reconstruction) to delayed microvascular (autologous) reconstruction. PMRT, when used, was to the expander in the staged group and prior to reconstruction in the delayed group. Expander had either prepectoral or subpectoral placement and results do not make a distinction. While the publication implies the spacer/expander was placed pending pathology results and would be replaced as soon as possible if PMRT was not needed, the results indicate a median of 8 months (interquartile range 3 to 16 months) in the staged group and 15 months (9 to 30 months) in the delayed group. In patients with delayed reconstruction, those with PMRT had sooner reconstruction than those without (median 12 months vs. 15 months), suggesting there may be differences in baseline characteristics. The publication does not indicate whether complications were measured after reconstruction, mastectomy or combined, but these were generally similar except for seroma (higher in delayed group without PMRT) and infection (higher in delayed group with PMRT). Cosmetic outcomes were not assessed. Differences in PROs were not statistically significant; however, PROs were only measured at the end of the study and not a specific time after surgery and therefore are generally a long-term assessment. Factors used in multivariate model were not reported and discussion suggests baseline differences may confound the complication rates.

### *Interval Between Radiotherapy and Further Reconstruction*

During the systematic review process, an ancillary question arose regarding how long after PMRT the surgeon should wait before performing delayed autologous reconstruction or expander-implant exchange. While this was not a specific question in the review protocol, relevant studies were noted. Studies included for other questions offer guidance as to current practice. They were consistent in waiting at least 3 months to avoid the period of acute radiation injury for both delayed autologous reconstruction (58, 64, 65) and for expander-implant exchange after PMRT to the expander (66-69). While 3 months is considered an

absolute minimum, and 3 to 6 months sometimes acceptable (64, 66), a minimum of 6 months was more commonly used (58, 68-70).

For autologous reconstruction after PMRT, Fosnot et al. (65) reported on vascular complications of 109 delayed flaps. Numbers of patients in each group were not reported; however, there was a large difference between <3 months and > 3 months. Vascular complication rates were 66% at <3 months delay after completion of PMRT, 20% at 3-12 months delay, 14% at 12-120 months delay, and 19% at >120 months. The probability of a difference between <3 months and 12-120 months groups was  $p=0.06$ . Unfortunately, no data are available to discriminate times between 3 and 12 months. An additional study (233) reported reoperation rates in 189 patients with abdominal flap reconstruction after PMRT. Reoperations were higher with a delay less than 6 months (21.4% for 14 patients), compared with 13.2% for 6-12 months (68 patients) and 4.7% for  $\geq 12$  months (107 patients). This suggests a delay of 6-12 months is sufficient. Due to low numbers of patients and events and differences in baseline characteristics, there is greater uncertainty in the results for the group with <6 months delay; the primary evaluation just subdivided between <12 months or  $\geq 12$  months. A review by Koesters et al. (63) suggests that instead of an arbitrary time, surgeons may use clinical assessment of the skin quality and laxity to avoid operating on tissue that is acutely tight, inflamed and predisposed to complications.

Two studies by the same clinical group are often cited; they compared reconstructive (expander-implant) failure according to duration between PMRT to the expander and expander-implant exchange. Fowble et al. (72) preferred timing of at least 6 months and therefore fewer patients were included in the shorter time groups. Reconstructive failure was 50% (3/6 patients) with an interval of 0 to 2.9 months, 15.4% (2/13 patients) with an interval of 3 to 5.9 months, and 17.4% (8/46 patients) with an interval of  $\geq 6$  months. Warren Peled et al. (71) reported expander-implant failure of 22.4% (11/49) with  $\leq 6$  months versus 7.7% (3/39) with >6 months ( $p=0.036$ ). They also subdivided the first group and found failure of 28.6% (6/21) with <3 months and 17.9% (5/28) with 3 to 6 months. The second study was the rationale for the use of a delay of at least 6 months by this clinical group in subsequent patients, including two of the studies included for other questions in this review (68, 69).

### **Question 3: Nipple-Sparing Mastectomy Issues**

#### ***Risk of Bias and Quality of the Evidence***

Question 3A is based on comparative studies and ROBINS-I comments apply. Questions 3B and 3C are based on both comparative studies and non-comparative studies; comments below only apply to the comparative studies. Non-comparative studies provide rates for outcomes from larger studies (see earlier section on inclusion criteria). Due to the large number of studies and general agreement in results, the combined data for all studies are considered to have low risk of bias and high certainty of evidence. Not all studies are equivalent in patient characteristics and those with more advanced disease have worse oncologic outcomes. This is a characteristic of the disease and not an indicator of bias.

A general analysis according to domains in the ROBINS-I tool follows:

- For Domain 1, the inclusion criteria specify that studies were only included if they attempted to minimize bias due to confounding by use of multivariable/multivariate analysis, propensity score or other matching, or narrow selection criteria such that patients are likely to have similar characteristics (and confirmed in tables of baseline characteristics). Studies with large difference in baseline characteristics were excluded unless such factors were adjusted for. There is some variability in how well studies achieved matching and appropriateness of variables in multivariate analysis, and

therefore bias is low to moderate. Those that would be rated as more than moderate were generally excluded; some concerns are detailed in the data tables.

- Domain 2 (bias in selection due to using variables after start of intervention) does not apply (low risk of bias).
- Domain 3 (bias in classification of interventions) is also low as there is a clear difference between nipple-sparing mastectomy and skin-sparing mastectomy.
- Domain 4 (bias due to departures from intended interventions) also does not apply (low risk of bias). Studies either excluded patients who started with NSM but had to be converted to non-NSM (SSM or ASM) or included them in the SSM arm (for Question 3A only).
- Domain 5 (missing data) is potentially serious as data were extracted from medical charts and data may not be recorded uniformly or completely. There is no evidence that recording completeness would vary according to treatment/intervention.
- Domain 6 (bias in outcome measurements) is rated as low for total complications and some specific complications, while moderate for other complications such as necrosis which have no standardized definition. Risk of bias is low for oncologic outcomes such as recurrence and death.
- Domain 7 (bias in selection of reported results) is considered to be of low bias.

The overall risk of bias is dependent mainly on selection of variables in multivariate analysis or matching and therefore often equal to assessment of Domain 1 (low to moderate risk). The reader is referred to the data tables and the description of individual studies in the following sections. Most studies have low to moderate risk of bias. There is inconsistency between studies on degree of necrosis.

***Question 3a. In patients with breast cancer who are candidates for skin-sparing mastectomy (SSM)/ NSM and reconstruction is there a difference in outcomes between NSM and SSM?***

Nine studies (10 publications) comparing NSM and SSM are summarized in [Table 4-4](#) (73-79, 92, 234, 235). Two of these (73-75) identified patients for NSM, and then those with involved or close margins on frozen section analysis had the nipple-areolar complex (NAC) removed and therefore considered as having SSM. Groups are expected to be similar as all patients met the same criteria until the time of mastectomy. There were no significant differences in complications or cancer-related outcomes. Cho et al. (76) removed the nipple if positive retroareolar margins were found in the frozen-section biopsy of retroareolar tissue and excluded these patients from the NSM group. They used both propensity-score matching and Kaplan-Meier and Cox proportional hazard regression to compare NSM and total/SSM and found no differences in 5-year DFS, OS, or LRFS. When they applied their model to the SEER dataset, they found NSM had better OS, likely due to younger patients with less advanced cancer in the SEER set.

A fourth study (77) offered NSM to 187 patients with stage IIIa cancer with a clinically normal nipple and no skin involvement; use of preoperative imaging was not mentioned. Thirty-five patients were found to have cancer involvement on subareolar frozen section biopsy and were converted to SSM, while 333 patients were preoperatively assigned to SSM. Preoperative criteria for NSM and SSM were the same, so SSM may have been by patient choice, but this is not stated explicitly. After adjustment for patient and tumour characteristics there was no difference in DFS (HR=1.004, p=0.991) or OS (HR=0.866, p=0.813). These four studies suggest that both NSM and SSM have similar oncologic results when pathologic analysis of

retroareolar/excised tissue does not show tumour involvement. This is explored more in 3b and 3c.

The other five studies (78, 79, 92, 234, 235) did not report on surgical methods or whether pathologic analysis of resected tissue was conducted. Kelly et al. (92) reported unadjusted data that indicated NSM required less aesthetic revision operations (13.8% vs. 32.6%,  $p<0.001$ ), and resulted in better BREAST-Q scores on Psychosocial Well-Being and Sexual Well-Being and some components of Satisfaction with Breasts. They included only the outcome of Dissatisfaction with Breasts in multivariate analysis and found no difference between groups. Racz et al. (79) also found better scores on Sexual Well-Being for the NSM group, and this was significant on multivariable analysis, whereas there were no differences in Satisfaction with Breasts and Psychosocial Well-Being scales. They did find that nipple reconstruction and/or tattooing modified the Sexual Well-Being scores; NSM versus SSM without these was better ( $p=0.008$ ) but NSM and SSM were similar if nipple reconstruction/tattooing was used ( $p=0.182$ ). Wang et al. (234) reported that the rate of any complication (initial or adjusted data) was higher in the NSM group, but they included nipple ischemia/eschar/necrosis, which occurred in 16.5% of NSM patients and made up a large portion complications but by definition of SSM could not occur in SSM. Most other complications (unadjusted values) were higher in the SSM group. They did not subdivide by major or total complications but noted that only 2 of 36 patients with nipple complications required nipple removal. Reoperations rates within 90 days difference were not significantly different in multivariate analysis ( $p=0.695$ ).

Two studies were conducted in Japan. Ogiya et al. (78) found 7-year local recurrence (LR) of 2.6% NSM versus 3.8% SSM in patients with non-invasive cancer, and 6.6% versus 4.8% for invasive cancer. Multivariate analysis only compared results to total mastectomy. Of NSM with recurrence, 13.7% involved the nipple, which is high compared with most other studies. Sasada et al. (235) looked at the impact of RT in patients with involved surgical margins. They found involved surgical margins in 8.6% of NSM, including 1.8% of cases with involved nipple margins, while 6.4% of SSM cases had involved margins. In patients with involved margins and PMRT, LR was compared with patients with total mastectomy; in NSM they reported HR=1.26 ( $p=0.696$ ) and in SSM HR=0.65 ( $p=0.515$ ).

### **Questions 3b and 3c**

***3b) In patients with breast cancer, do oncologic outcomes for NSM vary according to the criteria used in selecting patients for NSM (e.g., tumour to nipple distance) or how nipple/areolar involvement is assessed (e.g., clinical examination, mammography, MRI, other imaging, biopsy of areola/nipple/nipple core, frozen/intraoperative or permanent section)?***

***3c) In patients with breast cancer and NSM, what surgical factors have been reported that influence the rates of nipple viability or necrosis and retention of sensation after NSM?***

Patient selection and surgical factors in NSM were often dealt with in the same studies and therefore these were combined during data extraction. [Table 4-5](#) summarizes 79 studies in 85 publications (68, 75, 77, 86-91, 93-98, 101-106, 110-114, 117, 120, 123-126, 131-133, 236-285). These include six studies (86-91) comparing tumour-to-nipple distance (TND), while most of the others are non-comparative. Two studies from Question 3a (75, 77) are of relevance.

No RCTs were found. Studies were conducted mostly in USA (20 studies), Italy (19 studies), Korea (15 studies), and Japan (6 studies), with 11 other countries contributing 20 studies. Most were non-comparative studies that met the criteria of having at least 100 patients and had details on patient selection or surgical methods.



### *Effect of Tumour-to-Nipple Distance*

Six studies compared effect of TND on outcomes (86-91). One study (90) calculated TND using magnetic resonance imaging (MRI), ultrasound, or mammography, while another used these three imaging techniques but did not specify how TND was calculated (91). The other studies used MRI to measure TND. Cutoffs of 1 cm, 2 cm, or 5 cm were compared. Studies generally excluded patients with preoperative evidence of NAC involvement and conducted intraoperative/frozen section pathology analysis of the nipple base; patients with nipple involvement had the NAC or nipple removed. Differences in oncologic outcomes for TND <2 cm versus >2 cm did not appear to favour either group; these were small and were not statistically significant (86-88, 91). Similarly, there were no differences when comparing TND ≤2 cm, 2 to 5 cm, or >5 cm (89). Wu et al. (90) used propensity-score matching to adjust for age at diagnosis, T stage, N stage, molecular subtype, and RT status in the comparison of TND ≤1 cm versus >1 cm. This study was larger than the other and had 495 patients per group. There were no significant differences in local or regional recurrence or distant metastasis at 5 years, nor in 10-year local recurrence-free survival (LRFS) or DFS. These studies suggest that for patients without preoperative evidence of NAC involvement, as long as frozen section and permanent pathology are conducted and are negative (or NAC excised in positive cases), TND <2 cm or <1 cm does not predict worse recurrence or survival. MRI may give information about the probability of NAC involvement as this increases with decreased TND, raise suspicion if frozen section pathology is negative, and influence surgical strategy (286). As noted in subsequent sections, frozen section analysis is not used at some institutions, or used selectively, and permanent/final pathology alone may be used.

### *Recurrence, Survival, and Necrosis*

A summary of recurrence, survival, and necrosis rates is provided in [Table 4-6](#). These studies report on approximately 30,500 patients, although multiple publications by the same authors may report on the same patients; excluding these there are approximately 24,200 patients.

Oncologic outcomes reported in the studies varied, though LR and LR in the NAC were most common, and reported in 40 and 39 of the studies, respectively. As expected, recurrence was higher in subgroups with higher stage cancer. Direct comparison between studies is difficult due to differences in follow-up times, cancer stage and other disease and patient characteristics, adjuvant treatment, and whether data are reported on a per-patient or per-breast reconstruction basis.

Two studies compared outcomes in patients with and without NACT (which is correlated to higher stage); LR was 2.8% and 2.0% in patients without NACT and 9.8% and 7.0% in patients with NACT (249, 257). Two additional studies were conducted in patients receiving NACT (263, 264) and reported higher rates of distant metastasis (DM; 11.9% and 19.6%) than most studies (median 4.3%). A study in patients with locally advanced breast cancer (77% received NACT) (117) reported higher rates of recurrence and lower survival (LR 7.2%, 5-year DFS 70%) than most studies. One other study, by Benediktsson et al. (238), had much worse recurrence (locoregional recurrence [LRR] 16.2%) and survival (5-year DFS 68%, 10-year DFS 60%) results than most of the others. Inclusion criteria were patients with multifocal disease or tumours >3 cm size suggesting patients may have been at higher risk; the authors also mentioned that many patients for whom RT would be standard practice by the end of the study did not receive RT. In the subgroup with RT, LRR was 8.5% while it was 28.4% in patients without RT. Median follow-up was 13 years (much longer than most) and may contribute to higher rates of LRR. Results excluding the two studies with only NACT and the other two studies mentioned above are summarized in [Table 4-7](#). Median values were 3.4% LR, 3.6% DM, 96.7% 5-year OS, and 92.0%

5-year DFS. Of particular relevance is that the rate of LR in the NAC is very low (median 0.5%, average 1.2%). This is similar to the results of a recent systematic review on oncologic outcomes by Zaborowski et al. (287) that included 17 retrospective studies and reported weighted mean LR of 5.4% and recurrence involving the NAC of 1.3%.

Of the 42 studies that reported recurrence rates in the NAC, 17 reported none (8 from USA, 6 Italy, 1 Brazil, 1 Germany, 1 Canada) and an additional 8 reported <1% recurrence in the NAC. Only one study from China, two studies from Japan, and five from Korea (4 from the same group) reported >2% recurrence in the NAC. Wu et al. (260-262) reported that when LRR occurred, 5-year post-recurrence DFS was higher for NAC recurrence (89.1%) than when recurrence was in the skin/chest wall (73%) or regional (59.4%).

### *Total Skin-sparing Mastectomy*

Five studies from the USA (four from the same group at University of California (68, 101, 102, 117) and one from University of Arkansas for Medical Sciences (239)) reported that no NAC recurrence occurred when using total skin sparing mastectomy (TSSM). Boneti et al. (239) conducted complete removal of the glandular NAC while preserving the skin and refer to this as TSSM; they suggest the term NSM is confusing, and it is actually nipple skin-sparing mastectomy. Sbitany et al. of the University of California group indicate that TSSM uses more aggressive surgical dissection relative to NSM and greater reduction in vascularity of the NAC (107). Reduction in nipple perfusion after TSSM is greater than after NSM and single-stage reconstruction should be avoided to minimize the risk of NAC necrosis. This aggressive surgery may account for the absence of recurrence in the NAC in these studies. Other studies with NSM may use similar or less aggressive surgery (leaving more NAC tissue), and differences may contribute to the range of both NAC recurrence and NAC necrosis observed in this review.

### *Incision Location and Other Risk Factors*

Five studies focused on incision type (103, 104, 112, 272, 281), while four others focused on factors affecting necrosis (110, 113, 124, 131). Park et al. reported complete nipple necrosis of 21.3% periareolar, 11.3% radial, and 3.4% inframammary fold (IMF) incision (112). Multivariate analysis found risk factors were periareolar incision (vs. IMF; OR=3.628, 95% CI=1.596 to 8.250, p=0.002); TND (OR=0.712, 95% CI=0.546 to 0.927, p=0.012); breast weight (OR=1.002, 95% CI=1.000 to 1.004, p=0.014). Seki et al. also found higher rates of complete nipple necrosis with periareolar incisions than for IMF incisions (3.3% vs. 0) (103). Salibian et al. found higher rates of major ischemic complications (including major mastectomy flap necrosis and/or full NAC necrosis requiring debridement) with IMF incisions (25%) and inverted-T incisions (36.1%) than vertical (5.8%) or lateral radial (7.8%) incisions (272). In multivariate analysis, inframammary (OR=4.382) and inverted-T incisions (OR=3.952) were independently associated with increased risk of major ischemic complication. Cavalcante et al. (281) compared IMF and periareolar incisions and reported complications in 15.3% versus 35% (p=0.0002, OR=0.33, 95% CI=0.14 to 0.79). NAC necrosis was a large portion of complications and occurred in 8.5% versus 22.4% of patients (aOR=0.34, 95% CI=0.13 to 0.88, p=0.025). Moo et al. (110) reported necrosis by incision type as follows: 12.1% lateral IMF (OR=0.41, aOR=0.35); 19.0% central IMF (OR=0.64, aOR=0.54); 29.8% lateral radial (OR=1.0 as reference); 37.3% inferior periareolar/lateral extension (OR=1.25, aOR=1.24); and 41.2% superior periareolar/lateral extension (OR=1.38, aOR=1.59). They also found necrosis was higher with specimen (mastectomy tissue) weight >400 g, fill volume >200 mL, a subpectoral expander, and surgeons with less experience.

Braun et al. (131) found rates of necrosis varied with incision type: 12.4% IMF incision versus 21.2% radial (p=0.1). Larger mastectomy weight, implant weight, and implant volume

were also risk factors. NAC necrosis rates were higher in the retrospective set of patients (15.1%) than in the prospective set (6.7%); the latter used more IMF incisions, prepectoral implants, and SPY (a fluorescence imaging platform using indocyanine green [ICG] angiography).

Lai et al. (113) found that periareolar incisions had higher risk of NAC ischemia or necrosis compared with upper outer radial incisions (OR=5.33,  $p<0.001$ ) (113). In multivariate analysis, Ahn et al. (124) found periareolar incision was a predictor of NAC necrosis (OR=4.281,  $p<0.0015$ ) and indicated that periareolar incision is known to decrease blood flow to the NAC. Holland et al. (104) studied patients with prepectoral reconstruction and reported NAC complications in of 25% with superior periareolar incision and 7.4% with IMF incision ( $p=0.033$ ); in multivariable regression a periareolar incision was associated with increased odds of nipple necrosis (OR=3.6,  $p=0.018$ ).

Lin et al. (111) reported on lessons learned in 3035 NSM with immediate implants. Relative rates of nipple necrosis by incision type were inferolateral IMF (reference, 1.0), horizontal radial OR=3.823 (95% CI=1.081 to 13.515,  $p=0.037$ ); vertical inferior OR=2.124 (95% CI=0.453 to 9.944,  $p=0.339$ ); periareolar OR=14.235, (95% CI=6.248 to 32.435,  $p<0.001$ ); and extension of prior incision OR=2.98 (95% CI=0.657 to 13.511,  $p=0.157$ ). Preoperative RT and smoking were also risk factors for nipple necrosis. Complications including nipple necrosis (1.9% vs. 0.88%), infection (4.2% vs. 2.8%), and explantation (5.1% vs. 3.5%) were higher with expanders than direct-to-implant reconstruction.

Other studies on broader topics also commented on incision type. Vladimir et al. reported a complication rate of 70.4% with periareolar incision and 8.3% with lateral incision (253). Chirappapha et al. found 25% NAC necrosis with superior circumareolar or periareolar incisions versus 13% with other incisions (270). Kim et al. (77) indicated that periareolar incisions were used initially but due to high rates of skin necrosis they switched to lateral incisions. Boneti et al. noted that vertical infra-areolar incisions are preferred as IMF incisions can remove the inframammary blood supply (239). Warren Peled et al. (101) indicate that the preferred incisions switched over time with more recent operations using mostly superior areolar/mastopexy and inframammary incisions. Rates of nipple necrosis decreased after use of periareolar incisions were minimized and free nipple grafts and NAC-crossing incisions were eliminated. If periareolar incisions are necessary, they should be limited to less than one-third of the circumference of the NAC. Reports or reviews by Colwell et al. (115, 288, 289) did not meet our inclusion criteria but suggest that an inferolateral IMF incision minimizes complications and gives best cosmesis for most patients, although lateral radial incisions may be best for preserving nipple blood supply and are the safest choice for those with less experience or if complicating scars are present, and vertical incisions may be more suitable for some large or ptotic breasts.

### *Other Factors Affecting Necrosis Rates*

While there was no direct comparison, several authors commented on the effect of skin tension on necrosis. Viability of the NAC depends on preservation of the blood supply to the nipple, ducts, and surrounding skin (123). Immediate fixed-volume implants may put more tension on the skin flaps than tissue expanders that are gradually inflated. Ahn et al. (124) indicated that higher skin tension may interfere with blood flow and be the cause of higher rates of necrosis with direct-to-implant and autologous reconstruction. When using tissue expanders they prefilled them to about one-third of final volume to minimize tension. Holland et al. (104) also ensured tissue expanders were filled to prevent significant wrinkling but not to an extent that would place tension on the closure or pressure on overlying skin (104). Park et al. (112) noted that breast volume or weight is a risk factor for necrosis and that this may be due to increase skin tension and longer distance from the blood source to the nipple which both decrease nipple blood supply (112). Pek et al. (125) used a skin paddle incorporated into

the closure if excessive tension was anticipated. Ng et al. (126) note that Asian women have relatively smaller breast envelopes and therefore increased potential for skin tension leading to nipple necrosis than in Western counterparts. Warren Peled et al. also advocate using only minimal expansion of thin mastectomy skin flaps, with two-stage expander-implants being preferred to minimize ischemic complications and necrosis (101). These findings are consistent with a systematic review by Robertson, 2017 (290) that suggests skin tension should be minimized to reduce necrosis. Ng et al. found that a switch from electrocautery to sharp dissection with tumescence resulted in a decrease in full-thickness necrosis from 12.8% to 1.3% and partial-thickness necrosis from 33.3% to 13.0% and reduction in operating time from 202.9 to 183.5 minutes (25). This study did not meet our inclusion criteria as there were <100 patients.

#### *Studies at the European Institute of Oncology, Italy*

In Italy, six studies were conducted at the European Institute of Oncology (265, 267-269). The study by Petit et al. (265) and associated publications (266, 267, 270) included their experience with 1001 cases of NSM together with NAC intraoperative RT (ELIOT or IORT). A later publication by Galimberti et al. (268) included 1989 patients and may overlap with the earlier ones; it found no difference between patients with or without ELIOT/IORT. Authors indicated that IORT use decreased over time and was eventually abandoned as NAC excision decisions were being made on intraoperative frozen sections.

#### *Studies University of Ulsan College of Medicine, Korea*

In Korea, seven of the studies were conducted at the Asan Medical Centre at the University of Ulsan College of Medicine, with the six more recent ones by Wu et al. (90, 258-264). Some of these had overlapping patient populations. Wu et al. (258) reported 4.1% recurrence at the NAC and 4.4% other LR as first events and corresponding 5-year recurrences of 3.5% and 3.4% in patients with ductal carcinoma in situ (DCIS). Wu et al. (259) found a lower recurrence in patients with invasive cancer (4.5% locoregional recurrence, including 3% NAC recurrence). A larger study (260-262) commencing in the same year as the others included all patients with NSM and reported LR in 7.5% of patients, including 3.1% involving the NAC. In patients with LR, reconstruction loss was 16% (262). Two subsequent publications (263, 264) with more recent surgeries focused on patients with NSM after NACT and therefore likely more advanced stage. As indicated earlier, rates of recurrence were higher in these studies than in most of the others. It is unknown whether this is due to differences in the patients or surgical techniques.

#### *Studies in the United States*

In the United States, five of the studies were conducted at the University of California (68, 101, 102, 104, 117), three at New York University Langone Health (271-273), and five at Massachusetts General Hospital, Boston (94, 95, 97, 98, 111), as well as individual studies elsewhere. The researchers at University of California improved their procedure over time and report on these changes in the included studies and several other publications. As a result, rates of recurrence and nipple necrosis tend to be lower than in several of the other publications in this literature review.

### University of California Experience

The University of California group led by Laura Esserman began performing TSSM in 2001 and after key improvement it became their procedure of choice (101). They continued to make serial improvements to reduce ischemic complications. The initial revision was to eliminate use of periareolar incisions; in most patients they used IMF incisions or superior areolar/mastopexy incisions with less than one-third of NAC circumference. For implants they switched to use of two-stage reconstruction (expander-implant) and used minimal (50 to 100 mL) intraoperative expander fill. With these changes, nipple necrosis decreased from 13% to 1.8%. They also extended the patient criteria to allow those with tumours under the NAC if not directly involving the nipple itself, tumours with skin involvement that respond well to NACT, patients with previous (>6 months) circumareolar incisions for breast reduction or augmentation, and (using a superior areolar/mastopexy incision) patients with moderate ptosis.

For oncologic control, they evolved to allow TSSM even if tumours were close (<1 cm) to the NAC provided MRI (used only for tumours close to the nipple by clinical examination or mammography) demonstrates no clear involvement of the NAC. They do not use subareolar frozen section analysis but instead examine serial sections of the removed tissue at final pathologic analysis. If final pathology detected tumour in the nipple tissue specimen, they conducted repeat excision or NAC removal at the time of expander-implant exchange or autologous flap revision, or RT alone without further surgery. Tumours in or near the nipple skin are treated in the same way as other positive skin margins using repeat excision, resection of the involved skin, or PMRT. Repeat excision is used to ensure removal of residual ductal tissue or residual tumour, although all these specimens had only fibrous tissue and scar without residual ductal tissue or cancer. In cases of invasive cancer in the nipple specimen, NAC excision is usual, but they will attempt NAC preservation using repeat excision in patients with strong desire to retain the NAC. In the 2012 publication, there were 20 nipple specimens containing tumour; 16 had re-excision or NAC removal and all were negative for residual tumour.

Their next publication further discusses the evolution of technique and provides more outcome results (68). The preferred drain prophylactic antibiotic was switched from cephalexin to trimethoprim-sulfamethoxazole and the interval between PMRT and expander-implant exchange increased from 3 months to 6 months. The study overlaps with the previous publication but contains 32 cases of cancer on final pathology (15 in situ and 17 invasive). Of the in situ cases, 2 had nipple skin resection, 3 PMRT and 10 no additional treatment. Of the invasive cases 10 had resection of the nipple skin, 5 PMRT alone, and 2 no treatment because margins were not involved. Of the cases without resection there were no LRR in the NAC skin, although follow-up was only a median of 22 months. No mention is made regarding the pathological status of resected tissue. Yearly data are provided, and there is wide variation in treatment characteristics and outcomes from year to year such that trends are not apparent. A subsequent publication by Amara et al. adds an additional year of patient accrual (102). While there is the same number of cases with nipple involvement, the treatment was not the same as reported previously; Amara et al. indicate 11 repeat excision, 8 NAC removal, 5 PMRT, 8 no further treatment. This is further broken down by DCIS and invasive cancers: for DCIS there were 4 re-excisions, 3 NAC removal, 2 PMRT, and 5 no treatment; for invasive cancer there were 7 re-excisions, 5 NAC removal, 3 PMRT, and 3 no treatment. All cases with no treatment had tumour in the nipple without extension to the margins. There were no recurrences in the DCIS cases. In the invasive cases there was 1 LR (not involving the NAC) in the re-excision group, 3 DM in the PMRT group, 1 LR/DM in the no treatment group (not involving the NAC), and no recurrence in the NAC removal group. In patients with nipple involvement and PMRT, the PMRT was administered for other primary indications (e.g., tumour size or lymph node involvement). Use of complete NAC excision decreased over time. For nine margin

excisions, five had scar or fibrous tissue and four had benign breast tissue; two additional cases are pending. This publication mentions that frozen section analysis is not performed due to potential false-negative results and low rate of tumour involvement. At the time of writing (2015) the only indication for NAC removal was extensive tumour involvement of the subareolar margin and nipple specimen in final pathology. In the absence of PMRT treatment, and pathology specimen showing definitive involvement of the anterior aspect of the excised nipple tissue, they performed re-excision of the margin. In these cases, none of the re-excisions have shown invasive or in situ cancer. No patients have shown LR in the NAC.

The most recent publication included is by Holland et al. (104) studying a more recent patient population undergoing prepectoral reconstruction. They compared superior periareolar incision (about 50% of circumference based on the photos, and thus exceeding the guideline of less than one-third in previous publications) to IMF incisions and found IMF incisions resulted in less NAC complications and nipple necrosis requiring debridement. As a result, they have moved away from superior periareolar incisions if the patient is a candidate for IMF incisions; for patients (such as with grade II ptosis) who require superior periareolar approach they have added a lateral extension.

### *Nipple Sensation and Erection*

For question 3c nipple sensation and erection were among the outcomes of interest. These were not reported in most studies. Fortunato et al. (240) noted that 8% of patients had some NAC sensation in the first month after surgery and 17% at 6 months; this was generally described as minimal or partial. Rossi et al. (123) found nipple sensitivity and erectile capacity were insufficient in most patients. Petit et al. (265) compared patient feeling in the areola when touched to that in the contralateral areola without surgery. Using a scale of 0 to 10 and groupings of 0 to 3 as poor, 5 to 6 as good, and 7 to 10 as excellent, they found average value for sensitivity was 2. At least partial sensitivity of the NAC was recovered in only 15% of patients 1 year after the operation. In the study by Stanec et al. (242), NAC sensation was evaluated at every postoperative physical examination and again before the end of the study. While most had >1 year follow-up, the median follow-up was 63 months. The influence of the length of follow-up on sensation recovery is not reported. The patients scored the degree of sensation to light touching compared with the non-operated breast on a scale of 0 to 4 (0 being no sensation, 1 for more decrease, 2 for less decrease, 4 for normal sensation). At the final assessment they found that 16% had no sensation, 27% more decrease (large decrease), 35% less decrease, and 22% normal sensation. While all these studies indicate NAC sensation is low after NSM, this was not the focus of the studies; they did not explore contributing factors or ways to improve this, and measurement/evaluation was either not reported or suboptimal.

A prospective study by Black et al. specifically on breast sensation after NSM was conducted at Weill Cornell Medical College in New York City, New York (120). They included patients with immediate expander-implant reconstruction (64 prepectoral and 22 subpectoral) or autologous reconstruction with neurotized DIEP flaps (106 patients). The autologous group had more hypertension, diabetes, and higher BMI (mean 26.9 vs. 23.8 kg/m<sup>2</sup>) than the implant group. Sensation was evaluated using a pressure-specified sensory device and measured at nine regions per breast (NAC, and outer and inner superior, medial, inferior, and lateral regions) at predefined timepoints along the clinical course, both before and after mastectomy/reconstruction. Mean preoperative sensation threshold was 14.1 g/mm<sup>2</sup> in the NAC and 16.5 to 20.0 g/mm<sup>2</sup> in other locations. Short-term (<1 year) and long-term (≥4 years) post-operation, the autologous group had sensation thresholds of 67.4 and 38.5 g/mm<sup>2</sup> at the NAC, 62.2 to 73.2 and 37.5 to 40.8 g/mm<sup>2</sup> in the inner quadrants and outer inferior quadrant, and 42.5 to 56.2 and 25.9 to 32.0 g/mm<sup>2</sup> in the other outer quadrants. Sensation threshold was worse in the patients with implant reconstruction: at <1 and ≥4 years post-operation sensation

thresholds were 79.2 and 45.2 g/mm<sup>2</sup> at the NAC, 72.3 to 79.1 and 50.9 to 66.2 g/mm<sup>2</sup> in the inner quadrants and outer inferior quadrant, and 48.9 to 61.6 and 35.2 to 48.0 g/mm<sup>2</sup> in the other outer quadrants. This study did not report surgical details such as incision type, although an earlier study by this group used inframammary incisions for NSM (291). Authors suggest that while neurotization of the flap likely contributes to the better sensation compared with implants, better sensation is also expected (based on other studies) with non-neurotized flaps and that randomized studies are needed. The same authors have conducted several other studies. One comparing staged versus immediate DIEP reconstruction (292) reported much better sensation at 18 months than in the study by Black et al. at the 1-year timepoint. It is unclear whether it is due to additional recovery between 12 and 18 months or differences in sensation between patients. A third study reported baseline values for one group almost double that in the second group (15 to 27 vs. 8 to 12 g/mm<sup>2</sup> for various locations) (293) and illustrates the importance of comparing sensation to baseline values, preferable on a patient instead of aggregate basis.

### *Treatment of Patients with Tumour Detected in Resection Specimens*

Patients with subareolar resection specimens with tumour detected were most commonly treated with NAC resection. When subareolar samples were involved by tumour on intraoperative/frozen-section pathology, the most common treatment was NAC resection during the same operation. Some more recent studies removed the nipple but retained the areola (e.g., Fregatti et al. (89); Smith et al. (98); Tang et al. (97); Shanno et al. (95)), or excised only the portion of the areolar with involved margins. Tang et al. (97) reported full NAC excision decreased over time, with only the nipple removed in 38% of cases in 2007 to 2011 and 62% of cases in 2012 to 2014. Shanno et al. (95) also reported 50% only nipple removal in 2009 to 2015 and 89% nipple-only excision in 2016 to 2019. Three of these studies were conducted at the same institution. Some studies considered LCIS or atypical hyperplasia to be negative results and did not result in NAC excision. Shanno et al. (95) included 134 patients with atypia without nipple or NAC excision and none developed recurrence in the NAC or periareolar skin. In some cases, further dissection either as confirmation or in an attempt to obtain clear margins was conducted. When NAC involvement is suspected based on final pathology of subareolar resection specimens, resection of the nipple or NAC is usual practice; however, RT or no treatment is sometimes used. Of studies where nipple or NAC was excised and underwent pathologic analysis, rates of involvement were variable (0 to 100%): Fregatti et al. (89) 63.6%; Fortunato et al. (240) 58%; Rossi, et al. (123) 100% (17% invasive, 72% in situ, 11% LIN III); Santoro, et al. (243) 52%; Agresti et al. (249) 41%; Cont et al. (250) 45%; Warren Peled et al. (101) 0%; Amara et al. (102) 0%; Shanno et al. (95) 24%; Spoor et al. (106) 59.5%; and Zhu et al. 9.1% (96). Possible factors are patient selection and imaging used, extent of excision of breast tissue, how margins and orientation of samples were marked, and use of re-excision prior to eventual NAC removal.

In patients with tumour on pathology but no nipple excision, Spoor et al. (106) found no recurrence in 20/20 patients. Petit et al. (265) used ELIOT (intraoperative RT) or delayed RT in patients with NSM. Intraoperative frozen section analysis was performed and the margin further revised if tumour was present in the initial sample. NAC was excised in patients with both samples containing tumour or with poor blood supply and high risk of necrosis which contraindicated RT. Of the patients with NSM and RT, 86 cases had tumour on final pathology, and in 79 cases only the first but not second frozen section sample was involved; no recurrence in the preserved NAC was found. It is noted that median follow-up was only 20 months. A study by the same group (Galimberti et al. (268)) with at least 5 years follow-up (median 94 months) and likely involving some of the same patients reported 1.8% NAC recurrence, and no statistically significant difference between patients with ELIOT/IORT to the NAC and those

without (although the group without RT is small). They did not report whether cases with tumour on final pathology were included.

Warren Peled et al. (101) used only permanent pathology analysis and repeated excision for tumours near or in the nipple skin (all results were negative) or used PMRT. Cases with invasive cancer in the nipple had repeat excision if patients were highly motivated to preserve the NAC (7 cases) or NAC removal (9 cases) or PMRT (4 cases); all 16 patients with re-excision or NAC removal had no residual tumour. There were no NAC recurrences with median follow-up of 28 months. Similar results by the same group were reported in Wang et al. (68). Of 32 cases with tumour on final pathology, 12 had nipple skin resection, 8 had PMRT, and 12 had no treatment; there were no recurrences in the NAC skin. Another paper from this group by Amara et al. (102) had 32 breasts with positive margin or nipple tissue, of which 11 had repeat incision, 5 had PMRT, 8 NAC removal, and 8 no further treatment; they also reported no recurrence in the preserved NAC skin.

Shanno et al. (95) found no significant difference in periareolar recurrence for patients with nipple excision compared with those with NAC excision. For patients with tumour in the nipple margin (excluding 4 patients without <1 year of follow-up), 64 had nipple excision, 34 had NAC excision, 15 had no excision (9 clear margins, 2 planned RT, 2 small amount of cancer, 2 only lymphovascular invasion). There were 2 recurrences as subareolar nodules, both in patients with initial nipple-only excision.

### *Intraoperative Frozen Section versus Definitive/Final Pathology*

While some of the above studies compared assessment of resected subareolar tissue by frozen section or permanent/final pathology, it was not the focus of any of the studies. Most studies that gave details of sampling and pathology analysis used intraoperative/frozen-section analysis and based decisions to excise the NAC on these results. However, some major institutions have implemented policies of using only final/definitive pathology.

Fregatti et al. (89) used definitive pathological examination of the retroareolar margin of the excision or nipple duct bundle to determine whether to excise the nipple. They note that permanent section analysis is more accurate and can distinguish between benign atypia and intraductal carcinoma that would be false positive in frozen section leading to unnecessary NAC excision, is more able to detect small foci of cancer that could be false negative on frozen sections, and allows time for consultation with the patient. Serio et al. (105) indicated that San Giovanni-Addolorata Hospital, Rome, Italy has used only definitive pathology since 2016 and that intraoperative pathology may have freezing artifacts that interfere with diagnosis, and false-positive and false negative cases.

Massachusetts General Hospital (affiliated with Harvard Medical School; Tang et al. (97), Smith et al. (98), Webster et al. (94), Shanno et al. (95)) and the University of California (Warren Peled et al. (101, 117), Wang et al. (68), Amara et al. (102), and Holland et al. (104)) appear to be leading centres in the field of breast reconstruction with many publications describing advancement of technique and clinical studies. They do not use frozen section analysis but instead do intensive ductal excision and base decisions on final pathology. The Massachusetts General Hospital group notes that practice is based in part on their earlier studies on techniques to ensure complete excision of duct tissue such as by Rusby et al. (294). Both groups have many other relevant studies, although they did not meet the inclusion criteria.

Studies on this topic but not meeting our inclusion criteria may provide further information (295-304). In general, frozen section analysis is specific but less sensitive. Alperovich et al. conducted one of the largest studies compared results for 307 breasts (301) and found sensitivity of frozen section analysis to be 0.58 and specificity of 1. The high specificity may be in part because the pathologists were cautious about reporting equivocal



frozen section analysis as positive due to the possibility of unneeded NAC resection. Of 20 positive subareolar biopsies only 6 resected specimens (NAC) had evidence of diseases.

Hogan et al. (296) also found that of nine cases of NAC excision due to intraoperative findings, six were benign and DCIS was found in three. A study by D'Alonzo et al. (298) evaluated the accuracy of sub-areolar/nipple tissue analysis in predicting NAC involvement. Compared with final pathology there were 6% false negative (3 cases of DCIS) and 11.5% false positive (3 cases of low-grade DCIS). They found that of 25 cases in which the frozen section was positive and the NAC was removed, only 10 had tumour in the NAC at conclusive pathology. Sensitivity of subareolar examination at predicting NAC involvement was 57.7%. Status of the margin facing the NAC, as well as size and number of tumour foci on subareolar tissue sample were associated with NAC status on multivariate analysis. With no ink on tumour, the risk of NAC involvement was <10%. Some studies use two biopsies, with the second being just beneath the retained NAC (305).

#### *Other Topics of Concern, Although Not Addressed Sufficiently in the Included Primary Studies* Sensation

An early anatomic study found that cutaneous innervation of the NAC is primarily via the anterior and lateral cutaneous branches of the fourth intercostal nerve; the third and fifth intercostal nerves contribute to a lesser extent (306) but are involved in overall breast sensation. A systematic review of innervation of the female breast and nipple (307) found, based on 19 studies, that anterior and lateral cutaneous branches of the second to sixth intercostal nerves innervate the breast skin, and that the NAC is innervated mainly by the anterior and cutaneous branches of the third to fifth intercostal nerves. The anterior and lateral cutaneous branches of the fourth intercostal nerve supply the largest area of the NAC and breast skin and are the most important to spare or repair during reconstructive surgery. The lateral branch is the most consistent contributory nerve to the NAC.

Careful identification of the nerves, in particular the fourth intercostal nerve, and avoiding damage during surgery is important in maintaining or restoring sensation to the NAC. Sensory nerve preservation should be considered unless it would compromise oncologic safety (308). When cutting these nerves is unavoidable, sensory nerve coaptation, neurotization, or innervated reconstruction may be possible. Collaboration of breast and plastic surgeons can aid in identification and preservation of the lateral fourth intercostal nerve during mastectomy and allow a longer length of sensory nerve to be maintained (121, 122). A loupe magnification for identification and sharp dissection to avoid thermal injury (as may occur with electrocautery) is recommended. A study using the ACS-NSQIP data found neurotization techniques used in 1.58% (218 patients) of autologous reconstructions and 0.037% (22 patients) of non-autologous reconstructions (implants and expander-implants) (309). Adoption is increasing, from a rate of 0.02% in 2015 to 0.65% in 2019. This study included any use of neurotization in breast reconstruction and NSM is not specifically mentioned.

Selection of incision site is important in both preservation of blood supply and minimizing nerve damage. The group at Massachusetts General Hospital prefers use of an inferolateral IMF incision (111, 114, 115) as there are less complications including nipple and skin necrosis. Surgeons at University of California use primarily IMF incision or superior periareolar incision encompassing less than one-third of the areolar circumference (101, 104, 116, 117), with others being much less frequently used. For patients who are candidates for either type of incision, the inframammary location is preferred due to much lower rate of NAC complications (7.4% vs. 25%) (104). Wong et al. at the University of Kentucky also use inferolateral incisions for TSSM (118). These incision decisions are based on NAC complications, and not retention of sensation.

A group of plastic surgeons from various institutions in the USA published a resource in 2024 to guide breast and plastic surgeons in mastectomy techniques that preserve nerves, including applied anatomy of breast innervation and steps to incorporate nerve-sparing mastectomy and breast neurotization (119). For most patients they prefer an inferolateral IMF incision, although a Wise Pattern reduction incision may be beneficial in patients with grade 3 ptosis or macromastia. The inferolateral incision allows better visualization and exposure of the lateral intercostal nerves and good cosmetic results, while an inferior vertical incision may be useful especially for surgeons with less experience in neurotization. Further details are in the guide.

Several publications designed to address sensation after NSM did not meet our inclusion criteria, most often due small numbers of patients (310-315) or insufficient descriptions of the patients and surgery used (316). One study provided normative data for testing with Semmes-Weinstein monofilaments in Caucasian women of varying breast size (317). Use of sensory innervation/neurotization in patients with NSM and either implant or autologous reconstruction has also been reported in smaller studies (291, 308, 318-323). These procedures have been reported to add 10 to 20 minutes to the overall operating time (321, 323). Four systematic reviews included 23 to 37 publications on neurotization in breast reconstruction and found improvements in clinical and psychosocial outcomes (324); that neurotization improved the rate, quality, and magnitude of sensory recovery (325); postoperative sensation returns spontaneously and unpredictably and that neurotization enhances the magnitude and rapidity of sensory restoration (326); and that sensory recovery of innervated flaps was superior and started earlier with higher chance of approaching normal values (327). A systematic review restricted to studies using Semmes-Weinstein monofilaments to measure sensation included 11 studies and found a lower threshold (higher sensitivity) in patients with neurotization (6.69 g/mm<sup>2</sup> vs. 38.85 g/mm<sup>2</sup>) (328). These reviews also noted heterogeneity in studies and that standard methodology in future studies is needed.

Surgical repair of transected nerves requires tension-free coaptation (329). If the two nerve ends are too far apart to join, then a bridge using a nerve graft may be required. A systematic review of nerve gap repair (not breast cancer) found meaningful recovery rates of 81.9% with allograft, 71.8% with autograft, and 62.2% with conduit; differences were statistically significant comparing either type of graft to conduit (330). Cost of the allograft is higher (\$5623 based on 2018 US Medicare data) but offset by lower operating room costs and avoidance of the need for a donor site. The only allograft currently available is Avance® (Axogen; Alachua, FL, USA) and according to the company, costs vary by application, presumably due to the length of allograft required; as of 2023 the cost in the US is highest for breast reconstruction neurotization at \$10,200 (331).

In some flap reconstructions it is possible to connect nerves in the flap to the cut nerves in the mastectomy site without the use of nerve grafts, and one plastic surgery practice has even named it TruSense® (PRMA Plastic Surgery, San Antonio, TX, USA) ((332, 333). The guide by Coopey et al. (119) mentioned earlier also describes total autogenous breast neurotization when allografts are not available. When an allograft is used, Axogen (Alachua, FL, USA) refers to this as Resensation® (334). Their website lists 143 surgeons in the USA; while products are available in Canada it appears not to be covered by OHIP for use in breast reconstruction (335).

#### Question 4. Implant Location

**Does the use of prepectoral implants for postmastectomy breast construction result in differences in outcomes than subpectoral implants?**

Results for Question 4 are summarized in [Table 4-8](#), [Table 4-9](#), and [Table 4-10](#). [Table 4-8](#) contains 26 studies with prepectoral reconstruction compared with subpectoral reconstruction, with use of ADM similar in each arm (66, 69, 134-138, 140, 154, 336-352). All except four compare prepectoral versus dual-plane reconstruction. [Table 4-9](#) consists of five studies where patients initially had subpectoral implants and due to complications (in particular animation deformity or pain) had conversion to prepectoral implants (30, 142-145). [Table 4-10](#) reports five studies where use of ADM is different in each arm, such as prepectoral with ADM versus subpectoral without ADM (70, 153, 154, 353, 354). It is difficult to interpret whether differences in outcomes are due to the ADM or implant location. Results should be interpreted together with those of Question 5, which deals with ADM.

Of the 26 studies in the [Table 4-8](#), 3 were conducted in Italy, 2 in Korea, 2 in France, and the rest in the United States. There was a high proportion of contralateral prophylactic mastectomies in many of the studies. In the various studies implants could be prepectoral (directly under the skin, with or without ADM), subpectoral (under the pectoralis major muscle) without specifying whether the lower pole is covered, submuscular (total coverage of implant beneath the pectoralis major and serratus anterior), dual-plane (upper portion under the pectoral muscle but with the lower portion only under the skin (ADM or other mesh used in most patients), or subpectoral and subfascial (under pectoralis major muscle and fascia of serratus anterior muscle). While we included only comparative studies, we included studies that compared any combination of these. As submuscular and subpectoral are often used interchangeably, as well as subpectoral and dual-plane, we used the study methods (where available) to classify studies and only relied on these terms in the absence of surgical/reconstructive details. Initial breast size, implant size, skin flap circulation, patient and surgeon preference, and other patient factors often determined the location of implant. Patients with poor perfusion or thin skin flaps as assessed during surgery were often placed in the non-prepectoral group. In some studies, patients with risk factors such as smoking or diabetes were also not considered for prepectoral implants. Multivariate or multivariable analysis was used in 10 studies, although often for only a subset of outcomes.

#### ***Risk of Bias and Quality of the Evidence***

A general analysis according to domains in the ROBINS-I tool follows:

- For Domain 1, the inclusion criteria specify that studies were only included if they attempted to minimize bias due to confounding by use of multivariable/multivariate analysis, propensity score or other matching, or narrow selection criteria such that patients are likely to have similar characteristics, and this was confirmed in tables of baseline characteristics. Studies with large difference in baseline characteristics were excluded unless such factors were adjusted for. There is some variability in how well studies achieved matching and appropriateness of variables in multivariate analysis, and therefore bias is low to moderate. Those that would be rated as more than moderate were generally excluded; some concerns are detailed in the data tables.
- Domain 2 (bias in selection due to using variables after start of intervention) does not apply (low risk of bias).
- Domain 3 (bias in classification of interventions) is also low to moderate depending on the terminology the authors used. Prepectoral is clear, whereas in a few studies it is

not clear whether total submuscular or partial submuscular (subpectoral or dual-plane) were used. These studies are categorized separately in the data tables.

- Domain 4 (bias due to departures from intended interventions) also does not apply (low risk of bias).
- Domain 5 (missing data) is potentially serious as data were extracted from medical charts and data may not be recorded uniformly or completely. There is no evidence that recording completeness would vary according to treatment/intervention.
- Domain 6 (bias in outcome measurements) is rated as low for total complications and some specific complications, while moderate for other complications such as necrosis which have no standardized definition.
- Domain 7 (bias in selection of reported results) is considered to be of low bias.

The overall risk of bias is therefore dependent mainly on selection of variables in multivariate analysis or matching and therefore often equal to assessment of Domain 1 (low to moderate risk). The reader is referred to the data tables and the description of individual studies in the following sections. Non-standardized definitions for specific complications likely contributes to a small extent and are only relevant for a few outcomes such as the distinction between complete or partial necrosis. Most studies have low to moderate risk of bias.

### ***Prepectoral versus Submuscular***

Two studies in Italy by members of the same group compared prepectoral foam-coated implants versus submuscular textured implants (134, 135). The final decision on type of reconstruction was based on flap thickness and perfusion. ADM was not used. Complications and recurrence were similar, while operating time was longer in the submuscular group. Franceschini et al. (134) found that the prepectoral groups had better aesthetics (excellent 65.6% vs. 11.3%), less chronic pain in the pectoral region (none or very mild 79.7% vs. 21.0%), less shoulder dysfunction (4.7% vs. 40.3%), less contralateral operations for symmetry (3.6% vs. 100%), and more skin sensibility (48.4% vs. 29.0%). The study by Scardina et al. (135) was in patients who had received NACT; symmetrization procedures were required in 28% versus 82% of patients with unilateral mastectomy.

### ***Prepectoral versus Subpectoral (Either Submuscular or Dual-Plane)***

Two studies (336, 337) compared prepectoral versus subpectoral (both submuscular and dual-plane used in the study). Darrach et al. (336) found that opioid use in the first 24 hours was lower in the prepectoral group. Kraenzlin et al. (337) found higher rates of mastectomy flap and NAC necrosis resulting in a higher rate of return to the operating room in the prepectoral group, but fewer clinic visits overall. Infection was lower in the prepectoral group, but not significantly after adjusting for mastectomy weight. Hematoma was found in 2.0% versus 4.9% ( $p=0.07$ ) and cellulitis in 7.8% versus 12.5% ( $p=0.09$ ).

### ***Prepectoral versus Dual-Plane***

The most frequent comparison was prepectoral versus dual-plane and was made in 22 studies (66, 69, 136-138, 140, 154, 338-352, 354). In dual-plane placement, ADM or other mesh was generally used to cover and support the lower half (lateral pole) of the expander or implant (the portion not under the pectoralis major muscle) and sutured to the lower border of the pectoralis muscle and in the area of the IMF. ADM was usually used with prepectoral implants to provide support of the lower pole and/or to provide an additional layer between the skin envelope and the implant. The expander or implant could be wrapped entirely with ADM (most

common), the pocket after SSM/NSM lined entirely with ADM, or ADM used only on the anterior surface and posterior lower pole. There is an assumption that the development and use of ADM has made prepectoral (and to lesser extent dual-plane) feasible. Most used ADM or other mesh in all patients, although Plachinski et al. (344) decided on prepectoral use depending on quality of tissue coverage and surgeon preference and thus used it in 69.9% of prepectoral implants and 90.3% subpectoral (lower pole coverage). Most also used ADM or mesh in all dual-plane implants, although Houvenaeghel et al. (154, 354) used TIGR<sup>®</sup> Matrix (Novus Scientific, Uppsala, Sweden) resorbable synthetic mesh in 54.3% of prepectoral patients and 1.7% of subpectoral patients. It is included here because they conducted regression analysis with ADM use as one of the factors. Some of the more recent studies found in the updated search used ADM in most prepectoral cases but only a portion (65% to 74%) of dual-plane cases (348-351).

Banuelos et al. (137) reported on complications in obese patients ( $\text{BMI} \geq 30 \text{ kg/m}^2$ ) and used ADM in 93.7% of prepectoral cases and 93.2% of subpectoral cases. They found that while obesity increases complications and failure rates, these were similar in both groups and therefore is not a contraindication for consideration of prepectoral implants; additional care may be needed with  $\text{BMI} > 35 \text{ kg/m}^2$ . While methods indicated multivariate analysis was to be used, adjusted results were not reported. Asad et al. also studied the effect of obesity ( $\text{BMI} \geq 30 \text{ kg/m}^2$ ) and used ADM in 95.1% prepectoral and 70% of subpectoral reconstructions (348). Overall complications, explanations, and infections were lower in the prepectoral group.

Most studies found little or no significant differences in complications. Copeland-Halperin et al. (136) found lower postoperative pain, as measured by opioid use and refills in the prepectoral group. Bozzuto et al. (342) also measured postoperative pain in matched groups and using multivariate analysis and found significantly lower patient-reported pain and opioid use until discharge. Holland et al. (347) also found lower opioid use in the prepectoral group ( $p < 0.001$ ,  $p = 0.048$  multivariable analysis) and maximum patient-reported pain ( $p < 0.004$ ,  $p = 0.001$  multivariable analysis).

Avila et al. (140) found lower rates of ischemic complications of nipple necrosis, mastectomy flap necrosis, and nipple loss due to necrosis in the prepectoral group and no differences in infection, hematoma, seroma, implant loss/exchange in univariate analysis. A composite outcome of overall complications found rates of 5.91% versus 9.41% ( $p = 0.1842$ ), with similar results after multivariate analysis ( $\text{OR} = 0.61$ ,  $p = 0.190$ ). Gabriel et al. (66) found in univariate analysis that the prepectoral group had lower rates capsular contraction, infection, and seroma. Multivariate logistic regression was conducted of the outcome of any complication and found prepectoral group was better (14.7% vs. 25.8%,  $p = 0.030$ ;  $p = 0.013$ ). In contrast, Plachinski et al. (344) found no difference in major complications but higher rates of minor complications (21.7% vs. 7.8%) in the prepectoral group, mostly due to differences in seroma (20.5% vs. 4.9%). The prepectoral group had shorter hospital stays, fewer expansion visits, less animation deformity, and less prescriptions for muscle relaxants. Ribuffo et al. (345) found lower rates of any complication, seroma, hematoma in the prepectoral group. They did not perform multivariate analysis, but patient characteristics were well-balanced. They also found lower animation deformity (0 vs. 68.7%), and better aesthetic results in the prepectoral group. Houvenaeghel et al. (354) found higher patient satisfaction and shorter duration of surgery for prepectoral implants.

The largest study was by Hung et al. (351). They found higher rates of early complications with prepectoral reconstruction in the first (expander) stage in bivariate but not multivariate analysis and higher rates of late infection after 30 days ( $\text{HR} = 2.4$ ,  $p = 0.01$ ). There were no differences in second stage (implant) early complications, but higher late infection rates ( $\text{HR} = 5.3$ ,  $p = 0.03$ ) with prepectoral implants. Houvenaeghel et al. (154) found higher rates of overall complications within 90 days for the prepectoral group but after multivariate regression there were no differences in overall or grade 2 to 3 complications. Asaad et al. (349)

found no differences in complications; only 33.7% completed PROs and therefore sample size was too small for PROs. Hassan et al. (350) found no significant differences. Min et al. (138) found that prepectoral reconstruction had less seroma and implant migration than dual-plane reconstruction.

### ***Conversion from Subpectoral to Prepectoral***

Conversion to prepectoral placement in patients with previous subpectoral or dual-plane implants suffering from animation deformity or other implant-related issues was reported in five publications (30, 142-145) summarized in [Table 4-9](#). In these cases, patients would serve as their own controls for outcomes related to the presenting complaints. ADM was used for all of the implant revisions in three of the studies and 81.3% in the study by Holland et al. (30). In the latest study by Salgarello et al. (145) ADM was only used in the first seven patients, while the remaining patients had polyurethane foam-coated implants. Publications by Sigalove et al. and by Gabriel et al. (142) include several of the same authors and the patient population may overlap. In these two studies, surgical complications were 3.9% and 3.2%. In the study by Sigalove et al. (144), most patients had animation deformity (99.2%), pain (99.2%), and asymmetry (96%), sometimes accompanied by implant malposition (68.5%), capsular contracture (16.9%) or rippling (1.6%). All presenting complaints were resolved and did not recur. In Gabriel et al. (142), 94.1% of patients had animation deformity and 89.2% had pain; after revision to prepectoral placement all animation deformity was resolved; pain was not measured but no patients complained. Complaints were animation deformity, implant distortion, and tightness in the study by Jones et al. (143). After revision surgery all animation deformity was resolved, and most patients had improved range of shoulder movement; there was also improvement in overall breast aesthetics including better cleavage appearance. Minor contour deformity and rippling were treated with fat grafting in 18.3% of patients. Revision surgery complications included 4.2% infection, 2.1% seroma, and 0.7% for hematoma, dehiscence, partial necrosis, explantation. No capsular contraction occurred in the 44 months follow-up and authors attributed this to use of ADM and a biofilm reduction protocol. Holland et al. (30) included patients with animation deformity and this was resolved in all patients. This study had higher rates of complications, with 2.5% requiring reoperation and 13.8% treated for infections, but no reconstructive failures. Asymmetry occurred in 21.25% of patients, and was lower when ADM was used (15.4% vs. 47.0%). Similarly, capsular contraction occurred in 6.25% of patients (1.5% with ADM and 26.7% without). Preoperative fat grafting was used in patients with <1 cm of subcutaneous tissue before prepectoral conversion operation (52.5% of patients). These patients had less asymmetry, capsular contraction, and cosmetic revision surgery. Salgarello et al. (145) conducted a cosmetic evaluation and reported high scores (2/2) in most patients. Mild capsular contracture occurred in most patients (47.1% Baker grade 1a, 42.5% grade 1b, 10.4% grade 2), and pain resolved in all patients. All measures on the BREAST-Q also improved (values of 23 to 40 prior to replacement increased to 83 to 96).

### ***Studies Where Plane of Implant and ADM Use are Both Varied***

Five studies compared prepectoral to submuscular or subpectoral (dual-plane) placement of implants in which ADM use was different in each arm (70, 153, 154, 353, 354). These studies are summarized in [Table 4-10](#). Except for the second Houvengaeghel publication (154), mesh or ADM use was 0% versus 100% and therefore cannot be adjusted for in matching or multivariate analysis. Comparison therefore is only to a system of reconstruction such as prepectoral with ADM versus subpectoral without ADM; the relative importance of ADM compared with plane of implant cannot be determined. These studies could also be considered as part of Question 5 on ADM use, with the same limitations.

Bettinger, 2017 (70) found complications to be 13.33% prepectoral with ADM versus 6.49% submuscular without ADM. Adjusted relative risk is given compared with a third arm, but appears that the difference is not significant. Talwar, 2024 (353) compared prepectoral (96.6% had ADM) versus submuscular (4.8% had ADM) and found the prepectoral group had more surgical site infection, seroma, expander loss, and less mastectomy flap necrosis and NAC necrosis. They suggested that staging reconstruction to allow complete eradication of infection and proper wound healing and vigilant sterile technique may be beneficial. The higher rate of gram-negative organisms may be related to prolonged drain use in the prepectoral group. Whether the higher rates of complications are due to implant plane or use of ADM is unknown; ADM used were non-sterile forms.

Houvenaeghel et al. (354) used TIGR Matrix in 86.6% of prepectoral and 0.9% of subpectoral patients. There were no significant differences in complications and patient satisfaction was better with the prepectoral group. Duration of surgery was less in the prepectoral group. An additional analysis of the same study (154) with more patients indicated use of prepectoral reconstruction increased sharply over time. Use of mesh peaked at 92% for prepectoral implants in 2021 and decreased to 6.7% in 2023 due to reports of a negative impact on complication rate. Overall, mesh was used in 54.3% prepectoral and 1.7% subpectoral implants. Using multivariate regression, there were no differences in complications or grade 2 to 3 complications, or patient satisfaction. Smoking, larger breasts (cup size >C), higher American Society of Anesthesiologists (ASA) status, mesh use, and areolar or inverted T incision increased complications, while smoking, mesh use, greater mastectomy weight (>300 g), and diabetes increased grade II-III complications.

Chen et al. (153) took the opposite approach to most studies and used ADM or poly-4-hydroxybutyrate mesh (P4HB) in dual-plane implants but no ADM/mesh in prepectoral implants. A Cox proportional-hazards model was used only for capsular contracture. Capsular contraction was higher in the P4HB group (HR=1.60, p=0.01 compared with no mesh), while dual-plane implants with ADM and prepectoral implants without ADM/mesh were similar (HR=0.85, p=0.38). Prepectoral and dual-plane with ADM had similar rates of necrosis, infection, and revision surgery, while necrosis and infection were lower with the P4HB mesh. Multivariate analysis was not used for these outcomes.

### ***Plane of Implants Summary***

Overall, studies found that placing implants under muscle required slightly longer operations and resulted in higher levels of postoperative pain, but similar surgical complications. Longer term, animation deformity is an adverse effect that may occur with implants placed under muscle. Revision surgery to change implants from submuscular/subpectoral to prepectoral eliminated animation deformity and greatly reduced pain, while improving cosmetic results and PROs. Surgical complications may depend more on surgical technique than plane of implant. Avila et al. (140) noted that evolution of technique to preserve subdermal vascular supply, use of gentle retraction, and careful dissection in the supra-areolar region has improved results. As noted in Question 3, the size of expander/implant and rate of expansion may influence rates of complications. Subpectoral placement was often used if patients were judged not suitable for prepectoral implants, and therefore it is difficult to assign outcomes specifically to location of implants. Several studies have suggested ADM use contributes to infection, and the next question should be looked at for this topic.



**Question 5: Acellular Dermal Matrix**

**After therapeutic mastectomy, do outcomes differ for breast reconstruction using human-derived acellular dermal matrix (ADM), synthetic absorbable matrix, or no scaffolding/matrix? Are there differences in outcomes between different human ADMs or different synthetic absorbable matrices?**

**Background**

A list of some of the different ADM mentioned in publications is provided in [Table 4-11](#). Animal-derived products are generally used in Europe, while both human-derived and animal-derived products are used in the USA. Animal-derived products and non-absorbable synthetic mesh are not included in this review. AlloDerm™ (LifeCell Corporation, Branchburg, NJ, USA) appears to be the most widely investigated and used human-based ADM in Canada and the USA; all studies included in this review in which the ADM was specified used AlloDerm in at least one arm of the study.

Until 2010, AlloDerm was provided as an aseptic freeze-dried form that needed to be rehydrated for 30 minutes prior to use (355). FlexHD is another aseptic product, but stored in alcohol instead of being freeze-dried (356, 357). AlloDerm RTU (ready to use) became available in 2010 and is terminally sterilized to a Sterility Assurance Level (SAL) of  $10^{-3}$  and requires soaking for 2 minutes (148, 358). More recently it has been renamed as AlloDerm SELECT™ Regenerative Tissue Matrix (AlloDerm SELECT RTM or AlloDerm RTM) and is sold by Allergan Aesthetics an AbbVie company. Many studies do not specify the type of AlloDerm, and it can be assumed based on the year of patient enrollment. DermACELL (LifeNet Health, Virginia Beach, VA, USA), AlloMax, DermaMatrix, and NeoForm are sterile products with an SAL of  $10^{-6}$  (357, 359). ADM may be modified during manufacturing or by the end user. The regular or confluent form is unmodified. It may be perforated (360) by punching holes by the surgeon, or more uniformly during production. ADM may be meshed by cutting slits that increase expansion and surface area (150, 361-364) and improve fluid egress, and presumably reduce seroma formation. Fenestration generally refers to cutting slits (especially staggered to allow expansion) but sometimes refers to perforating. Especially for prepectoral use where the entire expander or implant is wrapped, modifications allow better and neater fitting and sometimes allows smaller pieces of ADM, thus reducing cost. Products may be shaped by the user during surgery to fit the implant, such as the butterfly wrap (365), the wonton or ravioli technique (366, 367), or using Kirigami cutting (368).

**Overview of Results**

Comparisons of human-derived ADM or synthetic mesh are reported in 59 publications summarized in [Table 4-12](#), [Table 4-13](#), [Table 4-14](#), and [Table 4-15](#) (67, 111, 139, 149, 151-158, 217, 218, 283, 355, 369-411). Two studies were conducted in Korea, one in Canada, the MROC study in the USA and Canada, and the rest in the USA. Additional publications with prepectoral implants in one arm were summarized in Question 4. Of the included publications, 30 (26 studies) in [Table 4-12](#) addressed use of ADM compared with no ADM (67, 111, 155-158, 217, 218, 283, 369-389). Only two used the same surgery/implant position with and without ADM (67, 155). Twenty (15 studies) in [Table 4-13](#) compared different ADMs (111, 149, 283, 390-406), 8 in [Table 4-14](#) investigated different treatment or form of ADM (139, 355, 389, 407-411), and 4 in [Table 4-15](#) compared synthetic mesh to either ADM or none (151-154). There were three RCTs (plus one terminated early), while the others were non-randomized comparative studies (4 prospective, 1 unclear, the rest retrospective).



### ***Risk of Bias and Quality of the Evidence***

Of the four RCTs for Question 5 on ADM use, all had high risk of bias (see [Appendix 4](#)) as assessed by the Cochrane RoB2 tool and evaluated as providing low certainty of evidence.

A general analysis according to domains in the ROBINS-I tool follows for comparative studies that were not randomized:

- For Domain 1 (confounding), the inclusion criteria specify that studies were only included if they attempted to minimize bias due to confounding by use of multivariable/multivariate analysis, propensity score or other matching, or narrow selection criteria such that patients are likely to have similar characteristics (and confirmed in tables of baseline characteristics). Risk of bias is therefore low to moderate depending on the quality of adjustments.
- Domain 2 (bias in selection due to using variables after start of intervention) does not apply (low risk of bias). Risk of bias was considered to be low to moderate.
- Domain 3 (bias in classification of interventions) is low.
- Domain 4 (bias due to departures from intended interventions) also does not apply (low risk of bias) as ADM was either used or not used.
- Domain 5 (missing data) is potentially serious as data were extracted from medical charts and data may not be recorded completely but is not expected to vary according to treatment/intervention.
- Domain 6 (bias in outcome measurements) is rated as low. Outcomes without sufficient events for multivariate analysis were either noted or not extracted.
- Domain 7 (bias in selection of reported results) is considered to be of low bias.

The overall risk of bias is dependent mainly on selection of variables in multivariate analysis or matching and often equal to assessment of Domain 1 (low to moderate risk). The reader is referred to the data tables and the description of individual studies in the following sections. Most studies have low to moderate risk of bias.

The overall certainty of evidence is moderate for outcomes of total complications and for the difference in specific complications being small. Overall certainty of exact values for specific complications is very low due to low numbers of studies for each comparison, low event rates, and variability between studies.

### ***ADM versus No ADM - Studies with AlloDerm***

AlloDerm use was compared with no ADM in 11 studies conducted in the USA (67, 155-158, 378, 384-388) (see [Table 4-12](#)). The only RCT was terminated early due to slow accrual (386) with 70 patients; while the primary outcome was postoperative pain, the baseline pain levels were not the same. ADM was usually used with either subpectoral or dual-plane implants. Most non-ADM groups had either complete muscle coverage (submuscular), or dual-plane under pectoralis major muscle plus the lower pole under the skin/subcutaneous tissue or serratus anterior muscle fascia.

Only two used the same surgery/implant position with and without ADM (67, 155). Nahabedian et al. (155) used dual-plane implants with or without ADM. Infection rate was 5.85% with ADM and 5.0% without. Warren-Peled et al. (67) used ADM along the inferolateral border of the pectoralis major muscle, with the non-ADM group having the same implant placement but without ADM. The inferior aspect of the pectoralis major was left intact at the inferior origin superior to the IMF. Technical refinements to reduce NAC complications to <5% had been made prior to this prospective study, and then three cohorts of consecutive patients were

studied (no ADM 2006 to 2007, with ADM 2007 to 2008, selective ADM for patients with thinner skin flaps 2008 to 2010). Groups were not equivalent and the difference in PMRT use was statistically significant. Multivariate analysis was not used except to compare groups. Infection was 15.8% with selective ADM use, 20% in the ADM cohort, and 27.8% without ADM ( $p=0.04$ ); expander-implant loss was 5% with selective ADM, 7% in the ADM cohort, 17.8% in the cohort without ADM ( $p=0.001$ ); unplanned return to the operating room was 10% with selective ADM, 11% in the ADM cohort, and 23.3% without ADM ( $p=0.004$ ); and skin flap necrosis 6.2% with selective ADM, 6% in the ADM cohort, and 11.1% without ADM ( $p=0.26$ ). After adjusting for age and BMI, they found use of PMRT increased the risk of complications between two-fold and six-fold. Given unequal use of PMRT between groups, as well as higher rates of therapeutic mastectomy in the no ADM group, these alone could account for differences in complications observed. While the study may be too small for multivariate analysis, its omission makes conclusions of low value. This placement varies from the usual dual-plane or submuscular placement and with these modifications ADM use may only be required in select cases.

The other studies used a dual-plane approach with ADM covering the inferior pole and attached to the pectoralis major muscle and IMF area. Four studies compared dual-plane implants with ADM to submuscular implants without ADM (384, 385, 387, 388). Differences in outcome could be due to patient selection, use of ADM, or differences in plane of implants; multivariate analysis cannot control for the latter two variables. Therefore, these studies can only be used to compare dual-plane plus ADM to submuscular without ADM but do not address the role of ADM. Vardanian et al. (385) found that the dual-plane plus ADM group had lower rates of capsular contracture, IMF problems, and mechanical shift in multivariate analysis, and also less overall complications in univariate analysis. Aesthetic outcomes were rated as significantly better in the dual-plane group. Parks et al. (387) used logistic regression for expander loss and found no difference; multivariate analysis was not used for other outcomes, although they reported seroma was higher in the dual-plane plus ADM group. Weichman et al. (388) did not report the multivariate results; unadjusted data showed higher rates of major complications, infections, flap necrosis, and explantation in the ADM group and no difference in seroma or hematoma. The study by Sbitany et al. (384) found similar rates of complications but did not adjust for the fact that the ADM group had greater expander size and intraoperative fill volume.

Three publications from Brigham and Women's Hospital in Boston (156-158) used dual-plane with ADM compared with either total (submuscular) coverage or dual-plane position for the group without ADM but did not subdivide results according to implant position. The publications therefore have the same limitations as those with submuscular implants. Due to high seroma rates with ADM in the first study (14.1% ADM vs. 2.7% without,  $OR=4.24$ ,  $p=0.018$ ), as well as higher rates of necrosis and infection (157), the authors made modifications to their procedure (158) and found the rate of seroma decreased (4.7% vs. 1.4%,  $p=0.2277$ ), although skin flap necrosis was still very high (28.3% vs. 5.5%,  $p=0.0003$ ). This may have been partially due to the much higher intraoperative fill volume in the ADM group (298.1 mL vs. 96.5 mL,  $p<0.001$ ), as well as higher mastectomy specimen weight and BMI; these are all risk factors for necrosis but were not adjusted for. A third study at the same institution but by different investigators reported surgical complications of 19.5% versus 12.3% ( $OR=1.76$ ,  $p=0.036$ ) and infection rates of 6.8% versus 2.5% ( $OR=3.25$ ,  $p=0.097$ ). Other outcomes were not analyzed with multivariate analysis; major skin necrosis was 11.7% versus 8.3% ( $p=0.282$ ) and seroma 7.1% versus 3.9%,  $p=0.136$ . As in the other studies, mastectomy weight, initial expander or implant volume, and final implant volume were higher in the ADM group but only BMI and ADM use were included in multivariate analysis. They did not take into account that some patients in the non-ADM group had submuscular implants.

Two studies at Northwestern Memorial Hospital in Chicago (369, 370) used either AlloDerm or FlexHD® (Musculoskeletal Transplant Foundation [MTF], Edison, NJ, USA) with dual-plane implants versus none for submuscular implants. Differences in complications were not statistically significant. Two studies were conducted in Korea (371, 372). The first used human ADM (non-fenestrated) either dual-plane or to fill the gap in almost submuscular insertion versus submuscular without ADM (371). In matched analysis there were no differences in skin flap complications, infection, overall complications, major complications, and reconstructive failure; seroma rates were 4.0% versus 8.5% ( $p=0.065$ ). The second did not specify type of ADM, but previous reports by the same authors used mainly AlloDerm or CGDerm/CGCryoDerm (372-374). They compared ADM to cover inferolateral aspects of the tissue expander versus no ADM using serratus anterior muscle fascia and found no difference in hematoma.

#### ***ADM versus No ADM - Studies With AlloDerm RTU***

Weichman et al. (389) compared Alloderm RTU with dual-plane implants to no ADM with submuscular implants in a prospective cohort study. Flap necrosis, major flap necrosis, infection, and cellulitis requiring intravenous (IV) antibiotics were higher with AlloDerm RTU, but differences were not statistically significant. As baseline differences existed and multivariate analysis was not used, interpretation of the results is uncertain.

#### ***ADM versus No ADM - Studies With Type of ADM Not Specified***

The MROC study (217, 218) reported on use of ADM in immediate reconstruction with expanders. While prospective, it did not attempt to differentiate between ADM type and did not report the expander/implant or ADM location. Use of ADM was highly surgeon-specific, with either used in most patients (49.6% of surgeons) or rarely used (25.8% of surgeons). ADM and BMI had significant interaction on outcomes of any complication or major complications. There was no significant difference in PROs using the BREAST-Q instrument.

Lin et al. (111) compared use of ADM (AlloDerm [most common], FlexHD, Vicryl, Vicryl/ADM hybrid, SurgiMend) versus none in immediate implant-based reconstruction. There was no difference in rates of overall complications or nipple necrosis.

Studies using the ASPS-TOPS database (376) and the ACS-NSQIP database (379-381, 383) used CPT (Current Procedural Terminology codes, USA) and/or ICD (International Statistical Classification of Diseases and Related Health Problems; formerly International Classification of Diseases) codes to identify expander/implant-based breast reconstruction with ADM. These codes do not give information about specific ADM used nor the location of ADM and implant for the ADM group. While such studies contain large numbers of patients, they are limited in the amount of information on patient and disease characteristics, surgical technique, and outcomes. Panucci et al. (376), using ASPS-TOPS found tissue expander loss of 2.58% with ADM versus 1.88% without ( $OR=1.42$ ,  $p=0.026$ ) but noted statistically significant outcomes may be clinically trivial and ADM may improve the ability to perform breast reconstruction. Using the ACS-NSQIP database, Luo et al. (381) found higher rates of surgical site infection (3.9% vs. 3.4%,  $RR=1.10$ ,  $p=0.03$ ) and reoperation (7.4% vs. 6.0%,  $RR=1.15$ ,  $p<0.001$ ) and no difference in dehiscence (0.7% vs. 0.7%,  $RR=1.02$ ,  $p=0.86$ ). Graziano et al. (383) reported  $OR=0.997$  ( $p=0.017$ ) for superficial wound infection; while statistically significant due to the large database, this difference is not clinically meaningful.

Kilmer et al. (377) used the PearlDiver insurance-based database, also without information on specific ADM use or location, for patients with immediate implant or expander (plane not specified). They only conducted multivariate analysis for risk factors for implant removal, and ADM had  $OR=1.22$  ( $p<0.001$ ).

Other studies (369-375) used human ADM versus none, but listed more than one type of ADM or did not specify the type at all. Seth et al. (369) found slightly higher rates of various complications with ADM (OR=1.17 to OR=1.64) but these were not statistically significant. Jordan et al. (370), Woo et al. (371), Lee et al. (372) found no significant difference in complications. Pires et al. (375) also found no significant difference in complications within three months. Plotsker et al. (378) compared prepectoral reconstruction with or without ADM and found no statistically significant differences in expander loss, although the study was underpowered. Multivariate analysis was not used for other complications; in univariate analysis there were no significant differences.

### ***Comparison of Different ADM***

Various ADM products are compared in 19 publications of 15 trials summarized in [Table 4-13](#) (111, 149, 283, 390-406). The BREASTrial (396-399) was an RCT comparing AlloDerm to DermaMatrix used as an inferolateral sling. Arms were also not balanced, with the DermaMatrix arm having more advanced disease (stage III or IV 18.7% vs. 37.6%) and correspondingly higher use of chemotherapy and PMRT and more smokers (0% vs. 9.4%). With only 64 patients per group the study was underpowered to find difference in complication rates and had insufficient events for multivariate analysis. The REaCT investigators (390, 391) conducted an RCT comparing non-fenestrated AlloDerm RTU versus DermACELL for dual-plane implants. Groups had 31 patients each; due to the small size there were imbalances in mastectomy weight, smoking status, location of incisions, heart disease, breast size, and ptosis grade. There were no significant differences in complications. The AlloDerm group had better PROs of Satisfaction with Breasts and Overall Satisfaction at 3 months but no difference at 12 months. A third RCT by Broyles et al. (404) included 117 patients with AlloDerm RTU and 113 with Flex HD pliable. While no differences were found, the study was underpowered due to lower than anticipated complication rates; only 22 events occurred.

The other studies were non-randomized retrospective studies. Three compared AlloDerm RTU to DermaCELL. Johnson et al. (394) found higher rates of seroma with the AlloDerm and no differences in surgical site infection. Zenn et al. (395) found no seroma in either group, and very low rates of hematoma (0 vs. 0.8%) and infection (0.8% vs. 1.7%). Berger et al. (393) found similar 90-day complication rates.

AlloDerm was compared with FlexHD in six studies, plus the RCT by Broyles mentioned already. Palaia et al. (149) compared these with additional comparison with or without fenestration. In the comparison of AlloDerm versus FlexHD there were no differences in seroma, infection, or explantation; extrusion was higher in the AlloDerm group. Cosmetic score was higher in the AlloDerm group ( $8.7 \pm 1.5$  AlloDerm vs.  $8.4 \pm 1.7$  FlexHD,  $p=0.0717$ ; multivariate  $p=0.0466$ ) but it is unclear whether this is a meaningful difference. In a comparison of fenestrated versus non-fenestrated ADM, seroma was lower in the fenestrated group; there were no differences in infection, extrusion, explantation, or cosmetic scores. Seth et al. (400) found no differences in total complications, flap necrosis, expander migration, hematoma, seroma, exposure/dehiscence; infection was 10.3% versus 5.2% (multivariate OR=2.11,  $p=0.09$ ). Liu et al. (401) reported surgical site infection of 8.5% versus 14.4% ( $p=0.15$ ; multivariate OR=0.44,  $p=0.053$ ) and no difference in delayed healing; events were too low to analyze other complications. Ranganathan et al. (402) found no difference in seroma, delayed wound healing, return to operating room, or implant exposure. Major infections were lower in the AlloDerm group (8.1% vs. 17.7%, OR=0.50,  $p=0.049$  on a per-patient basis; 5.3% vs. 12.7%, OR=0.35,  $p=0.004$  on a per-breast basis). The study by Sobti et al. (403) was more recent and used AlloDerm (60% RTU and 31% freeze-dried) or FlexHD (primarily pliable perforated); they found no differences in complications. Chu et al. (392) found no difference in expander loss (OR=1.37,  $p=0.658$ ); other complications were not included in the multivariate analysis.

Keifer et al. (405) compared AlloDerm to Cortiva and found no difference in overall complications, seroma/hematoma, or infection. Mastectomy flap necrosis was 0.6% versus 4.8% ( $p=0.022$ ;  $p=0.059$  by logistic regression but based on only 8 events). Authors concluded complications were equivalent. Hadad et al. compared AlloDerm (aseptic) using more (traditional dual-plane) or less (patching lateral area of reconstruction; pectoralis not released) and found more seroma (3% vs. 0%,  $p=0.01$ ) and infection (9% vs. 1%,  $p<0.05$ ) with the dual-plane procedure. It is not possible to attribute differences to ADM use as surgery was also different. Lin et al. (111) compared AlloDerm, FlexHD and Vicryl (or Vicryl hybrid). AlloDerm had numerically lower unadjusted rates of overall complications, skin flap necrosis, explantation, and reconstructive failure, while FlexHD and Vicryl/Vicryl Hybrid were equivalent. Rates were similar for nipple necrosis, hematoma, and seroma. Type of ADM/mesh was not included in the multivariate analysis.

### ***Different ADM Preparations/Treatments***

Eight studies compared various forms of ADM (139, 355, 389, 407-411) and are summarized in [Table 4-14](#). Five compared AlloDerm (aseptic/freeze-dried) to AlloDerm RTU (sterile) (355, 407-410) and one made the same comparison and included an additional arm of contoured + fenestrated ADM (presumably RTU/sterile based on years used) (407). One compared DermACELL or MegaDerm with fenestration (139). The same group (411) compared sterile (irradiated) DermACELL or MegaDerm to nonsterile CGCryoderm (all fenestrated)

Hanson et al. (410) used propensity-score matching of AlloDerm aseptic versus sterile/RTU resulting in 384 matched pairs, and found higher early complications (37.5% vs. 28.9%,  $p=0.011$ ) in the aseptic group. Surgical site complications were similar in the first stage (expander) (21.4% vs. 16.7%,  $p=0.103$ ) and lower with aseptic AlloDerm in the second stage (0.3% vs. 3.9%,  $p<0.001$ ); the later result may be due to relatively low complications rates in both groups. Infection rates were similar (9.6% vs. 7.8%,  $p=0.354$ ), while failure was higher with aseptic AlloDerm (7.8% vs. 4.4%,  $p=0.050$ ).

Parikh et al. (355) compared AlloDerm aseptic versus sterile/RTU. In multivariate regression of primary outcomes, they found no difference in any complication or in infections requiring iv antibiotics, but explantation was 18.0% versus 12.0% (OR=1.570,  $p=0.0161$ ). Other complications were low and differences not statistically significant; multivariate analysis was not conducted.

Widmyer et al. (409) used aseptic AlloDerm until 2011 and then sterile/RTU AlloDerm thereafter, with the last 123/227 RTU patients receiving the perforated contoured form (results not reported separately). They found higher rates of infection, implant loss, and unplanned reoperation in the aseptic group, and no significant differences in seroma, hematoma, or necrosis. Multivariate analysis was not conducted; however, due to the consecutive nature of assignments, patient characteristics were similar between groups, other than that the aseptic group was younger, had lower BMI, and used more expanders (87% vs. 36%). These factors would be expected to lower the risk of complications and therefore do not detract from the results.

Frey et al. (407) compared AlloDerm aseptic versus RTU versus contoured and fenestrated. The groups were not equivalent, with a switch to more NSM and direct-to-implant reconstruction over time and corresponding switch to AlloDerm RTU and then contoured plus fenestrated ADM. This could contribute to the increasing rates of minor mastectomy flap necrosis over time, and higher rates of major mastectomy flap necrosis in the contour arm than the RTU arm. Multivariate analysis was not conducted. Infection rates were highest with aseptic AlloDerm, intermediate with sterile RTU AlloDerm, and lowest with contour fenestrated AlloDerm (major infection 11.0% vs. 4.3% vs. 1.7%; minor infection 7.7% vs. 3.0% vs. 0%). The study by Weichman et al. (389) likely overlaps with the study by Frey et al. (407), and found

no difference in flap necrosis between aseptic and RTU/sterile AlloDerm; infection was 20.0% aseptic versus 8.5% RTU ( $p=0.0088$ ) and cellulitis (deep infection requiring IV antibiotics) was 12.2% versus 4.7% ( $p=0.069$ ).

Yuen et al. (408) used multivariable model only for the outcome of cellulitis and found this higher in the sterile/RTU group (12.5% vs. 21.0%,  $p=0.129$ ;  $aOR=0.269$ ,  $p=0.011$ ); however, they noted that cellulitis was significantly higher in patients with  $BMI \geq 30 \text{ kg/m}^2$  and for patients with lower BMI the type of ADM had no effect on outcome. The model included only obesity, NACT, and type of ADM. Due to differences in BMI between groups, small numbers of patients with  $BMI < 30 \text{ kg/m}^2$ , and the large effect of BMI on outcomes, these results may be less reliable than other studies which found the opposite results.

The study of Han et al. (139) comparing prepectoral wrap-around or anterior ADM coverage using DermACELL or MegaDerm (both fenestrated during operation) found similar rates of complications and noted the wrap-around can make the breast more ptotic in shape. Multivariate analysis was not used. The other study by this group compared sterilized (DermACELL or MegaDerm) versus non-sterilized ADM (CGCryoderm), with all fenestrations during operation. Surgical complications were similar, but implant failure was 3.4% versus 0%. As multivariate analysis was not used, it is unclear whether there are any difference due to sterilization and not baseline differences in patients.

### ***ADM Plus Synthetic Mesh versus ADM Alone***

Four studies had comparisons of synthetic mesh (151-154) and are summarized in [Table 4-15](#). The study by Sigalove et al. (151) explored using a bioabsorbable synthetic mesh (GalaFLEX) to replace part of the ADM (AlloDerm) that would otherwise be used as a means of minimizing cost. AlloDerm alone was therefore compared with AlloDerm + GalaFLEX. When using both materials, AlloDerm was used to cover the lower third of the expander, and the rest of the expander was covered with GalaFLEX. Any complication rates were 7.6% with AlloDerm alone and 6.4% in the combined group ( $p=0.590$ ). Any skin necrosis was higher in the AlloDerm group (5.2% vs. 1.2%,  $p=0.011$ ); this could be due to differences in patient or disease characteristics or transition in operating methods. There were no significant differences in infection, major skin necrosis, seroma, capsular contracture, prosthesis exposure, or prosthesis loss. The study authors noted that GalaFLEX is stiffer and gives a more stable pocket, but AlloDerm is preferred for the lower pole to allow for expansion.

Levy et al. (152) compared AlloMax (fenestrated) versus P4HB. Major complications and infection were higher with AlloMax, but differences were not significant after univariate analysis. Chen et al. (153) compared prepectoral (no ADM) to dual-plane with either ADM or P4HB. Necrosis and infection were lower with P4HB (no multivariate analysis), but capsular contraction was higher in univariate and multivariate analysis. Houvenaegh et al. (154) compared TIGR Matrix to none in mostly prepectoral implants. In regression analysis mesh use was associated with a higher rate of complications.

## **Question 6. Autologous Fat Grafting**

**What are the benefits and risks of autologous fat grafting (lipofilling) as an adjunct to breast reconstruction?**

### ***Risk of Bias and Quality of the Evidence***

Two RCTs on fat grafting provided data for specific applications and outcomes. Gentilucci et al. (161) used fat grafting after RT and was rated as low risk of bias and provides high-quality of evidence for this use. The Breast Trial (168-171) used fat grafting alone with primary outcomes of QoL and reconstruction quality. It was rated as having some concerns due to deviations from intended interventions but otherwise low risk of bias. It provides moderate



certainty of evidence for benefit but is not generalizable to use of fat grafting to smoothing or filling of defects.

A general analysis according to domains in the ROBINS-I tool follows for non-randomized comparative studies:

- Studies were only included if they attempted to minimize bias due to confounding by use of propensity score or other matching (11 studies), multivariable/multivariate analysis (7 studies), or selection criteria such that patients are likely to have similar characteristics (with confirmation in table(s) of baseline characteristics; 3 studies). Due to this requirement in the inclusion criteria, studies had moderate to low risk of bias in Domain 1. In the overall review, matching studies tended to be of higher quality than others, and for Question 6 there was a much larger portion of matching used.
- Domain 2 (bias in selection due to using variables after start of intervention) does not apply (low risk of bias).
- Domain 3 (bias in classification of interventions) is low.
- Domain 4 (bias due to departures from intended interventions) also does not apply (low risk of bias).
- Domain 5 (missing data) is potentially serious as data were extracted from medical charts and data may not be recorded uniformly or completely. There is no evidence that recording completeness would vary according to treatment/intervention.
- Domain 6 (bias in outcome measurements) is rated as low for total complications and some specific complications, while moderate for other complications such as necrosis which have no standardized definition.
- Domain 7 (bias in selection of reported results) is considered to be of low bias.

The overall risk of bias is dependent mainly on selection of variables in multivariate analysis or matching and often equal to assessment of Domain 1 (low to moderate risk). The reader is referred to the data tables and the description of individual studies in the following sections. Oncologic outcomes were the primary concern and due to low-moderate risk of bias, combined with consistency of results (see following section and meta-analyses) and large number of studies, we consider the level/quality/certainty of evidence for oncologic outcomes to be high. When also considering consistency and generalizability of results, there is moderate to high level of evidence for benefit such as aesthetics and QoL, low to moderate level of evidence for specific complications. It is noted that complications depend greatly on surgical technique and expertise.

### **Overview of Results**

Twenty-nine publications of 24 studies on autologous fat grafting are summarized in [Table 4-16](#) (159-161, 168, 170-172, 412-433). There were two RCTs and two prospective non-randomized studies; the rest were retrospective non-randomized comparative studies. One of the major concerns with fat grafting is whether there is increased cancer recurrence or lower survival. To address this, data that report on these outcomes have been summarized in forest plots in [Figures 4-1](#), [4-2](#), and [4-3](#). These figures indicate that there is no significant difference in cancer recurrence with fat grafting compared with no fat grafting. Results for survival outcomes are based on fewer studies and events but suggest fat grafting also does not affect survival.

The BREAST Trial (168, 170, 171, 412) randomized patients to reconstruction with fat grafting alone or to reconstruction with expander-implants. A negative pressure external device was used before and after fat grafting sessions. The power calculation required 86 patients per group, while only 64 and 68 patients completed follow-up. Patients with BMI >30

kg/m<sup>2</sup> or with breast size more than a C cup (unless contralateral reduction was desired) were excluded. Using the Breast-Q, they found at the 12-month assessment that the fat grafting group had higher Satisfaction with Breasts (70.3 vs. 60.4,  $p=0.002$ ), Physical Well-Being Chest (79.9 vs. 72.3,  $p=0.007$ ), and Satisfaction with Outcome (73.9 vs. 66.3,  $p=0.04$ ). These differences were also clinically relevant. Sexual Well-Being was different at baseline (54.4 vs. 61.1); this improved over time in the fat grafting group (61.5 at 12 months) but decreased in the implant group (58.6 at 12 months). Because of differences at baseline, the difference in Sexual Well-Being between groups at 12 months was not statistically significant. The fat grafting group had less non-oncologic serious adverse events, while oncologic events were similar up to 1 year. Long-term results are not yet available. For non-serious adverse events, the fat grafting group had higher rates of seroma and hematoma. Most others adverse events were specific to the technique used: the fat grafting arm had irritation/itch/pain or blisters due to BRAVA external expander, fat necrosis, or donor site pain; while the implant group had implant or expander rupture or migration and capsular contracture. An additional exploratory study suggested better sensibility with fat grafting (168).

Figure 4-1. Effect of Fat Grafting on Cancer Recurrence (various types)






Figure 4-2. Effect of Fat Grafting on Locoregional and Distant Recurrence)





Figure 4-3. Effect of Fat Grafting on Survival Outcomes



The other RCT, by Gentilucci et al. (161), included 30 patients with fat injections and 30 without who had expander-implant reconstruction and PMRT. The fat injections were used after PMRT and prior to expander-implant exchange. The group with fat injections had less complications ( $p=0.07$ ) including delayed wound healing, seroma, implant extrusion and dermal fibrosis; less disability measured with the LENT-SOMA scale; and better aesthetic evaluation. Capsular contraction was similar but of lower grade in the fat injection group. The fat injection group had soft adipose tissue thickness of 0.36 at first session and 1.78 at time of expander removal, while the group without fat grafting had thickness of 0.42 at time of expander removal ( $p<0.001$ ).

The MROC study (159) included 165 patients with contour irregularities or volume deficits and fat grafting between years 1 and 2. Patients with fat grafting had lower QoL than controls before fat grafting and QoL similar to controls afterwards, suggesting that fat grafting is beneficial in patients with contour irregularities or other defects.

The other prospective study used stromal vascular fraction (SVF)-enriched fat transfer compared with fat transfer or none (422). There were no differences in LR, LRR, or DFS; distant metastasis was 7.3% versus 3.1% versus 3.1%. Adjusted odds ratios indicated no significant differences for any recurrence events ( $aOR=1.92$ ,  $p=0.477$  for enriched vs. control;  $aOR=1.26$ ,  $p=0.778$  for normal fat transfer vs. control). DFS from the time of NSM was 37, 34, and 38 months. The SVF group had only 41 patients; it did not meet our criteria of 50 patients for this group and results are less reliable than for the other two comparisons. Many of the other studies matched patients with and without lipofilling and looked for oncologic events as summarized in [Figures 4-1 to 4-3](#).

As indicated above, most studies that reported oncologic outcomes found no significant effect of fat grafting. An exception is the study by Lee et al. (430) that reported lower survival rates with fat grafting; however, there are several concerns with data analysis. Methods state that patients were categorized by timing of fat graft in relation to primary operation (mastectomy), as fat grafting  $\leq 12$  months or  $>12$  months after mastectomy. It is implied but not stated explicitly that fat grafting was a one-time event that took place during the same operation as expander-implant exchange. It is assumed that corresponding controls were patients with expander-implant exchange  $\leq 12$  months or  $>12$  months after mastectomy. Results indicate the median time between mastectomy and expander-implant exchange was 12.0 months and therefore one-half of patients should have had the second operation after 12 months. This is contradicted by the statement that 203/267 patients had the second-stage operation within 1 year and 64/267 at  $>12$  months. Of patients with expander-implant exchange within 12 months, 112 of 203 had fat grafting and 91 did not. While the authors state groups had similar baseline characteristics, data indicate the fat graft group had more axillary dissection and positive lymph nodes, higher stage disease, more lymphovascular invasion, and received more adjuvant chemotherapy and hormone therapy. Follow-up after the second operation was longer for the fat grafting group. These factors suggest that patients with fat grafting had a higher baseline risk of recurrence. There were ten recurrences with fat grafting and three without, and three versus zero breast-cancer related deaths. The 5-year DFS was 93.4% versus 98.7%, and the 5-year locoregional recurrence-free survival (LRRFS) was 95% versus 100%. Survival curves showed no differences until approximately 55 months. Median follow-up was 65 months, suggesting that almost half of patients were censored and did not contribute to 5-year DFS and 5-year LRRFS. The univariable analysis found ADM use had the largest effect ( $HR=35.8$ ) on LRRFS but it was not included in multivariate analysis; tumour stage, lymphovascular invasion, BMI, and fat grafting all contributed to increased rates of LRRFS and the contribution of fat grafting alone is unknown. Many of these factors were imbalanced in the groups. While multivariate analysis was conducted, we consider that the number of events

is insufficient to conduct reliable multivariable analysis. The authors state there were no differences in outcomes with or without fat grafting when fat grafting and expander-implant exchange occurred after 12 months; however, the data when looked at in isolation suggest a protective effect of fat grafting (6.9% vs. 14.3% recurrence; 95.2% vs. 89.0% 5-year LRRFS; 95.2% vs. 82.1% 5-year DFS). This is based on small numbers of patients (29 with fat grafting and 35 without). The combined recurrences in both analyses were 12 versus 8 events, and this could be due to unequal baseline characteristics. Combined data have been included in the forest plots. The reversal in outcome depending on timing of expander-implant exchange could be an artifact and authors of the current review do not consider it to be a reliable conclusion.

Kim et al. (416) found that complications increased with fat graft volume, with a mean volume of 45.2 mL without complications and 67.5 mL with complications. Complications tend to be minor such as fat necrosis and cyst formation. Calabrese et al. (160) reported lower rates of capsular contracture (7.14% vs. 21.53%) with fat grafting, as well as lower rates of hematoma, implant displacement/rotation, pain, and revision surgery within 3 years. Using the BREAST-Q, patients with fat grafting reported significantly better for several scales of Satisfaction (softness, natural appearance and feel to touch, natural part of body) and of Physical Well-Being (pain in chest muscles; breast tightness, pulling, nagging feeling, sharp pains, aching feeling, throbbing feeling). There were no differences in Psychosocial and Sexual Well-Being questions.

Cason et al. (172) reported on imaging and biopsies after fat grafting. They found more palpable masses (38.0% vs. 18.3%). These were mostly normal or benign on imaging and biopsies were only required in 11.8% versus 7.5% of patients. Fat necrosis was the most frequent radiologic interpretation and is generally identifiable on imaging.

Palve et al. (428) studied use of implants and lipofilling in LD reconstruction and suggested that fat grafting can replace implant use and allow less aggressive subcutaneous tissue harvesting in the LD site. Escandon et al. (432) compared LD with or without immediate fat transfer and found no differences in breast site complications. There were higher rates of secondary fat grafting in patients with initial fat grafting and the authors suggested this could be due to patient factors regarding those who chose initial fat grafting. The group with immediate fat transfer had less wound disruption at the donor site, possible due to less aggressive flap harvesting in patients also having fat grafting.

## Other Technical Notes

Several publications in the literature review identified issues that the surgeons should be aware of. A systematic review of these topics was not conducted and inclusion in this section on its own should not be the basis of a change in practice.

### *Sentinel Lymph Node Biopsy*

Boneti et al. indicated that isosulfan blue dye for sentinel lymph node biopsy (SLNB) should be avoided as it causes skin flap necrosis and permanent staining and that technetium-99m sulfur colloid should be used instead (239). Kim et al. also indicated to use radioisotope for SLNB instead of blue dye as the dye may be a risk factor for necrosis (77). ICG may be another option (434).

### *Necrosis and Blood Flow*

Karin et al. (141) discuss use of MRI blood flow information to preserve the NAC blood supply. Blood flow was internal mammary artery perforator dominant to the NAC in 92% and preserved in 89% of patients. Complete nipple necrosis occurred in one patient with IP

dominant blood supply but for which the blood supply was not preserved. Garwood, 2009 (127) suggests electrocautery may cause damage to vessels in the 1 to 3 mm layer of dermal tissue and result in necrosis. Nitroglycerin paste has been used to reduce necrosis (435-438). A systematic review (439) suggests dimethyl sulfoxide may also improve skin flap survival, enhance skin expansion, and stimulate wound healing; its use is less common than nitroglycerin paste. Some publications indicated they did not use nitroglycerin paste because patients were not remaining in hospital.

### *Quilting*

Reducing dead space using flap fixation with quilting sutures has reduced seroma formation (438, 440-444). Quilting involves suturing skin flaps to the underlying muscle and reduces seroma (445). Some studies have eliminated drains in conjunction with these techniques.

### *Negative Pressure*

Negative pressure (446) has sometimes been used. A Cochrane Collaboration systematic review on this topic is available (447) and indicates there are several ongoing trials.

### *Indocyanine Green Angiography*

Use of ICG angiography allows visualization of blood flow in the tissue of interest and reduced rates of flap loss (130). Reviews on this topic have been conducted by others (448, 449). Several studies used ICG angiograph to monitor skin flaps and autologous flaps (131-139). One indicated use was discontinued after they became more proficient at clinical assessment (140).

### *Involved Margins*

When positive/involved surgical margins are detected, it is unclear whether to use re-excision, RT, or none. Sasada et al. (235) found 7-year LR 1.9% with RT and 12.6% without (aHR=0.17, 95%CI=0.04 to 0.80).

### *Timing of Surgical Complications*

The ACS NSQIP database used only complications within 30 days of surgery. Studies using the Nationwide Readmissions Database which includes early (0 to 30 days) and late (31-90 days) readmissions found there are significant numbers of readmissions for infections and wound complications in autologous reconstruction that occur after 30 days (450). For surgical wound-related admissions the rate was 4.3%, with 65.4% of these early and 34.6% late. An increase to 36 days after surgery captured 75% of readmissions. With breast implants, 50.7% of readmissions for infections occurred between 31 and 90 days after operation (451). A study using ACS NSQIP data noted that for immediate reconstruction it is difficult to distinguish complications related to reconstruction from those due to the mastectomy (231).

## **DISCUSSION AND CONCLUSIONS**

Breast reconstruction is an area of rapid growth in research and knowledge. In the literature search there were approximately 1100 publications per year in 2014, increasing to about 1500 by 2018 and around 2000 in the latest years. Many of these reported on experience of various surgeons in case reports or other retrospective series, as well as basic research on

various topics. Most of the studies included in this systematic review were retrospective studies using hospital records to compare different treatments or factors, with randomized trials being rare. As expected with this study design, patient characteristics were often not reported in detail and there were differences between groups being compared because treatment was designed based on patient and disease characteristics instead of by random allocation or other method to ensure equivalence. Most studies had too few patients and too few events to allow meaningful multivariate/multivariable analysis. Surgical information was often not reported in sufficient detail to allow assignment of outcomes to differences in technique. We did, however find 229 studies that met the inclusion criteria. Through this process it became clear that studies clearly evaluating and documenting surgical experience and the effectiveness of systematic and well-documented changes in procedures would also be valuable in addressing some of the questions. These studies illustrate what has been achievable by surgeons and groups that have established expertise in various aspects of NSM and breast reconstruction and may provide some guidance to other oncologic and reconstructive surgeons. For this reason, the observations from some of these studies supplement the results of the systematic review.

For many questions, we were unable to conclude that treatment A is better than B, and found rather that both alternatives had acceptable outcomes, often with different profiles of complications that could mean appropriateness for some patients but not others. Patient characteristics (such as comorbidities affecting wound healing and risks of infection and tissue necrosis), breast size and implant size, ptosis, and receipt of RT interact with other factors and therefore decisions tend to be quite individualized.

Our overall conclusions are that all the variations of reconstruction are oncologically safe and there is a role for each. This is based on the aggregate data and moderate certainty of evidence. Complication profile varies and suitability may vary depending on patient characteristics. Immediate and delayed reconstruction, prepectoral/subpectoral (dual-plane)/submuscular plane, use of ADM, use of fat grafting, use of NSM all have their role, and moderate certainty evidence exists to support this. Evidence is of lower quality in guiding the best approach as there are often competing risks and benefits that can be modified by surgical technique and patient comorbidities, a need for values judgement, and decisions about what complications are more acceptable and treatable.

### **Question 1. Patient and Disease Factors**

We identified over 1000 publications in preliminary screening that explored patient or disease factors that may influence outcomes. These include studies designed to investigate the effect of a specific factor such as smoking or obesity, as well as studies that did not meet our inclusion criteria for Questions 2 to 6 but conducted multivariate or similar analysis and identified other risk factors affecting outcomes. Limitations of time and resources meant that we could not evaluate most of these studies and instead relied on systematic reviews for the more commonly investigated topics. Future work may explore some of the other patient and disease factors that may affect outcomes.

Studies found small or no increase in complications with increasing age after controlling for comorbidities and other factors. Reconstruction had positive benefits on QoL. Kim et al. used age as a continuous predictor in a set of 4379 patients and found complications (mastectomy skin flap/nipple necrosis, infection, seroma) increased by 1 to 2% per year of age (37). Comparing free flap reconstruction in patients age 70 to 74 years versus age <55 years, Honig et al (221) found there were small increases in rates of delayed healing (35.7% vs 29.2%,  $p=0.036$ ), skin necrosis (15.3% vs 10.7%,  $p=0.039$ ), and hematoma (9.3% vs 5.3%,  $p=0.005$ ); they concluded an age cutoff was not warranted. A study using the ACS-NSQIP database for patients with pedicled flaps found a small increase in overall complications (OR=1.010, 95% CI=1.004 to 1.006,  $p=0.002$ ), severe complications (OR=1.043, 95% CI=1.019 to 1.068,  $p<0.001$ ), and wound

complications (OR=1.009, 95% CI=1.000 to 1.018, p=0.053), but concluded the effect of age does not have strong predictive power and may not be clinically relevant on its own. (38).

Patient factors such as smoking and diabetes, which are well known to affect circulation and healing may increase risk of certain complications, but on their own are not absolute contraindications to reconstruction. Aesthetic outcomes may be worse for patients with obesity. NSM may not be feasible without repositioning of the nipple in patients with a higher degree of obesity or ptosis. Obesity is also a risk factor for surgical complications, and the risk increases with grade/degree of obesity. Effects of various factors may be additive and together make reconstruction (or certain types of reconstruction) to be considered inadvisable. As risk profiles of different reconstructions vary (outside scope of this review), some patients may be considered poor candidates for specific reconstructions. Several studies reviewed for other questions indicated that large breast size (or mastectomy weight) and large implant size were risk factors for complications as these are associated with poorer skin perfusion. Risk can be reduced by ensuring expanders or implants do not put pressure on the skin or tension on the closure and may mean lower initial expansion or smaller implants.

## **Question 2. Timing of Reconstruction**

Evidence on timing of reconstruction was very limited. For an individual patient, risks for one option such as immediate reconstruction may be considered too high and delayed reconstruction is recommended by the surgeon. Alternatively, when both immediate and delayed reconstruction are both considered of acceptable risk, immediate may be preferred due to better short to medium term psychological outcomes. There is consistent evidence for this, although limited in this review.

As a general principle, immediate reconstruction will require a longer and more complex operation than mastectomy alone, but with mastectomy alone the reconstruction will require an additional operation with its own set of complications. It is therefore difficult to compare the total level of complications for both mastectomy and reconstruction, or alternatively to measure complications only due to reconstruction but not mastectomy. Very few studies mentioned or accounted for this. In general, mastectomy alone is shortest operative duration, followed by mastectomy plus implants; mastectomy plus autologous reconstruction requires the longest operating time. Some patients due to comorbidities may not be good candidates for a longer operation and for this reason delayed reconstruction may be advised. Immediate reconstruction may not be advised following SSM or NSM in cases when the skin shows poor perfusion. In these cases, a short delay in reconstruction may occur (e.g., 2 weeks) and a temporary expander is sometimes used. This may be preplanned, or decided during the mastectomy operation. Patient preference is a major factor, with many preferring immediate reconstruction in order not to have to wake up from the operation (and live like that for months or years) without a breast. Others may be undecided about reconstructive options and a delay gives them additional time. BREAST-Q scores tend to be lowest between mastectomy and reconstruction, and then improve gradually following reconstruction, illustrating a negative effect of delayed reconstruction. Some other guidelines suggest that immediate reconstruction should be the norm. NICE recommends to “offer immediate breast reconstruction to women who have been advised to have a mastectomy, including those who may need RT, unless they have comorbidities that rule out reconstructive surgery” (452).

RT is known to cause an increase in complications, including capsular contracture when expanders or implants are used, delayed healing, and worse aesthetic results. The increased complications exist, regardless of timing of reconstruction, but may have a different profile. For two-stage implants, irradiation of expanders is common, thus avoiding irradiation after the final implant, and this has been found to decrease the rate of capsular contracture compared with irradiation of the implant (60). Results were similar with PMRT then delayed implant-

based reconstruction. However, grade III complications and reconstructive failure were lowest in the immediate group. Staged or delayed-immediate or immediate-delayed with an expander or temporary implant after SSM or NSM has been used to maintain the skin flap and provides a breast mound while awaiting reconstruction. This allows time for recovery prior to reconstruction or while awaiting final pathology or other information that determines the need for PMRT. It has also been used on the assumption that PMRT to an expander is preferable to irradiation of the final implant or autologous flap. Several small studies (not meeting our sample size criteria) have used this with good results. Christopher et al. (64) found less fat necrosis and skin necrosis in the delayed group, but infection and wound dehiscence during the expander-delay stage which increased the overall complication rate in the delayed group. Overall, there is limited evidence regarding optimal timing of reconstruction and the decision may come down to patient preference, individual risks for specific complications, and ability of surgeons to minimize or treat the complications.

### **Question 3. Nipple-Sparing Mastectomy**

Studies found that NSM and SSM have equivalent oncologic outcomes, and that risks of LR in patients who had NSM are low, provided adequate assessment of NAC involvement is conducted. For patients considered suitable for SSM, NSM may also be considered. A small (<1 cm or <2 cm) TND was not an absolute contraindication for attempting NSM. Most studies considered inflammatory breast cancer, Paget disease, nipple involvement and nipple retraction as contraindications and patients were excluded. Lowest recurrence rates were found in studies that specified that nipple coring or sampling of ducts in the core occurred. It is not possible to determine whether duct sampling or nipple coring is essential or is an indication of better-quality studies and surgeon expertise. Studies with the highest rates of LR or recurrence in the NAC were conducted in Asia and did not mention duct sampling/coring. Worse outcomes could be due to patient factors or surgical procedures.

The studies indicate wide variability of complications and other outcomes depending on patient and disease factors, as well as surgeon expertise and techniques used. Surgeon factors include type of incision used, degree of excision of breast tissue, tension on skin (which may be reduced by lower filling of expanders, smaller implants, or surgical delay before reconstruction), methods to assess vascularity/blood supply, dissection methods, use and duration of surgical drains, antibiotic use, and whether attempts were made to identify and preserve, or reconnect nerves.

### **Question 4. Plane of Implants**

Animation deformity, pain, and asymmetry are well-known complications of submuscular and to a lesser extent dual-plane implants and may be of serious concern for some patients. Removal of implants and replacement with prepectoral implants resolved the presenting complaints and improved BREAST-Q scores. Prepectoral implants avoid these complications as well as generally being a shorter operation. Use of ADM and synthetic mesh allowed a rapid increase in prepectoral and dual-plane reconstruction. The ADM or mesh allowed implant placements that previously were not feasible. However, there is concern with increased infection and other complications with ADM (see Question 5). A few studies have adapted the process to allow prepectoral or dual-plane reconstruction without ADM and this appears to be a promising approach for some patients.

Most studies on prepectoral reconstruction used ADM for full or anterior coverage and several studies used ADM in dual-plane reconstruction to create a sling supporting the lower pole of the expander or implant. Short-term postoperative pain was lower with prepectoral reconstruction. There was generally little difference in complications between these two

approaches, and the profile varied among studies. Overall, prepectoral location appears to have slightly less complications. It should be noted that patients deemed not suitable for prepectoral reconstruction were often converted to subpectoral reconstruction and this may influence the reported results.

Details of reconstruction, including type and location of implants or autologous tissue should be documented in the clinical records and available to radiologists when conducting follow-up imaging.

### **Question 5. Acellular Dermal Matrix Use**

Increased rates of infection and seroma have been reported with the use of ADM. Both of these appear modifiable by selection and treatment of ADM prior to use. AlloDerm is the most frequently studied material in the included studies and was aseptically processed but not sterilized until 2010, after which AlloDerm RTU terminally sterilized to a SAL of  $10^{-3}$  replaced it. Some other products have SAL  $<10^{-6}$ . In earlier studies meshing was done in the clinic prior to use and pre-meshed or perforated forms are now marketed. Some current studies report lower infection rates, and this may be due to changes in processing as well as reduced handling and better infection control in the clinic. Meshing allows better conformation to the implant, reduced size of ADM and therefore cost, and better exchange of fluid (thought to reduce seroma), and better integration into the tissue. Surgical factors may be important, as illustrated by a decrease in seroma rate from 14.1% to 4.7% in the ADM groups and 2.7% to 1.4% without ADM after modification of procedures at Brigham and Women's Hospital in Boston (156-158).

As noted in Question 4, comparisons are often confounded by change in both plane and ADM use. Generally, differences in complications were none or slightly increased with ADM but not statistically significant. Many studies reported no significant difference between use of ADM or no ADM. Studies with the ASPS-TOPS and ACS-NSQIP databases found small increase in surgical site infection, expander loss, and reoperation, but differences may not be clinically significant. Studies comparing AlloDerm to other ADM found no consistent differences. Studies comparing AlloDerm aseptic to AlloDerm RTU found more complications including infection with the aseptic form, although this is of mostly historic importance in comparing older studies. Studies of synthetic absorbable mesh were too limited to comment on the relative value of ADM versus synthetic mesh.

### **Question 6. Autologous Fat Grafting**

Studies indicated there were no significant differences in cancer recurrence with or without fat grafting. Fat grafting was found to have several benefits. Fat grafting was most commonly used to treat contour irregularities or volume deficits and improved aesthetic results, QoL, and outcomes of the BREAST-Q. This appears to be a well-accepted and effective use. A small RCT (161) also reported benefit after PMRT and prior to expander-implant exchange. The group with fat injections had less complications, including delayed wound healing, seroma, implant extrusion and dermal fibrosis; less disability measured with the LENT-SOMA scale; and better aesthetic evaluation. Capsular contraction was similar but of lower grade in the fat injection group. This and other studies suggest fat grafting may help in healing of tissue after RT damage and improve the quality of the radiated skin (453). One study (428) found fat grafting may replace implants used in conjunction with LD flap reconstruction. Another application of fat grafting is for total breast reconstruction, without the use of implants or autologous flaps. This may be done with pre-expansion such as in the randomized BREAST Trial (168, 170, 171, 412). Good results have been obtained; however, patients need to be very



committed to this process. Non-comparative studies (454, 455) have reported good results without pre-expansion.

Palpable masses as a result of fat necrosis may occur in patients who have received fat transfer. Fat necrosis was the most frequent radiologic interpretation and is generally identifiable on imaging without biopsy in most cases. Details of reconstruction and location and type of implants, autologous reconstruction, and fat grafting should be detailed in the clinical history and available to radiologists to aid in interpretation and avoid false positive diagnosis.

A recent book (2023) on the topic of fat transfer in plastic surgery covers much of the background and technical details (456). Several chapters are of relevant to breast reconstruction. Zingaretti et al. (457) discuss hybrid fat transfer using implants and fat transfer. Berrino and Berrino (453) discuss total reconstruction with serial lipofilling and indicate multiple fat injections can be used in patients with preserved submammary fold and relaxed mastectomy site skin. Expansion (internal or external) is required in patients when the submammary fold has been violated and moved upwards during mastectomy. Internal expansion, sometimes referred to as Reverse Expansion and Lipofilling (REAL) uses an expander gradually inflated and then serially deflated with fat injection at each session (453, 458). Its use after NSM or SSM is also detailed (459). The UK guideline is reference document on lipomodelling of the breast that may also be useful (176).

## EVIDENCE TABLES

Table 4-1. Systematic Reviews and Meta-analyses .....	91
Table 4-2. Effect of Age on Reconstructive Outcomes .....	99
Table 4-3. Question 2: Immediate versus Delayed.....	102
Table 4-4. Question 3a: NSM versus SSM .....	118
Table 4-5. Question 3b: Oncologic and nipple outcomes according to criteria for NSM patient selection & Question 3c: Surgical factors influencing nipple outcomes .....	123
Table 4-6. Question 3b/c: Summary Statistics for Patients with NSM .....	186
Table 4-7. Question 3b/c: Summary Statistics for Patients with NSM, Excluding Four Studies* .....	186
Table 4-8. Question 4: Comparisons of Prepectoral, Subpectoral, and/or Dual-plane Reconstruction. A. Prepectoral versus Other, ADM use Similar .....	187
Table 4-9. Question 4: Comparisons of Prepectoral, Subpectoral, and/or Dual-plane Reconstruction. B. Conversion of subpectoral to prepectoral .....	209
Table 4-10. Question 4: Comparisons of Prepectoral, Subpectoral, and/or Dual-plane Reconstruction. C. Prepectoral, Subpectoral, and/or Dual-plane Reconstruction; ADM different in each arm .....	215
Table 4-11. Types of Mesh .....	220
Table 4-12. Question 5: Acellular Dermal Matrix. A. ADM versus none .....	221
Table 4-13. Question 5: Acellular Dermal Matrix. B. Comparison of ADMs .....	239
Table 4-14. Question 5: Acellular Dermal Matrix. C. ADM Treatments .....	251
Table 4-15. Question 5: Acellular Dermal Matrix. D. Comparison of synthetic mesh .....	257
Table 4-16. Question 6: Autologous Fat Grafting .....	261

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q1](#)[Back to Start of Tables](#)**Table 4-1. Systematic Reviews and Meta-analyses**

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
Comorbidities/patient factors						
BMI or obesity						
Panayi, 2018 (42)	Impact of obesity on outcomes in breast reconstruction: A systematic review and meta-analysis	Effect of obesity (BMI >30 kg/m <sup>2</sup> )	Cochrane, PUBMED, and EMBASE from inception to June 1, 2016	Conducted in line with Cochrane Handbook; published protocol; GRADE to assess methodological quality; used Quality of Reporting of Meta-analyses guidelines; reported in line with PRISMA criteria	33 studies (29 with enough data for meta-analysis; 71,368 pts, 20,061 obese) Only non-RCTs were found	Complications, obese vs. other: surgical RR=2.29 (fat necrosis RR=1.65, seroma RR=1.96, partial flap failure RR=1.60, total flap failure RR=1.97, wound dehiscence RR=2.51, wound infection RR=2.34, hernia RR=1.67); medical RR=2.89, return to operating room RR=1.91  Subgroups of surgical complications (obese vs. non-obese): implants RR=2.64, autologous RR=2.59  With just comparative studies, RR=2.36 for surgical complications  Surgical complications by class of obesity: class I (30-34.9 kg/m <sup>2</sup> ) RR=1.32; class II (35-39.9 kg/m <sup>2</sup> ) RR=1.84; class III (>40 kg/m <sup>2</sup> ) RR=1.66
Tan, 2022 (219)	Deep inferior epigastric perforator (DIEP) flap safety profile in slim versus non-slim BMI patients: A systematic review and meta-analysis	DIEP in slim vs. non-slim pts; autologous DIEP	Cochrane, EMBASE, OVID Medline, PubMed, and Web of Sciences; searched Feb 1, 2021; looked at reference lists of retrieved articles	Followed PRISMA guidelines; quality assessed using MINORS	7 studies, 574 pts slim (low BMI; mean 22.9 kg/m <sup>2</sup> ) and 901 pts non-slim (mean BMI 27.9 kg/m <sup>2</sup> )	No difference in complete or partial flap loss, fat necrosis, all complications, abdominal wound healing, infections, seroma
ElAbd, 2022 (43)	Autologous versus alloplastic reconstruction for patients with obesity: A systematic review and meta-analysis	Autologous vs. implants in pts with obesity Definition of obesity not reported; data tables suggest cutoff ≥30	PubMed, Cochrane, Google Scholar, Embase from inception to Dec 31, 2020; cross-bibliography review of included studies	Followed PRISMA protocol; included controlled studies; quality assessment using MINORS	12 studies (7 in meta-analysis); 11,895 pts (3845 autologous, 8050 implants), mean BMI 33.8±1.9 kg/m <sup>2</sup>	Autologous compared with implants: lower infection, hematoma, seroma, reconstructive failure; no difference in skin necrosis, wound dehiscence; worse deep vein thrombosis, pulmonary embolism, better BREAST-Q (but p>0.05)

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
Diabetes						
Liu, 2022 (39)	Impact of diabetes on outcomes in breast reconstruction: A systematic review and meta-analysis	Complications in pts with diabetes	PubMed, Embase, and MEDLINE from inception to Nov 1, 2020  Included comparative studies only (prospective observational or retrospective cohort studies and case-control studies)	Conducted in accordance with PRISMA, registered on PROSPERO	38 studies in meta-analysis 151,585 pts, including 9299 with diabetes	<ul style="list-style-type: none"> <li>Overall complications 11.6% vs. 5.6%, OR=2.04, p&lt;0.0001 [35 studies]; in subset with quality score &gt;9: 10.2% vs. 3.5%</li> <li>Surgical complications 7.7% vs. 3.3%, OR=2.23, p&lt;0.0001 [15 studies]; in subset with quality score &gt;9: 7.8% vs. 2.5%</li> <li>Implant loss/flap failure 2.5% vs. 1.6%, OR=1.68, p=0.0003 [10 studies]</li> <li>Infection 6.8% vs. 2.5%, OR=3.88, p&lt;0.0001 [4 studies]</li> <li>Skin necrosis 23.8% vs. 6.5%, OR=2.82, p=0.001 [4 studies]</li> <li>Length of hospital stay &gt;5 days: 41.0% vs. 34.7%, OR=1.31, p&lt;0.01 [3 studies]</li> </ul>
Mortada, 2023 (40)	The impact of diabetes mellitus on breast reconstruction outcomes and complications: A systematic literature review and meta-analysis	Complications in pts with diabetes	PubMed, MEDLINE, Cochrane until Jan 2022  Included RCTs, prospective or retrospective cohort/comparative, case-control, or case series	Followed PRISMA, Cochrane review methods, registered in PROSPERO	43 studies in qualitative synthesis 19,731 diabetes, 197,812 without  Subset of 5 studies in meta-analysis; 13,293 diabetic and 114,845 non-diabetic	<p>No difference in risk of total flap loss (RR=1.04, p=0.892), wound infection (RR=1.25, p=0.579), or total flap complications (RR=1.17, p=0.417); higher wound dehiscence (RR=2.18, p&lt;0.0001)</p> <p>Other complications only reported in 1 or 2 studies and therefore not included in meta-analysis:</p> <ul style="list-style-type: none"> <li>Donor site hernia/abdominal bulge 3.8% vs. 4.1%</li> <li>Abdominal flap necrosis at donor site 3.8% vs. 2.0%</li> <li>Mastectomy flap necrosis 5.6% vs. 5.5%</li> <li>Seroma 9.1% vs. 9.8%</li> <li>Flap hematoma 2.1% vs. 4.4%</li> <li>Flap thrombosis 1.2% vs. 0.9%</li> <li>Partial flap loss 0.4% vs. 0.4%</li> </ul> <p>There is correlation between diabetes and impaired wound healing; data support using caution and clinical reasoning, but that diabetes is not a contraindication to reconstruction</p>
Smoking						
Theocharidis, 2018 (41)	Current evidence on the role of smoking in plastic surgery elective procedures: A systematic review and meta-analysis	Role of smoking in facelift, abdominoplasty, breast reduction, breast reconstruction	PubMed and Cochrane January 1950 to October 2016	Conducted according to PRISMA	26 for breast reconstruction 21,639 pts divided as 1841 smokers and 19,798 non-smokers	<p>Pts with breast reconstruction, ever smokers vs. non-smokers:</p> <ul style="list-style-type: none"> <li>Postoperative complications OR=1.91, 95% CI=1.69-2.17;</li> <li>Donor site complications OR=1.59, 95% CI=1.27-1.99, p&lt;0.001</li> <li>Infection OR=1.66, 95% CI=1.05-2.63, p=0.03</li> <li>Fat necrosis OR=1.62, 95% CI=1.06-2.48, p=0.024</li> <li>No significant difference in hematoma, seroma, mastectomy flap necrosis, reoperation</li> </ul>

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
					22,647 pts when divided as 2578 ever smokers and 20,069 non-smokers	
Various Predictors						
Mrad, 2022 (44)	Predictors of complications after breast reconstruction surgery: A systematic review and meta-analysis	Effect of age, diabetes, hypertension, obesity/BMI, smoking, RT, COPD	MEDLINE and Cochrane CENTRAL from inception to March 2022  RCTs and observational studies	Conducted in accordance with PRISMA	33 studies (18 reported on multiple complications), over 100,000 pts	<p>Any complication</p> <ul style="list-style-type: none"> <li>• Age OR=1.01, 95% CI=0.98-1.04, p=0.47</li> <li>• Diabetes OR=1.18, 95% CI=0.96-1.45, p=0.13</li> <li>• Hypertension OR=1.59, 95% CI=1.23-2.05, p=0.0004</li> <li>• Obesity OR=1.66, 95% CI=1.37-2.01, p&lt;0.00001</li> <li>• RT OR=2.10, 95% CI=1.33-3.31, p=0.001</li> <li>• Smoking OR=2.43, 95% CI=1.54-3.82, p=0.0001</li> </ul> <p>Major/re-operative complications [14 studies]</p> <ul style="list-style-type: none"> <li>• Age OR=1.01, 95% CI=1.00-1.02</li> <li>• Diabetes OR=4.54, 95% CI=1.63-12.64</li> <li>• Hypertension OR=1.29, 95% CI=1.03-1.62</li> <li>• Obesity OR=1.08, 95% CI=1.03-1.13</li> <li>• RT OR=1.82, 95% CI=1.15-2.88</li> <li>• Smoking OR=1.46, 95% CI=1.08-1.97</li> </ul> <p>0 to 90 day readmission [2 studies]</p> <ul style="list-style-type: none"> <li>• Age OR=0.99, 95% CI=0.97-1.01, p=0.33</li> <li>• COPD OR=1.30, 95% CI=0.97-1.72, p=0.07</li> <li>• Diabetes OR=1.59, 95% CI=1.30-1.95, p&lt;0.00001</li> <li>• Hypertension OR=1.65, 95% CI=1.06-2.57, p=0.03</li> <li>• Obesity OR=2.19, 95% CI=1.65-2.91, p&lt;0.00001</li> <li>• RT OR=1.72, 95% CI=0.89-3.32, p=0.11</li> <li>• Smoking OR=2.13, 95% CI=1.05-4.34, p=0.04</li> </ul> <p>Seroma [1 study]</p> <ul style="list-style-type: none"> <li>• Diabetes OR=1.51, 95% CI=1.02-2.24, p=0.04</li> </ul> <p>Infection [4 studies]</p> <ul style="list-style-type: none"> <li>• Age OR=1.03, 95% CI=0.91-1.16, p=0.67</li> <li>• COPD OR=1.05, 95% CI=0.76-1.45, p=0.77</li> <li>• Diabetes OR=1.44, 95% CI=0.84-2.48, p=0.19</li> </ul>

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
						<ul style="list-style-type: none"> <li>Hypertension OR=3.71, 95% CI=1.14-12.07, p=0.03</li> <li>Obesity OR=1.83, 95% CI=1.36-2.47, p&lt;0.0001</li> <li>RT OR=2.67, 95% CI=0.48-14.82, p=0.26</li> <li>Smoking OR=1.52, 95% CI=0.98-2.36, p=0.06</li> </ul> <p>Overall: age has no effect; diabetes worse for major complications, readmissions, seroma; hypertension worse for any complication, major complication, readmission, infection; COPD very limited data; obesity worse for any complication major complication, readmission, infection; smoking worse for any complication, major complication, readmission, RT worse for any complication, major complication, infection</p>
Prior Surgery						
Abdominal scars						
Chung, 2021 (46)	Effects of pre-existing abdominal scar on postoperative complications after autologous breast reconstruction using abdominal flaps: A systematic review and meta-analysis	Existing abdominal scars vs. control without	Medline and Cochrane database until March 2020 Exclude case reports and case series <10 pts	Conducted according to PRISMA	11 studies, 2109 pts and 2792 flap transfers (1094 scars and 1698 without)	<p>Flap complications (complete flap loss, partial flap loss, fat necrosis) 19% vs. 18%, RR=1.12, 95% CI=0.95-1.32</p> <ul style="list-style-type: none"> <li>Complete flap loss 1.6% vs. 0.9%, RR=1.36, 95% CI=0.70-2.65, p=0.36</li> </ul> <p>Donor-site complications (seroma, infection, wound dehiscence or delayed wound healing, abdominal bulge or hernia) 19.5% vs. 14.5%, RR=1.35, 95% CI=1.13-1.62, p=0.001</p> <ul style="list-style-type: none"> <li>Delayed wound healing or dehiscence 10.3% vs. 6.0%, RR=1.83, 95% CI=1.35-2.46, p&lt;0.0001</li> <li>Abdominal weakness or hernia 4.6% vs. 4.5%, RR=1.19, 95% CI=0.78-1.81, p=0.42</li> <li>Donor-site wound problems RR=1.83, 95% CI=1.35-2.46</li> </ul> <p>Technical modifications may be used to overcome constraints of the previous scar</p> <p>Careful preoperative planning based on CTA in case of uncertainty or specific concerns should be used</p>
Abdominal surgery						
Bond, 2021 (45)	The impact of prior abdominal surgery on complications of abdominally based autologous breast	Previous abdominal surgery, excluding liposuction	PubMed, Scopus, and Web of Science until April 2020	Used PRISMA	16 articles, 4718 pts and 5723 flaps; this includes 1656 pts	<p>Donor-site delayed wound healing RR=1.27, 95% CI=1.00-1.61</p> <p>Flap complications of total and partial flap loss, fat necrosis, infection, reoperation; and donor site complications of seroma,</p>

Guideline 17-10 v2

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
	reconstruction: A systematic review and meta-analysis		Excluded case series of <10 pts		(2236 flaps) with prior surgery 14 retrospective cohort, 2 retrospective case-control studies	hematoma, infection, and abdominal wall morbidity had no statistically significant differences Number of events for many outcomes is small; rates varied widely between studies
Augmentation surgery						
Chicco, 2021 (47)	Systematic review and meta-analysis of complications following mastectomy and prosthetic reconstruction in patients with and without prior breast augmentation	Previous breast augmentation followed by cancer diagnosis and NSM or SSM plus implants	PubMed/MEDLINE, Embase, Scopus Jan 1966-Feb 2020 Comparative studies only	Followed PRISMA	6 studies, 241 breasts with prior augmentation and 1441 without	Early complications: 36.7% vs. 24.8%, OR=1.57, 95% CI=0.94-2.64, p=0.09 Hematoma: 3.39% vs. 2.15%, OR=2.68, 95% CI=1.00-7.16, p=0.05 No difference in seroma, infection, skin flap necrosis, prosthesis loss Late complications: 10.1% vs. 19.9%, OR=0.53, 95% CI=0.06-4.89, p=0.57 Overall complications 36.5% vs. 31.2%, OR=1.23, 95% CI=0.76-2.00, p=0.40
Oncologic factors						
Neoadjuvant chemotherapy						
Varghese, 2021 (48)	A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction	Neoadjuvant chemotherapy; immediate implant or autologous reconstruction	PubMed, Embase, Cochrane Library, 1995 to Sept 2, 2020	According to PRISMA guidelines Registered in PROSPERO Comparative studies (all observational); studies used appropriate matching of patients in both arms	17 studies with 3249 pts; including 575 NACT and 2674 without NACT	Overall complications: RR=0.91, 95% CI=0.74-1.11, p=0.34 Flap loss: RR=0.94, 95% CI=0.46-1.94, p=0.87 Implant/expander loss: RR=1.54, 95% CI=1.04-2.29, p=0.03 Hematoma (RR=0.99, p=0.97), wound complications (RR=1.15, p=0.22) no significant difference Delay in adjuvant therapy RR=1.59, 95% CI=0.66-3.87, p=0.30

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
Antiestrogen therapy						
Spera, 2020 (220)	Perioperative use of antiestrogen therapies in breast reconstruction: A systematic review and treatment recommendations	Current use of antiestrogens	MEDLINE, PubMed, and EBSCO Host from Dec 1977 to May 2018  Only observational studies because no RCTs were found	Reported in agreement with PRISMA; review is compliant with Cochrane Handbook for Systematic Reviews of Interventions, evaluated studies using MINORS	7 studies with 3248 pts and 4086 flaps  3074 without hormone modulators, 676 with SERM, 367 with AIs	SERMs at the time of reconstruction vs. none: <ul style="list-style-type: none"> <li>• Flap loss 9.8% vs. 5.3%, RR=1.78, 95% CI=1.31-2.43, p=0.0003</li> <li>• Donor site complications 7.4% vs. 3.1%, RR=2.33, 95% CI=1.36-4.00, p=0.0021</li> <li>• Flap wound complications 15% vs. 21.6%, RR=1.06, 95% CI=1.01-1.10, p=0.02</li> <li>• Venous thromboembolic events 1% vs. 0.3%, RR=0.993, 95% CI=0.983-1.00, p=0.089</li> </ul> Concurrent AI use: <ul style="list-style-type: none"> <li>• Flap loss 1.3% vs. 5.3%, R=0.2469, 95% CI=0.08-0.77, p=0.01</li> <li>• Donor site complications 11.2% vs. 3.1%, RR=3.40, 95% CI=2.05-5.64, p&lt;0.0001</li> <li>• Flap wound complications 30.3% vs. 21.6%, RR=1.31, 95% CI=0.94-1.82, p=0.11</li> <li>• Venous thromboembolic events 0% vs. 0.3%</li> </ul>
Adjuvant radiotherapy (PMRT)						
Hong, 2021 (51)	The effect of previous irradiation for patients with prosthetic breast reconstruction: A meta-analysis [note: despite title, they used PMRT not previous RT]	Immediate reconstruction with implants; PMRT vs. no PMRT  Does not mention whether RT to expander or implant; included 1- and 2-stage implants	PubMed, Embase, Cochrane Library until March 2020	Guided by PRISMA; assessed studies using Newcastle-Ottawa Scale (NOS)	19 studies with 6757 pts  4 prospective, 15 retrospective	Reconstructive failure OR=2.57, 95% CI=1.55-4.26, p<0.001 [14 studies]  Capsular contracture OR=5.99, 95% CI=3.12-11.47, p<0.001 [11 studies]  Overall complications OR=2.52, 95% CI=1.68-3.79, p<0.001 [12 studies]  Patient satisfaction lower OR=0.29, 95% CI=0.16-0.52, p<0.001 [3 studies]  Worse aesthetic results OR=0.25, 95% CI=0.12-0.52, p<0.001 [3 studies]
Zugasti, 2021 (52)	The impact of adjuvant radiotherapy on immediate implant-based breast reconstruction surgical and satisfaction outcomes: A systematic review and meta-analysis	Adjuvant RT: immediate expander/implant based  PMRT to either expander or	PubMed until April 2021 and published in Q1-Q2 medical journals  Only comparative studies	Cochrane Handbook for Systematic Reviews of Interventions; MOOSE guidelines: PRISMA	14 studies with 11,958 reconstructions: 2311 PMRT and 9647 control	Early complications <ul style="list-style-type: none"> <li>• Surgical site infection RR=2.44, 95% CI=1.97-3.01, p&lt;0.00001 [9 studies]</li> <li>• Mastectomy skin flap necrosis RR=1.62, 95% CI=1.27-2.08, p=0.0001 [8 studies]</li> <li>• Seroma and hematoma RR=1.10, 95% CI=0.85-1.43, p=0.47 [9 studies]</li> </ul>



Guideline 17-10 v2

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
		implant vs. no PMRT		Studies assessed with Newcastle-Ottawa Quality Assessment Form for Observational Studies		<ul style="list-style-type: none"> <li>• Implant extrusion or exposure RR=3.44, 95% CI=2.18-5.43, p&lt;0.00001 [5 studies]</li> </ul> <p>Late complications</p> <ul style="list-style-type: none"> <li>• Capsular contracture (III-IV) RR=1.64, 95% CI=1.17-2.31, p=0.004 [7 studies]</li> <li>• Revision surgery RR=1.64, 95% CI=1.17-2.31, p=0.004 [3 studies]</li> <li>• Reconstruction failure RR=3.32, 95% CI=2.82-3.91, p&lt;0.00001 [12 studies]</li> </ul> <p>Aesthetics and Satisfaction (BREAST-Q) [2 studies]</p> <ul style="list-style-type: none"> <li>• Satisfaction with Breast: mean difference -11.41 (95% CI is -13.88 to -8.95), p&lt;0.00001 [2 studies]</li> <li>• Satisfaction with Outcome: mean difference -6.91 (95% CI is -9.47 to -4.35), p&lt;0.00001</li> </ul>
Pu, 2018 (50)	The role of PMRT in patients with immediate prosthetic breast reconstruction: A meta-analysis	Immediate implant PMRT (to expander or implant) vs. none	PubMed, Embase, the Cochrane Library databases, Web of Science, Chinese Biomedical Database, Chinese Scientific Journals until 2016	Well-controlled cohort comparative studies (all used multivariate analysis) Quality assessed by Jadad scoring system; included PRISMA flowchart	15 trials with 5314 pts: 1069 PMRT and 4245 no PMRT	<p>Overall complications OR=3.45, 95% CI=2.62-4.54, p&lt;0.00001 [9 studies]</p> <p>Reconstruction failure OR=2.59, 95% CI=1.46-4.62, p=0.001 [10 studies]</p> <p>Capsular contracture OR=5.26, 95% CI=2.73-10.13, p&lt;0.00001 [11 studies]</p> <p>Worse patient satisfaction with PMRT: OR=0.28, 95% CI=0.19-0.42, p&lt;0.00001 [3 studies]</p>
Magill, 2017 (49)	Determining the outcomes of post-mastectomy radiation therapy delivered to the definitive implant in patients undergoing one- and two-stage implant-based breast reconstruction: A systematic review and meta-analysis	Adjuvant RT to definitive implant (not expander)	MEDLINE, Embase until October 2016	PRISMA, registered with PROSPERO	7 studies with 2921 pts (520 PMRT, 2401 control)	<p>Capsular contracture (Grade III or IV) OR=10.21, 95% CI=3.74-27.89, p&lt;0.00001 [7 studies]</p> <p>Revisional surgery OR=2.18, 95% CI=1.33-3.57, p=0.002 [7 studies]</p> <p>Reconstructive failure (removal or replacement of implant) OR=2.52, 95% CI=1.48-4.29, p=0.0007 [6 studies]</p> <p>Patient satisfaction: lower with PMRT OR=0.29, 95% CI=0.15-0.57, p=0.0003 [4 studies]</p> <p>Cosmetic outcome: OR=0.287, 95% CI=0.11-0.67, p=0.005 [4 studies]</p>

Citation	Title	Topic	Search details	Review details	Number of included studies; number of patients	Results or conclusions
Liew, 2021 (53)	Does post-mastectomy radiation therapy worsen outcomes in immediate autologous breast flap reconstruction? A systematic review and meta-analysis	Immediate autologous with vs. without PMRT (or immediate vs. delayed with PMRT)	MEDLINE, Embase, Cochrane CENTRAL to November 2020  Excluded case reports and case series or <10 pts	Registered on PROSPERO; conducted in accordance with PRISMA; evaluated studies with ROBINS-I Tool	21 studies, 3817 pts: 939 immediate + PMRT, 2462 immediate without PMRT, 416 PMRT and delayed  5 prospective, 16 retrospective, no RCTs	Immediate with vs. without PMRT [16 studies]: Fat necrosis RR=1.91, 95% CI=1.45-2.52, p<0.00001 [12 studies] Secondary surgery RR=1.62, 95% CI=1.06-2.48, p=0.03 [4 studies] Volume loss RR=8.16, 95% CI=4.26-15.63, p<0.00001 [4 studies] Revisional operations RR=0.95, 95% CI=0.80-1.13, p=0.54 Infection RR=1.14, p=0.60 [8 studies] Healing complications RR=1.23, p=0.17 Hematoma RR=1.14, p=0.81 [3 studies] Seroma formation RR=1.19, p=0.67 [4 studies] Total flap loss RR=0.80, p=0.81 [7 studies] Partial flap loss/necrosis RR=0.34, p=0.15 [4 studies] Skin contracture and hyperpigmentation higher with PMRT [2 studies]  Cosmetic results (observer-reported) better in 4/5 studies without PMRT, and no difference in 1/5  Higher risks but not necessarily clinically significant, immediate reconstruction with PMRT is still viable option

**Abbreviations:**

ACS/NSQIP, American College of Surgeons/National Surgical Quality Improvement Program; AIs, aromatase inhibitors (eg, anastrozole, exemestane, letrozole); BMI, body mass index; BRA, Breast Reconstruction Risk Assessment score; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CTA, computed tomography angiography; DIEP, deep inferior epigastric perforator flap; MINORS, methodological index for non-randomized studies; MOOSE, Meta-analysis Of Observational Studies in Epidemiology; NACT, neoadjuvant chemotherapy; NOS, Newcastle-Ottawa Scale; NSM, nipple-sparing mastectomy; OR, odds ratio; PMRT, postmastectomy radiotherapy; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO, International Prospective Register of Systematic Reviews, University of York, UK; pts, patients; RCT, randomized controlled trial; ROBINS-I, Risk of Bias In Non-randomized Studies of Interventions; RR, risk ratio; RT, radiotherapy; SERMs, selective estrogen receptor modulators (e.g., tamoxifen, raloxifene); SSM, skin-sparing mastectomy

Table 4-2. Effect of Age on Reconstructive Outcomes

Study	Study name or database and location	Years of study	Topic or comparison	Age, # pts	Pt or study details	Statistical design/comparison	Outcomes
Prospective Study							
Santosa, 2016 (222)	MROC; USA (9 centres) and Canada (2 centres)	2012-2014	Effect of age on outcomes	>60, n=234 45-60, n=803 <45, n=494	Prospective Age ≥18 y; implant or autologous, ≥2 y follow-up after reconstruction	Mixed-effects regression models: independent variables with statistically significant effects in the univariate analysis (p <0.05) or known predictors of postoperative complications (BMI, laterality, and smoking status) included	Complications, > 60 y and 45-60 y compared to <45 y as reference group Any complication OR=1.46, 95% CI=0.99-2.15, p=0.059; OR=1.23, 95% CI=0.93-1.62, p=0.140 Major complication OR=1.43, 95% CI=0.93-2.18, p=0.101; OR=1.16, 95% CI=0.85-1.57, p=0.349 PROs (excluded pts with reconstructive failure) at 2 y post-reconstruction, age >60 compared to younger pts (<45 y): Implants <ul style="list-style-type: none"><li>• Satisfaction with Breasts -5.05, p=0.025</li><li>• Psychosocial Well-Being 3</li><li>• Physical Well-Being -2</li><li>• Sexual Well-Being 4.25, p=0.04</li></ul> Autologous <ul style="list-style-type: none"><li>• Satisfaction with Breasts 3</li><li>• Psychosocial Well-Being 8.21, p&lt;0.01</li><li>• Physical Well-Being 6.07, p&lt;0.01</li><li>• Sexual Well-Being 10.39, p&lt;0.01</li></ul>
Single-institution retrospective studies							
Kim, 2024 (37)	Memorial Sloan Kettering Cancer Center, New York, NY	2017-2022	Effect of age on outcome after PMRT	4370 pts >70, n=168 60-69, n=701 50-59, n=1413 40-49, n=1681 <40, n=676	Retrospective Age ≥18 y; autologous or 2-stage implant	Multivariable generalized estimating equation (GEE) models for longitudinal data for BREAST-Q domains  Multivariable logistic regression models for complications that were significantly different across age groups univariably.  Age was a continuous predictor. Covariates were selected based on a hypothesized relationship with the outcome	Complications: mastectomy skin flap/nipple necrosis, infection, seroma higher in older pts. With age as continuous variable, OR per year of age increase: <ul style="list-style-type: none"><li>• Mastectomy skin flap/nipple necrosis OR=1.02, 95% CI=1.01-1.03, p&lt;0.001</li><li>• Infection OR=1.01, 95% CI=1.00-1.03, p=0.038</li><li>• Seroma OR=1.02, 95% CI=1.00-1.03, p=0.024</li><li>• Hematoma OR=1.01, 95% CI=1.00-1.03, p=0.14</li></ul> PROs by BREAST-Q using multivariable generalized estimating equations (GEE) models for repeated measures with age at surgery as continuous variable

Study	Study name or database and location	Years of study	Topic or comparison	Age, # pts	Pt or study details	Statistical design/comparison	Outcomes
							<ul style="list-style-type: none"> <li>• Satisfaction with breasts lower in older pts (<math>\beta = -0.06</math>, 95% CI= <math>-0.12</math> to <math>-0.01</math>, <math>p=0.033</math>)</li> <li>• Psychosocial Well-Being higher in older pts (<math>\beta = 0.14</math>, 95% CI=<math>0.09</math> to <math>0.20</math>, <math>p&lt;0.001</math>)</li> <li>• No difference in Physical Well-Being of Chest (<math>\beta = -0.03</math>, 95% CI= <math>-0.08</math> to <math>0.02</math>, <math>p=0.2</math>)</li> <li>• No difference in Sexual Well-Being (<math>\beta = -0.04</math>, 95% CI= <math>-0.11</math> to <math>0.02</math>, <math>p=0.2</math>)</li> </ul>
Honig, 2024 (221)	University of Pennsylvania, Philadelphia, Pennsylvania	2005-2018	Free flap reconstruction and risk at greater age	2598 pts; median age 51y >75, n=19 70-74, n=68 65-69, n=164 60-64, n=327 55-59, n=394 <55, n=1625	Retrospective	<p>Risk-adjusted logistic regression models controlling for demographics (race, body mass index, smoking history) and comorbidities (diabetes, pulmonary disease, hypertension, and vascular disease) to determine association of age and outcomes.</p> <p>Analysis modelled age over a continuous spectrum instead of discrete categories; outcomes reported at 5-y intervals from median age (51 y) of cohort</p>	<ul style="list-style-type: none"> <li>• After multivariate analysis, age in 5-year categories, age 70-74 vs age &lt;55; p values appear to be based on trend over full age range</li> <li>• Delayed healing 35.7% vs 29.2%, <math>p=0.036</math></li> <li>• Skin necrosis 15.3% vs 10.7%, <math>p=0.039</math></li> <li>• Hematoma 9.3% vs 5.3%, <math>p=0.005</math></li> <li>• Venous thromboembolism 2.1% vs 1.4%, <math>p=0.381</math></li> <li>• Flap loss 2.2% vs 2.5%, <math>p=0.574</math></li> <li>• Seroma 9.1% vs 7.6%, <math>p=0.548</math></li> <li>• Infection 6.9% vs 6.8%, <math>p=0.588</math></li> <li>• Multiple surgical complications 10.3% vs 8.0%, <math>p=0.364</math></li> </ul> <p>Risk of hematoma, delayed healing, and skin necrosis increase <math>\approx 0.2\%</math> per year. No increase in VTE or free flap loss. Authors concluded that age cutoff does not appear warranted</p>
Chang, 2011 (223)	UCLA Medical Center	2002-2009	Microvascular reconstruction in pts with advanced age	650 pts, 818 reconstructions: $\geq 60$ n=122 60-69, n=103 70+, n=19 <50, n=411 50-59, n=285	Retrospective Microvascular free-flap reconstruction	$\chi^2$ analysis with a trend test for comorbidities and outcomes; multivariate analysis using logistic regression to evaluate age, BMI, previous surgeries	<p>Surgical complications:</p> <p>26.2% age 60-69 31.6% age 50-59 29.0% age &lt;50</p> <p>Age was not predictive of surgical complications when used as a continuous variable</p>
Multi-institution Database Studies							
Cuccolo, 2020 (38)	ACS-NSQIP	2005-2016	Age or frailty and pedicled flaps, all types of surgery (not just breast)	Breast: $\geq 80$ , n=31 70-79, n=377 60-69, n=1834	Retrospective Complications only recorded for 30 days post-operation	<p>Variables with <math>p&lt;0.05</math> on univariate analysis included in multivariable binary logistic regression</p> <p>Age appears to be a continuous variable in multivariable</p>	<p>For breast, effect of age on complications (30 days postoperatively); rates per each additional year of age</p> <p>All-cause complications</p> <p>Authors concluded that the effect of age does not have strong predictive power and may not have clinical relevance on its own</p>

Study	Study name or database and location	Years of study	Topic or comparison	Age, # pts	Pt or study details	Statistical design/comparison	Outcomes
				50-59, n=3084 18-49, n=3199		analysis, as discussion indicates OR gives increase in risk per one additional year of age	Frailty index had much stronger predictive capacity than age
Butz, 2015 (224)	ACS-NSQIP	2005-2012	30-day complications after reconstruction with advanced age	≥65, n=1624 <65, n=10,140	Retrospective Complications limited to those within 30 days follow-up (common medical and surgical perioperative complications)	Multivariable linear and logistic regression to control for demographics and comorbidities	Complications, compared to age <65: overall, unadjusted: 6.8% vs 5.2% With multivariate adjustment, by reconstruction type Implants: <ul style="list-style-type: none"> <li>Any complication 6.1% vs 4.2%, aOR=1.16, 95% CI=0.85-1.57, p=0.346</li> <li>Surgical-site infection 3.5% vs 2.5%, aOR=0.98, 95% CI=0.66-1.47, p=0.929</li> <li>Return to operating room 7.0% vs 6.8%, aOR=0.90, 95% CI=0.68-1.18, p=0.440</li> <li>Other complications no significant difference though too few to meet our criteria for multivariate analysis</li> </ul> Autologous: <ul style="list-style-type: none"> <li>Any complication 10.1% vs 8.9%, aOR=1.16, 95% CI=0.71-1.88, p=0.555</li> <li>Individual complications too few for multivariate analysis, although venous thromboembolism appears elevated (2.2% vs 0.8%, aOR=3.67, 95% CI=1.20-11.22, p=0.023)</li> </ul>

**Abbreviations:**

ACS-NSQIP, American College of Surgeons-National Surgical Quality Improvement Program; BMI, body-mass index; CI, confidence interval; DIEP, deep inferior epigastric perforator flap; MROC, Mastectomy Reconstruction Outcomes Consortium; NSQIP, National Surgical Quality Improvement Program; OR, odds ratio; PMRT, post-mastectomy radiation therapy; PRO, patient-reported outcome; pts, patients

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q2](#)[Back to Start of Tables](#)**Table 4-3. Question 2: Immediate versus Delayed**

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
Immediate vs. Delayed								
Jeevan, 2014 (225); Jeevan, 2011 (226)	England, Wales, Scotland	2008-2009	Audit of provision of mastectomy and reconstruction (immediate, delayed) and associated complications and QoL  Patients with mastectomy + immediate reconstruction or with delayed reconstruction (mastectomy was previously) from Jan 2008 to March 2009	Operative/clinical data for 3,389 (21%) immediate; 1,731 delayed (after previous mastectomy); 13,096 no reconstruction  6,882 responses to 3-month questionnaire (1,553 immediate, 692 delayed, 4,637 none)  7,110 responses to 18-month questionnaires  3,304 immediate: 1207 (36.5%) expander/implant, 722 (21.9%) pedicle flap + implant, 920 (27.8%) pedicle flap,	Breast cancer or DCIS, unilateral mastectomy, or primary reconstruction in 2008-2009  Pts without reconstruction were older and more frail, higher BMI and other comorbidities  Most immediate reconstruction was an implant (with or without a flap), while majority of delayed reconstruction used only a flap  In delayed reconstruction, 14% implant-only pts and 45% with flaps had RT; RT use in immediate reconstruction not reported  Proportion invasive and DCIS not equivalent: invasive 2311 vs. 1347; DCIS 927 vs. 231  Immediate group had less positive lymph nodes	Prospective cohort; national audit; data from charts and questionnaires (subset of BREAST-Q) sent to pts (3 months and 18 months after surgery)  Multiple logistic regression to calculate risk-adjusted procedure rates by Cancer Networks and risk-adjusted outcomes by type of surgery and considered age, smoking status, BMI, co-morbidities, ASA grade and ECOG score, and previous treatments (e.g., adjuvant RT or chemotherapy)  QoL adjusted for age, deprivation index, performance status, smoking status, postoperative chemotherapy or RT  QoL not adjusted for baseline scores	Percent of pts offered immediate reconstruction varied from 24% to 75% in different Networks (regions)  Authors state (data not reported) that inpatient mastectomy site complications, adjusted for pt characteristics, did not vary between immediate and no reconstruction; delayed reconstruction had less mastectomy site complications [this may be due to mastectomy being completed previously and associated complications not accounted for in this study].  Adjusted risks of implant-related complications were not statistically associated with type of reconstruction or timing (immediate vs. delayed)  The risk of flap-related complications varied with flap type but was not associated with timing of procedure  18-month adjusted QoL scales [Satisfaction with Breast Appearance, Emotional/Psychosocial Well-Being, Physical Well-Being, Sexual Well-Being], immediate vs. delayed scores  • Implant only: breast appearance 54 vs. 56; emotional 65 vs. 66; physical 74 vs. 76; sexual 44 vs. 49	Patient-reported complications in 3 months after discharge do not appear to be adjusted and therefore data not extracted  Two different questionnaires were used (mastectomy alone; immediate or delayed reconstruction)  Size of clinically significant differences in Breast Q scales were not reported; Voineskos et al. proposed that 4 points is a clinically useful minimal important difference score (213)  Authors indicate that results “should not be interpreted as indicating the relative effectiveness of the various procedures. Each procedure is associated with distinct and different treatment pathways. The choice of operation is likely to reflect women’s views, values and expectations” (Jeevan, 2011, page 8 (226)). There may also be

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
				455 (13.8%) free flap  1699 delayed: 280 (16.5%) expander/implant, 432 (25.4%) pedicle flap + implant, 433 (25.5%) pedicle flap, 554 (32.6%) free flap			<ul style="list-style-type: none"> <li>• Pedicle with implant: breast appearance 63 vs. 68; emotional 72 vs. 76; physical 75 vs. 76; sexual 50 vs. 58</li> <li>• Autologous pedicle flap: breast appearance 64 vs. 69; emotional 70 vs. 74; physical 73 vs. 77; sexual 49 vs. 56</li> <li>• Free flap: breast appearance 63 vs. 73; emotional 70 vs. 78; physical 75 vs. 80; sexual 49 vs. 63</li> </ul>	a response shift if values/views change such as during wait for delayed reconstruction
Yoon, 2018 (56)  See also Wilkins, 2018 (215); Kulkarni, 2017 (214)	The Mastectomy Reconstruction Outcomes Consortium (MROC) Study, 11 institutions (9 USA and 2 Canada)  <a href="#">NCT01723423</a>	2011-2017	Complications and PROs of immediate vs. delayed postmastectomy reconstruction	4436 pts in full study; this publication 1806 immediate vs. 151 delayed (complete data for 1639 and 147 pts)  Implants: 1275 immediate vs. 27 delayed  Latissimus Dorsi: 45 immediate vs. 18 delayed  Autologous: 486 immediate vs. 106 delayed	Breast cancer or prophylaxis; primary (first-time) reconstruction; 1 or 2-stage implant or autologous  For expander-implant pts they had to be at least 3 months after expander-implant exchange  Exclude previous augmentation, reduction, or reconstruction  Exclude from PRO analysis if reconstruction failure  2-y complication and PRO data available	Prospective, multicentre cohort design; followed STROBE guidelines for cohort studies  Each subcategory of complication was separately modelled using a mixed-effects logistic regression model adjusted for age, race, BMI, procedure type, diabetes, laterality, radiation, chemotherapy, and lymph node management  BREAST-Q, PROMIS, EORTC QLA-BR23 surveys before and 1 and 2 years postoperatively; 1 year data not included in publication  Medical records reviewed 1 and 2 years	Significant baseline differences  Comparison of immediate vs. delayed after controlling for clinical covariates: any complications OR=2.63 (p<0.001), major complications OR=1.92 (p=0.016)  Preoperative (before reconstruction) PROs: Delayed patients scored significantly lower on most subscales (except depression)  2 years postoperatively: no statistically significant differences in adjusted PROs for immediate vs. delayed  BREAST-Q for Patient Satisfaction, Psychosocial, Sexual, Physical Well-Being; PROMIS for physical function, anxiety, depression, fatigue, sleep disturbance, satisfaction in social roles, pain interference; EORTC for body image and sexual functioning	Primary outcome: change from baseline in HRQoL using PROs

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
						after reconstruction; major complications defined as those requiring re-hospitalization or re-operation; failure defined as complications requiring implant or flap removal		
Wilkins, 2018 (215)	The Mastectomy Reconstruction Outcomes Consortium (MROC) Study, USA (9 institutions) and Canada (2 institutions); <a href="#">NCT01723423</a>	2011-2017	Complications and PROs of postmastectomy reconstruction	4436 pts in full study; 2234 for complications analysis: 2076 immediate vs. 158 delayed	Breast cancer or prophylaxis; primary reconstruction; implant or autologous	Prospective, multicentre cohort design; mixed effects logistic regression	Immediate vs. delayed Any complications OR=1.82, 95% CI=1.11-2.99, p=0.017  Major complications OR=1.17. 95% CI=0.68-2.00, p=0.566 [note difference compared with results in Yoon, 2018 ]	
Kulkarni, 2017 (214)	The Mastectomy Reconstruction Outcomes Consortium (MROC) Study, USA (19 institutions) and Canada (2 institutions); <a href="#">NCT01723423</a>	2011-2017	Pain after postmastectomy reconstruction and patient-specific factors	2667 pts; 2487 immediate and 180 delayed	Breast cancer or prophylaxis; primary reconstruction; implant or autologous	Prospective, multicentre cohort design; mixed effects logistic regression	BREAST-Q Physical Well-Being Chest and Upper Body scale: immediate reconstruction was related to lower Physical Well-Being at 1 week post operation (p<0.0001)  No significant difference for immediate vs. delayed for postoperative MPQ-affective pain (p=1.00); postoperative MPQ-sensory pain (p=0.46); postoperative NPRS pain score p=0.17	
Knoedler, 2024 (227)	ACS-NSQIP database (risk-adjusted, case-mix adjusted,	2008-2021	Immediate vs. delayed for implant (one stage) or autologous reconstruction	21,560 pts 11,237 implant (9791 immediate, 1446 delayed)	Breast cancer, by ICD codes; implant-based or autologous reconstruction Excluded immediate-delayed (use of expander)	30-day outcomes were in database  For broad categories (general, surgical, medical, or any complication)	Complications, immediate vs. delayed, implants  • Any (PSW) OR=2.41, 95% CI=1.69-3.44, p<0.001 • Any (MV) OR=2.56, 95% CI=1.84-3.65, p<0.0001	Complications  General=30-day mortality, reoperation, readmission, unplanned readmission



Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
	outcomes-based registry)		Patients with breast cancer according to CPT codes	10,323 autologous (8378 immediate, 1945 delayed)	<p>or 2-stage expander-implant</p> <p>Pt characteristics similar for immediate vs. delayed except as follows:</p> <p>A) for implants: ethnicity because immediate has 21% unknown; tumour type (22% vs. 4.1% in situ and 1.7% vs. 38% unknown); ASA class (22% vs. 28% severe); disseminated cancer 22% vs. 1.7%</p> <p>B) for flaps: tumour type (23% vs. 2.7% in situ and 2.6% vs. 28% unknown); ASA class (30 vs. 39% severe)</p> <p>Larger differences between implant and flap groups for obesity (26% vs. 40%), ASA group (noted above), disseminated cancer (1.9% in flap groups)</p> <p>SSLNB and ALND were rare in delayed cases (&lt;2%) but high in immediate (52% and 18% implants; 47% and 16% flaps)</p> <p>Type of surgeon (general or plastic) for implants was 30% plastic surgeon for immediate and 97% for delayed; for flaps was 50% plastic surgeon for</p>	<p>compared immediate vs. delayed by 2 methods: (a) with PSW estimated by logistic regression and adjusted for confounders to calculate casual ORs for overlap population (pts eligible for both immediate and delayed); (b) univariable and MV regression adjusting for confounders</p> <p>Authors indicate that “adjusted ORs for other risk factors were obtained from the same analysis” but provide no details</p>	<ul style="list-style-type: none"> <li>General (PSW) OR=2.48, 95% CI=1.68-3.68, p&lt;0.0001</li> <li>General (MV) OR=2.68 95% CI=1.86-3.98, p&lt;0.0001</li> <li>Surgical (PSW) OR=3.66, 95% CI=2.11-6.36, p&lt;0.0001</li> <li>Surgical (MV) OR=3.40, 95% CI=2.10-5.75, p&lt;0.0001</li> <li>Medical (PSW) OR=1.26, 95% CI=0.39-4.01, p=0.70</li> <li>Medical (MV) OR=1.43, 95% CI=0.49-4.97, p=0.53</li> </ul> <p>Complications, immediate vs. delayed, flaps</p> <ul style="list-style-type: none"> <li>Any (PSW) OR=1.28, 95% CI=1.09-1.50, p=0.003</li> <li>Any (MV) OR=1.29, 95% CI=1.10-1.52, p=0.002</li> <li>General (PSW) OR=1.37, 95% CI=1.12-1.67, p=0.002</li> <li>General (MV) OR=1.38 95% CI=1.14-1.69, p=0.001</li> <li>Surgical (PSW) OR=1.13, 95% CI=0.93-1.36, p=0.21</li> <li>Surgical (MV) OR=1.13, 95% CI=0.94-1.37, p=0.19</li> <li>Medical (PSW) OR=1.15, 95% CI=0.77-1.71, p=0.49</li> <li>Medical (MV) OR=1.08, 95% CI=0.74-1.61, p=0.70</li> </ul> <p>Complications, immediate vs. delayed (any type)</p> <ul style="list-style-type: none"> <li>Any (PSW) OR=1.33, 95% CI=1.16-1.52, p&lt;0.0001</li> <li>Any (MV) OR=1.39, 95% CI=1.20-1.60, p&lt;0.0001</li> </ul>	<p>Surgical =superficial incisional infection, deep incisional infection, organ space infection, dehiscence, bleeding</p> <p>Medical =pneumonia, reintubation, pulmonary embolism, ventilator &gt;48h, renal insufficiency, urinary tract infection, cerebral vascular accident/stroke, myocardial infarction, deep vein thrombosis, sepsis, septic shock</p> <p>Notes:</p> <ul style="list-style-type: none"> <li>Database did not have data on hematoma or seroma</li> <li>Only has complication up to 30 days and therefore no information on capsular contraction, aesthetics, sensation, oncologic outcomes</li> <li>While immediate reconstruction has higher complications this may not all be clinically relevant, or may be offset by better aesthetics and body image in short term (and less anxiety and depression)</li> <li>Database does not have information on mastectomy and reconstruction technique/approach, or</li> </ul>

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
					<p>immediate and 93% for delayed</p> <p>Impatient setting for implants was 49% for immediate 6.2% for delayed; for flaps was 95% for immediate and 91% for delayed</p>		<ul style="list-style-type: none"> <li>• General (PSW) OR=1.52, 95% CI=1.28-1.80, p&lt;0.0001</li> <li>• General (MV) OR=1.56 95% CI=1.32-1.86, p&lt;0.0001</li> <li>• Surgical (PSW) OR=1.19, 95% CI=1.01-1.41, p=0.04</li> <li>• Surgical (MV) OR=1.23, 95% CI=1.04-1.46, p=0.02</li> <li>• Medical (PSW) OR=1.05, 95% CI=0.72-1.51, p=0.82</li> <li>• Medical (MV) OR=1.02, 95% CI=0.71-1.49, p=0.92</li> </ul> <p>While not compared statistically and not adjusted for confounders, implant-based reconstruction had lower rates of complications than autologous reconstruction; this may be due to higher rates of obesity and more complex operations for autologous reconstruction and factors such as breast size that were not recorded</p>	<p>use of neoadjuvant and adjuvant chemotherapy or RT</p> <ul style="list-style-type: none"> <li>• Delayed reconstruction requires 2 operations, and it is unclear whether complications of each were added together; for any/general/surgical/m medical complications, all were higher in immediate group; this may reflect a combination of mastectomy + reconstruction complications being captured</li> </ul>
Autologous Reconstruction								
Kroll, 1995 (228)	The University of Texas M.D. Anderson Cancer Center, Houston, Texas One surgeon	1985-1993	Aesthetic results for immediate vs. delayed	237 pts (267 breasts); 104 immediate vs. 133 delayed	Breast cancer with TRAM flap reconstruction	Aesthetic outcomes based on postoperative photographs; scored by 9 judges (no plastic surgeons) from 1 (poor) to 4 (excellent); multiple regression analysis	Aesthetic scores: 3.25 immediate (mostly SSM) vs. 2.82 delayed (p=0.0001); after multiple regression analysis p=0.0001	Immediate reconstruction may have better results because of associated use of SSM
Fosnot, 2011 (65)	University of Pennsylvania School of Medicine, Philadelphia, PA	2005-2009	Effect of RT on vascular complications in autologous free flap, prior RT vs. no RT	226 prior RT (109 delayed), 799 no prior RT (95 delayed)	Free flap breast reconstruction Preoperative RT include RT to chest wall and axilla on operative side for previous BCS or Hodgkin disease	Retrospective Multiple binary logistic regression	<p>Final logistic regression included hypertension, dyslipidemia, preoperative chemotherapy, preoperative XRT, relayed reconstruction, initial target (IMA)</p> <p>Previous RT group had more vascular problems 17.3% vs. 9.6%, p=0.001; in</p>	

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
	3 reconstructive surgeons				RT group had more dyslipidemia, neoadjuvant chemotherapy, delayed reconstruction		final logistic regression model OR=1.68, 95% CI=1.04-2.70, p=0.04  Delayed reconstruction had more vascular complications, 15.2% vs. 10.4%, p=0.05; in final regression model OR=1.14, 95% CI=0.69-1.91, p=0.61	
Prantl, 2020 (59)	22 German cancer centres  Data from German Society of Plastic, Reconstructive and Aesthetic Surgeons registry on free flap breast reconstruction	2011-2019	Immediate vs. delayed autologous DIEP free flap	<ul style="list-style-type: none"> <li>• 3926 pts with 4577 reconstructions</li> <li>• 897 pts (1136 flaps) immediate</li> <li>• 3016 pts (3441 flaps) delayed</li> </ul>	<p>Breast cancer; initial or salvage DIEP flaps</p> <p>No significant differences regarding perioperative risk factors such as BMI, comorbidities (diabetes mellitus, coagulopathy), or smoking</p> <p>Immediate group had more family history and genetic disposition (and more bilateral reconstruction) and less chemotherapy and neoadjuvant RT</p> <p>Delayed group had 29.4% with complications after other reconstruction such as implants (1.1% in immediate group)</p> <p>Transcutaneous doppler probe used for flap monitoring in 19.3% vs. 53.1% of pts</p>	<p>Retrospective study of pts in prospective German database containing follow-up data for 3 months</p> <p>No multivariate analysis but similar risk factors</p>	<p>Medical complications 6.6% vs. 6.4%, p=0.777</p> <p>Partial free-flap loss 1.0% vs. 1.2%, p=0.706</p> <p>Total free-flap loss 2.3% vs. 1.9%, p=0.516</p> <p>Revision surgery 7.7% vs. 9.8%, p=0.039</p> <p>Day 1 postoperative mobilization 82.1% vs. 68.7%, p&lt;0.001</p> <p>Mean length of hospital stay 7.3 days vs. 8.9 days, p&lt;0.001</p>	
Beugels, 2018 (229)  Overlaps with Joosen, 2021 (230)	Maastricht University Medical Center in the Netherlands and 2 community	2010-2017	Complications after immediate vs. delayed DIEP flap reconstruction	737 pts, 910 DIEP flaps; 397 immediate and 513 delayed	<p>All pts with DIEP flap reconstruction</p> <p>Excluded stacked flaps and mixed bilateral (immediate and delayed) reconstruction</p>	<p>Median follow-up 9 vs. 10 months</p> <p>ORs were corrected for unilateral vs. bilateral, university vs. community, BMI, smoking, RT,</p>	<p>Primary outcome was major (total or partial flap loss, venous congestion) and minor (infection, hematoma, seroma, fat necrosis, wound problems including dehiscence and superficial skin necrosis related to reconstruction but not</p>	Immediate group had more seroma and hematoma, and less wound problems

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
[recurrence outcomes]	hospitals (VieCuri Medical Center, Venlo, and Zuyderland Medical Center, Sittard-Geleen)			<p>Immediate 61.2% oncologic reasons; delayed 88.3% oncologic reasons</p> <p>Subset with breast cancer: 243 immediate, 453 delayed</p>	<p>Pts with preoperative or high chance of PMRT were advised to have delayed; rest were eligible for immediate reconstruction</p> <p>SSM used with immediate reconstruction</p> <p>Immediate pts more likely to have genetic predisposition, lumpectomy in medical history and more likely to have prophylactic mastectomy</p> <p>Delayed pts more likely to have breast cancer and therefore RT, chemotherapy, endocrine therapy</p>	<p>chemotherapy, endocrine therapy in multivariable models</p> <p>Location of deep inferior epigastric artery perforators with hand-held Doppler device; preoperative imaging with magnetic resonance angiography of the abdomen for patients treated at university hospital; used internal mammary vessels in all cases; flaps monitored after reconstruction with Doppler signals, colour, capillary refill</p>	<p>mastectomy flap) recipient-site complications</p> <p>Patients with breast cancer, adjusted data:</p> <p>Major complications 7.8% vs. 9.9%, aOR=0.75, p=0.347</p> <ul style="list-style-type: none"> <li>total flap loss 0.8% vs. 2.4%, aOR=0.30, p=0.139</li> <li>partial flap loss 3.3% vs. 4.9%, aOR=0.61, p=0.311</li> <li>venous congestion 4.1% vs. 3.8%, aOR=1.11, p=0.804</li> </ul> <p>Minor complications 25.5% vs. 24.7%, aOR=1.18, p=0.391</p> <ul style="list-style-type: none"> <li>Infection 7.4% vs. 7.7%, aOR=1.12, p=0.739</li> <li>Hematoma 10.7% vs. 3.1%, aOR=3.68, p&lt;0.001</li> <li>Seroma 2.9% vs. 0.7%, aOR=8.32, p=0.003</li> <li>Fat necrosis 11.1% vs. 12.8%, aOR=0.95, p=0.831</li> <li>Wound problems 7.8% vs. 16.3%, aOR=0.52, p=0.020</li> </ul>	
Joosen, 2021 (230)  Overlaps with Beugels, 2018 (229) [complications]	Maastricht University Medical Center and two community hospitals (VieCuri Medical Center Venlo and Zuyderland Medical Center Sittard), The Netherlands	2010-2018	Recurrence after immediate vs. delayed DIEP flap reconstruction	862 pts, 919 DIEP flaps; 347 immediate and 572 delayed	<p>Diagnosis of breast cancer;</p> <p>Excluded prophylactic mastectomy, metastasis at time of mastectomy, recurrence prior to reconstructive surgery</p> <p>Immediate group had greater history of lumpectomy (30.5% vs. 15.4%), less history of expander/implant (1.2%</p>	<p>Retrospective cohort study</p> <p>Analyzed on per-patient basis, Cox proportional hazards (multivariable) regression analysis</p> <p>Median follow-up from mastectomy 46 vs. 86 months</p>	<p>LR 1.5% vs. 1.7%, HR=0.804, p=0.400; adjusted HR=2.890 (95% CI=1.536-5.437, p=0.001)</p> <p>Regional recurrence 3.7% vs. 2.4%, HR=0.306, p&lt;0.001; adjusted HR=0.912 (95% CI=0.627-1.327), p=0.631</p> <p>DM 2.8% vs. 6.9%, HR=1.351, p=0.085; adjusted HR=5.244, 95% CI=3.395-8.102, p&lt;0.001</p>	<p>Local and regional recurrence results switch in direction from HR to adjusted HR</p> <p>Note: there were &lt;25 events for LR and 25 for regional recurrence and therefore these outcomes do not meet our criteria for conducting multivariate analysis</p>

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
	10 plastic surgeons				vs. 29.0%), less oncological treatment (RT 32.3% vs. 47.0%; chemotherapy 49.1% vs. 68.8%; endocrine therapy 41.7% vs. 54.9%), lower stage disease (stage II-IV 26.0% vs. 45.0%)			
Shammas, 2023 (57)	Duke University, Durham, NC	2014-2018	Free flaps, immediate vs. delayed vs. staged	3310 pts, 2310 (69.8%) immediate, 388 (11.7%) delayed, 612 (18.5%) staged (delayed-immediate using tissue expander at time of mastectomy)	<p>Breast cancer diagnosis, mastectomy, eventual free-flap reconstruction (based on ICD-9, ICD-10, or Current Procedural Terminology codes)</p> <p>Delayed indications include uncertain need for RT, medical comorbidities, tenuous mastectomy skin flaps, pending final decision on type of breast reconstruction</p> <p>Excluded distant metastasis, implants, expander prior to mastectomy or after time of initial mastectomy</p> <p>Group differences: bilateral mastectomy 37.0% vs. 19.6% vs. 28.9%; Lymph node surgery 61.0% vs. 51.8% vs. 70.3%; chemotherapy 33.2% vs. 55.8% vs. 57.4%; RT 5.7% vs. 49% vs. 40%; ADM 8.5% vs. 9.5% vs. 73.5%</p>	<p>Retrospective using IBM MarketScan commercial claims and encounters and Medicare supplemental databases</p> <p>Complications 90 days after mastectomy and 90 days after free-flap procedure</p> <p>Modified Poisson regression adjusting for several factors (adjusting for age, comorbidity index, urban/rural ZIP code, geographic region, employment status, laterality of mastectomy, lymph node surgery at the time of mastectomy, chemotherapy before or after mastectomy, radiation before or after mastectomy, other cancer diagnoses, use of ADM)</p>	<p>Surgical complications 32.0% vs. 42.3% vs. 57.8%</p> <p>Systemic complications 10.4% vs. 11.9% vs. 17.5%</p> <p>Any complication 38.4% vs. 46.9% vs. 64.2%</p> <p>Adjusted RR for at least one complication: immediate vs. delayed RR=0.78, 95% CI=0.68-0.88, p&lt;0.001; immediate vs. staged RR=0.60, 95% CI=0.53-0.67, p&lt;0.001; delayed vs. staged RR=0.77, 95% CI=0.67-0.88, p&lt;0.001</p> <p>Results in subgroup without RT: immediate vs. delayed RR=0.78, 95% CI=0.66-0.90, p=0.001; immediate vs. staged RR=0.62, 95% CI=0.55-0.70, p&lt;0.001; delayed vs. staged RR=0.80, 95% CI=0.67-0.96, p=0.020</p>	
Huang, 2022 (58)	New York-Presbyterian/Weill Cornell	2011-2020	Autologous DIEP: complications with immediate	248 pts (443 breasts); 193 pts (344	2 cohorts were comparable in age, body mass index, and	Retrospective cohort study	Major complications: breast hematoma 3.2% vs. 2.0%, p=0.541; anastomotic failure 1.2% vs. 1.0%, p=1; partial or	Authors suggest lower rate of skin necrosis in delayed group may be due to

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
	Medical Center, New York, New York  2 plastic surgeons and several breast surgeons; initial mastectomy often performed elsewhere		vs. delayed-immediate (immediate expander/implant later exchanged for flap)	breasts) immediate; 55 pts (99 breasts) delayed-immediate	comorbidities (p>0.05); active smokers 7.3% vs. 1.8%  Differences in preoperative (reconstructive) therapies (chemotherapy 16.6% vs. 67.3%, RT 15.0% vs. 54.5%, hormone therapy 10.9% vs. 72.7%, previous breast surgery 39.4% vs. 100%)  Exclude if no immediate reconstruction, device removal due to complications prior to flap reconstruction		complete flap loss 0 vs. 0; venous thromboembolism 1.0% vs. 1.8%  Other complications similar except breast skin necrosis 16.0% vs. 2.0%, p<0.001	additional time to revascularize and heal after mastectomy  Based on their experience, should wait minimum 6 months after completing PMRT before expander-implant exchange
Marquez, 2023 (231)	ACS NSQIP data  See also Knoedler, 2024 (227) for both implant and autologous results using same database; Kalmar, 2024 (232)	2010-2020	Autologous free flaps  Cases with mastectomy according to CPT codes (did not look for cancer codes so may include prophylactic or for other reasons)	15,596 pts: 7,907 immediate; 976 delayed immediate; 6713 delayed	Limited demographic information reported (age, race, BMI, diabetes, hypertension, ASA class); unclear what BMI categories are  3 timing modalities: mastectomy and concurrent flap reconstruction; flap with removal of expander (delayed immediate); flap alone (no mention of mastectomy; delayed reconstruction)	Queried database for top 4 diagnosis at time of reoperation  Multivariate analysis using single-step multinomial logistic regression with covariates of age, race, BMI, diabetes, hypertension, ASA classification, and laterality of reconstruction	No significant difference in surgical site infections, wound dehiscence, or DVT  Increase in transfusions and more reoperations in immediate group  Using multivariate analysis: odds of surgical complications higher for immediate vs. delayed (odds of complications 1.244, p<0.001), immediate vs. delayed-immediate (1.439, p<0.001), but not delayed immediate vs. delayed (0.864, p=0.223)	Authors note for immediate reconstruction that “it is difficult to distinguish between complications related to the mastectomy versus those related to reconstructive efforts”  High proportion of delayed in this study  Used less covariates than Knoedler, 2024 (227)
Kalmar, 2024 (232)	ACS NSQIP data  See also Knoedler, 2024 (227) for both implant and	2015-2020	Autologous free flaps, immediate vs. delayed	9788 pts: 4451 immediate, 5337 delayed  65% unilateral mastectomy	Delayed reconstruction has increased over time (46.9% in 2015, 58.6% in 2020)	Retrospective cohort  Multivariate regression	Rate of flap failure 1.3% vs. 1.3%, p=0.920; multivariate aOR=1.060, p=0.836	Report indicates flap failure was removed from the NSQIP database in 2015 and data are limited to pts with ICD codes indicating reoperation

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
	autologous results using same database; Marquez, 2023 (231)		Epidemiologic trends and flap failure  Used CPT codes for mastectomy and for free flap reconstruction (not codes for cancer)	and reconstruction			Flap failure, unilateral subset 1.2% vs. 1.1%, p=0.701; bilateral subset 1.4% vs. 1.7%, p=0.516  Flap failure decreased over time (2.7% in 2015, 1.2% in 2020)	Database only has complications within 30 days; no information on staging, chemotherapy, RT; no information on plane or type of flap
<b>RT Studies</b>								
Immediate vs. immediate-delayed vs. delayed								
Ulrikh, 2024 (60)	N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia	2016-2021	Simultaneous or delayed implant-based reconstruction	466 pts 158 pts immediate 1-stage then PMRT 210 pts immediate 2-stage with PMRT to expander 98 pts delayed, with PMRT before reconstruction	Breast cancer with mastectomy, adjuvant RT, reconstruction  Hypertension varied 10.1% vs. 17.6% vs. 23.5%, as did smoking history 13.3% vs. 18.1% vs. 22.4%	Binary logistic regression models to identify risk factors	Complications:  Clavien-Dindo grade I-II is mild, Grade III is severe: any grade 15.8% immediate vs. 22.9% 2-stage vs. 26.5% delayed; grades I-II (seroma or infection requiring oral antibiotics) 6.3% vs. 5.3% vs. 6.2%; grade III 9.5% vs. 17.6% vs. 20.4%  Capsular contracture grades III-IV (clinically significant): 15.2% vs. 2.9% vs. 2.0%  Reconstructive failure (explantation) 10.8% vs. 19.1% vs. 17.3%	Age, obesity, diabetes mellitus, hypertension, smoking history were not correlated with occurrence of complications  Single stage has less complications except higher rate of capsular contracture
PMRT to expander vs. PMRT to implant								
Yoon, 2020 (216)  2-yr follow-up	The Mastectomy Reconstruction Outcomes Consortium (MROC) Study, USA (9 institutions)	2012-2015	Complications and PROs of immediate 2-stage implant reconstruction; PMRT to implant vs. PMRT to expander	• 80 PMRT to implant (expander/implant exchange then PMRT; 72 with PRO data)	SSM (~90%) and/or NSM for breast cancer or prophylaxis; first time 2-stage reconstruction with expander-implants, and receipt of PMRT to either expander or implant	Prospective, multicentre cohort design; followed STROBE guidelines for cohort studies;  Mixed-effects logistic regression models for complications adjusted	<ul style="list-style-type: none"> <li>Overall complications, PMRT to implant vs. PMRT to expander: 41.3% vs. 40.1%, OR=1.25, 95% CI=0.69-2.25, p=0.459</li> <li>Major complications 32.5% vs. 34.6%, OR=1.18, 95% CI=0.62-2.22, p=0.615</li> <li>Reconstructive failure 10.0% vs. 19.8%, OR=0.72, 95% CI=0.28-1.83, p=0.488</li> </ul>	

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
	and Canada (1 institution) <a href="#">NCT01723423</a> 1 site contributed 67.5% of pts who had PMRT to the implant		Complications at one and 2 years after reconstruction  PRO surveys before reconstruction and 1 and 2 years afterwards  BREAST-Q (Satisfaction with Breasts, Psychosocial Well-Being, Physical Well-Being, and Sexual Well-Being)  PROMIS-29 (physical function, anxiety, depression, fatigue, sleep disturbance, satisfaction with participation in social roles, and pain interference; for negative constructs such as anxiety, depression, fatigue, and sleep disturbance, higher scores	237 PMRT to expander; 262 with PRO data)	Excluded previous failed breast reconstruction, augmentation or reduction; autologous reconstruction  Excluded reconstructive failure, or pts without complete 2-year follow-up from PROs  Similar pt characteristics except ADM use 32.5% vs. 59.1%; adjuvant chemotherapy 92.5% vs. 60.8%	for baseline pt characteristics; models for PRO adjusted for patient characteristics and baseline (before reconstruction) PROs	Preoperative PROs (not adjusted) were similar  2-year PROs in 72 vs. 190 pts, in adjusted results PMRT to implant group had lower anxiety ( $\beta = -4.8$ , $p=0.01$ ), depression ( $\beta = -2.9$ , $p=0.05$ ), fatigue ( $\beta = -4.4$ , $p=0.03$ ); other PROs had no significant differences  Minimal clinically important difference of PROMIS is 3-4.5, and therefore clinical significance of differences found is debatable	



Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
			correspond to worse outcomes)  EORTC QLQ-BR23 (body image and sexual functioning subscales)					
RT studies, immediate + PMRT vs. PMRT + delayed								
Billig, 2017 (61)	The Mastectomy Reconstruction Outcomes Consortium (MROC) Study, USA (10 institutions and Canada (1 institution); <a href="#">NCT01723423</a> )	2012-2015	Immediate then PMRT vs. PMRT then delayed autologous reconstruction  Complications reported 1 and 2 years after reconstruction  PRO prior to reconstruction (but after mastectomy in delayed group) and 1 and 2 years after reconstruction  Used BREAST-Q domains of Satisfaction with Breasts, Psychosocial Well-Being, Physical Well-Being (chest and upper body), Physical Well-Being (abdomen), and	108 immediate and 67 delayed	Mastectomy with immediate or delayed abdominally based autologous breast reconstruction, PMRT  Exclude pts with RT before mastectomy, tissue expanders/implants at time of reconstruction, both immediate and delayed reconstruction  Groups had different types of reconstruction: type free TRAM 0.9% vs. 29.9%, DIEP 70.4% vs. 58.2%, SIEA 22.2% vs. 7.5%; bilateral 34.3% vs. 13.4%	Prospective, multicentre cohort design; followed STROBE guidelines for cohort studies  Immediate group recruited and had PRO assessment before mastectomy + reconstruction; delayed group recruited after mastectomy and therefore assessed between mastectomy and reconstruction (212)  Mixed-effects logistic regression model for complications and for PROs  Model for complications included RT timing, plus clinical and demographic characteristics  Model for PROs included baseline (prior to reconstructive surgery) values of	Any breast complication at 1 year: 25.9% vs. 26.9%, $p=0.540$ ; logistic regression immediate vs. delayed OR=0.64, 95% CI=0.20-2.04, $p=0.442$ (at 2 years OR=1.14, 95% CI=0.31-4.17, $p=0.848$ )  Any donor-site complication 39.8% vs. 16.4%, $p=0.244$ ; adjusted data not reported  Significant baseline differences; immediate had better PROs preoperatively than delayed group  Prior to reconstruction (before mastectomy in immediate group but after mastectomy for delayed group), the immediate group had better Satisfaction with Breasts (59.5 vs. 36.3, $p<0.001$ ), Psychosocial Well-Being (66.1 vs. 50.0, $p<0.001$ ), and Sexual Well-Being (52.1 vs. 29.8, $p<0.001$ ) and differences are likely due to presence/absence of breasts; Physical Well-Being (abdominal) was 87.3 vs. 82.9 ( $p=0.058$ )  After reconstruction, in the adjusted data there were no significant differences between immediate and delayed at 1 year after reconstruction; at 2 years the delayed group had better Physical Well-Being (chest and upper	<25 events for individual complications  For PROs, baseline refers to before reconstruction (212), and therefore before mastectomy only for the immediate group; for delayed group the baseline would have been after mastectomy (and presumably after PMRT)  PRO model adjusted for baseline prior to reconstruction; there was no baseline prior to mastectomy for delayed group and therefore baseline does not measure the same state; adjustment in model may be inappropriate in determining effect of timing of reconstruction  p values at year 1 and 2 adjusted for covariates and baseline PROs; table indicates Mean values adjust for covariates but not Preoperative values and therefore difficult to

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
			Sexual Well-Being			outcome variable, clinical and demographic characteristics  At least 1 year follow-up after reconstruction	body) (70.5 vs. 80.6, p=0.048) but no other differences	interpret (should adjust both pre and post measures for covariates; unclear if this is an error)  Due to study design, cannot make conclusion from PRO data if there is long-term difference in immediate vs. delayed; delayed group appears to have sharp decline after mastectomy (and PMRT) then recovers after reconstruction  Ideal study design (not in this report): should have delayed group with PROs prior to mastectomy, prior to PMRT, after PMRT but prior to reconstruction, then 1 and 2 years after reconstruction and there should be standardized (or at least reported) time between mastectomy, PMRT, and reconstruction  Study is only partially prospective, as delayed group was recruited subsequent to mastectomy and delay between mastectomy and reconstruction not reported
Staged (delayed-immediate; expander + RT then reconstruction) vs. immediate +RT								
Christopher, 2022 (64)	University of Pennsylvania Health System,	2005-2018	Reconstructive outcomes with staged autologous	132 pts, 66 immediate and 66 staged, matched 1:1 by	Autologous reconstruction with abdominal flaps and PMRT	Retrospective, propensity-matched 1:1 by age, BMI, comorbidities	In staged group, 28 pts (42.4%) had any tissue expander complication, of which 4 were prior to PMRT, 8 during PMRT, 16 after PMRT [presumably captures both	Complications were not prohibitive but vary according to group

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
	Philadelphia, Pennsylvania		reconstruction (delayed immediate: subpectoral tissue expander at time of mastectomy, followed by PMRT then reconstruction) vs. immediate reconstruction then PMRT	propensity score	<p>Staged group had subpectoral expander</p> <p>Groups were similar except for chemotherapy (51.1% vs. 87.9% before reconstruction; 60.0% vs. 13.6% after reconstruction)</p> <p>In immediate group, RT was median 3 months (ICR 2-5) after reconstruction; in staged group there was median 9 months (ICR 6-12) after RT before reconstruction (waited at least 3-6 months)</p>	(diabetes, hypertension, tobacco use); univariate analysis	<p>mastectomy and PMRT complications]; there were 7 wound dehiscence, 19 infection, 8 expander exposure, 2 failure to expand</p> <p>Complications after reconstruction (immediate vs. staged):</p> <ul style="list-style-type: none"> <li>• Surgical site infection 4.55% vs. 1.52%, p=0.619</li> <li>• Delayed healing 18.2% vs. 6.06%, p=0.059</li> <li>• Hematoma 6.06% in both</li> <li>• Seroma 9.09% vs. 1.52%, p=0.115</li> <li>• Fat necrosis 24.2% vs. 9.09%, p=0.034</li> <li>• Skin necrosis 18.2% vs. 0, p&lt;0.001</li> <li>• Flap loss due to vascular compromise 1.52% vs. 0, p=1.00</li> <li>• Other 12.1% vs. 4.55%, p=0.206</li> </ul> <p>Revision Surgery for asymmetry 42.4% vs. 12.1%, p&lt;0.001</p>	<p>Staged group had less complications due to reconstruction but need to also consider expander phase complications (mostly related to RT); it is possible that some revision in immediate group was due to RT as well, but this information was not recorded</p> <p>No mention of type of mastectomy or stage of cancer, although 52.3% vs. 61.3% had nipple-areolar reconstruction (suggested they did not have NSM)</p> <p>Timing between mastectomy and PMRT not reported for delayed group</p>
Delayed immediate (staged) vs. delayed								
Hassan, 2023 (62)	The University of Texas MD Anderson Cancer Center	2016-2022	[Delayed-immediate (staged; skin preserving with expander to maintain skin and breast mound appearance) then autologous] vs. [delayed autologous] PMRT (if used) was to expander in delayed-immediate; it was prior to	<p>812 pts with 1002 reconstruction: 330 staged vs. 672 delayed</p> <p>With PMRT: 129 staged vs. 435 delayed</p> <p>Without PMRT: 201 vs. 237 (includes 37 vs. 10 preoperative RT)</p>	<p>Autologous flaps</p> <p>Expander in subpectoral or prepectoral plane, with or without ADM</p> <p>Excluded immediate autologous reconstruction, or implant-based reconstruction</p> <p>RT in subset of pts: preoperative 3.0% vs. 5.5%; PMRT 39.1% vs. 64.7%</p> <p>More NSM (9.5% vs. 5.7%) and SSM (71.9% vs. 54.2%)</p>	<p>Multivariable regression</p> <p>Expanders deflated to 150 mL prior to PMRT and then reinflated ≈ 2-4 weeks after PMRT completed</p> <p>72 breast surgeons, 33 plastic surgeons</p> <p>PMRT pts: time to PMRT median 1 month in both groups; median 1 month from start to end of PMRT; median 8 months staged vs. 10 months delayed from</p>	<p>Primary outcome was development of flap-related complications, including infection, wound dehiscence, skin flap necrosis, seroma, hematoma, arterial and venous thrombosis, and flap loss; publication does not indicate if these were measured after reconstruction, mastectomy, or both</p> <p>Expander complications of exposure, capsular contractures, explantation were reported separately and authors state pts and surgeons accept a higher complication rate to obtain better final aesthetic results</p> <p>Reported mixture of univariate analysis (no correction for confounders), or</p>	<p>Delayed group without PMRT had longer time from mastectomy to flap reconstruction; may be due to more complex pathologic findings and more comorbidities</p> <p>Without PMRT, staged group had shorter hospital stay, and lower rates of 30-day readmissions, seroma</p> <p>In pts with PMRT, staged group had shorter hospital stay, lower 30-day readmission, less infection</p>

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
			reconstruction in delayed cases  Note: reconstruction is delayed in both arms, the difference is the staged arm has temporary expander		in delayed-immediate group  ALND 27.2% vs. 50.5%; SLNB 62.4% vs. 35.7%  NACT 36.7% vs. 60.1%; adjuvant chemotherapy 72.7% vs. 76.3%	end of PMRT to reconstruction  Pts without PMRT: median 8 months staged vs. 15 months delayed from mastectomy to reconstruction  PROs measured in October 2022 for all patients (not at specific time after surgery)	multivariate odds ratios or beta coefficients  Pts without PMRT, excluding expander-related complications (only those with >25 events): <ul style="list-style-type: none"><li>Any breast-related complication 21.4% vs. 26.2%, <math>p=0.244</math> (univariate)</li><li>Surgical complications, OR=0.65, 95% CI=0.40-1.07, <math>p=0.094</math></li><li>Seroma OR=0.42, 95% CI=0.19-0.94, <math>p=0.036</math></li><li>30-day readmission 5.5% vs. 9.3%, <math>p=0.132</math>; OR=0.44, 95% CI=0.20-0.97, <math>p=0.042</math></li><li>Reoperation 6.5% vs. 8.4%, <math>p=0.436</math>; OR=0.81, <math>p=0.528</math></li><li>Hospital stay 4.0 vs. 4.2 days, <math>p=0.178</math>; B -0.32, <math>p=0.045</math></li></ul> <ul style="list-style-type: none"><li>No significant differences in Satisfaction with Breast (<math>B</math> 1.4, 95% CI= - 9.9 to 12.7, <math>p=0.806</math>), Psychosocial Well-Being (<math>B</math> -2.2, 95% CI= -11.7 to 7.2, <math>p=0.640</math>), or Sexual Well-Being (<math>B</math> 6.7, 95% CI= -6.4 to 19.9, <math>p=0.312</math>)</li></ul> Patients with PMRT <ul style="list-style-type: none"><li>Any breast-related complication 22.5% vs. 25.1%, <math>p=0.550</math> (univariate)</li><li>Surgical complications OR=1.68, 95% CI=1.28-2.21, <math>p=0.579</math></li><li>Infection 3.9% vs. 10.3%, <math>p=0.023</math>; OR=0.33, 95% CI=0.13-0.87, <math>p=0.023</math></li><li>30-day readmission 4.7% vs. 14.7%, <math>p=0.002</math>; OR=0.29, 95% CI=0.12-0.69, <math>p=0.005</math></li><li>Reoperation 5.4% vs. 10.6%, <math>p=0.078</math>; OR=0.50, 95% CI=-0.21-1.15, <math>p=0.104</math></li></ul>	Similar patient satisfaction after multivariate adjustment for staged and delayed groups in long term; no data on short-term; baseline data not recorded  Factors used in multivariate model not reported and adjustment may have been insufficient to adjust for baseline differences; the discussion notes factors may confound the complication rates  Authors indicate they did not assess cosmetic outcomes

Citation	Study name and location	Years of study	Topic or comparison	Number of patients	Patient characteristics	Design	Results	Other
							<ul style="list-style-type: none"><li>Hospital stay 3.0 vs. 4.2 days, <math>p&lt;0.001</math>; B -1.15, <math>p&lt;0.001</math></li><li>No significant differences in Satisfaction with Breast (B - 3.7, 95% CI= -15.7 to 8.2, <math>p=0.543</math>), Psychosocial Well-Being (B - 7.3, 95% CI= -18.5 to 4.0, <math>p=0.203</math>), or Sexual Well-Being (B 0.5, 95% CI= -12.9 to 13.9, <math>p=0.942</math>)</li></ul> Tissue expander capsular contraction was 14.7% with PMRT and 3.5% without PMRT, univariate analysis $p<0.001$	

**Abbreviations:**

ACS-NSQIP, American College of Surgeons National Surgical Quality Improvement Program; ADM, acellular dermal matrix; aOR, adjusted odds ratio; ALND, axillary lymph node dissection; ASA status, American Society of Anesthesiologists physical status classification system; BCS, breast-conserving surgery; BMI, body mass index; CI, confidence interval; CPT, Current Procedural Terminology; DBCG, Danish Breast Cancer Group; BCT, breast-conserving therapy = breast-conserving surgery +RT); DCIS, ductal carcinoma in situ; DIEP, deep inferior epigastric artery perforator; DM, diabetes mellitus; DTI, direct to implant; DVT, deep venous thrombosis; ECOG, Eastern Cooperative Oncology Group; EORTC QLQ-BR23, European Organisation for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire; HR, hazards ratio; HRQoL, health related quality of life; HTN, hypertension; ICD-9, International Classification of Diseases, Ninth Revision; IMA, internal mammary artery; ICR, Institute of Cancer Research; LABC, locally advanced breast cancer; LR, local recurrence; MPQ, McGill Pain Questionnaire-Short Form (MPQ-SF); MROC, Mastectomy Reconstruction Outcome Consortium; MS-TRAM, muscle-sparing transverse rectus abdominus muscle; MV, multivariable analysis; NPRS, Numerical Pain Rating Scale; NSM, nipple-sparing mastectomy; OR, odds ratio; PMRT, postmastectomy radiotherapy; PRO, patient-reported outcomes; PROMIS-29, Patient-Reported Outcomes Measurement Information System-29; PSW, propensity score weighting; pts, patients; QoL, quality of life; RCT, randomized control trial; RR, risk ratio; RT, radiotherapy; SF-36, 36-Item Short Form Survey; SIEA, superficial inferior epigastric artery; SSM, skin-sparing mastectomy; SLN, sentinel lymph node biopsy; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; TRAM, transverse rectus abdominis musculocutaneous flap; XRT, external beam radiation therapy

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q3a](#)[Back to Start of Tables](#)**Table 4-4. Question 3a: NSM versus SSM**

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Patient characteristics	Evaluation	Results
NSM vs. SSM								
Gerber, 2003 (73) Gerber, 2009 long-term follow-up (74)	University of Rostock, Rostock, Germany	1994-2000	NSM vs. SSM (NSM planned) vs. MRM  Pts with MRM did not have reconstruction and are not reported in this table	134 planned NSM but follow-up data only for 114 pts  61 had NSM, 51 had NAC resected (i.e., SSM), 2 converted to MRM	Not stated but appears prospective  Follow-up at least 18 months; mean 59 months	Inclusion criteria: breast cancer, margins by sonography or mammography $\geq 2$ cm from nipple, no skin involvement; age <75 y, BMI 21-35 kg/m <sup>2</sup> , no central tumour location, no contraindication for flap reconstruction  Patients meeting inclusion criteria were offered choice of NSM with reconstruction or MRM (no reconstruction); pts in NSM group with intraoperative concerns received SSM  2 pts with planned NSM had involved margins <5 mm) and were included in MRM group	Intraoperative frozen section of the base of the NAC: 51 pts had NAC removed due to >25% tumours cells in ducts, with tumour <2 cm from NAC and suspicious cells in base not clearly identified as tumour/benign by frozen section  SSM group is those pts converted from NSM due to frozen section results	Pt characteristics similar  Complications:  20% vs. 20%  After mean 101 months follow-up there were no significant differences: local recurrence 11.7% vs. 10.4%, isolated distant metastasis 23.3% vs. 25.0%, breast-cancer specific death 21.7% vs. 20.8%  Aesthetic results evaluated by surgeons: excellent results 73.8% vs. 78.4% at 59 months; 51.7% vs. 47.9% at 101 months; RT and large weight change were risk factors for decreased scores; patient ratings did not change as much
Jeon, 2010 (75)	Yeungnam University College of Medicine, Daegu, South Korea	1996-2006	NSM vs. SSM, according to frozen section analysis  Mastectomy by 1 surgeon, reconstruction by 2 surgeons	133 NSM; 69 SSM	Mean follow-up 67.6 months	Breast cancer, no clinically palpable lymph nodes, no infiltration or abnormalities in NAC visually or radiologically, Tis-2, N0-1; <4 positive nodes on ALND for invasive cancer; immediate reconstruction  Adjuvant chemotherapy if lymph node metastases, or >T2; hormones if hormone receptor positive; no PMRT	Frozen section analysis of retroareolar resection margin determined NSM or SSM; NAC sacrificed if positive on frozen section  SSM group is those pts converted from NSM to SSM due to cancer in	Local recurrence 9.0% vs. 5.8%, p=0.585  5-y local recurrence-free survival 92.1% vs. 95.2%, p=0.652

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Patient characteristics	Evaluation	Results
							frozen section <2 mm from cut surface	
Kim 2010 (77)	Asan Medical Center, Seoul, Korea	2001-2006	NSM vs. SSM with immediate pedicled TRAM reconstruction  Reconstruction by 1 plastic surgeon	152 NSM (187 attempted but 35 converted to SSM), 368 SSM  115 of NSM pts had prospective follow-up	Retrospective; prospective follow-up of complications in subset  Kaplan-Meier and multivariate (Cox proportional hazards) survival analysis  Median follow-up 60 vs. 67 months	Stage 0-IIIa, indications for SSM or NSM were any stage, any tumour size, any tumour-areolar distance; NSM offered if clinically normal nipple and no skin involvement  NAC preserved when palpation, shape, and colour of nipple were normal and NAC ducts tumour-free in frozen biopsies  Reconstruction using TRAM flaps  For NSM, radioisotope used instead of blue dye for SLNB as dye is risk factor for skin necrosis	Thin layer of glandular tissue was taken from under the areola for frozen sectioning  NSM attempted in 187 pts but 35 had positive results on subareolar frozen biopsy and converted to SSM	5-y DFS 89% vs. 87.2%, p=0.695;  5-y OS 97.1% vs. 95.8%, p=0.669; local failure 2% vs. 0.,8%, p=0.27  After adjustment for patient and tumour characteristics, DFS HR=1.004, 95% CI=0.52-1.93, p=0.991; OS HR=0.866, 95% CI=0.26-2.85, p=0.813  In 115 NSM, any NAC necrosis in 26 pts: 11 (9.6%) complete, 15 partial; NAC recurrence 1.3%
Wang, 2020 (234)	Yale University School of Medicine,	2010-2017	Complication, reoperation, and length of stay for NSM vs. SSM  Single centre, 22 surgeons (although 5 surgeons conducted about 90% of operations)	217 NSM, 581 SSM	Retrospective  Bivariate analysis then multivariate analyses using clinicopathologic variables that were significant (p≤0.05)	All pts with NSM or SSM; indications for NSM instead of SSM were at discretion of surgeon; individual surgeon was a predictor of receiving NSM  NSM pts were younger, more private insurance, lower BMI, smaller breasts, more prophylactic, lower stage disease, less diabetes, more implant-based reconstruction  Prophylactic 20.7% vs. 5.9%	None reported	Complication rates 27.6% vs. 21.9%, p=0.091; after multivariate analysis of therapeutic cases: NSM had higher complication rate, OR=1.822, 95% CI=1.163-2.853, p=0.009  Increased complication rate appears due to inclusion of nipple necrosis/ischemia (16.5% vs. 0%) as NSM was lower for most other complications  36 pts (16.5%) nipple ischemia, eschar, or necrosis; only 2 pts required nipple removal  Reoperation within 90 days: 8.3% vs. 12.6%, p=0.104; multivariate analysis of therapeutic cases OR=0.876, 95% CI=0.453-1.696, p=0.695

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Patient characteristics	Evaluation	Results
								Length of stay $\geq 2$ days: 69.1% vs. 79.7%, $p=0.002$ ; after multivariate analysis of therapeutic cases there was no difference, OR=0.701, 95% CI=0.442-1.111, $p=0.130$  High volume surgeons had lower rates of complications and reoperation
Kelly, 2022 (92)	Massachusetts General Hospital (MGH) or Mass General Brigham Salem Hospital	2009-2019	Patient Satisfaction with Breasts after NSM vs. SSM; BREAST-Q $\geq 1$ y after immediate reconstruction  Comparisons for groups with NSM/SSM 1-5 years ago and those with NSM/SSM 6-10 years ago	247 NSM and 184 SSM completed postoperative survey	Retrospective, from prospectively maintained NSM and SSM databases  Linear regression; multivariate logistic regression to identify risk factors for dissatisfaction	NSM or SSM and immediate reconstruction without reconstruction failure or operation within 2 months of survey  SSM was recommended instead of NSM if clinical or imaging evidenced of NAC involvement, LABC with skin involvement, inflammatory, significant size reduction, expected poor nipple position  NSM group had lower BMI, smaller breasts, were younger, more likely premenopausal, less hypertension and smoking, more genetic risk factors and prophylactic surgery  26.1% of SSM had nipple reconstruction	Surgical or pathological evaluation not mentioned  Used six BREAST-Q modules: Psychosocial Well-Being, Sexual Well-Being, Satisfaction with Breasts, Satisfaction with Implants, Physical Well-Being: Chest, and Effects of Radiation  Baseline values (before mastectomy) were not measured	NSM required less aesthetic revision operations (13.8% vs. 32.6%, $p<0.001$ ) (data not adjusted)  37.8% response rate (69.7% for paper and 13.0% for electronic surveys)  Dissatisfaction with breasts: multivariate analysis OR=0.95, $p=0.812$  Other outcomes were not adjusted using multivariate analysis; in the shorter follow-up group (1-5 years) NSM better than SSM for Psychosocial Well-Being and Sexual Well-Being modules and some components of Satisfaction with Breasts; differences were smaller and not statistically significant in the 6-10 years group  1.2% (3 pts) NSM group had nipple excision for positive margins
Racz, 2022 (79)	Mayo Clinic Rochester, MN	2011-2015	PROs with or without reconstruction and NSM vs. SSM using BREAST-Q for mastectomy with reconstruction	198 NSM, 336 SSM	Retrospective review of prospective database  BREAST-Q mailed to all pts with mastectomy in database	Identified pts by ICD-9 codes in database  NSM or SSM for breast cancer or significantly elevated risk of breast cancer, and reconstruction with expander/implant and autologous reconstruction	Reason for NSM vs. SSM not reported  No information on operation or pathology	NSM vs. SSM  <ul style="list-style-type: none"> <li>Satisfaction with Breasts mean 71.8 vs. 70.2, <math>p=0.21</math>, multivariable <math>p=0.984</math></li> <li>Psychosocial Well-Being mean 81.9 vs. 81.3, <math>p=0.47</math>, multivariable <math>p=0.929</math></li> <li>Sexual Well-Being mean 64.5 vs. 58.0, <math>p=0.002</math>, multivariable <math>p=0.033</math> (effect size 4.69 points)</li> </ul>



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Patient characteristics	Evaluation	Results
					Linear regression for multivariable analysis adjusting for potential confounders  PROs using BREAST-Q	NSM pts were younger, lower BMI, more prophylactic; less neoadjuvant chemotherapy, and axillary surgery, or PMRT  93% of reconstruction used implants  In SSM, 64% had no nipple reconstruction or tattoo, 12% had reconstruction, 8% tattoo, 17% reconstruction and tattoo		NSM vs. SSM + nipple reconstruction: Sexual Well-Being scores similar, multivariable p=0.182; NSM vs. SSM without tattoo or reconstruction p=0.008, 6.34 points in favour of NSM  Individual components of satisfaction score: NSM more favorable for natural appearance, appearance unclothed  Individual components of Sexual Well-Being score: NSM better sexual confidence unclothed, sexual attractiveness when unclothed
Cho, 2023 (76)	Severance dataset from Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea  Validated results by using the SEER database	2010-2017  SEER 2000-2018	Is NSM with immediate reconstruction inferior to total or SSM for 5-y DFS and OS?	Severance 611 pts: 151 NSM, 460 total/SSM  SEER 14,770 NSM; 485,245 total mastectomy	Propensity-score matching; survival by Kaplan-Meier and Cox proportional hazard regression  Severance: median follow-up 53 months NSM and 71 months other	Severance: pts with mastectomy; excluded LCIS, DCIS, bilateral, metastasis, or without immediate reconstruction  Pts with suspected NAC invasion were not eligible for NSM  SEER: breast cancer pts; excluded bilateral non-cancer deaths, SEER does not include DFS data  SEER data: NSM younger (51.3 vs. 59.5), different in most surgical groups, NSM younger, lower TNM stage, grade	Severance: frozen-section biopsy of retroareolar tissue in NSM, nipple removed if retroareolar margin was positive and excluded from NSM group	Severance: DFS; secondary endpoints LRFS, DMFS, OS  <ul style="list-style-type: none"> <li>• LR 0 vs. 9 (2.0%)</li> <li>• Regional recurrence 6 (4.0%) vs. 8 (1.7%)</li> <li>• DM 10 (6.6%) vs. 27 (5.9%)</li> <li>• Death: 0 vs. 4 (0.9%)</li> <li>• 5-y LRFS 95.8% vs. 96.8%, HR=1.22, p=0.68</li> <li>• 5-y DMFS 93% vs. 93.7%, HR=1.25, p=0.55</li> <li>• 5-y DFS 89.1% vs. 90.7%, HR=1.15, 95% CI=0.65-2.03, p=0.64</li> <li>• 5-y OS 97.3% vs. 97.4%, HR=1.05, 95% CI=0.34-3.20, p=0.93</li> </ul> With propensity score matching (NSM matched 1:2 with total/SSM): <ul style="list-style-type: none"> <li>• 5-y DFS 89.7% vs. 89.4%, HR=1.04, 95% CI=0.54-2.01, p=0.91</li> <li>• OS 97% vs. 97.3%, HR=1.07, 95% CI=0.30-3.87, p=0.91</li> </ul> SEER database: OS HR=0.60, 95% CI=0.54-0.67, p<0.001

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Patient characteristics	Evaluation	Results
Ogiya, 2023 (78)	12 hospitals, Japan	2008-2016	LR after immediate breast reconstruction	4153 cases: 1192 NSM (359 non-invasive, 831 invasive) 1409 SSM (445 non-invasive, 960 invasive) 1552 total mastectomy	STROBE reporting guidelines Invasive and non-invasive analyzed separately Stepwise regression, Cox proportional hazard model for LR	BCS or mastectomy depending on expected margin and breast shape, and pt preference; mastectomy if BRCA positive  NSM if nipple could be preserved based on imaging and palpation and pt wished to keep the nipple  Excluded NACT  Tissue expanders in 88.1% of pts  Median follow-up 75 months		Of 73 NSM with LR, 10 (13.7%) involved nipple  For 7y LR, due to missing variables, only data for 53% non-invasive and 91% invasive pts used for analysis:  Non-invasive cancer; univariate results for 187 NSM and 267 SSM: 7-y LR 2.6% vs. 3.8%  Invasive cancer, results for 776 NSM and 894 SSM: 7-y LR 6.6% vs. 4.8% (HR compared with total mastectomy 3.112 and 1.872, univariate; HR 2.738 and 1.723 multivariate
Sasada, 2024 (235)	Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society 12 institutions	2008-2016	RT for involved surgical margins after immediate reconstruction	1431 NSM, 1593 SSM  123 NSM and 102 SSM with involved margins	Retrospective  Median follow-up 75 months  HRs adjusted for previously reported risk factors	Breast cancer, mastectomy, immediate reconstruction  NSS, SSM, or total mastectomy depending on institutional standards and pt preference  PMRT if lymph node involvement, large tumours, involved margins  Involved margins are invasive or in situ tumour on ink	Not reported	Involved surgical margins: in 123 cases (8.6%) of NSM; 102 cases (6.4%) of SSM  Involved nipple margins in 26 cases (1.8%) of NSM  LR in pts with involved surgical margins, HR compared with total mastectomy  NSM: HR=1.26, 95% CI=0.37-4.03, p=0.696  LR, SSM: HR=0.65, 95% CI=0.18-2.36, p=0.515

\*Usually year of diagnosis or initial surgery

#### Abbreviations:

ADM, acellular dermal matrix; ALND, axillary lymph node dissection; ASM, areolar-sparing mastectomy; BCS, breast conserving surgery; BCSS, breast cancer-specific survival; BMI, body mass index; BRCA, BRest Cancer gene; CI, confidence interval; DCIS, ductal carcinoma in situ; DFS, disease-free survival; DMFS, distant metastasis-free survival; DTI, direct to implant; ELIOT, intraoperative electron-beam radiotherapy; HR, hazard ratio; ICD-9, International Classification of Diseases, Ninth Revision; ILC, invasive lobular carcinoma; LABC, locally advanced breast cancer; LCIS, lobular carcinoma in situ; LR, local recurrence; LRR, locoregional recurrence; MGH, Massachusetts General Hospital; MRM, modified radical mastectomy; MRI, magnetic resonance imaging; NAC, nipple-areolar complex; NACT, neoadjuvant chemotherapy; NCDB, National Cancer Database, American College of Surgeons, with data from >1500 Commission on Cancer-accredited facilities in the United States and ≈70% of newly diagnosed cancers in the United States; NSM, nipple-sparing mastectomy; OR, odds ratio; OS, overall survival; PMRT, postmastectomy radiotherapy; PRO, patient-reported outcomes; pts, patients; RT, radiotherapy; SEER, Surveillance, Epidemiology, and End Results database, SLNB, sentinel lymph node biopsy; SSM, skin-sparing mastectomy; TND, tumour-nipple distance; TNM, tumour, node, metastasis staging system; TRAM, transverse rectus abdominis musculocutaneous flap; TSSM, total skin-sparing mastectomy; US, ultrasound

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q3b/c](#)[Back to Start of Tables](#)**Table 4-5. Question 3b: Oncologic and nipple outcomes according to criteria for NSM patient selection & Question 3c: Surgical factors influencing nipple outcomes**

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Tumour-Nipple Distance											
Ryu, 2016 (86)	Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	2008-2014	NSM with TND <2 cm, negative frozen biopsy at nipple base	251 pts, 266 NSM: TND <2 cm in 145, TND ≥2 cm in 121	Retrospective review  2 groups by TND similar except TDN<2 cm group had lower tumour size, stage, chemotherapy use and more ER/PR+ and hormonal therapy  Mean follow-up 28.4 vs. 22.2 months	All pts who underwent NSM + IBR for breast cancer  Exclude collagen-vascular disease, prophylactic (TND not measurable)	Preoperative MRI to define TND measured as shortest distance between tumour border and base of nipple; in case of NACT used MRI after NACT completed  Inclusion: skin island (removed skin) <10 cm at largest dimension,  Exclusion: clinical evidence of NAC involvement, inflammatory cancer, LABC with skin involvement, bloody nipple discharge	Intraoperative frozen biopsy at nipple base; NAC or nipple removed if positive for invasive ductal or lobular carcinoma, lymphovascular invasion, ductal carcinoma in situ, atypical ductal hyperplasia with necrosis, or lobular neoplasia/lobular carcinoma in situ  371 attempted NSM but 78 excluded due to positive results under NAC at frozen biopsy (n=76) or permanent biopsy (n=2) and 27 excluded because TND not clearly defined	Very low event rates; no difference between TND < 2 cm or ≥2 cm: LRR 3 (2.1%) vs. 3 (2.5%), metachronous contralateral breast cancer 2 (1.3%) vs. 1 (0.8%), DM 1(0.7%) vs. 1 (0.8%) or death (none in either group)  DFS p=0.894, LRFS reported as p=0.594 in figure and p-0.509 in text	Incision placement at discretion of surgeons: 27.4% radial incision, 30.1% lateral, 32.0% periareolar  Subcutaneous dissection removed maximum amount of glandular tissue and raised NAC as full-thickness skin flap by electrocautery  Ducts just below NAC sharply excised and sent for intraoperative frozen biopsy and permanent biopsy	Did not report by TND  Reported by time periods 2008-2010 (n=43) and 2011-2014 (n=223): Total nipple necrosis 0 and 1 (0.4%); partial nipple necrosis 5 (11.6%) and 3 (1.3%); partial areola necrosis 2 (4.7%) and 3 (1.3%)  One NAC excision because of total nipple necrosis
Alsharif, 2019 (87)	Samsung Medical Center, Seoul, Korea	2008-2014	Long-term outcomes by TND <2 cm or ≥2 cm	245 pts; 128 <2 cm TND and 117 ≥2 cm TND	Mean follow-up 60.5 months  Note that groups were not equivalent	<2 cm TND group had smaller tumours (median 0.7 cm vs. 3.0 cm, p=0.005), more DCIS (32.0% vs.	Pts evaluated for signs of skin, NAC, or nipple involvement as indicated by retracted nipple	Intraoperative frozen biopsy to confirm negative margin at nipple base and also analyzed by permanent sections	LRR: 4 pts (3.1%) in <2 cm group vs. 6 pts (5.1%) including 1 (0.8%) vs. 3 (2.6%) in nipple	7.0 cm long radial incision, nipple tissue just behind the dermis was sharply dissected at the nipple-dermal junction and	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
					and event numbers are low	16.2%), less invasive ductal carcinoma (57.8% vs. 72.6%), and received less chemotherapy  IBR after mastectomy in all pts	Preoperative breast MRI to measure TND between tumour and base of the nipple; in pts with NACT, measurement was done after NACT and pts with pathological complete response were excluded	If frozen sections positive for invasive cancer, DCIS, atypical ductal hyperplasia with necrosis, or lobular neoplasia the NAC was removed and pts excluded from the study	DM 2.3% vs. 5.1% 3 deaths (1.2%): 1.6% vs. 0.9%  No significant difference in DFS or LRFS	dissected; glandular tissue removed by subcutaneous dissection using electrocautery  Follow-up every 6 months for 5 years and then annually	
Balci, 2019 (88)	Istanbul, Turkey	2007-2017	Oncologic safety with TND <2 cm	193 pts; 59 with TND <2 cm, 134 with TND ≥2 cm	Retrospective  Median follow-up 62 months  Groups similar in tumour size and nodal involvement	NSM with immediate reconstruction, invasive cancer  Excluded pure DCIS, neoadjuvant chemotherapy  Immediate implant or tissue expander reconstruction, with ADM if needed	Exclude if clinical evidence of NAC involvement (nipple retraction, Paget changes, and pathologic nipple discharge), inflammatory breast cancer, no MRI  MRI, mammography, and ultrasound used to determine TND and tumour size  TND defined as distance from base of the nipple to the closest edge of the tumour	Nipple base (biopsy of nipple/subareolar margin) negative for invasive or in situ cancer by frozen-section or paraffin histopathology; NAC removed if positive for carcinoma; LCIS or atypical hyperplasia was not counted as involvement	4 LR (6.7%) with TND <2 cm vs. 5 LR (3.73%) + 3 DM with TND ≥2 cm  Recurrence with invasion of NAC: 1 (1.69%) in TND <2 cm group; 2 (1.49%) in TND ≥2 cm  10-y DFS 93.2% vs. 96.3%, p=0.368	lateral incisions ≥2 cm from the nipple were preferred; IMF incisions less often; periareolar and skin-reducing incisions in sporadic cases with very large ptotic breasts  Hydro-dissection used for NAC and skin isolation	Wound dehiscence: 2 (3.38%) vs. 3 (2.23%)  Total nipple necrosis: 3 (5.08%) vs. 1 (0.74%)  Partial flap necrosis: 2 (3.38%) vs. 3 (2.23%)

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Fregatti, 2020 (89)	Ospedale Policlinico San Martino, Genoa, Italy	2012-2018	Effect of TND by MRI vs. permanent section analysis	246 pts	Retrospective Median follow-up 31-33 months	<p>Therapeutic NSM</p> <p>Exclude large breast size or ptosis that would result in unacceptable nipple position</p> <p>2-stage expander-implant in 214 pts, immediate implant in 32 pts</p> <p>Pts with TND <math>\leq 2</math> cm compared with 2-5 cm had a significantly higher rate of invasive ductal carcinoma (72% vs. 51%, <math>p &lt; 0.003</math>), less lobular cancer (13% vs. 26%), and more excision margins less than 2 mm (42% vs. 5%, <math>p &lt; 0.001</math>)</p>	<p>No clinical signs of direct NAC involvement such as bloody nipple discharge, nipple retraction, Paget disease, and no NAC involvement by imaging</p> <p>Excluded inflammatory, LABC with skin involvement or NACT</p> <p>All pts had MRI to measure TND</p>	<p>Duct bundle by definitive pathology</p> <p>Retroareolar margin excised and marked with a stitch</p> <p>If definitive pathological examination of the retroareolar margin or nipple duct bundle detected invasive cancer, DCIS, or atypia the nipple was excised but often retaining areola (ASM); these pts were excluded from NSM group</p> <p>11 retroareolar specimens positive at definitive pathology (6 DCIS, 4 close/positive margins, 1 atypia);</p> <p>Nipple excised in 7 pts and NAC in 4 pts; final re-excision specimen examination showed residual disease in 7 pts (63.6%).</p>	<p>In NSM: LRR 4 (3.4%) with TND <math>\leq 2</math> cm, 2 (2.6%) with TND between 2 and 5 cm, 1 (2.7%) with TND <math>&gt; 5</math> cm</p> <p>No NAC recurrence</p> <p>LR 2.4% vs. 1.3% vs. 2.7%</p> <p>DFS <math>&gt; 96\%</math></p> <p>In pts with ASM or SSM: 4/11 (36%) had LR far from NAC excision</p>	<p>Incision at surgeon discretion; S italic incision was most frequent except for patients having skin-reducing NSM in which inframammary or inverted T incision was used</p> <p>Skin flaps raised in Cooper's ligament plane up to the edge of the areola by electrocautery, tumescence, or sharp dissection; at areola edge the dissection was on the deep side of the areola dermis stopping beneath the nipple</p> <p>Nipple duct bundle isolated and grasped with a curved clamp, most duct tissue removed while leaving intact the vessels travelling into the nipple skin, duct bundle divided above and below clamp, and contents of clamp sent for definitive pathology</p> <p>Flap thickness of 3-5 mm carefully checked to avoid residual breast tissue on skin flaps</p>	<p>Nipple epidermolysis in 23/235 pts (9.8%) with NSM</p> <p>Full-thickness nipple necrosis and loss in 3 pts (1.3%)</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										SLNB for invasive and DCIS	
Wu, 2021c (90)	Asan Medical Center, Seoul, Korea	2003-2015	Oncologic safety of NSM with TND $\leq 1$ cm vs. $>1$ cm	1369 pts: after matching was 495 pts TND $\leq 1$ cm and 495 pts TND $>1$ cm	Retrospective Propensity-score matching to reduce effect of confounders on oncologic outcomes between TND groups Median follow-up (matched groups) 109 and 112 months	Primary breast cancer with immediate reconstruction NSM indications: any stage, size Exclusions: pT4 disease, synchronous distant metastasis, incomplete data	Any TND allowed, calculated from tumour to nipple using MRI, ultrasound, or mammography; if multifocal or multicentric then used closest lesion to the nipple for calculations  Inclusion: clinically normal NAC and no skin involvement or inflammatory disease	Retroareolar frozen-section biopsy and permanent biopsy in all pts; nipple $\pm$ areola immediately removed if positive for malignancy and converted to SSM or ASM and excluded from NSM cohort	LR 54 vs. 42 cases (10.9% vs. 8.5%) LR in NAC 29 vs. 19 (5.9% vs. 3.8%) cases Regional recurrence 16 vs. 23 pts (3.2% vs. 4.6%) DM 33 vs. 29 cases (6.7% vs. 5.9%) Death 5.5% vs. 4.8% 5-y cumulative LR 8.1% vs. 6.3%, p=0.268; NAC recurrence 5.1% vs. 2.8%, p=0.072; regional recurrence 2.0% vs. 3.6%, p=0.125; DM 5.9% vs. 4.8%, p=0.480 10-y LRFS 87.1% vs. 90.7%, p=0.164, HR=1.331, 95% CI=0.889-1.992 10-y DFS 77.9% vs. 81.6%, p=0.222, HR=1.191, 95%	Details not reported  <u>Other</u> Authors concluded that TND $\leq 1$ cm is not contraindication to NSM	Not reported

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
									CI=0.899-1.577, p=0.222		
Kim, 2020 (91)	Pusan National University Hospital, Busan, Korea	2007-2015	Experience with NSM with immediate reconstruction NSM outcomes No comparison of selection criteria or surgical procedures	251 pts, 251 NSM 119 TND $\leq 2$ cm; 132 TND $> 2$ cm,	Retrospective Mean follow-up 68 months	Excluded NACT 79% had adjuvant RT  <25 events for multiple linear regression	Pts with breast cancer and no tumour invasion to NAC by bilateral mammography, ultrasound, MRI, and physical exam  Mean TND $2.5 \pm 1.7$ cm; 119 (47.4%) $\leq 2$ cm and 69 (27.5%) $\leq 1$ cm	Frozen section biopsy of retroareolar tissue; central nipple duct margin evaluated by intraoperative and permanent pathology; NAC removed (converted to SSM or other procedure and excluded from study) if cancer or atypical cells found in frozen section or permanent section 15 pts (6.0%) positive surgical margins but no additional surgery as all breast tissue was removed; they received RT	11 (4.4%) LRR: 1 local recurrence in NAC, 10 in chest wall or skin  Systemic recurrence in 16 pts (6.4%), consisting of 11 pts (4.4%) only systemic and 5 (2.0%) also with LRR  5 (2.0%) breast cancer related deaths  5-y OS 98.0% for invasive cancer and 100% in situ  4.4% LRR: 5.0% with TND $\leq 2$ cm; 3.8% with TND $> 2$ cm  6.4% DM: 5.0% with TND $\leq 2$ cm; 7.6% with TND $> 2$ cm	Mayo scissors for sharp dissection; electrocautery only used for bleeding control to minimize thermal injury to the skin envelope  Removed entire breast tissue at level of subcutaneous fat layer	4 (1.6%) partial nipple necrosis; no additional surgery needed
Non-comparative studies											
Beller, 1981 (236)	Münster University Women's Hospital,	1974-1980	No comparison; NSM + optional	135 NSM: 110 T1 and 25 T2	Prospective, non-RCT, no comparison	Initially stage T1N0, later allowed T+N+, (110 pts T1 and	$\geq 3$ cm from areola at start of study (later allowed closer to	Frozen section of areola base and wedge excision of nipple; NAC	T1: one death (0.9%)	Subcutaneous mastectomy including complete removal of visible	Necrosis of NAC: 0 if skin reduction not needed, 3% if

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
	Münster, Germany		Delayed reconstruction (6-12 months; after RT)		Follow-up depended on time of enrolment (>72 months for first pts and 0-6 months for last pts)	25 pts >T1), ≤55 y old; chemotherapy (if node positive), lymphadenectomy, RT  Delayed reconstruction after skin healing and RT, generally 6-12 months later	areola if the areola was histologically tumour free)	removed if carcinoma found in frozen or permanent sections	T2+: 3 deaths (12%)  No recurrence in areola  Recurrence or metastasis: 6 pts T1 (5.5%), 6 pts T2+ (24%)  3% CBC: 2.2% T1 and 4.0% T2	glandular tissue (≈95%) with a lateral IMF incision and excision of nipple and areola base, sharp dissection of glandular and fatty tissue from the skin, resection of fascia of pectoralis major muscle.  In large breasts, skin was reduced 5 cm below the lower edge of the areola	skin reduction needed (25 pts) due to large breasts (impairment of vascular supply)
Psaila, 2006 (237)	Universita Cattolica "Sacro Cuore" - Rome - Italy	2002-2004	NSM, no comparison	139 NSM	Retrospective, mean 18 months follow-up (12-36 months)	All pts with NSM and immediate reconstruction (127 implant and 12 DIEP flap); 103 T1, 26 T2; 10 pts had recurrence after QuaRT  Exclude age >70 y, LN+	NSM decided on after preoperative mammography, ultrasound, pathology  Exclusion criteria: nipple retraction, tumour >3.5 cm, centrally located, TND <2 cm, Paget disease, ematic nipple secretion with cytological evidence for neoplastic cells	Touch prep cytology biopsy and intraoperative touch prep cytology of undersurface of areolar flap  1 pt with NAC involvement converted to SSM	Recurrence rates similar to radical mastectomy but data not reported	Skin incisions near the tumour and a skin ellipse up to a distance of 0.5-1 cm to the areolar lateral border removed.  Subcutaneous dissection by scissors; dissection along the superficial fascia	1% NAC necrosis, 18% NAC depigmentation, 75% loss of NAC sensitivity
Benediktsson, 2008 (238)	Huddinge University Hospital, Stockholm, Sweden	1988-1994	Survival with NSM + immediate reconstruction	216	Prospective, follow-up every 3 months for 5 y then at least	Primary unilateral breast cancer, not suitable for partial mastectomy	See population	Biopsy from adjacent to the remaining gland tissue sent for frozen section; NAC removed (11	LRR 52 pts; 5-y 16.2%, 10-y 20.8%  DM 44 pts (20.4%)	A 5-mm thick plate of gland tissue with a 2 cm diameter was left beneath the nipple to preserve the blood supply of the NAC	Not reported



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
					<p>annually; median 13 y, minimum 11.6 y (or until death)</p> <p>75% of operations by 2 co-authors, 6 others breast surgeons for rest</p>	<p>because of large (&gt;3 cm) or multifocal carcinoma (74%); or reoperation after partial mastectomy &lt;3 months earlier and multifocality or residual tumour highly suspected (47.7%))</p> <p>40.3% LN+, 47 pts with RT</p> <p>27 silicone submuscular implants, 189 subcutaneous saline implants</p> <p>Authors indicate more pts would receive RT by policy in effect by time of publication</p>		<p>pts) if malignant cells found at frozen section (1 of these negative at final pathology)</p> <p>3 additional positive at final pathology</p>	<p>DFS 51.3%; 5-y 68.0%, 10 y 60.0%</p> <p>OS 76.4%; 5-y 83.5%, 10=y 80.5%</p> <p>34 LRR were in same quadrant as primary tumour; authors state this may suggest inadequate surgery</p> <p>LRR with RT: 4 pts (8.5%); LRR without RT: 48 pts (28.4%)</p> <p>Note median 13 y follow-up, lack of RT, larger size and multifocality may account for higher rates of recurrence</p>		
Jeon, 2010 (75)	Yeungnam University College of Medicine, Daegu, South Korea	1996-2006	<p>NSM vs. SSM, according to frozen section analysis</p> <p>No comparison of selection criteria or surgical procedures</p>	133 NSM; 69 SSM	<p>Mean follow-up 67.6 months (71.4 months NSM, 60.2 months SSM)</p> <p>No multivariate analysis</p>	<p>Breast cancer</p> <p>Adjuvant chemotherapy if lymph node metastases, or &gt;T2; hormones if hormone receptor</p>	NSM if no clinically palpable lymph nodes, no infiltration or abnormalities in NAC visually or radiologically, Tis-2, N0-1; <4 positive nodes on	Frozen section analysis of retroareolar resection margin determined NSM or SSM; NAC sacrificed if positive on frozen section	<p>Local recurrence 12 pts (9.0%; 8 pts in NAC and 4 skin) vs. 4 pts (5.8%, all skin), p=0.585</p> <p>5-y local recurrence-free survival 92.1%</p>	Generally used hemispherical incision around areola and transverse incision extending ≈ 4 cm to outside and inside; if previous BCS then used previous radial incision as possible	<p>Also in Q3a</p> <p>For NSM: NAC necrosis in 3 cases (2.3%): 2 partial (1.5%) and 1 complete necrosis (0.8%, NAC removed</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
			Mastectomy by 1 surgeon, reconstruction by 2 surgeons			positive; no PMRT  More chemotherapy in NSM group (60.1% vs. 44.9%)  Pts with involvement of NAC were more likely to have DCIS, central or diffuse tumours	ALND for invasive cancer; immediate reconstruction	52 patients had tumour invasion of the cut surface; 50 found in both frozen and 2 only on permanent sections  SSM group is those pts converted from NSM to SSM due to cancer in frozen section <2 mm from cut surface	vs. 95.2%, p=0.652	Removed subcutaneous fat and breast tissue leaving about 1 cm fat; preserved blood vessels flowing into areola by careful dissection  Cut surface of breast parenchyma below areola painted with blue dye and sectioned for frozen section examination; if cancer on cut surface or within 2 mm the NAC complex was resected for ≈0.5-1.0 cm	and converted to SSM)
Kim 2010 (77)	Asan Medical Center, Seoul, Korea	2001-2006	NSM vs. SSM with immediate pedicled TRAM reconstruction  No comparison of selection criteria or surgical procedures	152 NSM, 368 SSM  115 of NSM pts had prospective follow-up	Retrospective ; prospective follow-up of complications in subset  Kaplan-Meier and multivariate (Cox proportional hazards) survival analysis  Median follow-up 60 vs. 67 months	Stage 0-IIIa, indications for SSM or NSM were any stage, any tumour size, any tumour-areolar distance  Reconstruction using TRAM flaps  For NSM, radioisotope used instead of blue dye for SLNB as dye is risk factor for skin necrosis	NSM offered if clinically normal nipple and no skin involvement NSM attempted in 187 pts but 35 had positive results on subareolar frozen biopsy and had SSM  NAC preserved when palpation, shape, and colour of nipple were normal and NAC ducts tumour-free in frozen biopsies	Thin layer of glandular tissue under areola taken for frozen section analysis	5-y DFS 89% vs. 87.2%, p=0.695; 5-y OS 97.1% vs. 95.8%, p=0.669; local failure 2% vs. 0.,8%, p=0.27  After adjustment for patient and tumour characteristics, DFS HR=1.004, 95% CI=0.52-1.93, p=0.991; OS HR=0.866, 95% CI=0.26-2.85, p=0.813	Lateral incision for SSM; either periareolar incision with lateral extension or lateral incision alone for NSM; periareolar used early in series but high skin necrosis so not used in later pts  Lateral margins dissected down to lateral border of pectoralis major, subdermal glandular tissue undermined in retroareolar area leaving 1-2 mm of intact dermis; NAC dissection by	In 115 NSM, any NAC necrosis in 26 (11 complete, 15 partial); NAC recurrence 1.3%

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										monopolar cautery using low level of cutting current	
Boneti, 2011 (239)	University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA	1998-2010	TSSM vs. SSM No comparison of selection criteria or surgical procedures	152 pts and 281 breasts TSSM	Retrospective review Follow-up 25.3 ± 18.8 months for TSSM group No multivariate analysis	Breast cancer (94.9%), high-risk lesions (1.7%), prophylactic (3.7%)  SLNB: stopped using blue dye because of skin flap necrosis and permanent staining of skin and switched to Tc99m sulfur colloid  Immediate reconstruction with implant or expanders	All SSM and TSSM cases with reconstruction; excluded LABC with skin involvement, inflammatory, collagen vascular disease, smoking within previous 6 months, RT if signs of radiation damage  TSSM or SSM decided based on NAC involvement, breast size, ptosis  TSSM if absence of NAC involvement on clinical exam or imaging (mammography, ultrasound, or MRI)	Nipple core biopsy for intraoperative touch prep and permanent evaluation  TSSM converted immediately to SSM if nipple core intraoperatively showed malignancy (2.5%); NAC removed in reoperation if involvement shown on final pathology	LRR in 7 of 152 pts (4.6%) No recurrence in NAC	Skin flaps by developing dissection plane with serial dilation and blunt dissection in the plane between the breast and subcutaneous tissue; at NAC used cold blade or scissors to sharply separate overlying skin, aiming for thickness ≤7 mm	2 NAC necrosis requiring excision (1.3%) 9 skin flap necrosis (5.9%)  Vertical infra-areolar incision preferred as less severe skin loss; IMF incision can remove the inframammary blood supply
Fortunato, 2013 (240)	San Giovanni-Addolorata Hospital, Rome, Italy	2003-2012	NSM outcomes No comparison of selection criteria or surgical procedures	121 pts, 138 NSM (122 for cancer); of these 124 NSM were in 2009-2012	Retrospective review Median follow-up 26 months	Pts necessitating mastectomy 60% multifocal or multicentric cancers, 22% LABC, 3% contralateral, 1.5%	No clinical evidence of NAC invasion or retraction, ≥1 cm tumour to NAC  Since 2009 used mammography,	Intraoperative serial histologic exam of retroareolar tissue using toluidine blue and hematoxylin-eosin staining	1 LRR outside NAC; 6 systemic relapse (DM), 1 contralateral cancer, 1 death	Generally radial lateral or italic S incision, paying attention to not compromise periareolar blood supply; skin flaps carefully raised at level of Cooper's	4.3% total NAC necrosis; 4% partial skin flap necrosis; 10% skin desquamation/minimal necrosis

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
						recurrence, 11.5% prophylactic	sonogram, and MRI for all cases  Inclusion in pts with cancer: $\geq 1$ cm from NAC, negative retroareolar margin; no clinical involvement of NAC, Paget disease, bloody discharge, inflammatory carcinoma	NAC removed (near margin or < 2mm from ink) in 11/31 cases (35%) with TND <1 cm and 8/62 cases (12.9%) with TND > 1 cm; NAC removed more in first half of study, 17/69 vs. 8/69. Of NAC removed, 58% had residual cancer at definitive exam		ligaments with electrocautery at low setting and avoiding excessive traction  Maintained 2-3 mm retroareolar thickness  Submuscular tissue expander or prosthesis used	Nipple necrosis or skin desquamation in 25 pts  8% had some NAC sensation in first month, 17% after 6 months (typically minimal or partial)  Table II with NAC events is missing from publication
Sakurai, 2013 (241)	Wakayama, Japan	1985-2004	NSM vs. mastectomy  Mastectomy group not relevant to current review and data not extracted  NSM outcomes  No comparison of selection criteria or surgical procedures	788 NSM	NO RT used  No multivariate analysis  Median follow-up 87 months	Invasive or non-invasive breast cancer, not restricted to small tumours/early stage; 38.6% stage 1, 28.3% stage 2A, 17.9% stage 2B, 12.1% Stage 3, 0.4% stage 4  Immediate reconstruction (autologous free dermal fat graft implant) at pt request	NSM if pt desired to preserve NAC, mastectomy if believed risk of recurrence outweighed benefit of NSM  Other criteria for NSM: macroscopically intact, no involvement by frozen section	NAC resected if evidence of neoplastic involvement on frozen sections	Local recurrence 8.2%: NAC relapse 3.7% (2.7% nipple, 0.5% areola, 0.5% nipple and areola); skin flap 4.6%  NAC removed if recurrence in this area  DFS: 5-y 86%, 10-y 83%, 15-y 75%  OS: 5-y 93%, 10-y 88%, 15-y 87%	NSM incision varied: periareolar, lateral, IMF depending on location and size of tumour  For NSM, thin flap ( $\approx 5$ mm) of subcutaneous adipose tissue left close to the tumour and >1 cm thick in location >2 cm from tumour; nipple everted and major ducts removed from the lumen; tissue under NAC carefully treated to preserve vessels that feed the nipple	No nipple necrosis (0/788)

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Stanec, 2014 (242)	University Hospital "Dubrava," Zagreb, Croatia	1997-2012	NSM and SSM experience  NSM outcomes  No comparison of selection criteria or surgical procedures	361 pts (421 breasts) with NSM or SSM  After imaging or frozen section analysis, 252 pts NSM (288 breasts of which 47 or 16% were prophylactic )	Retrospective using medical records  NAC sensation reevaluated each examination and end of study (most >1 y follow-up); 0=no sensation and 4=normal sensation	Pts could indicate preference for radical mastectomy, quadrantectomy, oncoplastic BCS, NSM.  Autologous reconstruction (mostly LD) in 65.5%, 3.8% LD plus implant, 30.6% implant only	Patients screened for NSM eligibility using mammography, ultrasound, MRI, and biopsy. Pts with cancer in NAC (125 breasts) received SSM.	For NSM, intraoperative frozen section of subareolar tissue found 25 occult involvement of NAC (7.7%) and NAC removed (followed as SSM); on final histological examination 12 (4.2%) had DCIS or invasive cancer and nipple was removed and followed up as NSM	Outcomes after 15 years: local recurrence 3.7%; local recurrence in NAC 1.2%; LRR 5.5%; death from DM 3.6%; DM still alive 0.8%	Omega pattern incision (periareolar with lateral extension) with modification according to breast anatomy	Partial necrosis (epidermolysis ), of NAC in 27 pts (9.4%), total or full-thickness necrosis (eschar) in 2 pts (0.7%)  Depigmentation persisted in 12/27 pts  NAC sensation: 0 (none) 16%, 27% large decrease, 35% less decrease, 22% normal
Rossi, 2015 (123)	Morgagni-Pierantoni Hospital, Forli, Italy	2006-2014	NSM outcomes  No comparison of selection criteria or surgical procedures	252 NSM planned, 199 NSM (178 pts) and 53 SSM conducted		23 (9.1%) risk reducing (prophylactic) NSM, 83 (33%) in situ carcinoma, 127 (50.4%) invasive, 19 (7.5%) C5 preoperative cytology  Immediate reconstruction with subpectoral implant or expander	Mammography, ultrasound, MRI if available  Exclusion if infiltration of skin or NAC (within 2 cm of nipple base), inflammatory, pathologic nipple discharge, Paget disease  Relative contraindications : significant large/ptotic breast, active smoking, extensive lymphovascular	After mastectomy was completed a 3-5 mm thick layer of tissue removed from retroareolar area of specimen for frozen section analysis; if neoplastic tissue found then the NAC removed and converted to SSM. By nipple eversion the central ducts are transected at the base of the nipple and dissected, nipple is cored	1 LR  0 LR in NAC after NSM  6 DM (3%)	Italic S incision from lateral edge of areola to external equatorial line which permits access to axillary lymph nodes; NAC isolation by hydrodissection of the areola	0 complete necrosis of the NAC  25 partial transient ischemia of the NAC with epidermolysis  Nipple sensitivity and erectile capacity of the nipple insufficient in most pts

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
							invasion, previous RT, diabetes, obesity	53 (21%) converted to SSM due to cancer found in retroareolar tissue (all confirmed at definitive histology)  Removed NAC had 9 invasive cancer, 38 in situ carcinoma, 6 LIN III  If definitive histology positive, then either NAC removal, RT, or follow-up			
Santoro, 2015 (243)	San Giovanni-Addolorata Hospital Rome, Italy	2007-2015	NSM after NACT  NSM outcomes  No comparison of selection criteria or surgical procedures	186 NSM, including 51 after NACT	Retrospective review  Median follow-up 35 months	Invasive or intraductal carcinoma  Minimum follow-up 12 months; 72% for multifocal or multicentric disease, 22% for LABC, 6% for contralateral cancer after previous mastectomy  Immediate reconstruction with tissue expander or prosthesis under pectoralis major and serratus	Pts requiring mastectomy, no clinical evidence of NAC invasion or retraction, $\geq 1$ cm clinical-radiological distance between tumour and NAC, no Paget disease, bloody discharge, or inflammatory carcinoma  All pts evaluated by mammography, ultrasound, and MRI; whole body CT scan and bone scan if receiving NACT	Intraoperative serial histological exam of retroareolar tissue, using staining; 23 pts had nipple removal due to cancer cells $< 2$ mm from margin and of these NAC showed no residual cancer in 11/23 (48%)	DFS at median 35 months was 89.7%  Local relapse 1.6%;  No NAC recurrence  8.6% systemic relapse (DM) and 5 pts died (3%)  4 new contralateral cancers (2%)	Radial lateral or italic "S" incision, paying attention not to compromise periareolar blood supply; skin flaps raised with low setting electrocautery at level of Cooper's ligaments, avoiding excessive counter traction  No more than 2-3 mm retroareolar thickness maintained	Full thickness NAC necrosis in 8 pts (4%)  Minimal NAC necrosis or desquamation not requiring surgery, or simple debridement with primary skin closure in 31 pts (17%)  Skin flap complications 7%

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
						anterior muscles	Excluded large and ptotic breasts at start of study but not later on				
Seki, 2015 (244)	Keio University Hospital, Shinjuku-ku, Tokyo, Japan	2003-2013	Local recurrence NSM vs. mastectomy  NSM outcomes  No comparison of selection criteria or surgical procedures	121 NSM	Retrospective review of prospective database  Median follow-up 28 months	Stage 0-III breast cancer without indication for BCS by MRI, ultrasound, and mammography	NSM not allowed if suspicion of tumour involvement in the NAC or skin by imaging	Frozen section analysis of subareolar tissue in NSM found tumour involvement of NAC in 5 pts (4.1%) and the NAC was removed; 2 (1.7%) additional cases of NAC involvement by permanent section (one had NAC removed, the other had RT)	NSM group: LR in 5 pts (4.1%) 5-y LR 7.6%  DM in 6 pts (5.0%)  5-y distant metastasis 7.4%  5-y OS 98.4%  In pts with LR, 2 had NAC recurrence and 3 skin flap recurrence	Not reported	Nipple necrosis in 3 pts (2.5%)
Fujimoto, 2016 (245)	Yokohama City University Medical Center, Yokohama, Japan	2004-2010	Outcomes of immediate reconstruction using free flaps after NSM or SSM  No comparison of selection criteria or surgical procedures	136 pts: NSM attempted in 107 pts and received in 100 pts; 29 initially SSM plus 7 converted from NSM	Retrospective review  Median 75 months follow-up:	Operable stage 0-IIIa, immediate reconstruction using free flaps,	No clinical evidence of NAC involvement, self-selected to possibility of NSM or SSM  Exclusions: LABC with skin involvement, inflammatory breast cancer, nipple retraction or discharge	NSM converted to SSM (removal of NAC) because of intraoperative frozen section subareolar tumour positivity in 7/107 pts  11 pts (8%) with positive margins in permanent sections (3 partial breast RT, 5 whole breast RT, 3 no RT)	5-y RFS 91.9% Recurrence: 9.6% overall 2.9% LR alone, including 0.7% NAC and 2.2% skin 2.2% both LRR and DM 2.9% DM alone 1.5% contralateral 2.2% death	Lateral incision along IMF line; subdermal glandular tissue undermined in retroareolar are leaving 1-2 mm intact dermis; SLNB in same incision with injection of indigo carmine around subareolar area	Total NAC necrosis in 1 pt (0.7%)  Partial NAC necrosis in 9 pts (6.6%)



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Moo, 2016 (246)	Weill Cornell Medicine, New York, NY, USA	2007-2013	Oncologic outcomes after NSM  No comparison of selection criteria or surgical procedures	413 pts (721 NSM)  Numbers add to 708 NSM but text says 721 NSM	Retrospective  Follow-up median 32 months		Pts given option of NSM depending on breast size and ptosis  NSM excluded if NAC involved clinically or on imaging, suspicion of carcinoma-related nipple discharge, inflammatory, Paget disease	Retroareolar biopsy with permanent section; frozen section according to surgeon preference; nipples excised if positive pathology (ASM)  28 NAC biopsies (7.6%) positive on either permanent or frozen section; of these 7 were negative on frozen section and positive on permanent section; 20 NAC were removed  Pt with ASM were excluded	23 pts (6.3%) with recurrence:  8 (2.2%) LRR (1 at NAC);  9 (2.4%) DM;  6 (1.6%) both LRR and DM  Estimated RFS 93.6% at 36 months	NSM via IMF incision	Not reported
Shimo, 2016 (247)	St. Marianna University School of Medicine, Kanagawa, Japan	2000-2013	Surgical and oncologic safety of NSM vs. conventional total mastectomy  Only extracted NSM data; no comparison of selection criteria or surgical procedures	413 pts (425 breasts) NSM; 878 total mastectomy	Retrospective  Median 46.8 months follow-up  Multivariate analysis was not conducted	Primary breast cancer	NSM eligibility: no suspected cancer infiltration to NAC on MRI, extensive intraductal spreading and multicentric disease difficult to treat with BCS, and patient preference	Excluded if retroareolar frozen sections positive for carcinoma (all were negative)  Retroareolar biopsies were negative on both frozen and permanent histological diagnosis  Recurrence at NAC treated with complete NAC resection	DM 7.5%  Survival 96.8% (appears from graph to be 5-y OS)  Local recurrence 5.8%, including 10 cases (2.3%) at the NAC  NAC recurrence associated with DM and lower survival  Survival and recurrence did not differ from	Periareolar or lateral incision and an IMF incision depending on main tumour location, pt preference, and physician consideration; most were lateral incisions  Thick cutaneous adipose tissue left unless close to tumour to preserve blood flow to the NAC	96 ischemic nipple complications (22.6%), all which resolved with alprostadi ointment  Nipple erosion 0.9%  Nipple necrosis 1.4%



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
									total mastectomy but no multivariate analysis (excluded from Q3a)	Tissue under NAC treated carefully to avoid nipple necrosis	
Tang, 2016 (97)	Massachusetts General Hospital, Boston, MA, USA	2007-2014	NSM outcomes No comparison of selection criteria or surgical procedures	766 pts with 1326 NSM; 27% unilateral and 73% bilateral  642 (48%) therapeutic and 684 (52%) prophylactic	Median follow-up of 36 months	All pts with NSM and immediate reconstruction	Exclude if clinical or imaging evidence of NAC involvement, LABC with skin involvement, inflammatory cancer, bloody nipple discharge, marked ptosis (for cosmetic reasons)  TND measured in later pts but not used as criteria to include/exclude	Nipple/subareolar margin specimen containing superficial retroareolar tissue and ductal tissue from nipple sent for permanent pathology; final anterior margin is the underside of nipple and areola dermis; margins considered positive if they contained invasive cancer or DCIS  Decision to remove NAC or only the nipple made by breast and plastic surgeons. In therapeutic NSM group, nipple or NAC removed for 9/11 (82%) when margins had invasive cancer and 28/32 (88%) with DCIS  Of 19 pts with nipple-only excision for positive margins, 2	Positive margins in 6.7% therapeutic and 0.4% prophylactic NSM  In NSM with positive nipple margins, no recurrences occurred at nipple/NAC excision site  In breasts with positive nipple margins there were 3 chest wall recurrences (2 in observation alone and 1 with NAC excision); in breast with therapeutic NSM and negative margins there were no recurrences at nipple/NAC but 6 (1%) chest wall recurrences	Flaps raised in Cooper's ligament plane, leaving <1 cm subcutaneous fat in most pts  No subcutaneous fat was left under areola  Rate of positive margins decreased over time (11% in 2007-2011 vs. 5.4% in 2012 to 2014).  Removal of full NAC decreased over time; nipple only was removed in 38% in 2007-2011 and 62% in 2012-2014	Total nipple necrosis leading to nipple loss in 18 breast (1.4%)  In pts without previous RT or PMRT, nipple necrosis was 0.9% and breast skin necrosis 2.4%

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
								<p>had DCIS but clear areolar margins and the 3rd had ILC with partial areola excision</p> <p>Precursor lesions such as LCIS, atypical lobular hyperplasia, atypical ductal hyperplasia, flat epithelial atypia were documented but not considered positive margins and nipple/NAC was not routinely excised</p>			
Smith, 2017 (98)	Massachusetts General Hospital, Boston, MA, USA	2007-2012	<p>Long term oncologic safety of NSM</p> <p>No comparison of selection criteria or surgical procedures</p>	297 pts, 311 NSM	<p>Retrospective review</p> <p>51 months median follow-up</p>	<p>Most pts had implant reconstruction (65.0% single stage, 31.4% expander, 2.2% tissue flap)</p> <p>18% received PMRT</p>	<p>Exclusion: radiologic or clinical evidence of nipple involvement; LABC with skin involvement, inflammatory breast cancer, bloody nipple discharge, or if breast size and/or ptosis would result in unacceptable nipple location</p> <p>Preoperative MRI used in 35.5% at surgeon discretion</p>	<p>If nipple margin in permanent sections contained invasive cancer or DCIS it was considered positive and nipple excised, often with retention of most of the areola</p> <p>Nipple margin positive in 20 breasts (6.4%) of which 10 excised nipple papilla and 9 entire NAC, 1 pt had tumour 2mm from inked margin and had no additional surgery</p>	<p>3-y DFS 95.7%, 5-y DFS 92.3%</p> <p>17 recurrence: 11 (3.7%) LRR and 8 (2.7%) DM (this includes 2 pts with both LRR and DM)</p> <p>No recurrence in NAC in this group of 311 pts or entire 2182 NSM conducted from 2007-2016</p> <p>No recurrence at site of excised nipple or NAC for pts treated for positive margins</p>	<p>Incision placement at surgeon discretion; majority used inferolateral incisions</p> <p>Skin flap raised in Cooper's ligaments plane, usually with electrocautery</p> <p>At NAC, areola skin flaps raised leaving nipple duct bundle intact to be sharply divided immediately below the NAC dermis and sent permanent pathology</p> <p>Frozen section used rarely because less accurate, and difficult to</p>	<p>1.7% total nipple necrosis resulting in NAC excision in study with overlapping pt population that included 51.2% NSM for risk reduction (see Coopey, 2013 (248))</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										distinguish benign atypia from DCIS	
Agresti, 2017 (249)	NCT02471742  Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy	2009-2013	Oncologic safety of NSM after NACT (primary chemotherapy, PC)  No comparison of selection criteria or surgical procedures	422 pts NSM: 361 first line NSM (no NACT) and 61 after NACT (NSM-PC)	Propensity-score matching Match 2: cT2-3 pts before NACT using clinical tumour size: 61 NSM-PC and 61 NSM; Match 3 using pathological tumour size (after NACT if used): pT1-3 after NACT: 61 NSM-PC and 183 NSM  Annual follow-up; median follow-up 42.5 months NSM, 46.0 months NSM after NACT	Invasive breast cancer,  NACT group: T2-T3N0-N1  Non-NACT group: T1-T3N0-N1  Excluded progressive disease during NACT, synchronous DM, other clinical disease affecting optimal therapy  2-stage submuscular or 1 stage dual-plane implants	Tumour nodule without skin adherence  TND <1 cm allowed  Exclude if nipple retraction, Paget disease, inflammatory changes of the breast, bloody nipple discharge	Sample for frozen analysis from base of NAC analyzed; invasive or DCIS in main ducts evaluated  Include in study only if retroareolar main ducts free of neoplastic tissue at frozen section examination  NAC involvement in frozen section or final pathology in 54 pts (12.8%, of which 3.1% was infiltrating and 9.7% DCIS); subdivided by NACT it was 13.3% NSM, 9.8% NSM-PC  51/54 pts with involvement had NAC resection and 3 had RT  No further disease found in excised NAC in 30 pts; involvement found in 21 pts (5 infiltrating, 16 non-infiltrating)	NAC and NAC-PC groups not equivalent before matching so difference is likely not due to NACT  LR 2.8% NAC; 9.8% NAC-PC  1 pt in NAC-PC group had LR in NAC	Radial Italic S-like incision in equatorial/upper external site of the breast if A-C cup size [was very small number of larger breasts D or DD]  Skin layer 1-2 mm thick left to preserve essential capillaries supplying the skin; fascia of major pectoral muscle preserved if oncologic safety allowed, areola dissected away from underlying tissue even if thin disc of gland tissue remained  If tissue containing main ducts under nipple was observed, the nipple was inverted for complete removal of this tissue which was sent for frozen section examination	Data in Figure 2 appear mislabeled in comparison to text and Table 6  1 pt had NAC necrosis due to insufficient vascular supply and had NAC resection

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Cont, 2017 (250)	Candiolo Cancer Institute-FPO, IRCCS, Candiolo (Turin), Italy	2010-2015	Oncologic safety of NSM; factors correlated with subareolar and/or nipple duct involvement  No comparison of selection criteria or surgical procedures	518 pts	Retrospective  Mean follow-up of 33 months	Invasive or DCIS, not amenable to BCS, willing to have immediate reconstruction  Excluded: prophylactic mastectomy or for non-malignant lesions or LCIS	All pts with breast cancer and scheduled for NSM had preoperative breast MRI and intraoperative assessment of NAC status  No clinical evidence of NAC or skin involvement  Exclusion: LABC and no NACT or no response to NACT, inflammatory, Paget disease,	If subareolar ducts or proximal nipple ducts were involved (invasive carcinoma, DCIS, ductal intraepithelial neoplasia DIN1c-DIN3) in frozen section or definitive pathology (26.1% of cases), the NAC was removed unless the pt refused (19 pts)  Intraoperative pathology subareolar or nipple ducts found 100 involved vs. 135 final pathology of ducts; however, NAC was only involved in 45% of the NAC removed  Positive margin defined as margin with ink on tumour	2.7% local relapse 12/14 were in same quadrant as the primary tumour  No relapse in patients with PMRT  One case (0.2%) of NAC recurrence as Paget disease of the nipple	Details of biopsy reported but not mastectomy  <u>Other</u>  Involvement of subareolar ducts or nipple ducts only correctly predicted NAC involvement in 45% of NAC resected  Authors suggest adjuvant RT to the tumour site instead of NAC	Not reported
Huang, 2018 (251)	Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China; and Liuzhou People's	2007-2016	Recurrence and survival in young patients  NSM outcomes  No comparison of selection criteria or surgical procedures	163 NSM; including 58 pts stage IIA	Median follow-up 39 months	Stage 0-IIIB breast cancer, age <35 y, adjuvant treatment; contraindication to BCS by imaging (MRI, ultrasound, mammography) or pts who	NSM excluded if possible tumour involvement of NAC or surrounding skin by imaging, tumour to NAC distance <2 cm, nipple discharge, Paget's disease	Frozen section of retroareolar tissue to confirm no invasion of NAC borders, but no mention of results	Recurrence 22 pts (13.5%)  LR only: 6 cases (3.7%)  Systemic recurrence only: (DM) 15 cases (9.2%)	Puncture point for biopsy as far from NAC and close to lump as possible	Nipple necrosis in 4 pts (2.5%)  Partial necrosis of breast skin or autologous flap 11.0%; complete necrosis 0.6%

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
	Hospital Liuzhou, Guangxi, China					<p>rejected BCS, immediate implant or autologous reconstruction (but allowed delayed in 9.2%)</p> <p>Excluded bilateral cancer, neoadjuvant treatment, no pathological data, no follow-up records</p> <p>NSM for pts contraindicated for BCS by imaging or pt preference</p>			<p>LR+DM: 1 pt (0.6%)</p> <p>Of LR cases, 2 had NAC recurrence</p> <p>5-y LR 4.3%</p> <p>5-y DFS 86.5%</p> <p>5-y OS 94.5%</p>		
Dornellas de Barros, 2019 (252)	Hospital Sírío-Libanês, São Paulo, Brazil	2005-2015	<p>Oncological safety of NSM</p> <p>NSM outcomes</p> <p>No comparison of selection criteria or surgical procedures</p>	152 pts (161 breasts)	Retrospective Mean follow-up 43.5 months	<p>Infiltrating breast cancer, clinically negative axilla or axilla with movable level I-II lymph nodes cN0-cN1), negative SLNB</p> <p>Reconstruction with silicone implants in 84.9%</p>	<p>Tumour diameter &lt;3.0 cm, TND by imaging and physical examination &gt;2.0 cm</p> <p>Exclusion: clinical evidence of skin/NAC involvement, occult breast cancer, nipple discharge and more than 3</p>	<p>Include if clear margins on intraoperative and definitive analysis</p> <p>Sub-NAC margin analyzed by imprint cytology and frozen sections; if negative in frozen and paraffinized sections the NAC was preserved; if positive margins in any examination</p>	<p>7 LR (4.4%), 4 DM (2.6%), 5 deaths (3.3%)</p> <p>5-y LRFS 97.6%, 5-y RFS 98.3%, 5-y OS 98.3%</p> <p>No NAC recurrence</p>	<p>Either total skin sparing or removing a small paddle of skin over the tumour</p> <p>Vertical radial incision from areola to IMF going around up to 25% of the areolar circumference I the axillary direction was most common</p> <p>Skin flaps raised with a diathermy knife: cut made in the thin fascia between the</p>	Not reported

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
							centres/foci of neoplasia	the NAC was removed  Nipple inverted, ducts arranged inside the central bundle were excised and examined in definitive analysis		subcutaneous fat and glandular tissue; removal of mammary glandular corpus and axillary Spence tail along the pectoralis major muscle fascia, leaving flaps ≈0.5 cm in sub-NAC area and 0.5-1.0 cm elsewhere  If superficial and peripheral neoplasia ≥2 cm from areolar border and ≤2 cm in depth from skin, an elliptical skin paddle incision was made in the overlying tumour area and might be extended to areolar border  Perforator branches from 2 <sup>nd</sup> and 3 <sup>rd</sup> internal thoracic vessels had to be preserved to maintain NAC irrigation  Nipple was inverted after gland removal and ducts in central bundle were excised with a pointed-end knife	
Ng, 2019 (126)	National Cancer Centre Singapore and	2005-2015	Surgical and oncologic outcomes after NSM	130 pts, 139 NSM	Median 43 months follow-up	Mostly early-stage cancer (89%), 86% for cancer treatment and	NSM not used if cancer involving NAC (assessed by imaging, with additional	Intraoperative frozen section of nipple base for all pts, nipple preserved only if	12 (10%) recurrence  5 (4%) local recurrences,	5 main incisions used: 65% periareolar with or without extension, 22% radial, 11% unknown	2 (1.4%) complete NAC necrosis

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
	Singapore General Hospital		No comparison of selection criteria or surgical procedures			14% risk-reduction; 80% autologous reconstruction	magnification of retroareolar region or MRI if requested by surgeon) or inflammatory cancer	no malignancy or atypical cells	including 2 NAC recurrences 7 (6%) DM 2-y OS 97%, 5-y OS 90%		13 (9%) partial NAC necrosis
Valero, 2020 (93)	Memorial Sloan Kettering Cancer Center, New York, NY, USA	2003-2016	Indications, complication, and long-term outcomes of therapeutic NSM  No comparison of selection criteria or surgical procedures	449 pts, 777 NSM: 467 NSM for cancer and 310 contralateral prophylactic NSM	Retrospective  Median follow-up 39.4 months	Invasive cancer (72%) or DCIS (27%)  96.0% stages 0-II, 94.7% had SLNB or ALND, 7.9% PMRT  Excluded bilateral prophylactic or risk-reducing without cancer diagnosis  87.1% expander/implant reconstruction, 10.0% implant	375 (76.4%) of NSM were in 2011 or later, 65.5% had MRI  Exclusion: LABC, extensive disease in periphery of the breast, direct invasion of the nipple, tumours ≤1 cm from nipple on imaging,  Methods indicate pts with risk factors of nipple necrosis were excluded (prior radiation, smoking, cup size C or larger) but results state 5.6% were current smokers and 7.1% had prior radiation	21 (4.5%) nipple excisions, including 14 with involved nipple margin	15 (3.3%) recurrence, 7 (1.6%) deaths 3 LRR, 11 DM, 1 LRR plus DM  No recurrences in NAC	Not reported	Not reported
Vladimir, 2019 (253)	Oncology Institute of Vojvodina, Serbia	2010-2015	Complications and risk factors of NSM	246 pts	Retrospective  Median follow-up 5 y	Pts with cancer histopathologically confirmed on core biopsy or time of	Preoperative clinical and imaging (ultrasound, mammography;	All pts had fast frozen section examination of subareolar core tissue; cancer	4 (1.6%) LR 11 (4.5%) DM	88.62% curve incision in upper lateral quadrant, 11.38% semicircle incision on areola edge	2 (0.8%) NAC necrosis; 3 (1.2%) skin and NAC necrosis

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
						surgery and having immediate submuscular reconstruction with silicone implants	MRI if could not otherwise exclude multicentricity)	detected 18 pts (6.82%) and converted to SSM and not included in study			Periareolar incision accounted for 11% of NSM but 51% of complications  Complication rate 70.4% with periareolar incision and 8.3% with lateral incision, p>0.05 (note based on only 27 periareolar and 218 lateral incisions)
Li, 2020 (254)	Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China	2014-2015	Pt satisfaction and aesthetic outcome  No comparison of selection criteria or surgical procedures	215	Follow-up 24 months	Histopathologic ally diagnosed breast cancer  Excluded tumour completely adherent to chest wall, history of smoking	Tumour margin >2 cm from NAC by high resolution ultrasound (but results say mammography)  Excluded tumour approaching the NAC, tumour margin < 2 cm, NAC involvement	Biopsy tissue from nipple base, beneath the areola, and subcutaneous tissue of the skin of the tumour site were evaluated; none were positive by frozen-section biopsy or permanent section	No local recurrence	IMF incisions in methods but lateral incision in results  A very steep and sharp dissection for mastectomy, then fascia of pectoralis muscle removed; dissection under subdermal area and the flap of 2-3 mm dermis and very thin subcutaneous fat layer was raised  Papilla of nipple left untouched	No comparison of different incisions; type of incision used is ambiguous
Metere, 2020 (255)	Italy	2002-2017	Long-term outcomes of NSM	894 pts	Retrospective	>10 months follow-up	Tumour to NAC $\geq$ 2 cm	Histological examination of retroareolar ducts;	LRR in 76 pts (8.5%): local 44 pts (4.9%),	Skin incision on case-by-case basis: radial, italic S, IMF	NAC necrosis in 57 pts (6.4%)



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
			No comparison of selection criteria or surgical procedures		Follow-up 18 to 60 months	Immediate reconstruction with tissue expanders or definitive implants		NAC removed if positive results	regional 32 pts (3.6%) DM in 26 pts (2.9%)	Subcutaneous tissue dissected with electrical scalpel; thickness of subcutaneous tissue must be uniform, except 2-3 mm at NAC  Unstick the gland from the pectoral fascia and open axillary cavity for SLNB	Nipple necrosis in 25 pts (2.8%)  Depigmentation in 28 pts (3.1%)
Parvez, 2020 (256)	McGill University Health Centre, Montreal, Quebec, Canada	2013-2018	Surgical and oncologic outcomes of NSM  No comparison of selection criteria or surgical procedures	175 pts	Retrospective review  Median 24 months follow-up	Primary or recurrent invasive or in situ breast cancer	NAC decision made by surgeon; included NSM for revision of margins and incidental breast cancers following prophylactic NSM	Intraoperative frozen sections of NAC margin obtained if there was clinical suspicion of a close or involved margin; excluded if histological NAC involvement found  Positive margins defined as invasive or in situ disease at inked margin; close margin as DCIS within 2 mm of inked margin	LR in 8 cases (4.6%) including 1 NAC recurrence 12 (6.9%) DM OS 98.3% (3 deaths) DFS 88.6%  Positive margins 10 pts (5.7%), including 3 (1.7%) NAC and 7 (4.0%) non-NAC; also 4 (2.3%) NAC close margins; 4 NAC excised	52.6% used lateral incision, 18.9% inframammary, 15.4% wise pattern (skin reduction)  13 NSM involved free nipple grafting	Nipple necrosis, 4 cases (2.2%) requiring surgical debridement (2 of which had free nipple grafting)
Scardina, 2021 (132)	Sacred Heart Catholic University, Rome, Italy	2018-2021	Experience with NSM and immediate prosthetic prepectoral reconstruction without ADM	209 pts, 269 breasts	Retrospective review  Median follow-up 14 months	NSM when BCS could not give adequate local control (cannot get clear margins) or cosmetic results (large tumour	Clinical assessment, ultrasound, mammography, MRI  Exclusions for NSM: inflammatory,	Retroareolar tissue marked with surgical thread and excised for frozen section analysis	1 (0.48%) LR 2 (0.96%) regional axillary node recurrence	NSM through radial incision on external quadrants, with axillary or IMF incision in selected pts  Skin carefully dissected off breast:	2/209 (0.96%) had full thickness (complete) necrosis that required excision

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
			No comparison of selection criteria or surgical procedures			<p>compared with breast size, extensive or multicentric disease, contraindications to RT, patient preference)</p> <p>Relative (not absolute) contraindications: obesity (BMI &gt;30 kg/m<sup>2</sup>, large breasts with severe ptosis, previous RT, active smoking</p> <p>Implant with micropolyurethane foam coated shell surface in subcutaneous plane</p>	<p>LABC infiltrating skin or NAC</p> <p>Decision on reconstructive plane made in operating room after accessing flap thickness and perfusion: perfusion with indocyanine green dye fluoroangiography and photodynamic eye (PDE) imaging system</p>			<p>mastectomy skin flap elevated from glandular tissue and dissected off breast by electrocautery; dissection of skin flaps and NAC; elevated gland on the PP plane preserving superficial pectoral fascia and avoiding medial perforators; retroareolar tissue marked with surgical thread and excised for frozen section analysis; skin flaps trimmed if needed to remove residual breast tissue</p>	
Webster, 2023 (94)	Massachusetts General Hospital, Boston, MA, USA	2008-2019	<p>Oncologic safety of NSM in BRCA mutation carriers with breast cancer</p> <p>No comparison of selection criteria or surgical procedures</p>	<p>105 pts, 114 therapeutic NSM</p> <p>99 (94%) pts had bilateral NSM, including 5 (4.8%) for bilateral cancer</p>	<p>Retrospective review of single institution database</p> <p>Median 70 months follow-up</p> <p>Intention-to-treat analysis, even if nipple</p>	<p>Pts with breast cancer and BRCA1 or BRCA2 mutation who had NSM and immediate reconstruction</p> <p>Included contralateral prophylactic mastectomy where cancer was found on</p>	<p>Excluded if direct involvement of nipple or areola on physical examination or imaging, inflammatory breast cancer, skin involvement</p>	<p>Nipple/subareolar margin status by permanent histopathology assessment and excision recommended if invasive cancer or DCIS found</p> <p>5 (4.4%) positive nipple margins on final pathology; all had nipple excision</p>	<p>No recurrence in retained NAC or site of nipple excised for positive margins</p> <p>LRR 3 pts, 2.6%</p> <p>DM 4 pts, 3.8%</p> <p>OS 96% (4 deaths)</p> <p>BCSS 97% (3 deaths)</p>	<p>Removal of ductal tissue from within and beneath nipple and areola</p> <p>Indicates surgical details in Colwell, 2010 (114)</p> <p>Inferolateral incision that preserves NAC viability</p>	<p>1 pt with bilateral cancer had partial NAC necrosis in both breasts; nipples were preserved after surgical debridement</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
					subsequently removed	final histopathology examination (4 cases (4.3%))  Excluded if pt and surgeon believed final nipple position and cosmetic result would be poor, metastatic disease within 4 months of initial cancer diagnosis, and pts with <1 y follow-up		(3 with NAC excision)	Rates are for therapeutic NSM for LRR, per pt for DM and survival  No new cancers in concurrent prophylactic mastectomies that were negative on initial testing		
Zarba Meli, 2023 (257)	Italy	2010-2020	NSM after NACT  No comparison of selection criteria or surgical procedures	417 pts and 433 NSM: 111 pts with 112 NSM after NACT; 306 pts with 321 NSM without NACT	Retrospective  Median follow-up 69 months	Breast cancer requiring mastectomy  Excluded recurrent or bilateral cancer  Immediate reconstruction with expander or prosthesis	Excluded if bloody nipple discharge, Paget disease, clinical or radiologic evidence of NAC invasion, inflammatory  Pts receiving NACT were assessed for systemic disease using whole-body CT and bone scan or total body PET and CT; MRI used after NACT to assess response  In NACT group, 20 pts with TND	Close margins were <2 mm from inked surface; pts with positive margin in retroareolar area (ink on tumour) advised to have NAC resection; other cases discussed  NAC removed in 17 cases (3.9%) for inadequate margins intraoperatively or at definitive pathology; definitive pathology showed no cancer in NAC in 7 cases	At 5 years:  LR in 14 pts (3.2%); 7% with NACT, 2% without  LRR in 21 pts (4.8%); 9.8% vs. 3.2%  No significant difference between NACT and no NACT after adjusting for stage  No LRR in 34 pts with pCR and 14% in NACT pts with residual disease	In early phase used radial lateral or italic "S" incision; since 2015 used IMF approach  Obtained thin skin flaps (≈3-5 mm) especially in the retroareolar area	Full-thickness NAC necrosis 17 NSM (3.9%), minimal NAC necrosis 60 NSM (13.8%)

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
							<1 cm before NACT and response allowed NSM in 16		1 NAC recurrence (pt without NACT) 5-y OS 95.1% 5-y DFS 87.6%		
Wu, 2019 (258)	Asan Medical Center, Seoul, Korea	2003-2015	Long-term outcomes after NAC in invasive cancer  No comparison of selection criteria or surgical procedures	944 pts, 962 NSM	Retrospective  Median follow-up 85 months; every 3-6 months for 5 years then annually	NSM and immediate reconstruction for invasive cancer  Excluded NACT or palliative surgery  Immediate autologous or prosthetic reconstruction	Indications for NSM: clinically normal NAC and no skin involvement offered option of NSM; shape, colour, palpated features of nipple normal	Retroareolar frozen section in all cases; subdermal glandular tissue undermined in retroareolar area leaving 1-2 mm intact dermis; thin layer of glandular tissue collected under areola for review; NAC preserved if NAC ducts tumour free	39 recurrence (4.1%) at NAC as first event 42 cases (4.4%) LR outside NAC as first event 5-y recurrence at NAC 3.5% (n=34); 5-y local recurrence outside NAC 3.4% (n=33) 10-y DMFS 89.3% in pts with recurrence at NAC and 94.3% in pts without recurrence 10-y OS 100% in pts with recurrence at NAC and 94.5% without recurrence (overall 94.7%)	85.9% lateral radial incision, 11.1% periareolar with lateral extension, 3% other  Subdermal glandular tissue undermined in retroareolar area leaving 1-2 mm intact dermis; thin layer of glandular tissue under areola for review after frozen section obtained; SLNB or ALND	Not reported
Wu, 2020 (259)	Asan Medical Center, Seoul, Korea	2003-2015	LRR after NSM in pts with DCIS and immediate	199 NSM	Retrospective  Median follow-up 97 months	Consecutive pts with pure DCIS and breast reconstruction	Inclusion: clinically normal nipple and no skin involvement;	Retroareolar frozen-section biopsy in all pts; nipple ± areola immediately	10-y LRR 4.5%, including 3% NAC recurrence 10-y OS 98.5%	SLNB in most (91.5%) pts and none were positive	Not reported

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
			reconstruction without RT  No comparison of selection criteria or surgical procedures			NSM indications: significant extension of DCIS compared with breast volume, multicentric disease, margin involvement after BCS, pt preference  Exclusion: microinvasion, history of prior RT, synchronous contralateral invasive breast cancer	shape, colour, palpated features of nipple were normal  Positive surgical margin defined as tumour touching ink in the mastectomy specimen	removed if positive for malignancy and converted to SSM or ASM  If retroareolar tissue positive at final pathology, the nipple ± areola was removed and pt excluded from NSM cohort  No pts had evidence of tumour involvement at retroareolar resection margin	LRR as first event in 10 pts (5%): 5 had NAC recurrence, 3 chest wall, one axillary node, and 1 NAC + bilateral axillary lymph node metastasis	Surgical details not reported	
Wu, 2021a (260); Wu, 2021b (261); Wu, 2022b (262)	Asan Medical Center, Seoul, Korea	2003-2016	LRR; DM and survival after local recurrence after NSM  Reconstruction loss due to LR after NSM  No comparison of selection criteria or surgical procedures	1696 pts	Retrospective  Median follow-up 84 months: follow-up every 3-6 months for 5 y then annually	Primary breast cancer with immediate reconstruction  Any tumour stage, size, with indications for mastectomy  Immediate autologous or prosthetic reconstruction	Inclusion: clinically normal nipple and no skin involvement; shape, colour, palpated features of nipple were normal; any TND	Retroareolar frozen-section biopsy confirmed to be tumour-free	LRR as first event in 172 pts (10.1%): 117 (6.9%) LR alone, 44 (2.6%) regional alone; 11 pts (0.6%) LR + regional; therefore LR 128 pts or 7.5% and regional 55 pts or 3.2%  52 (3.1%) involving NAC  DM in 30 cases (1.8%)  Subset of pts with recurrence	SLNB or ALND in all pts  Surgical details not reported  Thickness of remaining skin flap generally 7-8 mm; SLNB or ALND	Not reported  Reconstruction loss in 21/128 (16%) of pts with LR

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
									<p>and median post-recurrence follow-up of 54 months:</p> <ul style="list-style-type: none"> <li>• In 172 pts with LRR: 5-y post-recurrence DFS was 73.7% (89.1% for NAC recurrence, 73% for skin/chest wall, 59.4% for regional recurrence groups)</li> <li>• In 172 pts with LRR: 5-y post-recurrence DMFS was 79.4% (96% for NAC, 82.8% for skin/chest wall, and 59.7% for regional recurrence groups)</li> <li>• In 172 pts with LRR: 5-y post-recurrence OS 91%</li> </ul>		
Wu, 2021d (263)	Asan Medical Center, Seoul, Korea	2010-2016	NSM after NACT  No comparison of selection criteria or surgical procedures	310 pts, 319 NSM	Retrospective  Mean follow-up 63 ± 22 months	All pts with NSM and NACT for breast cancer  Indications for NSM: any stage, size	Inclusion: any TDN, clinically normal nipple; normal shape, colour, and palpated features of nipple; no skin	Retroareolar frozen-section biopsy and permanent biopsy: nipple ± areola removed if nipple margin was positive for	LRR as first event in 38 cases (11.9%), including 6 (1.9%) in the NAC  Of LLR, 13 had isolated LRR, 16	Not reported	Not reported

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
						Exclude synchronous distant metastasis, recurrence disease	involvement or inflammatory cancer	malignancy and converted to SSM or ASM and excluded from NSM cohort  pCR in 40 pts (12.5%)	had regional recurrence, 2 concurrent LR and regional recurrence, 7 LRR and DM  DM as first event in 37 pts (11.9%)  25 deaths due to breast cancer (8.1%)  5-y cumulative LRR 11.0% including 1.9% NAC  5-y LRR-free survival 87.3%, DM-free survival 87.8%, OS 91.3%  CBC 3.9%		
Wu, 2022a (264)	Asan Medical Center, Seoul, Korea	2010-2016	NACT: NSM + IBR vs. CM alone (data not extracted) in LABC  No comparison of selection criteria or surgical procedures	217 NSM	Follow-up every 3 to 6 months for 5 years then annually; mean follow-up 70 months	Clinical stage IIB to IIIC, NACT, indications for mastectomy; immediate reconstruction  Excluded T4, recurrent	Excluded inflammatory  NSM offered if no involvement of NAC or skin clinically and on imaging (MRI, ultrasound, or mammography) after NACT; also offered if initial nipple or subareolar involvement before but not after NACT	If retroareolar frozen section or permanent biopsy margin was positive, NSM was converted to SSM or ASM and excluded from NSM group	LR 6.7%, including 3 pts (1.4%) at the NAC  Regional recurrence (internal mammary or supraclavicular lymph nodes or ipsilateral axillary) 9.6%  Distant metastasis 19.6%  6-y local RFS 91.6%	Not reported	Not reported

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
							In NSM group, median TND 2.4 cm; 29.2% had TND $\leq 1$ cm before NACT; 30 pts (14.4%) with tumour extension in subareolar area before NACT but resolved after NACT and underwent NSM		6-y DFS 70.5% 6-y Distant metastasis-free survival 79.8% 6-y OS 87.6%  No nipple recurrence in pts converted by NACT from involved to resolved subareolar extension		
Petit, 2009 (265)	European Institute of Oncology, Milan, Italy	2002-2007	ELIOT (800 pts) or delayed one-shot RT following operation (201 pts)	1001 NSM, including 29 bilateral	Median follow-up 20 months based on 83% of pts	Carcinomas or DCIS	Inclusion criteria: primary tumours $\geq 1$ cm outside areola margins, absence of nipple retraction or bloody discharge and absence of retroareolar microcalcifications; multifocality accepted as long as all tumour sites were distant from the areola	Intraoperative frozen section (repeated if initially positive) and assessment of blood supply by local bleeding and colour of the NAC by the plastic surgeon  1171 NSM, of which 131 excluded (68 positive intraoperative frozen section of retroareolar tissue on both sections; poor blood supply and high risk of NAC necrosis contraindicating RT); NAC removed and ELIOT not used  In 1,001 included pts, first frozen	14 (1.4%) LR of which 10 close to tumour site and all far from NAC (no recurrence in NAC)  LR ELIOT 1.6% vs. delayed 0.5%, $p=0.22$  No recurrence in preserved NAC with positive final pathology (86 cases) nor in those that were positive in first but not second frozen section (79 cases)  DM in 36 pts (3.6%)	Skin incision above the tumour, dissected glandular tissue from the plane of the dermis and from the pectoral fascia; thin layer of glandular tissue left beneath areola to preserve blood supply  Thin specimen from retroareolar area for immediate frozen section; when positive a further layer of tissue removed underneath the NAC and if also positive the NAC was removed  ELIOT delivered to NAC in a single fraction in 800 NSMs; in other pts RT was	NAC total necrosis in 35 cases (3.5%), NAC partial necrosis in 55 cases (5.5%); NAC was removed in 50 cases (5%)  Average sensitivity of areola and periareolar area was 2 out of 10; partial NAC sensitivity recovered in 15% of pts at one year after operation  Slight change in areolar



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
								<p>section was positive but not the second exam of retroareolar tissue in 81 cases and NAC was preserved</p> <p>In 1,0001 included pts, final pathology found cancer cells in 86 cases (8.6%); 79 NAC were preserved (23 invasive, 53 intraductal)</p>	<p>DM ELIOT 3.5% vs. delayed 4%, p=0.74</p> <p>4 deaths (0.4%)</p> <p>No significant difference between ELIOT and delayed RT</p> <p>Lack of recurrence in NAC is promising, but is short follow-up</p>	<p>delayed until after the operation due to poor vascularization of the nipple that required further observation</p>	<p>pigmentation in 20% of pts</p>
Lohsiriwat, 2012 (266)	European Institute of Oncology, Milan, Italy	2002-2008	NSM with ELIOT; focus on Paget disease in recurrence	861 NSM	Median follow-up 50 months	<p>713 invasive and 148 intraepithelial neoplasia; Stages I-III</p> <p>ELIOT to areolar plus 1 cm margin around then immediate breast reconstruction with implant or autologous tissue</p>	<p>Inclusion: no clinical or radiological nipple involvement, no inflammatory signs, no previous irradiation</p> <p>Excluded: bilateral, LABC, prophylactic mastectomy, neoadjuvant RT or chemotherapy</p>	<p>Excluded if positive margins on retroareolar frozen section</p>	<p>36 (4.18%) local recurrence, including 7 (0.8%) Paget disease</p> <p>11 (1.3%) NAC recurrence (including 7 Paget disease)</p> <p>Average latency from NSM to Paget disease LR was 32 months</p>	<p>Sharp dissection using surgical blade and/or diathermy knife; dissection at plane just beneath the dermis allowing total removal of breast parenchyma and retention of subdermal vessels and thin layer of subcutaneous fat and subdermal vascular network</p> <p>5 mm extra-areolar flap and areolar flap recommended</p> <p>Terminal ducts inside nipple removed</p>	<p>Paget disease recurrence: 4 cases with NAC erosions, 2 crusted lesions, 1 ulcerated NAC</p>
Lohsiriwat, 2013 (267)	European Institute of Oncology, Milan, Italy	2002-2007	Pts with NAC excision because of necrosis to	934 NSM: 40 with NAC removal	Retrospective Study of NAC necrosis	Pts with NSM for breast cancer treatment	NSM contraindications : tumour behind the NAC, nipple retraction,	Exclude if tumour cells present on retroareolar frozen section	Not reported	Various incision locations and mastectomy techniques used	40 (4.2%) NAC necrosis requiring removal

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
			those with successful NSM		requiring excision Median follow-up 50 months <50 per group; not enough pts with necrosis to analyze subgroups	Exclude if previous chest wall irradiation, bilateral breast cancer, benign disease, prophylactic mastectomy, neoadjuvant therapy	bloody nipple discharge, inflammatory cancer, retroareolar microcalcification	Pts with positive margins on frozen section of retroareolar tissue were excluded		Glandular tissue dissected between gland and subdermal layer leaving thin layer at least 5 mm to preserve subdermal vessels; 5 mm extra-areolar flap and areolar flap recommended to avoid flap necrosis; at areolar edge a separate slice of tissue sent for frozen examination; ELIOT on NAC (n=707) unless NAC perfusion seemed critical or ELIOT machine not available (174 received delayed ELIOT and 53 no ELIOT)	Group without IORT had highest incidence of NAC necrosis; this could be because surgeon withheld IORT due to poor perfusion and not related to IORT use  Group with expander had higher necrosis, but selection bias as expanders often because of risk factors (ptosis, large breast, smoker, poor vascularization )
Galimberti, 2018 (268)  May overlap with Petit, 2009 (265) which was restricted to primary tumours $\geq 1$ cm outside areola margins	European Institute of Oncology, Milan, Italy	2003-2011	Oncologic outcomes of NSM for invasive or in situ breast cancer	1989  IORT to 1342 invasive and 197 in situ  No IORT in 369 invasive and 81 in situ	Retrospective  Follow-up every 6 months  Follow-up at least 5 y; median 94 months	Consecutive women who had NSM for invasive or non-invasive breast cancer; minimum follow-up 5 years  Exclude metastatic disease, bilateral synchronous breast cancer,	Exclude if pathological secretion from the nipple, Paget disease, phyllodes tumour, inflammatory or recurrent breast cancer,  Allowed: NACT, any TND	Excluded if positive intraoperative retroareolar frozen section, in which case SSM usually performed	102 (5.1%) LR: 11 cases (4%) in in situ group and 91 (5.3%) in invasive group  36 (1.8%) NAC recurrence: 9 (3.2%) in situ and 27 (1.6%) invasive groups  157 (7.9%) LRR 11 in situ group,	Not reported (assumed to be similar to Petit, 2009 (265)  <u>Other</u>  No statistically significant difference in OS or recurrence between pts with IORT to NAC and those without ELIOT (IORT with electrons) to NAC in	66 (3.3%) NAC removed for necrosis: 6 (2.2%) in situ group, 60 (3.5%) invasive group  NAC necrosis declined over time: 4.8% in 2003-2005 to 1.4% in 2009-2011

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
						<p>other non-breast primary cancer, BRCA mutation carriers without cancer (bilateral prophylactic mastectomy)</p> <p>SLNB or ALND in some cases</p> <p>Immediate reconstruction in all cases: 1706 implant, 290 expander, 15 autologous</p>			<p>146 invasive group</p> <p>199 (10.0%) DM: 2 (0.7%) in situ group and 197 (11.5%) invasive group</p> <p>107 other cancer: 17 (6.1%) in situ and 90 (5.3%) invasive</p> <p>131 (6.6%) deaths: 3 (1.2%) in situ group and 128 (6.5%) invasive group</p> <p>109 breast cancer deaths: 1 (0.4%) in situ and 108 (6.2%) invasive group</p> <p>5-y OS 96.5%: 99.2% in situ and 96.1% invasive group</p> <p>10-y OS 91.2%: 98.8% in situ and 90.0% invasive</p>	<p>1342/1711 pts (78.4%) with invasive cancer and 197/278 (70.9%) with in situ disease; and additional 114 pts (6.7%) with invasive carcinoma received external beam RT</p> <p>IORT use decreased over time and was abandoned in 2011 as they realized flap vascularization was the key to reducing necrosis and intraoperative retroareolar frozen section was a reliable way to ascertain NAC disease</p>	Include in Q1b
Vicini, 2021 (269)	European Institute of Oncology, Milan, Italy	2003-2017	<p>Feasibility of NSM after previous breast surgery</p> <p>No comparison of selection criteria or</p>	368 pts, 387 NSM	Median follow-up 54 months from NSM	<p>Previous (primary) surgery was 89.2% quadrantectomy; 2.8% non-oncologic resection; 8% cosmetic</p>	NSM contraindicated for T4 neoplasms, involvement of retroareolar tissue, microcalcifications close to	Not reported	<p>In 117 pts with recurrence at least 6 months after initial quadrantectomy (at median 36 months)</p>	<p>Not reported</p> <p>Various skin incisions</p>	<p>Complete NAC necrosis in 11 cases (2.8%)</p> <p>Partial NAC necrosis in 21 cases (5.4%)</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
			surgical procedures			(augmentation, reduction, mastopexy)	subareolar region, malignant nipple discharge, Paget disease		5-y OS 99.1%, 95% CI=93.9-99.9 [1 event] 5-y DFS 93.8%, 95% CI=86.5-97.2 [11 events]		
Chirappappa , 2014 (270)	European Institute of Oncology, Milan, Italy	2012-2013	Breast morphology and necrotic complications	113 pts, 124 NSM	Prospective At least 1 month follow-up for all pts	113 carcinoma, 11 prophylactic NSM  Exclude if previous RT, neoadjuvant chemotherapy  ELIOT delivered to NAC unless prophylactic NSM  7 autologous, rest implants ± expander	Primary tumours outside areolar margins and not centrally located  Excluded nipple retraction or bloody discharge, retroareolar microcalcifications, inflammatory signs, inflammatory cancer, Paget disease	Thin tissue beneath retroareolar area removed separately for frozen section examination; if positive the NAC was removed and pt excluded	Not reported	Recorded volume of breast removed by measurements of mastectomy specimen  Cutaneous incision (96 superolateral, 18 superior circumareolar, 10 other) located above the tumour site, glandular tissue dissected close to dermis and from pectoral fascia; ELIOT delivered unless poor blood perfusion (in which case NAC RT was delayed)  Expanders, when used, were inflated ≥3 weeks after NSM	Partial NAC necrosis in 15 NSM (12.1%)  Total NAC necrosis in 4 NSM (3.5%)  NAC removed in 5 cases (4%)  Association between NAC necrosis and volume of breast removed, p=0.04; NAC necrosis 6% when volume <750 cm <sup>3</sup> and 23% when volume >750 cm <sup>3</sup>  25% NAC necrosis with superior circumareolar or periareolar incisions vs. 13% with other incisions

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Warren Peled, 2012a (101)	University of California, San Francisco, CA, USA	2001-2010	Oncologic safety and complications with TSSM	428 pts, 657 TSSM 399 pts with cancer 212 unilateral therapeutic; 187 therapeutic + contralateral prophylactic; 29 bilateral prophylactic	Retrospective 2001-2004; prospective 2005-2010  Median follow-up 28 months	245 breasts (37.3%) for risk-reduction so only results reported separately for therapeutic reasons meet this review inclusion criteria  Various autologous and one- or two-stage implants	MRI only if tumour is close to nipple on clinical examination or mammography; exclude if clear tumour involvement  Excluded clinical evidence of nipple or skin involvement at time of mastectomy (will perform TSSM if initial skin involvement shows good response to NACT)	Do not use frozen section analysis and instead use permanent pathology  If tumour near or in the nipple skin: repeat excision, resection of involved skin or PMRT; all repeat excisions were negative for cancer  If invasive cancer in nipple specimen: repeat excision if pt are highly motivated to preserve NAC  In final pathology, 20 (3%) of nipple tissue specimens had tumour (11 in situ, 9 invasive); 7 repeat excision; 9 NAC removal (8/9 invasive cases), 4 RT  Re-excision or NAC removal at time of expander exchange or autologous flap revision  All 16 removed NAC and re-excised nipple tissue specimens were	Outcomes for subgroup of 412 therapeutic cases:  4 (1%) LR alone  8 (1.9%) DM alone  4 (1%) LR + DM  16 (3.9%) any recurrence  0 NAC recurrence	Inversion of nipple and complete excision of all nipple tissue at the dermal junction  Various incisions	Therapeutic and prophylactic not reported separately  <u>Other</u>  Nipple necrosis decreased after periareolar incisions minimized and ceased used of free nipple grafts and NAC-crossing incisions  1.5% total nipple necrosis, 2% partial nipple necrosis, 11.9% flap necrosis

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
								negative for residual tumour			
Wang, 2014 (68)	University of California, San Francisco, CA, USA	2005-2012	TSSM; effect of systemic changes in technique on complications	633 pts, 981 cases including 350 (36%) prophylactic and 626 therapeutic	Prospective collection and retrospective review  Median follow-up 29 months	Relative contraindications: gigantomastia and grade III ptosis	<p>MRI used if tumour was close to nipple on clinical examination or mammography</p> <p>Eligible for TSSM if MRI found no direct tumour involvement of the NAC, even if &lt;1 cm TND</p> <p>Allowed pts treated with NACT who met criteria after NACT</p> <p>Excluded pts with evidence of nipple or skin involvement at time of mastectomy</p>	<p>On final pathology, nipple specimens in therapeutic cases had 15 (2.4%) in situ carcinoma and 17 (2.7%) invasive carcinoma: 2 in situ and 10 invasive had nipple skin resection; 3 in situ and 5 invasive had PMRT; 10 in situ and 2 invasive (with margins not involved) received no treatment</p>	<p>Oncologic outcomes in therapeutic cases (excluding stage IV):</p> <p>5-y cumulative LRR 3% (14 cases): 3.7% stage 0, 0 stage I, 4.5% stage II, 6.9% stage III</p> <p>No recurrence in NAC skin in cases that did not have nipple resection</p> <p>5-y DM 4.2% (15 cases); 0.8% stage 0, 1.5% stage I, 4.6% stage II, 17.7% stage III</p> <p>All patients (including 7 stage IV cases):</p> <p>Overall 5-y survival 93% (19 deaths); 97% stage 0, 98% stage I, 96% stage II, 74% stage III, 33% stage IV</p>	<p>Significant changes in technique over time, stopped using free nipple grafts and NAC-crossing incisions, adopted TSSM as standard procedure in 2005</p> <p>After 2005 any periareolar incisions incorporated &lt;1/3 NAC circumference</p> <p>Incisions 58% inframammary, 30% superior periareolar, 3% radial, 4% lateral</p> <p>TSSM with inversion of nipple and excision of all nipple tissue at the dermal junction</p> <p>Prophylactic antibiotics switched to trimethoprim-sulfamethoxazole instead of cephalexin in 2009</p>	<p>Prophylactic and therapeutic not reported separately</p> <p>Complications decreased over time; by 2012, 3.5% superficial nipple necrosis, 1% complete nipple necrosis; 3.0% minor skin flap; necrosis, 4.4% major skin flap; necrosis</p> <p>Discontinued immediate implants (0.3%) by 2006 in favour of gradual expansion (89%) to minimize NAC and skin-flap necrosis; 10.2% autologous</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
											Other When PMRT used, increased waiting time to 6 months after RT before expander-implant exchange
Amara, 2015 (102)	University of California, San Francisco, CA, USA	2005-2013	Strategies for managing nipple involvement; changes in outcomes over time for TSSM	748 pts, 1173 breasts; 440 (38%) prophylactic, 733 (62%) therapeutic	Retrospective review of prospectively collected database 31.3 months follow-up	Note: PMRT was determined by primary indications (tumour size or LN status and not only NAC involvement)	TSSM for all pts without clinical involvement of the NAC or skin at mastectomy and no significant ptosis or macromastia; also pts with skin involvement and good response to NACT  MRI initially used to assess NAC involvement, but no longer used routinely unless for other reasons such as NACT response	NAC had positive margin or involvement of nipple tissue in 32 breasts (2.7% of total, 4.7% of therapeutic, 0% prophylactic): 18 invasive and 14 in situ; treated by repeat incision (11 cases, 34%), RT to NAC as part of PMRT (5 cases, 16%), NAC removal (8 cases, 25%), or no further treatment (8 cases, 25%); complete NAC excision decreased over time  Of re-excisions, 5 had only scar/fibrous tissue, 4 had benign breast tissue, and	LRR 6.2% [unclear if this is therapeutic or all TSSM]  In pts with initial NAC involvement: 1 LR and 1 LR+DM  No recurrence in preserved NAC skin; no recurrence in DCIS  In invasive cancer with initially positive NAC pathology: 1/7 re-excisions had LR (not in nipple), 3/3 with RT had DM, 0/5 with NAC removal had recurrence, 1/3 without	Preferred incision was IMF (53%), superior areolar (38%)  Removal of nipple tissue through inversion of nipple and excision of nipple tissue at the dermal junction  Subareolar margin deep to the NAC marked with a suture on mastectomy specimen and closely examined  Nipple completely cored out and new nipple margin sent as a separate specimen	Not reported

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
								2 are scheduled (not yet excised)	treatment had LR + DM		
Warren Peled, 2016 (117)	University of California, San Francisco, CA, USA	2005-2013	TSSM outcomes in LABC	139 pts with LABC (stage IIb-III)	Retrospective review of prospectively collected data  Mean follow-up 41 months	Stage IIb (25 pts) Stage III cancer (114 pts); most received neoadjuvant (77%) or adjuvant chemotherapy (20%)  Exclude if significant ptosis, large breast size  Immediate breast reconstruction (92% expander-implant, 8% autologous)	Exclude if clinical involvement of NAC in examination or imaging  TSSM offered to pts with initial skin involvement but no skin involvement after NACT	Nipple tissue evaluated during final pathology	LR as in 7 pts (5%), DM in 21 pts (15.1%), LR + DM in 3 pts (2.2%)  All LR was in pts with residual disease at mastectomy (not complete response to NACT), and all eventually developed DM  No recurrence in preserved NAC skin  5-y EFS 70%	Removal of nipple tissue through inversion of nipple and excision of nipple tissue at the dermal junction  Preferred incision was IMF or superior areolar/mastopexy  <u>Other</u> PMRT in 63%; given before expander-implant exchange without deflation of expander	2 (1.4%) NAC necrosis  5 (3.6%) mastectomy skin flap necrosis
Holland, 2023 (104)	University of California, San Francisco, CA, USA  Single institution	2015-2018	Impact of incision location on NAC complications in prepectoral reconstruction	108 pts, 181 reconstructions (91 prophylactic); 113 (62%) superior periareolar incisions vs. 68 (38%) IMF incisions	Retrospective review  Multivariable binary logistic regression for outcome of any nipple necrosis	Immediate 2-stage prepectoral breast reconstruction after NSM	Pts with immediate two-stage prepectoral reconstruction after NSM  Eligibility of NSM based on accepted oncologic criteria, breast size, degree of ptosis	All retroareolar breast tissue removed in mastectomy and analyzed on permanent section	Not reported	Superior periareolar incision in 62% and IMF incision in 38%  NAC and skin flap viability assessed by clinical examination without indocyanine green angiography or other adjuvant assessments  Skin expanders filled at surgeon discretion to prevent skin wrinkling but not to place tension on	Without adjustment: any NAC complications by incision location: 25% periareolar vs. 7.4% IMF, p=0.003; nipple necrosis requiring debridement 9.7% vs. 1.5%, p=0.033  <u>Other</u>



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										closure or pressure on skin	In multivariable regression, hypertension (OR=4.1, p=0.004), smoking (OR=9.6, p=0.029), and a periareolar incision (OR=3.6, p=0.018) were independently associated with an increased odds of any nipple necrosis
Frey, 2019 (271)	New York University Langone Health, New York, NY, USA	2006-2017	Outcomes and risk factors including TND in NSM	312 pts, 496 NSM (all therapeutic) ; 128 pts with unilateral cancer and 184 pts with bilateral cancer	Retrospective Binary logistic regression Average follow-up 48.25 months	Pts with therapeutic NSM (biopsy proven or strongly suggestive imaging); excluded pts with prophylactic contralateral mastectomy Immediate reconstruction	NSM candidate if therapeutic mastectomy without clinical evidence of NAC involvement  Relative contraindications (presence of multiple factors may exclude NSM): NACT, active smoking, severe macromastia or breast ptosis, significant chest/NAC asymmetry	Subareolar tissue sent for frozen (n=362) and permanent section (n=496) analysis; NAC removed if either was positive; positive rates 6.9% in both	LR in 8 NSM, 1.6% per NSM or 2.6% per pt  Two of the recurrences were in the NAC  Regional recurrence in 3 NSM, 0.6% per NSM or 1.0% per pt  LRR in 10 NSM in 9 pts; 2.0% per NSM or 2.9% per pt  DM in 4 pts (1.3%)	Not reported	Not reported  <u>Other</u> MRI in only 5 pts with recurrence so too few to do subgroup analysis

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
							TND assessed by MRI in 171 NSM				
Salibian, 2021 (272)	New York University Langone Health, New York, NY, USA	2007-2019	Incision choice in NSM and outcomes	163 pts, 279 NSM; 229 breasts with cancer	Retrospective	<p>All pts with NSM and immediate reconstruction with microvascular tissue transfer and <math>\geq 1</math> y follow-up</p> <p>Excluded delayed and delayed-immediate reconstruction</p>	<p>Excluded nipple-areola complex involvement, inflammatory cancer; TND <math>\leq 1</math> cm later in study</p> <p>Relative contraindications : smoking, NACT, prior RT, poor breast skin quality, severe NAC/chest wall asymmetry, grade III ptosis and severe macromastia</p> <p>Internal mammary vessels were preferred recipient vessels for reconstruction</p>		Not reported	<p>NSM using sharp dissection with minimal electrocautery at the level of the breast capsule; flaps assessed based on skin-edge bleeding, flap thickness, visible dermis; indocyanine green angiography was precluded by use of epinephrine-containing infiltration before mastectomy</p> <p>Incision type was based on tumour size/location, breast size and skin excess, previous scars, lymph node status, and pt desires; periareolar incisions avoided</p>	<p>Full NAC necrosis in 11 cases (3.9%)</p> <p>Partial NAC necrosis in 19 cases (6.8%)</p> <p><u>Other</u></p> <p>Subgroup analysis has &lt;25 events so not extracted</p> <p>Higher rates of major ischemic complications with IMF incisions (25%) and inverted-T incisions (36.1%) than vertical (5.8%) or lateral radial (7.8%) incisions (101). In multivariate analysis inframammary (OR=4.382) and inverted-T incisions (OR=3.952) were independently associated with increased risk</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Boyd, 2022 (273)	New York University Langone Health, New York, NY, USA	Review of data in 2021	Recurrence in therapeutic NSM with median 10 y follow-up	120 pts, 126 NSM	Retrospective Median 10 y follow-up, average 124.4 months	Pts with therapeutic NSM (biopsy proven or strongly suggestive imaging); excluded pts with prophylactic contralateral mastectomy	Excluded nipple-areola complex involvement	Positive frozen subareolar biopsy 7.3% (6/82 NSM) and permanent subareolar pathology 9.5% (12/126); NAC removed if positive; these pts were kept in the recurrence analysis	4 recurrences, 3.17% per NSM or 3.33% per pt 2 LR, 1.59% per NSM or 1.67% per pt 2 regional recurrence, 1.59% per NSM or 1.67% per pt 3 LRR, 2.4% per NSM or 2.5% per pt 2 DM (1.7%)	Not reported	Not reported  <u>Other</u> Recurrences too few so further data not extracted
Radovanovic, 2010 (274)	Oncology Institute of Vojvodina, Serbia	2004-2008	Early complications after NSM and immediate silicone implants	205 pts, 214 NSM	Prospective	Consecutive pts with breast cancer and NSM and immediate reconstruction with fixed volume silicone implants placed under the pectoralis major and serratus anterior muscles  Unilateral NSM in 196 pts, bilateral 9 pts	Preoperative diagnosis with physical examination, ultrasound, mammography, fine needle aspiration or core biopsy  Contraindications were inflammatory, extensive skin involvement, Paget disease	Frozen section analysis of subareolar tissue; if cancer cells the NAC was removed  NAC removed in 4 cases	Not reported	Lateral incision usually extended to upper outer quadrant for axillary access; other incisions if previous excisional biopsy or BCS	7.5% any skin flap or NAC necrosis:  1% NAC necrosis; major skin flap necrosis 4%, minor skin necrosis 3%
Folli, 2012 (275)	Italy	2006-2010	Use of hydrodissection	115 pts and NSM; 101 cancer and 14 risk-reduction		Retrospective in Cohort 1 and prospective in Cohort 2	Contraindications: carcinoma infiltration skin or NAC, inflammatory, pathologic	A 3-5 mm thick layer of tissue removed from retroareolar area and submitted for margin evaluation	1 LR (0.9%)  No recurrence in NAC	Italic S incision from lateral edge of areola to external equatorial line  Cohort 1 (until June 2009; 74 pts): NAC	No cases of complete necrosis requiring NAC removal

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
						Median follow-up 19 months	discharge from nipple  Relative contraindications : previous RT<, smoking, diabetes, recent per/subareolar surgery, large breasts NAC to IMF > 8 cm	on frozen section; if neoplastic tissue detected the NAC was removed and converted to SSM  20 cases (17.4%) converted to SSM  Removed NAC were examined for breast glandular tissue in permanent sections; found in 12/13 (92%) in cohort 1 and 1/7 (14%) in cohort 2		dissected by sharp isolation, coring the nipple to remove all glandular tissue  Cohort 2 (July 2009 - 2010; 41 pts): as cohort 1 but preceded by hydrodissection of the areola by injection of saline/adrenaline into the deep subareolar dermis to obtain complete detachment of skin, then isolation of areola by dissecting the swollen plane with scissors and the nipple cored	
Lee, 2013 (276)	Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea	2009-2012	Risk factors of mastectomy flap complications	125 pts, 130 NSM	Retrospective  Prospectively collected database  Multivariate analysis but too few events and did not report for NAC	Lateral incisions for NSM, immediate reconstruction; exclude prior partial mastectomy or RT  2 prophylactic, 47 stage 0, 45 stage I, 34 stage II, 2 stage III  70 autologous and 60 two-stage implants	Inclusion based on clinical, radiological, and pathological evaluations	Intraoperative frozen section analysis on retroareolar duct regions; NAC removed when neoplasm found	Not reported	Lateral incisions  Used electrocautery	15 nipple complications: total nipple necrosis in 5 cases (3.8%), partial loss in 10 cases (7.7%)  Necrosis rates decreased over time

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Huston, 2015 (277)	New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY, USA	2006-2012	Impact of scarring from previous BCS on NAC viability	318 NSM: 122 with previous lumpectomy and 196 without	Retrospective Prospectively collected database  Follow-up at 2 weeks, 1 month, 2 months, 6 months, then yearly	Breast cancer (51% multifocal lesions), NSM via IMF incision  Single or 2-stage implant reconstruction	Candidate for SSM with no nipple involvement, tumour >2 cm from nipple, could attend frequent follow-up to examine NAC	Frozen section of deep dermis of nipple; if it had malignant or atypical cells then NSM was converted to ASM or SSM	In pts with prior lumpectomy: LR 3 cases (2.5%) DM 2 cases (1.6%)	Flaps infiltrated with local anesthetic, incision ≈12 cm long along IMF, subdermal dissection with sharp scissors leaving flap 3-5 mm thick, marking suture placed on breast gland immediately deep to NAC for the pathologist, NAC inverted and sharply cleaned of glandular tissue, additional specimen scraped from the deep dermis of the nipple for frozen section, gland resected off pectoralis muscle using electrocautery	NAC ischemia (epidermolysis or necrosis) in 65/318 NSM (20.4%)  Pts with prior lumpectomy: ischemia in 30/122 (24.6%), including 20 NSM (16.4%) epidermolysis and 10 (8.2%) necrosis; 2 (1.6%) required operative debridement; 7 NSM (5.7%) had NAC depigmentation  Without prior lumpectomy: ischemia 17.9%
Ahn, 2018 (124)	Yonsei University College of Medicine, Korea	2010-2016	Ischemia and necrosis after NSM	207 pts, 220 NSM (4 prophylactic)	Retrospective Multivariate analysis	NSM and immediate reconstruction; implants in the subpectoral plane with ADM sling or autologous flaps	Breast cancer or phyllodes tumour (1 pt)	Intraoperative frozen section for sub-NAC tissue	Not reported	Glandular tissue removed along superficial mammary fascia and pectoral fascia, skin flap thickness 3-5 mm, various skin incisions used  <u>Other</u> Authors suggest skin tension may interfere with blood flow and be the cause of	NAC ischemia (clinical ischemic colour change in any portion of NAC) in 141 cases (64.1%)  NAC necrosis (full thickness) requiring surgical reoperation (debridement

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										<p>higher rates of necrosis with DTI and autologous reconstruction</p> <p>Second intercostal artery was always sacrificed; it is the principal perforator for the NAC and may have been reason for very high rates of ischemia and necrosis</p> <p>52.3% of incisions were periareolar plus radial</p>	<p>and repair) in 69 cases (31.3%)</p> <p>Grade 4/5 ischemia 24.1%; necrosis in this group is 19.5% of all pts</p> <p>Ptosis, periareolar incision, and reconstruction other than 2-stage (expander) implant were predictors of NAC necrosis</p>
Pek, 2018 (125)	Singapore General Hospital	2005-2015	Aesthetic outcomes and NAC necrosis in Asian pts	133 pts, 142 NSM	Mean follow-up 37 months	NSM for cancer (85.9% of NSM) or risk reduction (14.1%)	<p>Intraoperative frozen section of retroareolar tissue; NAC removed if involved</p> <p>80% autologous reconstruction (115 NAC); 2 stage expander/ implant in subpectoral plane; DTI</p>		LR in 5 NSM (3.52%)	<p>Previous biopsy or BCS scars often incorporated into new incision; mastectomy skin flaps assessed for thickness and NAC viability; if not excessively thin and the NAC was healthy there was immediate closure; skin paddle from flap incorporated if excessive tension was anticipated otherwise used primary closure with release of sutures if</p>	<p>NAC necrosis in 17 breasts (12.0%); total NAC necrosis in 4 breasts (2.8%) and partial in 13 (9.2%)</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										<p>signs of NAC necrosis developed</p> <p>Delayed primary closure if NAC viability threatened and banked a skin paddle</p> <p>The banked paddle was used in case of partial or total NAC necrosis</p>	
Radovanovic , 2018 (278)	Oncology Institute of Vojvodina, Serbia	2004-2012	Surgical complications after NSM	435 pts, 441NSM	Retrospective  Follow-up weekly if complications , otherwise every 3 months the first year then 6 months for 2 years, then yearly  Mean follow-up 79 months	Pts with breast cancer, NSM as initial procedure or after BCS, implant reconstruction with contoured profile fixed-volume gel-filled prostheses	Not reported	Subareolar tissue excised and sent for frozen analysis  NAC excised in 24 cases (5.4%) due to cancer cells in subareolar tissue by frozen section or final analysis; NAC preserved if no malignant cells	LR in 32 pts (7.3%); 2 recurrences in NAC  DM 68 pts (15.6%)  Deaths 53 pts (12.2%)	Lateral incision in 81.2% extending to upper outer quadrant allowing axillary access; other incisions if previous excisional biopsy or BCS to incorporate previous incision  Breast tissue and fat entirely removed except under NAC; subareolar tissue removed for frozen analysis;	NAC necrosis in 1 cases (0.2%);
Pallara, 2019 (279)	San Giovanni-Addolorata Hospital and Campus Bio-Medico University of Rome, Rome, Italy	2013-2015	Expander-implant vs. DTI	162 pts: 56 expander, 106 DTI	Retrospective  Multivariate analysis  Median follow-up 35 months	Reconstruction in pts with breast cancer; either submuscular expander-implant or DTI	Main indicator was multicentric tumours without NAC involvement	Not reported  NAC removed due to positive retroareolar margins on definitive histological exam in 3 pts	1 recurrence in each group (1.79% expander/implant and 0.94% DTI)	Radial incision in 90% of NSM (but discussion says IMF in most cases) skin flaps dissected with low-voltage electric scalpel, keeping ≈3 mm thickness, hydrodissection of NAC with saline solution to aid	8.0% partial NAC necrosis: expander 2 pts (3.6%), DTI 11 pts (10.4%)  4.3% total NAC necrosis: expander 3 pts (5.4%), DTI 4 pts (3.8%)

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										retroareolar dissection; viability of mastectomy skin flaps checked and nonviable flaps excised if no skin margin bleeding; expander or DTI determined by defect size	
Park, 2020 (112)	Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea	2009-2018	Complications according to incision type	275 pts, 290 NSM 61 periareolar, 53 radial, 176 IMF	Retrospective  Follow-up recommended every 6 months  Median follow-up 67 months, 54 months, 34.5 months  Multivariate analysis for risk factors of NAC necrosis  81% of cases by one surgeon	NSM and immediate reconstruction  Mostly invasive breast cancer  Exclude if previous augmentation  SLNB or ALND depending on nodal status  Implants inserted in subpectoral plane (89% DTI, 6.6% expander) and ADM used; or autologous (4.5%)	NAC invasion not suspected  Invasive or in situ cancer (283 NSM), phyllodes tumour (2 NSM), prophylaxis (5 NSM)  TND (to nipple base) by MRI except if NAC; used 1 cm increments in multivariate analysis  For breast weight, multivariate analysis is risk per 1 g increase in breast weight	Subareolar margin analyzed by frozen section; if cancer invasion found the NAC was resected then the pt excluded	LR by incision type: 2 (3.3%) periareolar, 1 (1.9%) radial, 6 (3.4%) IMF  2-y local RFS 98.4%, 98.1%, 97.6%, differences not significant  Overall complications 42.6% periareolar, 35.8% radial, 18.8% IMF incision	Incisions either periareolar (part of either upper or lower side of areola plus radial incision), radial (lateral side of NAC and extending obliquely to axilla), IMF (lower outer arc along crease of IMF)  Skin flap along superficial mammary fascia using electrocautery with thickness ≈7-15 mm	45 (15.5%) NSM with nipple necrosis (described as NAC necrosis or ischemia in abstract): 19 (31.1%) periareolar, 9 (17.0%) radial, 17 (9.7%) IMF  25 (8.6%) NSM with complete nipple necrosis: 13 (21.3%) periareolar, 6 (11.3%) radial, 6 (3.4%) IMF  Risk factors: periareolar incision (vs. IMF; OR=3.628, 95% CI=1.596-8.250, p=0.002); TND (OR=0.712, 95% CI=0.546-0.927, p=0.012);



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
											breast weight (OR=1.002, 95% CI=1.000-1.004, p=0.014)
Seki, 2020 (103)	Saitama Medical Center, Saitama, Japan	2013-2019	Outcomes of periareolar incisions	181 pts; 31 IMF and 150 periareolar incision	Retrospective Median follow-up 18.3 months IMF, 79.0 months periareolar	Primary operable breast cancer and NSM without intraoperative NAC resection  Submuscular expanders or implants, or autologous reconstruction (0% IMF, 13.3% periareolar)	Imaging including mammography, ultrasound, MRI to identify NSM candidates  Excluded if intraoperative NAC resection	NAC involvement by intraoperative sub-nipple biopsy; if involvement was suspected the NAC was resected  Surgical margins on side of skin and chest wall and under NAC by permanent pathology	RFS, HR=0.528, 95% CI=0.054-5.127, p=0.860	Incision based on pt preference, breast size, radiological findings  For IMF, incision ≈10 cm along IMF; for periareolar, incision was along lower areola  For periareolar: incision in lower half of areolar circumference, Lap protector attached to protect the wound, breast tissue dissected from subcutaneous tissue in all directions, mammary gland lifted from pectoralis major fascia and adhesion under pectoralis major muscle dissected; deflated expander folder and inserted  IMF incision details not reported	Complete nipple necrosis (spanning entire layer from epidermis to dermis of the nipple) in 0 pts IMF incision and 5 pts (3.3%) periareolar incision  Epidermal nipple necrosis (only in epidermis of nipple) in 5 pts (16.1%) and 24 pts (16.0%)
Najmiddinov , 2022 (133)	Seoul National University Bundang Hospital,	2014-2021	Conventional (c-NSM) or modified (m-NSM)	516 pts, 580 NSM: 143 c-NSM, 437 m-NSM	Retrospective Average follow-up	Exclude stage IV, delayed reconstruction, PMRT	Excluded NAC or skin involvement, inflammatory	Not reported	10 recurrence (2.2%; 4 pts or 3% c-NSM, 6 pts or 1.8% m-NSM)	Lateral radial, IMF, and inverted T incisions most	4 (0.9%) partial NAC necrosis: 3 (2.3%) c-NSM,

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
	Seongnam, South Korea		Modified preserves the anterior lamellar fat layer		41.92 and 31.98 months		cancer, Paget disease		LR 3 pts (0.6%; 2 pts or 1.5% c-NSM, 1 pt or 0.3% m-NSM)  DM 2 pts (0.4%; 1 pt or 0.8%, and 1 pt 0.3%)	common, periareolar not used  <u>c-NSM</u> : After incision, skin flaps elevated with the Bovie coagulator on the superficial fascial plane anteriorly; skin flaps developed along superficial layer of superficial fascia resulting in an even flap; plane between pectoralis major fascia and pectoralis major muscle was posterior plane of dissection  <u>m-NSM</u> : skin incision as c-NSM; main difference was anterior plane of dissection was performed along with the breast capsule (anterior capsule of corpus mammae), breast parenchyma separated from subcutaneous fat layer by the breast capsule to give the anatomic dissection plane which maximizes preservation of anterior lamellar fat layer and increases mastectomy flap thickness; when	1 (0.3%) m-NSM, p=0.074  1 (0.2%) total NAC necrosis: 1 (0.8%) c-NSM and 0 m-NSM, p=0.287  Wound healing complications (p=0.023), reconstruction failure (p=0.005) and implant rippling (p=0.06) higher in c-NSM  Panel assessment (blinded to treatment group) of aesthetics: 2.38±0.95 in c-NSM and 3.14±0.61 in m-NSM, p<0.001; scores 1-4 with 4 being excellent  Breast-Q reconstruction module (122 pts): m-NSM had improved QoL

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										tumour is close to the breast capsule dissection above the tumour area is along the superficial layer of superficial fascia as in c-NSM for oncologic safety; posterior dissection plane same as c-NSM  In both m-NSM and c-NSM sharp dissection was performed and electrocautery limited to hemostasis to prevent thermal damage to the flap  Pts evaluated intraoperatively with indocyanine green angiography for perfusion quality  Mean flap thickness by CT (n=37, n=41) after at least 12 months: 6.32±1.15 mm c-NSM, 8.48±1.81 mm m-NSM, p=0.02	(psychosocial, sexual)
Lai, 2023 (113)	Changhua Christian Hospital, Central Taiwan	2011-2021	Risk factors for NAC ischemia necrosis	441 NSM with 369 reconstructions	Retrospective Multivariate logistics	Primary operable breast cancer, excluded if no information on skin excision or NAC ischemia necrosis status	Not reported  Ischemia necrosis grade 0 (normal), grade 1 (transient ischemia injury, <25% nipple volume loss after recovery), grade 2 (loss of 25-75%), grade 3	Not reported	Not reported	Skin incisions: 83 (18.9%) upper outer incision (radial incision), 107 (24.3%) peri-areolar-related incision (with or without axillary incision), 243 (55.2%) single axillary incision (endoscopic or robotic assisted),	41 NSM (9.3%) had NAC ischemia/ necrosis events (defined as grade 2-3)  6.6% (29 NAC) grade 1, 8.4% (37 NAC) grade

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
							(loss of >75-100% of volume resulting in surgical excision or loss of NAC)			and 7 (1.6%) infra-mammary + axillary incisions	2, 0.9% (4 NAC) grade 3  In multivariate analysis, periareolar-related incision (compared with upper outer radial) had odd ratio=5.33 (p<0.001) of NAC ischemia necrosis; larger breast (mastectomy specimen >450 g also risk factor (OR=4.6, p=0.03)
Cadili, 2023 (280)	Providence Breast Centre, Providence Health Care, University of British Columbia	2012-2018	Nipple margin assessment in NSM	NSM 337 pts, including 242 for breast cancer	Retrospective  Median follow-up 33.7 months	72% for cancer	Not reported	Nipple margin assessments in 296/337 (87.8%) of NSM; either shave margin under NAC or coring of nipple  Surgical nipple margin assessment in 222/242 pts with cancer (91.7%)  Of 10 pts with positive nipple margin, 7 had NAC excised, 3 (all with DCIS) had observation; none had LR	Positive margins in 10 pts (3.4% of all NSM or 4.1% of NSM in pts with cancer)  15 recurrences in 222 pts with cancer who had margin assessment: 4 local to skin (not NAC), 4 regional, 7 distant; none of these had positive margins on mastectomy specimens	Not reported	Not reported

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Cavalcante, 2023 (281)	Fortaleza General Hospital, Fortaleza, Ceará, Brazil	2015-2022	Inframammary vs. periareolar incision for NSM	152 pts, 180 NSM; 104 IMF, 76 periareolar	Retrospective STROBE criteria Multivariate analysis	Early-stage breast cancer or risk-reducing mastectomy and immediate reconstruction with IMF or periareolar incisions  ADM not used  Mastectomy weight mean 246.8 g vs. 312.7 g; BMI normal (<25 kg/m <sup>2</sup> ) in 70.2% vs. 55.6%  Therapeutic 43.3% vs. 55.3%  Direct to implant 50% vs. 31.6%  Prepectoral 81.7% vs. 96.1%	Not reported	Not reported	Not reported	IMF incision 6-8 cm in length following natural lower outline of breast but not exceeding the anterior axillary line; periareolar generally in lower portion between 3-0 o'clock or upper between 0-12 o'clock (with or without lateralization)  Incision type by surgeon's preference, clinical criteria (breast volume and ptosis), pt preference  NSM by international guidelines: electric scalpel following anatomic plane (superficial fascia of breast); no minimum flap thickness used; if axilla management needed then IMF fold group had separate incision in axilla while periareolar group used same excision	Complications 16 (15.3%) vs. 27 (35%), p=0.0002, OR=0.33, 95% CI=0.14-0.79  NAC necrosis 9 (8.5%) vs. 17 (22.4%), p=0.002, OR=0.33, 95% CI=0.14-0.79; adjusted OR=0.34, 95% CI=0.13-0.88, p=0.025  Too few other complications to do multivariate analysis
Moo, 2023 (110)	Memorial Sloan Kettering Cancer Center (MSKCC), New York,	2018-2020	Skin-flap necrosis after NSM  Quality improvement initiative to	299 pts with 515 NSM	Prospective 15 breast surgeons, 10 plastic surgeons	54.8% prophylactic, 45.2% therapeutic  85.4% tissue expander,	Not reported	Not reported	Not reported	Intraoperative variables are in data table  Data presentation for univariable and multivariable analysis	Necrosis, per pt basis: 71/299 (23.7%); necrosis occurred in 11% of those

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
	New York, USA		Identify modifiable risk factors for skin-flap necrosis after NSM		Necrosis categories by SKIN score  Multivariable logistic regression with model chosen by backward selection;	5.22% direct implant, 8.3% autologous flap				<p>of variables associated with nipple and skin-flap necrosis after NSM is confusing</p> <p>Results for most variables that were significant in univariable analysis were not reported after multivariable regression; those reported are often inconsistent with univariable results but not commented on by authors</p> <p>Necrosis by incision type:</p> <ul style="list-style-type: none"> <li>•12.1% lateral IMF, OR=0.41, aOR=0.35</li> <li>•19.0% central IMF, OR=0.64, aOR=0.54</li> <li>•29.8% lateral radial (OR=1.0 as reference)</li> <li>•37.3% inferior periareolar/lateral extension, OR=1.25, aOR=1.24</li> <li>•41.2% superior periareolar/lateral extension, OR=1.38, aOR=1.59</li> <li>•61.5% inferior radial, OR=2.07, [aOR=0.56 but only 8 events so unreliable or error</li> </ul>	<p>with hypertension and 2.6% without (p=0.006)</p> <p>Mastectomy skin flap necrosis by 2 weeks: 23.3% (120/515), including 45.8% (55/120) with nipple necrosis only, 27 superficial (SKIN category B), 73 partial (C), 20 full-thickness (D)</p> <p>Higher necrosis with periareolar incision (see surgery details column), specimen weight &gt;400 g, fill volume &gt;200 mL, subpectoral expander, surgeon with less experience</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										in calculation for aOR]	
Serio, 2023 (105)	The Breast Center of the San Giovanni-Addolorata Hospital, Rome, Italy	2016-2021	NSM for cancer, omitting intraoperative examination of retroareolar margins (IERM)	162 pts	Retrospective Median 46 months follow-up	NSM offered except if clinical and/or radiological NAC involvement, pathological nipple discharge, Paget disease of the nipple, breast cancer with skin involvement, inflammatory breast cancer, or severe comorbidities  Exclude if surgical delay (autonomization of the NAC)  NACT allowed if major or complete response allowing safe resection	Preoperative MRI to measure tumour NAC distance (TND)  15% of pts had TND <10 mm and 25% of these had close or very close margins, suggesting increased risk but not exclusion of NSM	Retroareolar margin marked with single stay suture and analyzed; margins classified as positive (ink on tumour), negative (no ink on tumour), <1 mm (very close), 1-2 mm (close), >2 mm	17 cases close or very close and 5 recommended for NAC excision and no residual cancer found  LR at median 46 months follow-up: 5 pts (3%), including 1 (0.6%) at NAC  DM 10 pts (6%)  Close or very close margin was not associated with LR or DM; but table suggests lack of statistical significance is due to low number of events (LRR OR=4.46, 95% CI=0.384-52.067, p=0.28; DM OR=3.8, 95% CI=0.640-22.459, p=0.12)  Authors suggest policy of not conducting intraoperative pathology has advantages including avoiding false	Skin flaps dissected at Coopers ligament (usually with min 3-5 mm thickness) using radiofrequency device to cut and coagulate soft tissue;	5 pts had NAC removed due to nipple necrosis

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
									positives and second incision for NAC resection; this assumes final pathology analysis will occur		
Black, 2024 (120)	Weill Cornell Medical College, New York, NY.	Not stated	Impact of reconstruction on sensation	192 pts: 106 autologous via neurotized DIEP, 86 2-stage implants (64 prepectoral)	Single surgeon, single institution, retrospective, breast surgeons and 1 plastic surgeon	<p>NSM with immediate reconstruction</p> <p>2-stage implants with expander exchange after 3 months (no RT) or after 6 months (with RT); or use of DIEP flaps</p> <p>Autologous group had more comorbidities (higher BMI, hypertension, diabetes) but better restoration of sensation; the relative contribution of type of implant and neurotization cannot be determined</p>	Not reported	Not reported	Not reported	<p>Patients with DIEP flaps had neurotization using donor and recipient nerves: donor nerves were a sensory branch of T10, T11, or T12 thoracoabdominal nerves within the DIEP flap, recipient nerve was anterior cutaneous branch of T3 intercostal nerve near the internal mammary recipient vessels; Avance nerve graft was used for nerve coaptation</p> <p>Sensory testing using pressure-specified sensory device that measured 1-point static cutaneous sensation thresholds (0-100 g/mm<sup>2</sup>) at 9 regions per breast (inner and outer superior, medial, inferior, lateral; and NAC)</p>	<p>Preoperative threshold 14.1 g/mm<sup>2</sup> for NAC, 16.5 to 20.0 for other sites</p> <p>After mastectomy: sensation greatly reduced, most strongly at NAC and surrounding inner regions (threshold for implants 72.3-83.3 g/mm<sup>2</sup> and 64.1 -73.2 for autologous) at &lt;1 year</p> <p>Long term (&gt;4 years) was further improvement (implant 45.2 at NAC, 50.9-66.2 inner, 35.2-58.4 outer areas; autologous 38.5 at NAC,</p>



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
										Testing pre-mastectomy and postmastectomy at various time points	37.5-47.7 inner, 25.9 - 40.8 outer) but still less than pre-surgery
Golijanin, 2024 (282)	Oncology Institute of Vojvodina, Sremska Kamenica, Republic of Serbia	2013-2016	LR by subtype (Ki67 or molecular) in NSM with primary implants	156 pts: 53 invasive	Retrospective  Follow-up mean 59.26 months  Cox proportional hazards model applied in multivariate analysis fir KR	Breast cancer and NSM with primary implant reconstruction with fixed volume silicone prosthesis  122 pts received NACT due to advanced disease  78.8% received RT  Implants were placed between pectoralis major and serratus anterior muscle	Excluded inflammatory breast cancer, extensive skin involvement, Paget's disease, breast cancer lesions with direct extension to skin beyond the dermis (considered LABC)  Preoperative clinical examination, ultrasound, mammograph (or MRI if mammogram unclear) and core biopsy	Subareolar tissue sample and frozen section assessed intraoperatively; NAC removed if positive findings  2 pts with T4 tumours had infiltration of pectoralis muscle but not skin; in pts with T3 tumours close to subcutaneous tissue a decision of safety of the margin was made (must not be present on margins)	LR in 17 pts (10.9%)  Stage, Ki67 and HER2, size of tumour or implant were not risk factors for LR  Low ER/PR was risk factor for LR (ER+ OR=1.238, p=0.010)	Lateral incision (adjusted if prior biopsy or BCS due to scars and aesthetics) and removal of breast and fat tissue;  NSM only continued if no tumour cells at margins of removed subcutaneous tissue	Not reported
Lin, 2024 (111)  Liston, 2024 (283)  See also Shanno, 2024 (95)	Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA	2007-2019	NSM complications  Expander vs. direct-to-implant  Plane of reconstruction (Q4)	2043 direct to implant and 992 expander-implant	Single institution, retrospective  At least 2 years follow-up post-operatively	NSM and implant-based reconstruction  Excluded delayed or autologous reconstruction  Most operations by 3 breast	Not reported	Not reported	Not reported	Type of incision, no other details	Nipple necrosis by incision type: Inferolateral inframammary fold (reference, 1.0), horizontal radial OR=3.823, 95% CI=1.081-

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
			Use of ADM (Q5)			surgeons and plastic surgeons					13.515, p=0.037; vertical inferior OR=2.124, 95% CI=0.453-9.944, p=0.339; periareolar OR=14.235, 95% CI=6.248-32.435, p<0.001; extension of prior incision OR=2.98, 95% CI=0.657-13.511, p=0.157
Shanno, 2024 (95) See also Lin, 2024 (111)	Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA	2007-2019	Management of NSM with tumour or atypia in margins	3158 NSM; 117 margins with tumour and 164 with atypia  1583 for invasive cancer or DCIS; 1575 for risk reduction or symmetry	Median follow-up 67 months  6 breast surgeons and 8 plastic surgeons		Broad eligibility for NSM  Exclude if direct tumour involvement of NAC on examination or imaging, inflammatory breast cancer, most pts with bloody nipple discharge  ASM if nipple involvement without areola involvement on preoperative examination or imaging	Nipple margin specimens not oriented due to small size; frozen section analysis not performed  A positive nipple margin if invasive cancer, DCIS, LVI in the nipple margin on permanent analysis; atypia was documented but not considered positive  Decision about surgical management on case-by-case basis, but generally	Positive margins in 117 NSM (3.7%); 113 (7.1%) in NSM for known cancer, 4 (0.3%) in prophylactic NSM  Atypia in 154 (5.2%) nipple margins: 110 (6.9%) therapeutic NSM and 54 (3.4%) prophylactic NSM  For pts with tumour in nipple margin: 4 excluded (too short follow-up), 64 (57%) nipple excision (2 with	Areola skin flaps raised, curved clamp grasps nipple duct bundle under the NAC dermis and clamped tissue is sharply divided above and below the clamp and the tissue in the clamp comprises the nipple margin  Over time shifted towards removal of nipple and preservation of areola; 50% nipple-only in 2009-2015 and 89% nipple-only excisions in 2016-2019	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
							<p>Excluded stage IV breast cancer at diagnosis or within 4 months</p> <p>Excluded if nipple excised in initial NSM procedure due to poor position or gross tumour involvement</p>	<p>nipple or NAC excised when nipple margins were positive and retained if atypia</p> <p>If nipple/NAC was excised the tissue was examined</p> <p>75 (77%) excisions for positive nipple margins contained no residual tumour; 23 (24%) had malignancy</p> <p>79% received systemic therapy, 35% PMRT, 21% neither</p>	<p>later NAC excision due to close/positive margins); 34 (30%) NAC excision, 15 (13%) no excision (9 with clear margins in nipple margin specimen, 2 planned RT, 2 small extent of cancer, 2 LVI only</p> <p>Of pts with positive nipple margins: 2 (1.8%) recurrence as subareolar nodule involving the dermis; both had had nipple-only excisions and no residual malignancy in excised nipples</p> <p>No significant difference in periareolar recurrence for nipple-only vs. NAC excision; 2/64 (3.1%) vs. 0/34 (0%)</p> <p>12 (11%) DM and/or LRR outside NAC,</p>	<p>Nipple or NAC excision at median 35 days after NSM, either alone or with other procedures</p>	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
									<p>including 2 (1.8%) LRR and 7 (6.1%) DM, and 3 (2.7%) both</p> <p>Overall LRR including areola was 6.2% and DM 8.8%; overall recurrence 12%</p> <p>OS at median 67 months follow-up 94%</p> <p>BCSS was 96%</p> <p>In pts with atypia in nipple margins: 164 nipples in 144 pts; in early pts 10 pts had excision (6 NAC and 4 nipple-only); no excisions in later pts</p> <p>At median 60 months was no recurrence in NAC or periareolar skin; 2 (1.3%) other LRR (both in pts with malignant tumour)</p>		
Nashimoto, 2024 (284)	Kameda Medical Center,	2006-2015	Recurrence and survival with NSM, SSM	245 cases: 152 NSM, 49 SSM, 44	Mean follow-up 78.42 months in NSM group	DCIS, Excluded risk-reducing mastectomy	Clinical and imaging without skin or muscle involvement considered for	Intraoperative subareolar tissue biopsy in all cases of NSM; if positive	Of 152 NSM: 5 (3.3%) recurrence, 4 (2.6%) LRR, 0	SLNB with blue dye and radioisotopes; NSM used axillary incision plus partial periareolar (1/4	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
	Chiba, Japan		in Japanese pts with DCIS	simple mastectomy	Single centre, retrospective  Cox proportional hazards model for affect of surgical technique on RFS adjusting for age and BMI		NSM or SSM; NSM if no clinical nipple discharge, Paget disease, infiltration of NAC on MRI  If NAC infiltration was uncertain on MRI they were evaluated individually	the NSM was converted to SSM  No cases of positive surgical margins required reoperation or RT	DM, 1 (0.7%) death  Estimated 5-y LR (Kaplan-Meier) 2.4% (0-5.0)  Of 4 LR, 2 subcutaneous, 1 areola, 1 lymph node, 0 nipple; all were excised	circumference nearest axilla), mastectomy flaps created in subdermal plane using electrocautery or scissors; endoscopic assistance muscle dissection	
Sagir, 2024 (285)	Istanbul, Turkey	2020-2023	Lateralized parabolic multiplanar incision to reduce necrosis in NAC	243 pts, 326 breasts	Retrospective  Mean follow-up 24.6 months	NSM and immediate implant-based reconstruction; therapeutic or prophylactic (numbers not reported)  Anatomical textured implants and ADM in all pts  160 unilateral, 83 bilateral; 41 prepectoral, 202 dual-plane  Exclude autologous, tissue expanders, skin reduction, delayed reconstruction, previous breast surgery, PMRT or previous RT		Not reported	Not reported	Lateralized parabolic multiplanar incision (from axilla curved down to level of nipple but 4-5 cm away from areola)	Full-thickness necrosis in NAC in 12 cases (3.6%) and required debridement or excision  Full thickness skin flap necrosis in 9 pts (2.7%)

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
Spoor, 2024 (106)	PALGA database, the Netherlands	2000-2021	Intraoperative frozen section in NSM; compared it to permanent section	640 pts, 662 intended NSM	Single centre retrospective  Median follow-up of 20 pts with positive histo-pathology was 53 months	Therapeutic NSM and immediate reconstruction with intraoperative frozen section and definitive analysis or SSM with nipple banking (56 SSM)  Specimen considered positive if invasive carcinoma non-special type, lobular carcinoma, DCIS, LCIS		Sample sent for intraoperative frozen section; if positive the nipple is excised immediately (if possible only protruding part with lactiferous ducts excised, leaving the areola, otherwise resect areola as well)  If negative frozen section but positive permanent section, excision of nipple is offered  If nipple or NAC excised it is analyzed  Frozen section analysis had sensitivity of 75.2% and specificity of 98.5%	105/662 (15.7%) positive on frozen section; of these 97 were positive on definitive analysis; 32 negative frozen section analysis were positive on definitive analysis  Positive on either analysis was 137 (20.7%); of these 115 nipples were resected and 68 (59.5%) had tumour cells and 47 (40.5%) had no tumour cells; 22 pts did not have nipple resection  In 20 pts without nipple resection none had LRR by 53 months follow-up	Base of nipple through periareolar incision with lateral extension; nipple everted and gland tissue excised with sharp dissection; in early years used nipple banking as a graft in groin	Not reported
Zhu, 2024 (96)	Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Hangzhou China	2015-2020	Accuracy of subareolar frozen section in NAC	137 pts, nipple retained in 126 pts	Retrospective  Median follow-up 48 months  Cox regression analysis; prognostic factors	Primary invasive breast cancer, consecutive cases with NSM  Immediate reconstruction (autologous or implant)	Excluded if clinical NAC involvement (nipple depression or discharge), radiologically suspected NAC involvement, inflammatory,	Subareolar frozen sections for all cases; if positive margin could either (a) subareolar reshaping, (b) nipple excision with areolar preservation, (c)	Nipple retained in 126/137 pts  Areola retained but nipple excised in 5 breasts  Of 15 breasts with positive nipple margin in	A piece of tissue ≈5 mm thick under areola and including retroareolar tissue and ductal tissue beneath bottom of nipple excised using a cold knife and sent	16/127 nipples had necrosis

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
					entered in multivariate analysis to identify risk factors of recurrence		Paget's disease of the nipple	<p>NAC excision, (d) observation as determined by surgeon</p> <p>Samples sent for permanent histology; NAC if removed had permanent histology evaluation</p> <p>Frozen section analysis had sensitivity of 81.8% and specificity of 95.3%</p>	<p>frozen section, 3 (20%) had subareolar shave, 5 (33%) nipple excision, 6 (40%) NAC excision, 1 (6.7%) observation only</p> <p>Final pathology found tumour involvement or ADH in 9/15 breasts</p> <p>2/123 negative frozen sections had ADH</p> <p>All positive margins with NAC retained had ADH on final pathology</p> <p>1/11 nipples removed had residual tumour involvement (9.1%)</p> <p>5 (4.3%) had NAC recurrence as first event, 4 (3.4% breast skin or chest wall recurrence, 2 (1.7%) DM</p>	for frozen section analysis	
Braun, 2023 (131)	University of Kansas Medical Center,	2015-2019 training;	Model of factors	Retrospective (training cohort), 181	Included predictors within clinical	NSM and immediate implant-based reconstruction	Pts with tumour >2 cm from NAC or risk-reduction;	Not reported	Not reported	In retrospective set, type of incision was 66% IMF, 33% radial, 2% Wise pattern;	Rates of necrosis in

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	Criteria for NSM	Pathology	Oncologic outcomes	Surgery Details	Nipple viability and necrosis
	Kansas City, KS	2020-2021 test	<p>affecting NAC necrosis</p> <p>Derived model used age, BMI, pack-years smoking, hypertension, NACT, history of breast RT, history of breast augmentation, previous breast incision and type, breast cup size, planned implant size or expander fill (use 0 if filled with air).</p> <p>Incision type is important but not included due to data limitations (only had 2 types with non-significant necrosis difference)</p>	<p>pts and 305 breasts</p> <p>Prospective (test cohort) 62 pts and 119 breasts</p>	<p>history, physical examination, or surgeon-control</p> <p>Mean follow-up 17.7 months</p>	<p>(expander or direct-to-implant)</p> <p>Exclude autologous, NAC excision due to surgical pathology results</p> <p>Diabetes, hypertension, smoking higher in pts with necrosis</p>	<p>surgeon also considered BMI, breast size, ptosis, prior RT, uncontrolled diabetes, and smoking but were no absolute contraindications</p>			<p>plane of reconstruction was 73% prepectoral and 27% submuscular</p> <p>Details from records for retrospective set, necrosis vs. none:</p> <ul style="list-style-type: none"> <li>• Specimen weight mean 477 g with necrosis vs. 371 g without necrosis, <math>p&lt;0.001</math></li> <li>• Implant weight mean 221 g vs. 128 g, <math>p&lt;0.001</math></li> <li>• Implant volume mean 306 mL vs. 238 mL, <math>p=0.008</math></li> </ul> <p>Results for prospective set not reported</p> <p>There were significant differences between retrospective and prospective data sets in use of IMF incision (increased from 65.9% to 82.3%), prepectoral implants (increased from 73.1% to 95.2%), implant weight (increased from mean 142.31 g to 233.47 g), use of intraoperative SPY (increased from 37.7% to 61.3%)</p>	<p>retrospective/training set:</p> <p>12.4% IMF incision vs. 21.2% radial, <math>p=0.1</math> [not used in model because other types of incisions were rare]</p> <p>14.8% prepectoral vs. 15.9% submuscular, <math>p=1</math></p> <p>NAC necrosis was 46/305 breasts (15.1%) in retrospective set and 8/119 breasts (6.7%) in prospective set</p>



\*Year of diagnosis or initial surgery

**Abbreviations:**

ADH, atypical ductal hyperplasia; ADM, acellular dermal matrix; ALND, axillary lymph node dissection; ASBrS NSMR, American Society of Breast Surgeons Nipple Sparing Mastectomy Registry; ; aOR, adjusted odds ratio; ASM, areola-sparing mastectomy; BCS, breast conserving surgery; BCSS, breast cancer-specific survival; BMI, body mass index; CBC, contralateral breast cancer; CI, confidence interval; CSS, cancer-specific survival; CT, computed tomography; DCIS, ductal carcinoma in situ; DFS, disease-free survival; DIEP, deep inferior epigastric perforator; DM, distant metastasis; DMFS, distant metastasis free survival; DTI, direct to implant; EFS, event-free survival; ELIOT, intraoperative electron-beam radiotherapy; ER/PR, estrogen receptor/progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IDC, invasive ductal carcinoma; IBR, immediate breast reconstruction; IMF, inframammary fold; ILC, invasive lobular carcinoma; IORT, intraoperative radiation therapy; LABC, locally advanced breast cancer; LCIS, lobular carcinoma in situ; LD, latissimus dorsi island flap; LCIS, lobular carcinoma in situ; LIN III, lobular intraepithelial neoplasia Grade 3; LN+, lymph node positive (at least one axillary lymph node contains cancer); LLR, locoregional recurrence; LR, local recurrence; LRFS, local recurrence-free survival; LVI, lymphovascular invasion; MRI, magnetic resonance imaging; ms-TRAM, muscle-sparing transverse rectus abdominis musculocutaneous flap; NAC, nipple-areolar complex; NACT, neoadjuvant chemotherapy; NME, non-mass enhancement on MRI; NSM, nipple-sparing mastectomy; OR, odds ratio; OS, overall survival; PALGA, 'Pathologisch Anatomisch Landelijk Geautomatiseerd Archief', Pathological Anatomy National Automated Archive, The Netherlands, [www.palga.nl](http://www.palga.nl); pCR, pathologically complete response; PET, positron emission tomography; PMRT, postmastectomy radiotherapy; PRO, patient-reported outcomes; pts; patients; QuaRT, quadrantectomy, complete axillary dissection and radiotherapy; RFS, recurrence-free survival; RT, radiotherapy; SEER, Surveillance, Epidemiology, and End Results database, USA; SIEA, superficial inferior epigastric artery flap; SKIN, Skin Ischaemia and Necrosis score, a validated tool (460); SLNB, sentinel lymph node biopsy; SSM, skin-sparing mastectomy; SPY, SPY fluorescence imaging platform using indocyanine green angiography; TND, tumour-to-nipple distance; TRAM, transverse rectus abdominis musculocutaneous flap; TSSM, total skin-sparing mastectomy

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q3b/c](#)[Back to Start of Tables](#)**Table 4-6. Question 3b/c: Summary Statistics for Patients with NSM**

Measure	LR	LR in NAC	RR	LRR	CBC	DM	Death	5-y OS	5-y DFS	Total nipple necrosis	Partial NAC necrosis	Flap necrosis
# Studies	45	42	13	24	7	39	14	14	12	45	36	27
Minimum (%)	0.0	0.0	0.7	0.9	0.9	0.0	0.4	83.5	68.0	0.0	0.9	0.4
Maximum (%)	10.9	6.0	9.6	16.2	3.9	20.4	12.2	99.1	98.3	19.5	23.7	23.3
Average (%)	4.0	1.2	2.9	5.1	2.0	5.6	3.6	94.6	87.4	2.8	7.9	7.4
Median (%)	3.7	0.5	1.8	3.9	2.0	4.0	2.6	95.8	90.5	1.7	6.9	6.3

**Abbreviations:** CBC, contralateral breast cancer; DFS, disease-free survival; DM, distant metastasis; LR, local recurrence; LRR, locoregional recurrence; NAC, nipple-areolar complex; OS, overall survival; RR, regional recurrence

**Table 4-7. Question 3b/c: Summary Statistics for Patients with NSM, Excluding Four Studies\***

Measure	LR	LR in NAC	RR	LRR	CBC	DM	Death	5-y OS	5-y DFS	Total nipple necrosis	Partial NAC necrosis	Flap necrosis
# Studies	42	39	11	22	6	35	13	12	10	44	36	26
Minimum (%)	0.0	0.0	0.7	0.9	0.9	0.0	0.4	90.0	86.0	0.0	0.9	0.4
Maximum (%)	10.9	6.0	3.9	10.1	2.6	15.6	12.2	99.1	98.3	19.5	23.7	23.3
Average (%)	3.9	1.2	2.0	4.3	1.7	4.3	3.3	95.9	91.1	2.8	7.9	7.5
Median (%)	3.4	0.5	1.7	3.8	1.8	3.6	2.2	96.7	92.0	1.9	6.9	6.6

**Abbreviations:** CBC, contralateral breast cancer; DFS, disease-free survival; DM, distant metastasis; LR, local recurrence; LRR, locoregional recurrence; NAC, nipple-areolar complex; OS, overall survival; RR, regional recurrence

\*Excluded two studies in patients who received neoadjuvant chemotherapy (which is correlated with higher-stage disease), one in patients with locally advanced breast cancer, and one with survival rates far outside the range of all other studies (68% 5-y DFS, compared to the next lowest value of 86%).

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q4](#)[Back to Start of Tables](#)**Table 4-8. Question 4: Comparisons of Prepectoral, Subpectoral, and/or Dual-plane Reconstruction. A. Prepectoral versus Other, ADM use Similar**

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
Prepectoral vs. submuscular											
Franceschini, 2021 (134)	Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy	2018-2019	Prepectoral without ADM vs. submuscular after NSM  Single institution	82 prepectoral, 95 submuscular	Retrospective  Follow-up 20 months submuscular and 16 months prepectoral	NSM and immediate implant reconstruction  Exclude from NSM: inflammatory carcinoma, LABC infiltrating the skin or NAC, previous RT  Relative contraindications to NSM: obesity (BMI >30 kg/m <sup>2</sup> ), large breasts with severe ptosis, and active smoking  Prepectoral or submuscular decision using algorithm including anamnestic, morphological, functional, and oncologic criteria; digital mammography to predict postmastectomy skin flap thickness; final decision in operating room based on flap thickness and perfusion	Not used	Prepectoral micro-polyurethane-foam-coated implants (microthane) without ADM in subcutaneous plane	Anatomical textured implants, submuscular-subfascial pocket dissection  Total coverage of implant beneath the pectoralis major and serratus anterior	Mean operative time: unilateral 247 vs. 319 min, p<0.001; bilateral 306 vs. 368 min, p=0.041  Length of hospital stay: no difference  Overall major complications: no difference  NAC recurrence 0% vs. 1.05%; regional recurrence 1.2% vs. 2.1%; 1 DM (brain) in submuscular group  <u>PRO for QoL at 6 months after surgery</u>  Aesthetics: excellent 65.6% vs. 11.3%, good 26.6% vs. 21.0%, satisfactory 6.3% vs. 46.8%, insufficient 1.6% vs. 12.9%, poor 0 vs. 8.1%, p<0.001  Chronic pain in pectoral region:	Other: use blunt dissection to separate skin flap from mammary gland, preserving medial perforators; use perfusion testing

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						assessment using indocyanine green dye fluoroangiography  NSM usually by radial incision on external quadrants, with axillary or IMF in select cases				<p>none 50% vs. 12.9%, very mild 29.7% vs. 8.1%, mild 12.5% vs. 12.9%, tolerable 6.3% vs. 43.5%, distressing 1.6% vs. 17.7%, very intense 0 vs. 4.8%, <math>p&lt;0.001</math></p> <p>Shoulder dysfunction/ impaired arm motility: 4.7% vs. 40.3%, <math>p&lt;0.001</math></p> <p>Skin sensibility: 48.4% vs. 29.0%, <math>p=0.025</math></p> <p>Sexual/ relationship life compromised: 28.1% vs. 38.7%, <math>p=0.208</math></p> <p>Contralateral operation for symmetry in unilateral NSM: 3.6% vs. 100%, <math>p&lt;0.001</math></p>	
Scardina, 2022 (135)	Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy	2018-2021	Prepectoral vs. submuscular after NACT, mostly NSM (92%)  Single institution	90 prepectoral, 56 submuscular	Retrospective  Follow-up 33 months submuscular and 20 months prepectoral	Histologically proven breast cancer, use of NACT, conservative mastectomy (NSM or SSM), immediate implant  Excluded: inflammatory or LABC, BMI >30	Not used	Polytech implant with micro-polyurethane foam-coated shell surface that does not require ADM	Beneath the pectoralis major muscle	<p>Mean operating time 244 vs. 300 min</p> <p>Implant loss 1.11% vs. 1.80%</p> <p>NAC recurrence 0% vs. 1.78%</p> <p>LR 1.11% vs. 3.57%</p>	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						kg/m <sup>2</sup> , previous RT, active smoking  Digital mammogram to assess breast tissue coverage and potential flap thickness, quality, vascularization  NSM 135 pts, SSM 8 pts, bilateral skin-reducing mastectomy 3 pts  Therapeutic unilateral 51.4%, bilateral 48.6%  Type of reconstruction based on flap thickness and perfusion assessed with indocyanine green dye fluoro-angiography				DM 1.11% vs. 1.78%  Symmetrization procedure required in 28% vs. 82% (p=0.03) of pts with unilateral mastectomy	
Prepectoral vs. subpectoral (submuscular or dual-plane)											
Darrach, 2021 (336)	Johns Hopkins University, Baltimore, MD	2017-2018	Prepectoral vs. subpectoral (submuscular or dual-plane); in-patient and prescribed opioid use  Single institution, 5 oncologic surgeons, 6	133 pts prepectoral, 89 pts subpectoral (complete or dual-plane)	Retrospective	Pts with breast cancer (except 1 prophylactic due to BRCA2 mutation)  Immediate expander-based reconstruction; all pts ordered acetaminophen, celecoxib, and gabapentin, and subpectoral patients	All prepectoral pts  Subpectoral in pts with dual-plane placement	Placement between mastectomy flap and pectoralis major  ADM either complete coverage or shelf for the lower pole; secured to	Placement beneath the plane of the pectoralis major and atop the pectoralis minor/chest wall  Either full coverage with pectoralis major and serratus	Opioid use in first 24 h: 22.2 vs. 44.5 OME, p=0.003  Opioid prescribed on discharge: 308.42 vs. 336.99 OME, p=0.3197	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
			plastic surgeons			cyclobenzaprine; narcotics as needed  Excluded if preoperative opioids, return to operating room or ICU  Prepectoral group had more NSM (56% vs. 27%)  59% vs. 51% bilateral mastectomy		expander tabs and chest wall	anterior or partial with pectoralis major superiorly and ADM shelf inferiorly		
Kraenzlin, 2021 (337)	Johns Hopkins Hospital, Baltimore, MD	2016-2018	Prepectoral vs. subpectoral (total submuscular or dual-plane) complications  5 general surgeons, 6 plastic surgeons, single institution	169 pts (308 breasts) prepectoral; 117 pts (184 breasts) subpectoral	Retrospective  Multilinear regression for infection	Tissue expanders  56.2% vs. 28.2% NSM  Bilateral mastectomy 59.2% vs. 53.0%  Prepectoral had lower weight mastectomies (565 vs. 656 g)  Technology such as fluorescein or indocyanine green for mastectomy skin flap perfusion were not used	100% prepectoral covering either anterior surface or lower pole (ADM secured to expander tabs and chest wall); 65.8% subpectoral (cases with partial subpectoral coverage)	In space between mastectomy flap and pectoralis muscle with no manipulation of pectoralis major  4/6 surgeons determined safest plane by visual assessment of flaps, mastectomy weight, BMI, smoking status, comorbidities	Implant between pectoralis major and pectoralis minor/chest wall with surgical elevation of pectoralis major  Partial subpectoral coverage along with ADM or total subpectoral coverage with elevation of pectoralis major and serratus anterior	Clinic visits before definitive reconstruction 6.4 vs. 8.8, $p<0.01$ ; anesthesia time lower for prepectoral ( $p<0.01$ ), partial necrosis rates higher (21.7% vs. 10.9%, $p<0.01$ ; mastectomy flap 15.6% vs. 7.1%, $p<0.01$ ; NAC 10.9% vs. 4.9%, $p=0.02$ ; return to operating room for debridement 6.2% vs. 3.8%, $p=0.26$ )  Infection 11.0% vs. 17.4%, $p=0.045$ , $p=0.21$ after logistic regression to adjust for mastectomy weight	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
										Hematoma 2.0% vs. 4.9%, p=0.07 Cellulitis 7.8% vs. 12.5%, p=0.09	
Prepectoral vs. subpectoral (dual-plane)											
Sbitany, 2017 (69)	University of California, San Francisco	2012-2016	Prepectoral vs. dual-plane after NSM  5 surgical oncologist for mastectomies, 1 reconstructive surgeon	51 prepectoral (84 breasts)  115 partial submuscular (dual-plane) (186 breasts)	Retrospective  Follow-up 12.5 ± 5.1 months submuscular and 11.1 ± 5.8 months prepectoral	Immediate expander-implant reconstruction after NSM using superior periareolar incision  Prepectoral if intraoperative assessment of adequate and viable skin flaps, skin envelope not excessively large or ptotic, oncologically safe; if skin flap thin then used little or no expansion at placement and waited 3 weeks before starting  Dual-plane if threatened or exceedingly thin skin flaps, tumour within 1 cm of chest wall, stage 3 or 4 or inflammatory  Same incisions used to replace expander with implant, unless PMRT was used	ADM in all pts: for prepectoral expander ADM covered anterior surface and posterior lower pole; for dual-plane expander ADM covered lower half  Author now fenestrates ADM to allow more rapid integration and fluid drainage (may have not occurred in earlier pts)	No muscle manipulation; location of inframammary suture line marked about 0.5 cm below planned IMF location; ADM placed in breast pocket and sutured in place with double layer used at lower pole; expander inserted; ADM folded up and over the entire anterior surface of the expander and sutured to chest wall	After NSM, pectoralis major lifted off chest wall from its lateral border and pocket created; inferior border released at its insertion to ribs VI and VII; muscle covered upper half of tissue expander; ADM used to cover and support lower half of expander and sutured to lower released border of pectoralis muscle and to chest wall about 1 cm below planned IMF and carrying onto the serratus muscle  Partial submuscular /partial ADM	Overall complications for initial surgery 17.9% vs. 18.8%, p=0.49  Revision operation for IMF repositioning: 2.4% vs. 3.2%	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
									coverage (dual-plane)		
Sinnott, 2018 (338)	South Nassau Communities Hospital, Oceanside, New York  Bridgeport Hospital-Yale New Haven Health, Bridgeport, Connecticut	2010-2017	Prepectoral vs. partial subpectoral; impact of PMRT on outcomes  Single plastic surgeon	274 (426 breasts) prepectoral (241 pts or 370 breasts without PMRT, 45 pts or 56 breasts with PMRT)  100 pts (163 breasts) partial subpectoral (87 pts or 140 breasts without PMRT, 21 pts or 23 breasts with PMRT)	Retrospective  Multivariable logistic regression for outcome of capsular contraction only in PMRT pts  Mean follow-up subpectoral 31.9 ± 22.4 months and 19.0 ± 16.9 months	Direct-to-Implant (97.2% vs. 72.4%) or expander-implant  Unilateral (% breasts): prepectoral 44.5%, subpectoral 37%  Prophylactic (% breasts): prepectoral 45.5%, subpectoral 37.4%  No preoperative RT; TND >2 cm on MRI, negative retroareolar biopsy  Wise-pattern or modified-Wise pattern incisions only  NAC harvested as full thickness graft and grafted to new location  PMRT to stage III cancers and selectively to stage II cancers with 1-3 positive nodes	Strattice ADM in all pts	Deepithelialized dermal flap was created from surplus lower-pole breast skin and soft tissue; ADM sewed to medial aspect of pocket, superior aspect of pectoralis major, and superior aspect of inferior deepithelialized dermal flap; implant placed in pocket and ADM sewed down to the chest wall, serratus fascia, and inferior deepithelialized dermal flap	Deepithelialized dermal flap was created from surplus lower-pole breast tissue; pectoralis major muscle dissected off the chest wall and inferior aspect sewed to the superior aspect of the inferior deepithelialized dermal flap; a lateral Strattice ADM patch sewn to the dermal flap, pectoralis major muscle, and lateral chest wall fascia; implant placed in the pocket which was closed by placing the last lateral sutures into the ADM.	Capsular contracture (4-grade Baker scale) 5.2% vs. 9.8%, p=0.0588; multivariate analysis p=0.198	Note: <50 pts in each PMRT groups so exclude this analysis  <25 events so exclude multivariate results except capsular contraction; groups not equivalent and high portion prophylactic so exclude other non-adjusted results
Copeland-Halperin, 2019 (136)	Northern Virginia	2015-2017	Prepectoral vs. dual-plane postoperative opioid use	94 prepectoral (37 direct-to-implant and 56 expander, 1 both), 58 dual-plane (6 direct-to-	Retrospective  Multivariate regression for opioid use	Excluded pts with history of substance abuse, chronic pain, opioid medication  Flaps evaluated with SPY fluorescent	AlloDerm or DermACEL in all pts	Not reported	Not reported	No significant differences in age, BMI, hypertension, diabetes, tobacco use	Groups similar so unadjusted results may be valid; <25 events so does not meet inclusion



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
			2 surgeons, one hospital	implant, 52 expander)		indocyanine green imaging				Median postoperative opioid use: 4 vs. 7 days, p=0.009; adjusted IRR=0.68, p=0.016  Opioid refills 10.6% vs. 29.3%, p=0.005; adjusted OR=0.34, p=0.027  Any complication 0% vs. 5.3%, p=0.298	criteria for multivariate analysis
Avila, 2020 (140)	MedStar Georgetown University Hospital, Washington, DC, or New York University Langone Health	2014-2018	Prepectoral vs. subpectoral after NSM  6 breast surgeons, 7 plastic surgeons, 1 institution	228 pts (405 breasts): 202 subpectoral, 203 prepectoral	Retrospective  Mixed-effects multivariate logistic regression only for composite outcome of any complications	NSM and implants  86.2% bilateral mastectomy  Direct-to-implant 73.9% vs. 33.2%  Prepectoral use increased over time and subpectoral decreased  Prepectoral not used if active smoking, tumour abutting pectoralis  Underfill expanders or delay reconstruction if question of poor flap perfusion intraoperatively  All prepectoral NSM and consecutive subpectoral until	ADM (DermACELL ) in all/most pts  Method of use varied by surgeon: most used anterior ADM wrap with a slip of pectoralis muscle (or none) to minimize superior pole contour abnormalities; others used anterior wrap with posterior spanning sutures on	Not reported	Not reported	Overall complications (composite complications including NAC necrosis, skin flap necrosis, infection, wound dehiscence, hematoma, seroma): 5.91% vs. 9.41%, p=0.1842; multivariate OR=0.61, p=0.190  Ischemic complications (including nipple loss due to necrosis) 0.49% vs. 2.97%, p=0.015  Nipple necrosis 0.49% vs. 2.97%, p=0.0676	Other: evolution of technique to preserve subdermal vascular supply, retraction is gentle and calculated, careful dissection in supra-areolar region has improved results.  Indocyanine green to assess the mastectomy flap vascular supply used earlier in case series but decreased as

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						<p>same number as prepectoral pts</p> <p>Meticulous attention during NSM to stay within plane of dissection in the anterior breast capsule, pointing heat sources away from mastectomy flaps, and limiting over-retraction</p>	the back table			<p>Mastectomy flap necrosis 0.49% vs. 5.45%, p=0.0030</p> <p>Nipple loss 1.48% vs. 3.96%, p=0.14 (due to disease 1.48% vs. 0.99%, p=1.0; due to necrosis 0 vs. 2.97%, p=0.015)</p> <p>Unintended reoperation within 30 days: 3.94% vs. 8.42%, p=0.0663; not significant in multivariate analysis</p> <p>No significant differences in infection, hematoma, seroma, implant loss/exchange</p>	experience improved
Banuelos, 2020 (137)	Mayo Clinic, Rochester, Minn.	2012-2016	Prepectoral vs. subpectoral complications in obese pts  Five plastic surgeons and four breast surgeons, 1 institution	<p>110 pts (189 breasts) prepectoral</p> <p>83 pts (147 breasts) subpectoral</p> <p>Prepectoral: 131 breasts BMI &lt;35 kg/m<sup>2</sup>, 58 BMI ≥35 kg/m<sup>2</sup></p> <p>Subpectoral: 103 breasts</p>	Retrospective  Median follow-up 17 months prepectoral and 18.1 months subpectoral	<p>BMI ≥30 kg/m<sup>2</sup></p> <p>Immediate 2-stage implants using textured expanders initially filled to 50% to 75% capacity with air then switched to saline after 2 weeks</p> <p>Bilateral prophylactic 11% vs. 18% of pts</p> <p>Prophylactic mastectomy 28.8%</p>	<p>ADM used in 93.7% vs. 93.2% of breasts</p> <p>Expanders completely wrapped with thick ADM with fenestrations</p>	At discretion of plastic surgeon and pt  Intraoperative indocyanine green chorioangiography using the SPY system in 57.7%	Intraoperative indocyanine green chorioangiography using the SPY system in 34%	<p>Any complication 19.6% vs. 20.4%, p=0.773.</p> <p>3.2% vs. 3.4% hematomas, 5.3% vs. 3.4% seromas, 2.7% vs. 4.1% wound dehiscences, 3.2% vs. 4.1% skin flap necrosis, 7.9% vs. 11.6% infections, 6.4% vs. 8.2% device losses (explantation); all</p>	<p>Methods indicate multivariate analysis but cannot find results</p> <p>Rate of bilateral cancers (33% vs. 30%) is extremely high</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
				BMI < 35 kg/m <sup>2</sup> , 44 BMI ≥35 kg/m <sup>2</sup>		vs. 36.7% of mastectomies  42.9% of mastectomies were NSM vs. 21.1%				differences not significant  Authors found some complications increase with BMI, with cutoff around 35 to predict increased risk	
Gabriel, 2020 (66)	Loma Linda, California; Winfield, Illinois; Portland, Oregon; Vancouver, Washington	2009-2017	Prepectoral vs. dual-plane complications in pts with high BMI  Single surgeon	Prepectoral June 2013-October 2017; 68 pts (129 breasts)  Dual-plane July 2009-August 2017; 65 pts (128 breasts)	Retrospective  Stepwise multivariate logistic regression for outcome of any complication  Average follow-up 24.1 ± 2.0 months dual-plane vs. 22.7 ± 3.5 months prepectoral	Oncologic pts with immediate reconstruction  BMI >30 kg/m <sup>2</sup>  Excluded from study if direct-to-implant, delayed, revision surgery, hemoglobin A1c >7.5%, active smoking  Excluded from prepectoral if not clear margins, extensive skin involvement, chest wall involvement, inflammatory  In early part study additional prepectoral exclusion were BMI >40 kg/m <sup>2</sup> with comorbidities, prior RT, immune-compromised, size > 5 cm, deep tumours, late-stage, chest wall involvement, grossly	AlloDerm Select ADM in all pts	1 or 2 pieces AlloDerm (1 AlloDerm Ready to Use, plus if needed 2 piece Contour AlloDerm; majority or all of expander was wrapped with ADM before insertion into prepectoral space  Initially filled with air to 70-80% capacity, then exchanged for saline during expansion starting 14-21 days after operation  Closed negative-pressure therapy for 7 days	1 large piece ADM sutured to edge of elevated pectoralis major muscle and anchored to IMF  Expander filled to 70% to 80% capacity with saline then expanded starting 14-21 days after operation  Closed negative-pressure therapy for 7 days	Dual-plane offered to pts with oncologic contraindications to prepectoral and had more RT and chemotherapy  Any complication 14.7% vs. 25.8%, p=0.030; p=0.013 in multivariate analysis  Capsular contraction 0.8% vs. 7.0%, p=0.019; infection 2.3% vs. 9.4%, p=0.018; seroma 3.1% vs. 13.3%, p=0.003  8.6% of dual-plane pts were converted to prepectoral	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						<p>positive axillary involvement</p> <p>Decision on immediate reconstruction based on mastectomy flap perfusion (delayed if poor perfusion)</p> <p>RT if used was applied to fully inflated or partially deflated expander</p>					
Kim, 2020 (339)	Ewha Womans University Mokdong Hospital, Seoul, Korea	2015-2020	<p>Prepectoral vs. dual-plane complications</p> <p>Single institution, single plastic surgeon</p>	53 prepectoral, 114 subpectoral	Retrospective Hierarchical regression analysis controlling for demographic characteristics and ADM size for outcome of hemovac duration and pain score	<p>Unilateral immediate direct-to-implant with ADM</p> <p>Demographics similar in the two groups, except BMI higher in prepectoral group (mean 23.92 vs. 22.65 kg/m<sup>2</sup>, p=0.01)</p> <p>Excluded previous BCS, RT</p> <p>NSM used (88.7% vs. 88.6%) unless preoperative evidence of nipple involvement; nipple excised if intraoperative frozen biopsy found malignant cells in tissue under the</p>	MegaDerm or CG CryoDerm ADM in all pts	No muscle manipulation; implant wrapped to cover entire anterior surface and as much posterior surface as single large ADM sheet allowed or using 2 small sheets; placed in prepectoral location	<p>Inferior costal origin of pectoralis major muscle detached; ADM placed between pectoralis major muscle and IMF and sutured; ADM used to cover inferior pole of implant; implant placed in subpectoral-ADM pocket</p>	<p>Pts received postoperative patient-controlled analgesia for 48 h</p> <p>Pain reported by pt using visual analogue scale at 12 h, 24 h, 7 days: mean pain score at 12 h 4.49 vs. 4.10, p=0.18; at 24 h 2.66 vs. 2.36, p=0.29; at 7 days 1.08 vs. 0.80, p=0.14</p> <p>Days to drain removal: 11.09 vs. 14.93 days, p&lt;0.01</p> <p>No significant difference in total complications or specific compilations</p>	Pain may have been masked by patient-controlled analgesia

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						<p>nipple and defined as SSM</p> <p>Lateral straight radial incisions and periareolar incisions; care to maintain well vascularized subcutaneous tissue layer</p> <p>Decision of prepectoral or dual-plane made considering intraoperative assessment and discussion with pt</p>				Regression model not suitable for pain scores	
Nealon, 2020 (340)	Massachusetts General Hospital, Boston, Mass.  5 surgical oncologists and 2 plastic surgeons	2014-2018	Prepectoral with Vicryl or Vicryl + ADM  Subpectoral with ADM or Vicryl	<p>114 prepectoral vs. 142 subpectoral with various mesh and/or ADM</p> <p>104 ADM vs. 67 Vicryl vs. 85 Vicryl + ADM</p> <p>Prepectoral: 0 ADM alone, 30 Vicryl, 85 Vicryl + ADM</p> <p>Subpectoral: 104 ADM, 37 Vicryl, 0 Vicryl+ ADM</p>	<p>Retrospective</p> <p>Univariate analysis</p> <p>Penalized logistic regression</p>	Direct-to-implant	ADM (AlloDerm or FlexHD), Vicryl (synthetic)	Prepectoral: Vicryl mesh folded into a pocket then used to envelop and support the silicone implant; in cases where ADM was also used it was fashioned on the anterior side of the Vicryl pocket and sutured along the IMF toward the axilla for added support	Subpectoral: pectoralis major muscle elevated along inferior and lateral margin, ½ sheet Vicryl or ADM sutured on each side along IMF and lateral mammary crease; implant placed in pocket	<p>Prepectoral vs. subpectoral</p> <p>Overall complications 14.0% vs. 19.7%, p=0.151; penalized regression OR=0.85 (95% CI=0.25-2.75), p=0.785</p> <p>Revision 10.5% vs. 28.2%, p&lt;0.0001; penalized regression OR=0.35 (95% CI=0.08-1.31), p=0.122</p> <p>&lt;25 events for individual complications, so data not extracted</p>	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
Belmonte, 2021 (341)	University of Virginia, Charlottesville, VA	2017-2019  Control 2015-2019	Prepectoral vs. partial submuscular  1 surgeon prepectoral; 4 surgeons partial submuscular	Prepectoral: 131 pts, 224 breasts  Partial submuscular: 347 pts, 535 breasts	Retrospective	Prepectoral: All consecutive pts (2017-2019) with immediate expander-implant reconstruction  Control was partial submuscular (2015-2019)  NSM 36% vs. 31%; 57% vs. 63% SSM of breasts  Bilateral 71% vs. 54% of pts  41% vs. 35% of mastectomies were contralateral	Prepectoral: used confluent contoured Flex HD meshed intraoperatively 1:1.5  Partial submuscular : with AlloDerm RTU or Flex HD either confluent or perforated	Not reported	Not reported	On breast basis  Major infection 2% vs. 3%, p=0.37  Minor infection 5% vs. 6%, p=0.89  Seroma 6% vs. 10%, p=0.054  Explantation 5% vs. 6%, p=0.77  Skin necrosis 10% vs. 8%, p=0.34  Wound dehiscence requiring repair 11% vs. 6%, p=0.028; but surgeon used a lower threshold for repair in prepectoral cases	Multinomial logistic regression only for aesthetics; plane of implant not included in analysis
Bozzuto, 2021 (342)	MedStar Georgetown University Hospital, Washington, DC	2015-2017	Prepectoral vs. subpectoral after NSM: postoperative pain during hospital stay and opioid use  Single institution, 7 breast surgeons (2 did 88% of cases)	73 pts prepectoral, matched to 73 pts subpectoral (dual-plane?)	Retrospective  Matched by age and stage  Multivariate analysis	NSM, immediate reconstruction with implant or expander-implant  Mostly pts with cancer; 9.6% vs. 15.1% of pts prophylactic  80.8% vs. 75.3% bilateral mastectomy  ≈48% vs. 53% of all mastectomies were prophylactic	Used in both groups, details not reported	Pt selection at discretion of reconstructive surgeon preoperatively and depending on mastectomy flap perfusion  Small slip (<2 cm) pectoral muscle raised in some pts as part of ADM attachment	Behind pectoralis muscle, additional ADM support  Standard subpectoralis dissection by dividing the junction of serratus anterior and pectoralis major border to the sternal border, IMF,	On multivariate analysis: prepectoral group had lower postoperative pain on visual analogue scale (3.94 vs. 5.25, p<0.001), in-hospital opioid use until hospital discharge (17.14 mg OME vs. 63.03 mg, p=0.03), length of stay (21.36 h vs. 26.28 h, p=0.02)	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
									and second costal cartilage		
Haddock, 2021 (343)	University of Texas Southwestern Medical Center	2012 onward (≈2020)	Prepectoral vs. dual-plane perioperative outcomes  Single institution, 3 breast surgeons, 2 reconstructive surgeons	102 prepectoral matched to 102 pts subpectoral	Retrospective, propensity-score matched; multivariate analysis	Immediate bilateral tissue expanders; excluded direct-to-implant  Standard of care by reconstructive surgeons switched from dual-plane to prepectoral reconstruction in 2017, but without changes in mastectomy technique; <5% were poor candidates for prepectoral reconstruction (high BMI, smoking, large pendulous breasts, poor tissue quality) and decision made considering intraoperative flap quality	AlloDerm; see next columns	Tent-type approach with single sheet of AlloDerm covering anterior aspect of expander; deflated expander positioned under the AlloDerm avoiding the skin then AlloDerm sutured to pectoralis major muscle; intraoperative saline expansion up to but not after detectable tension on skin closure	Single sheet of AlloDerm for dual-plane reconstruction; intraoperative saline expansion limited by skin flap tension	Overall perioperative complications 32% vs. 31%, p=1.000  Major complications requiring surgery 21% vs. 21%  Hematomas, seromas, impaired wound healing, infection not significantly different  No increased risks of prepectoral reconstruction in multivariable analysis	
Plachinski, 2021 (344)	The Medical College of Wisconsin, Wauwatosa, Wis.	2016-2019	Prepectoral vs. subpectoral (partial or dual-plane) complications  Single institution	83 pts vs. 103	Retrospective  Mean follow-up 15.59 months prepectoral and 21.39 months subpectoral  Logistic regression modeling	Therapeutic or prophylactic mastectomy, ≥2 y follow-up  Immediate expander or permanent implant; decision based on clinical assessment	AlloDerm ADM  Prepectoral: 69.9% with complete or anterior coverage  Subpectoral: 90.3% with ADM for	Subcutaneous pocket, use of ADM depending on quality of tissue coverage and surgeon preference	Partial muscle coverage with ADM to coverage the lower pole	No difference in major complications, 30.1% vs. 30.1%, p=0.997  Minor complications 21.7% vs. 7.8%, p=0.006 mostly due to seroma: seroma 20.5% vs. 4.9%, p=0.001;	Authors have since implemented steps to try to reduce seroma

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						<p>Skin flap viability assessed with SPY angiography</p> <p>Mean BMI 28.12 vs. 26.14 kg/m<sup>2</sup>, p=0.023; mean mastectomy weight 559.6 g vs. 428.4 g</p>	coverage of lower pole			<p>prepectoral had shorter hospital stay (p=0.007), fewer visits for expansion (p&lt;0.001), less animation deformity (p=0.005); less muscle relaxant prescriptions (13.7% vs. 86.6%, p&lt;0.001); similar pain score (p=0.65), capsular contraction (p=0.791), infections p=0.826)</p>	
Ribuffo, 2021 (345)	Italy	2010-2018	<p>Prepectoral vs. dual-plane complications</p> <p>7 breast-dedicated centres</p> <p>Prepectoral approach adopted in 2015 on</p>	<p>172 pts (207 breasts) prepectoral</p> <p>470 pts (509 breasts) dual-plane</p> <p>Prepectoral: 137 unilateral therapeutic, 35 bilateral (therapeutic or prophylactic)</p> <p>Dual-plane: 431 unilateral therapeutic, 39 bilateral therapeutic or prophylactic</p>	<p>Retrospective</p> <p>Minimum follow-up 1 year</p> <p>Mean follow-up 27.8 months dual-plane and 16.5 months prepectoral</p>	<p>Pts with breast cancer, immediate direct-to-implant reconstruction</p> <p>Prepectoral approach adopted in 2015 on</p> <p>Small-medium size breasts and ptosis grade 1-2 by Regnault scale</p> <p>Exclude BMI &gt;30 kg/m<sup>2</sup>, age &gt;65 years, active smoking, previous breast surgery, comorbid conditions (uncontrolled diabetes, immunogenic disorders,</p>	ADM in all pts	<p>Complete coverage with preshaped Strattice or bovine pericardium-derived ADM using overlay tenting technique; implant placed inside ADM then placed in prepectoral space and sutured to muscular fascia</p>	<p>ADM hammock to cover lower lateral pole of implant</p> <p>Pectoralis major muscle dissected and detached from chest wall to create retropectoral pocket; implant put in place, SurgiMend ADM used as sling to cover lower lateral pole of implant and suture to pectoralis major muscle</p>	<p>Complications 20.77% vs. 32.02%, p=0.026</p> <p>Seroma 4.34% vs. 11.2%, p=0.004</p> <p>Hematoma 1.45% vs. 4.71%, p=0.045</p> <p>Surgical site infection 1.93% vs. 3.93%, p=0.2518</p> <p>Wound dehiscence not different, p=0.7893</p> <p>Animation deformity 0% vs. 68.7%</p> <p>Capsular contracture 8.7%</p>	



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						<p>congestive heart failure, cardiovascular diseases including hypertension, pulmonary disease, chronic hepatic diseases), previous RT</p> <p>Pt characteristics well balanced including reasons and type of mastectomy and use of chemotherapy</p>				<p>vs. 13.87%, p=0.1818</p> <p>Implant removal 2.42% vs. 3.93%, p=0.3766</p> <p>Aesthetics by blinded evaluators better in prepectoral: bilateral prepectoral 8.3, unilateral prepectoral 7.2, bilateral dual-plane 6.8, unilateral dual-plane 5.3</p>	
Walker, 2021 (346)	Wake Forest Baptist Hospital, Winston-Salem, NC	2014-2018	<p>Prepectoral vs. subpectoral complications in pts stratified by BMI</p> <p>Reconstruction by a single surgeon, switched from subpectoral to prepectoral in summer 2016</p>	<p>92 pts prepectoral, 103 pts subpectoral</p> <p>BMI 25-35 kg/m<sup>2</sup>: 54 pts and 60 pts; not enough pts in other BMI groups</p>	<p>Retrospective</p> <p>Mean follow-up 10.9 months prepectoral and 16.1 months subpectoral</p>	<p>Implant-based reconstruction (with or without expander depending on preoperative and desired breast size); delayed or immediate depending on pt circumstances (RT, preference, flap viability)</p> <p>Most pts bilateral reconstruction (89% vs. 96%)</p> <p>BMI higher in prepectoral pts (30.2 vs. 27.8 kg/m<sup>2</sup>, p=0.0088)</p>	<p>Prepectoral: wrapped entire prosthesis</p> <p>Subpectoral: used inferolateral ADM sling</p>	<p>ADM wrapped entire prosthesis, sewn to itself on the posterior surface, then inserted in breast pocket just superficial to pectoralis major muscle; sutured to chest wall; expander if used was filled to 50-55% of total volume</p>	<p>Pocket developed using electrocautery in loose areolar tissue plane between pectoralis major and minor; inferolateral sling by suturing ADM to chest wall at IMF and lateral breast curve then inserted prosthetic; expander if used was filled to 25%-30% of total volume</p>	<p>Any major complication: 10.9% vs. 4.9%, p=0.18 (no seroma or flap necrosis; infection 5.4% vs. 3.9%, hematoma 2.2% vs. 0%; asymmetry 1.1% vs. 0%, implant exposure 2.2% vs. 1.0%)</p> <p>Any minor 25.0% vs. 22.3%, p=0.74 (seroma 6.5% vs. 8.7%; infection 16.3% vs. 12.6%; hematoma 0% vs. 1%, flap necrosis 0% vs. 1.9%, asymmetry 9.8% vs. 2.9%)</p>	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
Holland, 2022 (347)	University of California, San Francisco	2012-2019	Prepectoral vs. submuscular opioid use after reconstruction  Single surgeon	117 pts prepectoral 211 pts subpectoral	Retrospective  Multivariate linear regression to control for confounding for outcome of opioid use and NRS pain scores	NSM (76.9% vs. 88.6%) or SSM plus lymph node surgery as indicated; immediate reconstruction with tissue expanders  Excluded if preoperative OME $\geq 60$ , methadone use, fibromyalgia, concurrent surgeries (hysterectomy, fat grafting)  34.2% vs. 34.6% bilateral  Reason for mastectomy not reported, but 62.4% vs. 78.2% had either SLNB or ALND	ADM in both groups: prepectoral to wrap entire expander, subpectoral as sling	Choice of plane directed by preoperative discussion and intraoperative skin flap evaluation  ADM to wrap entire expander	ADM as a supportive sling between IMF and inferior border of pectoralis major muscle	Prepectoral had lower opioid use (45.0 vs. 80.0 OME, $p < 0.001$ ; $p = 0.048$ on multivariable analysis), maximum pain scores while admitted (5/10 vs. 7/10, $p < 0.004$ ; $p = 0.001$ on multivariable analysis)  Pain Score using Numerical Rating Scale (NRS), with 0 is no pain and 10 the worst imaginable pain	
Houvenaeghel, 2024 (154)  See also Houvenaeghel, 2022 (354)  NEW	Marseille, France  M-IBR-PPRP-IPC 2022-014	2019-2023	Prepectoral vs. subpectoral complications and satisfaction  11 surgeons, surgeons were significantly different between groups	324 prepectoral (increased from 3.1% in 2019 to 61.7% in 2023) 529 subpectoral	Retrospective  Univariate and multivariate (binary logistic regression) for complications	Immediate implant-based reconstruction (100% vs. 94.7% direct-to-implant) 66.4% vs. 44.6% NSM; 33.0% vs. 54.8% SSM  108 bilateral prophylactic and 61 bilateral primary breast cancer, 1 bilateral for LR	Resorbable synthetic TIGR Matrix 9 (1.7%) subpectoral, 176 (54.3%) prepectoral  Prepectoral use varied by year: 20%, 14%, 92%, 85%, 6.7% for years 2019 to 2023;	Use increased with time (compared with 2019, OR=209.79 for prepectoral in 2023)  Many surgeons had strong preference for placement	Not reported (no information on submuscular location)	Complications within 90 days of surgery (all or Grade 2-3; Clavien Dindo classification)  • Complications 20.4% vs. 15.3%, $p = 0.036$ ; regression OR=0.846, $p = 0.529$ • G2-3 complications 13.0% vs. 9.8%, $p = 0.097$ ;	In regression analysis:  Smoking, larger breasts (cup size >C), higher ASA status, mesh use, incision (areolar, inverted T) had higher complications  Smoking, mesh use, mastectomy

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						Implant position and mesh use was at surgeon discretion	note dramatic fall in 2023 due to reports of negative impact on complication although this study data do not support this conclusion			regression OR=0.916, p=0.784 • Implant loss 6.5% vs. 4.7%, p=0.271 • Reoperation 10.8% vs. 7.4%, p=0.056  Pt satisfaction: very good/good 75.9% vs. 73.1%  Incision: central 33.0% vs. 50.9%; inferior fold 42.6% vs. 16.3%; rest similar	weight >300 g, diabetes increased grade II-III complications
Asaad, 2023a (348)	Corewell Health, Grand Rapids, MI, USA  MD Anderson Cancer Center, Houston, Texas, USA	2017-2019	Effect of obesity on prepectoral vs. subpectoral outcomes	209 pts and 284 breasts: 184 prepectoral, 100 subpectoral	Retrospective PROs using BREAST-Q  Univariate and multivariable marginal Cox proportional hazard models to calculate hazard ratios for risk factors	BMI $\geq 30$ kg/m <sup>2</sup> at time of immediate reconstruction with expander placement, with or without implant exchange  Exclude direct-to-implant or delayed-immediate, or change in plane  Plane was at surgeon's discretion  NSM 4.9% vs. 4%, SSM 94.6% vs. 96%  Immediate 92.9% vs. 90%  Expander-implant 72.3% vs. 62%;	ADM use 95.1% vs. 70%  AlloDerm, Surimend, or Dermacell, depending on surgeon preference	Above pectoralis muscle	Dual-plane or submuscular	• Overall complications 37% vs. 50% p=0.047 • Device explantation 12.5% vs. 25%, p=0.008; multivariate HR=0.51, p=0.034 • Infections 25% vs. 38%, p=0.024; multivariate HR=0.61, p=0.022 • Other outcomes (wound dehiscence, necrosis, implant exposure, capsular contracture, seroma, hematoma) not	Prepectoral had less complications, infections, explanations in obese pts  No difference in PROs, but noted that there was no preoperative data

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						<p>expander alone 27.7% vs. 38%</p> <p>ADM use: AlloDerm 71.7% vs. 61%, Surgimend DermACELL 15.2% vs. 7%, Dermacell 8.2% vs. 2%; none: 4.9% vs. 30%</p>				<p>significantly different</p> <ul style="list-style-type: none"> <li>• Satisfaction With Breast 45.50 vs. 41.57, p=0.469</li> <li>• Psychosocial Well-Being 39.30 vs. 39.43, p=0.915</li> <li>• Sexual Well-Being 17.0 vs. 17.17, p=0.931</li> <li>• Subset with BMI <math>\geq 35</math> kg/m<sup>2</sup> (38 vs. 22 pts): any breast-related complication 38% vs. 68%, p=0.032; explantation 16% vs. 32.3%, p=0.13</li> </ul>	
Asaad, 2023b (349)	<p>Corewell Health, Grand Rapids, MI, USA</p> <p>University of Texas M. D. Anderson Cancer Center, Houston, TX, USA</p>	2018-2019	Prepectoral vs. subpectoral (dual-plane) complications and satisfaction	481 pts, 694 breasts: 573 prepectoral, 121 subpectoral	Retrospective Univariate and multivariable frailty models to calculate HR for risk factors at surgery; PRO using BREAST-Q scales of Satisfaction with Breast, Psychosocial Well-Being, and Sexual Well-Being	<p>2-stage implant-based reconstruction</p> <p>Excluded direct-to-implant, delayed immediate, switch in planes</p> <p>Plane was based on surgeon practice</p> <p>Immediate reconstruction in 96% in both groups</p>	<p>ADM used in 97.2% vs. 65.3%</p> <p>AlloDerm 76.4% vs. 58.7%, Surgimend 13.6% vs. 5.8%, DermACELL 7.2% vs. 0.8% based on surgeon preference</p>		Dual-plane	<p>Overall complications 29.3% vs. 28.9%, p=0.887</p> <p>Explantation 11.3% vs. 14%, p=0.436</p> <p>Rates for individual complications were similar (no significant differences)</p> <p>Tissue expander placement complications: any complications 26% vs. 25.6%, no</p>	<p>PROs, 33.7% response rate; 121 prepectoral and 28 subpectoral (not enough to meet our inclusion criteria), no differences</p> <p>Median time to permanent implant exchange shorter in prepectoral group, 150 vs.</p>

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
										differences in any complication  Outcomes of permanent Implants: Any complication 3.3% vs. 3.3%, no significant differences in any	200 days, p<0.001
Hassan, 2024 (350)	University of Texas MD Anderson Cancer Center	2016-2019	Prepectoral vs. subpectoral	172 pts with 179 reconstructions: 101 prepectoral, 78 subpectoral	Retrospective  Univariate and multivariable marginal Cox proportional hazards models to generate hazard ratios  Mean follow-up 39.7 months	Pts with immediate expander-implant reconstruction: expander then PMRT then exchange for implant  Excluded delayed-immediate, delayed, direct-to-implant  PMRT to chest wall, undissected lymphatics, boost to mastectomy flap and nodes	94.1% vs. 69.2%: AlloDerm 72.3% vs. 60.3%; SurgiMend 10.9% vs. 1.3%; DermACELL 10.9% vs. 7.7%		Not reported; does not mention whether dual-plane or submuscular, but use of ADM in 67.2% suggests large portion is dual-plane	Breast-related complications 26.7% vs. 21.8%, p=0.274; HR=1.33, 95% CI=0.74-2.44, p=0.347  Device infection 18.8% vs. 15.4%, p=0.307; HR=1.37, 95% CI=0.67-2.86  Skin flap necrosis 5.0% vs. 1.3%, p=0.232  Device explantation 20.8% vs. 14.1%, p=0.117; HR=1.72, 95% CI=0.84-3.57	
Hung, 2023 (351)	Vanderbilt University Medical Center, Nashville, TN, USA	2013-2019	Early and late complications prepectoral vs. subpectoral expanders	854 pts: 649 submuscular expanders, 205 prepectoral expanders	Retrospective  Surgical outcomes up to 1 year after final reconstruction, median follow-up 13.1 months	2-stage expander-implants; 96; 25.4% vs. 14.8% NSM; 96.1% vs. 95.1% immediate	AlloDerm and later Allergan  ADM in 93.2% vs. 73.7%	Surgeon assesses skin flap perfusion prior to deciding plane; subpectoral dual-plane if flaps deemed too thin for prepectoral placement;		Complications within 30 days  First stage: early complications similar (38.6% vs. 32.6%, p=0.2); failure 8.1% vs. 2.2% (p<0.01), seromas (18.4% vs. 9.1% (p<0.01),	Early and late complications for each stage

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
					Cox proportional hazard models to predict risks of complications			prepectoral if flaps have appropriate thickness and perfusion		<p>infection 14.8% vs. 6.6% (p&lt;0.01); these were all non-significant (P&gt;0.05) after multivariate analysis</p> <p>First stage: late complications 46.3% vs. 33.3% (p&lt;0.01), infection 19.9% vs. 6.1% (p=0.01; HR=2.4), wound dehiscence 6.3% vs. 2.4% (p=0.01)</p> <p>Second stage: early 17.5% vs. 16.0% (p=0.63), no differences</p> <p>Second stage: late complications 16.5% vs. 16.0% (p=0.97), infection 6.3% vs. 2.0% (p=0.02; HR=5.3, p=0.03)</p> <p>Pooled early and late infection: first stage HR=2.2 (p=0.02), second stage HR=4.9 (p=0.01)</p>	
ElSherif, 2024 (352)	Cleveland Clinic, Cleveland, OH, USA	2016-2019	Prepectoral vs. submuscular (but used ADM so	320 pts, 525 NSM: 203 prepectoral, 322 submuscular	Retrospective 7 breast surgeons and 7 plastic surgeons	NSM for cancer or prophylactic (51% vs. 49%), immediate tissue expander or direct implant reconstruction	ADM in 99% vs. 88%	2 techniques used. A. Sizer covered with ADM then sutured to pectoralis	Generally if tumour close to or involving muscle as a posterior margin, in a larger breast	<p>Nipple necrosis 7% vs. 9%, p=0.71</p> <p>Reconstruction failure 8% vs. 4%, p=0.093</p>	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
			maybe dual-plane)		Mixed effects logistic regression models to compare nipple necrosis and construction failure by adjusting other covariates  Multivariate analysis could not be reliably performed due to low numbers of complications and nipple loss	Direct implant in 300 mastectomies  23% vs. 56% expanders  Inframammary (75% vs. 67%) and lateral incisions (11% vs. 15%) were most common		major muscle; implant or partially filled expander introduced with Keller Funnel  B. ADM sutured around implant in burrito fashion then sutured to pectoralis muscle, drains placed, wound closed	volume, or poor flap/skin quality		
Min, 2024 (138)	University of Ulsan, College of Medicine, Seoul, Korea	2017-2020	Prepectoral vs. partial muscle-splitting subpectoral vs. dual-plane subpectoral  2017-2018 generally used dual-plane; subsequently plane according to surgeon preference	349 pts: 92 prepectoral, 169 partial muscle-splitting, 86 dual-plane	Retrospective  1 institution, 3 plastic surgeons  At least 2 years follow-up  Multivariate linear regression	Breast cancer, unilateral direct-to-implant reconstruction  Excluded conversion to other method, implant removal, bilateral reconstruction, history of breast surgery  Circulation of mastectomy skin flap evaluated with indocyanine green angiography	Human ADM, either CGDerm or MegaDerm	Prepectoral pocket  ADM to encase entire anterior surface and most of the posterior surface using a square piece folded/trimmed /sutured to wrap the implant and inserted in prepectoral plane, sutured to pectoralis muscle only if breast was too ptotic or had	Partial muscle-splitting: pectoralis major muscle split parallel to muscle fibre at upper portion of muscle to slightly cover upper edge of sizer; muscle partially elevated from chest wall, manually fenestrated ADM fixed to edge of splitting muscle and IMF;	No differences in rippling (p=0.62), visible implant edges on upper pole (p=0.62), capsular contracture  Prepectoral had lower seroma (p=0.008), animation deformity (0 vs. 0 vs. 5.81%, p<0.001), breast pain (3.26% vs. 3.51% vs. 13.95%, p=0.002), upward migration (1.09%	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
						No aesthetic revisions such as fat grafting		wide pocket and was risk of implant malposition	implant inserted, ADM trimmed and sutured to lateral chest wall  Dual-plane subpectoral: elevate at inferior border of pectoralis major muscle, manually fenestrated ADM sutured along edge of detached pectoralis muscle and IMF, implant inserted, ADM trimmed and sutured to lateral chest wall	vs. 4.68% vs. 38.37%, p<0.001)  In multivariate analysis, dual-plane had more seroma (OR=4.223, p=0.002) and implant upward migration (OR=74.292, p<0.001) than prepectoral	

\*Year of diagnosis or initial surgery

**Abbreviations:**

ADM, acellular dermal matrix; ALND, axillary lymph node dissection; ASA status, American Society of Anesthesiologists physical status classification system; BCS, breast conserving surgery; BMI, body mass index; CI, confidence interval; DM, distant metastasis; HR, hazard ratio; IMF, inframammary fold; IRR, incidence rate ratio; LABC, locally advanced breast cancer; LR, local recurrence; NAC, nipple-areolar complex; NACT, neoadjuvant chemotherapy; NSM, nipple-sparing mastectomy; OME, oral morphine equivalents; OR, odds ratio; PMRT, postmastectomy radiotherapy; PRO, patient-reported outcomes; pts, patients; QoL, quality of life; RT, radiotherapy; SLNB, sentinel lymph node biopsy; SSM, skin-sparing mastectomy; TND, tumour-to-nipple distance



[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q4](#)[Back to Start of Tables](#)**Table 4-9. Question 4: Comparisons of Prepectoral, Subpectoral, and/or Dual-plane Reconstruction. B. Conversion of subpectoral to prepectoral**

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details: revision reconstruction, prepectoral	Subpectoral details: original implant (subpectoral or dual-plane)	Outcomes	Other
Conversion subpectoral to prepectoral (pts are own controls)											
Gabriel, 2018 (142)  May overlap with Sigalove, 2019 (144)	Loma Linda University Medical Center, Loma Linda, California  Central DuPage Hospital/ Northwestern Medicine, Winfield, Illinois  Compass Oncology, Portland, Oregon and Vancouver, Washington	2011-2016	Prepectoral revision of dual-plane reconstruction due to animation deformity  Author's practices	57 pts (102 breasts)	Retrospective  Mean 16.7 months follow-up after revision surgery	Previous 2-stage implant reconstruction and animation deformity  Excluded current smokers, poor skin quality/perfusion, uncontrolled diabetes, RT (except for implant-based latissimus flap reconstruction)	AlloDerm ADM, perforated or pie-crusted	<b>Revision reconstruction, prepectoral</b>  New pocket above pectoralis muscle; direct-to implant or expander depending on skin flap thickness and tightness; implant or expander placed in pocket and covered with ADM; ADM tacked to subcutaneous tissue superiorly and IMF inferiorly with 3-4 cm cuff on chest wall  Expander (if used) was fully inflated at time of operation	<b>Original implant, dual-plane</b>  Dual-plane  Original implant removed via IMF incision, removal of lower-pole capsule and ADM (if present) and anterior capsule if possible  Facelift scissor used instead of electrocautery if mastectomy flap was too thin  Pectoralis major muscle sutured down to lower pole and chest wall	Presenting complaint (% breasts): 94.1% animation deformity, 95.1% pain, 89.2% animation deformity and pain, 7.8% implant malposition  After revision: no animation deformity; pain not measured but not pts complained of pain  Complications with revision surgery 3.9% of breasts: 2% seroma, 2% skin necrosis, 1% wound dehiscence, 3.9% implant removal and replacement	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details: revision reconstruction, prepectoral	Subpectoral details: original implant (subpectoral or dual-plane)	Outcomes	Other
								Autologous fat grafting used at secondary surgery in pts requiring additional soft tissue coverage			
Sigalove, 2019 (144)  May overlap with Gabriel, 2018 (142)	Loma Linda University Medical Center, Loma Linda, California  Central DuPage Hospital/ Northwestern Medicine, Winfield, Illinois  PeaceHealth Southwest Medical Center, Vancouver, Washington	2015-2018	Prepectoral revision with Inspira implants of dual-plane reconstruction  Pts in one author's practice  Inspira round implants have higher fill ratio than standard round implants and higher gel cohesivity	64 pts (124 breasts)	Retrospective  Mean 18.9 months follow-up	Consecutive pts with dual-plane implants undergoing revision due to animation deformity (99.2% of breasts), pain (99.2%), asymmetry (96.0%), implant malposition (68.5%), size change (26.6%), capsular contracture (16.9%), or rippling (1.6%)  Contraindications of revision surgery: poor skin quality or perfusion, thin subcutaneous tissue, uncontrolled diabetes, current smoking  ½ pts obese; ¼ pts had controlled diabetes  93.8% bilateral; 50.8% SSM, 49.2% NSM	AlloDerm ADM, perforated or pie-crusted and GalaFLEX bioabsorbable mesh	Site change to prepectoral; see Gabriel, 2018 (142)  ADM placed anterior to the implant, GalaFLEX mesh posterior to the implant and both secured to the chest wall and IMF inferiorly  Implants were wrapped with ADM ± absorbable mesh depending on implant size  Autologous fat grafting used as needed (47% of breasts) in secondary procedure; if tissues were thin at presentation	Implant removal; see Gabriel, 2018 (142)  96% IMF incision; new incision in IMF created if earlier scar was a central mastectomy scar unless it used latissimus dorsi flap  Lower pole ADM, if present, was removed together with capsule	3.2% complications (4 breasts in 3 pts): 1.6% implant loss 1.6% seroma; 0.8% each hematoma, surgical site infection, skin necrosis  No capsular contracture  All presenting complaints (prior to revision surgery) were resolved and did not recur	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details: revision reconstruction, prepectoral	Subpectoral details: original implant (subpectoral or dual-plane)	Outcomes	Other
								then fat grafting was used preoperatively for thickening of the flaps			
Jones, 2019 (143)	University of Illinois College Medicine, Peoria, Illinois  Brown University Warren Alpert Medical School at Rhode Island Hospital, Providence, Rhode Island  Louisiana State University School of Medicine, New Orleans, Louisiana	2015-2018	Subpectoral to prepectoral conversion  Single plastic surgeon	90 pts (142 breasts)	Retrospective  Average follow-up 77 weeks (17.8 months)	Patients with subpectoral reconstruction and complaints of animation deformity, implant distortion and tightness  Subpectoral to prepectoral implant change  Excluded pts with RT only if skin was thin, tight, and telangiectatic, no other exclusions	AlloDerm ADM for prepectoral replacement	<b>Revision reconstruction, prepectoral</b>  Prepectoral plane identified between superficial aspect of pectoralis major muscle and overlying upper mastectomy flap; ADM trimmed to create teardrop shape and sutured to anterior aspect of pectoralis major muscle at its cusp with the overlying mastectomy skin flap and sutured to leave an inferior access window for implant insertion;	<b>Original implant, subpectoral or dual-plane</b>  Incision through original mastectomy scar; upper flap everted, junction of pectoralis major muscle and ADM incised with electrocautery; broad-based dissection allows muscle to be returned to the chest wall without tension; pectoralis major sutured to rib periosteum	100% resolution of animation deformity  Most pts reported improved range of shoulder movement  Improvement in overall breast aesthetics including better cleavage appearance  Complications with revision surgery: 4.2% infection; 2.1% seroma; 0.7% hematoma, dehiscence, partial necrosis, explantation  28.9% minor contour deformity and 4.9% rippling treated with fat grafting in 18.3% of pts  No capsular contraction by 44 months follow-up; attributed to use of anterior ADM coverage and use of	Note: authors indicate skin flaps can be considered vascular-delayed

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details: revision reconstruction, prepectoral	Subpectoral details: original implant (subpectoral or dual-plane)	Outcomes	Other
								implant inserted under the ADM and anterior ADM sutured to chest wall along the IMF		biofilm reduction protocol including using a Keller funnel to insert the implant	
Holland, 2020 (30)	University of California, San Francisco	2015-2018	Conversion of subpectoral to prepectoral due to animation deformity  Single institution, single surgeon	80 breasts in 45 pts, including 35 pts with bilateral conversion in 70 breasts  52.5% had preoperative fat grafting due to <1 cm subcutaneous tissue	Retrospective  Median follow-up 15.2 months	All pts who had subpectoral to prepectoral conversion to treat animation deformity  Required to have enough overlying subcutaneous ties to mask contour of ne implant and provide durable layer of vascularized tissue above the implant; ideal candidates had ≥1 cm of subcutaneous tissue on the pinch test and otherwise had preoperative fat grafting (52.5%) if appropriate donor sites; if no donor sites either did not do exchange or removed stretched and excess thin skin  Smoking cessation and improvement of poorly controlled diabetes and other	AlloDerm ADM used in 81.3% of revisions to prepectoral implants	<b>Revision reconstruction, prepectoral</b>  Plane between pectoralis major and overlying subcutaneous tissue developed using low electrocautery and sharp dissection to free the pectoralis muscle from the overlying muscle and create a pocket; pectoralis major muscle sutured to chest wall  Cohesive gel implants were preferred to reduce rippling; envelope	<b>Original implant, subpectoral or dual-plane</b>  Removal of implant, separation of the pectoralis major muscle from overlying skin flap, attachment of muscle to chest wall  Typically used same incision as previously; in NSM generally a superior periareolar on IMF; in other pts was transverse breast scar  Inferior border of pectoralis muscle incised and capsule and implant	Resolution of animation deformity in all pts  Complications: 2 (2.5%) required reoperation (1 hematoma and 1 infection); 11 (13.8%) treated for infection  No reconstructive failures  21.25% had asymmetry and 11.25% had cosmetic revision  Capsular contraction in 6.25%  Pts with ADM had less asymmetry (15.4% vs. 47.0%, p=0.01), capsular contracture (1.5% vs. 26.7%, p=0.01)  Pts with preoperative fat grafting had less asymmetry (11.9% vs. 31.6%, p=0.05), less	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details: revision reconstruction, prepectoral	Subpectoral details: original implant (subpectoral or dual-plane)	Outcomes	Other
						comorbidities was required prior to surgery 10 breasts (12.5%) had had RT 63.8% had NSM		around implant supported with ADM covering the entire anterior surface and small portion of posterior/ inferior surface; no touch technique used to place implants in pocket; implant not sutured in place; skin closed in layers	removed along with ADM if present unless there was thin overlying skin	capsular contracture (0% vs. 13.2%, p=0.02), cosmetic revision surgery (4.8% vs. 18.4%)  Postoperative prophylactic antibiotics in 60% of pts and associated with fewer infections (2.1% vs. 31.3%, p<0.01)	
Salgarello, 2023 (145)	Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy	2018-2022	Submuscular (subpectoral?) to prepectoral conversion	63 pts, 87 breasts	Retrospective	Complaints of animation deformity, chronic pain, poor cosmetic results (retained breast, soft tissue waterfall, asymmetry)  Adequate layer of subcutaneous fat (about 8 mm) in mastectomy skin flaps as determined by pinch test in upper pole and ultrasound  Lipofilling in some patients with thinner flaps	Used in first 7 pts, complete coverage	18 pts (7 no RT and 11 with RT) had lipofilling prior to exchange  Subpectoral pocket opened at lower edge of pectoralis major muscle and expander or implant explanted; capsule from lower edge of pectoralis major to IMF was excised and lower edge sutured to	7 pts with anatomical microtextured implants and ADM, rest with polyurethane foam-coated implants	Cosmetic evaluation with 0-2 points Likert scale  Breast contour score of 2 for 81.6% and score of 1 for 18.4%  IMF crease was 2 in 74.7% and 1 in 25.3%  Breast position 2 in 87.36% and 1 in 12.64%  Breast projection 2 in 84% and 1 in 16%  Breast shape 2 in 97.7% and 1 in 2.3%	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details: revision reconstruction, prepectoral	Subpectoral details: original implant (subpectoral or dual-plane)	Outcomes	Other
						If previous RT, damage was evaluated and exchange only if LENT-SOMA score grades 1-2; they were candidates for fat grafting		posterior capsule on the chest wall		Overall score was 2 in 96.5% and 1 in 3.5%  Capsular contracture score Baker 1a in 47.1%, 1b in 42.5%, 2 in 10.4%  Pain resolved in all pts  BREAST-Q improved from preoperative values: Satisfaction with Breasts 37 to 94 at 12 moths; Psychosocial Well-Being 40 to 86; Sexual Well-Being 34 to 83; Physical Well-Being Chest 23 to 94, animation deformity 38 to 96	

\*Year of diagnosis or initial surgery

**Abbreviations:**

ADM, acellular dermal matrix; IMF, inframammary fold; LENT-SOMA, Late Effects on Normal Tissue—Subjective, Objective, Management, Analytic system for grading of side effects after radiotherapy; NSM, nipple-sparing mastectomy; pts, patients; RT, radiotherapy; SSM, skin-sparing mastectomy

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q4](#)[Back to Start of Tables](#)**Table 4-10. Question 4: Comparisons of Prepectoral, Subpectoral, and/or Dual-plane Reconstruction. C. Prepectoral, Subpectoral, and/or Dual-plane Reconstruction; ADM different in each arm**

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
Prepectoral vs. submuscular											
Bettinger, 2017 (70)	Kaiser Permanente Medical Center San Jose, San Jose, Calif  Single institution	2008-2015	Prepectoral with ADM  Dual-plane with ADM sling (Classic method, <50 pts)  Submuscular (no ADM)	213 pts, 294 breasts: 110 pts (165 breasts) prepectoral; 40 pts (52 breasts) classic (ADM sling), 63 pts (77 breasts) no ADM	Retrospective  Multivariate analysis  Minimum follow-up ranged from 6 months to 6 years	Consecutive reconstructions for breast cancer or prophylactic  Surgical technique left to discretion of surgeon; no information reported about pt selection/assignment to plane of implant  Exclude mesh other than AlloDerm  34% prophylactic  28% of mastectomies were contralateral  Implant placement typically 3 months after chemotherapy or 6 months after RT	AlloDerm (thick)  Prepectoral with ADM  Dual-plane with ADM sling (Classic method)  Submuscular (no ADM)			Complications limited to Clavien score grade IIIB (requiring surgical, endoscopic, or radiological intervention under general anesthesia) for seroma, infection, hematoma, skin and nipple necrosis, expander deflation, expander or implant loss  Expander complications: 13.33% prepectoral with ADM vs. 6.49% submuscular without ADM  With Classic =1, prepectoral adjusted RR=0.25 (95% CI=0.06-1.00; no ADM adjusted RR=0.12 (95% CI=0.02-0.72); prepectoral to no ADM RR=2.08 (calculated)	Note: <50 pts classic so should be excluded from comparisons

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
										Implant complications: too few for analysis	
Talwar, 2024 (353)	University of Pennsylvania  Protocol no. 850387	2018-2021	Prepectoral vs. submuscular implants	350 pts, 634 breasts: 197 prepectoral, 437 total submuscular  After matching, 146 breasts in each group  Only difference is ADM use, which depends on plane	Retrospective  3 plastic surgeons  1:1 propensity score match to control for baseline difference	Direct-to-implant or staged implants  Excluded dual-plane implants, prepectoral implant with latissimus flap  52.7% breast cancer, 47.3% prophylactic mastectomy  65% SSM; 89.7% 2-stage reconstruction	AlloDerm and FlexHD (not sterile) used in most prepectoral (97.5%); ADM not in submuscular (3%); 96.6% and 4.8% in matched cohorts	Pts with smaller breasts and confined postmastectomy pocket or health-appearing mastectomy skin flaps from well-trusted breast surgeon;  Less likely if PMRT or unilateral reconstruction		Entire and matched cohorts  Surgical site infection 14.7% vs. 3.9%, p<0.001; matched 15.8% vs. 3.4%, p<0.001  Cellulitis 6.6% vs. 2.3% p=0.014; matched 6.2% vs. 3.4%, p=0.411  Seroma 21.8% vs. 11.4%, p<0.001; matched 26.0% vs. 10.3%, p<0.001  Expander loss 16.2% vs. 2.3%, p<0.001; matched 20.5% vs. 2.7%, p<0.001  Implant loss 5.1% vs. 1.8%, p=0.044; matched 2.7 vs. 2.1%, p=1  Total explantation 21.3% vs. 4.1%, p<0.001; 23.3% vs. 4.8%, p<0.001  Mastectomy flap necrosis 3.0% vs. 9.2%, p=0.01; matched 4.1% vs. 10.3%, p=0.070	Time-to-event analysis: time to infection 95.6 versus 160.8 days, p=0.034; prepectoral infections more often treated surgically 93.1% vs. 47.1%, p<0.001  Non-sterile ADM, and longer use of drains may contribute to infection



Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
										NAC necrosis 2.5% vs. 11.0%, p<0.001; matched NAC necrosis 0.7% vs. 7.5%, p=0.008	
Prepectoral vs. subpectoral (dual-plane)											
Chen, 2023b (153)	Weill Cornell Medicine, New York, NY	2012-2021	Prepectoral (no ADM) vs. dual-plane with ADM vs. dual-plane with P4HB	220 pts, 393 samples: 161 prepectoral (no mesh), 122 dual-plane with ADM, 96 dual-plane with P4HB [and 14 with total submuscular, less than current review threshold]	Retrospective, univariate; Cox proportional-hazards model	2-stage reconstruction  No significant baseline differences between groups	Prepectoral (no ADM) vs. dual-plane with ADM vs. dual-plane with P4HB	Anterior to pectoralis muscle and directly under the soft tissue	Dual-plane: partially subpectoral with support material  Total submuscular: complete envelopment by pectoralis and serratus anterior muscles	Mean time to full expansion 53.4 vs. 104 vs. 68.8 days  Necrosis 11.8% vs. 13.1% vs. 4.2%  Infection 13.0% vs. 13.1% vs. 7.3%  Revision surgery 46.6% vs. 46.7% vs. 41.7%  Capsular contraction 30.4% vs. 34.4% vs. 47.9%;  Capsular contraction, univariate: OR=1.20 (95% CI=0.73-1.98, p=0.47) compared with dual + ADM; OR=2.10 (95% CI=1.25-3.56, p=0.005) compared with dual + P4HB  Capsular Contracture, multivariate: dual + ADM vs. prepectoral HR=1.00 (95%	

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
										CI=0.66-1.52, p=0.99); dual + P4HB vs. prepectoral HR=1.58 (95% CI=1.05-2.36, p=0.03)	
Houvenaeghel, 2022 (354)  See also Houvenaeghel, 2024 (154)	Marseille, France  M-IBR-PPRP-IPC 2022-014	2020-2022	Prepectoral vs. subpectoral post-surgical outcomes and pt satisfaction  8 surgeons (4 only did subpectoral)	98 prepectoral, 218 subpectoral	Retrospective  Univariate and multivariate analysis (binary logistic regression) for complications	Immediate implant-based reconstruction  68.4% vs. 36.2% NSM; 31.6% vs. 62.8% SSM  48 bilateral (19 prepectoral and 29 subpectoral)  14.3% vs. 15.1% prophylactic  Incisions for NSM usually (91%) in breast inferior fold	TIGR Matrix (resorbable synthetic mesh): 86.6% prepectoral pts, 0.9% subpectoral pts	Most used TIGR Matrix  Other details not reported	Not reported  (no information on implant location)	Complications 17.3% vs. 12.9% (p=0.301; multivariate OR=1.172, p=0.664); Grade 2-3 13.2% vs. 10.1% (p=0.441; multivariate OR=1.193, p=0.672)  Patient satisfaction (good or very good): 74.5% vs. 62.4%, p=0.035  Duration of surgery 80 vs. 100 min, p<0.0001; multivariate OR=0.48, p=0.007	
Houvenaeghel, 2024 (154)  See also Houvenaeghel, 2022 (354)	Marseille, France  M-IBR-PPRP-IPC 2022-014	2019-2023	Prepectoral vs. subpectoral complications and satisfaction  11 surgeons, surgeons were significantly different	324 prepectoral (increased from 3.1% in 2019 to 61.7% in 2023)  529 subpectoral	Retrospective  Univariate and multivariate (binary logistic regression) for complications	Immediate implant-based reconstruction (100% vs. 94.7% direct-to-implant)  66.4% vs. 44.6% NSM; 33.0% vs. 54.8% SSM	Resorbable synthetic TIGR Matrix  9 (1.7%) subpectoral, 176 (54.3%) prepectoral  Prepectoral mesh use	Use increased with time (compared with 2019, OR=209.79 for prepectoral in 2023)  Many surgeons had strong	Not reported  (no information on submuscular location)	Complications within 90 days of surgery (all or Grade 2-3; Clavien Dindo classification)  • Complications 20.4% vs. 15.3%, p=0.036; regression	In regression analysis:  Smoking, larger breasts (cup size >C), higher ASA status, mesh use, incision (areolar, inverted T)

Citation	Study name and location	Years of study*	Topic or comparison	Number of patients	Design	Population	ADM use	Prepectoral details	Subpectoral details	Outcomes	Other
			between groups			108 bilateral prophylactic and 61 bilateral primary breast cancer, 1 bilateral for LR  Implant position and mesh use was at surgeon discretion	varied by year: 20%, 14,%, 92%, 85%, 6.7% for years 2019 to 2023; note dramatic fall in 2023 due to reports of negative impact on complications	preference for placement		OR=0.846, p=0.529 • G2-3 complications 13.0% vs. 9.8%, p=0.097; regression OR=0.916, p=0.784 • Implant loss 6.5% vs. 4.7%, p=0.271 • Reoperation 10.8% vs. 7.4%, p=0.056  Pt satisfaction: very good/good 75.9% vs. 73.1%  Incision: central 33.0% vs. 50.9%; inferior fold 42.6% vs. 16.3%; rest similar	had higher complications  Smoking, mesh use, mastectomy weight >300 g, diabetes increased grade II-III complications

\*Year of diagnosis or initial surgery

**Abbreviations:**

ADM, acellular dermal matrix; ASA status, American Society of Anesthesiologists physical status classification system; CI, confidence interval; HR, hazard ratio; LR, local recurrence; NSM, nipple-sparing mastectomy; OR, odds ratio; P4HB, poly-4-hydroxybutyrate; PMRT, postmastectomy radiotherapy; pts, patients; NAC, nipple-areolar complex; RT, radiotherapy; SSM, skin-sparing mastectomy

Table 4-11. Types of Mesh

Human ADM	Porcine ADM	Bovine ADM	Synthetic, absorbable	Synthetic, partially absorbable	Synthetic, permanent
<ul style="list-style-type: none"><li>• AlloDerm</li><li>• Allomend</li><li>• DermACELL</li><li>• DermaMatrix</li><li>• Cortiva (formerly AlloMax and NeoForm)</li><li>• FlexHD</li><li>• SimpliDerm</li><li>• CGCryoDerm, CGDerm</li><li>• Epiflex</li><li>• MegaDerm</li></ul>	<ul style="list-style-type: none"><li>• Strattice</li><li>• Artia</li><li>• Permacol</li><li>• Meso Biomatrix</li><li>• Native</li><li>• Protexa</li><li>• Braxon</li></ul>	<ul style="list-style-type: none"><li>• SurgiMend</li><li>• I-real</li><li>• Veritas</li><li>• Tutomesh</li></ul>	<ul style="list-style-type: none"><li>• Vicryl/polyglactin mesh</li><li>• Poly-4-hydroxybutyrate (P4HB); bioabsorbable in 18-24 months</li><li>• GalaFLEX (P4HB)</li><li>• Phasic (P4HB)</li><li>• TIGR Matrix (long-term resorbable mesh with dual stages of fast and slow resorbing fibres)</li><li>• Seri Surgical Scaffold, bioresorbable silk (discontinued)</li><li>• DuraSorb (resorbable polydioxanone mesh)</li></ul>	<ul style="list-style-type: none"><li>• Seragyn: polypropylene and absorbable polyglycolic acid</li></ul>	<ul style="list-style-type: none"><li>• TiLOOP Bra (titanium coated polypropylene mesh)</li><li>• Surgimesh (non-woven polypropylene microfibers)</li><li>• SURGIMESH®PET (polyester)</li><li>• Breform (woven polyester)</li></ul>

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q5](#)[Back to Start of Tables](#)**Table 4-12. Question 5: Acellular Dermal Matrix. A. ADM versus none**

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
ADM (human) vs. none										
Seth, 2012 (369)	Northwestern Memorial Hospital, Chicago, Illinois  1 institution, 7 mastectomy surgeons, 6 reconstructive surgeons	2006-2008	Retrospective  Multiple regression  Mean follow-up 23.2 vs. 24.4 months	AlloDerm or FlexHD vs. none	Under pectoralis major and ADM vs. submuscular	417 pts (592 breasts): 199 breasts ADM, 393 breasts no ADM	Consecutive series of immediate expander reconstruction and implant exchange  RT, if used, was before implant exchange  Preoperative RT was exclusion factor for ADM use   Calculated 30% of mastectomies were contralateral; cancer not mentioned	With ADM: Pectoralis muscle disinserted, ADM sutured to lower pole defect, inferior aspect of ADM sutured to IMF and lateral aspect to serratus muscle fascia, expander inserted  Authors stated no difference in complications between AlloDerm and FlexHD, but data not shown	Effect of ADM (multiple regression):  <ul style="list-style-type: none"> <li>• Total complications OR=1.37, 95% CI=0.87-2.17, p=0.17;</li> <li>• Infection OR=1.67, 95% CI=0.81-3.47, p=0.16;</li> <li>• Major flap necrosis OR=1.32, 95% CI=0.70-2.49, p=0.41;</li> <li>• Non-operative OR=1.36, 95% CI=0.7-2.39, p=0.33;</li> <li>• Operative OR=1.64, 95% CI=0.95-2.83, p=0.08;</li> <li>• Explantation or conversion to flaps OR=1.17, 95% CI=0.63-2.19, p=0.62</li> </ul>	
Jordan, 2014 (370)	Northwestern University, Chicago, Illinois  1 surgeon	2011-2012 after ADM algorithm; 2008-2009 before ADM algorithm	Retrospective  Multiple logistic regression for effect of algorithm	ADM (AlloDerm or FlexHD) or none	ADM: Inferior aspect of pectoralis major released; crescent-shaped piece of ADM affixed to reconstitute the	193 breasts before algorithm (84% used ADM)  179 breasts after	NSM or SSM and immediate tissue-expander reconstruction  <u>Algorithm for ADM use vs. total muscular coverage</u>  BMI: high and large breasts use delayed reconstruction	Resource-sensitive algorithm for selective acellular dermal matrix use with indications and contraindications	Complications 22.8% before algorithm vs. 20.7% after, p=0.138; after adjusting for confounders no difference (p>0.05) for infection, seroma, flap	Follow-up too short for long-term complications (capsular contraction)

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
			Algorithm to decide on ADM use vs. no algorithm		inferior and lateral borders of the breast  No ADM: serratus anterior fascia or muscle elevated to cover expander/ implant	algorithm (36% used ADM)	or ADM; high and small breasts ± ADM; low and large breasts ± ADM; low and small breasts use no ADM  Radiation: preoperative no ADM; anticipated PMRT use ADM  SLND+ use ADM  Pectoralis: intact and wide ± ADM; intact and narrow use ADM; compromised use ADM  Flap vascularity: good and skin excess use ADM; good and no skin excess do not use ADM; poor do not use ADM	based on body mass index, breast size, radiation therapy, flap vascularity, and pectoralis anatomy	necrosis, explantation, overall complications; aesthetics 2.75/4 vs. 3.03/4, p=0.138	Note: algorithm appears to be for type of surgery and not specifically ADM use as ADM is used in absence of complete submuscular coverage
Woo, 2017 (371)	Sungkyunkwan University School of Medicine and Ewha Womans University Mokdong Hospital, Seoul, South Korea  5 ablative surgeons and 4 reconstructive surgeons	2010-2016	Retrospective propensity-score matched cohort analysis using mastectomy weight, drain days in situ, and initial inflation  Multivariable generalized estimating equation analysis to adjust for surgeons	ADM (human, non-fenestrated) vs. none	ADM covered inferolateral portion of expander (dual-plane, or to fill gap in otherwise submuscular insertion)  Total submuscular in group without ADM (use of serratus anterior muscle and/or serratus fascia)	Before matching 533 pts (574 breasts)  Matched groups: 199 ADM reconstructions and 199 non-ADM	Immediate expander-implant reconstruction  ADM used non-selectively (consecutively) from Nov 2013 if the pt agreed and it was available	Not reported	No significant difference in skin flap complications (16.1% vs. 16.1%, p>0.999), seroma (4.0% vs. 8.5%, p=0.065), infection (3.0% vs. 3.5%, p=0.781), overall complications (21.1% vs. 26.1%, p=0.251), major complications (13.1% vs. 19.1%, p=0.110), reconstruction failure (2.0% vs. 2.0%, p>0.999)	
Lee, 2020 (372)	Sungkyunkwan University School of Medicine,	2010-2018	Retrospective  Multivariate for effect of BMI and	ADM (not specified)  Mainly AlloDerm	ADM: coverage of inferolateral aspects of tissue expander	738 pts ADM, 693 pts no ADM	Immediate unilateral reconstruction with expander in subpectoral pocket, ADM		Hematoma: ADM vs. no ADM by multivariate analysis, OR=0.919, 95%	

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
Lee, 2018, 2019 (373, 374)	Seoul, South Korea		predictors of hematoma	or CGDerm/ CGCryoDer m based on Lee, 2018, 2019 (373, 374)	No ADM: serratus anterior muscle fascia		according to surgeon preference		CI=0.409-2.068, p=0.839	
Pires, 2024 (375)	University of Utah School of Medicine	2020-2022 Stopped use of ADM in May 2021 and excluded dates May-July 20-21 to allow learning without ADM	Retrospective review 1 institution, 3 plastic surgeons Multiple variable mixed effects logistic regression for effect of ADM or no-ADM on outcomes	AlloDerm, DermACELL, or Cortiva, meshed at 1:2 or 1:1.5 ratio using a skin graft mesher	Prepectoral ADM vs. no ADM	69 pts (98 breasts) with ADM 55 pts (98 breasts) no ADM	Consecutive pts with mastectomy and concurrent prepectoral expander ADM group had less NACT but more adjuvant chemotherapy Used tabbed tissue expanders Any concern for mastectomy flap viability prompted reconstructive delay (and not addition of ADM)	Concerns of mastectomy flap viability prompted reconstructive delay	Post-operative outcomes within 3 months <ul style="list-style-type: none"> <li>•Hematoma 1% vs. 3.1%, p=0.62</li> <li>•Seroma 27.6% vs. 37.8%, p=0.10; multivariate OR=3.21 (95% CI=0.9-11.44, p=0.07)</li> <li>•Dehiscence 3.1% vs. 5.1%, p=0.52</li> <li>•Minor infection 10.2% vs. 14.3%, p=0.38</li> <li>•Major infection 8.2% vs. 8.2%, p=1.00</li> <li>•Any infection OR=0.89, 95% CI=0.40-1.95, p=0.76</li> <li>•Mastectomy flap necrosis 8.2% vs. 5.1%, p=0.39</li> <li>•Unplanned reoperation 15.3% vs. 17.3%, p=0.70; OR=1.41, 95% CI=0.43-4.69, p=0.57</li> </ul>	No independent associations between seroma, hematoma, wound dehiscence, mastectomy skin flap necrosis, infection, unplanned return to the operating room, or explantation after controlling for age, body mass index, history of diabetes, tobacco use, neoadjuvant chemotherapy, and postoperative RT  Note that other than seroma, any infection, and return to operating room, the number of events was small multivariate

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
									•Explantation 6.1% vs. 12.2%	results were not extracted
ADM (not specified) vs. none**										
Sorkin, 2017 (217)	MROC study 10 centres (USA and Canada), 58 surgeons	2012-2015	Prospective Bivariate analysis and mixed-effects regression  2-year follow-up from time of expander placement	Did not attempt to differentiate between ADM types	Not reported	1297 pts: 655 ADM, 642 no ADM	Tissue expander for immediate unilateral or bilateral reconstruction after mastectomy for breast cancer or prophylaxis (14.0% vs. 6.7%)	Most surgeons either used ADM in most pts (49.6% of surgeons) or rarely used ADM (25.8% of surgeons)	Overall complications, OR=1.21, p=0.263; major complications OR=1.43, p=0.052; wound infections OR=1.49, p=0.118, reconstructive failure OR=1.55, p=0.089 at 2 years after reconstruction  PRO with BREAST-Q: no difference in Satisfaction with Breasts, Psychosocial Well-Being, Sexual Well-Being, Physical Well-Being, and Postoperative Pain.	Trend but not significant towards higher risks with ADM for major complication and failure
Ganesh Kumar, 2021 (218)	MROC study 10 centres in USA and 1 in Canada, 58 plastic surgeons	2012-2015	Prospective Multivariable analysis for interaction of moderators and ADM for complications, wound infection	MROC did not record implant pocket type as a variable	Not reported	1451 pts: 738 with ADM, 713 no ADM	Immediate expander-implant-based reconstruction  DTI group small (102 ADM and 9 without ADM) and was excluded  ADM use determined primarily by surgeon preference and practice patterns  Data not collected on RT technique, implant/expander volumes, intraoperative details		There was an interaction between ADM and BMI for complications  No significant ADM effect (measured with BREAST-Q) on Satisfaction with Breast ( $\beta = -1.95$ , p=0.20), Psychosocial Well-Being ( $\beta = -0.26$ , p=0.85), Sexual Well-Being ( $\beta = -2.28$ , p=0.18), or Physical Well-Being ( $\beta = -0.82$ ,	



Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
							40% drop rate (dropout rate?) over 2 years of study		p=0.46) 2 years postoperatively	
Pannucci, 2013 (376)	ASPS-TOPS database, USA	2008-2011	Multivariable logistic regression	CPT codes 15330 or 15331 (ADM but not specified)	Available in <30% of cases and therefore not used	14,249 pts: ADM 3,450 pts 8,746 pts had complete data and included in regression (2,905 with ADM)	Expander/implant-based reconstruction, immediate or delayed; excluded mastopexy/augmentation pts		30-day rates of tissue expander or implant loss 2.58% vs. 1.88%, use of ADM associated with increase in expander/implant loss, OR=1.42, 95% CI=1.04-1.94, p=0.026	Note that 30 days is too short for several outcomes  Authors indicate that clinically trivial results may exhibit statistical significance, and that ADM may improve surgeons' ability to perform breast reconstruction
Kilmer, 2024 (377)	PearlDiver, a national (USA) insurance-based database	2011-2019	Query of CPT codes for mastectomy and immediate implant or expander  Proportion matching for age, region, comorbidities  Complications within 90 days by univariate and multivariate analysis	ADM vs. none, type not reported	Not reported	26,266 ADM vs. 23,100 non-ADM	Pts with mastectomy in insurance database  CPT codes for mastectomy and immediate expander or implant, with or without same-day ADM  Exclude flaps, pts without insurance	Insurance databased does not have surgical details, implant placement, skin thickness or quality, ADM placement, ADM type, incision type	Infection 4.7% vs. 4.4%, p=0.178  Seroma 3.9% vs. 4.0%, p=0.520  Implant removal 4.9% vs. 3.9%, p<0.001  Explantation in direct-to-implant 8.2% vs. 6.3%, p=0.02  <ul style="list-style-type: none"> <li>• Multivariate analysis for factors in implant removal: ADM OR=1.22, p&lt;0.001</li> <li>• Direct-to-implant OR=2.00</li> <li>• COPD, depression, diabetes, hypertension, obesity, tobacco us, coronary artery</li> </ul>	Risk factors for implant removal were tobacco use, hypertension, depression, obesity, ADM use, direct-to-implant surgery

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
									disease all had OR between 1.19 and 1.26 (similar to ADM impact)	
Lin, 2024 (111) Liston, 2024 (283) See also Shanno, 2024 (95)	Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA	2007-2019	Single institution, retrospective  At least 2 years follow-up post-operatively  NSM complications  Expander vs. direct-to-implant	AlloDerm (most common), FlexHD, Vicryl, Vicryl/ADM hybrid, SurgiMend	Not reported	1705 pts and 3035 breasts: number with ADM not reported	NSM and implant-based reconstruction  Excluded delayed or autologous reconstruction  Most operations by 3 breast surgeons and plastic surgeons  Surgeons chose plane of reconstruction and type of ADM/mesh based on experience or preference, pt characteristics, and treatment plan  Mostly subpectoral dual-plane or prepectoral, but also total muscle coverage; these are not mentioned as factors in the multivariable analysis		ADM or mesh vs. muscle only complications: <ul style="list-style-type: none"><li>• Overall 9.06% vs. 10.33%; multivariate OR=0.749 (95% CI=0.404-1.391, p=0.361)</li><li>• Nipple necrosis 1.07% vs. 2.89%, p&lt;0.05; multivariate OR=1.087 (95% CI=0.346-3.415, p=0.886)</li></ul> Without multivariable analysis: <ul style="list-style-type: none"><li>• Skin flap necrosis 3.44% vs. 5.37%</li><li>• Infection 3.26% vs. 3.72%</li><li>• Explantation 4.15% vs. 3.31%</li><li>• Hematoma 1.32% vs. 2.89%, p&lt;0.05</li><li>• Seroma 1.00% vs. 1.65%</li><li>• Ruptured prosthesis 0.61% vs. 0.41%</li></ul>	Complications, AlloDerm vs. Flex HD vs. Vicryl (or Vicryl hybrid) [estimated from graphs]  Overall: 8.3% vs. 10.2% vs. 11.8%  Skin flap necrosis; 2.5% vs. 5.8% vs. 5.8%  Infection 3.1% vs. 2.4% vs. 4.5%  Explantation 3.4% vs. 6.3% vs. 6.3%  Rates of nipple necrosis, hematoma, seroma, ruptured prosthesis similar between groups

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
									<ul style="list-style-type: none"> <li>Reconstruction failure 2.86% vs. 3.31%</li> </ul>	
Plotsker, 2024 (378)	Memorial Sloan Kettering Cancer Center, New York, NY	2018-2021	Retrospective  Post hoc power analysis, 28.5% for expander loss with and without ADM; 66% power to detect difference in overall complications  Logistic regression	ADM, type not stated	Prepectoral	741 pts, 1225 breasts: 643 pts ADM, 98 pts no ADM; 1060 breasts ADM, 165 breasts no ADM	<p>Tissue expander-based reconstruction in prepectoral plane</p> <p>Exclude if direct-to-implant</p> <p>ADM decided on basis of quality and thickness of mastectomy flap or at surgeon's discretion</p> <p>Hypertension 18.4% vs. 29.6%; cardiovascular diseases 14.5% vs. 27.6%; SPY angiography 54.8% vs. 23.5%; NSM 21.2% vs. 11.2%, mean mastectomy weight 540.8 g vs. 750.3 g</p> <p>Horizontal incision except 5 Wise pattern without ADM</p>	Not reported	<ul style="list-style-type: none"> <li>Tissue expander loss 3.8% vs. 6.7%, OR=0.55 (95% CI=0.27-1.22, p=0.095); multivariate OR=0.73 (95% CI=0.358-1.523, p=0.413)</li> <li>Any complication 20.8% vs. 22.5%, OR=0.92 (95% CI=0.61-1.41, p=0.683)</li> <li>TE exposure 1.8% vs. 4.2%, OR=0.42 (95% CI=0.16-1.19, p=0.073)</li> <li>Infection/cellulitis 7.6% vs. 12.1%, OR=0.61 (95% CI=0.35-1.08, p=0.067)</li> <li>Full-thickness mastectomy flap necrosis 2.6% vs. 1.2%, OR=2.23 (95% CI=0.55-19.46, p=0.416)</li> </ul> <p>Seroma 8.6% vs. 9.1%, OR=0.95 (95% CI=0.53-1.81, p=0.882)</p>	<p>Expander loss might be clinically significant, need larger sample size as study was underpowered</p> <p>Study suggests ADM may not be necessary in some patients with prepectoral expanders</p>

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
ACS-NSQIP database ADM type not specified)										
Davila, 2013 (379)	ACS-NSQIP database (250 sites)  Northwestern University, Feinberg School of Medicine, Chicago, IL, USA	2006-2010	Retrospective  Multivariate analysis	Any ADM; used ICD and CPT codes	ADM-assisted vs. submuscular (authors define as partial or total pectoralis and/or serratus muscular coverage without ADM)	12,249: 1717 ADM and 7442 without ADM	Total mastectomy and tissue expander simultaneously (immediate)	Not reported	<p>Total complications 5.5% vs. 5.3%, p=0.68; multivariate 5.6% vs. 5.3%, OR=1.07 (95% CI=0.85-1.35), p=0.57</p> <p>Infections 3.8% vs. 3.3%, p=0.27; multivariate 3.9% vs. 3.3%, OR=1.20 (95% CI=0.91-1.60), p=0.20</p> <p>Prosthesis failure 1.0% vs. 0.8%, p=0.30; multivariate 1.1% vs. 0.8%, OR=1.39 (95% CI=0.82-2.37), p=0.23</p> <p>Reoperation within 30 days: 6.9% vs. 6.9%, p=1.00; multivariate 7.0% vs. 6.9%, OR=1.01 (95% CI=0.82-1.25), p=0.91</p>	
Winocour, 2015 (380)	ACS-NSQIP database  Mayo Clinic, Rochester, MN	2005-2011	Retrospective  Multivariable analysis  Focused on surgical site infections		Not reported	12,163 pts: 1890 ADM, 10,273 no ADM	Mastectomy as primary procedure and with concurrent (immediate) tissue expander (CPT 19357); ADM (CPT 15330) or no ADM	Not reported	Focused on surgical site infections: 4.5% vs. 3.2%, p=0.005; multivariable analysis OR=1.2, 95% CI=0.9-1.5, p=0.26	
Luo, 2022 (381)  Wells, 2022 (382)	ACPS-NSQIP database  University of Utah School of Medicine, Salt	2012-2019	Retrospective  Multivariable modified Poisson regression for	ADM vs. non-ADM	Not reported	49,049 cases  20,776 (42.4%) ADM, 28,273	Tissue expander (CPT 19357); immediate if expander and mastectomy codes together, otherwise considered delayed	Not reported	Surgical site infection 3.9% vs. 3.4%, p=0.003; multivariate RR=1.10 (1.01-1.21), p=0.03	Notes that database does not record ADM type; plane of ADM (complete

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
[background to database]	Lake City, Utah		surgical site infection, dehiscence, reoperation			(57.6%) no ADM	Excluded BMI outside of 1.5 interquartile range (18.2 to 35.0 kg/m <sup>2</sup> ); or if missing data from ASA classification, height, weight, operating time		<p>Reoperation 7.4% vs. 6.0%, <math>p&lt;0.001</math>; multivariate RR=1.15 (1.08-1.23), <math>p&lt;0.001</math></p> <p>Dehiscence 0.7% vs. 0.7%, <math>p=0.73</math>; multivariate RR=1.02 (0.82-1.27), <math>p=0.86</math></p>	<p>submuscular, subpectoral, dual-plane); modifications; surgical technique; does not measure outcomes specific to breast reconstruction such as seroma, flap necrosis, reconstructive failure, capsular contracture; tracks outcomes for only 30 days</p> <p>Wells, 2022 (382) also indicates it does not include plastic surgery-specific variables; does not specify type of ADM, type of expander, anatomic location of expander (prepectoral, subpectoral), antibiotics, preoperative RT, chemotherapy; outcomes limited to 30 days after surgery (cannot measure effectiveness such as aesthetics, pt satisfaction, time to exchange,</p>

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
										capsular contraction)
Graziano, 2024 (383)	ACPS-NSQIP database  Memorial Sloan Kettering Cancer Center	2015-2020	Retrospective; logistic regression for complications	Not available	ADM use increased over time: 44.2% in 2015 and 65.8% in 2020	22,087 ADM 17,713 no ADM	Immediate breast reconstruction; CPT codes for direct to implant reconstruction, or immediate or delayed 2-stage implant-based reconstruction or autologous immediate breast reconstruction; plus codes for ADM  Only codes for simple, modified radical, or radical mastectomy		30-day complications (not multivariate analysis)  <ul style="list-style-type: none"> <li>Overall complications 9.8% vs. 9.3%, p=0.072</li> <li>Surgical complications 9.3% vs. 8.6%, p=0.027 (including deep infections, 0.6% vs. 0.7% and superficial infection 1.9% vs. 1.6%)</li> <li>Major medical complications 1.1% vs. 1.1%, p=0.810</li> </ul>	On multivariate analysis, ADM use had association with superficial wound infection, OR=0.997, p=0.017
AlloDerm vs. none										
Nahabedian, 2009 (155)	Georgetown University Hospital, Washington, DC  8 breast surgeons, 1 reconstructive surgeon, 2 institutions	2006-2008	(unclear whether prospective or retrospective)  Mean follow-up 17 months	AlloDerm vs. none	Dual-plane with upper 2/3 under pectoralis major muscle and lower 1/3 under AlloDerm or mastectomy skin flap	361 pts (476 breasts): 76 pts (100 breasts) with ADM and 285 pts (376 breasts) without ADM	In AlloDerm group, 60 immediate, 7 delayed, 6 revision, 3 revision augmentation  Expanders generally filled 40%-70% capacity with AlloDerm and 10%-20% capacity without AlloDerm; determined by contact point between upper and lower mastectomy skin flaps to ensure no undue tension  Cancer in 66/100 breasts with ADM		Infections 5.85% vs. 5.0%	33% breasts not cancer in ADM group, no details of non-ADM group  Calculated 24% contralateral

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
Sbitany, 2009 (384)	Rochester, New York  2 reconstructive surgeons at different practices	2004-2007	Retrospective	AlloDerm	ADM partial subpectoral (extension of pectoralis muscle), one author  No ADM submuscular (under pectoralis major and serratus anterior) one author	100 pts (172 expanders): 50 ADM, 50 no ADM	100 consecutive expander reconstructions by 2 surgeons  In submuscular group, at exchange a capsulotomy performed along inferior third allowing IMF to descend		Mean expander size 482 mL vs. 393 mL, p=0.002  Intraoperative fill volume 412 mL vs. 130 mL, p=0.0001  Mean number of fills 1.72 vs. 4.31, p=0.0001  Complications 9 vs. 7, p=0.79	Calculated 42% contralateral; no mention of whether pts have cancer  Pt groups similar; differences in age, BMI, smoking, PMRT but not statistically significant as only 50 pts/group
Chun, 2010 (157)	Brigham and Women's Hospital/ Faulkner Hospital, Boston, Mass.  21 mastectomy surgeons, 7 plastic and reconstructive surgeons	2002-2008	Retrospective	AlloDerm	ADM: released inferior origin of pectoralis major muscle and inset ADM between IMF and inferior border of pectoralis major  No ADM: either total submuscular coverage or partial submuscular and subcutaneous tissue coverage	283 pts (415 breasts): 269 ADM, 146 no ADM	Expander or implants for immediate reconstruction  Autologous flap included if used in conjunction with tissue expander or implant (68 latissimus dorsi flaps and 1 pedicled transverse rectus abdominis flap); this was 3.3% of ADM group and 41% of non-ADM group	Pts similar for age, smoking RT, cancer stage  BMI and mastectomy specimen weight higher in ADM group  Diabetes (3.7% vs. 0.68%) and hypertension (12.6% vs. 0.69%) higher in ADM group but not included in multivariate analysis	Seroma 14.1% vs. 2.7%; OR=4.24, 95% CI=1.28-14.0, p=0.018  Necrosis 23.4% vs. 8.9%  Infection 8.9% vs. 2.1%; OR=5.37, 95% CI=1.63-17.6, p=0.006  Mean implant volume 459.3 mL vs. 340.8 mL, p<0.001  Mean intraoperative fill volume 322.7 mL vs. 131.2 mL, p<0.0001  Analysis excluding flap reconstructions: seroma 13.9% vs. 2.4%, p=0.0038; major infection 8.5% vs. 1.2%, p=0.0199	32% of mastectomies were contralateral  Discussion indicates BMI and preoperative RT used in multivariate analysis; other factors may be needed  Subsequent modification in technique resulted in lower seroma rates

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
Ganske, 2013 (158)	Brigham and Women's Hospital/ Faulkner Hospital, Boston, Mass.	2008-2010  2002-2008 prior to modificatio ns	Retrospective  Results after implementing modifications to reduce seroma  Univariate analysis	AlloDerm	See Chun, 2010 (157): inserted expander under pectoralis major muscle, lower portion covered with ADM Without ADM: either total submuscular coverage or partial submuscular and subcutaneous tissue coverage	179 after seroma- reducing modification: 106 ADM and 73 no ADM  150 pts (64 ADM and 86 no ADM) before modification (see Chun, 2010 (157)) but including only YC's pts	Changes were drainage of submastectomy skin flap pocket and sub-ADM pocket, addition of soft compression dressings and surgical bras  Bilateral mastectomies and reconstructions considered as 2 cases and statistics were adjusted for clustering	Age, BMI, and mastectomy specimen weight higher in ADM group	No multivariate analysis:  Seroma 4.7% vs. 1.4%, p=0.2277  Infection 3.8% vs. 0  Skin flap necrosis 28.3% vs. 5.5%, p=0.0003  Mean intraoperative fill volume 298.1 mL vs. 96.5mL, p<0.001	Rates of seroma and infection significantly lower than earlier study  Necrosis still very high with ADM
Liu, 2011 (156)	Brigham and Women's Hospital, Boston, Mass.	2004-2009	Retrospective  Multivariate analysis for overall complications, infection  At least 3 months follow- up	AlloDerm	ADM: implant under pectoralis major muscle and inferior (lower) portion subcutaneous with ADM  No ADM: completely submuscular or dual-plane	343 pts (470 breasts): 192 pts (266 breasts) with ADM, 151 pts (204 breasts) without ADM	Consecutive immediate prosthetic reconstruction  Mostly expander used, though in small portion of ADM group it was direct to implant  Excluded delayed or autologous flap reconstructions  ADM group had higher mean mastectomy weight (526 g vs. 457 g), higher initial volume (implant or expander; 188 mL v 75 mL), larger final implants (434 mL vs. 356 mL), more smokers (11.5% vs. 5%)  27% of mastectomies were contralateral	Authors indicate groups well- matched in RT, BMI, comorbidities	Surgical complications 19.5% vs. 12.3%, p=0.034; multivariate OR=1.76 (95% CI=1.03-3.01), p=0.036  Infection 6.8% vs. 2.5%, p=0.031; multivariate OR=3.25 (95% CI=0.80-13.12), p=0.097  Major skin necrosis 11.7% vs. 8.3%, p=0.282  Any skin necrosis 13.9% vs. 10.8%, p=0.310  Seroma 7.1% vs. 3.9%, p=0.136	



Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
Vardanian, 2011 (385)	University of California, Los Angeles  Single academic medical centre  4 primary surgeons performed reconstructions	2000-2008: ADM starting July 2004	Retrospective  Multivariate logistic regression  Same surgeons in both cohorts	AlloDerm	ADM: elevated pectoralis major, insert ADM between muscle and IMF and insert expander in pocket  No ADM: total muscular or partial with creation of pocket deep to pectoralis major and serratus anterior muscles with external bolsters to cover inferolateral aspect of breast	203 pts (337 breasts): 123 pts (208 breasts) ADM, 80 pts (129 breasts) no ADM	Implant-based immediate reconstruction  Same surgeons operated on both cohorts (no ADM until June 2004; ADM starting July 2004)  Most non-ADM used partial muscle coverage  40% of mastectomies were contralateral  93.5% vs. 83.7% of pts had cancer	Multivariate logistic regression adjusted for clinical characteristics (BMI, smoking, indication for reconstruction) and postoperative complications (infection, seroma, inframammary fold problems, capsular contracture, mechanical shift, bottoming-out, rippling, and wound problems)	Complications: 29.3% vs. 40.3%, univariate OR=0.61, 95% CI=0.38-0.97, p=0.038  Capsular contracture: 3.8% vs. 19.4%, univariate OR=0.16; multivariate OR=0.18, 95% CI=0.08-0.43  IMF problems: 8.2% vs. 19.4%, univariate OR=0.37; multivariate OR=0.49, 95% CI=0.23-1.01, p=0.055  Mechanical shift: 1.9% vs. 9.3%, univariate OR=0.19; multivariate OR=0.23, 95% CI=0.06-0.78  Seroma/hematoma 2.4% vs. 1.6%  Infections 1% vs. 2.3%  Wound problems 1% vs. 0%  Dehiscence 1% vs. 0%  Skin thinning 1% vs. 3.1%  Aesthetics on 4-point scale, with 4 being excellent: Overall	

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
									aesthetics 3.26 vs. 2.87, $p<0.05$ ; IMF outcome 3.35 vs. 2.94, $p<0.05$	
McCarthy, 2012 (386)	<a href="#">NCT00639106</a> Memorial Sloan-Kettering Cancer Center, New York, NY University of North Carolina at Chapel Hill, Chapel Hill, N.C	2008-2011	RCT, terminated early  Primary outcome of postoperative pain	AlloDerm	ADM: inferior-lateral portion of pocket created using ADM, neither serratus muscle /fascia nor rectus abdominis fascia elevated  No ADM: submuscular pocket involving serratus muscle/fascia and rectus abdominis fascia	49 ADM, 49 no ADM planned; actual 70 pts total	Age $\geq 21$ years, immediate expander/implant reconstruction  Exclude if prior RT or ALND, significant mastectomy flap ischemia or ALND at time of mastectomy	Difference of 2 points on 1-10 scale (20 points on 1-100 scale) considered clinically significant	Pain at baseline 7 vs. 1.4; removed 3 pts with unusually high baseline pain  Pain in 24h postoperative period 54.6 vs. 42.8, $p=0.19$  Pain in expansion phase 17.0 vs. 4.6, $p=0.65$  Pain at completion of expansion 5.6 vs. 4.6, $p=0.93$  Patient-reported Physical Well-Being (Chest and upper Body scales of BREAST-Q) were not different: 85.6 vs. 86.9 baseline; 65.8 vs. 68.2 immediate 24-hour postoperative; 68.6 vs. 69.3 expansion phase; 79.7 vs. 80.5 completion of expansion  No difference in narcotic use, $p=0.38$  Long-term aesthetic outcome, rate of capsular contracture,	Trial closed early at interim analysis due to slow accrual with 65 pts randomized; probability of obtaining positive result for primary endpoints was at most 11% for immediate postoperative pain and <1% for pain at expansion  ADM did not reduce pain, but numbers are small  Pain may be due to mastectomy process and not reconstruction; or may be due to sutures during reconstruction

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
									patient satisfaction, and QoL (Phase 2, will be separate publication)	
Parks, 2012 (387)	Metropolitan private practice group, Memphis, Tenn.  5 breast surgeons, 3 plastic surgeons	2001-2011; ADM 2005-2010; no ADM 2001-2005	Retrospective  Logistic regression model for tissue expander loss	AlloDerm	Subpectoral pocket with ADM sewn to pectoralis and IMF  No ADM: submuscular	346 pts (511 breasts): 232 pts (346 breasts ADM and 114 pts (165 breasts) without ADM	SSM or modified SSM, immediate reconstruction, tissue expander  Cancer or prophylaxis  32% of mastectomies were contralateral	Expander loss was a bright-line definition of infection	ADM was not a risk factor for expander loss: 11.6% vs. 8.5%; logistic regression OR=0.84 (95% CI=0.38-1.88), p=0.677  Seroma 30.0 vs. 15.7%, p<0.001  Skin necrosis 11.9% vs. 11.5%, p=0.88	
Warren Peled, 2012b (67)	University of California, San Francisco  4 breast surgeons, 1 plastic surgeon	2006-2010	Prospective  Mean follow-up 25.5 months  Logistic regression for complications in cases with PMRT; ORs adjusted for age and BMI using logistic model [note less than 25 pts per group for RT subsets]  No correction for comparison	AlloDerm	Inferior aspect of pectoralis major is left intact at inferior origin superior to IMF; ADM sutured inferiorly and laterally to chest wall at inferolateral aspect of expander to complete the pocket for expander  No ADM: expander placed in subpectoral pocket without added coverage of	450 cases in 288 pts  Cohort 1: 90 cases, years 2006-2007, no ADM  Cohort 2: 100 cases (65 pts), years 2007-2008, all used ADM  Cohort 3: 260 cases (160 pts), years 2008-2010, selective ADM	NSM (inversion and complete excision of nipple core at dermal junction) and immediate expander-implant reconstruction; earlier studies had found lower ischemic complications with 2-stage procedures and using initial minimal expansion  Excluded pts with clinical involvement of NAC or skin or with significant breast ptosis  Cohort 1: consecutive cases without ADM  Cohort 2: the next consecutive cases with ADM  Cohort 3: selective ADM in next 250 cases based on	By time of this study, technical refinements had reduced NAC complications to <5%  Use of PMRT was significantly different (23.3% vs. 14% vs. 12.7%) and PMRT was shown to have negative effect on infection, return to OR and expander-implant loss  The group without ADM had	<u>No multivariate analysis</u>  Infection (requiring oral or iv antibiotics): 15.8% selective ADM; 20% consecutive ADM; 27.8% no ADM. p=0.04  Unplanned return to operating room: 10% selective ADM; 11% consecutive ADM; 23.3% no ADM, p=0.004  Expander-implant loss 5% selective ADM; 7% consecutive ADM; 17.8% no ADM, p=0.001	Concluded that ADM reduced complications; maximum benefit in selected pts with thin mastectomy skin flaps and in pts with PMRT  The risk of infections, unplanned return to OR and expander-implant loss was higher in group with selective ADM than with consecutive ADM, suggesting ADM should be used in

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
			between groups		inferolateral expander		<p>mastectomy skin flap thickness (ADM used in thinner skin flaps)</p> <p>PMRT: 12.7% selective ADM, 14% consecutive ADM, 23.3% no ADM</p> <p>40.7% prophylactic (41.5% selective ADM, 45% consecutive ADM, 33.3% no ADM)</p>	<p>more neoadjuvant chemotherapy, more therapeutic mastectomy, more ALND</p> <p>Downward trend with time could have been partially related to other improvements and not just ADM</p>	<p>Skin flap necrosis: 6.2% selective ADM, 6% consecutive ADM, 11.1% no ADM, p=0.26</p> <p>Seroma 5.8% vs. 4% vs. 4.4%</p> <p>Hematoma 2.7% vs. 3% vs. 3.3%</p> <p>Nipple necrosis 1.2% vs. 1% vs. 0</p> <p>PMRT increased risk of infection (OR= 2.35 selective and OR=2.08 consecutive), return to OR (OR= 5.75 and 1.69) and expander-implant loss (OR=6.07 and 4.87)</p>	<p>pts who are likely to need PMRT</p> <p>No explanation of why ADM decreased infection, and selective ADM had bigger increase than use in all pts</p>
Weichman, 2012 (388)	New York University Langone Medical Center Single institution 7 ablative surgeons and 5 reconstructive surgeon	2007-2010	Retrospective Multivariate logistic regression but results not reported	AlloDerm	<p>All used pectoralis major muscle for coverage</p> <p>ADM: implant covered superiorly with pectoralis and inferior-laterally with ADM sling</p> <p>No ADM: implant total submuscular position with serratus muscle flap and rectus fascia if needed</p>	407 pts (628 breasts): 442 ADM, 186 no ADM	<p>Immediate 2-stage expander-implant</p> <p>No criteria for use of ADM</p> <p>Prophylactic 44.3% vs. 36.0%</p> <p>35% of mastectomies were contralateral</p>	<p>Expander size 408 mL vs. 385 mL, p=0.054</p> <p>Expander fill 169 vs. 135 mL, p=0.0013</p>	<p><u>No multivariate analysis</u></p> <p>Major complications 15.3% vs. 5.4%, p=0.001</p> <p>Infections requiring intravenous antibiotics 8.6% vs. 2.7%, p=0.001; any infection 13.6% vs. 7.5%, p=0.017</p> <p>Flap necrosis requiring excision 6.7% vs. 2.7%, p=0.015; any flap</p>	ADM results in more complications and should be used selectively

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of implant, mesh location	Number of patients	Population	Other details	Outcomes	Notes
									necrosis 8.3% vs. 3.2%, p=0.005 Explantation of tissue expander 7.7% vs. 2.7%, p=0.004 Seroma 1.8% vs. 3.2%, p=0.326 Hematoma 0.5% vs. 1.1%, p=0.586	
AlloDerm (various forms) vs. none										
Weichman, 2013 (389)	New York University Langone Medical Center 5 reconstructive surgeons	2010-2012 AlloDerm RTU Nov 2011-Oct 2012	Prospective cohort study  Univariate logistic analysis	AlloDerm RTU vs. none	Dual-plane with ADM vs. submuscular	546 breasts: 105 AlloDerm RTU, 351 no ADM	All pts undergoing immediate implant-based reconstruction, either with expander or direct implant  Indications for ADM use included lack of muscular coverage, cancer invasion to pectoralis major muscle, immediate implant reconstruction; relative indications included NSM, prior submuscular augmentation  <u>AlloDerm RTU vs. none</u> Specimen weight 587 g vs. 514 g, p=0.0746; 1-stage implant 15.2% vs. 0.8%, p=0.0001; NSM 49.2% vs. 31.9%, p=0.0012; ALND 24.8% vs. 14.5%, p=0.0141; expander size 440 vs. 397 mL, p=0.002; fill volume 206 vs. 148 mL, p=0.001; % fill 46.7% vs. 36.6%, p=0.0001	ADM: release of pectoralis major from IMF, addition of ADM as a sling  Submuscular (no ADM) by elevating pectoralis major muscle, serratus anterior muscle, and partial rectus fascia	<u>AlloDerm RTU vs. none</u> Flap necrosis 10.4% vs. 5.1%, p=0.0658 Major flap necrosis 5.7% vs. 3.4%, p=0.2678 Infection 8.5% vs. 5.7%, p=0.3602 Cellulitis (deep infection) requiring IV antibiotics 4.7% vs. 1.4%, p=0.0551	

\*Year of diagnosis or initial surgery

\*\*Studies only indicated use of ADM but not specific type. Studies in the United States have been included based on primarily human ADM being used in Canada and USA (although Strattice is also common in US), but studies in Europe excluded as non-human ADM is more common

**Abbreviations:**

ACS-NSQIP, American College of Surgeons National Surgical Quality Improvement Program; ACPS-TOPS, American Society of Plastic Surgeons Tracking Outcomes and Operations in Plastic Surgery database; ADM, acellular dermal matrix; ASA status, American Society of Anesthesiologists physical status classification system; BRCA, breast cancer gene; BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CPT, Current Procedural Terminology codes (USA); DTI, direct to implant; IMF, inframammary fold; ICD, International Classification of Diseases; MROC, Mastectomy Reconstruction Outcomes Consortium Study; NAC, nipple areolar complex; NACT, neoadjuvant chemotherapy; NSM, nipple-sparing mastectomy; OR, odds ratio; PMRT, postmastectomy radiotherapy; PRO, patient reported outcomes; pts, patients; RR, relative risk; RT, radiotherapy; RTU, ready to use; SSM, skin-sparing mastectomy; SLND, sentinel lymph node dissection

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q5](#)[Back to Start of Tables](#)**Table 4-13. Question 5: Acellular Dermal Matrix. B. Comparison of ADMs**

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
Arnaout, 2021 (390) Stein, 2021 (391)	<a href="#">NCT03064893</a> REaCT investigators Ottawa Hospital, Ottawa 3 oncologic and 3 reconstructive surgeons	2016-2018	RCT, randomized at the pt level using a web-based program and permuted variable block design, no stratification  If bilateral mastectomy, they received same type of ADM in both breasts	AlloDerm RTU vs. DermACELL	Subpectoral (dual-plane)	62 pts randomized (31 per group); 81 mastectomies (41 AlloDerm RTU, 40 DermACELL)	Immediate subpectoral reconstruction with permanent implant  ReACT prospective pragmatic clinical trial methodology  ADM was non-fenestrated  Excluded tissue expander, excluded prepectoral reconstruction  51.3% NSM (55.3% vs. 47.5%), 48.7% SSM (44.7% vs. 52.5%)  Mastectomy weight 600 g vs. 387 g  ADM prepared according to manufacturer instructions: AlloDerm RTU soaked at least 2 minutes in sterile saline or lactated Ringer solution 2 times; DermACELL was ready for use from the package  32% prophylactic mastectomies	Subpectoral (dual-plane): implant pocket created by elevation of pectoralis major muscle, ADM anchored to IMF and inferior part of the lateral boundary along the anterior maxillary line  Implant placed under pectoralis major muscle and free muscle edge secured to ADM  2 closed suction drains kept in place until output <20 mL per 24 h; maximum 14 days  IV antibiotics upon induction of anesthesia; oral antibiotics for 1 week after surgery	Primary outcome: •Seroma (assessed by drain duration), 10.8 d vs. 9.2 d, p=0.15  Secondary outcomes:  Major complications •Unplanned return to operating room 15.8% vs. 7.5%, p=0.28 •Loss of implant 5.3% vs. 5.0%, p=0.96  Minor complications •Seroma after drain removal 5.3% vs. 12.5%, p=0.28 •Infection requiring antibiotics 7.9% vs. 2.5%, p=0.32 •Red breast syndrome 2.6% vs. 2.5%, p=0.97 •Wound dehiscence 7.9% vs. 5.0%, p=0.68 •Hematoma 5.3% vs. 0, p=0.23 •Skin necrosis 5.3% vs. 10.0%, p=0.77 •Capsular contracture 2.6% vs. 0  Baseline BREAST-Q scores similar; at 3 months the AlloDerm	Despite being RCT, due to small size the two arms have some differences e.g., mastectomy weight (600 g vs. 387 g), location of incision, smoking status (9.7% vs. 3.2%), heart disease (16.1% vs. 9.7%), breast size ≥D cup 12.9% vs. 22.6%, Ptosis grade III or more (0% vs. 10.0%)  Multivariate controlling for preoperative Psychosocial Well-Being, Satisfaction with Breasts, Physical, and Sexual Well-Being found same results

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
									<p>group had higher satisfaction:</p> <ul style="list-style-type: none"> <li>•Satisfaction with Breasts 66.6 vs. 52.5, p=0.03</li> <li>•Overall Satisfaction with Results 84.6% vs. 60.9%, p=0.003</li> <li>•No significant difference in Psychosocial, Sexual, Physical Well-Being</li> </ul> <p>At 12 months no significant differences in PROM (p&gt;0.05)</p>	
Chu, 2023 (392)	Memorial Sloan Kettering Cancer Center, New York, NY, USA	2018-2021	Retrospective Multivariate logistic regression for impact of ADM type on tissue expander loss	726 pts: 115 AlloDerm, 57 FlexHD, (554 SurgiMend - outside scope of review)  Expanders: 194 AlloDerm, 93 FlexHD, 767 SurgiMend  Perforated: 94.8% AlloDerm 98.2% FlexHD, 100% SurgiMend	Prepectoral	726 pts, 1054 expanders	2-stage prepectoral reconstruction  Excluded direct-to-implant, subpectoral plane	ADM sutured to suture tabs then the chest wall	<p>Complications in 90 days, AlloDerm vs. FlexHD</p> <p>Seroma 11.9% vs. 4.3%</p> <p>Infection 5.7% vs. 3.2%</p> <p>Expander loss 4.1% vs. 3.2%; multivariate OR=1.37, p=0.658</p> <p>Expander exposure 1.5% vs. 1.1%</p>	
Berger, 2024 (393)	MedStar Georgetown University Hospital,	2014-2022	Retrospective 6 plastic surgeons	231 pts AlloDerm vs. 405 pts DermACELL	55.0% prepectoral but varied by ADM	738 pts, 1228 breasts	Patients with CPT code for biologic implant for breast or trunk		90-day complication rates are similar between groups	



Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
	Washington, DC (4 hospitals within multicentre hospital)		Multivariate logistic regression model for postoperative outcomes	vs. 102 pts SurgiMend PRS (351 vs. 712 vs. 165 breasts)	type: 47.6% vs. 58.6% vs. 55.8%		Immediate prosthesis-based breast reconstruction, either expander or direct-to-implant  Excluded if not breast reconstruction, was delayed, or if previous failed reconstruction  Surgery varied: NSM 41.9% vs. 72.1% vs. 47.3%		In multivariate analysis, the type of ADM was not independently predictive of any postoperative complication; authors used the reference to be SurgiMend so p values are not available for AlloDerm vs. DermACELL	
Johnson, 2022 (394)	University of Colorado, Aurora, Colorado  Single institution; 2 surgeons	2016-2020	Retrospective  Multiple logistic regression models for primary outcomes of seroma and infection	AlloDerm RTU vs. DermACELL	Subpectoral or prepectoral	150 pts (241 breasts): 88 pts (143 breasts) AlloDerm, 62 pts (98 breasts) DermACELL	AlloDerm RTU is a perforated sheet whereas DermACELL is not  AlloDerm RTU is partially terminally sterilized to 10 <sup>-3</sup>  ADM prepared according to manufacturer guidelines  Prepectoral 30.0% vs. 37.8%; subpectoral 70.0% vs. 62.2%  NSM 47.6% vs. 41.8%; SSM 52.4% vs. 58.1%  Immediate 2-stage reconstruction and had undergone at least first stage  38% contralateral mastectomy; 41% for prophylaxis	Subpectoral: pectoralis elevated and divided at inferomedial origin, ADM inset to IMF and lateral breast border  Prepectoral: pectoralis muscle not elevated; ADM placed in breast pocket and inset into superior, medial, and lateral border with sutures; second sheet of ADM inset into IMF, tissue expander inserted and tabs secured to superficial chest wall	Seroma: univariate 21.7% vs. 8.2%, p=0.005; multivariate p=0.04 (95% CI=1.02-6.07) in abstract; p=0.01, 95% CI=1.29-6.95 in text  Surgical site infection: univariate 13.3% vs. 13.3%, p=0.99; multivariate not analyzed  BMI was associated with higher rate of infection	Slight variations of results in different tables and in text
Zenn, 2016 (395)	Duke University Medical Center	Not stated;	Retrospective  Minimum follow-up 6	AlloDerm RTU vs. DermACELL	Not reported	140 pts (249 implants)	Consecutive pts before and after switch from AlloDerm to		Complications low in both groups	

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
	and Mt. Sinai Health System 2 surgeons	≈2012-2015	months and ranged 6 months to 2 years			70 pts (130 implants) AlloDerm RTU, 70 pts (119 implants) DermACELL	DermACELL; no difference in techniques  No statistical difference in age, indication, RT, or chemotherapy  44% contralateral mastectomy (46% vs. 41%)		Seroma, none  Hematoma 0 vs. 1 (0.8%)  Infection 1 (0.8% vs. 2 (1.7%))	
Agarwal, 2015 (396)  Design and methods	BREASTrial; <a href="#">NCT00872859</a>  University of Utah, Salt Lake City, Utah  Single centre, 1 reconstructive surgeon	2008-2011	RCT  2-year follow-up from definitive reconstruction  Multivariate analysis to correct for differences in pt/disease characteristic in Stage I and III of the trial, but not in Stages II due to fewer pts and events (397-399)	AlloDerm vs. DermaMatrix	ADM as inferolateral sling of the breast pocket	128 pts randomized (199 breasts)  64 pts AlloDerm (101 breasts), 64 pts DermaMatrix (98 breasts)  Loss to follow-up 5 vs. 7 pts (7 vs. 10 breasts)	Immediate expander for breast cancer or BRCA1/BRCA2 mutations  Definitive reconstruction with prosthesis (implant) or autologous tissue after PMRT (41%) and chemotherapy (49%)  At least 12 weeks after last PMRT before definitive reconstruction; at least 3 weeks after chemotherapy before definitive reconstruction  Prophylactic (breast basis): 49% vs. 45%; NSM 49% vs. 48%  Prophylactic (pt basis, no cancer): 21.9% vs. 17.2%	ADM prepared according to manufacturer instructions  Elevation of pectoralis major muscle, release of inferior attachments, placement of tissue expander, placement of ADM to constitute inferolateral pocket, placement of drains, inflation of expander filling as much dead space as possible without creating excessive tension on the skin	See other publications  •Stage 1 (from mastectomy to definitive reconstruction) •Stage II (definitive reconstruction until 3 months) •Stage III (3 months to 2 years after definitive reconstruction)	Arms not equivalent: smokers 0% vs. 9.4%; chemotherapy 39.1% vs. 59.4%; PMRT 31.3% vs. 50.0%; ALND 26.6% vs. 39.1%; cancer stage III or IV 18.7% vs. 37.6%  In general, DermaMatrix arm had more advanced disease
Mendenhall, 2015 (397)  Stage I of trial	BREASTrial; <a href="#">NCT00872859</a>  University of Utah, Salt Lake City, Utah	2008-2011	RCT  For stage I, variable significant on univariable analysis or clinically	AlloDerm vs. DermaMatrix		See above  Sample size too low as it is based on 2.5-fold difference in rate of grade 1-4	Both AlloDerm and DermaMatrix are decellularized, free-dried, aseptically processed, but not terminally sterile		Stage I results  Overall complications 33.6% vs. 38.8%, p=0.52; multivariate p=0.68	Multivariate analysis controlled only for obesity, RT, chemotherapy  Results appear to be per breast (not per patient);

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
			relevant were included in multivariable logistic regression model			complications when comparing arms and this is unrealistic			<p>Major complications 13.8% vs. 21.4%</p> <p>Skin necrosis 17.8% vs. 21.4%, p=0.66; multivariate p=0.74</p> <p>Infection 13.9% vs. 16.3%, p=0.29; multivariate p=0.71</p> <p>Seroma 6.1% vs. 3.1%, p=0.34</p> <p>Hematoma 0 vs. 2.0%, p=0.24</p> <p>Tissue expander loss 5% vs. 11.2%, p=0.11; too few events for multivariate analysis</p> <p>Time for expansion 42 days vs. 70 days, p&lt;0.001</p>	cancer status/ indication not included in multivariate analysis
Mendenhall, 2017 (398)  Stage II of trial	BREASTrial; <a href="#">NCT00872859</a>  University of Utah, Salt Lake City, Utah	2008-2011	<b>RCT</b>  Authors indicate there were too few pts and complications to allow multivariate analysis	AlloDerm vs. DermaMatrix		111 pts and 173 breasts were available for analysis in stage II of the trial			<p>Stage II (0-3 months after definitive reconstruction)</p> <p>Overall complications 15.4% vs. 18.3%, p=0.8</p> <p>Major complications 5.5% vs. 9.6%, p=0.2</p> <p>Infection 3.3% vs. 6.1%, p=0.3</p> <p>Skin necrosis 2.2% vs. 3.7%, p=0.5</p> <p>Implant loss 2.2% vs. 3.7%, p=0.5</p>	DermaMatrix group had more adjuvant chemotherapy, PMRT, higher stage disease, autologous reconstruction

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
Mendenhall, 2023 (399)  Stage III of trial	BREASTrial; <a href="#">NCT00872859</a>  University of Utah, Salt Lake City, Utah	2008-2011	RCT  Multivariable logistic regression for effect of matrix type, age, obesity, Radiation therapy, chemotherapy, type of reconstruction on complications	AlloDerm vs. DermaMatrix		108 pts (167 breasts available for analysis)			Stage III (3 months to 2 years after definitive reconstruction)  Overall complications 6% vs. 13.2%, p=0.3; multivariate p=0.52  Patient satisfaction questionnaire not validated (was before BREAST-Q and BRECON-31 became popular)	Only 10 complications so too few events for multivariate analysis
Palaia, 2015 (149)	North Westchester Surgical Services group  2 oncologic breast surgeons, 3 reconstructive plastic surgeons  Single centre	2006-2011	Retrospective  Multivariate regression  Stratified by ADM type and fenestration status  Postoperative data for at least 6 months after last reconstruction or complication	AlloDerm (± fenestration) vs. FlexHD (± fenestration)	Not reported	450 pts, 603 breasts  134 pts (179 breasts) AlloDerm (103 pts fenestrated, 31 without)  316 pts (424 breasts) FlexHD (259 pts fenestrated, 57 without)	Immediate 2-stage reconstruction with ADM  6x16 cm ADM in all pts  AlloDerm rehydrated in saline ≥45 minutes; FlexHD is prehydrated  Fenestration by cutting through full thickness of ADM with an 11 or 15 scalpel set at intervals of ≈1 cm; decision to fenestrate at surgeon's discretion	Not reported	Per breast outcomes  AlloDerm vs. FlexHD: • Seroma 14.0% vs. 12.3%, p=0.562; OR=0.84, p=0.7408 • Infection 11.2% vs. 9.2%, p=0.4558; OR=1.19, p=0.7877 • Extrusion 6.2% vs. 1.9%, p=0.0062; [multivariate OR=4.30, p=0.0031 but <25 events] • Explantation 8.9% vs. 7.3%, p=0.4959; OR=1.25, p=0.7547  Fenestrated vs. not: • Seroma 11.1% vs. 20.0%, p=0.0098; multivariate OR=0.34, p=0.0026;	Cosmetic score 8.7±1.5 AlloDerm vs. 8.4±1.7 FlexHD, p=0.0717; multivariate p=0.0466. It is unclear whether this small difference is meaningful to patients

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
									<ul style="list-style-type: none"> <li>No differences in infection, extrusion, explantation, cosmetic score</li> </ul>	
Seth, 2013 (400)	Northwestern Memorial Hospital, Chicago, Illinois 2 plastic surgeons	2006-2011	Retrospective Multiple regression  Mean follow-up 60.6 weeks	AlloDerm vs. FlexHD	Dual-plane	255 pts, 369 breasts 96 pts (136 breasts AlloDerm; 159 pts (233 breasts) FlexHD	<p>All pts in which AlloDerm (cryopreserved) or FlexHD (prehydrated) ADM was used; choice of product based on surgeon preference and pt factors</p> <p>Expander/implant reconstruction (4.4% and 6.4% autologous)</p> <p>Significant differences in age, BMI, indication, chemotherapy, size of ADM, expander size and intraoperative fill volume</p>	Lower border of pectoralis muscle disinserted with bovie electrocautery and ADM secured to lower pole defect, lower portion of ADM sutured to IMF and lateral aspect to serratus muscle fascia	<p>Total complications 19.1% vs. 19.3%, p=1.00; multiple regression OR=0.99, 95% CI=0.58-1.69, p=1.00</p> <p>Infection 10.3% vs. 5.2%, p=0.09; multivariate OR=2.11, 95% CI=0.95-4.71, p=0.09</p> <p>Flap necrosis (8.1% vs. 9.0%, p=0.85; multiple regression OR=0.88, p=0.85)</p> <p>No differences in univariate analysis (too few events multivariate) for expander migration (none), hematoma 2.9% vs. 1.3%, p=0.43), seroma (2.2% vs. 2.1%, p=1.00), exposure/dehiscence (5.9% vs. 6.4%, p=1.00)</p>	P values are identical before and after multiple regression analysis
Liu, 2014 (401)	University of Washington School of Medicine, Seattle, Washington	2006-2011	Retrospective Multivariate analysis; multiple logistic	AlloDerm vs. FlexHD vs. none	With ADM (not in methods, but background indicates ADM for	165 AlloDerm, 97 FlexHD, 177 no ADM	<p>Consecutive pts with 1 or 2-stage immediate reconstruction</p> <p>89.2% SSM, 4.3% NSM, 6.5% simple/total mastectomy</p>		<p>AlloDerm vs. FlexHD</p> <p>Surgical site infection 8.5% vs. 14.4%, p=0.15; multivariate</p>	Include in 5B as used multivariate analysis but only enough pts or events for

Guideline 17-10 v2

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
	Single institution		regression models		coverage of lower pole of the breast  No ADM: either partial submuscular with part of lower pole bare or coverage using serratus anterior or rectus abdominis fascia		34.7% of breasts prophylactic; 30% contralateral mastectomy  65% of mastectomies for oncologic reasons		OR=0.44, 95% CI=0.19-1.01, p=0.053  Delayed healing 21.2% vs. 18.6%, p=0.64; multivariate OR=1.12, 95% CI=0.58-2.19, p=0.74	infection and delayed healing
Ranganathan , 2015 (402)	University of Michigan Health System, Ann Arbor, Mich.  Reconstruction by 7 surgeons	1998-2013	Retrospective  Multivariate analysis: multinomial logistic model to investigate association of infection with pt characteristic  Mean follow-up 20.0 months (2.0 years AlloDerm, 1.4 years FlexHD)	AlloDerm vs. FlexHD	Not reported	309 pts (521 breasts)  AlloDerm: 123 pts (206 breasts)  FlexHD: 186 pts (315 breasts)	Implant-based reconstruction  93.2% immediate, 4.2% delayed, 2.6% both  Oncologic indication (by breast): 50.5% vs. 46.7%  ADM choice based on surgeon preference  41% contralateral mastectomy	Not reported	<u>Results per pt basis</u>  •Seroma 6.5% vs. 3.8%, p=0.27; OR=1.24 (95% CI=0.28-5.48), p=0.77 •Hematoma 6.5% vs. 5.4%, p=0.68 •Major infection (requiring IV antibiotics) 8.1% vs. 17.7%, p=0.039; OR=0.50 (95% CI=0.16-1.00), p=0.049 •Delayed wound healing 3.3% vs. 5.4%, p=0.38; OR=0.53 (95% CI=0.13-2.17), p=0.38	<u>Results per breast basis</u>  •Seroma 4.4% vs. 2.9%, p=0.36; OR=0.63 (95% CI=0.20-2.02), p=0.44 •Hematoma 4.4% vs. 3.2%, p=0.48 •Major infection (requiring IV antibiotics) 5.3% vs. 12.7%, p=0.011; OR=0.35 (95% CI=0.17-0.71), p=0.004 •Delayed wound healing 2.4% vs. 4.1%, p=0.30; OR=0.51 (95%

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
									<ul style="list-style-type: none"> <li>•Return to operating room 20.3% vs. 20.4%, p=0.98</li> <li>•Implant exposure 2.4% vs. 2.2%, p=1.0</li> </ul> <p>Infection lower with AlloDerm</p>	<p>CI=0.17-1.52), p=0.23</p> <ul style="list-style-type: none"> <li>•Return to operating room 13.6% vs. 14.3%, p=0.82</li> <li>•Implant exposure 1.5% vs. 1.3%, p=0.86</li> </ul>
Sobti, 2016 (403)	A tertiary academic medical centre, Boston, Mass.  Single plastic surgeon	2009-2015	Retrospective  Unadjusted logistic regression by pt and breast  Binomial regression to investigate association between covariates	AlloDerm (RTU or freeze-dried) vs. FlexHD (primarily Pliable Perforated)	Not reported	132 pts (224 breasts) with AlloDerm, 101 pts (170 breasts) FlexHD	ADM-based reconstruction; choice of ADM at surgeon's preference  AlloDerm when used: 68.9% RTU, 31.1% freeze-dried  FlexHD when used: 80.2% Pliable/Perforated, 18.8% Pliable, 0.9% Structural  90.2% vs. 98.0 direct to implant  41% contralateral reconstruction	Not reported	<p>Infection (by pt) 4.6% AlloDerm vs. 5.0% FlexHD, univariate p=0.89, binomial regression OR=0.69, 95% CI=0.17-2.56, p=0.56; by breast OR=0.78, 95% CI=0.22-2.72, p=0.69</p> <p>No differences in seroma, hematoma, explantation, delayed wound healing, explantation</p>	
Broyles, 2021 (404)	Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction with ADM  <a href="#">NCT03145337</a>  Multicentre, United States (7 sites)	2016-2018	RCT  1:1 blocked randomization per site  Designed as noninferiority trial  Multivariate models  Mean follow-up 10.7 months after completing	AlloDerm RTU vs. FlexHD Pliable; all matrixes were perforated	Prepectoral or partial submuscular	230 pts (384 breasts) were randomized  117 pts (197 breasts) AlloDerm RTU; 113 pts (187 breasts) FlexHD Pliable	Immediate implant-based reconstruction  Decisions of expander or direct-to-implant (25.6% vs. 21.2%) and of prepectoral (20.8% vs. 20.3%) or partial submuscular plane were at discretion of surgeon  SSM (53.0% vs. 60.2%) or NSM  40% contralateral reconstruction  Study did not measure PROs, aesthetics, long-term	Prepectoral: ADM placed to cover anterior surface of the tissue expander and sutured to the chest wall  Partial submuscular: inferior origin of pectoralis major muscle detached from chest wall and ADM inset between inferior	<p>Overall complications 7.1% vs. 4.3%, p=0.233</p> <p>Seroma 4.6% vs. 3.7%, p=0.801</p> <p>Infection 2.5% vs. 1.1%, p=0.450</p> <p>Explantation due to seroma or infection 2.0% vs. 1.6%, p=1.000</p> <p>Only 22 events overall, so multivariate results not extracted</p>	<p>Sample size of 106 pts/group calculated assuming complication rate and noninferiority limit of 8%; final sample size had 80% power to detect effect size odds ratio of 1.83</p> <p>Study underpowered due to lower than</p>

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
			reconstruction				outcomes such as capsular contraction	border of muscle and IMF		anticipated complication rates
Keifer, 2016 (405)	Emory University (2 reconstructive surgeons) and a private practice (1 reconstructive surgeon), Atlanta, Ga	2010-2015	Retrospective  At least 60 days follow-up  Binary logistic regression using GEE approach; data reported are uncorrected	AlloDerm vs. Cortiva	Not reported	166 pts, 298 breasts: 174 AlloDerm, 124 Cortiva	Tissue expander (198 breasts) or direct-to-implant (100 breasts)  51% vs. 39% of mastectomies due to cancer diagnosis  NSM 13.2% vs. 26.6%  44% contralateral reconstruction	Not reported	Overall complications 9.2% vs. 14.5%, p=0.195; logistic regression OR=0.55 (95% CI=0.24-1.27), p=0.160  Seroma/hematoma 5.2% vs. 5.6%, p=1.000  Infection 3.4% vs. 4.0%, p=1.000  Mastectomy flap necrosis 0.6% vs. 4.8%, p=0.022; logistic regression OR=0.089 (95% CI=0.007-1.092), p=0.059 [based on only 8 events]	Authors concluded that Cortiva has equivalent complication frequency to AlloDerm
Hadad, 2015 (406)	Brigham and Women's Hospital, Boston, Mass.  Single surgeon	2006-2011	Retrospective  At least 3-month follow-up	AlloDerm (aseptic), more vs. less	Traditional is dual-plane; minimal use ADM is closer to submuscular	265 pts, 380 breasts  108 breasts traditional ADM  225 breasts minimal-use ADM  35 breasts no ADM in high-risk reconstructions  12 breasts did not meet criteria	Prosthesis-based reconstructions (1 or 2 stage); did not include outcomes after exchange of expander for permanent implant  Traditional ADM sling with large piece of ADM (167.9 cm <sup>2</sup> ) along entire released inferior and lateral borders of pectoralis major and chest wall; mostly before 2006-2008; 28 breasts after 2008 because of unusually high pectoralis muscle with respect to IMF or tissue at IMF had excess skeletonization	No ADM: mostly for morbidly obese, used serratus and pectoralis minor muscle/fascia to form later border of breast pocket  With ADM: assess viability of skin, muscle integrity especially pectoralis major at inferior and medial origin; create wide subpectoral plane at lateral border of pectoralis, aggressive medial	Seroma: 3% traditional vs. 0% minimal ADM, p=0.01  Major skin necrosis 12.0% vs. 12.4%  Infection and reconstruction loss 9% traditional vs. 1% minimal ADM, p<0.05  Comparison for obese pts (BMI >30 kg/m <sup>2</sup> ) before and after 2009 when new pathway for ADM use started: 13 pts vs. 53 pts; ADM 207 cm <sup>2</sup> vs. 49 cm <sup>2</sup> ; major necrosis 23% vs.	Note that it is not only a decrease in ADM, but also alterations in surgery to allow this



Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
							<p>Minimal-use ADM (76 cm<sup>2</sup>) from 2009-2011 wherever feasible: patching of lateral area of reconstruction; pectoralis is more widely undermined but not released</p> <p>No ADM: high-risk reconstructions, mostly morbidly obese with excessive lateral chest wall tissue redundancy or comorbidities that would impair wound healing or ADM incorporation</p>	elevation of the muscle; inferiorly elevate the pectoralis to just below IMF; overall attachment of pectoralis remains intact; lateral opening under pectoralis starting at IMF curves towards axilla; one 8x16 cm thick ADM often sufficient for bilateral reconstruction	17%; seroma 15% vs. 6%, infection and loss of reconstruction 38% vs. 9%	
<p>Lin, 2024 (111)</p> <p>Liston, 2024 (283)</p> <p>See also Shanno, 2024 (95)</p>	Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA	2007-2019	<p>Single institution, retrospective</p> <p>At least 2 years follow-up post-operatively</p> <p>NSM complications</p> <p>Expander vs. direct-to-implant</p> <p>Plane of reconstruction (Q4)</p> <p>Use of ADM (Q5)</p>	FlexHD, AlloDerm, Vicryl, Vicryl/ADM hybrid, Surgimend	Not reported	1705 pts and 3035 breasts: number with ADM not reported	<p>NSM and implant-based reconstruction</p> <p>Excluded delayed or autologous reconstruction</p> <p>Most operations by 3 breast surgeons and plastic surgeons</p> <p>Surgeons chose plane of reconstruction and type of ADM/mesh based on experience or preference, pt characteristics, and treatment plan</p>		<p>ADM or mesh vs. muscle only complications:</p> <ul style="list-style-type: none"> <li>Overall 9.06% vs. 10.33%; multivariate OR=0.749 (95% CI=0.404-1.391, p=0.361)</li> <li>Nipple necrosis 1.07% vs. 2.89%, p&lt;0.05; multivariate OR=1.087 (95% CI=0.346-3.415, p=0.886)</li> <li>Skin flap necrosis 3.44% vs. 5.37%</li> <li>Infection 3.26% vs. 3.72%</li> <li>Explantation 4.15% vs. 3.31%</li> <li>Hematoma 1.32% vs. 2.89%, p&lt;0.05</li> </ul>	<p>Complications, AlloDerm vs. Flex HD vs. Vicryl (or Vicryl hybrid) [estimated from graphs]</p> <p>Overall: 8.3% vs. 10.2% vs. 11.8%</p> <p>Skin flap necrosis; 2.5% vs. 5.8% vs. 5.8%</p> <p>Infection 3.1% vs. 2.4% vs. 4.5%</p> <p>Explantation 3.4% vs. 6.3% vs. 6.3%</p> <p>Rates of nipple necrosis, hematoma, seroma, ruptured</p>

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant	Number of patients	Population	Surgical details	Outcomes	Other
									<ul style="list-style-type: none"><li>• Seroma 1.00% vs. 1.65%</li><li>• Ruptured prosthesis 0.61% vs. 0.41%</li><li>• Reconstruction failure 2.86% vs. 3.31%</li></ul>	prosthesis similar between groups

\*Year of diagnosis or initial surgery

**Abbreviations:**

ADM, acellular dermal matrix; ALND, axillary lymph node dissection; BREASTrial, Breast Reconstruction Evaluation Using Acellular Dermal Matrix as a Sling Trial; BRCA, breast cancer gene; BMI, body mass index; CI, confidence interval; CPT, Current Procedural Terminology codes (USA); GEE, general estimating equation approach; IMF, inframammary fold; IV, intravenous; NSM, nipple-sparing mastectomy; OR, odds ratio; PMRT, postmastectomy radiotherapy; PRO, patient reported outcome; PROM, patient reported outcome measure; pts, patients; REaCT, Rethinking Clinical Trials program; RCT, randomized control trial; RTU, ready to use; SSM, skin-sparing mastectomy

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q5](#)[Back to Start of Tables](#)**Table 4-14. Question 5: Acellular Dermal Matrix. C. ADM Treatments**

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	
Frey, 2015 (407)  Overlaps with Weichman, 2013 (389)	NYU Langone Medical Center, New York, NY  Multiple surgeons	2010-2014	Retrospective  Univariate analysis for risk factors for infection	Total submuscular coverage (no ADM)  AlloDerm: aseptic vs. sterile RTU vs. contoured & fenestrated	Submuscular without ADM  Dual-plane with ADM as an inferolateral sling	620 pts (1019 breasts)  Total submuscular 645 breasts, aseptic AlloDerm 91 breasts, AlloDerm RTU 164 breasts, AlloDerm contour fenestrated 119 breasts	Immediate tissue expander (86.5%) or permanent implant (13.4%)  Total submuscular position with elevation of pectoralis and serratus anterior muscles when possible  ADM use if congenital insufficiency or iatrogenic injury making total submuscular placement not possible; decision at surgeon discretion  Trends in type of surgery (more NSM) and direct to implant reconstruction and type of ADM over time (switch from aseptic to sterile to sterile contoured) may impact complication rates  39% of mastectomies were contralateral		Infection (oral antibiotics) 2.5% vs. 7.7% vs. 3.0% vs. 0  Major infection (iv antibiotics) 1.2% vs. 11.0% vs. 4.3% vs. 1.7%  Explantation 1.2% vs. 7.7% vs. 3.0% vs. 5.0%  Seroma 1.1% vs. 4.4% vs. 1.2% vs. 2.5%  Hematoma 1.2% vs. 1.1% vs. 0 vs. 0  Minor flap necrosis 2.9% vs. 2.2% vs. 4.9% vs. 10.9%  Major flap necrosis 2.9% vs. 11.0% vs. 3.7% vs. 6.7%	Groups were not equivalent:  Age 51.0 vs. 49.1 vs. 49.4 vs. 46.4 years old  Previous RT 6.7% vs. 3.3% vs. 7.3% vs. 0  PMRT 5.9% vs. 14.3% vs. 10.4% vs. 0  NSM 30.7% vs. 27.5% vs. 51.8% vs. 68.0%  Expander 96.6% vs. 83.5% vs. 77.4% vs. 46.2%  Direct implant 3.3% vs. 16.5% vs. 22.6% vs. 53.8%  Aseptic had more infections and flap necrosis than sterile RTU (see also Weichman, 2013 (389)) or submuscular  Contour had more flap necrosis than sterile RTU, possibly due to more direct implants
Weichman, 2013 (389)	New York University	2010-2012	Prospective cohort study	AlloDerm (aseptic) vs.	Dual-plane with ADM	90 aseptic AlloDerm,	All pts undergoing immediate implant-based	ADM: release of pectoralis major	<u>AlloDerm aseptic vs. RTU</u>	

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	
Overlaps with Frey, 2015 (407)	Langone Medical Center 5 reconstructive surgeons	Aseptic AlloDerm Nov 2010-Oct 2011  AlloDerm RTU Nov 2011-Oct 2012	Univariate logistic analysis	AlloDerm RTU  [see other table for AlloDerm RTU vs. none]		105 AlloDerm RTU	reconstruction, either with expander or direct implant  Indications for ADM use included lack of muscular coverage, cancer invasion to pectoralis major muscle, immediate implant reconstruction; relative indications included NSM, prior submuscular augmentation  <u>AlloDerm aseptic vs. RTU</u>  ADM groups similar in age, 1 or 2-stage implant, SLNB and ALND, indication for surgery, chemotherapy, expander size, fill amount and size, comorbidities, smoking  Specimen weight 697 g vs. 587 g, p=0.0485  BMI 26.6 vs. 24.92 kg/m <sup>2</sup> , p=0.0376  NSM 27.5% vs. 49.2%, p=0.0021  Prophylactic 38.8% vs. 32.3%	from IMF, addition of ADM as a sling	Flap necrosis 13.3% vs. 10.4% p=0.6571  Major flap necrosis 11.1% vs. 5.7%, p=0.1977  Infection 20.0% vs. 8.5%, p=0.0088  Cellulitis (deep infection) requiring IV antibiotics 12.2% vs. 4.7%, p=0.069	
Yuen, 2014 (408)	University of Arkansas for Medical Sciences  Mastectomy by 3 surgeons; single plastic surgeon	Feb-Aug 2012  Control June 2011-Jan 2012	Retrospective  Multivariable generalized linear mixed model for cellulitis	AlloDerm: aseptic/ freeze-dried vs. sterile/RTU	Dual-plane: internal hammock over lower one-third to one-half of the expander or implant	103 pts: 51 pts (96 breasts) AlloDerm (freeze-dried), 52 pts (100 breasts) AlloDerm RTU	Consecutive pts with immediate single or 2-stage implant reconstruction with ADM: AlloDerm RTU compared with historical controls in the previous 7 months with AlloDerm  Mean BMI $\geq 30$ kg/m <sup>2</sup> : 53% vs. 37%  Hypertension 39% vs. 23%	2 pieces 8×12 cm AlloDerm in medium-sized breasts or 10×20 cm pieces in larger breasts	Complication per breast, freeze-dried vs. RTU:  Seroma 18.8% vs. 22.0%, p=0.599;  Cellulitis 12.5% vs. 21.0%, p=0.129; multivariate analysis	Too few patients (27 and 19 per group with BMI $\geq 30$ kg/m <sup>2</sup> ) for subgroup analysis by BMI  Results opposite of those found in other studies, but small number of pts and groups not equivalent

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	
							Bilateral reconstruction 90% vs. 92%  Mostly NSM (TSSM) 80% vs. 90%  47% of mastectomies were contralateral		aOR=0.269, p=0.011  Explantation (all due to infection) 7.3% vs. 6.0%, p=0.780	
Parikh, 2018 (355)	Siteman Cancer Center in Saint Louis  6 breast surgeons, 3 plastic surgeons	2005-2015	Retrospective  Multivariate regression for primary outcomes  ≥2 years follow-up	AlloDerm: aseptic/freeze-dried (2005-2010) vs. sterile/RTU (2010-2015)	Dual-plane (partial submuscular)	1,285 pts (2,039 breasts)  612 pts (910 breasts) AlloDerm aseptic; 673 pts (1,129 breasts) AlloDerm RTU	Consecutive pts with immediate implant-based with expander or direct-to-implant reconstruction and AlloDerm ADM  Excluded prepectoral  Prophylactic mastectomy 0 vs. 7.3%  NSM 1.0% vs. 21.4%  Bilateral procedure 48.7% vs. 67.8%  Direct to implant 0 vs. 9.4%	Elevation of pectoralis major muscle, ADM used for coverage of lower pole as inferolateral sling  Non-perforated 8×16 cm sheet for expander or 10×20 cm sheet for direct to implant	Any complication, multivariate analysis OR=1.149 (95% CI=0.843-1.568), p=0.3794  Explantation 18.0% vs. 12.0%, p=0.0036; multivariate OR=1.570 (95% CI=1.087-2.267), p=0.0161  Infections requiring iv antibiotics 11.3% vs. 10.4%, p=0.6075; multivariate OR=1.064 (95% CI=0.7320-1.546), p=0.7455  Wound dehiscence 2.5% vs. 0.9%, p=0.3243  Flap necrosis 2.5% vs. 0.7%, p=0.1908  Seroma 5.2% vs. 6.0%, p=0.5735  Hematoma 1.1% vs. 1.9%, p=0.2531	Smoking, PMRT, BMI were independent predictors of any complication

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	
									Implant exposure, malposition, deflation, or rupture 2.5% vs. 0.7%, p=0.1908	
Widmyer, 2019 (409)	Summa Health System, Akron, Ohio  Single surgeon	2009-2016	Retrospective  Mean follow-up longer in freeze-dried group	AlloDerm: aseptic/ freeze-dried vs. sterile/ RTU	Subpectoral in aseptic group; 92% subpectoral and 8% prepectoral in sterile/RTU group	236 pts (378 breasts); 151 AlloDerm aseptic and 227 AlloDerm sterile RTU	Consecutive implant-based reconstructions, first pts (until 2011) received AlloDerm aseptic and later pts (starting in 2011) received AlloDerm sterile RTU  The last 123 breasts using AlloDerm RTU used perforated contoured form  Used broader definition of infection than most publications  94 unilateral, 142 bilateral  Cancer in 116 breasts (49% of pts, 31% of breasts), prophylaxis in 262 breasts (69%)  AlloDerm aseptic group younger and lower BMI  Expanders 87% vs. 36%  38% of mastectomies were contralateral	Not reported	Infection 17% vs. 7.9%, p=0.0083  Seroma 9.3% vs. 8.4%, p=0.85  Hematoma 2.0% vs. 1.8%, p=1.00  Skin necrosis 6.6% vs. 9.3%, p=0.45  Dehiscence 5.3% vs. 3.1%, p=0.29  Implant loss 9.3% vs. 3.5%, p=0.02  Unplanned reoperation 22.5% vs. 9.7%, p=0.001	Infection, explantation, reoperation lower in sterile AlloDerm RTU group, but no multivariate analysis  Results for perforated contoured ADM not reported separately
Hanson, 2018 (410)	The University of Texas M. D. Anderson Cancer Center	2006-2016	Retrospective  Propensity-score matching, stratified on unilateral and bilateral pts	AlloDerm: aseptic/dried vs. sterile/ RTU	Not reported (but excluded submuscular)	988 breasts; 53.8% freeze-dried, 46.2% RTU  384 propensity-score-	Immediate expander/implant (2-stage) reconstruction  Excluded total muscle coverage  Occurrence at surgical site included seroma, dehiscence, surgical-site		After matching:  Early complication 37.5% vs. 28.9%, p=0.011  Surgical site occurrence (first	

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	
			≥30 days postoperative follow-up (not part of matching) median 50 vs. 24 months			matched pairs	infection, or reconstructive failure ≈1/3 cases included prophylactic mastectomies 11% NSM Well matched except in ADM area (125.3 vs. 166.7 cm <sup>2</sup> ) and initial expansion (68.6 vs. 51.4 mL); final volume was similar (530.9 vs. 513.0 mL)		stage) 21.4% vs. 16.7%, p=0.103 Infection 9.6% vs. 7.8%, p=0.354 Failure 7.8% vs. 4.4%, p=0.050 Flap necrosis 24% vs. 18.2%, p=0.054 2 <sup>nd</sup> stage complication 0.3% vs. 3.9%, p<0.001	
Han, 2023a (139)	Yonsei University College of Medicine; & Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea	2018-2020	Retrospective  Multivariate analysis was not used  Single plastic surgeon	DermACELL or MegaDerm (both gamma-irradiated)  Fenestrated during operation to enlarge size of ADM	Prepectoral; wrap-around or anterior coverage with ADM	159 pts: 87 wrap-around, 72 anterior coverage	Immediate prepectoral direct to implant reconstruction  Presurgical ptosis evaluated using Regnault classification to determine placement: ptosis grade II or III had wrap-around placement; rest had anterior placement  Preoperative characteristics similar between groups	Skin flap evaluated by indocyanine green laser fluorescence; used direct-to-implant if skin flap viability was acceptable  Pocket, including IMF defined with sutures  For anterior coverage, ADM vs. sutured to anterior surface of pectoralis major, along superomedial part and IMF to create pocket  In wrap-around, meshed ADM completed wrapped around implant on a sterile table then inserted over pectoralis major	Overall complications in 13 pts (14.9%) vs. 9 pts (12.5) within 6 months, p=0.82  Infection 5.75% vs. 1.39%, p=0.38 early; 1.15% vs. 2.78%, p=0.59 late  Seroma 6.90% vs. 5.56%, p=1.0 early; 1.15% vs. 1.39%, p=1.0 late  Mastectomy flap necrosis 3.45% vs. 8.33%, p=0.38  Total drainage amount 762.1 mL vs. 805.9 mL, p=0.45  Capsular contracture 4.6% vs. 1.39%, p=0.38	Complication rates similar; wrap-around can make breast more ptotic in shape than anterior coverage

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	
								muscle with ≈ 4 fixation points to upper pole of pectoralis muscle or fascia	Sternal notch-to-nipple distance change 4.44% vs. 2.08%, p=0.03  Midclavicle-to-nipple distance change 4.94% vs. 2.64%, p=0.04	
Han 2023b (411)	Yonsei University College of Medicine; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea	2019-2020	Retrospective  Multivariate analysis not used  2 surgeons	ADM, radiation sterilized or not  Irradiated: DermACELL, MegaDerm  Non-irradiated: CGCryoderm  Fenestrated during operation to enlarge size of ADM	Prepectoral  ADM product randomly chosen depending on availability	357 pts: 175 sterilized, 182 not sterilized ADM	Immediate prepectoral direct-to-implant breast reconstruction  Comorbidities, sterilized vs. non-sterilized: hypertension 4.0% vs. 13.3%; diabetes 2.9% vs. 3.3%, dyslipidemia 1.1% vs. 4.9%, current smoker 2.3% vs. 3.3%  BMI and age similar	Skin flap evaluated by indocyanine green laser fluorescence; used direct-to-implant if skin flap viability was acceptable  Pocket, including IMF defined with sutures  ADM wrapped and sutured around the implant; implant inserted above pectoralis major muscle and incision site closed with sutures	Surgical complications  Seroma 9.7% vs. 6.6%, p=0.281  Infection 5.7% vs. 4.4%, p=0.634  Mastectomy flap necrosis 8.6% vs. 7.7%, p=0.761  Capsular contracture 8.0% vs. 7.1%, p=0.759  Implant failure 3.4% vs. 0, p=0.013	Similar rates of infection but sterilized group had more return to operating room (6 vs. 1 pt), explantation (4 vs. 0 pts)

\*Year of diagnosis or initial surgery

**Abbreviations:**

ADM, acellular dermal matrix; ALND, axillary lymph node dissection; aOR, adjusted odds ratio; BMI, body mass index; CI, confidence interval; IMF, inframammary fold; IV, intravenous; pts, patients; RTU, ready to use; NSM, nipple-sparing mastectomy; OR, odds ratio; PMRT, postmastectomy radiotherapy; pts, patients; RT, radiotherapy; SLNB, sentinel lymph node biopsy; TSSM, total skin-sparing mastectomy



[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results Q5](#)[Back to Start of Tables](#)**Table 4-15. Question 5: Acellular Dermal Matrix. D. Comparison of synthetic mesh**

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	Other
Sigalove, 2022 (151)	Washington State University, Vancouver, Wash.  3 breast oncologic surgeons, 1 reconstructive surgeon	2015-2020	Retrospective  Chi-square test or one-way analysis of variance  Follow-up average 41.9 vs. 15.0 months	AlloDerm (early period) vs. GalaFLEX + AlloDerm (later pts)	GalaFLEX-lower third of expander covered by AlloDerm and rest by GalaFLEX	AlloDerm alone 128 pts (249 breasts); AlloDerm-GalaFLEX 135 pts (250 breasts)	NSM, SSM, or skin-reducing mastectomy  GalaFLEX investigated as a partial replacement of AlloDerm to reduce cost  Consecutive pts with immediate expander-implant (2-stage) prepectoral reconstruction  Both groups well-matched except that BMI and obesity, preoperative chemotherapy, skin-reducing mastectomy, and bilateral reconstruction higher in AlloDerm alone group; NSM lower in AlloDerm alone group (33.7% vs. 54.0%)	Reconstruction when flap perfusion deemed adequate, as assessed clinically (early part of study) or a perfusion assessment device  Prepectoral space collapsed and adjusted to accommodate expander; expander wrapped with matrix (AlloDerm or AlloDerm on lower anterior portion and inferior gutter and GalaFLEX covering remainder of expander both anteriorly and posteriorly); matrix secured to pectoralis major muscle and subcutaneous tissue  2 drains with AlloDerm, or one drain with AlloDerm-GalaFLEX	Any complication 7.6% vs. 6.4%, p=0.590; all were in first year  Infection 1.6% vs. 2.0%, p=0.741  Major skin necrosis 2.8% vs. 0.8%, p=0.091  Any skin necrosis 5.2% vs. 1.2%, p=0.011  Seroma 2.8% vs. 3.2%, p=0.799  Capsular contracture 0.8% in each, p=0.997  Prosthesis exposure/extrusion 1.6% vs. 3.2%, p=0.245  Prosthesis loss	Skin necrosis lower in AlloDerm-GalaFLEX group, but could be due to differences in pt/disease characteristics and operating factors (expertise development and transition in methods to evaluate perfusion)  Authors indicate GalaFLEX is stiffer and therefore gives a more stable pocket but is not preferred for lower pole to allow for expansion

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	Other
Levy, 2020 (152)	Weill Cornell Medicine, New York, NY  Protocol 1604017199 R001	2011-2016	Retrospective  3 breast surgeons, 1 plastic surgeon  Follow-up 26 vs. 15 months  Multivariate analysis not used	AlloMax vs. Phasic™ (P4HB)  ADM was fenestrated with No. 15 scalpel blade  ADM or P4HB soaked in antibiotic saline for 60 seconds prior to use	Subpectoral (dual-plane)  AlloMax for first 112 pts, P4HB for next 62 pts	107 pts, 192 reconstructions with ADM vs. 62 pts (112 cases) with P4HB mesh	INSM or SSM, immediate expander-based reconstruction for breast cancer or prophylaxis  Baseline characteristics similar  2 different time periods: 2011-Oct 2014 for AlloMax; Oct 2014-2016 for P4HB	Pectoralis major released from inferior and inferomedial attachments to create submuscular pocket; ADM or mesh fixed to IMF and lateral chest wall; expander placed in pocket and cephalad portion of ADM or mesh trimmed and secured in place; expander filled with minimal amount of saline to unfold (no pressure on overlying skin)	Infection: 17.71% vs. 11.21%, p=0.18; OR=0.59, p=0.15  Time to drain removal 18 vs. 15 days, p=0.008  Major complications 24.11% vs. 14.52%, p=0.17, OR=0.55, p=0.14  Minor complications 9.82% vs. 11.29%, p=0.80; OR=1.11, p=0.83  Seroma 3.13% vs. 0.93%, p=0.43, OR=0.17, p=0.11  Necrosis 8.85% vs. 9.35%, p=1.00; OR=0.77 p=0.54  Need for reoperation 16.15% vs. 13.08%, p=0.51, OR=0.78, p=0.48  Explant 10.00% vs. 11.21%, p=0.70	Shorter follow-up in P4HB group  No significant differences in univariate analysis (ORs)  In pts with chemotherapy there were more reoperations in the ADM group, 14.94% vs. 0, p=0.0021
Chen, 2023b (153)	Weill Cornell Medicine, New York, NY	2012-2021	Retrospective, univariate; Cox proportional-hazards model	Prepectoral (no ADM) vs. dual-plane with ADM vs.	Prepectoral (no ADM) vs. dual-plane with ADM vs. dual-plane with P4HB	220 pts, 393 samples: 161 prepectoral (no mesh), 122 dual-plane with ADM, 96 dual-	2-stage reconstruction  No significant baseline differences between groups	Prepectoral: anterior to pectoralis muscle and directly under the soft tissue	Mean time to full expansion 53.4 vs. 104 vs. 68.8 days  Necrosis 11.8% vs. 13.1% vs. 4.2%	

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	Other
				dual-plane with P4HB		plane with P4HB [and 14 with total submuscular, less than current review threshold]		Dual-plane: partially subpectoral with support material	Infection 13.0% vs. 13.1% vs. 7.3%  Revision surgery 46.6% vs. 46.7% vs. 41.7%  Capsular contraction 30.4% vs. 34.4% vs. 47.9%;  Capsular contraction, univariate: OR=1.20 (0.73-1.98, p=0.47) compared with dual + ADM; OR=2.10 (95% CI=1.25-3.56, p=0.005) compared with dual +P4HB  Capsular Contracture, multivariate: dual + ADM vs. prepectoral HR=1.00 (95% CI=0.66-1.52, p=0.99); dual + P4HB vs. prepectoral HR=1.58 (95% CI=1.05-2.36, p=0.03)	

Citation	Study name and location	Years of study*	Design	Type of ADM or mesh	Plane of Implant, mesh location	Number of patients	Population	Surgical details	Outcomes	Other
Houvenaeghel, 2024 (154)  See also Houvenaeghel, 2022 (354)	Marseille, France  M-IBR-PPRP-IPC 2022-014	2019-2023	Retrospective  Univariate and multivariate (binary logistic regression) for complications  Prepectoral vs. subpectoral complications and satisfaction  11 surgeons, surgeons were significantly different between groups	Resorbable synthetic TIGR Matrix	176 (54.3%) prepectoral with TIGR Matrix, 9 (1.7%) subpectoral with TIGR Matrix  Prepectoral use varied by year: 20%, 14,%, 92%, 85%, 6.7% for years 2019 to 2023; dramatic decrease in 2023 due to reports of negative impact on complication	324 prepectoral (increased from 3.1% in 2019 to 61.7% in 2023)  529 subpectoral	Immediate implant-based reconstruction (100% vs. 94.7% direct-to-implant)  66.4% vs. 44.6% NSM; 33.0% vs. 54.8% SSM  108 bilateral prophylactic and 61 bilateral primary breast cancer, 1 bilateral for LR  Implant position and mesh use was at surgeon discretion		In regression analysis:  Smoking, larger breasts (cup size >C), higher ASA status, mesh use, incision (areolar, inverted T) had higher complications  Smoking, mesh use, mastectomy weight >300 g, diabetes increased grade II-III complications	

\*Year of diagnosis or initial surgery

**Abbreviations:**

ADM, acellular dermal matrix; ASA status, American Society of Anesthesiologists physical status classification system; BMI, body mass index; CI, confidence interval; GalaFLEX is a synthetic mesh that retains strength for at least 12 months and degrades to water and carbon dioxide in 18-24 months; HR, hazard ratio; IMF, inframammary fold; LR, local recurrence; NSM, nipple-sparing mastectomy; OR, odds ratio; P4HB, poly-4-hydroxybutyrate; pts, patients; SSM, skin-sparing mastectomy

[Back to Cover Page](#)

[Back to Section 4](#)

[Back to Section 4 Results](#)

[Back to Start of Tables](#)

Table 4-16. Question 6: Autologous Fat Grafting

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
Schop, 2021 (171) (protocol)  See Piatkowski, 2023 (170)	BREAST Trial <a href="#">NCT02339779</a>  7 hospitals in the Netherlands	2015-2019; final completion 2026 for secondary oncologic outcomes (estimated)	Fat grafting only  Pre-expansion + autologous fat transfer for full breast reconstruction vs. expander-implant	RCT, multicentre  Primary outcome QoL at 12 months after final surgery	196 planned: 98 autologous fat transfer, 98 expander-implant	History of or candidate for mastectomy; scheduled mastectomy (cancer or prophylactic) or previous mastectomy and desire breast reconstruction  Exclude active smoking, uncontrolled diabetes, BMI >30 kg/m <sup>2</sup> , breast size more than C cup unless contralateral reduction desired, substance abuse, chemotherapy within 4 weeks prior, history of or planned RT	Fat harvested with 2-3 mm incisions, infiltration with solution of saline/ lidocaine/ epinephrine, fat harvested with 10 mL syringe and blunt cannula, fat processed in Puregraft system to wash out contaminants (blood, oil from ruptured adipocytes), fat injected in microdroplets and aliquots fanning in different planes (prepectoral, interpectoral, retropectoral) and into deep and superficial dermis; shaping by layering the fat into different levels until desired contour achieved  Timing of BRAVA use is ambiguous:  NCT registry indicates the first fat transfer to deep tissue planes during primary mastectomy surgery  Schop, 2021 (171) indicates pre-expansion with BRAVA (external suction, 10+ hours/day for 4 weeks); figure suggests this is only prior	Outcomes:  Primary outcome is QoL by BREAST-Q questionnaire, using Emotional, Sexual and Physical Well-Being subscales  Other outcomes are quality of reconstruction by volume and shape (3D photos or MRI), patient satisfaction by BREAST-Q, aesthetic judgement by panel  Complications  Oncological outcomes up to 5 years	Power calculation assumes clinically relevant change in QoL is half a standard deviation, 90% power, dropout 15%

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
							<p>to 2<sup>nd</sup> and 3<sup>rd</sup> fat injections</p> <p>BRAVA worn for 2 weeks after initial grafting and pressure compression garment for 2-4 weeks</p> <p>Additional sessions of fat grafting (up to 5) as needed; on average 2 or more</p> <p>Control: tissue expander under major pectoralis muscle and 10 mL saline inserted; edges of major pectoralis and serratus anterior muscle sutured, drain inserted, skin closed; expansion starting after 14 days with 50-100 mL saline per visit (at least 3 weeks apart); after expansion the mastectomy scar, expander, and capsule removed, and implant inserted in muscular pocket</p>		
Piatkowski, 2023 (170)	BREAST Trial	2015-2019, with 12-month follow-up to 2021	See above	RCT 12 months follow-up	193 randomized; this publication 91 autologous fat transfer, 80 implants (18/98 refused implants); 64 and 68	<p>See Schop, 2021 (171)</p> <p>Type of surgery (NSM, SSM, other) not reported</p> <p>Pathological staging missing for 26.4% vs. 37.5% of patients and clinical staging not reported</p>	<p>After mastectomy, fat grafting in subpectoral and intra-pectoral areas</p> <p>Pre-expansion for 4 weeks and post-expansion for 2 weeks using EveBra Nonsurgical Natural Breast Enlargement [additional publication (168) states BRAVA device was used]</p>	<p>Breast-Q scores (scores 0-100 with higher scores being better satisfaction or QoL); result at 12 months; difference of <math>\geq 4</math> was clinically relevant (<math>\geq 3</math> for Physical Well-Being)</p> <p>Baseline scores were heterogeneous as some patients had already had</p>	<p>Additional publications with &lt;50 pts/group explored donor site satisfaction (412) and breast sensibility (168)</p> <p>Authors graded this as Level I evidence</p>

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
					completed follow-up	Staging not conducted in 17.6% vs. 16.3% denoted as preventive  Mean BMI 23.8 vs. 23.2 kg/m <sup>2</sup>	Harvested fat as above, purified using PureGraft 250 for unilateral cases or PureGraft 850 for bilateral cases	mastectomy and some also had an implant  Satisfaction with Breasts 70.3 vs. 60.4, p=0.002  Psychosocial Well-Being 69.6 vs. 68.3, p=0.66  Physical Well-Being: Chest 79.9 vs. 72.3, p=0.007  Sexual Well-Being 61.5 vs. 58.6, p=0.37  Satisfaction with Outcome 73.9 vs. 66.3, p=0.04  QoL change over time favoured fat transfer  Mean breast volume 300.3 ±111.4 mL vs. 384.1 ± 86.6 mL  Mean treatment duration 13.4 vs. 5.1 months  Oncologic serious adverse events (up to 1 year), 4 vs. 5, not significant  Non-oncologic serious adverse events 4 vs. 13  Adverse events 43 vs. 25; included 10 vs. 1 seroma, 7 vs. 2 hematoma, 2 vs. 6 infection, 7 vs. n/a abscess or fat necrosis, 7 vs. n/a blisters due to external expander (BRAVA), 4 vs. n/a irritation due to external	

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
								expander, 0 vs. 4 skin necrosis, n/a vs. 7 rupture or migration or capsular contraction (expander or implant)	
Gentilucci, 2020 (161)	Italy	2016-2017	Prophylactic lipofilling after RT vs. no lipofilling in expander-implant reconstruction	RCT Follow-up of 1 year after expander-implant exchange	60 pts: 30 pts with fat injections and 30 without	<p>Excluded if medical history of connective, metabolic, or skin diseases; metastatic breast cancer; family history of breast cancer or genetic background; intraepithelial malignancies</p> <p>Chemotherapy used if positive nodes; hormone therapy if ER+ and/or PR+</p> <p>All pts had immediate expander-implant reconstruction and external RT to whole breast and tumour bed boost</p>	<p>Fat injections using Coleman's technique after RT and before expander removal</p> <p>Fat purified and injected multi-directionally from superficial to deep layers throughout irradiated area; 3 fat injections were used with the first session 2-3 months after end of RT and thereafter every 3 months; expander removed 3 months after last fat injection and replaced with implant</p> <p>In group without lipofilling, expander replacement was 3-6 months after end of RT</p> <p>Skin biopsies at 5 cm from medial edge of mastectomy scar at time of each fat injection and expander removal; in second group at time of expander removal; samples measured for thickness and histological examination</p>	<p>Liponecrosis in 3.3% of lipofilling cases and was treated conservatively</p> <p>Delayed wound healing 3.3% vs. 13.2%; hematoma 3.3% vs. 0; seroma 10% vs. 16.5%; implant extrusion 0 vs. 6.6% (treated with latissimus dorsi flap reconstruction)</p> <p>Group without lipofilling had more complications, p=0.07</p> <p>Soft tissue thickness similar at end of RT, but increased in lipofilling group (51.8%, 109.6%, and 178.3% after 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> fat injections)</p> <p>Dermal fibrosis similar after RT, but disappeared in lipofilling group</p> <p>Capsular contraction Grade II 12 cases vs. 10 cases; Grade III 18 cases vs. 12 cases; Grade IV 0 cases vs. 8 cases; p&lt;0.01</p> <p>LENT-SOMA scale to measure degree of disability: there was significant reduction in</p>	



Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
								<p>scores after lipofilling but not in group without lipofilling</p> <p>Aesthetic evaluation by patient and independent plastic surgeon using visual analogue scale of 1 to 10: better in lipofilling group but data not reported</p>	
Bennett, 2017 (159)	The Mastectomy Reconstruction Outcomes Consortium (MROC) Study, USA (10 institutions) and Canada (1 institution); <a href="#">NCT01723423</a>	2012-2016	PROs comparing pts with fat grafting between years 1 and 2 vs. those without fat grafting between years 1 and 2; pts could have had fat grafting prior to end of 1 <sup>st</sup> year after start of reconstruction  Implant or autologous	Prospective, multicentre cohort design; followed STROBE guidelines for cohort studies  Multivariable analysis (mixed-effects regression)	4436 pts in full study; 2048 in this publication  165 pts with fat grafting between years 1 and 2	<p>First-time reconstruction after mastectomy and <math>\geq 2</math> years follow-up; breast mound reconstruction completed within 1 year of starting reconstruction</p> <p>Breast cancer (90.9% vs. 89.3%) or prophylaxis; primary reconstruction; implant (52.7% vs. 60.5%) or autologous</p> <p>Fat grafting used for contour irregularities or volume deficits</p> <p>Primary outcome: change from baseline PROs using BREAST-Q; 0 to 100 point scales with higher number indicating better HRQoL</p>	Not reported	<p>Patients who later had fat grafting had lower QoL before grafting compared with pts without, but similar QoL after fat grafting</p> <p>Results at 1 year after start of reconstruction; pts with subsequent fat grafting vs. pts without</p> <ul style="list-style-type: none"> <li>Breast Satisfaction 60.1 vs. 66.1, adjusted p=0.008</li> <li>Psychosocial Well-Being 67.2 vs. 73.5, adjusted p=0.03</li> <li>Physical Well-Being 72.5 vs. 76.2, adjusted p=0.33</li> <li>Sexual Well-Being 48.0 vs. 54.7, adjusted p=0.008</li> </ul> <p>Results at 2 years after start of reconstruction; pts with fat grafting during 2<sup>nd</sup> year vs. pts without</p>	Suggests that for pts with defects amenable to fat grafting, fat grafting improves QoL to level similar to those who did not require fat grafting

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
								<ul style="list-style-type: none"> <li>• Breast Satisfaction 65.6 vs. 66.0, adjusted p=0.72</li> <li>• Psychosocial Well-Being 73.2 vs. 75.3, adjusted p=0.73</li> <li>• Physical Well-Being 74.8 vs. 76.8, adjusted p=0.73</li> <li>• Sexual Well-Being 52.8 vs. 55.4, adjusted p=0.15</li> </ul>	
Petit, 2012 (413)	European Institute of Oncology (IEO) Breast Cancer Database, Milan, Italy	1997-2008	Lipofilling vs. none	Retrospective, matched 1 lipofilling to 2 without  Median follow-up 56 months from primary surgery and 26 months from lipofilling	321 lipofilling, 642 matched pts without lipofilling  Invasive cancer: 284 pts vs. 568 pts  In situ cancer 37 pts vs. 74 pts	<p>Primary breast cancer</p> <p>Excluded distant metastasis at diagnosis, recurrence prior to lipofilling, bilateral tumour, previous cancer, NACT</p> <p>Controls matched for age, year of surgery, type of surgery (quadrantectomy (38.9%) or mastectomy 61.1%), invasive (88.5%) or ductal intraepithelial neoplasia (10.9%) or lobular intraepithelial neoplasia (0.6%)), tumour size, ER status</p> <p>Controls were disease free at least until time of fat grafting of matched case</p> <p>Cases but not controls had complete clinical examination at time of lipofilling and declared</p>	<p>Method as published by Coleman: fat removed by liposuction from subcutaneous tissue, soft centrifugation to remove blood cell contaminants, and injected in area where needed</p> <p>Recently new techniques to increase percentage of preadipocytes and better graft take, but publication does not indicate whether these were used</p>	Local event (local or locoregional recurrence) HR=1.11, 95% CI=0.47-2.64, p=0.792; mastectomy subgroup HR=1.92, 95% CI=0.68-5.43, p=0.211	

Guideline 17-10 v2

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
						disease free, which may create a bias			
Gale, 2015 (414) Authors aimed to replicate study of Petit, 2012 (413)	Nottingham Breast Institute, Nottingham, UK	Initial treatment 1977-2013 Fat grafting 2007-2013	Fat grafting vs. none	Retrospective, matched 1:2 for date of operation, age, type of surgery, tumour histology, ER status, disease-free status at time equivalent to that of fat grafting  Multivariate Cox proportion hazard regression for recurrence  Mean follow-up 88 months after primary surgery and 32 months after fat grafting	211 pts fat grafting, 422 controls	Pts with previously treated malignant breast disease; 83.4% vs. 84.8% had mastectomy  Fat grafting indications: breast asymmetry, contour deformity, correction of RT-induced fibrosis, volume enhancement  Excluded if recurrence before fat grafting; controls had disease-free period at least as long as time from oncologic surgery and fat grafting of corresponding study pt	Fat grafting by Coleman technique without stem cell enhancement: injected tumescence solution of 150 mg of levobupivacaine in 1 liter of 0.9% normal saline using a blunt cannula  1:1,000,000 adrenaline	LR 0.95% vs. 1.90%, p=0.327  Regional nodal recurrence 0.95% vs. 0%, p=0.164  LRR 1.9% vs. 1.9%  DM 3.32% vs. 2.61%, p=0.691  New contralateral cancer 1.90% vs. 0.24%, p=0.224  Breast cancer-related death 1.90% vs. 3.32%, p=0.297  Any oncologic event: 7.1% vs. 4.7%, p=0.654	
Seth, 2012 (415)	Northwestern Memorial Hospital, Northwestern University, Chicago, Illinois  15 mastectomy surgeons, 6	1998-2008	Long-term outcomes with vs. without fat grafting	Retrospective  Mean follow-up 43.6 and 42.1 months (24.8 months after first fat-grafting)  Multiple linear regression for association of	886 pts (1202 breasts): 69 pts (90 breasts) fat-grafting and 817 pts (1112 breasts) non-fat grafting	Mastectomy with immediate tissue expander reconstruction, RT if needed, 2 <sup>nd</sup> -stage expander-implant exchange  Independent variables in multiple linear regression included age, BMI, smoking status, RT before or after	Fat harvesting and grafting using techniques of Coleman: harvest by syringe, fat separated and concentrated using gravity and manual separation of fluid from fat on a Telfa dressing without use of centrifugation; 20-200 cm <sup>3</sup> /breast injected	Local recurrence 0 vs. 17 breasts (0% vs. 1.5%), p=0.63  Survival 100% vs. 95.5% of pts, p=0.10  Pts were more likely to undergo subsequent fat grafting if they had a first-stage complication following tissue expander	

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
	reconstructive surgeons			first stage complications and subsequent fat grafting  Mean follow-up 43.6 and 42.1 months		mastectomy and reconstruction, ADM use, the individual mastectomy and reconstructive surgeon, and each complication subtype	(majority received 20-50 cm <sup>3</sup> ), injected primarily in superior portion of breast but generally in areas of visual depression; injections subcutaneously and intramuscularly	placement (p<0.0001), particularly an operative complication (p<0.0001)	
Kim, 2014 (416)	Yonsei University College of Medicine, Seoul, Korea	2005-2013	Long-term efficacy and safety of fat graft vs. none	Retrospective 28.7 months average follow-up	102 pts with fat grafting; 449 controls without fat graft	Breast cancer; fat grafting for secondary revision  Autologous (56 pts) and implant (46 pts) with fat grafting; controls were from same time period but without fat grafting	Donor sites were abdomen (91 pts) or thigh (11 pts); fat harvested by Coleman's technique: a tumescent solution of 1,000 mL normal saline, 20 mL 2% lidocaine, and 1 mL 1:100,000 epinephrine was injected into the fat harvest area, waited 20 minutes, fat harvested with two-hole 3 mm Coleman cannula on 50 mL Luer Lock syringe, centrifuged at 3000 rpm for 3 minutes, supernatant oil wicked off and discarded, fluid decanted, fat layer placed into syringes for transfer through Coleman cannulas into the soft-tissue deformities using small aliquots and multiple passes and tissue planes  Average 49.3 mL fat injected per breast	During follow-up of average 28.7 months, 17.6% had minor complications of fat necrosis (10 pts) or cyst formation 8 pts) and all were conservatively managed  Complications increased with graft volume: mean volume 45.2 mL without complications and 67.5 mL with complications  Fat resorption 32.9%  No infections or implant rupture  LRR 0.9% (1 pt) vs. 2% (9 pts)	
Masia, 2015 (417)	2 institutions in Barcelona, Hospital de	1989-2011	Fat grafting vs. none	Retrospective Median follow-up 60 months	207 pts: 100 pts (107 breasts) fat	Consecutive pts with mastectomy (for invasive or in situ carcinomas)	Fat harvested without anesthetic infiltration from fat deposits using 2-	LR in 3 pts before and 3 pts after fat grafting; LR in 6 pts in control group:	

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
	Santa Creu i Sant Pau and Clinica Planas			<p>from surgery to baseline and 29 months from baseline to most recent follow-up</p> <p>Control group follow-up 120 months</p> <p>Median follow-up for lipofilling group 60 months from surgery to baseline and 29 months baseline to most recent follow-up</p>	grafting vs. 107 controls	<p>and reconstruction using free flaps</p> <p>Exclude distant metastasis at diagnosis, recurrent tumours, BCS, &lt;12 months follow-up after fat grafting</p> <p>Overweight (BMI 25-30 kg/m<sup>2</sup>) 14% vs. 32.7%; alcohol use 10.2% vs. 3.7%, tobacco 31.8% vs. 40.2%, other characteristics similar</p> <p>Fat transfer group had more involved nodes (N2 13.6% vs. 4.9% and N3 4.8% vs. 2%) and more stage 3 cancers, more ER+ (69.2% vs. 50.9%)</p>	<p>3 mm diameter 1-2 blunt opening cannulas on 10 cc Luer-Lok syringes; centrifuged in Coleman machine for 1 min at 2000 rpm, fat layer transferrin in 3 cc syringes for injection</p> <p>Average 102.8 cc in 1<sup>st</sup> session and 96.2 cc in 2<sup>nd</sup> session</p>	<p>2.8% vs. 5.6%, HR=0.66, 95% CI=0.16-2.66</p> <p>Metastasis 1 vs. 4 pts</p> <p>DFS HR=0.66, 95% CI=0.16-2.66, p=0.555</p>	
Fertsch, 2017 (418)	Department of Plastic and Reconstructive Surgery at the SANA Klinik, Düsseldorf, Germany	2009-2013	Lipofilling vs. none	<p>Retrospective Matched controls</p> <p>Median follow-up 72.5 vs. 76.5 months from mastectomy; 32 vs. 31 months from startpoint to end of follow-up</p>	100 pts lipofilling, 100 pts matched control without lipofilling	<p>Pts with breast cancer, total mastectomy, and delayed DIEP flap reconstruction</p> <p>Exclude bilateral cancer, prophylactic mastectomy, recurrence prior to DIEP-flap or lipofilling</p> <p>Controls were recurrence-free up until start of study follow-up</p> <p>Matching by age (within 5 years), year of surgery, year of DIEP-flap, histopathology, HR and HER2 status, stage,</p>	Fat harvesting technique of Coleman	Recurrence 7 vs. 11 pts, HR=0.57, 95% CI=0.22-1.47, p=0.24	

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
						grade, recurrence risk factor group  29% vs. 52% overweight pts (BMI $\geq 25$ kg/m <sup>2</sup> )			
Myckatyn, 2017 (419)	4 centres (Memorial Sloan Kettering, M. D. Anderson Cancer Center, Alvin J. Siteman Cancer Center, and the University of Chicago)	2006-2011 study period (including recurrence monitoring)	Association between fat transfer and time to recurrence	Retrospective case cohort study; powered to detect risk ratio of $\geq 2$ for recurrence  Cox proportional hazards regression for association between fat transfer and recurrence in bivariate and multivariate models	225 recurrences (cases), 972 without recurrence (controls)  Fat transfer in 64 pts	Mastectomy and immediate reconstruction; invasive ductal carcinoma (stage I-III)  Cases were all recurrences; controls were 30% random sample of pts without recurrence during study period  Covariates: fat transfer, age, stage, smoking status, BMI, ER/PR/HER2 status, chemotherapy, RT, endocrine therapy	Fat transfer recorded as yes or no, no details	Recurrence, fat transfer vs. none: unadjusted HR=0.99 (95% CI=0.56-1.7), p=0.99; adjusted HR=0.97, (95% CI=0.54-1.8), p=0.93  Fat transfer not associated with higher risk of recurrence	
Silva-Vergara, 2017 (420)	Universidad Autónoma de Barcelona; and Hospital Clinic of Barcelona, Barcelona, Spain	2007-2015	Effect of lipofilling on recurrence	Retrospective Matched 1:2 (fat-grafting and controls)  Multivariate Cox proportional hazards regression model for LRR  Follow-up 88.7 vs. 86.8 months	205 fat grafting and 410 matched controls	Pts with history of cancer and 2-stage breast reconstruction  Mastectomy 71.7% vs. 69.8%; BCS 28.3% vs. 30.2%  Excluded prophylactic mastectomy, recurrence before fat grafting  Controls matched for date of primary cancer operation (within 3 years), age (within 5 years), type of cancer surgery, histopathology,	Fat grafting with few variations from Coleman technique and without stem cell enhancement; cites previous publication Silva-Vergara 2016 (421)  Tumescence included 1 L of 0.9% normal saline with adrenaline (1:1,000,000); lipoaspiration with 3 mm cannulas and vacuum pump at 40 kPa and intermediary 400 mL drainage bottle for fat storage; fat washed with saline solution,	Recurrence 14 vs. 32 pts, 6.8% vs. 7.8%, p=0.526  LR 2.4% vs. 3.2%, p=0.485  LRR 3.4% vs. 3.9%, p=0.525  DM 3.4% vs. 3.9%, p=0.590  Locoregional PFS HR=0.749, 95% CI=0.31-1.83, p=0.525  Mortality 2.9% vs. 3.4%, p=0.400  Subgroups with mastectomy:	

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
						<p>lymphatic involvement, and ER status</p> <p>Control had disease-free period at least as long as time between oncologic surgery and fat grafting for corresponding fat grafting pt</p> <p>Fat grafting mean 167 mL per session and mean of 1.5 sessions (mean 257 mL total); in pts with mastectomy mean volume 277.9 mL vs. 202.7 mL in BCS</p>	centrifuged at 2000 rpm (400 g) for 2 minutes, cellular fraction transferred to 10 mL syringes and injected with 1.9 mm blunt cannulas through several punctures	<p>LR 2.7% vs. 3.5%, p=0.567</p> <p>DM 4.1% vs. 4.9%, p=0.587</p> <p>Mortality 2.0% vs. 2.8%, p=0.323</p>	
Calabrese, 2018 (422)	Italy 1 different reconstructive surgeon for each fat grafting group	2007-2011	SVF-enriched fat transfer vs. fat transfer vs. none	<p>Prospective study</p> <p>Logistic regression for factors associated with recurrence</p> <p>≥5 years follow-up from 2<sup>nd</sup> stage of reconstruction</p> <p>Median follow-up 84, 75, 72 months from expander-implant exchange</p>	41 pts SVF + fat transfer, 64 pts fat transfer, 64 pts control	<p>Pts undergoing NSM and 2-stage reconstruction; age 18-75 years, histologically proven Tis-T2N0-N2M0 breast adenocarcinoma; no documented recurrence or systemic disease at enrollment</p> <p>Exclude other cancers except cervical/vulvar intraepithelial neoplasia, previous breast cancer, severe comorbidities</p> <p>Controls were pts who did not require fat grafting upon enrollment</p> <p>Fat grafting was at time of expander-implant exchange (median 10, 9, 12 months from first stage)</p>	<p>Coleman's technique for standard fat transfer using centrifugation of the lipoaspirate</p> <p>SVF-enrichment conducted as in RESTORE-2 trial (423) with adipose tissue divided into two parts: portion to enrich added to Celution system, Celase proteolytic enzyme added, then residual enzyme removed and cells (adipose-derived regenerative cells, ADRC) concentrated with the automated system; second portion purified by gravity sedimentation/floatation; ≈5 mL A added to second portion and this enriched fat graft transferred to breast</p>	<p>Any recurrence event: 4 vs. 4 vs. 3 events; 9.8% vs. 6.3% vs. 4.7%</p> <ul style="list-style-type: none"> <li>•Enriched vs. control adjusted OR=1.92, 95% CI=0.36-10.31, p=0.477</li> <li>•Normal fat transfer vs. control adjusted OR=1.26, 95% CI=0.25-6.42, p=0.778</li> </ul> <p>LR 0, 4.7%, 1.6%</p> <p>LRR 2.4% vs. 4.7% vs. 1.6%</p> <p>Systemic (distant) recurrence 7.3% vs. 3.1% vs. 3.1%</p> <p>DFS 19, 22, 25 months from last reconstructive stage; 37, 34, 38 months after NSM</p>	

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
						Pts with surgeon CC were in group 1 (SVF-enriched) and pts with surgeon DC were in group 2 (fat-grafting without enrichment)	<p>using 60 mL Toomey syringes</p> <p>Tissue expander removed, implant positioned, mastectomy flap dissection using a blunt cannula in a fan-shaped direction to include all over the breast mound represented by the new implant; dissection carried out from the surgical incision, in the subcutaneous space between skin and implant capsula along with pectoralis muscle fibers; fat transfer in this pre-tunneled plane using the Celbrush® for enriched group and standard cannulas for regular fat grafting</p> <p>Yearly follow-up including ultrasound; MRI for suspicious cases; continued for 5 years after 2<sup>nd</sup> stage procedure</p>		
Calabrese, 2020 (160)	Academic Hospital of Udine, University of Udine, Udine, Italy 1 surgeon Single institute	2010-2014	Fat grafting prior to or at time of exchange vs. no fat grafting at time of exchange in 2-stage implants  Note fat grafting allowed in both groups as a secondary	Retrospective Used STROCSS reporting criteria  Follow-up average 32.91 vs. 36.15 months	84 pts vs. 130 pts	<p>Unilateral mastectomy with implant-expander reconstruction; including 13.10% vs. 10% SSM and 8.33% vs. 6.92% NSM</p> <p>1 to 3 deflation-lipofilling sessions; if only 1 session it was at time of expander/implant exchange; 2 lipofilling sessions before</p>	<p>After expander, there were serial deflation-lipofilling (if multiple sessions of lipofilling planned) then positioning of definitive implant during last lipofilling session</p> <p>Fat positioned at the level of the mastectomy flap between skin and</p>	<p>Capsular contracture 7.14% vs. 21.53%, p=0.004</p> <p>Complications</p> <ul style="list-style-type: none"> <li>• Hematoma 0 vs. 4.62%, p=0.045</li> <li>• Seroma 2.38% vs. 3.85%, p=0.556</li> <li>• Implant infection 1.19% vs. 3.08%, p=0.372</li> </ul>	Expander/implant and lipofilling procedure details not reported; number of pts with deflation-lipofilling (more than 1 session of planned



Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
			procedure subsequent to final implant insertion, occurred in 21.43% vs. 26.15% of pts, p=0.431			expander-implant exchange for pts with RT or skin flap thickness <0.5 cm (pinch test with calipers and ultrasound)  Control without lipofilling  Tissue expanders were left in place for 13-19 weeks	periprosthetic capsule; deflation to be 10 cc superior to total amount of fat injected; if skin too tight after fat grafting a greater amount of saline was removed from the expander  Silicone gel implants were placed in subpectoral pocket	<ul style="list-style-type: none"><li>• Implant exposure 0 vs. 3.08%, p=0.104</li><li>• Rupture 0 vs. 0.77%, p=0.420</li><li>• Displacement/ rotation 10.72% vs. 29.24%, p=0.001</li><li>• Asymmetry 11.09% vs. 16.92%, p=0.314</li><li>• Pain 3.57% vs. 13.85%, p=0.013</li></ul> Reoperations <ul style="list-style-type: none"><li>• Prosthesis replacement 5.95% vs. 12.31%, p=0.127</li><li>• Prosthesis removal 0 vs. 1.54%, p=0.253</li><li>• Revision surgery within 3 years 21.43% vs. 34.62%, p=0.038</li><li>• Lipofilling 21.43% vs. 26.15%, p=0.431</li></ul> Aesthetics and PROs (BREAST-Q): fat grafting group reported significantly better for several scales of satisfaction (softness, natural appearance and feel to touch, natural part of body) and of Physical Well-Being (pain in chest muscles; breast tightness, pulling, nagging feeling, sharp pains, aching feeling, throbbing feeling)	lipofilling) not reported

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
								No differences in Psychosocial and Sexual Well-Being questions	
Krastev, 2019 (424)	Tergooi Hospital in Hilversum, the Netherlands  One surgeon for fat transfer	2006-2014; analyze 2016-2017	Autologous fat transfer vs. none  Mean follow-up 9.3 years (5.0 years after fat transfer) vs. 8.6 years from primary surgery	Retrospective matched cohort  Mean follow-up 9.3 years vs. 8.6 years (5.0 vs. 4.4 years after fat-grafting time point)	287 pts (300 breasts) fat grafting, matched 1:1 with 300 controls  161 vs. 150 mastectomy	Histologically confirmed breast cancer and who received fat transfer for correction of contour deformities; matching to pts without fat transfer based on age, type of oncologic surgery, tumour invasiveness, stage, same locoregional recurrence-free interval at baseline  Excluded prophylactic mastectomy, LRR	Tumescent infiltration, harvest (abdomen or upper legs) using closed low-pressure suction system (0.5 atm) and 3 mm multiple-hole cannula; centrifugation occasionally used to remove excess blood or oil from ruptured adipocytes  Purified fat transferred to 10 mL syringes and injected percutaneously into breast deformity with 2 mm blunt cannula in multiple passes and tissue planes; forked cannula used to perforate scar adhesions and fibrosis whenever necessary	Results in pts with BCS or mastectomy  LRR: 8 pts vs. 11 pts, 2.67% vs. 3.67%, rates per breast: HR=0.63 (95% CI=0.25-1.60), p=0.33; rates per pt: HR=0.64; 95%CI=0.25-1.62, p=0.34  DM adjusted HR=0.98, 95% CI=0.54-1.79, p=0.95  Breast cancer related mortality adjusted HR=0.38, 95% CI=0.15-0.92, p=0.03  Overall mortality 2.8% vs. 11%; adjusted HR=0.20, 95% CI=0.09-0.44, p<0.001 [OS 97.2% vs. 89.0%]  In pts with mastectomy: LRR unadjusted HR=0.78, 95% CI=0.23-2.73, p=0.71	Authors cannot explain the excess mortality in the non-fat graft group
Cason, 2020 (172)	Duke University Medical Center, Durham, NC	2010-2018	Influence of fat grafting on incidence of imaging and biopsies vs. no fat grafting	Retrospective  Propensity-matched 1:1  ≥6 months follow-up since fat grafting	93 matched pairs (93 fat grafted, 93 without)	Autologous or implant reconstruction  Excluded metastatic, bilateral prophylactic mastectomy, BCS  Propensity score using laterality, BMI, reconstruction timing	98.9% of liposuction was suction assisted  Fat processing: 12.5% centrifugation, 53.4% revolve system, 19.3% gravity, 14.98% other	Palpable masses 38.0% vs. 18.3%, p=0.003  Post-reconstruction imaging 47.3% vs. 29.0%, p=0.01  Biopsies performed 11.8% vs. 7.5%, p=0.32  Imaging predominately interpreted as normal	Higher detection of palpable masses but not biopsies as fat-related changes are identifiable on imaging

Guideline 17-10 v2

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
				Mean follow-up 4.4 vs. 4.1 years		Multivariate model to predict receipt of fat grafting		(27.9% vs. 33.3% BI-RADS 1) or benign (48.8% vs. 50.0% BI-RADS 2); 7.0% vs. 0% BI-RADS 3, 16.3% vs. 16.7% BI-RADS 4  Fat necrosis most frequent radiologic interpretation, 45.5% vs. 14.8%  5-y OS: 94.6% vs. 95.0%, p=0.49  5-y locoregional RFS 95.1% vs. 96.2%, p=0.888	
Vyas, 2020 (425)	University of Kentucky Markey Cancer Center, Lexington, KY  5 surgeons for lipofilling	2000-2017	Fat grafting vs. none	Retrospective, matched case control study  Follow-up ≥12 months  Cox proportional hazard model for recurrence using age, stage, fat grafting status  Median follow-up 42.5 months	72 pts (116 breasts) fat grafting, 181 pts (312 breasts) without fat grafting  Therapeutic mastectomy: fat grafting in 73 breasts vs. 200 breasts without  Prophylactic: fat grafting in 43 breasts vs. 112 without	Prophylactic or therapeutic mastectomy and breast reconstruction and at least 12 months oncologic follow-up  Matching 1:3 by age (5-year increments), surgical service, ASA class, wound class  Mean fat grafting 97.9 mL per pt; 74.1% had one grafting procedure	Fat harvested using 30 mL or 60 mL syringes and suction cannulas; centrifuged and oil and serous components decanted; processed fat transferred to 3 mL syringes and injected using blunt infiltration cannulas	Therapeutic mastectomy: LRR 8.2% vs. 8.5%, p=1.000  LRR and/or DM 8.2% vs. 9.0%, p=1.000  Median time to recurrence 31.5 vs. 37.0 months, p=0.973  Adjusted model for time to recurrence: HR=0.807, 95% CI=0.31-2.1, p=0.66	Suboptimal matching  Fat grafting group has less comorbidities that could affect short-term outcomes; higher stage disease, bilateral disease, BRCA1/2 positive  High rate of unknown data for pt/disease characteristics
Casarrubios, 2021 (426)	University Hospital Dr Negrín, Las Palmas de Gran Canaria, Spain	2011-2019	Fat grafting vs. none	Retrospective  Matched controls  Used STROBE reporting checklist	125 fat grafting, 125 matched controls  Of these, 80 vs. 82 pts with	History of breast cancer and reconstructed with fat grafting (alone in BCS pts; together with flaps or implants in pts with mastectomy) vs. no fat grafting; exclude if LR	Coleman technique with no additional cell enhancement  Fat grafting was prior to tissue expander insertion (6-183 months after oncologic surgery) in all	Pts with mastectomy: LRR 1.3% vs. 3.7%, p=0.429  DM 1.3% vs. 6.1%, p=0.135	<25 events so multivariate results not extracted  Control group had more lymphadenectomy

Guideline 17-10 v2

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
				Mean follow-up 47.2 months after lipofilling	mastectomy (rest had BCS)	<p>before fat grafting, positive margins, prophylactic mastectomy</p> <p>36.0% vs. 34.4% BCS</p> <p>Fat grafting alone in 45 pts with BCS; in rest of pts was used in combination with flaps or implants to improve shape (56 pts) or to improve skin quality prior to implants in pts with previous RT (24 pts)</p> <p>Matched by date of first oncological surgery, age, type of oncological surgery, histological subtype, HER-2 status, pN, smoking habit, diabetes mellitus</p> <p>Selected control pt had a disease-free period at least as long as the time window between oncologic surgery and the fat grafting procedure of the corresponding study patient</p>	except 1 pt; in 32.5% of mastectomy cases lipofilling was >3 years from cancer surgery	<p>Total recurrences 2.5% vs. 9.8%, p=0.097</p> <p>All pts:</p> <p>Locoregional PFS HR=0.40, 95% CI=0.10-1.61, p=0.183</p>	y and chemotherapy
Klinger, 2022 (427)	17 Senonetwork breast units, Italy	2000-2018	Recurrence and survival with vs. without fat grafting	<p>Retrospective</p> <p>Median 60 months follow-up (63 vs. 58 months)</p> <p>Reporting using STROBE guidelines</p>	<p>After matching: 466 fat graft and 923 no fat graft</p> <p>Mastectomy subgroup: 228 pts fat grafting and</p>	<p>Early breast cancer pts with invasive cancer: BCS (51.5% vs. 53.4%) or mastectomy (48.9% vs. 46.6%) in matched cohort</p> <p>Fat grafting only used for regenerative purpose of addressing painful scars,</p>	Fat grafting using Coleman technique	<p>LRR (includes both mastectomy and BCS) 3.9% vs. 6.1%, p=0.084</p> <p>LRFS calculated from lipofilling to last contact or recurrence for fat grafting; calculated from primary surgery to last contact or recurrence for no fat grafting; matched</p>	<p>5% difference in LRR considered to be equivalent (5% alpha error and 80% power)</p> <p>LRFS had different follow-up starting points so</p>

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
					430 non-fat grafting	post-actinic dystrophic tissue, local deformities		patients for follow-up time  LRFS aHR=0.73, 95% CI=0.41-1.30, p=0.291;  for mastectomy subgroup: aHR=0.32, 95% CI=0.11-0.92, p=0.034	difficult to interpret
Palve, 2022 (428)	Tampere University Hospital, Tampere, Finland	2008-2019	Techniques in latissimus dorsi reconstruction: addition of implants, lipofilling, or none	Retrospective  Univariable and multivariable logistic regression to compare reconstruction techniques  Median follow-up 88 months, 67 months, 117 months	291 flaps in 283 pts  161 implant enhanced, 73 lipofilled, 57 plain flaps	Latissimus dorsi reconstruction  Delayed reconstruction 89% vs. 78% vs. 77%	Not reported	Overall complications 66% vs. 75% vs. 74%, p=0.228  Seroma (all fluid collections requiring aspiration) 95% vs. 84% vs. 92%  Hematoma 58% vs. 33% vs. 80%  Major complications <ul style="list-style-type: none"> <li>• Partial flap necrosis 19% vs. 50% vs. 20%</li> <li>• Deep infections 23% vs. 17% vs. 0%</li> </ul>	Note: breast reconstruction but cancer not mentioned  Use of implant decreased over time (39% in 2008 to 11% in 2019) and fat grafting increased (11% in 2008 and 89% in 2019); authors suggest fat grafting can replace implant and allows less aggressive subcutaneous tissue harvesting in latissimus dorsi site than in none group (no implant or fat grafting)
Sorotos, 2022 (429)	Sapienza University of Rome, Rome, Italy  Single centre	2005-2017	Impact of fat transfer vs. none on LR	Retrospective  Cases matched 1:n with controls for age, histology, year of	902 pts, 1025 breasts: 464 fat transfer and 561 no fat transfer	Breast cancer, mastectomy (NSM, SSM, other), and breast reconstruction (implant or flap)	Fat harvested using dry technique (no tumescence) and processed by centrifugation (Coleman procedure) at 3000 rpm	Primary endpoint was LR LR 3.3% vs. 10.9%, HR=0.337, 95% CI=0.173-0.658, p=0.00007  Metastasis 2.5% vs. 15.4%	Large difference in LR before and after multivariate analysis (significant and in favour of fat

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
				<p>surgery, type of mastectomy</p> <p>Average follow-up 62.98 months (12-144 months) from primary reconstruction surgery</p> <p>Minimum follow-up of 3 years after first fat transfer</p>	<p>before matching</p> <p>After matching: 425 cases and 494 controls</p>	<p>Excluded distant metastases at diagnosis, recurrence, incomplete data of primary tumour, prophylactic mastectomy, BCS</p> <p>Fat transfer for total volume restoration (only in NSM) or aesthetic refinements after reconstruction</p> <p>Median time from primary surgery to first fat transfer was 11 months</p> <p>Control pts had disease-free period at least as long as interval between oncologic surgery and fat transfer of corresponding case</p> <p>Arms unbalanced for LN status (LN+ 34.0% vs. 47.3%), grade (grade 3 38.4% vs. 44.0%), HR+ (67.5% vs. 79.8%), HER2+ (21.5% vs. 31.3%), RT (31.6% vs. 46.7%), chemotherapy (46.9% vs. 72.7%)</p>	<p>for 3 minutes with no stem cell enhancement</p> <p>Fat injected into breasts in thin continuous strips with crisscrossed strokes at multiplanar levels using a 3-way stopcock connecting 10 mL syringes to 1 mL syringes for more precise delivery</p>	<p>Multivariate analysis LR HR=1.29, 95% CI=0.59-2.79</p>	<p>grafting to non-significant in favour of no fat grafting); maybe due to baseline imbalance of non-matched characteristics</p>
Lee, 2023 (430)	Sungkyunkwan University of Medicine, Seoul, South Korea  Single institution	2011-2016	Association of fat grafting during expander-implant exchange or not on cancer prognosis	<p>Retrospective cohort</p> <p>Univariable and multivariable Cox regression analyses</p>	Second stage (exchange) at ≤12 months: 112 fat grafting, 91 no fat grafting	Unilateral invasive cancer and immediate 2-stage implant after SSM or NSM mastectomy; contralateral prophylactic mastectomy allowed	Tissue expanders in subpectoral space with lateral surface covered with ADM or serratus anterior fascia; inflation within 1 month if there was complete wound healing; second stage	<p><u>Expander-implant exchange within 1 year</u></p> <p>Recurrence 8.9% vs. 3.3%</p> <p>LR 4.5% vs. 2.2%</p> <p>Regional lymph node recurrence 2.7% vs. 0</p>	Groups unbalanced in baseline characteristics: fat graft group had higher rate of SLNB + axillary dissection (30.4%)

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
			Stratified by timing of exchange ( $\leq 12$ months, $>12$ months)	Median follow-up 65.0 months from mastectomy and 53.0 months from 2 <sup>nd</sup> stage operation	Only 64 cases with exchange at $>12$ months (29 fat graft and 35 without) so data not extracted	<p>Excluded in situ cancer, bilateral cancer, distant metastasis at time of operation, neoadjuvant chemotherapy, prophylactic mastectomy without therapeutic mastectomy, recurrence after BCS; recurrence prior to insertion of implant</p> <p>Decision of fat grafting based on breast shape, expected aesthetic outcomes, and cost; was independent of oncologic status</p> <p>Most implants were textured, so only reported results for textured implants</p>	<p>operation <math>\geq 3</math> months after completion of expansion</p> <p>Tissue expander removed and implant inserted in same space</p> <p>Fat graft harvested using Coleman technique: infiltrating tumescent solution injected, adipose tissue harvested using closed manual pressure suction and 3 mm multiple-hole cannula; aspirate centrifuged to remove excel blood or oil from ruptured adipocytes; purified fat transferred to 10 mL syringe and injected to breast percutaneously into subcutaneous and prepectoral planes with 2 mm blunt cannula with maximum scatter of fat droplets</p>	<p>DM 3.6% vs. 1.1%</p> <p>Breast cancer-related death 2.7% vs. 0</p> <p>5-y LRRFS 95.0% vs. 100%, <math>p=0.026</math>; univariable <math>HR=6.325</math> (95% <math>CI=1.114-35.905</math>, <math>p=0.037</math>); multivariable <math>HR=33.127</math> (95% <math>CI=1.332-823.935</math>, <math>p=0.033</math>)</p> <p>5-y DFS 93.4% vs. 98.7%, <math>p=0.037</math>; univariable <math>HR=4.238</math> (95% <math>CI=1.011-17.759</math>, <math>p=0.048</math>); multivariable <math>HR=5.701</math> (95% <math>CI=1.164-27.927</math>, <math>p=0.032</math>)</p> <p>Very high survival and therefore too few events for reliable multivariable analysis</p> <p><u>Subset with expander-implant exchange at <math>&gt;1</math> yr</u></p> <p>Any recurrence 6.9% vs. 14.3%; LR 0% vs. 5.7%; regional recurrence 3.4% vs. 2.9%; DM 3.4% vs. 5.7%; 5-y LRRFS 95.2% vs. 89.0%; 5-y DFS 95.2% vs. 82.1%</p> <p><u>Both subgroups combined</u></p> <p>Any recurrence 8.5% vs. 6.3%; LR 3.5% vs. 3.2%; regional recurrence 2.8% vs. 0.8%; DM 3.5% vs. 2.4%; 5-y LRRFS 95.0% vs.</p>	<p>vs. 23.1%), node positive cancer (21.4% vs. 14.3%), higher stage (stage II 40.2% vs. 35.2%), LVI (31.3% vs. 24.2%), chemotherapy (49.1% vs. 41.8%)</p> <p>Suggests fat transfer group had higher baseline risk of recurrence</p> <p>In multivariate analysis, stage, LVI, were risk factors</p> <p>Using HRs for survival endpoints is problematic to interpret, as survival is a positive outcome, and HRs are normally used for events (not absence of events). It is unclear whether <math>HR=5.701</math> means better survival or worse survival for the fat grafting arm after</p>

Guideline 17-10 v2

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
								96.8%; 5-y DFS 94.3% vs. 94.4%	multivariate analysis
Strong, 2024 (431)	Data from Optum Clinformatics Data Mart  University of Michigan; and dVA Center for Clinical Management Research, VA Ann Arbor Healthcare, System, Ann Arbor, MI	2001-2018	Fat grafting vs. none	Retrospective from claims data for privately insured pts  Bivariate analysis on entire patient sample  Propensity score-matching estimated using multivariable logistic regression based on 60 baseline characteristics  At least 5 years enrollment time for assessment of metastasis and mortality	4709 pts:  361 fat grafting, matched to 361 controls	Patients with breast reconstruction after lumpectomy or mastectomy for breast cancer (including carcinoma in situ) according to ICD-9 or ICD-10  Fat grafting identified by CPT code and within 2 years of reconstruction  Excluded lymph node metastasis or distant metastasis at the time of initial breast cancer diagnosis  97.5% in each group had mastectomy; >99% had invasive carcinoma, 82.5% vs. 84.2% implant-based	Not reported	Matched groups:  Metastasis: 57/361 (15.8%) vs. 65/361 (18.0%), p=0.427  Lymph node metastasis 35/361 (9.7%) vs. 41/361 (11.4%), p=0.467; HR=0.831 (95% CI=0.529-1.305, p=0.421)  Distant metastasis 33/361 (9.1%) vs. 38/361 (10.5%), p=0.532; HR=0.848 (95% CI=0.532-1.352, p=0.489)  Mortality 14/361 (3.9%) vs. 24/361 (6.6%), p=0.096	
Escandon, 2024 (432)  NEW	University of Rochester Medical Center, NY, USA	2011-2021	Latissimus dorsi + immediate fat transfer vs. standard latissimus dorsi reconstruction	Retrospective	130 pts with 195 reconstructions:  119 with immediate fat transfer; 76 standard	Autologous breast reconstruction after total mastectomy using latissimus dorsi flaps, with or without immediate fat transfer  94.9% SSM	Volume of fat, plane of injection, and skin paddle de-epithelialization based on surgeon preference  Fat harvested from flanks/abdomen or thighs, processed using REVOLVE fat system, injected in latticed	Anesthesia time 541 vs. 520 min  Secondary fat grafting 61.3% vs. 23.7%, p<0.001  Less wound disruption at donor site 12.6% vs. 23.7%; authors indicated this could be due to more	Higher secondary fat grafting could be due to patient factors regarding those who chose to have initial fat grafting



Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
			Cox proportional-hazards models  Median follow-up 147.9 weeks		latissimus dorsi flap	Mean BMI 30.8 vs. 34.7 kg/m <sup>2</sup>  Smokers 4.2% vs. 11.8%  Similar comorbidities  69.7% vs. 71.1% therapeutic	multilayer technique with a 10 mL syringe and 3 mm Coleman cannula; quilting sutures for closure of the donor site  Median volume fat harvested was 125 mL and median volume transferred into latissimus dorsi flap was 70 mL; median volume to pectoralis major was 62 mL; 8.4% of mastectomy flaps received fat transfer (median 35 mL)	aggressive flap harvest in the absence of fat grafting and not due to fat grafting itself  Breast site complications were similar (no significant differences)	
Navarro, 2024 (433)	Institut Universitaire du Cancer de Toulouse - Oncopole, France	2007-2015	Impact of lipofilling on survival	Retrospective  Univariable and multivariable analyses using log-rank test and Cox proportional hazards model  Median follow-up 55.2 months	550 breasts: 136 lipofilling, 414 control without lipofilling	Immediate breast reconstruction after mastectomy for breast cancer  Exclude prophylactic, sarcoma, delayed reconstruction, reconstructive failure, or local recurrence before fat grafting  Excluded pts who had oncologic event or died within 24 months of surgery or without 24 months follow-up  SSM 89.0% vs. 88.2%; NSM 8.8% vs. 10.9%  73.5% vs. 88.2% implant  25.7% vs. 13.5% autologous with latissimus dorsi flap	Lipofilling using the Coleman technique  No pre-expansion  Fat harvested from knees, flanks, or thighs with closed suction system or a 10 mL syringe; centrifugation (1000 g for 2 min) sometimes used to remove excess blood or oil; densest fat reinjected with 10 cc syringe percutaneously	Recurrence or survival events in 7.4% vs. 10.4%  5-y RFS 90.9% vs. 92.3% p=0.9569; by multivariate analysis, aHR=0.93 (95% CI=0.46-1.88, p=0.833)  Recurrence 8/136 (5.9%) vs. 38/414 (9.2%)  LRR 6/136 (4.4%) vs. 20/414 (4.8%)  DM 5/136 (3.7%) vs. 22/414 (5.3%)  Cancer-related deaths 1/136 (0.7%) vs. 11/414 (2.7%)  Median time to recurrence after first surgery 52.3 vs. 45.7 months	

Citation	Study name and location	Years of study*	Topic or comparison	Design	Number of patients	Patient characteristics	Surgery/technique	Results	Other
						Multifocal tumours (34.6% vs. 25.2%)			

\*Usually year of diagnosis or initial surgery

Note: Coleman’s technique, Coleman, 2006 (19); Coleman, 2007 (461)

**Abbreviations:**

ADM, acellular dermal matrix; ADRC, adipose-derived regenerative cells; aHR, adjusted hazard ratio; ASA status, American Society of Anesthesiologists physical status classification system; BCS, breast conserving surgery; BI-RADS, Breast Imaging Reporting and Data System; BMI, body mass index; BRAVA, BRA like VACuum-based external tissue expander; BREAST Trial, Breast Reconstruction With External Preexpansion & Autologous Fat Transfer vs. Standard Therapy Trial; CI, confidence interval; CPT, Current Procedural Terminology codes (USA); DFS, disease-free survival; DIEP, deep inferior epigastric perforators; DM, distant metastasis; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; ICD, International Statistical Classification of Diseases and Related Health Problems; LENT-SOMA scale, Late Effects Normal Tissues (LENT)-Subjective, Objective, Management, Analytic (SOMA) scale; LR, local recurrence; LRR, locoregional recurrence; LRRFS, locoregional recurrence-free survival; LVI, lymphovascular invasion; MROC, Mastectomy Reconstruction Outcomes Consortium; MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy; n/a, not applicable; NSM, nipple-sparing mastectomy; OR, odds ratio; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor; PRO, patient-reported outcomes; pts; patients; QoL, quality of life; RCT, randomized controlled trial; RFS, recurrence-free survival; RT, radiotherapy; STROBE, strengthening the reporting of observational studies in epidemiology ([www.strobe-statement.org](http://www.strobe-statement.org)); SLNB, sentinel lymph node biopsy; SSM, skin-sparing mastectomy; STROCSS, Strengthening the Reporting of Cohort Studies in Surgery statement (462); SVF, stromal vascular fraction

## Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

### Section 5: Internal and External Review

#### INTERNAL REVIEW

The guideline was evaluated by the GDG Expert Panel and the PEBC Report Approval Panel (RAP) ([Appendix 1](#)). The results of these evaluations and the Working Group's responses are described below.

#### Expert Panel Review and Approval

Of the 15 members of the GDG Expert Panel, 14 members voted, for a total of 93% responses in December 2024 and January 2025. Of those who voted, 12 approved the document (86%) and 2 (14%) gave conditional approval. The areas of concern have been addressed by the Working Group. The main comments from the Expert Panel and the Working Group's responses are summarized in Table 5-1.

**Table 5-1. Summary of the Working Group's responses to comments from the Expert Panel.**

Comments	Responses
<p>1. It may be helpful to repeat in the Discussion key points on imaging from Section 2</p> <p>-Q3 (NSM) Discussion section: include that TND is not an absolute contraindication (instead of is not important), and that absolute contraindications are inflammatory breast cancer, Paget disease, nipple involvement and nipple retraction</p> <p>-Q6 (fat grafting) Discussion section: include that details should be provided in clinical history to avoid confusion and false positives in imaging</p> <p>-Include that type/location of implants or tissue should be documented to help interpret imaging (add to Section 2 and discussion)</p>	<p>This has been added to the relevant sections.</p>
<p>2. Justification for Recommendation 5 indicates AlloDerm is no longer in use. Clarify in Key Evidence that AlloDerm (aseptic/freeze-dried) is historical</p>	<p>The wording has been revised to clarify that the original AlloDerm was replaced by a terminally sterilized form referred to as AlloDerm RTU (ready-to-use).</p>
<p>3. In Justification for Recommendations 1.1 to 1.6, add: "Considering implant-based reconstruction in the immediate setting</p>	<p>This has been added.</p>

could be particularly beneficial for patients with limited options for autologous reconstruction due to slim body habitus.”	
4. In Recommendation 2 section, consider adding “Access to and resources for breast reconstruction vary across Ontario. Timely access to immediate breast reconstruction for patients who desire this and are good candidates, is critical to avoid being placed in a delayed breast reconstruction waiting list.”	This has been added to the Qualifying Statements.
5. In first recommendation (Overall Recommendation for Patient Education and Preoperative Evaluation) consider adding: decision to include patient’s genetic profile; discuss pros and cons and whether benefit outweighs the risks. There could be more language around consultation with genetics professionals for formal risk assessment preoperatively, as is standard practice in Ontario.  Recommendations may come from either ablative or reconstructive surgeon and then consensus and this is in keeping with later statements in the document that sometimes bilateral reconstruction is favoured for symmetry reasons in difficult-to-reconstruct cases (or when DIEP may be used and there is enough tissue for bilateral reconstruction)	Wording has been revised to incorporate these suggestions.
6. Document is only accessible to those surgeons (breast or plastic surgeons) due to terminology and needs modification for larger target audience. Consider including a glossary of terms, particularly for surgical procedures.	A glossary has been added.
7. Instead of “positive” specimens use “involved by tumour”	Suggested changes have been made.
8. Recommendation 1.1: Is there any evidence to say women above 70 have the same outcomes? Older age groups are routinely excluded from research. This should be qualified. That meta-analysis methodology for age is insufficient to make this recommendation given the way they analyzed mean ages from	We agree that methodology regarding use of age as a factor in the review by Mrad et al. is unclear and the analysis by age may be of little value. We have removed this review from key evidence for effect of age and conducted our own systematic review.

<p>included papers (which are all fairly low). This recommendation is more about setting an upper limit and the evidence does something different.</p> <p>Key Evidence: It is very difficult to tell from the systematic review whether extremes of age were included and what the 'elderly' cut off was. I cannot find it, or even tell what the range was as it only reports mean age, all of which are around mid-50's.</p>	
<p>9. Justification for Recommendations 1.1 to 1.6: The section on age may go better with Key Evidence.</p> <p>Is there a reason to single out age when talking about equity?</p>	<p>There is overlap in justification for 1.1 to 1.6 so it was decided to place this in one place instead of repeating after each recommendation. Our policy is to not use other guidelines as evidence, but rather to indicate in justification whether the current recommendations are consistent with or differ with those of other guidelines.</p> <p>Age alone is often used to determine treatment, and we believe it necessary to stress it should only be used in conjunction with other factors. We have also added this to the justification section for all Recommendations 1.1 to 1.6.</p>
<p>10. Recommendation 1.2: Data for implant-based and autologous reconstruction are different. Are there no relative contraindications? BMI 40 or 50 kg/m<sup>2</sup>? Again, this is about setting an upper limit and the evidence does something different.</p> <p>BMI is important: do you need to be more specific about classes of obesity and risks?</p>	<p>Risks according to class of obesity have been added. There is not a threshold to state an absolute contraindication. All items in Recommendation 1.2 are relative contraindications and need to be evaluated. The risk increases with severity of the condition. The Recommendation states that these are not absolute contraindications, with the implication they are relative contraindications. It is stated the risks of complications are higher in patients with these risk factors.</p>
<p>11. Recommendation 2 Key Evidence (Shammas et al) is very misleading as you want complications with immediate vs. delayed, not complications of mastectomy pooled with delayed reconstruction.</p>	<p>We disagree with this interpretation. Ideally you would consider all complications from the start of the first operation until completion of treatment and follow-up. Most studies do not report this in an equivalent manner for both groups.</p>
<p>12. Recommendation 2 Key Evidence (Hassan et al): In the PMRT group, skin-preserving reconstruction had a 10.6% tissue expander loss rate. Do you think that is significant and worth mentioning that 1 in 10 women will lose the expander and need to return to the operating room or possibly delay radiation?</p>	<p>Rates of expander loss have been added. The publication does not mention the treatment path for those with expander loss, nor whether expander loss was before, during, or after radiotherapy.</p>

13. Recommendation 3.1 Qualifying Statement: Surgical delay is more often done in prophylactic mastectomy or completion mastectomy when there is not an urgency to get to surgical management, so I think you need a qualifying statement such as “... or surgical delay when the oncologic treatment timeline allows”.	This has been revised.
14. Recommendation 3.2: I understand discussing NSM in this guideline but how to perform it and especially assess the NAC in a reconstruction guideline is overstepping the objectives here.	This is of direct relevance to the objective of providing guidance on “use of nipple-sparing mastectomy”. See Research Questions 3b and 3c for further details of scope.
15. Recommendation 3.3: The evidence for incision types in an NSM has very little evidence and ranking them is inappropriate. Softening it as to suggest IMF incision, and suggest not going periareolar makes sense.	We agree evidence is limited for exact order but believe the three categories are justified. The Recommendations and Qualifying Statements have been reworded to address the comments and remove some duplication in Recommendations 3.3a and 3.3b.
16. Recommendation 5 Key Evidence: clarify GalaFLEX and Phasic are both P4HB	This has been reworded.

### RAP Review and Approval

Three RAP members reviewed this document in December 2024 and January 2025. The RAP approved the document on January 13, 2025. The main comments from the RAP and the Working Group’s responses are summarized in Table 5-2.

**Table 5-2. Summary of the Working Group’s responses to comments from RAP.**

Comments	Responses
1. This is a remarkable document. It is extremely detailed in its examination of the evidence addressing each of the important clinical questions of relevance to postmastectomy breast reconstruction. It is a very well written and organized guideline on an extensive topic. This is a very comprehensive document, well written and clear.	
2. The size of the document may make access to the recommendations and supporting evidence less accessible to those who have need for this information. I wonder if the table of contents should list where to find specific recommendations as I suspect that surgeons using this document will have specific questions they would like to have	The Table of Contents has been expanded.

addressed and knowing where to find the recommendations related to the various questions might be useful.	
3. One minor suggestion for non-surgeons reading the document would be to spell out some acronyms such as DIEP (p8) or include the acronyms in the recommendation as in recommendation 3.1 dealing with nipple-sparing and skin-sparing mastectomy (p10)	Acronyms and abbreviations are defined the first time used, although some such as DIEP were missed and have been added. These have also been added to recommendations as recommendations are sometimes reproduced on their own.
4. Explain “animation deformity” in Recommendation 4	This has been added to the glossary.
5. Is there any indication of common doses used for PMRT? Can shorter regimes be safely used? Some RCTs are ongoing	Which patients required PMRT and technical considerations of its use were outside the scope of this work.

## EXTERNAL REVIEW

### External Review by Ontario Clinicians and Other Experts

#### *Targeted Peer Review*

Eleven targeted peer reviewers from across who are considered to be clinical and/or methodological experts on the topic were identified by the Working Group and Surgical Oncology program. Of these, six were contacted and four agreed to participate; one withdrew prior to the review ([Appendix 1](#)). Three responses were received. Results of the feedback survey are summarized in Table 5-3. The main comments from targeted peer reviewers and the Working Group’s responses are summarized in Table 5-4.

**Table 5-3. Responses to nine items on the targeted peer reviewer questionnaire.**

Question	Reviewer Ratings (N=2)				
	Lowest Quality (1)	(2)	(3)	(4)	Highest Quality (5)
1. Rate the guideline development methods.				2	1
2. Rate the guideline presentation.				1	2
3. Rate the guideline recommendations.				2	1
4. Rate the completeness of reporting.				1	2
5. Does this document provide sufficient information to inform your decisions? If not, what areas are missing?				2	1
6. Rate the overall quality of the guideline report.				1	2

	Strongly Disagree (1)	(2)	Neutral (3)	(4)	Strongly Agree (5)
7. I would make use of this guideline in my professional decisions.				1	2
8. I would recommend this guideline for use in practice.			1		2
9. What are the barriers or enablers to the implementation of this guideline report?	<ul style="list-style-type: none"> <li>• From a systems perspective, access to reconstructive surgeons, including those specializing in both implant based and autologous approaches, as well as neurotization and lipofilling, is likely to be variable in Ontario and across Canada as a whole. However this guideline sets the bar high which I think overall is a good thing.</li> <li>• Barriers to implementation will be to distribute and have the recipient read the document as practitioners are inundated with emails and documents to review.</li> <li>• Enabler is that a provincially developed guideline on this important topic will be of great interest to parties involved.</li> <li>• System resources to facilitate the MDT conversations are needed. The initial statement in the guideline suggests such collaboration is very routine, which is more challenging in non-urban centres outside of integrated cancer programs.</li> <li>• All general surgeons in Ontario do not have the same skill level and access to plastic surgeons who can offer all of these options in a timely fashion. Should community surgeons with no access or who are not comfortable with NSM via IMF then refer everyone?</li> <li>• There is resource variability including access to medical/radiation oncology input.</li> <li>• There is a variety of skill levels/training for general surgery. I do not think that most current graduates from general surgery residency would feel comfortable doing a NSM via IMF without extra training/mentorship. A recent National Delphi that I participated in of General Surgery curricula was divided on if NSM was “mandatory” for</li> </ul>				



	<p>exposure, never mind competence in performing.</p> <ul style="list-style-type: none"> <li>• Many of the recommendations here would not be available to patients outside of a high volume urban centre and they are referred, which carries implications on system capacity/access/timeliness when dealing with therapeutic mastectomy.</li> <li>• The guideline may cause issues for providers in low resource regions if patients bring this to demand surgeries that due to expertise or operating room availability within recommended cancer wait times aren't available in their region</li> </ul>
--	--

**Table 5-4. Summary of the Working Group's responses to comments from targeted peer reviewers.**

Comments	Responses
<p>1. Methodology is robust. The guideline is well organized. Recommendations are well written, consistent with the literature, and clinically relevant and appropriate.</p> <p>The guideline supporting the use of NSM is appreciated as we should be moving towards this as standard of care in Canada. Recommendation 3.3 on incision location and NSM complications are especially helpful, as this is an easily modifiable technical risk factor. Although data are still evolving, the discussion on sensation after NSM and neurotization was also felt to be valuable.</p>	<p>Thank you for the comments</p>
<p>2. For recommendation 5, the wording feels as though ADM is being recommended for all prepectoral implant based reconstructions as written, and I think should be kept more open; especially given cost and the rise in ADM alternatives or ADM-sparing prepectoral reconstruction here in Canada and elsewhere (i.e. in the UK, US, Korea), with data demonstrating similar complication rates as mentioned in your discussion.</p>	<p>This is covered in the Qualifying Statements. The Qualifying Statements have been rearranged to make this clearer. Additional background has also been added to Recommendation 4 (implant plane).</p>
<p>3. For recommendation 6, qualifying statement on optimal timing of lipofilling (i.e., after PMRT, before TE or at TE exchange) would be of interest, especially with respect to DTI reconstruction patients (i.e., how many months after RT could a post-mastectomy patient with DTI reconstruction safely undergo lipofilling for contour irregularities?)</p>	<p>A qualifying statement has been added to deal with timing. The first session of fat grafting is usually at the time of expander-implant exchange (463, 464) (27), or as a revisionary procedure several months after the final</p>

	<p>implant or autologous reconstruction. In some cases it is used at the time of expander insertion or autologous flap placement. In patients with poor mastectomy skin flap quality, fat grafting prior to expander-implant exchange may improve tissue quality and reduce complications. This may apply to patients who received RT, and those for which reconstruction is delayed due to poor skin flap quality (delayed-immediate reconstruction) (31).</p> <p>In patients requiring RT, fat grafting often occurs 3 to 6 months after the end of RT (31) although Gentilucci et al (161) conducted the first session of fat injection at 2-3 months after RT. Earlier times prior to severe tissue fibrosis have been suggested as having potential benefit (465) but need more investigation.</p>
4. “Breast surgeon” or “surgical oncologist/oncologic surgeon” is a more appropriate term than “ablative surgeon” which is a term I’ve never heard of.	Ablative surgeon refers to the surgeon removing the tissue and is used as such in some of the included publications. We have reworded to use more common terminology.
5. Recommendation 1.6: ...”and the these are greater than expander/implant reconstruction” relative to DTI or autologous reconstruction? This statement may need more clarification.	The sentence has been revised: ... and that these are greater in expander/implant reconstruction <b>than with autologous reconstruction.</b>
6. This documents provides sufficient information to inform my decision. One area I would be interested in was the recommendation of prepectoral breast implant placement in favor of post pectoral. I do wonder what the literature would suggest on the need for secondary procedures in the prepectoral group in as much as the need for fat grafting to help with the implant deformity, palpability, and wrinkling. Does this group of patients (prepectoral) necessitate as a whole more secondary procedures as compared to the subpectoral group?	Patients with prepectoral implants generally require more fat grafting for optimal aesthetic outcomes as there is more rippling and contour deformities (27). This may be offset by less clinical visits and shorter delay prior to definitive implant placement (337).
7. The guideline overemphasized the reconstruction/ plastic surgery aspects, especially with respect to technique .	The objectives of this work were to address specific issue related to reconstruction.

<p>8. Those deemed “technically” appropriate for NSM, as per whom? The oncologic aspect is covered but there isn’t much on the plastic side, this could be introduced as part of the discussion as currently it reads pretty strongly that this is the preferred approach for all and implies that most women are eligible for NSM; “if appropriate” but then no details which is somewhat counter to the level of detail provided about other technical parts. Concern that patients might see this as supporting a choice for NSM when it may not be appropriate technically or available in a timely manner.</p>	<p>The first clause of the recommendation is “In patients who are candidates for skin-sparing mastectomy (SSM)”. Patients not candidates for SSM would not be considered for NSM. It is outside scope to determine who is suitable for SSM.</p> <p>This is a decision to be made by the surgeon and if not considered appropriate the patient should be informed. Oncologic safety is the overall consideration; secondary is ability to obtain satisfactory aesthetic results. Other issues would generally affect SSM as well.</p> <p>“Timely matter” is outside scope of this document, and is an implementation issue.</p>
<p>9. Topics such as timing of reconstruction and coordination of immediate breast reconstruction between general and plastic surgery, with increasing indications for neoadjuvant therapy, genetic testing availability (to inform on CPM) in addition to the impact of RT were not delved into deeply and merely noted “that multidisciplinary discussion” should occur. Alternative options such as up front BCS to inform on adjuvant therapy were not mentioned, particularly to assist with coordination of subsequent IBR and allowing a fulsome MDT discussion (ie RT or not) and inclusion of genetics assessment. I feel this a very important and realistic component of the assessment in our publicly funded system and an important expansion to “if timing oncologically appropriate”. I would imagine that urgent coordinated flap time is not readily available everywhere.</p>	<p>Breast conservation surgery is outside of scope, as are factors involved in decision making regarding having mastectomy or reconstruction. The scope only involves mastectomy. Determination of RT is outside of scope.</p> <p>While we mention genetics assessment should be considered, details of this are outside of scope. The guideline only addresses issues related to how to conduct reconstruction, and therefore starts at the point where the decision for reconstruction has already been made.</p>
<p>10. I do not think that most current graduates from general surgery residency would feel comfortable doing a NSM via IMF without extra training/mentorship.</p>	<p>While the qualifications of surgeons and where it is done is not within scope, we agree that not all surgeons have the training and expertise to operate on patients desiring reconstruction, and especially conduct SSM and NSM. This is a factor in both complication rates and patient satisfaction. Several publications indicate that</p>

	general surgical training in Canada is not sufficient.
11. Re: Alternatives. No mention is made of going flat, external prosthetics, or use of oncoplastic BCS (ie reduction mammoplasty) is made. Should be included. The overarching emphasis is on IBR, and more explicit language around delayed reconstruction as an alternative should be mentioned and discussed a bit more detail. Given the technical aspects included, consider recommendations for mastectomy surgical considerations if patient desires reconstruction and IBR not appropriate/DBR is going to be considered, or patient is going flat for the interim or permanently.	The guideline objective states “For this document, ‘reconstruction’ refers to immediate or delayed reconstruction of the breast mound, not including aesthetic flat closure. The scope (see title and target population) is only patients who have decided on mastectomy; and want reconstruction. Question 2 is on immediate versus delayed reconstruction. Comparative data is limited, but psychological/QoL benefit of immediate reconstruction is clear. If a patient is not a candidate for immediate reconstruction due to comorbidities, then they were excluded from the studies comparing immediate versus delayed reconstruction.
12. I understand the guidelines are based on best evidence; however, they should be balanced by clear acknowledgement of the bias associated with these studies that derive their data from expert clinicians/centres. I note that in the type of recon old guideline there is more language discussing the level of evidence and highlighting limitations/bias compared to this version.	Our guidelines are based on the publishes studies, and these are generally conducted by those with expertise in the field. If surgeon training is suboptimal, that is a system issue but outside the scope of our work. If Ontario/Canadian hospitals are not achieving similar results it indicates a need for improvement. This was not within scope of the current work.
13. The guideline is very long. While one can scroll to the header of various topics, some seem very technical in nature, which is separate from oncologic safety and QOL outcomes from various selected procedures. One consideration is to separate the pure technical reviews into an appendix. We did this when SLNB was not yet standard of care but there was appetite to provide good evidence-based recommendations for best practice. Ie 3.3 - 3.7 such the thermal dissection, tension, incision etc are all purely technical and some apply to both SSM and NSM. As the outcomes and decision to proceed with various reconstructive techniques depends on health of the flap, agree it is important to highlight surgical factors in performing mastectomy to mitigate flap and nipple necrosis. Perhaps this can be referred to	As suggested by others, we created a detailed Table of Contents so the user could skip to the more relevant sections. In the final document, Section 1 will just include Recommendations and Qualifying Statements and so will be more concise for the reader just wanting this information.  The technical issues were part of the objectives of the work (see Research Question 3c) and therefore crucial to the guideline. We agree these issues in 3.3 to 3.7 apply to SSM as well. They affect the key outcomes for this question.

in “technical considerations for mastectomy” appendix and allows for expansion of some of the evidence in that section on the impact of flap quality on selection of size/recon choice and nipple preservation, particularly with implants.	
14. I think mention of the contents of appendix 6 should be made early on with either a link to the same or mention this is an add on, as otherwise a large chunk of overall recon considerations such as the T/E / implant vs auto is missing, along with TE/implant.	We have moved this to the start of the Recommendation section.
15. I also note there is nothing about women with indwelling augmentation, and either doing implant upsizing with/without skin envelop tightening.	This guideline only deals with patients undergoing mastectomy, and it is assumed this would include removing any existing implants.
16. On page 2-3 re CPM, the overall recommendations do not really reflect the evidence provided in the justification - that CPM should not be offered/discouraged in average risk women; I think this should be added to the qualifying statements and not left to the justification. Additionally, the justification statement that “MRI can be used to screen for contralateral cancer” is taken out of context, would reword. As it stands, may be interpreted as using MRI to screen for contralateral in all comers which is not what the CCO MRI guideline states.	We believe wording is appropriate and was suggested by those involved with high-risk patients.  The CCO MRI guideline states MRI should be considered if additional information could influence treatment and the key evidence indicates that MRI for contralateral cancer falls in this category. The intent of the guideline is that screening for contralateral cancer is a valid.
17. Recommendation/justifications for 1.1-1.6, especially 1.2 and 1.6: Appreciate the emphasis that comorbidities should NOT be absolute contraindications, however I think the language is not strong enough to emphasize the downstream implications of complications listed (which can be quite devastating) and the % risks, or recognizing that they are also additive. I.e DM, obesity and smoking with planned RT is not the same as someone who is just obese. Suggest adding wording around “careful risk assessment to inform a decision for IBR including implications on subsequent adjuvant oncology treatments should be balanced with anticipated improvement in QOL” can be added, along with including a validated risk tool like <a href="http://www.brascore.org">www.brascore.org</a> which provides a quantitative assessment for informed decision making. My concern that pts may use this to insist on IBR and that the plastic/general surgeon may feel these guidelines do not support their clinical judgement on outcomes.	We agree with this comment and have added a note at the start of the section as well as for recommendation 1.2.

<p>18. For 2 the Qualifying statement should include a point around the potential impact of IBR on treatment timeline and subsequent oncologic outcomes, which may be delayed due to system issues like access to coordinated OR surgical expertise. This is where alternatives such as up front BCS for timely tumour resection, informed adjuvant therapy decisions and the benefit of additional time to coordinate/refer for IBR without oncologic compromise could be mentioned. Can include data on delay to ablative surgery leading to worse outcomes (hence our wait time targets) in the Justification section</p>	<p>Upfront BCS is outside scope of this document. We have commented that waiting time may be a factor influencing the decision between immediate and delayed reconstruction.</p> <p>The intended user of this guideline is clinicians involved with breast cancer and they should be aware of recommended treatment times. Use of neoadjuvant therapy could be considered if delays are oncologically unacceptable (as was done during initial stages of COVID-10 pandemic) but is outside the scope of this work.</p>
<p>19. For 3.1 Consider rewording. Concern that the interpretation is that NSM is standard of care, full stop. Suggest language such as “There is evidence that SSM and NSM mastectomy are oncologically similar in women with no NAC involvement...the patient should be involved in the decision making between SSM and NSM and discussions should include technical feasibility given body habitus, aesthetic and functional outcome.” I note that alterations to sensation, erection, necrosis/death are only mentioned in passing further down and that while stated that it is “well established” that women prefer NSM there is zero evidence to support provided. In women who choose/are not suitable for NSM, include that nipple reconstruction is an option somewhere.</p>	<p>We intend that NSM should be standard of care for patients who desire this and have no contraindications.</p>
<p>20. For 3.4 Mentioning that reconnecting nerves sometimes may be attempted in autologous seems out of place and not supported elsewhere. Suggest moving down to the Justification section where mention of grafting etc and it’s position in Ontario is made (ie not widely available)</p>	<p>This is mentioned in Key Evidence. While ideally this would be a standard of care, we acknowledge a lack of expertise at this time. This is a system issue.</p>
<p>21. I think the first statement in the justification for Recommendation 4 (plane of implants) should be the Recommendation, which states there are roles for both planes, followed by the evidence based recommendations. Background should include the benefits/historic use of subpectoral which then supports the advocacy for the use of prepectoral as far as decreased animation</p>	<p>This statement has been added to recommendations. The background has been expanded to include some historical considerations. ADM is more fully discussed in Recommendation 5.</p>
<p>22. Is the cost of ADM an issue for some sites? This should also be mentioned if it is not universally covered for full coverage of the implant across</p>	<p>Background has been modified. Cost is mentioned under justification.</p>

Ontario as a consideration. Finally, in the Qualifying Statements, mention is made about dual plane without ADM (i.e., mastectomy flap or serratus slings); suggest including in the other areas where dual plane and ADM are noted in background, and Recommendation; currently reads as ADM for pre pec only.	
---	--

### **Professional Consultation**

Feedback was obtained through a brief online survey of healthcare professionals and other stakeholders who are the intended users of the guideline. The survey was sent to two groups of active contacts in the PEBC database. The first consisted of specific professions (Plastic Surgeon, Surgeon, Surgical Oncologist, Pathologist, Anatomical Pathologist, Laboratory Medicine, Radiologist, Interventional Radiologist, Radiation Oncologist, Medical Physicist, Neurologist, Family Practitioner, or Medical Oncologist) who were identified as having an interest in one or more of breast, reconstructive surgery, neurosurgery, or were part of the Breast Cancer Advisory Committee or Breast Disease Site Group or previous Breast Reconstruction Guideline Development Group. The second group consisted of contacts with an interest in breast or reconstructive surgery or neurosurgery but with no profession recorded in the database. The survey was sent to 195 people (185 in Ontario and 10 elsewhere) and 31 responses (15.9%) were received. The results of the feedback survey from 31 people are summarized in Table 5-5. The main comments from the consultation and the Working Group's responses are summarized in Table 5-6.

**Table 5-5. Responses to four items on the professional consultation survey.**

	Number (%)				
<b>General Questions: Overall Guideline Assessment</b>	<b>Lowest Quality (1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>Highest Quality (5)</b>
1. Rate the overall quality of the guideline report.	0	1 (3.2%)	0	13 (41.9%)	17 (54.8%)
	<b>Strongly Disagree (1)</b>	<b>(2)</b>	<b>(3)</b>	<b>(4)</b>	<b>Strongly Agree (5)</b>
2. I would make use of this guideline in my professional decisions.	0	0	5 (16.1%)	15 (48.4%)	11 (35.5%)
3. I would recommend this guideline for use in practice.	0	1 (3.2%)	3 (9.7%)	5 (16.1%)	22 (71.0%)
4. What are the barriers or	<b>Barriers</b> <ul style="list-style-type: none"> <li>Widespread dissemination to Multidisciplinary Teams is crucial.</li> </ul>				

<p>enablers to the implementation of this guideline report?</p>	<ul style="list-style-type: none"> <li>• Ensuring that practitioners in community settings are aware and utilizing the guideline.</li> <li>• Access to surgeons able to do bilateral mastectomies and nipple sparing procedures</li> <li>• Resources for community general surgeons could limit implementation. Lack of human health resources in terms of availability and access to plastic surgeons may be a limiting factor.</li> <li>• Access to plastic/reconstructive surgeons and operating room time/infrastructure (especially in specific institutions and regions) for both immediate and delayed reconstruction</li> <li>• Inequity of access to immediate breast reconstruction is a definite barrier in areas outside GTA.</li> <li>• Most reconstruction still occurs at tertiary centers yet some communities do offer selective reconstruction. There may be sporadic multidisciplinary support.</li> <li>• Access to multidisciplinary consultation</li> <li>• The availability of multidisciplinary surgical oncologist and plastic surgeon teams is key to implementation.</li> <li>• Discussions that involve plastic surgery are commonly not available at diagnosis and surgeons still in a mindset of "cancer first, reconstruction second" continue to be barriers to universal advancement and equity.</li> <li>• Variable surgical practices, expertise, and resources across the province (country) will preclude uniform implementation.</li> <li>• Access to timely preop evaluation by medical and radiation oncology</li> <li>• Ensuring that patients are able to access appropriate providers who will refer/consider this information in making decisions as to whether eligible to have this surgery.</li> <li>• Dissemination to the community and the buy in from physicians who need to treat patients post mastectomy with radiation because of high risk factors for local recurrence.</li> <li>• Dissemination of these recommendations may be challenging due to operating room bookings and coordination of general surgeons and plastic surgeons, small centers versus larger centers, use of residents and fellows in supervision of flaps, and use of equipment to monitor viability</li> <li>• Time constraints for informed decision making</li> <li>• NSM is not always an option. Discussion of OHIP-covered tattooing or nipple reconstruction with realistic restorative areola tattooing needs to be a discussion for psychological and physical wellbeing.</li> <li>• It is very dense. Perhaps a "compressed" version with bottom line recommendations on each section would be easier to access as a resource.</li> <li>• Primarily its length. It is extremely comprehensive. A shorter summary document would be helpful for more efficient ease of use.</li> </ul>
---	---



	<ul style="list-style-type: none"> <li>• The report while comprehensive is very long and dense, this may make it difficult for some people to read and absorb in full.</li> <li>• Follow-up of patients with nipple sparing should be with MRI and not all sites have one. Is there a role for mammography?</li> <li>• Workshops/Online dissemination and training may help bringing everyone to the table.</li> <li>• Access for adequate support for surgeons to manage increased volumes of complex reconstruction in pre and post op period (time for patient education, wound care, expansion etc.) Guidelines should include recommendations for advanced practice providers to support care of patients, guidelines for patient education and access to educational materials, need for "programs" to allow surgical teams to take to administration for adequate funding and trained personnel</li> <li>• A repository of up to date information such as OH-CCO needs to be user-friendly and standard of care. Enabling patients in educational decision-making is essential to creating equity.</li> <li>• I would like to see options of central booking or communication and support to small centers that repatriate post reconstruction. Everyone deserves the right to have this option. Bringing patients into the decision boards for dissemination of recommendations brings a perspective and opinions for the best breast cancer approaches for optimal outcomes.</li> <li>• Consider centralized provincial waitlist for delayed reconstruction.</li> </ul> <p><b>Enablers</b></p> <ul style="list-style-type: none"> <li>• The concise way the data is presented.</li> <li>• The document is clear and well-written</li> <li>• This is a comprehensive report summarizing the most recent evidence for this topic and includes many factors that influence outcomes.</li> <li>• This is an excellent, thorough, well written report that provides evidence for many different presenting scenarios</li> <li>• The guideline is very comprehensive..</li> <li>• Excellent guideline!</li> <li>• Thanks to everyone involved in putting this together. It is a very comprehensive document and worthwhile document. Congratulations! Great work!</li> <li>• This is a useful document which is educational for nonsurgical members of the oncology team and will further the goals of sharing decision-making for all treatment recommendations.</li> <li>• Takes patient preferences into consideration.</li> <li>• This guideline is comprehensive, evidence-based, and reader-friendly, making it an invaluable reference for those caring for breast cancer patients undergoing or considering post-mastectomy reconstruction. While its implementation largely depends on both the surgeon's and the patient's preferences,</li> </ul>
--	---

	which ultimately influence the choice of procedure, it remains a crucial tool to support informed decision-making in clinical practice.
--	---

**Table 5-6. Summary of the Working Group's responses to comments from professional consultants.**

Comments	Responses
1. Patients are in a vulnerable situation with a cancer diagnosis, often paralyzed by the diagnosis in front of them and entirely dependent on the opinion of the surgeons and breast cancer team. Education of these guidelines which also include the inclusion of OHIP-covered nipple reconstruction and OHIP-covered 3D high quality areola tattooing for optimal restoration need to be part of the equitable conversation after breast cancer.	Tattoos and nipple reconstruction have been added to the qualifying statements regarding NSM.
2. As a Pathologist, I am completely against intraoperative/frozen section pathologic analysis (for margins, presence or absence of tumor especially in ILC or ADH) due to false positive and frozen sections artifacts. Treatment decisions should be based on definitive/final pathology results. My suggestion is in the summary you add again since results show that frozen section result is not sensitive specially in patient post NAC, it is not recommended.	We agree. We state that "We recommend against intraoperative/ frozen section pathologic analysis. Treatment decisions should be based on definitive/final pathology results."
3. I understand that you can only use quality publications for consensus and recommendations but the most profound factor in success of most types of alloplastic breast reconstruction is the final thickness of the mastectomy flaps. Of all the lists of factors that contribute to complications this, from my point of view, is the most important. The mastectomy is the "first stage" of reconstruction but there are no standards and very little descriptive efforts on this topic.	We agree that flap thickness and perfusion are crucial (466). Most studies used poor perfusion as an exclusion criteria or criteria in determining what type of reconstruction to use, and therefore differences in flap thickness or perfusion was not compared.  How to conduct mastectomy was not part of this review or guideline (outside scope), other than for factors in NSM affecting nipple viability, necrosis, and sensation.
4. This is an outstanding and very comprehensive document. It may be valuable to have some summary statement that these recommendations are based on the information available today and that the field is constantly evolving. Techniques in breast reconstruction, such as plane of implant, use of ADM or other	In several places we state evidence is insufficient. We agree that the field is rapidly evolving.

meshes, use of fat grafting have evolved significantly in just the past few years. I would expect that to continue.	
<p>5. The results from the RT CHARM (Alliance 221505) RCT have been published in abstract form and presented in 2024. The full publication will likely be available soon. Some of the results may be relevant for this PEBC, including primary outcome of complications with radiotherapy that include any re-operation or hospitalization considered as non-routine, as well as any baker 3 or 4 contracture. Relevant secondary outcomes will include patient satisfaction and well-being at 24 months after radiation (Breast Q), and comparison of reconstruction complication rates based on reconstruction method and timing of reconstruction.</p> <p>RT CHARM results are out, albeit with 2-year data. Our centre has adopted the moderately hypo fractionated approach as a result. It is probably fair to say that the treatment course is still at the discretion of the RO, as it may be a centre-dependent or individualized approach to dose/fractionation in Ontario.</p>	We look forward to reporting of this trial results. The abstract does not contain sufficient details to include at this time.
6. The one recommendation I would have liked to see is to suggest advising patients that following fat grafting, they may experience palpable lumps that are most likely fat necrosis. This might pre-emptively alleviate anxiety.	We agree this is important. The qualifying statement states that "Palpable masses as a result of fat necrosis may occur in patients who have received fat transfer. These are generally benign on imaging and can be identified without biopsy in most cases"
7. The communication of the TND could be improved in that a TND of > 5 cm may not directly correlate with long-term outcomes, but that a TND in ref 82 was shown to be more likely associated with surgical margins of < 2 mm. It should be emphasized that the reporting of the TND is still an important finding on breast MRI. The way it is written negates this finding	While smaller TND are associated with positive surgical margins and are a risk factor for nipple involvement, they are not associated with outcomes, as once you determine positive margins the standard is to perform re-excision.
8. There are a few typographical errors in the document.	Thank you for this. The document has been read over again and corrected.
9. The other issue with the techniques described would be long term outcomes. Does one technique require ongoing surveillance? Do the implants require revision and thus subsequent surgery ( i.e. 10 years) vs autologous reconstruction and would that impact	Surveillance does not vary with type of reconstruction, but may vary with other risk factors. Implants are known to be non-permanent and may need replacing. Comparison of types of implants and flaps is outside the scope of the current work.

someone's decision for type of reconstruction. I am not directly in the field but I would use the guideline as a basis for change management.	
10. Not all patients need to discuss reconstruction before neoadjuvant chemotherapy. This bullet seems to single out patients wanting reconstruction who could possibly be best treated with neoadjuvant systemic treatment be sent for consultation with medical oncologist. Why not all patients who could benefit from neoadjuvant treatment? Why the "and/or radiation oncologist"? Does not make sense to "have and / or". Do radiation oncologists want to or feel the need to evaluate patient's pretreatment who may want reconstruction after neoadjuvant treatment?	Neoadjuvant therapy is not mentioned in the referred to section.
11. I do not agree with " along with a direct recommendation by the ablative or reconstructive surgeon (or consensus of these) for or against contralateral prophylactic mastectomy. Concurrent prophylactic mastectomy options should be discussed but a definite recommendation for or against is not universally correct. I would think it is an option just like mastectomy or lumpectomy for early breast cancer. To me a "recommendation" is made when there is medical evidence that a treatment will have direct benefit and be in the patient's best interest. This is not proven with prophylactic mastectomy in most cases. Otherwise we would be put in the crazy position of offering a lumpectomy and radiation for one breast with early stage disease and a prophylactic mastectomy for the contralateral breast.	Other reviewers suggested this be added and the authors agreed. We have modified wording slightly. There is medical evidence regarding oncologic outcomes in high-risk patients, and evidence of psychological benefit in cases where acceptable aesthetic results cannot be otherwise obtained. The recommend we refer to is the surgeon's judgement based on these factors; in their absence the surgeon's recommendation would be that there is no medical reason for contralateral mastectomy.
12. The technical description of how to perform nipple sparing mastectomy should be removed. This is not a technical syllabus or surgical atlas. This will also make for a more succinct guideline. This may foster more engagement.	This was part of the research question as defined by the sponsor and authors and therefore considered necessary to include.
13. A list of abbreviations is needed.	Terms are defined at the first use, as per standard practice. Abbreviations are all in common use, other than a few in tables and theses are defined for each table.
14. It would be helpful to make clear the local and distant recurrence rates for the various reconstruction procedures.	These are included in the data tables when reported in the publications meeting our inclusion criteria for the systematic review.

15. More discussion of skin sparing mastectomy (SSM) (pros and cons) in relation to NSM would be helpful to readers.	SSM and NSM are the same except for treatment of the nipple. This affects appearance, potentially sensation, and quality of life for some patients.
16. P12, it is mentioned that 'atypia is often misidentified in frozen section analysis', it would be better to say that 'frozen section analysis is not a reliable method of assessing epithelial cell atypia', or something similar.	We have made this change.
17. P17, describe what is meant by 'tumescence'.	This has been added to the Glossary
18. P20, please include a reference for 'a Sterility Assurance Level of 10 <sup>-3</sup> '	This has been added
19. P22, for the Breast Trial it is mentioned that there was no difference in oncologic events. Please include the time period over which this was observed.	This is up to 1 year. Long-term follow-up is ongoing to. This has been added

## CONCLUSION

The final guideline recommendations contained in Section 2 and summarized in Section 1 reflect the integration of feedback obtained through the external review processes with the document as drafted by the GDG Working Group and approved by the GDG Expert Panel and the PEBC RAP.

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results](#)

## References

1. National Cancer Institute. NCI Dictionary of Cancer Terms. National Cancer Institute, USA. Accessed 2025 Jan 23. Available at: <https://www.cancer.gov/publications/dictionaries/cancer-terms>.
2. Yamamoto T, Yamamoto N, Kageyama T, Sakai H, Fuse Y, Tsuihiji K, et al. Definition of perforator flap: what does a "perforator" perforate? *Glob Health Med*. 2019;1(2):114-6.
3. Sinna R, Boloorchy A, Mahajan AL, Qassemayr Q, Robbe M. What should define a "perforator flap"? *Plast Reconstr Surg*. 2010;126(6):2258-63.
4. Blondeel PN, Van Landuyt KH, Monstrey SJ, Hamdi M, Matton GE, Allen RJ, et al. The "Gent" consensus on perforator flap terminology: preliminary definitions. *Plast Reconstr Surg*. 2003;112(5):1378-83; quiz 83, 516; discussion 84-7.
5. Homsy C, Theunissen T, Sadeghi A. The Thoracodorsal Artery Perforator Flap: A Powerful Tool in Breast Reconstruction. *Plast Reconstr Surg*. 2022;150(4):755-61.
6. Hamdi M, Van Landuyt K, Hijjawi JB, Roche N, Blondeel P, Monstrey S. Surgical technique in pedicled thoracodorsal artery perforator flaps: a clinical experience with 99 patients. *Plast Reconstr Surg*. 2008;121(5):1632-41.
7. Brambilla L, Parisi P, Gatto A, Codazzi D, Baronetto N, Gilardi R, et al. A Retrospective Comparative Analysis of Latissimus Dorsi (LD) Flap Versus Thoracodorsal Artery Perforator (TDAP) Flap in Total Breast Reconstruction with Implants: A Pilot Study. *J Reconstr Microsurg*. 2022;38(6):451-9.
8. Butler PD, Wu LC. Abdominal perforator vs. muscle sparing flaps for breast reconstruction. *Gland Surg*. 2015;4(3):212-21.
9. Nahabedian MY, Dooley W, Singh N, Manson PN. Contour abnormalities of the abdomen after breast reconstruction with abdominal flaps: the role of muscle preservation. *Plast Reconstr Surg*. 2002;109(1):91-101.
10. Heo JW, Park SO, Jin US. Donor-site morbidities in 615 patients after breast reconstruction using a free muscle-sparing type I transverse rectus abdominis myocutaneous flap: a single surgeon experience. *J Plast Surg Hand Surg*. 2018;52(6):325-32.
11. Rozen WM, Ting JW, Grinsell D, Ashton MW. Superior and inferior gluteal artery perforators: In-vivo anatomical study and planning for breast reconstruction. *J Plast Reconstr Aesthet Surg*. 2011;64(2):217-25.
12. Allen RJ, Levine JL, Granzow JW. The in-the-crease inferior gluteal artery perforator flap for breast reconstruction. *Plast Reconstr Surg*. 2006;118(2):333-9.
13. Ben Aziz M, Rose J. Breast Reconstruction Perforator Flaps. 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan; cited 2025 Jan 23. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK565866/>.
14. Lohasammakul S, Tonaree W, Suppasilp C, Numwong T, Ratanalekha R, Han HH. Superficial Inferior Epigastric Artery Flap: Vascular Pattern and Territory Across the Midline. *J Reconstr Microsurg*. 2024;40(6):435-42.
15. Rajaram R, Cevik J, Bhindi N, Rozen WM. The anatomy of the superficial inferior epigastric artery: Cautious optimism and rightful reluctance for the championing of a minimally morbid abdominal flap. *J Plast Reconstr Aesthet Surg*. 2024;96:69-71.
16. Allen RJ, Haddock NT, Ahn CY, Sadeghi A. Breast reconstruction with the profunda artery perforator flap. *Plast Reconstr Surg*. 2012;129(1):16e-23e.

17. Dyrberg DL, Bille C, Gunnarsson GL, Frandsen TF, Salzberg CA, Sorensen JA, et al. Breast animation deformity. *Arch Plast Surg.* 2019;46(1):7-15.
18. Cerceo JR, Cai L, Yesantharao P, Thornton B, Nazerali R. Risk stratification in subpectoral to prepectoral pocket conversion to reduce post-reconstruction animation deformity. *J Plast Reconstr Aesthet Surg.* 2023;77:253-61.
19. Coleman SR. Structural fat grafting: More than a permanent filler. *Plast Reconstr Surg.* 2006;118(3 Suppl):108S-20S.
20. Catherine Bouteille MB, Laura Sabiani, Aurore Van Troy, Max Buttarelli, Arthur Bertrand, Axelle Charavil, Monique Cohen, Gilles Houvenaeghel. Lipofilling and Breast Reconstruction after Partial or Total Mastectomy. *Journal of Surgery and Research* 2024;7:395-407.
21. Pereira CT, Hill EE, Stasyuk A, Parikh N, Dhillon J, Wang A, et al. Molecular Basis of Surgical Coaptation Techniques in Peripheral Nerve Injuries. *J Clin Med.* 2023;12(4):1555.
22. Narakas AO, Hentz VR. Neurotization in brachial plexus injuries. Indication and results. *Clin Orthop Relat Res.* 1988(237):43-56.
23. Telich-Tarriba JE, Alvarez G, Cardenas-Mejia A. Sensory Nerve Transfers and Direct Neurotization: The New Frontier in Peripheral Nerve Surgery. *International Microsurgery Journal.* 2022.
24. Horen SR, Jahromi AH, Konofaos P. Direct Neurotization: Past, Present, and Future Considerations. *Ann Plast Surg.* 2021.
25. Ng T, Knowles S, Brackstone M, Doherty C. Mastectomy flap necrosis after nipple-sparing mastectomy and immediate implant-based reconstruction: An evaluation of tumescence and sharp dissection technique on surgical outcomes. *Breast J.* 2019;25(6):1079-83.
26. Gipponi M, Baldelli I, Atzori G, Fregatti P, Murelli F, Pesce M, et al. Tumescent Anesthesia in Skin- and Nipple-sparing Mastectomy: Results of a Prospective Clinical Study. *Anticancer Res.* 2017;37(1):349-52.
27. Darrach H, Kraenzlin F, Khavanin N, Chopra K, Sacks JM. The role of fat grafting in prepectoral breast reconstruction. *Gland Surg.* 2019;8(1):61-6.
28. Sbitany H. Important Considerations for Performing Prepectoral Breast Reconstruction. *Plast Reconstr Surg.* 2017;140(6S Prepectoral Breast Reconstruction):7S-13S.
29. Graziano FD, Henderson PW, Jacobs J, Salzberg CA, Sbitany H. How to Optimize Prepectoral Breast Reconstruction. *Aesthet Surg J.* 2020;40(Suppl 2):S22-S8.
30. Holland MC, Lentz R, Sbitany H. Surgical correction of breast animation deformity with implant pocket conversion to a prepectoral plane. *Plast Reconstr Surg.* 2020;145(3):632-42.
31. Turner A, Abu-Ghname A, Davis MJ, Winocour SJ, Hanson SE, Chu CK. Fat Grafting in Breast Reconstruction. *Semin Plast Surg.* 2020;34(1):17-23.
32. Muradali D, George FG, Erin C, Samantha F, George R, Kulkarni S, et al. Preoperative breast magnetic resonance imaging guideline. Toronto (ON): Ontario Health (Cancer Care Ontario); 2023 March 24. Program in Evidence-Based Care Guideline No.: 1-25 GL. Available from: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/70786>.
33. Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, et al. Contralateral prophylactic mastectomy consensus statement from the American Society of Breast Surgeons: Additional considerations and a framework for shared decision making. *Ann Surg Oncol.* 2016;23(10):3106-11.
34. Wright FC, Look Hong NJ, Quan ML, Beyfuss K, Temple S, Covelli A, et al. Indications for contralateral prophylactic mastectomy: A consensus statement using modified Delphi methodology. *Ann Surg.* 2018;267(2):271-9.

35. Ontario Health (Cancer Care Ontario). Hereditary cancer testing eligibility criteria: Version 3.1. Toronto: Ontario Health (Cancer Care Ontario); 2024 Oct 1. Cited 2025 Jan 13. Available from: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/70161>.
36. Ontario Health. Referral guidance for hereditary cancer genetic assessment. Toronto: Ontario Health; 2023 Apr 11. Cited 2025 Jan 13. Available from: <https://www.ontariohealth.ca/sites/ontariohealth/files/2023-04/CancerGeneticAssessmentReferralGuidance.pdf>.
37. Kim M, Ali B, Zhang K, Vingan P, Boe L, Ly CL, et al. Age Impacts Clinical and Patient Reported Outcomes following Post Mastectomy Breast Reconstruction. *Plast Reconstr Surg*. 2024;21:21.
38. Cuccolo NG, Sparenberg S, Ibrahim AMS, Crystal DT, Blankensteijn LL, Lin SJ. Does age or frailty have more predictive effect on outcomes following pedicled flap reconstruction? An analysis of 44,986 cases. *J Plast Surg Hand Surg*. 2020;54(2):67-76.
39. Liu Q, Aggarwal A, Wu M, Darwish OA, Baldino K, Haug V, et al. Impact of diabetes on outcomes in breast reconstruction: A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg*. 2022;75(6):1793-804.
40. Mortada H, Alwadai A, Bamakhrama B, Alsinan T, Hanawi MD, Alfaryan SM, et al. The impact of diabetes mellitus on breast reconstruction outcomes and complications: A systematic literature review and meta-analysis. *Aesthetic Plast Surg*. 2023;23:23.
41. Theocharidis V, Katsaros I, Sgouromallis E, Serifis N, Boikou V, Tasigiorgos S, et al. Current evidence on the role of smoking in plastic surgery elective procedures: A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg*. 2018;71(5):624-36.
42. Panayi AC, Agha RA, Sieber BA, Orgill DP. Impact of obesity on outcomes in breast reconstruction: A systematic review and meta-analysis. *J Reconstr Microsurg*. 2018;34(5):363-75.
43. ElAbd R, Prabhu N, Alibrahim A, Burke E, Williams J, Samargandi O. Autologous versus alloplastic reconstruction for patients with obesity: A systematic review and meta-analysis. *Aesthetic Plast Surg*. 2022;46(2):597-609.
44. Mrad MA, Al Qurashi AA, Shah Mardan QNM, Alqarni MD, Alhenaki GA, Alghamdi MS, et al. Predictors of complications after breast reconstruction surgery: A systematic review and meta-analysis. *Plast Reconstr Surg Glob Open*. 2022;10(12):e4693. <https://dx.doi.org/10.1097/GOX.0000000000004693>.
45. Bond ES, Soteropoulos CE, Yang Q, Poore SO. The impact of prior abdominal surgery on complications of abdominally based autologous breast reconstruction: A systematic review and meta-analysis. *J Reconstr Microsurg*. 2021;37(7):566-79.
46. Chung JH, Sohn SM, Jung SP, Park SH, Yoon ES. Effects of pre-existing abdominal scar on postoperative complications after autologous breast reconstruction using abdominal flaps: A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg*. 2021;74(2):277-89.
47. Chicco M, Ahmadi AR, Cheng HT. Systematic review and meta-analysis of complications following mastectomy and prosthetic reconstruction in patients with and without prior breast augmentation. *Aesthet Surg J*. 2021;41(7):NP763-NP70.
48. Varghese J, Gohari SS, Rizki H, Faheem M, Langridge B, Kummel S, et al. A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction. *Breast*. 2021;55:55-62.
49. Magill LJ, Robertson FP, Jell G, Mosahebi A, Keshtgar M. Determining the outcomes of post-mastectomy radiation therapy delivered to the definitive implant in patients



- undergoing one- and two-stage implant-based breast reconstruction: A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg.* 2017;70(10):1329-35.
50. Pu Y, Mao TC, Zhang YM, Wang SL, Fan DL. The role of postmastectomy radiation therapy in patients with immediate prosthetic breast reconstruction: A meta-analysis. *Medicine.* 2018;97(6):e9548.
  51. Hong WJ, Zhang GY, Chen CL, Li FW, Wang HB. The effect of previous irradiation for patients with prosthetic breast reconstruction: A meta-analysis. *Aesthet Surg J.* 2021;41(7):NP748-NP57.
  52. Zugasti A, Hontanilla B. The impact of adjuvant radiotherapy on immediate implant-based breast reconstruction surgical and satisfaction outcomes: A systematic review and meta-analysis. *Plast Reconstr Surg Glob Open.* 2021;9(11):e3910.
  53. Liew B, Southall C, Kanapathy M, Nikkhah D. Does post-mastectomy radiation therapy worsen outcomes in immediate autologous breast flap reconstruction? A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg.* 2021;74(12):3260-80.
  54. Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH, et al. Updated recommendations regarding the management of older patients with breast cancer: A joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). *Lancet Oncol.* 2021;22(7):e327-e40.
  55. Lee RXN, Cardoso MJ, Cheung KL, Parks RM. Immediate breast reconstruction uptake in older women with primary breast cancer: Systematic review. *Br J Surg.* 2022;109(11):1063-72.
  56. Yoon AP, Qi J, Brown DL, Kim HM, Hamill JB, Erdmann-Sager J, et al. Outcomes of immediate versus delayed breast reconstruction: Results of a multicenter prospective study. *Breast.* 2018;37:72-9.
  57. Shammass RL, Gordee A, Lee HJ, Sergesketter AR, Scales CD, Hollenbeck ST, et al. Complications, costs, and healthcare resource utilization after staged, delayed, and immediate free-flap breast reconstruction: A longitudinal, claims-based analysis. *Ann Surg Oncol.* 2023;30(4):2534-49.
  58. Huang H, Chadab TM, Wang ML, Norman S, Cohen LE, Otterburn DM. A comparison between immediate and babysitter deep inferior epigastric perforator flap breast reconstruction in postoperative outcomes. *Ann Plast Surg.* 2022;88(3 Suppl 3):S179-S83.
  59. Prantl L, Moellhoff N, von Fritschen U, Giunta RE, Germann G, Kehrer A, et al. Immediate versus secondary DIEP flap breast reconstruction: A multicenter outcome study. *Arch Gynecol Obstet.* 2020;302(6):1451-9.
  60. Ulrikh DG, Krivorotko PV, Bryantseva ZV, Pesotskiy RS, Bondarchuk YI, Amirov NS, et al. Reconstructive plastic surgery in combined treatment of breast cancer: Predictive risk factors of complications and reconstruction failure. [Russian]. *PA Herzen J Oncol.* 2024;13(3):13-9.
  61. Billig J, Jagsi R, Qi J, Hamill JB, Kim HM, Pusic AL, et al. Should immediate autologous breast reconstruction be considered in women who require postmastectomy radiation therapy? A prospective analysis of outcomes. *Plast Reconstr Surg.* 2017;139(6):1279-88.
  62. Hassan AM, Ray N, Govande JG, Paidisetty P, Largo RD, Chu CK, et al. Long-term surgical and patient-reported outcomes comparing skin-preserving, staged versus delayed microvascular breast reconstruction. *Ann Surg Oncol.* 2023;30(9):5711-22.
  63. Koesters EC, Chang DW. Radiation and free flaps: What is the optimal timing? *Gland Surg.* 2023;12(8):1122-30.

64. Christopher AN, Morris MP, Broach RB, Serletti JM. A comparative analysis of immediate and delayed-immediate breast reconstruction after postmastectomy radiation therapy. *J Reconstr Microsurg*. 2022;38(6):499-505.
65. Fosnot J, Fischer JP, Smartt JM, Jr., Low DW, Kovach SJ, 3rd, Wu LC, et al. Does previous chest wall irradiation increase vascular complications in free autologous breast reconstruction? *Plast Reconstr Surg*. 2011;127(2):496-504.
66. Gabriel A, Sigalove S, Storm-Dickerson TL, Sigalove NM, Pope N, Rice J, et al. Dual-plane versus prepectoral breast reconstruction in high-body mass index patients. *Plast Reconstr Surg*. 2020;145(6):1357-65.
67. Warren Peled A, Foster RD, Garwood ER, Moore DH, Ewing CA, Alvarado M, et al. The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: Results of a prospective practice improvement study. *Plast Reconstr Surg*. 2012b;129(6):901e-8e.
68. Wang F, Warren Peled A, Garwood E, Fiscalini AS, Sbitany H, Foster RD, et al. Total skin-sparing mastectomy and immediate breast reconstruction: An evolution of technique and assessment of outcomes. *Ann Surg Oncol*. 2014;21(10):3223-30.
69. Sbitany H, Piper M, Lentz R. Prepectoral breast reconstruction: A safe alternative to submuscular prosthetic reconstruction following nipple-sparing mastectomy. *Plast Reconstr Surg*. 2017;140(3):432-43.
70. Bettinger LN, Waters LM, Reese SW, Kutner SE, Jacobs DI. Comparative study of prepectoral and subpectoral expander-based breast reconstruction and Clavien IIIb score outcomes. *Plast Reconstr Surg Glob Open*. 2017;5(7):e1433.
71. Warren Peled A, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. *Plast Reconstr Surg*. 2012c;130(3):503-9.
72. Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, et al. Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2015;92(3):634-41.
73. Gerber B, Krause A, Reimer T, Muller H, Kuchenmeister I, Makovitzky J, et al. Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. *Ann Surg*. 2003;238(1):120-7.
74. Gerber B, Krause A, Dieterich M, Kundt G, Reimer T. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: An extended follow-up study. *Ann Surg*. 2009;249(3):461-8.
75. Jeon YS, Kang SH, Bae YK, Lee SJ. The oncologic safety of skin sparing mastectomy with or without conservation of the nipple-areolar complex: 5 years follow up results. [Korean]. *J Breast Cancer*. 2010;13(1):65-73.
76. Cho JH, Park JM, Park HS, Kim HJ, Shin DM, Kim JY, et al. Oncologic outcomes in nipple-sparing mastectomy with immediate reconstruction and total mastectomy with immediate reconstruction in women with breast cancer: A machine-learning analysis. *Ann Surg Oncol*. 2023;30(12):7281-90.
77. Kim HJ, Park EH, Lim WS, Seo JY, Koh BS, Lee TJ, et al. Nipple areola skin-sparing mastectomy with immediate transverse rectus abdominis musculocutaneous flap reconstruction is an oncologically safe procedure: A single center study. *Ann Surg*. 2010;251(3):493-8.
78. Ogiya A, Nagura N, Shimo A, Nogi H, Narui K, Seki H, et al. Long-term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases. *Ann Surg Oncol*. 2023;30(11):6532-40.

79. Racz JM, Harless CA, Hoskin TL, Day CN, Nguyen MT, Harris AM, et al. Sexual well-being after nipple-sparing mastectomy: Does preservation of the nipple matter? *Ann Surg Oncol*. 2022;06:06.
80. Zenn MR. Staged immediate breast reconstruction. *Plast Reconstr Surg*. 2015;135(4):976-9.
81. Tondur T, Hubens G, Tjalma WA, Thiessen FE, Vrints I, Van Thielen J, et al. Breast reconstruction after nipple-sparing mastectomy in the large and/or ptotic breast: A systematic review of indications, techniques, and outcomes. *J Plast Reconstr Aesthet Surg*. 2020;73(3):469-85.
82. Martinovic ME, Pellicane JV, Blanchet NP. Surgical Delay of the Nipple-Areolar Complex in High-risk Nipple-sparing Mastectomy Reconstruction. *Plast Reconstr Surg Glob Open*. 2016;4(6):e760.
83. Schwartz JC. A New Approach to Nipple-sparing Mastectomy and Reconstruction in the High Risk Ptotic Patient. *Plast Reconstr Surg Glob Open*. 2018;6(5):e1779.
84. Loreti A, Fanelli B, Abate O, Spallone D, Arelli F, Bruno E, et al. Surgical Delay of Nipple Areola Complex: A Powerful Technique to Extend the Indication of Nipple-Sparing Mastectomy. *Clin Breast Cancer*. 2023;23(3):255-64.
85. Lee PL, Ma IT, Schusterman MA, 2nd, Beiriger J, Ahrendt G, De La Cruz C, et al. Surgical Nipple Delay and its Expanded Indications for Nipple-sparing Mastectomy. *Plast Reconstr Surg Glob Open*. 2023;11(1):e4783.
86. Ryu JM, Nam SJ, Kim SW, Lee SK, Bae SY, Yi HW, et al. Feasibility of nipple-sparing mastectomy with immediate breast reconstruction in breast cancer patients with tumor-nipple distance less than 2.0 cm. *World J Surg*. 2016;40(8):2028-35.
87. Alsharif E, Ryu JM, Choi HJ, Nam SJ, Kim SW, Yu J, et al. Oncologic outcomes of nipple-sparing mastectomy with immediate breast reconstruction in patients with tumor-nipple distance less than 2.0 cm. *J Breast Cancer*. 2019;22(4):613-23.
88. Balci FL, Kara H, Dulgeroglu O, Uras C. Oncologic safety of nipple-sparing mastectomy in patients with short tumor-nipple distance. *Breast J*. 2019;25(4):612-8.
89. Fregatti P, Gipponi M, Zoppoli G, Lambertini M, Blondeaux E, Belgioia L, et al. Tumor-to-nipple distance should not preclude nipple-sparing mastectomy in breast cancer patients. Personal experience and literature review. *Anticancer Res*. 2020;40(6):3543-50.
90. Wu ZY, Kim HJ, Lee J, Chung IY, Kim J, Lee SB, et al. Oncologic safety of nipple-sparing mastectomy in patients with breast cancer and tumor-to-nipple distance  $\leq 1$  cm: A matched cohort study. *Ann Surg Oncol*. 2021c;28(8):4284-91.
91. Kim S, Lee S, Bae Y, Lee S. Nipple-sparing mastectomy for breast cancer close to the nipple: A single institution's 11-year experience. *Breast Cancer*. 2020;27(5):999-1006.
92. Kelly BN, Faulkner HR, Smith BL, Korotkin JE, Lanahan CR, Brown C, et al. Nipple-sparing mastectomy versus skin-sparing mastectomy: Does saving the nipple impact short- and long-term patient satisfaction? *Ann Surg Oncol*. 2022;29(2):1033-40.
93. Valero MG, Muhsen S, Moo TA, Zabor EC, Stempel M, Pusic A, et al. Increase in utilization of nipple-sparing mastectomy for breast cancer: Indications, complications, and oncologic outcomes. *Ann Surg Oncol*. 2020;27(2):344-51.
94. Webster AJ, Shanno JN, Santa Cruz HS, Kelly BN, Garstka M, Henriquez A, et al. Oncologic safety of nipple-sparing mastectomy for breast cancer in BRCA gene mutation carriers: Outcomes at 70 months median follow-up. *Ann Surg Oncol*. 2023;30(6):3215-22.
95. Shanno JN, Daly AE, Anderman KJ, Santa Cruz HS, Webster AJ, Pride RM, et al. Positive nipple margins in nipple-sparing mastectomy: Management of nipples containing cancer or atypia. *Ann Surg Oncol*. 2024;31(8):5148-56.

96. Zhu M, Mao J, Fang J, Chen D. Safety of Atypical Ductal Hyperplasia at the Nipple Margin in Nipple-Sparing Mastectomy. *J Breast Cancer*. 2024;16:16.
97. Tang R, Coopey SB, Merrill AL, Rai U, Specht MC, Gadd MA, et al. Positive nipple margins in nipple-sparing mastectomies: Rates, management, and oncologic safety. *J Am Coll Surg*. 2016;222(6):1149-55.
98. Smith BL, Tang R, Rai U, Plichta JK, Colwell AS, Gadd MA, et al. Oncologic safety of nipple-sparing mastectomy in women with breast cancer. *J Am Coll Surg*. 2017;225(3):361-5.
99. Simmons RM, Brennan M, Christos P, King V, Osborne M. Analysis of nipple/areolar involvement with mastectomy: Can the areola be preserved? *Ann Surg Oncol*. 2002;9(2):165-8.
100. Pacella SJ, Vogel JE, Locke MB, Codner MA. Aesthetic and technical refinements in latissimus dorsi implant breast reconstruction: A 15-year experience. *Aesthet Surg J*. 2011;31(2):190-9.
101. Warren Peled A, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. *Ann Surg Oncol*. 2012a;19(11):3402-9.
102. Amara D, Warren Peled A, Wang F, Ewing CA, Alvarado M, Esserman LJ. Tumor involvement of the nipple in total skin-sparing mastectomy: Strategies for management. *Ann Surg Oncol*. 2015;22(12):3803-8.
103. Seki H, Sakurai T, Maeda Y, Oki N, Aoyama M, Yamaguchi R, et al. Utility of the periareolar incision technique for breast reconstructive surgery in patients with breast cancer. *Surg Today*. 2020;50(9):1008-15.
104. Holland M, Wallace A, Viner J, Sbitany H, Piper M. Safety of incision placement with nipple-sparing mastectomy and immediate prepectoral breast reconstruction. *Plast Reconstr Surg Glob Open*. 2023;11(1):e4736.
105. Serio F, Manna E, La Pinta M, Arienzo F, Costarelli L, Zarba Meli E, et al. Intraoperative examination of retro-areolar margin is not routinely necessary during nipple-sparing mastectomy for cancer. *Ann Surg Oncol*. 2023;30(11):6488-96.
106. Spoor J, Heeling E, Collewyn RC, van der Ploeg IMC, Hoornweg MJ, Russell N, et al. Intraoperative frozen section of subareolar tissue in nipple-sparing mastectomy: Towards a less is more approach. *Eur J Surg Oncol*. 2024;50(6):108320.
107. Sbitany H, Wang F, Peled AW, Alvarado M, Ewing CA, Esserman LJ, et al. Tissue expander reconstruction after total skin-sparing mastectomy: Defining the effects of coverage technique on nipple/areola preservation. *Ann Plast Surg*. 2016;77(1):17-24.
108. Reynolds C, Davidson JA, Lindor NM, Glazebrook KN, Jakub JW, Degnim AC, et al. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: Can the nipple be preserved? *Ann Surg Oncol*. 2011;18(11):3102-9.
109. Hieken TJ, Boolbol SK, Dietz JR. Nipple-sparing mastectomy: Indications, contraindications, risks, benefits, and techniques. *Ann Surg Oncol*. 2016;23(10):3138-44.
110. Moo TA, Nelson JA, Sevilimedu V, Charyn J, Le TV, Allen RJ, et al. Strategies to avoid mastectomy skin-flap necrosis during nipple-sparing mastectomy. *Br J Surg*. 2023;110(7):831-8.
111. Lin AM, Lorenzi R, Van Der Hulst JE, Liao EC, Austen WG, Jr., Webster A, et al. A decade of nipple-sparing mastectomy: Lessons learned in 3035 immediate implant-based breast reconstructions. *Plast Reconstr Surg*. 2024;153(2):277-87.
112. Park S, Yoon C, Bae SJ, Cha C, Kim D, Lee J, et al. Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction. *Breast*. 2020;53:85-91.

113. Lai HW, Lee YY, Chen ST, Liao CY, Tsai TL, Chen DR, et al. Nipple-areolar complex (NAC) or skin flap ischemia necrosis post nipple-sparing mastectomy (NSM)-analysis of clinicopathologic factors and breast magnetic resonance imaging (MRI) features. *World J Surg Oncol*. 2023;21(1):23.
114. Colwell AS, Gadd M, Smith BL, Austen WG, Jr. An inferolateral approach to nipple-sparing mastectomy: Optimizing mastectomy and reconstruction. *Ann Plast Surg*. 2010;65(2):140-3.
115. Colwell AS, Tessler O, Lin AM, Liao E, Winograd J, Cetrulo CL, et al. Breast reconstruction following nipple-sparing mastectomy: Predictors of complications, reconstruction outcomes, and 5-year trends. *Plast Reconstr Surg*. 2014;133(3):496-506.
116. Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ. Optimizing the total skin-sparing mastectomy. *Arch Surg*. 2008;143(1):38-45.
117. Warren Peled A, Wang F, Foster RD, Alvarado M, Ewing CA, Sbitany H, et al. Expanding the indications for total skin-sparing mastectomy: Is it safe for patients with locally advanced disease? *Ann Surg Oncol*. 2016;23(1):87-91.
118. Wong L, Wilson RM, Snapp WK, Bole R, Vyas KS. Nipple pathology in total skin-sparing mastectomy: Implications for immediate reconstruction. *Ann Plast Surg*. 2016;76 Suppl 4:S340-3.
119. Coopey S, Keleher A, Daniele K, Peled AW, Gomez J, Julian T, et al. Careful where you cut: Strategies for successful nerve-preserving mastectomy. *Plast Reconstr Surg Glob Open*. 2024;12(5):e5817.
120. Black GG, Chen Y, Qin N, Wang ML, Huang H, Otterburn DM. An evolving landscape: Return of breast sensation after mastectomy varies by anatomic region and reconstructive method. *Ann Plast Surg*. 2024;92(4S Suppl 2):S91-S5.
121. Knackstedt R, Grobmyer S, Djohan R. Collaboration between the breast and plastic surgeon in restoring sensation after mastectomy. *Breast J*. 2019;25(6):1187-91.
122. Djohan R, Knackstedt R. Collaboration between breast and reconstructive surgery in optimizing outcomes for women with breast cancer. *Breast J*. 2020;26(1):42-6.
123. Rossi C, Mingozzi M, Curcio A, Buggi F, Folli S. Nipple areola complex sparing mastectomy. *Gland Surg*. 2015;4(6):528-40.
124. Ahn SJ, Woo TY, Lee DW, Lew DH, Song SY. Nipple-areolar complex ischemia and necrosis in nipple-sparing mastectomy. *Eur J Surg Oncol*. 2018;44(8):1170-6.
125. Pek WS, Tan BK, Ru Ng YY, Kiak Mien Tan V, Rasheed MZ, Kiat Tee Tan B, et al. Immediate breast reconstruction following nipple-sparing mastectomy in an Asian population: Aesthetic outcomes and mitigating nipple-areolar complex necrosis. *Arch Plast Surg*. 2018;45(3):229-38.
126. Ng YY, Tan VK, Pek WS, Chang JH, Sim Y, Ong KW, et al. Surgical and oncological safety of nipple-sparing mastectomy in an Asian population. *Breast Cancer*. 2019;26(2):165-71.
127. Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado M, Foster RD, et al. Total skin-sparing mastectomy: Complications and local recurrence rates in 2 cohorts of patients. *Ann Surg*. 2009;249(1):26-32.
128. Abbott AM, Miller BT, Tuttle TM. Outcomes after tumescence technique versus electrocautery mastectomy. *Ann Surg Oncol*. 2012;19(8):2607-11.
129. Xue EY, Schultz JJ, Therattil PJ, Keith JD, Granick MS. Indocyanine Green Laser Angiography in the Setting of Tumescence. *Eplasty*. 2019;19:e1.
130. Promny T, Huberth P, Muller-Seubert W, Promny D, Cai A, Horch RE, et al. The Impact of Technical Innovations and Donor-Site Mesh Repair on Autologous Abdominal-Based Breast Reconstruction-A Retrospective Analysis. *J Clin Med*. 2024;13(8):09.

131. Braun SE, Sinik LM, Meyer AM, Larson KE, Butterworth JA. Predicting complications in breast reconstruction: Development and prospective validation of a machine learning model. *Ann Plast Surg.* 2023;91(2):282-6.
132. Scardina L, A DIL, Sanchez AM, D'Archi S, Biondi E, Franco A, et al. Nipple sparing mastectomy with prepectoral immediate prosthetic reconstruction without acellular dermal matrices: A single center experience. *Minerva Surg.* 2021;76(6):498-505.
133. Najmiddinov B, Park JK, Yoon KH, Myung Y, Koh HW, Lee OH, et al. Conventional versus modified nipple sparing mastectomy in immediate breast reconstruction: Complications, aesthetic, and patient-reported outcomes. *Front Surg.* 2022;9:1001019.
134. Franceschini G, Scardina L, Di Leone A, Terribile DA, Sanchez AM, Magno S, et al. Immediate prosthetic breast reconstruction after nipple-sparing mastectomy: Traditional subpectoral technique versus direct-to-implant prepectoral reconstruction without acellular dermal matrix. *J Pers Med.* 2021;11(2):22.
135. Scardina L, Di Leone A, Biondi E, Carnassale B, Sanchez AM, D'Archi S, et al. Prepectoral vs. submuscular immediate breast reconstruction in patients undergoing mastectomy after neoadjuvant chemotherapy: Our early experience. *J Pers Med.* 2022;12(9):19.
136. Copeland-Halperin LR, Yemc L, Emery E, Collins D, Liu C, Mesbahi AN, et al. Evaluating postoperative narcotic use in prepectoral versus dual-plane breast reconstruction following mastectomy. *Plast Reconstr Surg Glob Open.* 2019;7(2):e2082.
137. Banuelos J, Abu-Ghname A, Vyas K, Sharaf B, Nguyen MT, Harless C, et al. Should obesity be considered a contraindication for prepectoral breast reconstruction? *Plast Reconstr Surg.* 2020;145(3):619-27.
138. Min K, Min JC, Han HH, Kim EK, Eom JS. Comparing outcomes of prepectoral, partial muscle-splitting subpectoral, and dual-plane subpectoral direct-to-implant reconstruction: Implant upward migration and the pectoralis muscle. *Gland Surg.* 2024;13(6):852-63.
139. Han WY, Han SJ, Eom JS, Kim EK, Han HH. A Comparative Study of Wraparound versus Anterior Coverage Placement of Acellular Dermal Matrix in Prepectoral Breast Reconstruction. *Plast Reconstr Surg.* 2023a;152(4):716-24.
140. Avila A, Bartholomew AJ, Sosin M, Deldar R, Griffith KF, Willey SC, et al. Acute postoperative complications in prepectoral versus subpectoral reconstruction following nipple-sparing mastectomy. *Plast Reconstr Surg.* 2020;146(6):715e-20e.
141. Karin MR, Pal S, Ikeda D, Silverstein M, Momeni A. Nipple sparing mastectomy technique to reduce ischemic complications: Preserving important blood flow based on breast MRI. *World J Surg.* 2023;47(1):192-200.
142. Gabriel A, Sigalove S, Sigalove NM, Storm-Dickerson TL, Rice J, Pope N, et al. Prepectoral revision breast reconstruction for treatment of implant-associated animation deformity: A review of 102 reconstructions. *Aesthet Surg J.* 2018;38(5):519-26.
143. Jones GE, King VA, Yoo A. Prepectoral site conversion for animation deformity. *Plast Reconstr Surg Glob Open.* 2019;7(7):e2301.
144. Sigalove S, Maxwell GP, Gabriel A. Outcomes utilizing Inspira implants in revisionary reconstructive surgery. *Plast Reconstr Surg.* 2019;144(1S: Utilizing a spectrum of cohesive implants in aesthetic and reconstructive breast surgery):66S-72S.
145. Salgarello M, Barone Adesi L, Macri G, Visconti G. When to consider prepectoral implant conversion after subpectoral implant breast reconstruction and how to plan it. *Aesthet Surg J.* 2023;43(12):NP1071-NP7.
146. Becker H, Fregosi N. The impact of animation deformity on quality of life in post-mastectomy reconstruction patients. *Aesthet Surg J.* 2017;37(5):531-6.

147. Nigro LC, Blanchet NP. Animation Deformity in Postmastectomy Implant-Based Reconstruction. *Plast Reconstr Surg Glob Open*. 2017;5(7):e1407.
148. Allergan Aesthetics: An AbbVie Company. AlloDerm Select™. AlloDerm Select Restore™ regenerative tissue matrix. Instructions for use. Markham, ON: Allergan Aesthetics. 2024 Feb 29. Modified 2024 Apr 3, cited 2024 Jun 10. Available from: <https://www.allerganaesthetics.ca/en/our-products/medical-devices>.
149. Palaia DA, Arthur KS, Cahan AC, Rosenberg MH. Incidence of seromas and infections using fenestrated versus nonfenestrated acellular dermal matrix in breast reconstructions. *Plast Reconstr Surg Glob Open*. 2015;3(11):e569.
150. Sweitzer K, Carruthers KH, Blume L, Tiwari, Pankaj, Kocak, Ergun. The biomechanical properties of meshed versus perforated acellular dermal matrices (ADMs). *Plastic and Reconstructive Surgery - Global Open*. 2021;9(3):e3454.
151. Sigalove S, O'Rorke E, Maxwell GP, Gabriel A. Evaluation of the safety of a GalaFLEX-AlloDerm construct in prepectoral breast reconstruction. *Plast Reconstr Surg*. 2022;150:75S-81S.
152. Levy AS, Bernstein JL, Xia JJ, Otterburn DM. Poly-4-hydroxybutyric acid mesh compares favorably with acellular dermal matrix in tissue expander-based breast reconstruction. *Ann Plast Surg*. 2020;85(S1 Suppl 1):S2-S7.
153. Chen Y, Wang ML, Black GG, Bernstein JL, Chinta M, Otterburn DM. Timeline and incidence of postoperative complications in prepectoral, dual-plane, and total submuscular alloplastic reconstruction with and without biosynthetic scaffold usage. *Ann Plast Surg*. 2023b;90(6S Suppl 5):S466-S71.
154. Houvenaeghel G, Bannier M, Bouteille C, Tallet C, Sabiani L, Charavil A, et al. Postoperative Outcomes of Pre-Pectoral Versus Sub-Pectoral Implant Immediate Breast Reconstruction. *Cancers (Basel)*. 2024;16(6):12.
155. Nahabedian MY. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation. *Plast Reconstr Surg*. 2009;124(6):1743-53.
156. Liu AS, Kao HK, Reish RG, Hergrueter CA, May JW, Jr., Guo L. Postoperative complications in prosthesis-based breast reconstruction using acellular dermal matrix. *Plast Reconstr Surg*. 2011;127(5):1755-62.
157. Chun YS, Verma K, Rosen H, Lipsitz S, Morris D, Kenney P, et al. Implant-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications. *Plast Reconstr Surg*. 2010;125(2):429-36.
158. Ganske I, Verma K, Rosen H, Eriksson E, Chun YS. Minimizing complications with the use of acellular dermal matrix for immediate implant-based breast reconstruction. *Ann Plast Surg*. 2013;71(5):464-70.
159. Bennett KG, Qi J, Kim HM, Hamill JB, Wilkins EG, Mehrara BJ, et al. Association of fat grafting with patient-reported outcomes in postmastectomy breast reconstruction. *JAMA Surg*. 2017;152(10):944-50.
160. Calabrese S, Zingaretti N, De Francesco F, Riccio M, De Biasio F, Massarut S, et al. Long-term impact of lipofilling in hybrid breast reconstruction: Retrospective analysis of two cohorts. *Eur J Plast Surg*. 2020;43(3):257-68.
161. Gentilucci M, Mazzocchi M, Alfano C. Effects of prophylactic lipofilling after radiotherapy compared to non-fat injected breasts: A randomized, objective study. *Aesthet Surg J*. 2020;40(10):NP597-NP607.
162. Maione L, Vinci V, Caviggioli F, Klinger F, Banzatti B, Catania B, et al. Autologous fat graft in postmastectomy pain syndrome following breast conservative surgery and radiotherapy. *Aesthetic Plast Surg*. 2014;38(3):528-32.

163. Lisa AVE, Murolo M, Maione L, Vinci V, Battistini A, Morengi E, et al. Autologous fat grafting efficacy in treating PostMastectomy pain syndrome: A prospective multicenter trial of two Senonetwork Italia breast centers. *Breast J.* 2020;26(9):1652-8.
164. Caviggioli F, Maione L, Forcellini D, Klinger F, Klinger M. Autologous fat graft in postmastectomy pain syndrome. *Plast Reconstr Surg.* 2011;128(2):349-52.
165. Caviggioli F, Maione L, Klinger F, Lisa A, Klinger M. Autologous fat grafting reduces pain in irradiated breast: A review of our experience. *Stem Cells Int.* 2016;2016:2527349.
166. Klomparens K, Simman R. Autologous fat grafting: Evaluation of efficacy in pain relief. *Plast Reconstr Surg Glob Open.* 2022;10(11):e4543.
167. Alessandri-Bonetti M, Egro FM, Persichetti P, Coleman SR, Peter Rubin J. The role of fat grafting in alleviating neuropathic pain: A critical review of the literature. *Plast Reconstr Surg Glob Open.* 2019;7(5):e2216.
168. Wederfoort JLM, Schop S, van der Broeck LCA, Hommes JE, van Kuijk SMJ, Timmermans F, et al. Superior sensibility after full breast reconstruction with autologous fat transfer. *Plast Reconstr Surg.* 2024;153(2):316-23.
169. Wederfoort JLM, Kleeven A, Hommes JE, Van Kuijk SMJ, van der Hulst R, Piatkowski A, et al. Aesthetic evaluation of breast reconstruction with autologous fat transfer vs. Implants. *Aesthetic Plast Surg.* 2023;47(2):593-604.
170. Piatkowski AA, Wederfoort JLM, Hommes JE, Schop SSJ, Krastev TK, van Kuijk SMJ, et al. Effect of total breast reconstruction with autologous fat transfer using an expansion device vs implants on quality of life among patients with breast cancer: A randomized clinical trial. *JAMA Surg.* 2023;158(5):456-64.
171. Schop SSJ, Hommes JE, Krastev TK, Derks D, Larsen M, Rakhorst H, et al. BREAST trial study protocol: Evaluation of a non-invasive technique for breast reconstruction in a multicentre, randomised controlled trial. *BMJ Open.* 2021;11(9):e051413.
172. Cason RW, Shammas RL, Broadwater G, Glenner AD, Sergesketter AR, Vernon R, et al. The influence of fat grafting on breast imaging after postmastectomy reconstruction: A matched cohort analysis. *Plast Reconstr Surg.* 2020;146(6):1227-36.
173. Lindegren A, Chanterreau MW, Bygdeson M, Azavedo E, Schultz I. Autologous fat transplantation to the reconstructed breast does not hinder assessment of mammography and ultrasound: A cohort study. *World J Surg.* 2016;40(5):1104-11.
174. Fiaschetti V, Pistolese CA, Fornari M, Liberto V, Cama V, Gentile P, et al. Magnetic resonance imaging and ultrasound evaluation after breast autologous fat grafting combined with platelet-rich plasma. *Plast Reconstr Surg.* 2013;132(4):498e-509e.
175. Fracol M, Allison S, Chu Y, Yan Y, Sood R, Feld LN, et al. The palpable nodule after autologous fat grafting: Distinguishing benign versus malignant lesions in breast reconstruction. *Plast Reconstr Surg.* 2022;150:20S-9S.
176. Skillman J, McManus P, Bhaskar P, Hamilton S, Roy PG, O'Donoghue JM. UK Guidelines for Lipomodelling of the Breast on behalf of Plastic, Reconstructive and Aesthetic Surgery and Association of Breast Surgery Expert Advisory Group. *J Plast Reconstr Aesthet Surg.* 2022;75(2):511-8.
177. Browman GP, Newman TE, Mohide EA, Graham ID, Levine MN, Pritchard KI, et al. Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: The role of practitioner feedback. *J Clin Oncol.* 1998;16(3):1226-31.
178. Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafni A, et al. The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. *J Clin Oncol.* 1995;13(2):502-12.



179. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. *CMAJ*. 2010;182(18):E839-42.
180. Ontario Health (Cancer Care Ontario), Program in Evidence-Based Care, McMaster University. Program in Evidence-Based Care handbook, June 2020. Hamilton: Program in Evidence-Based Care. 2022 June (accessed 2024 Dec 2). Available from: <https://www.cancercareontario.ca/sites/ccocancercare/files/assets/CCOPEBCHandbook.pdf>.
181. Program in Evidence-Based Care, McMaster University. PEBC toolkit: CCO/PEBC methods handbook. Hamilton: Program in Evidence-Based Care. Accessed 2024 Dec 2. Available from: [https://pebctoolkit.mcmaster.ca/doku.php?id=projectdev:pebc\\_methods\\_handbook&f](https://pebctoolkit.mcmaster.ca/doku.php?id=projectdev:pebc_methods_handbook&f).
182. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *J Clin Epidemiol*. 2009;62(10):e1-e34.
183. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: 10.1136/bmj.n71. See also: <http://www.prisma-statement.org/>.
184. Hidalgo B, Goodman M. Multivariate or multivariable regression? *Am J Public Health*. 2013;103(1):39-40.
185. Ebrahimi Kalan M, Jebai R, Zarafshan E, Bursac Z. Distinction between two statistical terms: Multivariable and multivariate logistic regression. *Nicotine Tob Res*. 2020;23(8):1446-7.
186. Katz MH. Multivariable analysis: A primer for readers of medical research. *Ann Intern Med*. 2003;138(8):644-50.
187. Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. *Fam Med Community Health*. 2020;8(1):e000262.
188. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. *Source Code Biol Med*. 2008;3(1):17.
189. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. *Am J Epidemiol*. 1989;129(1):125-37.
190. Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Jr., Moons KG, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. *Stat Med*. 2019;38(7):1276-96.
191. Riley RD, Snell KIE, Ensor J, Burke DL, Harrell FE, Jr., Moons KGM, et al. Minimum sample size for developing a multivariable prediction model: Part I - Continuous outcomes. *Stat Med*. 2019;38(7):1262-75.
192. VanVoorhis CRW, Morgan BL, editors. Understanding power and rules of thumb for determining sample sizes 2007.
193. Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing prediction models is not simply related to events per variable. *J Clin Epidemiol*. 2016;76:175-82.
194. van Smeden M, Moons KG, de Groot JA, Collins GS, Altman DG, Eijkemans MJ, et al. Sample size for binary logistic prediction models: Beyond events per variable criteria. *Stat Methods Med Res*. 2019;28(8):2455-74.
195. van Smeden M, de Groot JA, Moons KG, Collins GS, Altman DG, Eijkemans MJ, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. *BMC Med Res Methodol*. 2016;16(1):163.
196. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol*. 2007;165(6):710-8.

197. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*. 2017;358:j4008.
198. Higgins J, Savović J, Page M, Elbers R, Sterne J. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane handbook for systematic reviews of interventions* version 6.1 (updated September 2020). Cochrane, 2020. Available from: <https://training.cochrane.org/handbook> 2020.
199. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. *Cochrane handbook for systematic reviews of interventions* version 6.1 [Internet]. London (UK): Cochrane; 2020 Sept [cited 2021 Aug 13]. Available from: <https://training.cochrane.org/handbook>. [Note: version 6.3, 2022 was subsequently released ].
200. Higgins J, Sterne J, Savović J, Page M, Hróbjartsson A, Boutron I, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). *Cochrane Methods*. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1). <https://doi.org/10.1002/14651858.CD201601>.
201. Sterne J, Higgins J, Elers R, Reeves B, and the development group for ROBINS-I. Risk of bias in non-randomized studies of interventions (ROBINS-I): Detailed guidance [Internet]. Updated 2016 Oct 12. [cited 2021 Jul 16]. Available from: <http://www.riskofbias.info>
202. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919 (7 pp).
203. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898.
204. The Cochrane Collaboration. Review Manager (RevMan) [Computer program on internet]. Version 5.4. London (UK): Cochrane; 2020 [cited 2021 May 6]. Available from: <https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download>.
205. McKenzie DP, Thomas C. Relative risks and odds ratios: Simple rules on when and how to use them. *Eur J Clin Invest*. 2020;50(8):e13249 (6 pp).
206. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA*. 1998;280(19):1690-1.
207. Doi SA, Furuya-Kanamori L, Xu C, Lin L, Chivese T, Thalib L. Controversy and debate: Questionable utility of the relative risk in clinical research: Paper 1: A call for change to practice. *J Clin Epidemiol*. 2022;142:271-9.
208. Ranganathan P, Aggarwal R, Pramesh CS. Common pitfalls in statistical analysis: Odds versus risk. *Perspect Clin Res*. 2015;6(4):222-4.
209. Wilkins EG. The Mastectomy Reconstruction Outcomes Consortium (MROC) Study. ClinicalTrials.gov NCT01723423. Last updated 2017 July 13; cited 2024 Jul 12. Available from: <https://clinicaltrials.gov/study/NCT01723423>.
210. Sinha I, Pusic AL, Wilkins EG, Hamill JB, Chen X, Kim HM, et al. Late surgical-site infection in immediate implant-based breast reconstruction. *Plast Reconstr Surg*. 2017;139(1):20-8.
211. Pusic AL, Matros E, Fine N, Buchel E, Gordillo GM, Hamill JB, et al. Patient-reported outcomes 1 year after immediate breast reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study. *J Clin Oncol*. 2017;35(22):2499-506.
212. Wilkins EG, Cederna PS, Lowery JC, Davis JA, Kim HM, Roth RS, et al. Prospective analysis of psychosocial outcomes in breast reconstruction: One-year postoperative

- results from the Michigan Breast Reconstruction Outcome Study. *Plast Reconstr Surg.* 2000;106(5):1014-25; discussion 26-7.
213. Voineskos SH, Klassen AF, Cano SJ, Pusic AL, Gibbons CJ. Giving meaning to differences in BREAST-Q scores: Minimal important difference for breast reconstruction patients. *Plast Reconstr Surg.* 2020;145(1):11e-20e.
  214. Kulkarni AR, Pusic AL, Hamill JB, Kim HM, Qi J, Wilkins EG, et al. Factors associated with acute postoperative pain following breast reconstruction. *JPRAS Open.* 2017;11:1-13.
  215. Wilkins EG, Hamill JB, Kim HM, Kim JY, Greco RJ, Qi J, et al. Complications in postmastectomy breast reconstruction: One-year outcomes of the Mastectomy Reconstruction Outcomes Consortium (MROC) Study. *Ann Surg.* 2018;267(1):164-70.
  216. Yoon AP, Qi J, Kim HM, Hamill JB, Jagsi R, Pusic AL, et al. Patient-reported outcomes after irradiation of tissue expander versus permanent implant in breast reconstruction: A multicenter prospective study. *Plast Reconstr Surg.* 2020;145(5):917e-26e.
  217. Sorkin M, Qi J, Kim HM, Hamill JB, Kozlow JH, Pusic AL, et al. Acellular dermal matrix in immediate expander/implant breast reconstruction: A multicenter assessment of risks and benefits. *Plast Reconstr Surg.* 2017;140(6):1091-100.
  218. Ganesh Kumar N, Berlin NL, Kim HM, Hamill JB, Kozlow JH, Wilkins EG. Development of an evidence-based approach to the use of acellular dermal matrix in immediate expander-implant-based breast reconstruction. *J Plast Reconstr Aesthet Surg.* 2021;74(1):30-40.
  219. Tan MYL, Onggo J, Serag S, Phan K, Dusseldorp JR. Deep inferior epigastric perforator (DIEP) flap safety profile in slim versus non-slim BMI patients: A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg.* 2022;75(7):2180-9.
  220. Spera LJ, Cook JA, Dolejs S, Fisher C, Lester ME, Hassanein AH. Perioperative use of antiestrogen therapies in breast reconstruction: A systematic review and treatment recommendations. *Ann Plast Surg.* 2020;85(4):448-55.
  221. Honig SE, Habarth-Morales TE, Davis HD, Niu EF, Amro C, Broach RB, et al. Increased Patient Age as a Risk Factor Following Free Flap Reconstruction after Breast Cancer: A Single Institutional Review of 2,598 Cases. *J Reconstr Microsurg.* 2024;12:12.
  222. Santosa KB, Qi J, Kim HM, Hamill JB, Pusic AL, Wilkins EG. Effect of Patient Age on Outcomes in Breast Reconstruction: Results from a Multicenter Prospective Study. *J Am Coll Surg.* 2016;223(6):745-54.
  223. Chang EI, Vaca L, DaLio AL, Festekjian JH, Crisera CA. Assessment of advanced age as a risk factor in microvascular breast reconstruction. *Ann Plast Surg.* 2011;67(3):255-9.
  224. Butz DR, Lapin B, Yao K, Wang E, Song DH, Johnson D, et al. Advanced age is a predictor of 30-day complications after autologous but not implant-based postmastectomy breast reconstruction. *Plast Reconstr Surg.* 2015;135(2):253e-61e.
  225. Jeevan R, Cromwell DA, Browne JP, Caddy CM, Pereira J, Sheppard C, et al. Findings of a national comparative audit of mastectomy and breast reconstruction surgery in England. *J Plast Reconstr Aesthet Surg.* 2014;67(10):1333-44.
  226. Jeevan R, Cromwell D, Browne J, van der Meulen J, Pereira J, Caddy C, et al. National Mastectomy and Breast Reconstruction Audit 2011. A national audit of provision and outcomes of mastectomy and breast reconstruction surgery for women in England. Fourth Annual Report 2011. Leeds: The NHS Information Centre; 2011. Cited 2024 Jul 4. Available from: <https://associationofbreastsurgery.org.uk/media/1085/nmbra-annual-report-2011.pdf> and <https://files.digital.nhs.uk/publicationimport/pub02xxx/pub02731/clin-audi-supp-prog-mast-brea-reco-2011-rep1.pdf>.

227. Knoedler S, Kauke-Navarro M, Knoedler L, Friedrich S, Ayyala HS, Haug V, et al. The significance of timing in breast reconstruction after mastectomy: An ACS-NSQIP analysis. *J Plast Reconstr Aesthet Surg.* 2024;89:40-50.
228. Kroll SS, Coffey JA, Jr., Winn RJ, Schusterman MA. A comparison of factors affecting aesthetic outcomes of TRAM flap breast reconstructions. *Plast Reconstr Surg.* 1995;96(4):860-4.
229. Beugels J, Bod L, van Kuijk SMJ, Qiu SS, Tuinder SMH, Heuts EM, et al. Complications following immediate compared to delayed deep inferior epigastric artery perforator flap breast reconstructions. *Breast Cancer Res Treat.* 2018;169(2):349-57.
230. Joosen MEM, Schop SJ, Reinhoudt LL, van Kuijk SMJ, Beugels J, de Bruine AP, et al. The difference in local, regional and distant breast cancer recurrence between the immediate and delayed DIEP flap procedure; a retrospective cohort study. *Breast Cancer Res Treat.* 2021;188(2):389-98.
231. Marquez JL, Sudduth JD, Kuo K, Patel AA, Eddington D, Agarwal JP, et al. A comparison of postoperative outcomes between immediate, delayed immediate, and delayed autologous free flap breast reconstruction: Analysis of 2010-2020 NSQIP Data. *J Reconstr Microsurg.* 2023;39(8):664-70.
232. Kalmar CL, Montorfano L, Thayer WP, Kassis S, Higdon KK, Perdakis G. Timing of autologous tissue breast reconstruction does not affect free flap failure. *Ann Plast Surg.* 2024;92(6):663-6.
233. Baumann DP, Crosby MA, Selber JC, Garvey PB, Sacks JM, Adelman DM, et al. Optimal timing of delayed free lower abdominal flap breast reconstruction after postmastectomy radiation therapy. *Plast Reconstr Surg.* 2011;127(3):1100-6.
234. Wang M, Huang J, Chagpar AB. Is nipple sparing mastectomy associated with increased complications, readmission and length of stay compared to skin sparing mastectomy? *Am J Surg.* 2020;219(6):1030-5.
235. Sasada S, Nagura N, Shimo A, Ogiya A, Saiga M, Seki H, et al. Impact of radiation therapy for breast cancer with involved surgical margin after immediate breast reconstruction: A multi-institutional observational study. *Eur J Surg Oncol.* 2024;50(6):108360.
236. Beller FK, Schnepfer E. [Conservative primary operation of carcinoma of the breast: Subcutaneous mastectomy, lymphadenectomy and radiotherapy (author's transl)] konservative primäroperation des mammarkarzinoms: Subkutane mastektomie, lymphadenektomie und bestrahlung. *Dtsch Med Wochenschr.* 1981;106(11):329-34.
237. Psaila A, Pozzi M, Barone Adesi L, Varanese A, Costantini M, Gullo P, et al. Nipple sparing mastectomy with immediate breast reconstruction: A short term analysis of our experience. *J Exp Clin Cancer Res.* 2006;25(3):309-12.
238. Benediktsson KP, Perbeck L. Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: A prospective trial with 13 years median follow-up in 216 patients. *Eur J Surg Oncol.* 2008;34(2):143-8.
239. Boneti C, Yuen J, Santiago C, Diaz Z, Robertson Y, Korourian S, et al. Oncologic safety of nipple skin-sparing or total skin-sparing mastectomies with immediate reconstruction. *J Am Coll Surg.* 2011;212(4):686-93; discussion 93-5.
240. Fortunato L, Loreti A, Andrich R, Costarelli L, Amini M, Farina M, et al. When mastectomy is needed: Is the nipple-sparing procedure a new standard with very few contraindications? *J Surg Oncol.* 2013;108(4):207-12.
241. Sakurai T, Zhang N, Suzuma T, Umemura T, Yoshimura G, Sakurai T, et al. Long-term follow-up of nipple-sparing mastectomy without radiotherapy: A single center study at a Japanese institution. *Med Oncol.* 2013;30(1):481.

242. Stanec Z, Zic R, Budi S, Stanec S, Milanovic R, Vlajcic Z, et al. Skin and nipple-areola complex sparing mastectomy in breast cancer patients: 15-year experience. *Ann Plast Surg.* 2014;73(5):485-91.
243. Santoro S, Loreti A, Cavaliere F, Costarelli L, La Pinta M, Manna E, et al. Neoadjuvant chemotherapy is not a contraindication for nipple sparing mastectomy. *Breast.* 2015;24(5):661-6.
244. Seki T, Jinno H, Okabayashi K, Murata T, Matsumoto A, Takahashi M, et al. Comparison of oncological safety between nipple sparing mastectomy and total mastectomy using propensity score matching. *Ann R Coll Surg Engl.* 2015;97(4):291-7.
245. Fujimoto H, Ishikawa T, Satake T, Ko S, Shimizu D, Narui K, et al. Donor site selection and clinical outcomes of nipple-areola skin-sparing mastectomy with immediate autologous free flap reconstruction: A single-institution experience. *Eur J Surg Oncol.* 2016;42(3):369-75.
246. Moo TA, Pinchinat T, Mays S, Landers A, Christos P, Alabdulkareem H, et al. Oncologic outcomes after nipple-sparing mastectomy. *Ann Surg Oncol.* 2016;23(10):3221-5.
247. Shimo A, Tsugawa K, Tsuchiya S, Yoshie R, Tsuchiya K, Uejima T, et al. Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: Experience of 425 cases from a single institution. *Breast Cancer.* 2016;23(6):851-60.
248. Coopey SB, Tang R, Lei L, Freer PE, Kansal K, Colwell AS, et al. Increasing eligibility for nipple-sparing mastectomy. *Ann Surg Oncol.* 2013;20(10):3218-22.
249. Agresti R, Sandri M, Gennaro M, Bianchi G, Maugeri I, Rampa M, et al. Evaluation of local oncologic safety in nipple-areola complex-sparing mastectomy after primary chemotherapy: A propensity score-matched study. *Clin Breast Cancer.* 2017;17(3):219-31.
250. Cont NT, Maggiorotto F, Martincich L, Rivolin A, Kubatzki F, Sgandurra P, et al. Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy. *Breast Cancer Res Treat.* 2017;165(1):85-95.
251. Huang J, Mo Q, Zhuang Y, Qin Q, Huang Z, Mo J, et al. Oncological safety of nipple-sparing mastectomy in young patients with breast cancer compared with conventional mastectomy. *Oncol Lett.* 2018;15(4):4813-20.
252. Dornellas de Barros ACS, Carvalho HA, Andrade FEM, Nimir C, Sampaio MMC, Makdissi FB, et al. Mammary adenectomy followed by immediate reconstruction for treatment of patients with early-infiltrating breast carcinoma: A cohort study. *Sao Paulo Med J.* 2019;137(4):336-42.
253. Vladimir S, Milan R, Zoran R, Ferenc V, Dejan L, Mladen D. Early postoperative complications and local relapses after nipple sparing mastectomy and immediate breast reconstruction using silicone implants. *Arch Oncol.* 2019;25(1):9-12.
254. Li X, Wang Y. Skin- and nipple-areola-sparing mastectomy with immediate breast reconstruction using transverse rectus abdominis myocutaneous flap and silicone implants in breast carcinoma patients. *Oncol Res Treat.* 2020;43(7-8):354-61.
255. Metere A, Fabiani E, Lonardo MT, Giannotti D, Pace D, Giacomelli L. Nipple-sparing mastectomy long-term outcomes: Early and late complications. *Medicina.* 2020;56(4):08.
256. Parvez E, Martel K, Morency D, Dumitra S, Meguerditchian AN, Dionisopoulos T, et al. Surgical and oncologic outcomes of nipple-sparing mastectomy for a cohort of breast cancer patients, including cases with high-risk features. *Clin Breast Cancer.* 2020;20(4):353-8.
257. Zarba Meli E, De Santis A, Cortese G, Manna E, Mastropietro T, La Pinta M, et al. Nipple-sparing mastectomy after neoadjuvant chemotherapy: Definitive results with a long-term follow-up evaluation. *Ann Surg Oncol.* 2023;30(4):2163-72.

258. Wu ZY, Kim HJ, Lee JW, Chung IY, Kim JS, Lee SB, et al. Breast cancer recurrence in the nipple-areola complex after nipple-sparing mastectomy with immediate breast reconstruction for invasive breast cancer. *JAMA Surg.* 2019;154(11):1030-7.
259. Wu ZY, Kim HJ, Lee J, Chung IY, Kim JS, Lee SB, et al. Recurrence outcomes after nipple-sparing mastectomy and immediate breast reconstruction in patients with pure ductal carcinoma in situ. *Ann Surg Oncol.* 2020;27(5):1627-35.
260. Wu ZY, Han HH, Kim HJ, Lee J, Chung IY, Kim J, et al. Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: Patterns and prognostic significance. *Eur J Surg Oncol.* 2021a;47(6):1309-15.
261. Wu ZY, Han HH, Kim HJ, Lee J, Chung IY, Kim J, et al. Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction. *Data Brief.* 2021b;35:106837.
262. Wu ZY, Han HH, Han J, Kim HJ, Lee J, Chung IY, et al. Impact of local breast cancer recurrence on reconstructed breast in nipple-sparing mastectomy with immediate reconstruction. *J Plast Reconstr Aesthet Surg.* 2022b;75(8):2535-41.
263. Wu ZY, Kim HJ, Lee JW, Chung IY, Kim JS, Lee SB, et al. Oncologic outcomes of nipple-sparing mastectomy and immediate reconstruction after neoadjuvant chemotherapy for breast cancer. *Ann Surg.* 2021d;274(6):e1196-e201.
264. Wu ZY, Han HH, Kim HJ, Chung IY, Kim J, Lee SB, et al. A propensity score-matched analysis of long-term oncologic outcomes after nipple-sparing versus conventional mastectomy for locally advanced breast cancer. *Ann Surg.* 2022a;276(2):386-90.
265. Petit JY, Veronesi U, Orecchia R, Rey P, Martella S, Didier F, et al. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: One thousand and one cases of a five years experience at the European Institute of Oncology of Milan (EIO). *Breast Cancer Res Treat.* 2009;117(2):333-8.
266. Lohsiriwat V, Martella S, Rietjens M, Botteri E, Rotmensz N, Mastropasqua MG, et al. Paget's disease as a local recurrence after nipple-sparing mastectomy: Clinical presentation, treatment, outcome, and risk factor analysis. *Ann Surg Oncol.* 2012;19(6):1850-5.
267. Lohsiriwat V, Rotmensz N, Botteri E, Intra M, Veronesi P, Martella S, et al. Do clinicopathological features of the cancer patient relate with nipple areolar complex necrosis in nipple-sparing mastectomy? *Ann Surg Oncol.* 2013;20(3):990-6.
268. Galimberti V, Morigi C, Bagnardi V, Corso G, Vicini E, Fontana SKR, et al. Oncological outcomes of nipple-sparing mastectomy: A single-center experience of 1989 patients. *Ann Surg Oncol.* 2018;25(13):3849-57.
269. Vicini E, De Lorenzi F, Invento A, Corso G, Radice D, Bozzo S, et al. Is nipple-sparing mastectomy indicated after previous breast surgery? A series of 387 institutional cases. *Plast Reconstr Surg.* 2021;148(1):21-30.
270. Chirappapha P, Petit JY, Rietjens M, De Lorenzi F, Garusi C, Martella S, et al. Nipple sparing mastectomy: Does breast morphological factor related to necrotic complications? *Plast Reconstr Surg Glob Open.* 2014;2(1):e99.
271. Frey JD, Salibian AA, Lee J, Harris K, Axelrod DM, Guth AA, et al. Oncologic trends, outcomes, and risk factors for locoregional recurrence: An analysis of tumor-to-nipple distance and critical factors in therapeutic nipple-sparing mastectomy. *Plast Reconstr Surg.* 2019;143(6):1575-85.
272. Salibian AA, Bekisz JM, Frey JD, Thanik VD, Levine JP, Karp NS, et al. Comparing incision choices in immediate microvascular breast reconstruction after nipple-sparing mastectomy: Unique considerations to optimize outcomes. *Plast Reconstr Surg.* 2021;148(6):1173-85.

273. Boyd CJ, Salibian AA, Bekisz JM, Axelrod DM, Guth AA, Shapiro RL, et al. Long-term cancer recurrence rates following nipple-sparing mastectomy: A 10-year follow-up study. *Plast Reconstr Surg.* 2022;150:13S-9S.
274. Radovanovic Z, Radovanovic D, Golubovic A, Ivkovic-Kapicl T, Bokorov B, Mandic A. Early complications after nipple-sparing mastectomy and immediate breast reconstruction with silicone prosthesis: Results of 214 procedures. *Scand J Surg.* 2010;99(3):115-8.
275. Folli S, Curcio A, Buggi F, Mingozzi M, Lelli D, Barbieri C, et al. Improved sub-areolar breast tissue removal in nipple-sparing mastectomy using hydrodissection. *Breast.* 2012;21(2):190-3.
276. Lee KT, Pyon JK, Bang SI, Lee JE, Nam SJ, Mun GH. Does the reconstruction method influence development of mastectomy flap complications in nipple-sparing mastectomy? *J Plast Reconstr Aesthet Surg.* 2013;66(11):1543-50.
277. Huston TL, Small K, Swistel AJ, Dent BL, Talmor M. Nipple-sparing mastectomy via an inframammary fold incision for patients with scarring from prior lumpectomy. *Ann Plast Surg.* 2015;74(6):652-7.
278. Radovanovic Z, Ranisavljevic M, Radovanovic D, Vicko F, Ivkovic-Kapicl T, Solajic N. Nipple-sparing mastectomy with primary implant reconstruction: Surgical and oncological outcome of 435 breast cancer patients. *Breast Care.* 2018;13(5):373-8.
279. Pallara T, Cagli B, Fortunato L, Altomare V, Loreti A, Grasso A, et al. Direct-to-implant and 2-stage breast reconstruction after nipple sparing mastectomy: Results of a retrospective comparison. *Ann Plast Surg.* 2019;83(4):392-5.
280. Cadili L, Pao JS, McKeivitt E, Dingee C, Bazzarelli A, Warburton R. Nipple margin assessment at the time of nipple-sparing mastectomy. *Can J Surg.* 2023;66(3):E298-E303.
281. Cavalcante FP, Lima TO, Alcantara R, Cardoso A, Ulisses F, Novita G, et al. Inframammary versus periareolar incision: A comparison of early complications in nipple-sparing mastectomy. *Plast Reconstr Surg Glob Open.* 2023;11(11):e5367.
282. Golijanin D, Radovanovic Z, Radovanovic D, Dermanovic A, Starcevic S, Dermanovic M. Molecular subtype and risk of local recurrence after nipple-sparing mastectomy for breast cancer. *Oncol Lett.* 2024;28(2):389.
283. Liston JM, Hollenbeck ST. Discussion: A decade of nipple-sparing mastectomy: Lessons learned in 3035 immediate implant-based breast reconstructions. *Plast Reconstr Surg.* 2024;153(2):288-9.
284. Nashimoto M, Asano Y, Matsui H, Machida Y, Hoshi K, Kurosumi M, et al. Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: A single-center study. *Breast Cancer.* 2024;17:17.
285. Sagir M, Guven E, Saylik O, Dulgeroglu O, Uras C. A new convenient incision model of the nipple-sparing mastectomy: Lateralized parabolic multiplanar incision. *Aesthetic Plast Surg.* 2024;20:20.
286. Ponzzone R, Maggiorotto F, Carabalona S, Rivolin A, Pisacane A, Kubatzki F, et al. MRI and intraoperative pathology to predict nipple-areola complex (NAC) involvement in patients undergoing NAC-sparing mastectomy. *Eur J Cancer.* 2015;51(14):1882-9.
287. Zaborowski AM, Roe S, Rothwell J, Evoy D, Geraghty J, McCartan D, et al. A systematic review of oncological outcomes after nipple-sparing mastectomy for breast cancer. *J Surg Oncol.* 2023;127(3):361-8.
288. Colwell AS, Christensen JM. Nipple-sparing mastectomy and direct-to-implant breast reconstruction. *Plast Reconstr Surg.* 2017;140(5S Advances in Breast Reconstruction):44S-50S.



289. Colwell AS, Taylor EM. Recent advances in implant-based breast reconstruction. *Plast Reconstr Surg.* 2020;145(2):421e-32e.
290. Robertson SA, Jeevaratnam JA, Agrawal A, Cutress RI. Mastectomy skin flap necrosis: Challenges and solutions. *Breast Cancer (Dove Med Press).* 2017;9:141-52.
291. Huang H, Wang ML, Ellison A, Otterburn DM. Comparing autologous to device-based breast reconstruction: A pilot study of return in breast sensation. *Ann Plast Surg.* 2022;88(3 Suppl 3):S184-S9.
292. Lu Wang M, Qin N, Chen Y, De Freitas D, Huang H, Ellison A, et al. A comparative analysis of sensory return in delayed-immediate versus immediate neurotized deep inferior epigastric perforator flap breast reconstruction. *Ann Plast Surg.* 2023;15:15.
293. Lu Wang M, Qin N, Chadab TM, Chen Y, Huang H, Ellison A, et al. A pilot study comparing sensation in buried versus nonburied deep inferior epigastric perforator flaps. *Ann Plast Surg.* 2023;90(6S Suppl 5):S574-S7.
294. Rusby JE, Kirstein LJ, Brachtel EF, Michaelson JS, Koerner FC, Smith BL. Nipple-sparing mastectomy: Lessons from ex vivo procedures. *Breast J.* 2008;14(5):464-70.
295. Suarez-Zamora DA, Mustafa RA, Estrada-Orozco K, Rodriguez-Urrego PA, Torres-Franco F, Barreto-Hauzeur L, et al. Intraoperative sub-areolar frozen section analysis for detecting nipple involvement in candidates for nipple-sparing mastectomy. *Cochrane Database Syst Rev.* 2021;2021(4) (no pagination).
296. Hogan KO, Lai SM, Wagner JL, Fan F. The utility of intraoperative retroareolar margin frozen section assessment and the management of atypical epithelial proliferative lesions at the retroareolar margin in nipple-sparing mastectomies. *Ann Diagn Pathol.* 2021;51:151697.
297. Heinzen RN, de Barros A, Carvalho FM, Aguiar FN, Nimir C, Jacomo AL. Nipple-sparing mastectomy for early breast cancer: The importance of intraoperative evaluation of retroareolar margins and intra-nipple duct removal. *Gland Surg.* 2020;9(3):637-46.
298. D'Alonzo M, Pecchio S, Campisi P, De Rosa G, Bounous VE, Villasco A, et al. Nipple-sparing mastectomy: Reliability of sub-areolar sampling and frozen section in predicting occult nipple involvement in breast cancer patients. *Eur J Surg Oncol.* 2018;44(11):1736-42.
299. Suarez-Zamora DA, Barrera-Herrera LE, Palau-Lazaro MA, Torres-Franco F, Orozco-Plazas A, Barreto-Hauzeur L, et al. Accuracy and interobserver agreement of retroareolar frozen sections in nipple-sparing mastectomies. *Ann Diagn Pathol.* 2017;29:46-51.
300. Dent BL, Chao JW, Eden DJ, Stone BV, Swistel A, Talmor M. Nipple resection and reconstruction after attempted nipple-sparing mastectomy. *Ann Plast Surg.* 2017;78(1):28-34.
301. Alperovich M, Choi M, Karp NS, Singh B, Ayo D, Frey JD, et al. Nipple-sparing mastectomy and sub-areolar biopsy: To freeze or not to freeze? Evaluating the role of sub-areolar intraoperative frozen section. *Breast J.* 2016;22(1):18-23.
302. Duarte GM, Tomazini MV, Oliveira A, Moreira L, Tocchet F, Worschech A, et al. Accuracy of frozen section, imprint cytology, and permanent histology of sub-nipple tissue for predicting occult nipple involvement in patients with breast carcinoma. *Breast Cancer Res Treat.* 2015;153(3):557-63.
303. Kneubil MC, Lohsiriwat V, Curigliano G, Brollo J, Botteri E, Rotmensz N, et al. Risk of locoregional recurrence in patients with false-negative frozen section or close margins of retroareolar specimen in nipple-sparing mastectomy. *Ann Surg Oncol.* 2012;19(13):4117-23.



304. Luo D, Ha J, Latham B, Ingram D, Connell T, Hastrich D, et al. The accuracy of intraoperative subareolar frozen section in nipple-sparing mastectomies. *Ochsner J*. 2010;10(3):188-92.
305. Chan SE, Liao CY, Wang TY, Chen ST, Chen DR, Lin YJ, et al. The diagnostic utility of preoperative breast magnetic resonance imaging (MRI) and/or intraoperative sub-nipple biopsy in nipple-sparing mastectomy. *Eur J Surg Oncol*. 2017;43(1):76-84.
306. Jaspars JJ, Posma AN, van Immerseel AA, Gittenberger-de Groot AC. The cutaneous innervation of the female breast and nipple-areola complex: Implications for surgery. *Br J Plast Surg*. 1997;50(4):249-59.
307. Smeele HP, Bijkerk E, van Kuijk SMJ, Lataster A, van der Hulst R, Tuinder SMH. Innervation of the female breast and nipple: A systematic review and meta-analysis of anatomical dissection studies. *Plast Reconstr Surg*. 2022;150(2):243-55.
308. Morris BE, Van Spronsen NR, Shrout MA, Teven CM, Rebecca AM. Neurotization during breast reconstruction. *Plast Reconstr Surg Glob Open*. 2022;10(11):e4591.
309. Laikhter E, Shiah E, Manstein SM, Comer CD, Bustos VP, Lin SJ. Trends and characteristics of neurotization during breast reconstruction: Perioperative outcomes using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). *J Plast Surg Hand Surg*. 2022;56(5):291-7.
310. Yueh JH, Houlihan MJ, Slavin SA, Lee BT, Pories SE, Morris DJ. Nipple-sparing mastectomy: Evaluation of patient satisfaction, aesthetic results, and sensation. *Ann Plast Surg*. 2009;62(5):586-90.
311. Dossett LA, Lowe J, Sun W, Lee MC, Smith PD, Jacobsen PB, et al. Prospective evaluation of skin and nipple-areola sensation and patient satisfaction after nipple-sparing mastectomy. *J Surg Oncol*. 2016;114(1):11-6.
312. Rodriguez-Unda NA, Bello RJ, Clarke-Pearson EM, Sanyal A, Cooney CM, Manahan MA, et al. Nipple-sparing mastectomy improves long-term nipple but not skin sensation after breast reconstruction: Quantification of long-term sensation in nipple sparing versus non-nipple sparing mastectomy. *Ann Plast Surg*. 2017;78(6):697-703.
313. Chirappapha P, Srichan P, Lertsithichai P, Thaweevoradej P, Sukarayothin T, Leesombatpaiboon M, et al. Nipple-areola complex sensation after nipple-sparing mastectomy. *Plast Reconstr Surg Glob Open*. 2018;6(4):e1716.
314. Akdeniz Dogan Z, Farhadi J. Evaluation of sensation on mastectomy skin flaps following immediate breast reconstruction. *J Reconstr Microsurg*. 2020;36(6):420-5.
315. Najjari K, Ebrahimi M, Karoobi M, Rahimpour E, Vasigh M, Iranmanesh M, et al. Evaluation of sensation and necrotic complications after nipple-sparing mastectomy. *Middle East J Cancer*. 2022;13(4):641-7.
316. Hammond JB, Kandi LA, Armstrong VL, Kosiorek HE, Rebecca AM, Casey WJ, 3rd, et al. Long-term breast and nipple sensation after nipple-sparing mastectomy with implant reconstruction: Relevance to physical, psychosocial, and sexual well-being. *J Plast Reconstr Aesthet Surg*. 2022;75(9):2914-9.
317. Kasielska-Trojan A, Szulia A, Zawadzki T, Antoszewski B. The assessment of nipple areola complex sensation with Semmes-Weinstein Monofilaments-normative values and its covariates. *Diagnostics*. 2021;11(11):19.
318. Rodriguez C, Flores J, Torres-Salich M, Ponce B, Schaefer J, Tarrio E. Nipple-sparing mastectomy with immediate neurosensitization of the nipple areola complex. *Plast Reconstr Surg Glob Open*. 2019;7(8 Suppl).
319. Mori H, Okazaki M. Is the sensitivity of skin-sparing mastectomy or nipple-sparing mastectomy superior to conventional mastectomy with innervated flap? *Microsurgery*. 2011;31(6):428-33.

320. Warren Peled A, Peled ZM. Nerve preservation and allografting for sensory innervation following immediate implant breast reconstruction. *Plast Reconstr Surg Glob Open*. 2019;7(7):e2332.
321. Djohan R, Scomacao I, Knackstedt R, Cakmakoglu C, Grobmyer SR. Neurotization of the nipple-areola complex during implant-based reconstruction: Evaluation of early sensation recovery. *Plast Reconstr Surg*. 2020;146(2):250-4.
322. Tevlin R, Brazio P, Tran N, Nguyen D. Immediate targeted nipple-areolar complex re-innervation: Improving outcomes in immediate autologous breast reconstruction. *J Plast Reconstr Aesthet Surg*. 2021;74(7):1503-7.
323. Gfrerer L, Sager JE, Ford OA, Carty MJ, Verdial FC, Gadd MA, et al. Targeted nipple areola complex reinnervation: Technical considerations and surgical efficiency in implant-based breast reconstruction. *Plast Reconstr Surg Glob Open*. 2022;10(7):e4420.
324. Abbas F, Klomprens K, Simman R. Functional and psychosocial outcomes following innervated breast reconstruction: A systematic review. *Plast Reconstr Surg Glob Open*. 2022;10(9):e4559.
325. Shiah E, Laikhter E, Comer CD, Manstein SM, Bustos VP, Bain PA, et al. Neurotization in innervated breast reconstruction: A systematic review of techniques and outcomes. *J Plast Reconstr Aesthet Surg*. 2022;75(9):2890-913.
326. Weissler JM, Koltz PF, Carney MJ, Serletti JM, Wu LC. Sifting through the evidence: A comprehensive review and analysis of neurotization in breast reconstruction. *Plast Reconstr Surg*. 2018;141(3):550-65.
327. Beugels J, Cornelissen AJM, Spiegel AJ, Heuts EM, Piatkowski A, van der Hulst R, et al. Sensory recovery of the breast after innervated and non-innervated autologous breast reconstructions: A systematic review. *J Plast Reconstr Aesthet Surg*. 2017;70(9):1229-41.
328. Chou J, Hyland CJ, Kaufman Goldberg T, Broyles JM. Is nerve coaptation associated with improved sensation after microvascular breast reconstruction? A systematic review. *Microsurgery*. 2022;22:22.
329. Griffin MF, Malahias M, Hindocha S, Khan W, S. Peripheral nerve injury: Principles for repair and regeneration. *Open Orthop J*. 2014;8:199-203.
330. Lans J, Eberlin KR, Evans PJ, Mercer D, Greenberg JA, Styron JF. A systematic review and meta-analysis of nerve gap repair: Comparative effectiveness of allografts, autografts, and conduits. *Plast Reconstr Surg*. 2023;151(5):814e-27e.
331. Axogen. Corporate presentation May 9, 2023. nasdaq: axgn [powerpoint]. cited 2024 Sep 19. Available from: [https://static.seekingalpha.com/uploads/sa\\_presentations/495/93495/original.pdf](https://static.seekingalpha.com/uploads/sa_presentations/495/93495/original.pdf) 2023.
332. Pisano S, Floyd C, PMRA Plastic Surgery. Regaining breast sensation after mastectomy: Your questions answered. 2020 Jul 16; modified 2024 June 28; accessed 2024 Sept 13. Available from: <https://prma-enhance.com/breast-reconstruction/restore-feeling-after-mastectomy/>.
333. PMRA Plastic Surgery. TruSense® restore feeling after mastectomy. Restore feeling after mastectomy with TruSense®. 2020 Mar 19; modified 2024 June 3; accessed 2024 Sept 13. Available from: <https://prma-enhance.com/breast-reconstruction/restore-feeling-after-mastectomy/>.
334. Axogen Corporation. Resensation®. The potential to restore sensation after mastectomy. Mastectomy can leave you feeling numb. Resensation® is a surgical technique designed to restore sensation [blog]. Axogen. 2024 Aug. Cited 2024 Sept 19. Available from: <https://www.resensation.com/>.

335. Women's College Hospital BRA Day 2023. BRA Day 2023: Audience questions. Toronto: Women's College Hospital BRA Day 2023, cited 2024 Sept 19. Available at: <https://www.womenscollegehospital.ca/bra-day-2023-audience-questions/>.
336. Darrach H, Kraenzlin FS, Khavanin N, He W, Lee E, Sacks JM. Pectoral placement of tissue expanders affects inpatient opioid use. *Breast J*. 2021;27(2):126-33.
337. Kraenzlin F, Darrach H, Khavanin N, Kokosis G, Aliu O, Broderick K, et al. Tissue expander-based breast reconstruction in the prepectoral versus subpectoral plane: An analysis of short-term outcomes. *Ann Plast Surg*. 2021;86(1):19-23.
338. Sinnott CJ, Persing SM, Pronovost M, Hodyl C, McConnell D, Ott Young A. Impact of postmastectomy radiation therapy in prepectoral versus subpectoral implant-based breast reconstruction. *Ann Surg Oncol*. 2018;25(10):2899-908.
339. Kim JH, Hong SE. A comparative analysis between subpectoral versus prepectoral single stage direct-to-implant breast reconstruction. *Medicina*. 2020;56(10):13.
340. Nealon KP, Weitzman RE, Sobti N, Gadd M, Specht M, Jimenez RB, et al. Prepectoral direct-to-implant breast reconstruction: Safety outcome endpoints and delineation of risk factors. *Plast Reconstr Surg*. 2020;145(5):898e-908e.
341. Belmonte BM, Campbell CA. Safety profile and predictors of aesthetic outcomes after prepectoral breast reconstruction with meshed acellular dermal matrix. *Ann Plast Surg*. 2021;86(6S Suppl 5):S585-S92.
342. Bozzuto LM, Bartholomew AJ, Tung S, Sosin M, Tambar S, Cox S, et al. Decreased postoperative pain and opioid use following prepectoral versus subpectoral breast reconstruction after mastectomy: A retrospective cohort study: Pain after pre- versus subpectoral reconstruction. *J Plast Reconstr Aesthet Surg*. 2021;74(8):1763-9.
343. Haddock NT, Kadakia Y, Liu Y, Teotia SS. Prepectoral versus subpectoral tissue expander breast reconstruction: A historically controlled, propensity score-matched comparison of perioperative outcomes. *Plast Reconstr Surg*. 2021;148(1):1-9.
344. Plachinski SJ, Boehm LM, Adamson KA, LoGiudice JA, Doren EL. Comparative analysis of prepectoral versus subpectoral implant-based breast reconstruction. *Plast Reconstr Surg Glob Open*. 2021;9(7):e3709.
345. Ribuffo D, Berna G, De Vita R, Di Benedetto G, Cigna E, Greco M, et al. Dual-plane retro-pectoral versus pre-pectoral DTI breast reconstruction: An Italian multicenter experience. *Aesthetic Plast Surg*. 2021;45(1):51-60.
346. Walker NJ, Park JG, Maus JC, Motamedi V, Rebowe RE, Runyan CM, et al. Prepectoral versus subpectoral breast reconstruction in high-body mass index patients. *Ann Plast Surg*. 2021;87(2):136-43.
347. Holland M, Su P, Piper M, Withers J, Harbell MW, Bokoch MP, et al. Prepectoral breast reconstruction reduces opioid consumption and pain after mastectomy: A head-to-head comparison with submuscular reconstruction. *Ann Plast Surg*. 2022;89(5):492-9.
348. Asaad M, Hassan AM, Morris N, Kumar S, Liu J, Butler CE, et al. Impact of obesity on outcomes of prepectoral vs subpectoral implant-based breast reconstruction. *Aesthet Surg J*. 2023a;43(10):NP774-NP86.
349. Asaad M, Yu JZ, Tran JP, Liu J, O'Grady B, Clemens MW, et al. Surgical and Patient-Reported Outcomes of 694 Two-Stage Prepectoral versus Subpectoral Breast Reconstructions. *Plast Reconstr Surg*. 2023b;152(4S):43S-54S.
350. Hassan AM, Asaad M, Morris N, Kumar S, Liu J, Mitchell MP, et al. Subpectoral Implant Placement Is Not Protective against Postmastectomy Radiotherapy-Related Complications Compared to Prepectoral Placement. *Plast Reconstr Surg*. 2024;153(1):24-33.

351. Hung YC, McCarthy JT, Park BC, Chaker SC, Saad M, Braun SA, et al. Comparison of complication rates between subpectoral vs prepectoral techniques in prosthetic breast reconstruction. *Aesthet Surg J.* 2023;43(11):1285-92.
352. ElSherif A, Bernard S, Djohan R, Atallah A, Tu C, Valente SA. Nipple necrosis rate with submuscular versus prepectoral implant-based reconstruction in nipple sparing mastectomy: Does it differ? *Am J Surg.* 2024;230:57-62.
353. Talwar AA, Lanni MA, Ryan IA, Kodali P, Bernstein E, McAuliffe PB, et al. Prepectoral versus submuscular implant-based breast reconstruction: A matched-pair comparison of outcomes. *Plast Reconstr Surg.* 2024;153(2):281e-90e.
354. Houvenaeghel G, Cohen M, Sabiani L, Van Troy A, Quilichini O, Charavil A, et al. Mastectomy and immediate breast reconstruction with pre-pectoral or sub-pectoral implant: Assessing clinical practice, post-surgical outcomes, patient's satisfaction and cost. *J Surg Res (Houst).* 2022;5(3):500-10.
355. Parikh RP, Brown GM, Sharma K, Yan Y, Myckatyn TM. Immediate implant-based breast reconstruction with acellular dermal matrix: A comparison of sterile and aseptic alloderm in 2039 consecutive cases. *Plast Reconstr Surg.* 2018;142(6):1401-9.
356. Dieterich M, Faridi A. Biological matrices and synthetic meshes used in implant-based breast reconstruction - a review of products available in Germany. *Geburtshilfe Frauenheilkd.* 2013;73(11):1100-6.
357. Zenn M, Venturi M, Pittman T, Spear S, Gurtner G, Robb G, et al. Optimizing outcomes of postmastectomy breast reconstruction with acellular dermal matrix: A review of recent clinical data. *Eplasty.* 2017;17:e18.
358. Allergan Aesthetics: An AbbVie Company. AlloDerm™ regenerative tissue matrix. Product portfolio brochure. Allergan Aesthetics. 2022 Dec 22, cited 2024 Jun 10. Available from: <https://hcp.alloderm.com/resources#DownloadMaterials>; <https://hcp.alloderm.com/-/media/project/alloderm2022/downloadpdf/AlloDermPortfolioBrochure.pdf>.
359. Powers JM, Reuter Munoz KD, Parkerson J, Nigro LC, Blanchet NP. From salvage to prevention: A single-surgeon experience with acellular dermal matrix and infection in prepectoral breast reconstruction. *Plast Reconstr Surg.* 2021;148(6):1201-8.
360. Wood KL, Margulies IG, Shay PL, Ashikari AY, Salzberg CA. Complications after perforated versus nonperforated acellular dermal matrix use in direct-to-implant breast reconstruction: A propensity score analysis. *Plast Reconstr Surg Glob Open.* 2020;8(3):e2690.
361. Luo J, Willis RN, Jr., Ohlsen SM, Piccinin M, Moores N, Kwok AC, et al. Meshed acellular dermal matrix for two-staged prepectoral breast reconstruction: An institutional experience. *Arch Plast Surg.* 2022;49(2):166-73.
362. Zammit D, Kanevsky J, Meng F-Y, Dionisopoulos T. Meshed acellular dermal matrix: Technique and application in implant based breast reconstruction. *Plastic and Aesthetic Research.* 2016;3:254-6.
363. Scheflan M, Allweis TM, Ben Yehuda D, Maisel Lotan A. Meshed acellular dermal matrix in immediate prepectoral implant-based breast reconstruction. *Plast Reconstr Surg Glob Open.* 2020;8(11):e3265.
364. Gui G, Gui M, Gui A, Tasoulis MK. Physical characteristics of surgimend meshed biological adm in immediate prepectoral implant breast reconstruction. *Plast Reconstr Surg Glob Open.* 2022;10(6):e4369.
365. Hill EJR, Buck DW, 2nd. The "butterfly" wrap: A simplified technique for consistent prosthesis coverage in prepectoral breast reconstruction. *Plast Reconstr Surg Glob Open.* 2018;6(11):e2007.

366. Liliav B, Patel P, Jacobson AK. Prepectoral breast reconstruction: A technical algorithm. *Plast Reconstr Surg Glob Open*. 2019;7(2):e2107.
367. Sigalove S. Options in acellular dermal matrix-device assembly. *Plast Reconstr Surg*. 2017;140(6S Prepectoral Breast Reconstruction):39S-42S.
368. Lee YJ, Kanchwala SK, Cho H, Jolly JC, Jablonka E, Tanis M, et al. Natural shaping of acellular dermal matrices for implant-based breast reconstruction via expansile kirigami. *Adv Mater*. 2023;35(6):e2208088.
369. Seth AK, Hirsch EM, Fine NA, Kim JYS. Utility of acellular dermis-assisted breast reconstruction in the setting of radiation: A comparative analysis. *Plast Reconstr Surg*. 2012;130(4):750-8.
370. Jordan SW, Khavanin N, Fine NA, Kim JYS. An algorithmic approach for selective acellular dermal matrix use in immediate two-stage breast reconstruction: Indications and outcomes. *Plast Reconstr Surg*. 2014;134(2):178-88.
371. Woo KJ, Park JW, Mun GH, Pyon JK, Jeon BJ, Bang SI. Does the use of acellular dermal matrix increase postoperative complications of the first-stage reconstruction of immediate expander-implant breast reconstruction: A matched cohort study. *Ann Plast Surg*. 2017;79(4):341-5.
372. Lee KT, Lee H, Jeon BJ, Mun GH, Bang SI, Pyon JK. Impact of overweight/obesity on the development of hematoma following tissue expander-based breast reconstruction. *J Plast Reconstr Aesthet Surg*. 2020;19:19.
373. Lee KT, Eom Y, Mun GH, Bang SI, Jeon BJ, Pyon JK. Efficacy of partial- versus full-sling acellular dermal matrix use in implant-based breast reconstruction: A head-to-head comparison. *Aesthetic Plast Surg*. 2018;42(2):422-33.
374. Lee KT, Hong SH, Jeon BJ, Pyon JK, Mun GH, Bang SI. Predictors for prolonged drainage following tissue expander-based breast reconstruction. *Plast Reconstr Surg*. 2019;144(1):9e-17e.
375. Pires G, Marquez JL, Memmott S, Sudduth JD, Moss W, Eddington D, et al. Early Complications after Prepectoral Tissue Expander Placement in Breast Reconstruction with and without Acellular Dermal Matrix. *Plast Reconstr Surg*. 2024;153(6):1221-9.
376. Pannucci CJ, Antony AK, Wilkins EG. The impact of acellular dermal matrix on tissue expander/implant loss in breast reconstruction: An analysis of the tracking outcomes and operations in plastic surgery database. *Plast Reconstr Surg*. 2013;132(1):1-10.
377. Kilmer LH, Challa S, Stranix JT, Campbell CA. Case-matched Comparison of Implant-based Breast Reconstruction with and without Acellular Dermal Matrix. *Plast Reconstr Surg Glob Open*. 2024;12(3):e5660.
378. Plotsker EL, Graziano FD, Rubenstein RN, Haglich K, Allen RJ, Jr., Coriddi MR, et al. Early complications in prepectoral breast reconstructions with and without acellular dermal matrix: A preliminary analysis of outcomes. *Plast Reconstr Surg*. 2024;153(4):786-93.
379. Davila AA, Seth AK, Wang E, Hanwright P, Bilimoria K, Fine N, et al. Human acellular dermis versus submuscular tissue expander breast reconstruction: A multivariate analysis of short-term complications. *Arch Plast Surg*. 2013;40(1):19-27.
380. Winocour S, Martinez-Jorge J, Habermann E, Thomsen K, Lemaine V. Early surgical site infection following tissue expander breast reconstruction with or without acellular dermal matrix: National Benchmarking Using National Surgical Quality Improvement Program. *Arch Plast Surg*. 2015;42(2):194-200.
381. Luo J, Moss WD, Pires GR, Rhemtulla IA, Rosales M, Stoddard GJ, et al. A nationwide analysis evaluating the safety of using acellular dermal matrix with tissue expander-based breast reconstruction. *Arch Plast Surg*. 2022;49(6):716-23.

382. Wells MW, Chang IA, Gatherwright JR, Festekjian JH, Delong MR. Postsurgical outcomes with meshes for two-stage prosthetic breast reconstruction in 20,817 patients. *Plast Reconstr Surg Glob Open*. 2022;10(12):e4699.
383. Graziano FD, Plotsker EL, Rubenstein RN, Haglich K, Stern CS, Matros E, et al. National Trends in Acellular Dermal Matrix Utilization in Immediate Breast Reconstruction. *Plast Reconstr Surg*. 2024;153(1):25e-36e.
384. Sbitany H, Sandeen SN, Amalfi AN, Davenport MS, Langstein HN. Acellular dermis-assisted prosthetic breast reconstruction versus complete submuscular coverage: A head-to-head comparison of outcomes. *Plast Reconstr Surg*. 2009;124(6):1735-40.
385. Vardanian AJ, Clayton JL, Roostaeian J, Shirvanian V, Da Lio A, Lipa JE, et al. Comparison of implant-based immediate breast reconstruction with and without acellular dermal matrix. *Plast Reconstr Surg*. 2011;128(5):403e-10e.
386. McCarthy CM, Lee CN, Halvorson EG, Riedel E, Pusic AL, Mehrara BJ, et al. The use of acellular dermal matrices in two-stage expander/implant reconstruction: A multicenter, blinded, randomized controlled trial. *Plast Reconstr Surg*. 2012;130(5 Suppl 2):57S-66S.
387. Parks JW, Hammond SE, Walsh WA, Adams RL, Chandler RG, Luce EA. Human acellular dermis versus no acellular dermis in tissue expansion breast reconstruction. *Plast Reconstr Surg*. 2012;130(4):739-46.
388. Weichman KE, Wilson SC, Weinstein AL, Hazen A, Levine JP, Choi M, et al. The use of acellular dermal matrix in immediate two-stage tissue expander breast reconstruction. *Plast Reconstr Surg*. 2012;129(5):1049-58.
389. Weichman KE, Wilson SC, Saadeh PB, Hazen A, Levine JP, Choi M, et al. Sterile "ready-to-use" AlloDerm decreases postoperative infectious complications in patients undergoing immediate implant-based breast reconstruction with acellular dermal matrix. *Plast Reconstr Surg*. 2013;132(4):725-36.
390. Arnaout A, Zhang J, Frank S, Momtazi M, Cordeiro E, Roberts A, et al. A randomized controlled trial comparing Alloderm-RTU with DermACELL in immediate subpectoral implant-based breast reconstruction. *Curr Oncol*. 2021;28(1):184-95.
391. Stein MJ, Arnaout A, Lichtenstein JB, Frank SG, Cordeiro E, Roberts A, et al. A comparison of patient-reported outcomes between Alloderm and Dermacell in immediate alloplastic breast reconstruction: A randomized control trial. *J Plast Reconstr Aesthet Surg*. 2021;74(1):41-7.
392. Chu JJ, Nelson JA, Kokosis G, Haglich K, McKernan CD, Rubenstein R, et al. A cohort analysis of early outcomes after Alloderm, FlexHD, and Surgimend use in two-stage prepectoral breast reconstruction. *Aesthet Surg J*. 2023;43(12):1491-8.
393. Berger LE, Spoer DL, Huffman SS, Haffner ZK, Tom LK, Parkih RP, et al. Acellular dermal matrix-assisted, prosthesis-based breast reconstruction: A comparison of SurgiMend PRS, AlloDerm, and DermACELL. *Ann Plast Surg*. 2024;93(1):34-42.
394. Johnson AC, Colakoglu S, Siddikoglu D, Li A, Kaoutzanis C, Cohen JB, et al. Impact of dermal matrix brand in implant-based breast reconstruction outcomes. *Plast Reconstr Surg*. 2022;150(1):17-25.
395. Zenn MR, Salzberg CA. A direct comparison of Alloderm-Ready to Use (RTU) and DermACELL in immediate breast implant reconstruction. *Eplasty*. 2016;16:e23.
396. Agarwal JP, Mendenhall SD, Anderson LA, Ying J, Boucher KM, Liu T, et al. The breast reconstruction evaluation of acellular dermal matrix as a sling trial (BREASTrial): Design and methods of a prospective randomized trial. *Plast Reconstr Surg*. 2015;135(1):20e-8e.
397. Mendenhall SD, Anderson LA, Ying J, Boucher KM, Liu T, Neumayer LA, et al. The BREASTrial: Stage I. Outcomes from the time of tissue expander and acellular dermal

- matrix placement to definitive reconstruction. *Plast Reconstr Surg*. 2015;135(1):29e-42e.
398. Mendenhall SD, Anderson LA, Ying J, Boucher KM, Neumayer LA, Agarwal JP. The BREASTrial Stage II: ADM breast reconstruction outcomes from definitive reconstruction to 3 months postoperative. *Plast Reconstr Surg Glob Open*. 2017;5(1):e1209.
  399. Mendenhall SD, Moss WD, Graham EM, Carter G, Agarwal JP. The BREASTrial Stage III: Acellular dermal matrix breast reconstruction outcomes from 3 months to 2 years postoperatively. *Plast Reconstr Surg*. 2023;151(1):17-24.
  400. Seth AK, Persing S, Connor CM, Davila A, Hirsch E, Fine NA, et al. A comparative analysis of cryopreserved versus prehydrated human acellular dermal matrices in tissue expander breast reconstruction. *Ann Plast Surg*. 2013;70(6):632-5.
  401. Liu DZ, Mathes DW, Neligan PC, Said HK, Louie O. Comparison of outcomes using AlloDerm versus FlexHD for implant-based breast reconstruction. *Ann Plast Surg*. 2014;72(5):503-7.
  402. Ranganathan K, Santosa KB, Lyons DA, Mand S, Xin M, Kidwell K, et al. Use of acellular dermal matrix in postmastectomy breast reconstruction: Are all acellular dermal matrices created equal? *Plast Reconstr Surg*. 2015;136(4):647-53.
  403. Sobti N, Liao EC. Surgeon-controlled study and meta-analysis comparing FlexHD and AlloDerm in immediate breast reconstruction outcomes. *Plast Reconstr Surg*. 2016;138(5):959-67.
  404. Broyles JM, Liao EC, Kim J, Heistein J, Sisco M, Karp N, et al. Acellular dermal matrix-associated complications in implant-based breast reconstruction: A multicenter, prospective, randomized controlled clinical trial comparing two human tissues. *Plast Reconstr Surg*. 2021;148(3):493-500.
  405. Keifer OP, Jr., Page EK, Hart A, Rudderman R, Carlson GW, Losken A. A complication analysis of 2 acellular dermal matrices in prosthetic-based breast reconstruction. *Plast Reconstr Surg Glob Open*. 2016;4(7):e800.
  406. Hadad I, Liu AS, Guo L. A new approach to minimize acellular dermal matrix use in prosthesis-based breast reconstruction. *Plast Reconstr Surg Glob Open*. 2015;3(7):e472.
  407. Frey JD, Alperovich M, Weichman KE, Wilson SC, Hazen A, Saadeh PB, et al. Breast reconstruction using contour fenestrated Alloderm: Does improvement in design translate to improved outcomes? *Plast Reconstr Surg Glob Open*. 2015;3(9):e505.
  408. Yuen JC, Yue CJ, Erickson SW, Cooper S, Boneti C, Henry-Tillman R, et al. Comparison between freeze-dried and ready-to-use Alloderm in alloplastic breast reconstruction. *Plast Reconstr Surg Glob Open*. 2014;2(3):e119.
  409. Widmyer AS, Mirhaidari SJ, Wagner DS. Implant-based breast reconstruction outcomes comparing freeze-dried aseptic Alloderm and sterile ready-to-use Alloderm. *Plast Reconstr Surg Glob Open*. 2019;7(12):e2530.
  410. Hanson SE, Meaie JD, Selber JC, Liu J, Li L, Hassid VJ, et al. Aseptic freeze-dried versus sterile wet-packaged human cadaveric acellular dermal matrix in immediate tissue expander breast reconstruction: A propensity score analysis. *Plast Reconstr Surg*. 2018;141(5):624e-32e.
  411. Han WY, Han SJ, Kim EK, Han HH, Eom JS. A comparison of clinical outcomes of acellular dermal matrix with and without radiation sterilization process in immediate prepectoral direct-to-implant breast reconstruction. *J Plast Reconstr Aesthet Surg*. 2023b;87:461-6.
  412. Wederfoort JLM, van Santbrink E, Hommes JE, Heuts EM, Van Kuijk SMJ, van der Hulst R, et al. Donor site satisfaction following autologous fat transfer for total breast reconstruction. *Aesthet Surg J*. 2023a;43(1):40-8.



413. Petit JY, Botteri E, Lohsiriwat V, Rietjens M, De Lorenzi F, Garusi C, et al. Locoregional recurrence risk after lipofilling in breast cancer patients. *Ann Oncol.* 2012;23(3):582-8.
414. Gale KL, Rakha EA, Ball G, Tan VK, McCulley SJ, Macmillan RD. A case-controlled study of the oncologic safety of fat grafting. *Plast Reconstr Surg.* 2015;135(5):1263-75.
415. Seth AK, Hirsch EM, Kim JYS, Fine NA. Long-term outcomes following fat grafting in prosthetic breast reconstruction: A comparative analysis. *Plast Reconstr Surg.* 2012;130(5):984-90.
416. Kim HY, Jung BK, Lew DH, Lee DW. Autologous fat graft in the reconstructed breast: Fat absorption rate and safety based on sonographic identification. *Arch Plast Surg.* 2014;41(6):740-7.
417. Masia J, Bordoni D, Pons G, Liuzza C, Castagnetti F, Falco G. Oncological safety of breast cancer patients undergoing free-flap reconstruction and lipofilling. *Eur J Surg Oncol.* 2015;41(5):612-6.
418. Fertsch S, Hagouan M, Munder B, Schulz T, Abu-Ghazaleh A, Schaberick J, et al. Increased risk of recurrence associated with certain risk factors in breast cancer patients after DIEP-flap reconstruction and lipofilling-a matched cohort study with 200 patients. *Gland Surg.* 2017;6(4):315-23.
419. Myckatyn TM, Wagner IJ, Mehrara BJ, Crosby MA, Park JE, Qaqish BF, et al. Cancer risk after fat transfer: A multicenter case-cohort study. *Plast Reconstr Surg.* 2017;139(1):11-8.
420. Silva-Vergara C, Fontdevila J, Weshahy O, Yuste M, Descarrega J, Grande L. Breast cancer recurrence is not increased with lipofilling reconstruction: A case-controlled study. *Ann Plast Surg.* 2017;79(3):243-8.
421. Silva-Vergara C, Fontdevila J, Descarrega J, Burdio F, Yoon TS, Grande L. Oncological outcomes of lipofilling breast reconstruction: 195 consecutive cases and literature review. *J Plast Reconstr Aesthet Surg.* 2016;69(4):475-81.
422. Calabrese C, Kothari A, Badylak S, Di Taranto G, Marcasciano M, Sordi S, et al. Oncological safety of stromal vascular fraction enriched fat grafting in two-stage breast reconstruction after nipple sparing mastectomy: Long-term results of a prospective study. *Eur Rev Med Pharmacol Sci.* 2018;22(15):4768-77.
423. Perez-Cano R, Vranckx JJ, Lasso JM, Calabrese C, Merck B, Milstein AM, et al. Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: The RESTORE-2 trial. *Eur J Surg Oncol.* 2012;38(5):382-9.
424. Krastev T, van Turnhout A, Vriens E, Smits L, van der Hulst R. Long-term follow-up of autologous fat transfer vs conventional breast reconstruction and association with cancer relapse in patients with breast cancer. *JAMA Surg.* 2019;154(1):56-63.
425. Vyas KS, DeCoster RC, Burns JC, Rodgers LT, Shrout MA, Mercer JP, et al. Autologous fat grafting does not increase risk of oncologic recurrence in the reconstructed breast. *Ann Plast Surg.* 2020;84(6S Suppl 5):S405-S10.
426. Casarrubios JM, Frances M, Fuertes V, Singer M, Navarro C, Garcia-Duque O, et al. Oncological outcomes of lipofilling in breast reconstruction: A matched cohort study with 250 patients. *Gland Surg.* 2021;10(3):914-23.
427. Klinger M, Losurdo A, Lisa AVE, Morengi E, Vinci V, Corsi F, et al. Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: A multicenter Italian retrospective study. *Breast Cancer Res Treat.* 2022;191(2):355-63.
428. Palve J, Luukkaala T, Kaariainen M. Comparison of different techniques in latissimus dorsi breast reconstruction: Plain, immediately lipofilled, and implant enhanced. *Ann Plast Surg.* 2022;88(1):20-4.



429. Sorotos M, Paolini G, D'Orsi G, Firmani G, Timmermans FW, Santanelli di Pompeo F. Oncologic outcome of 1000 postmastectomy breast reconstructions with fat transfer: A single-center, matched case-control study. *Plast Reconstr Surg.* 2022;150:4S-12S.
430. Lee KT, Kim JH, Jeon BJ, Pyon JK, Mun GH, Lee SK, et al. Association of fat graft with breast cancer recurrence in implant-based reconstruction: Does the timing matter? *Ann Surg Oncol.* 2023;30(2):1087-97.
431. Strong AL, Syrjamaki JD, Kamdar N, Wilkins EG, Sears ED. Oncological safety of autologous fat grafting for breast reconstruction. *Ann Plast Surg.* 2024;92(1):21-7.
432. Escandon JM, Langstein HN, Christiano JG, Aristizabal A, Gooch JC, Weiss A, et al. Latissimus dorsi flap with immediate fat transfer (LIFT) for autologous breast reconstruction: Single institution experience. *Am J Surg.* 2024;228:185-91.
433. Navarro AS, Omalek D, Chaltiel L, Vaysse C, Meresse T, Gangloff D, et al. Oncologic safety of autologous fat grafting in primary breast reconstruction after mastectomy for cancer. *Eur J Surg Oncol.* 2024;50(4):107998.
434. Hounsshell CA, Kilgore LJ, Pruitt P, Wilder C, Balanoff CR, Wagner JL, et al. Evaluation of learning curve with Indocyanine Green (IcG) versus blue dye for sentinel lymph node biopsy in breast cancer. *Am J Surg.* 2024;227:218-23.
435. Yao A, Greige N, Ricci JA, Draper LB, Weichman KE. Topical Nitroglycerin Ointment Reduces Mastectomy Flap Necrosis in Immediate Autologous Breast Reconstruction. *Plast Reconstr Surg.* 2023;152(4):728-35.
436. Tang N, Li H, Chow Y, Blake W. Non-operative adjuncts for the prevention of mastectomy skin flap necrosis: A systematic review and meta-analysis. *ANZ J Surg.* 2023;93(1-2):65-75.
437. DeVito RG, Stranix JT. Is nitropaste effective in stressed flaps? *Ann Plast Surg.* 2023;90(6S Suppl 4):S356-S8.
438. Paffile J, McGuire C, Bezuhly M. Systematic review of patient safety and quality improvement initiatives in breast reconstruction. *Ann Plast Surg.* 2022;89(1):121-36.
439. Bou Zein Eddine S, Chiha T, Atallah J, Khouri K, Winograd JM, Tomczyk ERG. The use of topical dimethyl sulfoxide (DMSO) in plastic and reconstructive surgery: A narrative review. *Eur J Plast Surg.* 2024;47(1) (no pagination).
440. Kumar R, Sharma B, Modi G, Parihar S. Role of quilting technique in reducing seroma formation after modified radical mastectomy. *Asian J Pharm Clin Res.* 2024;17(2):116-8.
441. Rp R, Jose J, Av A. Seroma formation and its relationship with mechanical dead space obliteration following modified radical mastectomy. *Asian J Pharm Clin Res.* 2024;17(8):97-9.
442. Bhagchandani M, Shukla V, Maurya RK, Chaudhary A, Kumar K. A Comparative Study Between Mastectomy Flap Quilting Sutures with Axillary Drain Versus Conventional Sutures with Axillary and Pectoral Drain in Reducing Post-Modified Radical Mastectomy Seroma Formation. *Indian J Surg.* 2023:1-6.
443. Hakseven M, Avsar G, Cetindag O, Deryol R, Benk MS, Sirganci G, et al. Prospective study on avoiding seroma formation by flap fixation after modified radical mastectomy. *Am Surg.* 2024;90(4):533-40.
444. Shojaee L, Sayyadi S, Amani R, Nezamtabar Malekshah A. Investigating the effect of suture flap fixation on seroma formation in breast cancer patients undergoing mastectomy. *Eur J Plast Surg.* 2023;46(6):1093-8.
445. van Zeelst LJ, van der Waal DC, Keemers-Gels ME, van den Wildenberg FJH, Schlooz-Vries MS, Wijers CHW, et al. Effect of different quilting techniques on seroma formation after breast surgery: Retrospective study. *BJS Open.* 2023;7(2):07.

446. Paul R. Reduction in Seroma and Other Complications with a Novel Internal Negative Pressure System in Breast Reconstruction. *Plast Reconstr Surg Glob Open*. 2023;11(9):e5261.
447. Norman G, Shi C, Goh LE, Murphy MAE, Reid A, Chiverton L, et al. Negative pressure wound therapy for surgical wounds healing by primary closure. *Cochrane Database Syst Rev*. 2022;4(4):CD009261.
448. Lauritzen E, Damsgaard TE. Use of indocyanine green angiography decreases the risk of complications in autologous- and implant-based breast reconstruction: A systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg*. 2021;74(8):1703-17.
449. da Silva Neto E, Figueiredo PHM, Moro MG, de Oliveira APL, Assumpcao CB, Perina ALF, et al. Use of laser-assisted indocyanine green angiography in breast reconstruction: Systematic review and meta-analysis. *J Surg Oncol*. 2020;121(5):759-65.
450. Magno-Padron DA, Collier W, Kim J, Agarwal JP, Kwok AC. A Nationwide Analysis of Early and Late Readmissions following Free Tissue Transfer for Breast Reconstruction. *J Reconstr Microsurg*. 2020;36(6):450-7.
451. Collier W, Scheefer Van Boerum M, Kim J, Kwok AC. Are 30-Day Outcomes Enough? Late Infectious Readmissions following Prosthetic-Based Breast Reconstruction. *Plast Reconstr Surg*. 2019;144(3):360e-8e.
452. National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management. NICE guideline [NG101] Published: 18 July 2018 Last updated: 16 January 2024.
453. Berrino P, Berrino V. Postmastectomy total breast reconstruction by serial lipografting. In: Di Giuseppe A, Bassetto F, Nahia F (ed), *Fat transfer in plastic surgery: Techniques, technology and safety*, Chapter 25. Switzerland : Springer NatureSwitzerland AG, pp 355-363. [https://doi.org/10.1007/978-3-031-10881-5\\_25](https://doi.org/10.1007/978-3-031-10881-5_25).
454. Homsy P, Hockerstedt A, Hukkinen K, Kauhanen S. Total Breast Reconstruction with Lipofilling after Traditional Mastectomy without the Use of Tissue Expanders. *Plast Reconstr Surg*. 2023;152(3):483-91.
455. Piffer A, Aubry G, Cannistra C, Popescu N, Nikpayam M, Koskas M, et al. Breast reconstruction by exclusive lipofilling after total mastectomy for breast cancer: Description of the technique and evaluation of quality of life. *J Pers Med*. 2022;12(2):25.
456. Di Giuseppe A, Bassetto F, Nahia F (eds). *Fat transfer in plastic surgery: Techniques, technology and safety*. Switzerland : Springer NatureSwitzerland AG. <https://doi.org/10.1007/978-3-031-10881-5>.
457. Zingaretti N, Miotti G, Parodi PC. Hybrid fat transfer, breast implants, and fat. In: Di Giuseppe A, Bassetto F, Nahia F (ed), *Fat transfer in plastic surgery: techniques, technology and safety*, Chapter 25. Switzerland : Springer NatureSwitzerland AG, pp 365-374. [https://doi.org/10.1007/978-3-031-10881-5\\_26](https://doi.org/10.1007/978-3-031-10881-5_26).
458. Bassetto F, Grigatti M. Total breast reconstruction with “deflating technique”. In: Di Giuseppe A, Bassetto F, Nahia F (ed), *Fat transfer in plastic surgery: Techniques, technology and safety*, Chapter 22. Switzerland : Springer NatureSwitzerland AG, pp 315-318. [https://doi.org/10.1007/978-3-031-10881-5\\_22](https://doi.org/10.1007/978-3-031-10881-5_22).
459. Riccardo C, Valentina P, Luca F. Reverse expansion technique for breast reconstruction after skin-sparing and nipple-sparing mastectomy. In: Di Giuseppe A, Bassetto F, Nahia F (ed), *Fat Transfer in Plastic Surgery*, Chapter 35. Switzerland : Springer NatureSwitzerland AG, pp 465-472. [https://doi.org/10.1007/978-3-031-10881-5\\_35](https://doi.org/10.1007/978-3-031-10881-5_35).
460. Lemaine V, Hoskin TL, Farley DR, Grant CS, Boughey JC, Torstenson TA, et al. Introducing the SKIN score: A validated scoring system to assess severity of mastectomy skin flap necrosis. *Ann Surg Oncol*. 2015;22(9):2925-32.

461. Coleman SR, Saboeiro AP. Fat grafting to the breast revisited: Safety and efficacy. *Plast Reconstr Surg.* 2007;119(3):775-85; discussion 86-7.
462. Agha RA, Borrelli MR, Vella-Baldacchino M, Thavayogan R, Orgill DP. The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. *Int J Surg.* 2017;46:198-202.
463. Patel AA, Martin SA, Cheesborough JE, Lee GK, Nazerali RS. The safety and efficacy of autologous fat grafting during second stage breast reconstruction. *J Plast Reconstr Aesthet Surg.* 2021;74(4):792-9.
464. Maheta B, Yesantharao PS, Thawanyarat K, Akhter MF, Rowley M, Nazerali RS. Timing of autologous fat grafting in implant-based breast reconstruction: Best practices based on systematic review and meta-analysis. *J Plast Reconstr Aesthet Surg.* 2023;86:273-9.
465. Kenny EM, Egro FM, Ejaz A, Coleman SR, Greenberger JS, Rubin JP. Fat Grafting in Radiation-Induced Soft-Tissue Injury: A Narrative Review of the Clinical Evidence and Implications for Future Studies. *Plast Reconstr Surg.* 2021;147(4):819-38.
466. Nahabedian MY. Current Approaches to Prepectoral Breast Reconstruction. *Plast Reconstr Surg.* 2018;142(4):871-80.
467. Tsoi B, Ziolkowski NI, Thoma A, Campbell K, O'Reilly D, Goeree R. Safety of tissue expander/implant versus autologous abdominal tissue breast reconstruction in postmastectomy breast cancer patients: A systematic review and meta-analysis. *Plast Reconstr Surg.* 2014a;133(2):234-49.
468. Tsoi B, Ziolkowski NI, Thoma A, Campbell K, O'Reilly D, Goeree R. Systematic review on the patient-reported outcomes of tissue-expander/implant vs autologous abdominal tissue breast reconstruction in postmastectomy breast cancer patients. *J Am Coll Surg.* 2014b;218(5):1038-48.
469. Jhaveri JD, Rush SC, Kostroff K, Derisi D, Farber LA, Maurer VE, et al. Clinical outcomes of postmastectomy radiation therapy after immediate breast reconstruction. *Int J Radiat Oncol Biol Phys.* 2008;72(3):859-65.
470. Man LX, Selber JC, Serletti JM. Abdominal wall following free TRAM or DIEP flap reconstruction: A meta-analysis and critical review. *Plast Reconstr Surg.* 2009;124(3):752-64.
471. Egeberg A, Rasmussen MK, Sorensen JA. Comparing the donor-site morbidity using DIEP, SIEA or MS-TRAM flaps for breast reconstructive surgery: A meta-analysis. *J Plast Reconstr Aesthet Surg.* 2012;65(11):1474-80.
472. Atisha D, Alderman AK. A systematic review of abdominal wall function following abdominal flaps for postmastectomy breast reconstruction. *Ann Plast Surg.* 2009;63(2):222-30.
473. Khansa I, Momoh AO, Patel PP, Nguyen JT, Miller MJ, Lee BT. Fat necrosis in autologous abdomen-based breast reconstruction: A systematic review. *Plast Reconstr Surg.* 2013;131(3):443-52.
474. Gart MS, Smetona JT, Hanwright PJ, Fine NA, Bethke KP, Khan SA, et al. Autologous options for postmastectomy breast reconstruction: A comparison of outcomes based on the American College of Surgeons National Surgical Quality Improvement Program. *J Am Coll Surg.* 2013;216(2):229-38.
475. Sailon AM, Schachar JS, Levine JP. Free transverse rectus abdominis myocutaneous and deep inferior epigastric perforator flaps for breast reconstruction: A systematic review of flap complication rates and donor-site morbidity. *Ann Plast Surg.* 2009;62(5):560-3.
476. Chang EI, Liu TS, Festekjian JH, Da Lio AL, Crisera CA. Effects of radiation therapy for breast cancer based on type of free flap reconstruction. *Plast Reconstr Surg.* 2013;131(1):1e-8e.

477. Chun YS, Sinha I, Turko A, Yueh JH, Lipsitz S, Pribaz JJ, et al. Comparison of morbidity, functional outcome, and satisfaction following bilateral TRAM versus bilateral DIEP flap breast reconstruction. *Plast Reconstr Surg.* 2010;126(4):1133-41.
478. Garvey PB, Salavati S, Feng L, Butler CE. Perfusion-related complications are similar for DIEP and muscle-sparing free TRAM flaps harvested on medial or lateral deep inferior epigastric Artery branch perforators for breast reconstruction. *Plast Reconstr Surg.* 2011;128(6):581e-9e.
479. Momoh AO, Colakoglu S, Westvik TS, Curtis MS, Yueh JH, de Blacam C, et al. Analysis of complications and patient satisfaction in pedicled transverse rectus abdominis myocutaneous and deep inferior epigastric perforator flap breast reconstruction. *Ann Plast Surg.* 2012;69(1):19-23.
480. Nelson JA, Guo Y, Sonnad SS, Low DW, Kovach SJ, 3rd, Wu LC, et al. A comparison between DIEP and muscle-sparing free TRAM flaps in breast reconstruction: A single surgeon's recent experience. *Plast Reconstr Surg.* 2010;126(5):1428-35.
481. Tong WM, Bazakas A, Hultman CS, Halvorson EG. The transition from pedicle transverse rectus abdominis myocutaneous to perforator flap: What is the cost of opportunity? *Ann Plast Surg.* 2012;68(5):489-94.
482. Davila AA, Mioton LM, Chow G, Wang E, Merkow RP, Bilimoria KY, et al. Immediate two-stage tissue expander breast reconstruction compared with one-stage permanent implant breast reconstruction: A multi-institutional comparison of short-term complications. *J Plast Surg Hand Surg.* 2013;47(5):344-9.
483. Macadam SA, Ho AL, Cook EF, Jr., Lennox PA, Pusic AL. Patient satisfaction and health-related quality of life following breast reconstruction: Patient-reported outcomes among saline and silicone implant recipients. *Plast Reconstr Surg.* 2010;125(3):761-71.
484. Pompei S, Arelli F, Labardi L, Marcasciano F, Caravelli G, Cesarini C, et al. Breast reconstruction with polyurethane implants: Preliminary report. *Eur J Plast Surg.* 2012;35(6):441-7.
485. Singh N, Reaven NL, Funk SE. Immediate 1-stage vs. tissue expander postmastectomy implant breast reconstructions: A retrospective real-world comparison over 18 months. *J Plast Reconstr Aesthet Surg.* 2012;65(7):917-23.
486. Christensen BO, Overgaard J, Kettner LO, Damsgaard TE. Long-term evaluation of postmastectomy breast reconstruction. *Acta Oncol.* 2011;50(7):1053-61.
487. Costa MA, Rommer E, Peric M, Nguyen TJ, Shahabi A, Davis GB, et al. Incidence of surgical-site infection is not affected by method of immediate breast reconstruction. *Plast Reconstr Surg.* 2013;132(1):20e-9e.
488. Crosby MA, Card A, Liu J, Lindstrom WA, Chang DW. Immediate breast reconstruction and lymphedema incidence. *Plast Reconstr Surg.* 2012;129(5):789e-95e.
489. Crosby MA, Garvey PB, Selber JC, Adelman DM, Sacks JM, Villa MT, et al. Reconstructive outcomes in patients undergoing contralateral prophylactic mastectomy. *Plast Reconstr Surg.* 2011;128(5):1025-33.
490. Fischer JP, Nelson JA, Cleveland E, Sieber B, Rohrbach JI, Serletti JM, et al. Breast reconstruction modality outcome study: A comparison of expander/implants and free flaps in select patients. *Plast Reconstr Surg.* 2013;131(5):928-34.
491. Levine SM, Patel N, Disa JJ. Outcomes of delayed abdominal-based autologous reconstruction versus latissimus dorsi flap plus implant reconstruction in previously irradiated patients. *Ann Plast Surg.* 2012;69(4):380-2.
492. Mioton LM, Smetona JT, Hanwright PJ, Seth AK, Wang E, Bilimoria KY, et al. Comparing thirty-day outcomes in prosthetic and autologous breast reconstruction: A multivariate analysis of 13,082 patients? *J Plast Reconstr Aesthet Surg.* 2013;66(7):917-25.

493. Monrigal E, Dauplat J, Gimbergues P, Le Bouedec G, Peyronie M, Achard JL, et al. Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study. *Eur J Surg Oncol.* 2011;37(10):864-70.
494. Pestana IA, Campbell DC, Bharti G, Thompson JT. Factors affecting complications in radiated breast reconstruction. *Ann Plast Surg.* 2013;70(5):542-5.
495. Winters ZE, Haviland J, Balta V, Benson J, Reece-Smith A, Betambeau N. Integration of patient-reported outcome measures with key clinical outcomes after immediate latissimus dorsi breast reconstruction and adjuvant treatment. *Br J Surg.* 2013;100(2):240-51.
496. Yueh JH, Slavin SA, Adesiyun T, Nyame TT, Gautam S, Morris DJ, et al. Patient satisfaction in postmastectomy breast reconstruction: A comparative evaluation of DIEP, TRAM, latissimus flap, and implant techniques. *Plast Reconstr Surg.* 2010;125(6):1585-95.
497. Hart AM, Lechowicz MJ, Peters KK, Holden J, Carlson GW. Breast implant-associated anaplastic large cell lymphoma: Report of 2 cases and review of the literature. *Aesthet Surg J.* 2014;34(6):884-94.
498. Shah C, Kundu N, Arthur D, Vicini F. Radiation therapy following postmastectomy reconstruction: A systematic review. *Ann Surg Oncol.* 2013;20(4):1313-22.

# **Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer**

## **Appendices**

[Back to Cover Page](#)[Back to Section 3](#)[Back to Section 5](#)**Appendix 1: Participants, Affiliations, and Conflict of Interest Declarations****Table A1-1. Members of the Breast Reconstruction Working Group.**

Name and specialty	Affiliation	Declarations of Potential Conflicts of Interest
Toni Zhong Plastic surgery	University Health Network, Toronto, ON <ul style="list-style-type: none"> <li>• Plastic and Reconstructive Surgery</li> <li>• Director, Breast Reconstruction Program</li> <li>• Belinda Stronach Chair of UHN Breast Reconstructive Surgery</li> </ul> University of Toronto, Toronto, ON <ul style="list-style-type: none"> <li>• Adjunct Scientist, Canada Institute for Clinical Evaluative Sciences</li> <li>• Associate Professor, Institute of Health Policy, Management and Evaluation</li> <li>• Associate Professor, Department of Surgery</li> </ul>	None
Muriel Brackstone Surgical oncologist	London Regional Cancer Program, London, ON University of Western Ontario, London, ON <ul style="list-style-type: none"> <li>• Professor, Departments of Surgery and Oncology</li> <li>• Chair/Chief of General Surgery, Department of Surgery</li> </ul> Medical Director, Breast Care Clinic, St Joseph's Hospital, London, ON	None
Simon Frank Plastic surgery	Department of Surgery, The Ottawa Hospital, Ottawa, ON Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Ottawa, Ottawa, ON	None
Renee Hanrahan General surgery; oncologic and oncoplastic/ reconstructive breast surgery	Deputy Chief, Department of Surgery, Royal Victoria Regional Health Care Centre, Barrie Regional Surgical Oncology Lead, LHIN 12, Cancer Care Ontario Adjunct Lecturer, University of Toronto, Toronto, ON Clinical Associate, McMaster University, Hamilton, ON	None
Danny Vesprini Radiation oncology	Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Hospital, Toronto, ON Affiliate scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, ON Assistant Professor, Department of Radiation Oncology, University of Toronto, Toronto, ON	None
Christiaan Stevens Radiation oncology	Head, Radiation Treatment Program, and Medical Director, Royal Victoria Hospital, Barrie, ON Staff Radiation Oncologist, North Simcoe Muskoka Regional Cancer Program	Honoraria for chairing or moderating 2 speaker series on updates in oncological advancements to regional surgical, medical, and radiation oncologists.

	Adjunct Lecturer, Department of Radiation Oncology; Lecturer, Department of Family and Community Medicine, University of Toronto, Toronto, ON	
Frances C Wright General surgery	General Surgeon, Department of Surgery, Sunnybrook Health Sciences Centre Provincial Head of Surgical Oncology, Ontario Health (Cancer Care Ontario) Affiliate Scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute Professor, Department of Surgery and General Surgery; Professor, Health Policy, Management and Evaluation, University of Toronto, Toronto, ON	None
Vivian Miragias Patient Representative		None
Alyssa Vito Patient Representative		Senior scientist, POINT Biopharma, a clinical-stage biotech company making cancer therapies Grant Review Panel, The Canadian Cancer (\$1000 honorarium) Vanier Canada Graduate Scholarship and smaller grants from other cancer funding agencies during graduate school (graduated April 2021)
Glenn George Fletcher Health Research Methodologist	Program in Evidence-Based Care (PEBC), McMaster University	None

**Table A1-2. Members of the Expert Panel**

Name and specialty	Affiliation	Declarations of Potential Conflicts of Interest
Margaret Anthes Radiation Oncology	Thunder Bay Regional Health Sciences Centre	None
Petrina Causer Diagnostic Radiology	North York General Hospital	None
Daniel Charleton General Surgery	St. Mary's General Hospital	Honoraria for interviews with Canada Market Research to discuss new systemic therapy for breast cancer
Erin Cordeiro General Surgery	The Ottawa Hospital	None
Christopher Coroneos Plastic Surgery	Juravinski Cancer Centre; Division of Plastic Surgery, McMaster University; Department of Health Research Methods, Evidence, and Impact, McMaster University	RCTs on patient education and negative pressure wound therapy for the abdominal closure of free flap; several editorial/commentary/opinion pieces
Andrea Eisen Medical Oncology	Sunnybrook Health Sciences Centre; Juravinski Cancer Centre; OH (CCO)	None
Medhat El Mallah Radiation Oncology	Lakeridge Health	None
Kristen Gyetvai General Surgery	Windsor Regional Hospital	None
Joan Lipa Plastic Surgery	Sunnybrook Health Sciences Centre	Spouse is part owner of Clearpoint Medical; managerial responsibility as Chair of the Division of Plastic, Reconstructive and Aesthetic Surgery at University of Toronto (grants from Mentor Corporation and Allergan)



		[Abbvie] to support Journal Clubs, Resident Research Awards, Fellowship training/educational grants); co-supervisor of clinical fellow who receives educational grant from Allergan (administered by University of Toronto Advancement Office); on Board of Managers for MicroSurge Management (unpaid) which manages medical/surgical society meetings
Michael Lock Radiation Oncology	London Health Sciences Centre	None
Talia Mancuso Genetic Counsellor/OBSP High Risk Navigator	Sunnybrook Health Sciences Centre	None
Glykeria Martou Plastic Surgery	Kingston Health Sciences Centre	None
Fahima Osman General Surgery	North York General Hospital	Owner of MyJourney Health Inc (digital platform)
Elzbieta Slodkowska Pathology	Sunnybrook Health Sciences Centre	None

**Table A1-3. Members of the Report Approval Panel**

Name	Affiliation	Declarations of Potential Conflicts of Interest
Jonathan Sussman	Department of Oncology, McMaster University	None
Donna Maziak	Department of Surgery and Department of Epidemiology and Community Medicine, University of Ottawa; Thoracic Surgery, The Ottawa Hospital	None
William Evans	Professor Emeritus, Department of Oncology, McMaster University; Ontario Health (Cancer Care Ontario)	<p>Employment with Ontario Health Consulting</p> <ul style="list-style-type: none"> <li>Reformulary Committee - provide advice on new drugs for private insurance plans (monthly meetings)</li> <li>BMS Access Expert Community - provide advice on the early development of new products</li> <li>Boehringer Ingelheim - consultation on access to biomarkers in Canada</li> <li>Ottawa conference on smoking cessation - speaker</li> <li>Lilly- consult on abemaciclib; early phase oncology payer advisory Board</li> <li>Kite/Gilead -International Advisory Board on CAR T cell therapy for multiple myeloma</li> </ul>

**Table A1-4. Targeted Peer Reviewers**

Name	Affiliation	Declarations of Potential Conflicts of Interest
Stephanie Wong	Departments of Surgery and Oncology, McGill University; Segal Cancer Centre, Jewish General Hospital, Montreal, QC	None

Martin LeBlanc	Division of Plastic and Reconstructive Surgery, Dalhousie University, Halifax, NS	None
May Lynn Quan	Professor in the Departments of Surgery, Oncology, and Community Health Sciences, University of Calgary	None

In accordance with the PEBC Conflict of Interest (COI) Policy, the Working Group, Expert Panel members, RAP members, and external reviewers were asked to disclose potential conflicts of interest. Declarations are summarized in the above tables. The COIs declared above did not disqualify any individuals from performing their designated role in the development of this guideline, in accordance with the PEBC COI Policy. To obtain a copy of the policy, please contact the PEBC office by email at [ccopgi.mcmaster.ca](mailto:ccopgi.mcmaster.ca)

[Back to Cover Page](#)

[Back to Section 3 Search](#)

[Back to Section 4 Methods](#)

## Appendix 2: Literature Search Strategy

### Websites searched for Guidelines

Searched September 30 to Oct 5, 2021 (not available November 2022 - March 2023)

ECRI Guidelines Trust Database: <https://guidelines.ecri.org/> (being restructured, temporarily unavailable)

NICE Evidence Search: <https://www.evidence.nhs.uk/> (discontinued)

Canadian Partnership Against Cancer, Cancer Guidelines Database (CPAC Database): <https://www.partnershipagainstcancer.ca/> [unavailable]

Searched September 30 to Oct 8, 2021 and updated November 3, 2022

CPG Infobase: Clinical Practice Guidelines from the Canadian Medical Association (CMA): <https://www.cma.ca/En/Pages/clinical-practice-guidelines.aspx>

Agency for Healthcare Research and Quality: AHRQ (US): <https://www.ahrq.gov/research/findings/evidence-based-reports/>

NIHR (UK) HTA: <https://evidence.nihr.ac.uk/browse-content/>

CADTH (Canada): <https://www.cadth.ca/search?keywords>

BC Cancer Agency <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-guidelines>

Material reorganized at time of update <http://www.bccancer.bc.ca/health-professionals/clinical-resources>

Alberta Health service, cancer guidelines: <https://www.albertahealthservices.ca/info/cancerguidelines.aspx>

Saskatchewan Cancer Agency  
[http://www.saskcancer.ca/index.php?option=com\\_content&view=article&id=53%3Aclinical-practice-guidelines&catid=25%3Aclinical-resources-category](http://www.saskcancer.ca/index.php?option=com_content&view=article&id=53%3Aclinical-practice-guidelines&catid=25%3Aclinical-resources-category)

Cancer Care Manitoba: <https://www.cancercare.mb.ca/search/index.html>

Cancer Care Nova Scotia: <http://www.cdha.nshealth.ca/cancer-care-program>

NICE (UK) <https://www.nice.org.uk/guidance>

SIGN (UK) <https://www.sign.ac.uk/our-guidelines/>

ASCO <https://www.asco.org/research-guidelines/quality-guidelines/guidelines>

ESMO <https://www.esmo.org/guidelines/breast-cancer>

GIN <https://g-i-n.net/international-guidelines-library/>

British Association of Dermatologists  
<https://www.bad.org.uk/healthcare-professionals>

Cancer Council Australia <https://wiki.cancer.org.au/australia/Guidelines>

Geneva Foundation for Medical Education and Research <https://www.gfmer.ch/>

World Health Organization <https://www.who.int/publications/who-guidelines>

National Cancer Control Initiative (AUS) <https://www.canceraustralia.gov.au/publications-and-resources/clinical-practice-guidelines>

Medical Oncology Group of Australia <https://www.moga.org.au/about-moga>

Cancer Research UK <https://www.cancerresearchuk.org/about-us>

NHS (UK) <https://www.nhs.uk/>

Association of Breast Surgery (ABS), UK  
<https://associationofbreastsurgery.org.uk/professionals/clinical/guidance-platform>

British Association of Plastic Reconstructive and Aesthetic Surgeons (BAPRAS).  
<https://www.bapras.org.uk/professionals/clinical-guidance>

EUSOMA <https://www.eusoma.org/en/recommendations/other%2dguidelines/1-149-1->

58 guidelines were initially identified, and none were considered suitable for endorsement

## Search Feb 24, 2023. Medline, Embase, EBM Reviews - Cochrane Central Controlled Trials

## Database:

Embase &lt;1974 to 2023 February 23&gt;

EBM Reviews - Cochrane Central Register of Controlled Trials &lt;January 2023&gt;

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review &amp; Other Non-Indexed Citations, Daily and Versions &lt;1946 to February 23, 2023&gt;

Line	Query	Number of citations
1	exp breast neoplasms/ or exp breast cancer/ or paget's disease, mammary/ or exp Paget nipple disease/ or (ductal carcinoma or lobular carcinoma or ductolubular carcinoma or DCIS or LCIS).ti,kw. or ((breast: or mammar: or nipple:) adj3 (cancer: or tumour: or tumor: or neoplasm: or carcinoma: or adenocarcinoma: or Paget: disease)).ti,kw. or exp mastectomy/ or (mastectom: or PMRT or postmastectomy: or post-mastectomy: or post mastectom:).mp. [Breast Cancer terms]	1,108,147
2	1 and (exp mammaplasty/ or exp breast reconstruction/ or exp breast implants/ or breast endoprosthesis/ or exp breast prosthesis/ or implants, artificial/ or prosthesis/ or silicones/ or ((implant or implants or reconstruct: or autologous) adj4 (breast or mammar:)).ti,ab,kw.) [Breast Cancer and (Reconstruction or Implants)]	32,469
3	breast reconstruction.ti,kw,ab. or exp nipple-sparing mastectomy/ or ((prepectoral or pre-pectoral or subpectoral or sub-pectoral or premuscular or pre-muscular or submuscular or sub-muscular or submammary or sub-mammary or subglandular or sub-glandular or retroglandular or above muscle or subfascial or retropectoral or under muscle or dual-plane) and (breast: or mammar:)).mp. or Nipples/bs, dg, ir, re, su, tr or ((nipple: or skin:) adj4 (sparing or mastectomy)).mp. or nipple areola.mp. or nipple-areola.mp. or (tumo*r: adj3 nipple).mp. [Breast Reconstruction Terms]	35,701
4	(exp Surgical Flaps/ or exp deep inferior epigastric perforator flap/ or exp tissue flap/ or exp epigastric arteries/ or exp Transplantation, Autologous/ or exp Autografts/ or (diep or deep inferior epigastric or TRAM or transverse rectus abdomin: or pedicle or flap or flaps or autologous tissue or transverse rectus abdomin: or SIEA or superficial inferior epigastric artery or latissimus dorsi or thoracodorsal artery perforator or TDAP or lumbar artery perforator or LAP flap or LAP free flap or gluteal free flap or gluteal artery perforator or GAP flap or superior gluteal artery perforator or SGAP or inferior gluteal artery perforator or IGAP or upper gracilis or TUG or VUP or DUG or profunda artery perforator or PAP flap or lateral thigh perforator or LTP).mp.) and (breast: or mammary:).mp. [Autologous Breast Reconstruction Terms]	27,715
5	exp bioabsorbable mesh/ or exp surgical mesh/ or exp tissue scaffold/ or (bioabsorbable mesh or surgical mesh or surgical scaffold: or tissue scaffold:).mp. or exp acellular dermal matrix/ or exp Acellular Dermis/ or exp skin allograft/ or exp biodegradable implant/ or exp Tissue Scaffolds/ or exp Absorbable Implants/ or (((acellular or decellular: or dermal or biologic: or synthetic or absorbable) adj2 (matrix or matrices or matrixes or scaffold: or mesh)) or (acellular adj2 derm:) or ADM or HADM).mp. or (AlloDerm or Allomax or Cortiva or DermaCell or DermaMatrix or DermaPure or FlexHD or Flex HD or Graftjacket or hMatrix or Neoform or Repriza or BellaDerm or SimpliDerm or MODA or "matrice omologa dermica acellulata" or Epiflex or Megaderm).mp. or (GalaFlex: or GalaSHAPE: or GalaForm: or Phasix or Seri Surgical Scaffold or Seri or TIGR).mp. [ADM or synthetic matrix]	161,344
6	exp Transplantation, Autologous/ or exp autograft/ or exp autotransplantation/ or exp Adipose Tissue/tr or exp adipose tissue/su or ((autologous adj2 graft:) or (autologous adj2 fat:) or (fat: adj2 graft:) or (adipose adj2 derived) or lipofill: or lipomodel: or lipoinject: or fat transfer: or fat injection or BRAVA or Renuva).mp. [Autologous Fat Grafting]	163,641
7	(1 or 2 or 3 or 4) and (5 or 6) [(breast cancer or reconstruction) and (ADM or fat grafting)]	10,223
8	(2 or 3 or 4) not 7 [reconstruction other than ADM or fat grafting]	50,085
9	exp phase 3 clinical trial/ or exp "phase 3 clinical trial (topic)"/ or exp clinical trial, phase iii/ or exp clinical trials, phase iii as topic/ or exp phase 4 clinical trial/ or exp "phase 4 clinical trial (topic)"/ or exp clinical trial, phase iv/ or exp clinical trials, phase iv as topic/ or exp randomized controlled trial/ or exp "randomized controlled trial (topic)"/ or exp randomized controlled trials as topic/ or exp controlled clinical trial/ or "controlled clinical	5,317,659

	trial (topic)"/ or controlled clinical trials as topic/ or exp randomization/ or exp random allocation/ or exp double-blind method/ or exp single-blind method/ or exp double blind procedure/ or exp single blind procedure/ or exp triple blind procedure/ or exp placebos/ or exp placebo/ or ((exp phase 2 clinical trial/ or exp "phase 2 clinical trial (topic)"/ or exp clinical trial, phase ii/ or exp clinical trials, phase ii as topic/ or exp clinical trial/ or exp prospective study/) and random\$.tw.) or (((phase II or phase 2 or clinic\$) adj3 trial\$) and random\$).tw. or ((singl\$ or double\$ or treble\$ or tripl\$) adj3 (blind\$ or mask\$ or dummy)).tw. or placebo?.tw. or (allocat: adj2 random:).tw. or (rct or phase III or phase IV or phase 3 or phase 4 or randomi\$: or randomly).tw. or (random\$ adj3 trial\$).mp. or "clinicaltrials.gov".mp. [RCT search filter]	
10	(7 or 8) and 9 [RCTs]	4418
11	(7 or 8) and (systematic review: or meta-analys: or metaanalys: or meta analy:).ti.pt.	1312
12	(7 or 8) and (*practice guideline/ or practice guideline:.ti.)	136
13	(7 or 8) not (10 or 11 or 12) not (abstract or letter or comment or editorial or news or note).pt.	43,747
14	remove duplicates from 10	2789
15	remove duplicates from 11	821
16	remove duplicates from 12	123
17	limit 13 to yr="2022 -Current"	3352
18	limit 13 to yr="2020 - 2021"	5513
19	limit 13 to yr="2018 - 2019"	4290
20	limit 13 to yr="2015 - 2017"	5583
21	limit 13 to yr="2012 - 2014"	4735
22	limit 13 to yr="2008 - 2011"	4761
23	limit 13 to yr="2001 - 2007"	5341
24	limit 13 to yr="1990 - 2000"	5716
25	13 not (17 or 18 or 19 or 20 or 21 or 22 or 23 or 24)	4456
26	remove duplicates from 17	2115
27	remove duplicates from 18	3510
28	remove duplicates from 19	2735
29	remove duplicates from 20	3534
30	remove duplicates from 21	2883
31	remove duplicates from 22	2911
32	remove duplicates from 23	3323
33	remove duplicates from 24	3794
34	remove duplicates from 25	3180
35	or/26-34	27,985
36	26 or 27 or 28	8360
37	or/29-31	9328
38	32 or 33	7117
39	34	3180

Feb 28, 2023: Added truncation mark : to nipple areola and nipple-areola terms to capture areolar in line 3 (nipple areola: or nipple-areola:).mp  
After deduplication was 334 results

17-10 v2 search Feb 24, 2023. EBM Reviews - Cochrane Database of Systematic Reviews 2005 -


Database:

EBM Reviews - Cochrane Database of Systematic Reviews &lt;2005 to February 22, 2023&gt;

Line	Query	Number of citations
1	(ductal carcinoma or lobular carcinoma or ductolobular carcinoma or DCIS or LCIS or ((breast: or mammar: or nipple:) adj3 (cancer: or tumour: or tumor: or neoplasm: or carcinoma: or adenocarcinoma: or Paget: disease)) or (mastectomy: or PMRT or postmastectomy: or post-mastectomy: or post mastectomy:)).mp. [Breast Cancer terms]	557
2	1 and ((implant or implants or reconstruct: or autologous) adj4 (breast or mammar:)).mp. [Breast Cancer and (Reconstruction or Implants)]	23
3	(breast reconstruction or ((prepectoral or pre-pectoral or subpectoral or sub-pectoral or premuscular or pre-muscular or submuscular or sub-muscular or submammary or sub-mammary or subglandular or sub-glandular or retroglandular or above muscle or subfascial or retropectoral or under muscle or dual-plane) and (breast: or mammar:)) or ((nipple: or skin:) adj4 (sparing or mastectomy)) or nipple areola or nipple-areola or (tumo*r: adj3 nipple)).mp. [Breast Reconstruction Terms]	24
4	((diep or deep inferior epigastric or TRAM or transverse rectus abdomin: or pedicle or flap or flaps or autologous tissue or transverse rectus abdomin: or SIEA or superficial inferior epigastric artery or latissimus dorsi or thoracodorsal artery perforator or TDAP or lumbar artery perforator or LAP flap or LAP free flap or gluteal free flap or gluteal artery perforator or GAP flap or superior gluteal artery perforator or SGAP or inferior gluteal artery perforator or IGAP or upper gracilis or TUG or VUP or DUG or profunda artery perforator or PAP flap or lateral thigh perforator or LTP) and (breast: or mammary:)).mp. [Autologous Breast Reconstruction Terms]	32
5	(bioabsorbable mesh or surgical mesh or surgical scaffold: or tissue scaffold: or (((acellular or decellular: or dermal or biologic: or synthetic or absorbable) adj2 (matrix or matrices or matrixes or scaffold: or mesh)) or (acellular adj2 derm:) or ADM or HADM) or (AlloDerm or Allomax or Cortiva or DermACell or DermaMatrix or DermaPure or FlexHD or Flex HD or Graftjacket or hMatrix or Neoform or Repriza or BellaDerm or SimpliDerm or MODA or "matrice omologa dermica acellulata" or Epiflex or Megaderm) or (GalaFlex: or GalaSHAPE: or GalaForm: or Phasix or Seri Surgical Scaffold or Seri or TIGR)).mp. [ADM or synthetic matrix]	106
6	((autologous adj2 graft:) or (autologous adj2 fat:) or (fat: adj2 graft:) or (adipose adj2 derived) or lipofill: or lipomodel: or lipoinject: or fat transfer: or fat injection or BRAVA or Renuva).mp. [Autologous Fat Grafting]	64
7	(1 or 2 or 3 or 4) and (5 or 6) [(breast cancer or reconstruction) and (ADM or fat grafting)]	12
8	(2 or 3 or 4) not 7 [reconstruction other than ADM or fat grafting]	37
9	7 or 8	49

[Back to Cover Page](#)[Back to Section 4](#)[Back to Section 4 Results](#)

### Appendix 3: PRISMA Flow Diagram



Format adapted from: Page, 2021 (183)



**Appendix 4. Assessment of Bias in RCTs using the Cochrane Risk of Bias 2 (RoB2) Tool**

Study Analysis	Study ID	Experimental	Comparator	Outcome	D1	D2	D3	D4	D5	Overall
Intention-to-treat	<a href="#">NCT00639106</a> McCarthy, 2012 (386)	ADM	None	Postoperative pain; Pain in expansion phase						
Intention-to-treat	BREASTrial, stage I <a href="#">NCT00872859</a> Mendenhall, 2015 (397)	AlloDerm	DermaMatrix	Overall complications; other complication						
Intention-to-treat	BREASTrial, stage II <a href="#">NCT00872859</a> Mendenhall, 2017 (398)	AlloDerm	DermaMatrix	Overall complications; other complication						
Intention-to-treat	BREASTrial, stage III <a href="#">NCT00872859</a> Mendenhall, 2023 (399)	AlloDerm	DermaMatrix	Overall complications						
Intention-to-treat	<a href="#">NCT03145337</a> Broyles, 2021 (404)	AlloDerm RTU	FLEX HD pliable	Overall complications; other complication						
Per Protocol	REaCT investigators <a href="#">NCT03064893</a> Arnaout, 2021 (390)	Non-fenestrated AlloDerm RTU	DermACELL	Complications; QoL						
Intention-to-treat	Gentilucci, 2020 (161)	Expander, PMRT, fat grafting, expander-implant exchange	Expander, PMRT, expander-implant exchange (no fat grafting)	Soft adipose tissue thickness; complications; disability; aesthetics						
Per Protocol	BREAST Trial <a href="#">NCT02339779</a> Piatkowski, 2023 (168-171)	Fat grafting alone	Expander-implants	Breast-Q						

- Low risk of bias
- Some concerns
- High risk of bias

D1, Randomisation process ; D2, Deviations from the intended interventions; D3, Missing outcome data; D4, Measurement of the outcome; D5, Selection of the reported result

[Back to Cover Page](#)[Back to Section 4 Methods \(Data Extraction\)](#)[Back to Section 4 Results](#)[Back to Section 4 Results Q1](#)**Appendix 5: Quality Assessment by AMSTAR II of Systematic Reviews in Table 4-1\***

Citation	1. PICO components included	2. Protocol prior to review	3. Study design inclusion explanation	4. Comprehensive search strategy	5. Duplicate study selection	6. Duplicate data extraction	7. Details of excluded studies	8. Description of included studies	9a. RoB assessment (RCTs)	9b. RoB assessment (NRSIs)	10. Funding sources	14. Heterogeneity absent or discussed	15. Publication bias assessed	16. Reports COI	Overall rating of quality
Panayi, 2018 (42)	Y	Y	N	PY	N	N	Y	PY	N/A	Y	N	Y	N	Y	Moderate
Tan, 2022 (219)	Y	N	N	Y	N	N	N	Y	N/A	Y	N	Y	N	Y	Moderate
ElAbd, 2022 (43)	Y	N	N	PY	N	N	N	Y	N/A	Y	N	Y	N	Y	Moderate
Liu, 2022 (39)	Y	Y	N	PY	Y	N	N	Y	N/A	Y	N	Y	Y	Y	Moderate
Mortada, 2023 (40)	Y	Y	N	PY	N	N	N	Y	N/A	Y	N	Y	Y	Y	Moderate
Theocharidis, 2018	Y	PY	N	Y	Y	N	N	Y	N/A	N	N	Y	N	Y	Low
Mrad, 2022 (44)	Y	PY	N	Y	Y	N	N	Y	N/A	N	N	Y	N	PY	Low
Chung, 2021 (46)	Y	N	N	PY	N	N	N	Y	N/A	N	N	Y	Y	Y	Low
Bond, 2021 (45)	Y	N	N	Y	Y	N	Y	Y	N/A	Y	N	Y	Y	Y	Moderate
Chicco, 2021 (47)	Y	N	N	Y	N	N	Y	Y	N/A	N	N	Y	Y	Y	Low
Varghese, 2021 (48)	Y	Y	N	Y	Y	Y	N	Y	N/A	Y	N	Y	Y	Y	High
Spera, 2020 (220)	Y	N	PY	PY	Y	PY	N	Y	N/A	Y	N	Y	Y	Y	Moderate
Hong, 2021 (51)	Y	N	N	Y	Y	Y	N	Y	N/A	Y	N	Y	Y	Y	Moderate
Zugasti, 2021 (52)	Y	PY	N	PY	N	N	Y	Y	N/A	Y	N	Y	Y	PY	Moderate
Pu, 2018 (50)	Y	PY	N	Y	Y	N	N	Y	N/A	PY	N	Y	Y	Y	Low
Magill, 2017 (49)	Y	Y	N	Y	N	N	N	Y	N/A	N	N	Y	N	Y	Low
Liew, 2021 (53)	Y	Y	N	Y	Y	Y	N	Y	N/A	Y	N	Y	N	Y	High

\*AMSTAR II (197)

**Abbreviations:** COI, conflict of interest; NRSI, non-randomized study of intervention; PICO, population, intervention, comparison, and outcome; PY, probably yes; N, no; RCT, randomized controlled trial; RoB, risk of bias; Y, Yes; N/A, not applicable

[Back to Cover Page](#)[Back to Section 1](#)[Back to Section 2 \(Recommendations\)](#)

## Appendix 6: Question on Types of Breast Reconstruction from 17-10 Version 1 (January 2016, not updated)

### Recommendations from Section 2 and Systematic Review from Section 4

#### Recommendation 6: Autologous tissue versus implant-based reconstruction

- a) Women treated by mastectomy should be made aware that autologous tissue reconstruction and implant-based reconstruction are options for immediate or delayed reconstruction.
- b) Reconstruction methods should be selected based on patient and surgeon factors, because overall patient satisfaction and willingness to recommend reconstruction to others appear to be similar between autologous tissue and tissue-expander implant (TE/I)-based reconstructions. However, if women are candidates for either reconstruction, then they should be informed that TE/I reconstruction may be accompanied by a higher risk of reconstructive failure or soft tissue infection and that there is a trend toward decreased aesthetic satisfaction with TE/I reconstruction over time. In patients who have received textured implants, they should be informed of the risk for a rare type of lymphoma called anaplastic large cell lymphoma (ALCL) that is associated with textured implants.

#### Radiation setting:

- c) For women who have received prior RT to their breast as part of BCT, mastectomy with immediate autologous tissue reconstruction is the recommended option. Current evidence suggests that reconstruction using TE/I alone may be associated with an increased risk of complications.

#### Qualifying Statement

- Women desiring reconstruction in a previously radiated breast should be informed of the increased risk of complications compared with no radiation.

#### Key Evidence for Recommendation 6

- A systematic review by Tsoi et al. compared complications between TE/I and AAT reconstruction (467). This review included 14 studies of low to moderate quality with very small sample sizes. Findings from this review demonstrated a greater risk of reconstructive failure associated with TE/I than AAT reconstruction. Soft tissue infections were significantly higher in TE/I; however, infections requiring re-operation were not significantly different between TE/I and AAT reconstruction. Skin or flap necrosis was significantly higher in the AAT reconstruction group. No significant difference was observed in other complications such as wound dehiscence, deep vein thrombosis/pulmonary embolism, major complications, and reoperation.
- A second systematic review publication by Tsoi et al. compared patient-reported outcomes between TE/I reconstruction and AAT reconstruction (468). This review included 15 studies,

the majority of which were low quality. Levels of pain did not differ between types of reconstruction. General satisfaction with method of reconstruction evolved over time but essentially converged, with no significant difference between the two approaches. Aesthetic satisfaction remained constant in patients undergoing AAT reconstruction but declined over time following TE/I reconstruction. Overall patient satisfaction and willingness to recommend the surgery to others were similar between reconstruction types.

#### *Radiation setting:*

- Systematic reviews that compared the reconstructive options in patients who required PMRT reported that complications were significantly higher in the implant-based reconstruction group compared with the autologous tissue reconstruction group (467). In addition, a prospective single-centre study that examined 92 patients who underwent immediate reconstruction using autologous tissue (23 patients) compared with TE/I (69 patients) found that major complications, compromised functional status, and poor aesthetic outcomes were significantly associated with the use of TE/I (469).

#### **Interpretation of Evidence for Recommendation 6**

- Key outcomes used to inform the recommendations on autologous tissue versus implant-based reconstruction are adverse effects, patient satisfaction, and cosmesis of the final reconstructed result. Certainty of evidence for these outcomes is low, and the systematic reviews are made up of individual studies that are low in quality, have small numbers of patients, and there is repeated reporting of studies in the reviews. There is likely significant variability in the relative value that women would place on each of the key outcomes and this variability is expected to lead to different decisions regarding autologous tissue or implant-based reconstruction.
- Although some studies reported that tissue expander/implant reconstruction may be accompanied by a higher risk of reconstructive failure or soft tissue infection and that there is a trend toward decreased aesthetic satisfaction over time, the authors believe that this evidence is insufficient at this time to support one option being superior to the other in the absence of radiation.

#### **Recommendation 7 : Types of Autologous Tissue Reconstruction**

- In patients who will undergo unilateral autologous tissue reconstruction, pedicled TRAM, free TRAM, or DIEP flaps are all recommended options that are supported by positive patient-reported outcomes.
- In patients who will undergo bilateral autologous tissue reconstruction, DIEP flap is preferred over free or pedicled TRAM flap due to less functional disruption to the abdominal wall following surgery.
- Alternative autologous tissue donor types (e.g., gluteal flaps, thigh flaps) are suitable for selected patients in whom abdominal tissue is not available; however, the evidence on these types of reconstructions is very limited.
- All patients should be told of the risk of fat necrosis that can present as a nodule or mass after autologous tissue reconstruction, a benign condition that can mimic breast cancer

recurrence. The risk of fat necrosis is likely to be greater following DIEP flaps compared with TRAM flaps.

- LD flap with or without implants is another option to TE/I or autologous abdominal tissue reconstruction.

### Key Evidence for Recommendation 7

- One meta-analysis by Man et al. found approximately one-half the risk of abdominal bulge or hernia development following DIEP flaps compared with TRAM flaps (relative risk [RR], 0.49; 95% confidence interval [CI], 0.28 to 0.86) (470). Another meta-analysis showed a trend toward increased risk of abdominal bulge after TRAM flaps compared with DIEP flaps (RR, 0.80; 95% CI, 0.48 to 1.35;  $p=0.40$ ) (471).
- Objective measures of abdominal wall function using isometric dynamometry show that bilateral pedicled TRAM flaps suffer the most deficit (up to 40% deficit in trunk flexion and 9% deficit in trunk extension) and a significant decrease in ability to perform sit-up compared with DIEPs. Functional deficits assessed by physiotherapy measures also revealed the greatest deficit in both rectus and oblique muscles after bilateral pedicled TRAM flaps, followed by free TRAM, whereas DIEP flaps returned to their preoperative rectus and oblique muscle functions (472).
- The risk of fat necrosis has been found to be significantly greatest following DIEP flaps (14.4%,  $p<0.001$ ), followed by pedicled TRAM flaps (12.3%,  $p=0.04$ ), and free TRAM flaps (6.9%,  $P<0.001$ ) in a systematic review of 33 articles that analyzed more than 7233 flaps in 6394 patients (473).
- The largest retrospective national database study comparing 1079 LD flaps with 609 free flaps and 1608 pedicled TRAM flaps found that overall 30-day complications, flap failure and non-flap complications were all significantly lower in the LD group compared with the other two techniques (474).

### Interpretation of Evidence for Recommendation 7

Key outcomes used to inform the recommendations on the different types of autologous tissue reconstruction are adverse effects, QoL, and patient satisfaction. The certainty of the evidence for these outcomes is moderate. In terms of adverse effects, the trade-off between the development of compromised abdominal wall function and fat necrosis in the reconstructed breast needs to be presented to the patient in a balanced fashion, and the final choice between DIEP, free or pedicled TRAM flaps will be up to the individual patient. There is moderate evidence that the DIEP flap may be a superior option to pedicled TRAM flaps in the growing subgroup of patients wishing to undergo bilateral autologous reconstruction to better preserve their abdominal muscle function following surgery

## Section 4: Systematic Review

**Results and Discussion for Questions 4 only****CLINICAL QUESTIONS**

4. What are the risks and benefits associated with implant-based, autologous flap (i.e., deep inferior epigastric perforator [DIEP], transverse rectus abdominis myocutaneous [TRAM], superficial inferior epigastric artery [SIEA]) and combination (i.e., latissimus dorsi [LD] flap with implant) breast reconstruction?

***Clinical Question 4: Types of reconstruction******b) Comparisons between types of breast reconstruction******Systematic reviews***

Seven systematic reviews articles were identified that compared different types of breast reconstruction: two compared TE/I reconstructions with autologous abdominal reconstruction (467, 468) and five compared flap complications and/or donor site morbidity for various types of autologous abdominal reconstruction (470-473, 475).

Two publications by Tsoi et al. represented one systematic review comparing TE/I vs. autologous abdominal tissue (AAT) reconstruction for women with primary breast cancer: one presented patient-reported outcomes (468) and one presented surgical complication outcomes (467). Fourteen observational studies including 3244 reconstructed breasts were included that addressed surgical complications, all of which compared TE/I with one or more variations of TRAM flaps. Only six of the 14 studies involved more than 100 breasts and follow-up ranged from six to 60 months. Compared with patients receiving TE/I, patients undergoing AAT reconstruction were less likely to have reconstructive failure (1% vs. 5%; RR, 0.14; 95% CI, 0.06 to 0.32) and surgical site infections (6% vs. 9%; RR, 0.37; 95% CI, 0.25 to 0.55) but more likely to experience skin or flap necrosis (12% vs. 5%; RR, 2.79; 95% CI, 1.87 to 4.17). No statistically significant difference was demonstrated for infections leading to reoperation (1% vs. 0%; RR, 0.97; 95% CI, 0.22 to 4.16), hematoma or seroma (4% vs. 7%; RR, 0.56; 95% CI, 0.31 to 1.00), skin or flap necrosis requiring reoperation (10% vs. 3%; RR, 2.76; 95% CI, 0.80 to 9.46), wound dehiscence, deep venous thrombosis, pulmonary embolism, major complications, or reoperations, although results suggested a trend toward a lower seroma and hematoma rate in women undergoing AAT reconstruction. Tsoi et al. (467) also reported on complications that were specific to each method of reconstruction. In seven studies, the capsular contracture rate following TE/I reconstruction ranged from 0.0% to 33.3%. Complications specific to women undergoing AAT reconstruction included hernia, abdominal bulge, and impaired trunk function. In a subgroup of patients who received postoperative RT, major complications were less frequently reported in women who received AAT reconstruction compared with TE/I (18% vs. 24%; RR, 0.46; 95% CI, 0.29 to 0.73).

In the Tsoi et al. review (468), 15 articles representing nine studies (1393 patients) were identified that compared patient-reported outcomes between TE/I and AAT reconstruction. All abdominal tissue reconstructions were free or pedicled TRAM flaps and the studies included both immediate and delayed reconstructions. Four smaller studies of less than 100 patients reported similar rates of general and aesthetic satisfaction for the two reconstructive approaches while the five larger studies detected a tendency toward better satisfaction in women undergoing autologous tissue reconstruction. One study suggested that patients with AAT reconstruction had stable aesthetic satisfaction over time while patients with TE/I experienced declining aesthetic satisfaction. The limited data available for psychosocial and

functional outcomes suggest that reconstructive approach does not have a great impact on these outcomes.

Five systematic reviews compared flap complications and/or donor site morbidity for different types of AAT reconstruction. The most recent review by Khansa et al. focused specifically on fat necrosis and included 70 observational studies (473). The overall pooled fat necrosis rate was found to be 11.3% across 41 studies (10,764 flaps). Thirty-three articles reported fat necrosis by flap type: DIEP (14.4% fat necrosis), pedicled TRAM (12.3%), SIEA (8.1%), and free TRAM (6.9%). Predictors of necrosis included obesity, RT, active smoking, and abdominal scars. An older review by Sailon et al. published in 2009 reported a significant difference between DIEP and free TRAM flaps in overall necrosis rates across eight studies (25.5% vs. 11.3%;  $p < 0.001$ ) and total necrosis rates (4.2% vs. 1.6%;  $p = 0.044$ ) but no difference in partial necrosis rates (3.5% vs. 11.2%;  $p = 0.057$ ) (475). The 2012 meta-analysis by Egeberg et al. assessed donor site morbidity in five comparative observational studies (471). The risk of bulging and hernia was not significantly different between DIEP and muscle-sparing TRAM flap reconstruction. A 2009 review by Man et al. pooled the results of six studies comparing DIEP with free TRAM flaps; however, they reported significantly lower risk for hernia and bulge in women with DIEP flaps (RR, 0.49; 95% CI, 0.28 to 0.86) (470). Flap-related complications were more frequent with DIEP flaps while donor-site morbidity was more common with free TRAM flaps. Objective measures of abdominal function were reported to be slightly better for DIEP flaps than TRAM flaps in a 2009 systematic review by Atisha et al. (472); however, this did not appear to translate into deficits in performance of activities of daily living.

### *Primary studies*

Twenty-two primary studies were identified that were published between 2010 and 2013 that compared different types of breast reconstruction. Seven compared two or more types of autologous tissue reconstruction (474, 476-481), four compared different approaches to implant-based reconstruction (482-485) and 11 included patients with autologous tissue- and implant-based reconstruction (486-496) (see Appendix 6 Table 1).

Of the four studies investigating different approaches to implant-based reconstruction, one compared saline vs. silicone implants (483), two compared one-stage immediate implant reconstruction with the use of tissue expanders (482, 485) and one compared tissue expanders vs. expandable textured implants vs. polyurethane implants (484). Macadam et al. reported no significant difference between saline and silicone implants with respect to Satisfaction with Outcome, overall QoL, Physical Well-Being, or Sexual Well-Being in 143 patients. Satisfaction with Reconstructed Breasts, Psychological Well-Being, and Physical Well-Being were higher in the silicone implant group, however. Based on a retrospective review of insurance claims data, Singh et al. reported no significant difference in complication rates between one-stage immediate implant reconstruction and reconstruction using tissue expanders (485). A larger retrospective analysis of a national database by Davila et al. demonstrated significantly higher rates of 30-day morbidity and prosthesis failure in women undergoing one-stage direct implant compared with tissue expanders but no difference in reconstruction-related complications overall, wound disruption, surgical site infection, reoperation, or major medical complications (482). The study by Pompei et al. comparing tissue expanders, expandable textured implants, and polyurethane implants reported complication rates but did not conduct tests of statistical significance (484). The overall complication rate was highest for tissue expanders (14.7%) and lowest for polyurethane implants (5.0%).

Six retrospective single-centre studies included both a TRAM and a DIEP group: three investigated pedicled TRAM flaps (477, 479, 496) and three investigated free TRAM flaps (476, 478, 480). In one study, there was no significant difference between bilateral pedicled TRAM and DIEP in abdominal hernia or bulge or seroma/hematoma in the donor or recipient site;

however, donor site partial skin loss and wound dehiscence and recipient site fat necrosis were more frequent in the DIEP group (477). Another study reported no difference between pedicled TRAM and DIEP for flap loss, major fat necrosis, hematoma/seroma, infection, open wound, mastectomy skin loss, or aesthetic satisfaction but better general patient satisfaction in the DIEP group. Yueh et al. reported no significant difference in general or aesthetic satisfaction between pedicled TRAM and DIEP in a logistic regression analysis (496). Nelson et al. reported no significant difference between muscle-sparing free TRAM and DIEP flaps for intraoperative complications or postoperative minor or late complications but a higher rate of postoperative major complications in the DIEP group (arterial or venous thrombosis and flap necrosis) (480). Garvey et al. detected no significant difference in fat necrosis, partial flap necrosis, or overall complications between muscle-sparing TRAM and DIEP flaps (478). Chang et al. similarly reported no difference in early complications between free TRAM, muscle-sparing free TRAM, and DIEP flaps (476).

Nine studies included patients who received LD flap reconstructions: five included a group with LD flap alone (474, 486, 493, 495, 496) and six included LD flaps combined with an implant (487-489, 491, 493, 495). Yueh et al. reported that general and aesthetic satisfaction was lower for women receiving LD flap compared with abdominal flaps (496). Christensen et al. compared LD flaps with pedicled TRAM flaps and implants and concluded that LD flaps were associated with significantly higher patient satisfaction than implants (486). None of the 26 women who had LD flap reconstructions had major complications. Gart et al. reported that women with LD flaps had lower rates of overall complications, surgical site infections, and flap failure than free flaps and pedicled TRAM flaps (474). Monrigal et al. included women with LD flap reconstruction and LD flap reconstruction with implant (493). LD reconstructions had less necrosis than TRAM flap reconstructions and required fewer surgical revisions. Winters et al. compared autologous LD flap with LD flap plus implant and reported no statistically significant difference in early complications up to three months after surgery, long-term complications, or health-related QOL (495). Role functioning and pain were significantly better in the group that received LD flaps with implant compared with LD flaps alone. Levine et al. compared delayed LD flaps plus implant with delayed autologous abdominal flap reconstruction in previously irradiated patients (491). No statistically significant differences were found between groups in complications overall, reconstruction failures, or incidence of lymphedema. Costa et al. compared immediate LD flaps plus implant with implants alone and autologous reconstruction. There was no statistically significant difference in incidence of surgical site infections after adjustment for confounding factors (487). Another study by Crosby et al. of women undergoing reconstruction for unilateral breast cancer with a synchronous contralateral prophylactic mastectomy and reconstruction did not statistically compare outcomes between types of reconstruction, but the authors concluded that the risk of postoperative complications was similar for index mastectomy with reconstruction and prophylactic mastectomy with reconstruction (489).



**Appendix 6 Table 1. Breast reconstruction types.**

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
<b>Chun 2010 (477)</b> Retrospective, medical record review, single centre, consecutive patients	Immediate (n=86) or delayed (n=19) TRAM or DIEP; USA	Average 6.2 yrs (TRAM) and 2.3 yrs (DIEP)	Bilateral pTRAM Bilateral DIEP	105 58	Abdominal hernia: 2.9% vs. 0% (p=0.20) Abdominal bulge: 2.9% vs. 6.9% (p=0.22) Donor site partial skin loss/wound dehiscence: 3.8% vs. 10.3% (p=0.04) Abdominal donor site or recipient site seroma or hematoma: no significant difference in incidence Recipient site fat necrosis: 11.4% vs. 19.8% (p=0.04). 1 complete flap loss in DIEP group.	New back pain: 18.5% vs. 22.2% (p=0.77) Patient satisfaction: 79.7% very satisfied vs. 92.6% very satisfied (p=0.13) Physical function: no significant difference between groups
<b>Macadam 2010 (483)</b> Retrospective chart review, cross-sectional survey	Implant-based reconstruction for breast cancer or prophylaxis; USA & Canada	Mean 53.6 months (saline) and 31.4 months (silicone)	Saline implant (62% immediate) Silicone implant (83% immediate)	68 75	NR	Satisfaction with Breast: significantly higher in silicone group Satisfaction with Outcome: no significant difference between groups Psychological Well-Being: significantly better in silicone group Physical and Sexual Well-Being: no significant difference between groups QoL: No significant difference between groups overall. Higher physical functioning

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
						score in silicone group.
<b>Nelson 2010</b> (480) Retrospective cohort study, single centre, single surgeon	DIEP and muscle-sparing free TRAM; USA	12.1 months (only msfTRAM, only DIEP) and 14.0 months (msfTRAM and DIEP)	Only msfTRAM Only DIEP One msfTRAM and one DIEP	91 53 31	Intraoperative complications: 7.1% (msfTRAM) vs. 6.9% (DIEP) (p=0.93)  Postoperative major complications (arterial or venous thrombosis, flap necrosis): 0% (msfTRAM) vs. 3.9% (DIEP) (p=0.027)  Postoperative minor or late complications: No significant difference	--
<b>Yueh 2010</b> (496) Retrospective, single centre, cross-sectional survey	Postmastectomy breast reconstruction; USA	NR	Tissue expander/ implant  LD  pTRAM  DIEP	87  116 (90 with implants)  119  117	NR	General patient satisfaction: 56.3% vs. 56.9% vs. 70.6% vs. 80.3%  Aesthetic satisfaction: 48.3% vs. 59.5% vs. 76.5% vs 70.9%
<b>Christensen 2011</b> (486) Retrospective chart review, single centre	Breast reconstruction for cancer, no known recurrence; Denmark	NR	Implant  LD flap  pTRAM	206  34  123	Minor complications (chart review): 27% vs. 21% vs. 35% (p=0.30)  Major complications (chart review): 13% vs. 0% vs. 13%	Overall satisfaction: 64% vs. 81% vs. 84% (p=0.002)  Improved QoL: 83% vs. 88% vs. 90% (p=0.149)  Pleased with breast size compared with opposite breast: 50% vs. 54% vs. 80% (p<0.0001)  Pleased with breast shape: 36% vs. 65% vs. 77% (p<0.0001)  Pleased with how the breast feels: 41% vs.

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
						77% vs. 94% ( $p < 0.0001$ )
<b>Crosby 2011</b> (489) Retrospective, single centre, consecutive patients	Unilateral breast cancer with mastectomy and synchronous contralateral prophylactic mastectomy, bilateral immediate breast reconstruction, no prior or PMRT; USA	Mean 13.2 months	Implant Abdominal flap LD/implant	334 142 21	At least one complication: 30.5% vs. 30.3% vs. 42.9%  Index breast complications: 22.5% vs. 21.1% vs. 33.3%  Prophylactic breast reconstructions: 19.2% vs. 19.0% vs. 19.0%	--
<b>Garvey 2011</b> (478) Retrospective, single centre	Free-flap abdominal autologous reconstruction, flap perfused by either medial-only or lateral-only type II DIEA branch perforators; USA	Average 33.2 months (range 7.6 to 107.0 months)	DIEP msfTRAM	157 71	Fat necrosis: 10.2% vs. 11.3% ( $p=0.81$ )  Partial flap necrosis: 3.2% vs. 2.8% ( $p=1.0$ )  Fat necrosis/partial flap necrosis: 13.4% vs. 14.1% ( $p=0.89$ )  Any complication: 19.7% vs. 19.7% ( $p=1.0$ )	--
<b>Monrigal 2011</b> (493) Retrospective, single centre	Primary operative invasive breast cancer, neoadjuvant chemotherapy, and RT; no local recurrence, inflammatory or T4 cancer; France	Mean 96 months	LD/implant free TRAM LD Implant	107 56 25 22	Total early complications (necrosis, seroma, infection, hematoma): 17.8% vs. 33.9% vs. 20.0% vs. 13.6%  Early surgical revisions: 7.5% vs. 19.6% vs. 4% vs. 13.6%  Total delayed complications (implant complications, abdominal wall hernia, necrosis, lymphedema, functional discomfort, chronic pain, seroma): 24.3% vs. 26.8% vs. 20.0% vs. 40.1%	--

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
					Delayed surgical revisions: 3.7% vs. 7.1% vs. 0% vs. 27.3%	
<b>Crosby 2012</b> (488) Retrospective, single centre, consecutive patients	Breast cancer with immediate reconstruction; USA	Mean 56 months	Tissue expander/ implant LD/implant pTRAM Free flap	737 breasts 117 breasts 36 breasts 609 breasts	Lymphedema: 3.3% vs. 3.4% vs. 5.5% vs. 3.3%	--
<b>Levine 2012</b> (491) Retrospective, single centre	PMRT, delayed abdominal-based autologous reconstruction or LD flap plus implant; USA	Mean 22.7 months	Abdominal flaps LD/implant	75 56	Reoperation (vascular compromise): 4.0% vs. 0% Flap failure: 2.7% vs. 0% Partial flap loss: 4.0% vs. 2.7% Implant loss: N/A vs. 5.4% Seroma: 13.3% vs. 21.4% Hematoma: 5.3% vs. 1.8% Cellulitis: 2.7% vs. 0% Abdominal bulge: 1.3% vs. N/A	--
<b>Momoh 2012</b> (479) Retrospective, single centre, cross-sectional survey	pTRAM or DIEP for breast cancer or prophylaxis, immediate or delayed, excluded if different reconstruction on each breast or stage 4; USA	Mean 51.2 months (DIEP) and 74.4 months (pTRAM)	DIEP pTRAM	167 179	Total flap loss: 1.8% vs. 0% (per flap) (p=0.1249) Partial flap loss: 1.4% vs. 1.5% (per flap) (p=1.0000) Major fat necrosis: 15.2% vs. 11.7% (p=0.2940) Hematoma/seroma: 3.6% vs. 3.6% (p=1.0000) Infection: 0.5% vs. 2.5% (p=0.1068) Open wound: 2.8% vs. 3.0% (p=1.0000)	General patient satisfaction (based on 234 survey responses): 81.7% vs. 70.2% (p=0.0395) Aesthetic satisfaction: 72.5% vs. 77.2% (p=0.4086)

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
					Mastectomy skin loss: 10.1% vs. 5.6% (p=0.0875)	
<b>Pompei 2012</b> (484) Retrospective	Unilateral immediate breast reconstruction with implants; Italy	Median 51 months (range 12 to 90 months)	Tissue expanders Expandable textured implants Polyurethane implants	136 47 119	Infection: 0.7% vs. 2.1% vs. 0% Exposure/extrusion: 5.1% vs. 2.1% vs. 0.8% Total complications: 14.7% vs. 12.8% vs. 5.0%	--
<b>Singh 2012</b> (485) Retrospective, insurance claims data review	Implant breast reconstruction procedure during same visit as mastectomy, no death during 18-month postmastectomy study period, 17.8% RT; USA	18 months post-reconstruction	1-stage reconstruction Tissue expanders reconstruction	95 1221	No significant differences between groups. Complications of implant/graft/mesh: 28.4% vs. 27.4% (RR=1.03) Complications of tissue/artificial skin graft: 2.1% vs. 0.7% (RR=2.85) Hematoma: 6.3% vs. 2.9% (RR=2.14) Infection: 9.5% vs. 12.4% (RR=0.76) Necrosis: 1.1% vs. 3.3% (RR=0.32) Seroma: 6.3% vs. 4.5% (RR=1.4) Skin/connective tissue: 20.0% vs. 26.4% (RR=0.76)	--
<b>Tong 2012</b> (481) Retrospective, single centre, consecutive groups	Abdominal breast reconstruction; USA	NR	pTRAM Perforator flaps	69 69	Fat necrosis: 53.6% vs. 15.9% (p=0.0001) Fat necrosis requiring operation: 23.7% vs. 5.9% (p=0.0004) Partial flap necrosis: 20.6% vs. 7.2% (p=0.045) Abdominal bulge: 21.1% vs. 9.7% (p=0.32) Abdominal hernia: 8.8% vs. 1.6% (p=0.21)	--

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
					Hematoma: 1.5% vs. 10% (p=0.06) Full flap necrosis: 0% vs. 1.5% (p=1)	
<b>Chang 2013 (476)</b> Retrospective, single centre	Unilateral or bilateral microvascular breast reconstruction; 27% prior RT, 28% postoperative RT; 65% immediate reconstruction; USA	Minimum 5 yrs	DIEP msfTRAM free TRAM S-GAP  Other (tensor fasciae latae, pedicled TRAM flap, deep circumflex iliac artery flap, T12 perforator flap)	150 flaps 158 flaps 27 flaps 19 flaps 9 flaps	Early complications: no significant difference between flap types except higher breast wound breakdown in S-GAP group (10.5%; p<0.03)	--
<b>Costa 2013 (487)</b> Retrospective, national database	Mastectomy with immediate reconstruction, no NAC reconstruction, no death within 30 days of surgery; USA	NR	Prosthetic Autologous Hybrid	7333 1475 320	Surgical site infection within 30 days of surgery: 3.33% vs. 4.88% vs. 2.19% (p=0.005). Autologous vs. prosthetic unadjusted OR, 1.49 (95% CI, 1.13 to 1.95; p<0.004), adjusted OR, 1.14 (95% CI, 0.83 to 1.58; p=0.42).  Hybrid vs. prosthetic unadjusted OR, 0.65 (95% CI, 0.30 to 1.39; p=0.264), adjusted OR, 0.59 (95% CI, 0.27 to 1.27; p=0.18)	--
<b>Davila 2013 (482)</b> Retrospective, national database	Immediate tissue expander or implant reconstruction after mastectomy, no concomitant flap reconstruction, no simultaneous expander and implant; USA	NR	One-stage direct to implant Tissue expander	1528  9033	30-day morbidity: 6.8% vs. 5.4% (p=0.02)  Reconstruction-related complications: 5.5% vs. 4.4% (p=0.05)  Prosthesis failure: 1.4% vs. 0.8% (p=0.04)  Wound disruption: 0.8% vs. 0.4% (p=0.08)	--

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
					No significant difference in surgical site infections, reoperation rates (7.5% vs. 6.9%), or major medical complications	
<b>Fischer 2013</b> (490) Retrospective, single centre	Expander/implant or free flap reconstructions, senior surgeon's patients, no postoperative RT, <65 yrs, BMI 25-35 kg/m <sup>2</sup> ; USA	Minimum 4 yrs	Expander/ implants Free flaps	60  142	Hematoma: 6.7% vs. 2.8% (p=0.24) Seroma: 15.0% vs. 5.6% (p=0.03) Cellulitis: 10% vs. 2.8% (p=0.07) Delayed wound healing: 36.6% vs. 15% (p=0.003) Failure: 7.3% vs. 1.3% (p=0.008) Major complications: 13.3% vs. 7.0% (p=0.15) Minor complications: 43.3% vs. 46.5% (p=0.68) Free flap complications: flap loss (1.3%), fat necrosis (9.9%), hernia/bulge (2.8%) Expander/implant complications: capsular contracture requiring revision (18.3%), implant exposure (6.7%), implant infection (8%)	Rate of revision: 38.3% vs. 49.3% (p=0.17)  Contralateral balancing procedure: 33.3% vs. 18.3% (p=0.021)
<b>Gart 2013<sup>a</sup></b> (474) Retrospective, national database	Autologous tissue-based reconstruction, no mixed reconstruction types; USA	30-day follow-up	Free flap LD flap pTRAM	609 1079 1608	Overall 30-day complications: 19.4% vs. 7.1% vs. 13.4% (p<0.001). Flap complications 12.0% vs. 5.0% vs. 10.0% (p<0.001). Nonflap complications 11.3% vs. 3.2% vs. 5.7% (p<0.001).  Wound infection: 5.9% vs. 3.3% vs. 6.7% (p=0.001)  Graft/flap failure (30-day): 5.7% vs. 1.3% vs. 3.4% (p<0.001)	Reoperation: 15.6% vs. 5.7% vs. 9.9% (p<0.001)

Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
					Wound disruption: 2.0% vs. 0.6% vs. 1.4% (p=0.052) Pulmonary embolism: 0.2% vs. 0.1% vs. 0.9% (p=0.005). DVT 0.3% vs. 0.2% vs. 1.0 (p=0.019) Blood transfusion: 7.7% vs. 1.6% vs. 1.9% (p<0.001)	
<b>Mioton 2013<sup>b</sup></b> (492) Retrospective, national database	Autologous tissue-based or prosthetic reconstruction, no mixed reconstruction types, 25.9% delayed reconstruction; USA	30-day follow-up	Prosthetic Autologous	9786 3296	Overall 30-day complications: 5.38% vs. 12.47% (p<0.001) Surgical complications: 4.39% vs. 8.71% (p<0.001) Medical complications: 1.55% vs. 5.92% (p<0.001) Wound infection: 3.45% vs. 5.46% (p<0.001) Prosthesis/flap failure: 0.85% vs. 3.13% (p<0.001) Wound disruption: 0.44% vs. 1.24% (p<0.001)	Reoperation: 6.76% vs. 9.59% (p<0.001)
<b>Pestana 2013</b> (494) Retrospective	Mastectomy and breast reconstruction for breast cancer, pre- or post-operative RT; USA	Mean 6 yrs	Implant Autologous + implant Autologous	88 <sup>c</sup> 38 <sup>c</sup> 28 <sup>c</sup>	Reconstruction failure (estimated): 33% (implant) vs. 11% (autologous) <sup>d</sup>	--
<b>Winters 2013</b> (495) Prospective cohort, multi-centre	Stage 0-II breast cancer, immediate reconstruction; UK	NR	LD/implant LD alone	82 100	Early complications (up to 3 months): 66% vs. 51% (p=0.062) Any severe early complication: 46% vs. 29% Infection: 15% vs. 8% Fat necrosis: 13% vs. 16% Skin necrosis: 43% vs. 22%	Reoperation: 61% vs. 65% (p=0.685)



Author, publication year; study design	Study population	Follow-up	Procedure	# of participants	Complications	Other outcomes
					Long-term complications (4 to 12 months): 48% vs. 45% (p=0.845) Any severe long-term complication: 49% vs. 31% Capsular contracture: 15% vs. 0%	

**Abbreviations:** BMI: body mass index; CI: confidence interval; DIEA: deep inferior epigastric artery; DIEP: deep inferior epigastric perforator flap; LD: latissimus dorsi; msfTRAM: muscle-sparing free TRAM; N/A: not applicable; NAC: nipple-areolar complex; NR: not reported; OR: odds ratio; pTRAM: pedicled TRAM; QoL: quality of life; RR: relative risk; RT: radiotherapy; S-GAP: superior gluteal artery perforator flap; TRAM: transverse rectus abdominis myocutaneous; vs., versus; yrs: years

**Notes:**

- <sup>a</sup> Same pts as Mioton 2013
- <sup>b</sup> Autologous pts same as Gart 2013
- <sup>c</sup> Estimated from reported data
- <sup>d</sup> Unclear from article

## DISCUSSION

### Types of reconstruction

#### ***a) Autologous tissue vs. tissue expander/implant reconstruction***

There is only a single systematic review examining the rates of complications TE/I reconstructions and AAT (467). Only 14 studies were included, and the level of evidence is very low, the studies have small sample sizes, and overlap exists among the patient populations. While reoperation rate and major complications are equivalent between the methods of reconstruction, this review suggests a greater potential for reconstructive failure and soft tissue infection in TE/I reconstructions. More evidence and better-quality studies are required to determine the accuracy of this interpretation. Complications associated with implants, including risk of infection and very rare risk of ALCL should be discussed with patients (497).

A single systematic review examining patient related outcomes following different types of breast reconstruction exists (468). This study encompasses 15 studies of very low quality and there is no consistency among measurement method, duration of follow up, or outcomes assessed. This led to the inability to pool data. The trends from this review are for improved social well-being, emotional and mental health associated with reconstruction, regardless of type, similar levels of pain between methods of reconstruction, and similar overall satisfaction or willingness to recommend surgery to others. There is some suggestion that aesthetic satisfaction with TE/I reconstruction declines over time, while AAT satisfaction remains level; however, this needs to be validated with better quality studies and larger sample sizes. Consistency among outcome measures would significantly improve ability to assess patient-related outcomes.

#### ***Radiation***

Our current recommendation on the type of reconstruction following PMRT have examined autologous tissue separately from implant-based reconstructions, and have focused primarily on short- and long-term complications of PMRT. In all the systematic reviews that compared the reconstructive options in patients who required PMRT, it was found that complications are significantly higher in the implant group compared with the autologous tissue group (498). In addition, a 2008 prospective single-centre study that examined 92 patients who underwent IBR using autologous tissue (23 patients) compared with tissue expander (69 patients) found that major complications, compromised functional status, and poor aesthetic outcomes to be significantly associated with the use of tissue expanders (469).

#### ***b) Types of autologous tissue reconstruction***

Evidence is based on two meta-analyses and three systematic reviews; however, the analyzed studies share some common weaknesses. The reviews are based on individual studies that are made up of very small cohorts, mostly retrospective in design, from single institutions, and lacking uniform definition to define our interested outcomes such as abdominal bulge, hernia, weakness, and fat necrosis. The current literature comparing outcomes among different techniques is also severely limited by the great variability in surgical techniques, the degree to which rectus muscle may be injured or violated by the surgery, and the type of abdominal wall repair that occurs with the reconstruction. Higher level of evidence in the area will require data collected from multicentre, longitudinal studies with clearly defined primary outcomes that are both subjective and objective following pedicled or free TRAM and DIEP flaps.

**Quality assessment of included systematic reviews (AMSTAR).**

Systematic review	'A priori' design	Duplicate study selection and data extraction	Comprehensive literature search	Status of publication as inclusion criterion	List of included and excluded studies	Characteristics of included studies provided	Scientific quality of included studies assessed	Scientific quality of included studies used appropriately in formulating conclusions	Methods used to combine findings of studies appropriate	Likelihood of publication bias assessed	Conflict of interest included
Tsoi 2014a (467)	Y	Y	Y	N	N	Y	Y	Y	Y	Y	N
Tsoi 2014b (468)	Y	Y	Y	N	N	Y	Y	Y	Y	Y	N
Atisha 2009 (472)	N	N	Y	N	N	Y	N	N	N/A	N	N
Egeberg 2012 (471)	N	N	Y	Y	N	Y	N	N	Y	Y	N
Khansa 2013 (473)	N	N	N	N	N	N	N	N	N	N	N
Man 2009 (470)	N	N	Y	N	N	Y	N	N	Y	Y	N
Sailon 2009 (475)	N	N	N	N	N	Y	N	N	N	N	N

**Abbreviations:** N: no; N/A: not applicable; Y: yes

## Appendix 7: Guideline Document History

Guideline version	Systematic review		Publications	Notes and key changes
	Search dates	Data		
Original January 5, 2016	2008-May 2014	Full Report	Zhong T, Spithoff K, Kellett S, Boyd K, Brackstone M, Hanrahan R, Whelan T. Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options. Toronto (ON). Cancer Care Ontario. Program in Evidence-Based Care Series No.: 17-10	Not applicable
November 26, 2019	None	Warning added to cover page and Recommendation 6	PEBC Website	Warning on Increased risk for Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
March 3, 2021	None	Assessed as needing update	PEBC Website	Cover page indicates guideline is to be updated due to assessment in January 2021
November 2021	None	Interim change to Recommendations 3 and 8.	PEBC Website	<p>In the interim, the following changes were made in consultation with the Surgical Oncology Program and the Breast Cancer Advisory Committee to reflect current practice and concerns:</p> <p>Recommendation 3: In patients expected to require RT, the timing of breast reconstruction should be determined after multidisciplinary discussion including the general surgeon or surgical oncologist, medical oncologist, radiation oncologist, and plastic surgeon and with full consideration of the values and preferences of the patient.</p> <p>Recommendation 8: Acellular dermal matrix (ADM) is currently widely used in breast reconstruction. The US FDA has issued a safety communication indicating that the complication rate (reoperation, explantation, and infections) may vary depending on the type of ADM, and this is being investigated.</p>
Version 2, March 19, 2025	To Aug 2024	New report	New web publication	Additional question on reconstruction plane (prepectoral, subpectoral/ dual-plane, submuscular); question on type of reconstruction not updated